Clustering O 0 4.477418406167999e-05
of O 0 3.874402864312287e-06
missense O 0 0.002190128667280078
mutations O 0 0.00021611522242892534
in O 0 2.326645244465908e-06
the O 0 7.08240841049701e-05
ataxia B-Disease 1 0.9999842643737793
- I-Disease 1 0.9997106194496155
telangiectasia I-Disease 1 0.9999306201934814
gene O 0 5.048111688665813e-06
in O 0 1.013599586485725e-07
a O 0 2.000263521040324e-06
sporadic B-Disease 0 0.00014455772179644555
T I-Disease 1 0.9382702708244324
- I-Disease 0 0.44227734208106995
cell I-Disease 0 0.34087976813316345
leukaemia I-Disease 1 0.9415037035942078
. O 0 2.0248620785423554e-05

Ataxia B-Disease 1 0.999755322933197
- I-Disease 1 0.9998364448547363
telangiectasia I-Disease 1 0.9999653100967407
( O 0 0.010785818099975586
A B-Disease 1 0.999893069267273
- I-Disease 1 0.9999959468841553
T I-Disease 1 0.9999980926513672
) O 0 2.562880354162189e-06
is O 0 1.6110482192743802e-07
a O 0 1.690253498054517e-06
recessive B-Disease 0 0.00042488155304454267
multi I-Disease 1 0.7651921510696411
- I-Disease 1 0.9997395873069763
system I-Disease 1 0.8548262119293213
disorder I-Disease 1 0.945861279964447
caused O 0 8.51197328302078e-05
by O 0 1.2244283880136209e-06
mutations O 0 1.7001896139845485e-06
in O 0 1.4275893356341385e-08
the O 0 5.846683492904958e-08
ATM O 0 0.00018540702876634896
gene O 0 2.7816244596579054e-07
at O 0 1.2422973441061913e-06
11q22 O 0 4.345810157246888e-05
- O 0 0.0003028965729754418
q23 O 0 1.65993860719027e-05
( O 0 6.299912058693735e-08
ref O 0 5.418064756668173e-05
. O 0 5.2421729179741305e-08
3 O 0 4.709708889549802e-07
) O 0 1.3099926832182973e-07
. O 0 7.573966058771475e-07

The O 0 3.771789852180518e-05
risk O 0 0.0006317085935734212
of O 0 1.9694043658091687e-05
cancer B-Disease 1 0.893783450126648
, O 0 7.259607173182303e-06
especially O 0 1.6952935766312294e-06
lymphoid B-Disease 0 0.0002193211403209716
neoplasias I-Disease 0 0.005075522232800722
, O 0 3.918792401691462e-07
is O 0 1.0721357313059343e-07
substantially O 0 9.881177902570926e-06
elevated O 0 0.000344712141668424
in O 0 1.7563922938279575e-06
A B-Disease 1 0.9756213426589966
- I-Disease 1 0.999994158744812
T I-Disease 1 0.9999994039535522
patients O 0 0.0028362248558551073
and O 0 5.869348115083994e-06
has O 0 8.492706911056302e-06
long O 0 7.50733888708055e-05
been O 0 2.444886922603473e-05
associated O 0 9.450384823139757e-06
with O 0 7.729633216513321e-05
chromosomal O 1 0.9999639987945557
instability O 1 0.9984777569770813
. O 0 0.0003392095968592912

By O 0 7.0707224040234e-06
analysing O 0 0.0025192447938024998
tumour B-Disease 1 0.999932050704956
DNA O 0 0.0035069193691015244
from O 0 8.12164944363758e-06
patients O 0 2.2090480342740193e-05
with O 0 8.048569384300208e-07
sporadic B-Disease 0 9.064251935342327e-05
T I-Disease 1 0.8960955142974854
- I-Disease 0 0.14514167606830597
cell I-Disease 0 0.19202306866645813
prolymphocytic I-Disease 1 0.9601860642433167
leukaemia I-Disease 1 0.9932957291603088
( O 0 9.856717042566743e-06
T B-Disease 1 0.9376918077468872
- I-Disease 0 0.13141627609729767
PLL I-Disease 0 0.008962266147136688
) O 0 2.2490904427741043e-07
, O 0 1.3282017619076214e-07
a O 0 9.55650875766878e-07
rare O 0 3.83563747163862e-05
clonal B-Disease 0 0.10084769874811172
malignancy I-Disease 1 0.7301396131515503
with O 0 1.2323171176831238e-06
similarities O 0 7.884725619078381e-07
to O 0 2.9332932527381672e-08
a O 0 4.100249384464405e-07
mature B-Disease 0 1.2779330063494854e-05
T I-Disease 0 0.07837103307247162
- I-Disease 0 0.012884684838354588
cell I-Disease 0 0.04615168273448944
leukaemia I-Disease 1 0.5793938040733337
seen O 0 1.35102618514793e-05
in O 0 2.6850502763409168e-06
A B-Disease 1 0.9862889051437378
- I-Disease 1 0.9999417066574097
T I-Disease 1 0.9999912977218628
, O 0 1.200342808260757e-06
we O 0 1.611846656146554e-08
demonstrate O 0 3.261607517401899e-08
a O 0 2.1392347449022964e-08
high O 0 6.119142881289008e-07
frequency O 0 1.3869407844424586e-08
of O 0 2.3490864364816844e-08
ATM O 0 0.00029464965336956084
mutations O 0 6.90145134285558e-06
in O 0 2.3430688997905236e-06
T B-Disease 1 0.6046878099441528
- I-Disease 0 0.02692895568907261
PLL I-Disease 0 0.003896839451044798
. O 0 8.176187293429393e-06

In O 0 1.0400857718195766e-05
marked O 0 4.4165724830236286e-05
contrast O 0 1.5308722822737764e-06
to O 0 2.0781248721846168e-08
the O 0 2.8786605099639928e-08
ATM O 0 0.0002827125135809183
mutation O 0 2.6042202989629004e-06
pattern O 0 2.5201452444889583e-06
in O 0 2.043034555754275e-06
A B-Disease 1 0.9638382196426392
- I-Disease 1 0.9999799728393555
T I-Disease 1 0.9999966621398926
, O 0 1.9399001303099794e-06
the O 0 3.112461399723543e-08
most O 0 1.0749159784495532e-08
frequent O 0 3.574148976781544e-08
nucleotide O 0 9.413805059921287e-07
changes O 0 3.895057432146132e-08
in O 0 1.0172057329782547e-07
this O 0 1.0862349881790578e-06
leukaemia B-Disease 1 0.7645024061203003
were O 0 3.5692584788193926e-05
missense O 0 0.0008410907466895878
mutations O 0 3.77833130187355e-05
. O 0 2.8312863378232578e-06

These O 0 1.1733624205589877e-06
clustered O 0 3.512707553454675e-05
in O 0 2.5094533384617534e-07
the O 0 9.078122076289219e-08
region O 0 1.0916210158029571e-07
corresponding O 0 3.197168396695815e-08
to O 0 1.2145571659516463e-08
the O 0 7.500634069401713e-08
kinase O 0 7.742059096926823e-06
domain O 0 6.407585715351161e-07
, O 0 3.8498043863910425e-07
which O 0 4.5573202100968047e-08
is O 0 7.069186125363558e-08
highly O 0 3.371599461843289e-07
conserved O 0 2.7638390065476415e-07
in O 0 9.771332543095923e-08
ATM O 0 0.0009802913991734385
- O 0 0.000399110751459375
related O 0 1.2872811794295558e-06
proteins O 0 5.425863847108303e-08
in O 0 4.229150363244116e-08
mouse O 0 5.911338121222798e-06
, O 0 3.615894001995912e-07
yeast O 0 2.5553242721798597e-06
and O 0 7.35412015728798e-07
Drosophila O 0 8.25511961011216e-07
. O 0 1.2493331951191067e-06

The O 0 1.7162965377792716e-06
resulting O 0 6.576752184628276e-06
amino O 0 1.3554296174334013e-06
- O 0 0.00024525675689801574
acid O 0 2.263255510115414e-06
substitutions O 0 2.428618017802364e-07
are O 0 2.5340259668382714e-08
predicted O 0 1.6641296269881423e-06
to O 0 1.6344463560358236e-08
interfere O 0 5.781378575875351e-08
with O 0 4.825163557597989e-08
ATP O 0 0.0006888437201268971
binding O 0 1.722121965030965e-06
or O 0 2.621923442802654e-07
substrate O 0 4.392161645228043e-05
recognition O 0 1.7995159851125209e-06
. O 0 2.0206464341754327e-06

Two O 0 7.799765739946452e-07
of O 0 1.3063797155155044e-07
seventeen O 0 1.204566524393158e-05
mutated O 0 0.0001647022581892088
T B-Disease 0 0.14578638970851898
- I-Disease 0 0.0002782157971523702
PLL I-Disease 0 0.0001747451606206596
samples O 0 1.5651118019377463e-06
had O 0 5.572732675318548e-07
a O 0 2.1015911499944195e-07
previously O 0 5.1933784561697394e-05
reported O 0 0.00029121508123353124
A B-Disease 0 0.2980458438396454
- I-Disease 1 0.9915693402290344
T I-Disease 1 0.9996657371520996
allele O 0 5.206668356549926e-05
. O 0 2.29106785809563e-06

In O 0 8.494374924339354e-06
contrast O 0 2.7697924451786093e-05
, O 0 7.16601959993568e-07
no O 0 6.729773360802938e-08
mutations O 0 5.856035727447306e-07
were O 0 1.3286379498822498e-06
detected O 0 3.566873374438728e-06
in O 0 1.4678297688419661e-08
the O 0 4.098282246900453e-08
p53 O 0 1.622600223072368e-07
gene O 0 6.442449773658154e-08
, O 0 7.715914307482308e-08
suggesting O 0 1.4530878615914844e-06
that O 0 6.684830822223375e-08
this O 0 9.256621638087381e-07
tumour B-Disease 1 0.9999681711196899
suppressor O 0 0.003859056858345866
is O 0 4.973006753061782e-07
not O 0 5.318817386523733e-08
frequently O 0 2.3883154653958627e-07
altered O 0 1.2946138667757623e-06
in O 0 1.2739967303332378e-07
this O 0 1.0726608934419346e-06
leukaemia B-Disease 0 0.4559350907802582
. O 0 1.4374179954756983e-05

Occasional O 0 0.00021905280300416052
missense O 0 0.002099141478538513
mutations O 0 0.00014291738625615835
in O 0 3.954374676595762e-07
ATM O 0 0.0009076426504179835
were O 0 2.4548371584387496e-05
also O 0 3.4657550713745877e-06
found O 0 3.595750513341045e-06
in O 0 2.7486512408358976e-06
tumour B-Disease 1 0.9999085664749146
DNA O 0 0.0035217967815697193
from O 0 1.720064210530836e-05
patients O 0 1.3355028386285994e-05
with O 0 7.095688943081768e-07
B B-Disease 0 0.0035733620170503855
- I-Disease 0 0.08620809018611908
cell I-Disease 0 0.08927950263023376
non I-Disease 0 0.05864764004945755
- I-Disease 1 0.9993247985839844
Hodgkins I-Disease 1 0.9999594688415527
lymphomas I-Disease 1 0.6853473782539368
( O 0 5.456406029225036e-07
B B-Disease 0 4.9772450438467786e-05
- I-Disease 0 0.00048007589066401124
NHL I-Disease 0 5.883879930479452e-05
) O 0 2.7458471052455025e-08
and O 0 4.295061728498695e-08
a O 0 2.6100184413735406e-07
B B-Disease 0 4.250227357260883e-05
- I-Disease 0 0.00012758193770423532
NHL I-Disease 0 5.656493885908276e-05
cell O 0 3.0340490411617793e-05
line O 0 3.377969187567942e-05
. O 0 4.30698310083244e-06

The O 0 3.986947376688477e-06
evidence O 0 2.9651089334947756e-06
of O 0 1.1177297665199148e-07
a O 0 1.1602388667597552e-06
significant O 0 1.1491662235130207e-06
proportion O 0 3.2389107218477875e-06
of O 0 1.1301790436846204e-06
loss O 0 0.003782958723604679
- O 0 0.00034791979123838246
of O 0 6.229961400094908e-07
- O 0 0.006266073789447546
function O 0 5.082245593257539e-07
mutations O 0 1.1380429896235e-06
and O 0 2.7543583769329416e-07
a O 0 4.86038800318056e-07
complete O 0 3.6692551930173067e-06
absence O 0 1.6597962257947074e-06
of O 0 3.3649172337391065e-08
the O 0 1.0122278837343401e-07
normal O 0 4.065892866833565e-08
copy O 0 1.2698627926965855e-07
of O 0 1.652234082882842e-08
ATM O 0 3.244976687710732e-05
in O 0 5.388118395899255e-08
the O 0 5.130152302967872e-08
majority O 0 3.051667647469003e-07
of O 0 6.696942023154406e-07
mutated O 0 0.0029640994034707546
tumours B-Disease 1 0.9981698989868164
establishes O 0 1.1397828529879916e-05
somatic O 0 8.727682870812714e-05
inactivation O 0 0.019672881811857224
of O 0 7.99999355649561e-08
this O 0 8.340375501347808e-09
gene O 0 1.897437940101554e-08
in O 0 3.3215863393110112e-09
the O 0 3.8825593406954795e-08
pathogenesis O 0 6.932924407010432e-06
of O 0 1.5114751761302614e-07
sporadic B-Disease 0 6.341862899716944e-05
T I-Disease 1 0.9167697429656982
- I-Disease 0 0.02254430018365383
PLL I-Disease 0 0.00042163601028732955
and O 0 8.385398473365058e-07
suggests O 0 1.818380326312763e-07
that O 0 1.2065175525322047e-08
ATM O 0 1.4367889889399521e-05
acts O 0 6.156024028314278e-07
as O 0 5.780749461337109e-07
a O 0 3.0281235012807883e-05
tumour B-Disease 1 0.9998251795768738
suppressor O 0 0.008944530040025711
. O 0 8.984558917290997e-06

As O 0 4.407656888361089e-06
constitutional O 0 9.231689546140842e-06
DNA O 0 0.00034619320649653673
was O 0 8.946485468186438e-05
not O 0 4.1512443260671716e-08
available O 0 4.9223778830764786e-08
, O 0 1.3156127920410654e-07
a O 0 1.5592254385410342e-06
putative O 0 0.014654727652668953
hereditary O 1 0.8038433194160461
predisposition O 0 0.046887535601854324
to O 0 2.4105989723466337e-05
T B-Disease 1 0.8879968523979187
- I-Disease 0 0.007807528600096703
PLL I-Disease 0 0.00038823223439976573
will O 0 2.527904818805382e-08
require O 0 5.529700697337603e-09
further O 0 7.572446669712463e-09
investigation O 0 1.6326567902069655e-06
. O 0 3.9914789340400603e-07
. O 0 2.083492518067942e-06

Myotonic B-Disease 1 0.9998088479042053
dystrophy I-Disease 1 0.9998953342437744
protein O 0 0.0009300776291638613
kinase O 0 0.00107588863465935
is O 0 8.373259561267332e-07
involved O 0 6.837270234427706e-07
in O 0 2.632839901650641e-08
the O 0 1.0950782503016399e-08
modulation O 0 2.6508995887297715e-08
of O 0 6.194790902469549e-09
the O 0 6.352194503733699e-08
Ca2 O 0 1.1340041055518668e-05
+ O 0 9.114414751820732e-06
homeostasis O 0 4.749984509544447e-05
in O 0 8.020938935260347e-07
skeletal O 0 0.19429151713848114
muscle O 0 0.002648417605087161
cells O 0 1.6855718058650382e-05
. O 0 2.0484544620558154e-06

Myotonic B-Disease 1 0.9999085664749146
dystrophy I-Disease 1 0.9999719858169556
( O 0 0.040308695286512375
DM B-Disease 1 0.9999871253967285
) O 0 3.6856185033684596e-05
, O 0 1.2436154293027357e-06
the O 0 5.177390676180949e-07
most O 0 8.406966117036063e-06
prevalent O 0 0.009118004702031612
muscular B-Disease 1 0.9996259212493896
disorder I-Disease 1 0.8383550047874451
in O 0 2.9928374715382233e-05
adults O 0 0.0036311151925474405
, O 0 4.537302447715774e-05
is O 0 1.5585457731503993e-05
caused O 0 5.381931259762496e-05
by O 0 1.9789761154243024e-06
( O 0 7.545718858636974e-07
CTG O 0 0.0003778402751777321
) O 0 6.390376228182504e-08
n O 0 1.7950542314792983e-06
- O 0 3.7315539884730242e-06
repeat O 0 4.616188675754529e-07
expansion O 0 6.074453295923377e-08
in O 0 2.4432071921154375e-09
a O 0 6.0638707388704916e-09
gene O 0 5.192602792192247e-09
encoding O 0 7.95473908965505e-09
a O 0 1.714768842475678e-07
protein O 0 8.616444802100887e-07
kinase O 0 7.849606845411472e-06
( O 0 3.336516556373681e-07
DM B-Disease 1 0.9965830445289612
protein O 0 2.5139304398180684e-06
kinase O 0 1.1938005627598614e-05
; O 0 3.5902399986298406e-07
DMPK O 0 0.0007077741320244968
) O 0 2.3217188171997805e-08
and O 0 7.209517427497758e-09
involves O 0 5.059496999137991e-08
changes O 0 1.4444668572366481e-08
in O 0 2.035207380401971e-08
cytoarchitecture O 0 3.730711978278123e-05
and O 0 1.3203857633925509e-06
ion O 0 0.0002142739249393344
homeostasis O 0 0.0005388020654208958
. O 0 2.5284311959694605e-06

To O 0 1.286169435843476e-06
obtain O 0 8.415015599894105e-07
clues O 0 2.0096729258511914e-06
to O 0 3.862417585764888e-08
the O 0 3.710718488036946e-08
normal O 0 3.3051502867920135e-08
biological O 0 5.199146357881546e-07
role O 0 7.565130744069393e-08
of O 0 2.7710168382100164e-08
DMPK O 0 0.00010749767534434795
in O 0 1.1577392200479153e-07
cellular O 0 4.430412809597328e-05
ion O 0 0.00037627737037837505
homeostasis O 0 0.0006911932723596692
, O 0 1.6743848618716584e-07
we O 0 8.001729057127704e-09
have O 0 1.1852955950075739e-08
compared O 0 1.8504184140510915e-07
the O 0 6.735692892334555e-08
resting O 0 4.385247302707285e-05
[ O 0 7.62754780225805e-07
Ca2 O 0 3.481849262243486e-06
+ O 0 3.96758377974038e-06
] O 0 2.807049952480156e-07
i O 0 4.73981245363575e-08
, O 0 3.442735208025738e-09
the O 0 1.7822900932884522e-09
amplitude O 0 1.8516498556664374e-08
and O 0 6.460354029513837e-08
shape O 0 3.641564916279094e-08
of O 0 1.558891682407193e-08
depolarization O 0 9.390256309416145e-06
- O 0 0.00023082361440174282
induced O 0 5.365834294934757e-05
Ca2 O 0 9.0612529675127e-06
+ O 0 2.883975184886367e-06
transients O 0 5.2371698984643444e-05
, O 0 8.225777037296211e-08
and O 0 1.7000838070657665e-08
the O 0 3.828471317746107e-09
content O 0 4.108666296076535e-09
of O 0 3.236162227082673e-09
ATP O 0 1.5242236258927733e-05
- O 0 5.926669018663233e-06
driven O 0 6.764996101082943e-07
ion O 0 4.243753664923133e-06
pumps O 0 3.906709025613964e-06
in O 0 6.54427836366267e-08
cultured O 0 0.0001401111512677744
skeletal O 0 0.022304512560367584
muscle O 0 5.98992919549346e-05
cells O 0 2.3660938097691542e-07
of O 0 3.731507192128447e-08
wild O 0 6.610658601857722e-06
- O 0 0.005405330564826727
type O 0 1.2119686289224774e-05
and O 0 4.973380328010535e-06
DMPK O 0 0.02409297600388527
[ O 0 3.1831784781388706e-06
- O 0 0.0001731439697323367
/ O 0 1.672823418630287e-05
- O 0 0.00021006727183703333
] O 0 4.097206783626461e-06
knockout O 0 0.0003649973077699542
mice O 0 0.0001369494857499376
. O 0 1.962699798241374e-06

In O 0 2.266488991153892e-06
vitro O 0 0.0001598392118467018
- O 0 0.003115356434136629
differentiated O 0 7.698295667069033e-05
DMPK O 0 0.006532187573611736
[ O 0 3.890576408593915e-06
- O 0 0.00018821186677087098
/ O 0 1.822971535148099e-05
- O 0 0.0006902401801198721
] O 0 5.002879674975702e-07
myotubes O 0 3.6875035220873542e-06
exhibit O 0 2.843057131940441e-07
a O 0 1.1899692253791727e-07
higher O 0 1.2327402600931237e-06
resting O 0 2.7182011763215996e-05
[ O 0 3.368918726209813e-07
Ca2 O 0 3.0941089335101424e-06
+ O 0 2.5735241706570378e-06
] O 0 2.759645951755374e-07
i O 0 3.7271753683398856e-08
than O 0 3.396485759310508e-09
do O 0 3.936439174623274e-09
wild O 0 1.6065865793279954e-07
- O 0 0.00010667668539099395
type O 0 5.320265699992888e-06
myotubes O 0 0.0003679150831885636
because O 0 3.6982125806162e-08
of O 0 1.1014336109838041e-08
an O 0 2.5606030362723686e-07
altered O 0 2.1861878849449567e-06
open O 0 1.3697193423922727e-07
probability O 0 6.573662503228661e-09
of O 0 2.9599217299391967e-08
voltage O 0 2.849412521754857e-05
- O 0 0.0016757812118157744
dependent O 0 4.881123913946794e-06
l O 0 0.00015164661454036832
- O 0 3.767544694710523e-05
type O 0 1.2491569805206382e-06
Ca2 O 0 1.703589987300802e-06
+ O 0 4.2865912064371514e-07
and O 0 1.0963973551270101e-07
Na O 0 7.372093023150228e-06
+ O 0 1.078606373994262e-06
channels O 0 6.119580575614236e-07
. O 0 5.118287731420423e-07

The O 0 1.945831172633916e-06
mutant O 0 0.0001336853893008083
myotubes O 0 0.0007776509155519307
exhibit O 0 5.567007974605076e-06
smaller O 0 4.42433673697451e-07
and O 0 7.350691788587937e-08
slower O 0 9.836873005042435e-07
Ca2 O 0 2.772072093648603e-06
+ O 0 2.7279060077489703e-07
responses O 0 1.4297148354103228e-08
upon O 0 8.684006402859268e-09
triggering O 0 1.2428697573341196e-06
by O 0 5.453607698768792e-08
acetylcholine O 0 2.833157850545831e-05
or O 0 7.557270009783679e-07
high O 0 3.8542311813216656e-05
external O 0 2.0593648514477536e-05
K O 0 4.8668331146473065e-05
+ O 0 7.513573109463323e-06
. O 0 1.0625304867062368e-06

In O 0 5.6585436141176615e-06
addition O 0 6.940723778825486e-06
, O 0 4.5825109395991603e-07
we O 0 9.417701285485691e-09
observed O 0 1.9924730310094674e-08
that O 0 9.434650838358039e-10
these O 0 4.2967529534365667e-10
Ca2 O 0 1.2784041700797388e-06
+ O 0 3.2302550607710145e-06
transients O 0 8.149196219164878e-05
partially O 0 2.0832438167417422e-05
result O 0 8.839727883014348e-08
from O 0 1.548753125746316e-08
an O 0 3.1590523974500684e-08
influx O 0 7.32622567056751e-08
of O 0 1.7312943301206474e-09
extracellular O 0 1.7087482717670355e-07
Ca2 O 0 1.1444327583376435e-06
+ O 0 1.0470321143429828e-07
through O 0 2.864828596571556e-09
the O 0 3.150922367467501e-08
l O 0 0.00012127619265811518
- O 0 7.389618258457631e-05
type O 0 1.7211564227181952e-06
Ca2 O 0 8.121525752358139e-06
+ O 0 1.7351866290482576e-06
channel O 0 1.536143031444226e-06
. O 0 9.144714567810297e-07

Neither O 0 2.5695324438856915e-05
the O 0 3.4064728993143945e-07
content O 0 1.5910144668396242e-07
nor O 0 5.6611064280787105e-08
the O 0 3.584298635672667e-09
activity O 0 8.68379057550328e-09
of O 0 1.9121264571708707e-08
Na O 0 4.267789699952118e-05
+ O 0 1.5004667375251302e-06
/ O 0 3.913444288627943e-07
K O 0 7.428201911352517e-07
+ O 0 3.755398267912824e-07
ATPase O 0 1.8349800257055904e-06
and O 0 1.0895659130483182e-07
sarcoplasmic O 0 2.7783744371845387e-05
reticulum O 0 1.435743979527615e-05
Ca2 O 0 1.4823277524556033e-05
+ O 0 7.486957201763289e-06
- O 0 0.00015672121662646532
ATPase O 0 7.724342140136287e-05
are O 0 4.9430667559136054e-08
affected O 0 1.5154746790813078e-07
by O 0 5.400885925155308e-07
DMPK O 0 0.020246095955371857
absence O 0 3.613335138652474e-05
. O 0 3.689659934025258e-06

In O 0 2.704615326365456e-06
conclusion O 0 4.4554414557751443e-07
, O 0 1.5247383089445066e-07
our O 0 9.5487635576319e-09
data O 0 8.054284705849568e-08
suggest O 0 1.4608673382099369e-07
that O 0 2.706826407461449e-08
DMPK O 0 0.0008708597160875797
is O 0 8.83064430468039e-08
involved O 0 1.23158230280751e-07
in O 0 4.508196482788662e-08
modulating O 0 2.5869546789181186e-06
the O 0 3.0378920712337276e-08
initial O 0 5.1046967541878985e-08
events O 0 4.400605213561448e-09
of O 0 7.589132877683369e-09
excitation O 0 1.6972946923488053e-06
- O 0 0.0012034078827127814
contraction O 0 2.4752347599132918e-05
coupling O 0 5.861483714397764e-06
in O 0 8.97344398254063e-06
skeletal O 0 0.3812564015388489
muscle O 0 0.0004038927727378905
. O 0 7.703891355959058e-07
. O 0 4.5480733206204604e-06

Constitutional O 0 0.0011053517227992415
RB1 O 0 0.21543022990226746
- O 0 0.002691655419766903
gene O 0 1.7294823919655755e-05
mutations O 0 2.2488580725621432e-05
in O 0 1.439551397197647e-06
patients O 0 2.4868944819900207e-05
with O 0 2.242969458166044e-06
isolated O 0 0.00013912520080339164
unilateral B-Disease 0 0.00021293442114256322
retinoblastoma I-Disease 0 0.11212833970785141
. O 0 2.6168445401708595e-05

In O 0 7.19979607310961e-06
most O 0 4.350370090833167e-06
patients O 0 4.5870292524341494e-05
with O 0 3.968310466007097e-06
isolated O 0 0.0001608660677447915
unilateral B-Disease 0 0.0004389180685393512
retinoblastoma I-Disease 1 0.6872589588165283
, O 0 0.0015308507718145847
tumor B-Disease 0 0.06116427481174469
development O 0 2.2936686150387686e-07
is O 0 4.2402803046570625e-08
initiated O 0 7.61447950026195e-07
by O 0 8.21243588688958e-08
somatic O 0 6.858756933070254e-06
inactivation O 0 0.001080478192307055
of O 0 2.1368450120462512e-08
both O 0 1.6738381347636277e-08
alleles O 0 3.47237367748221e-08
of O 0 2.0984465720630396e-08
the O 0 2.000934955503908e-06
RB1 O 0 0.03650980070233345
gene O 0 4.215755325276405e-06
. O 0 1.5576425766994362e-06

However O 0 5.4714510042686015e-05
, O 0 5.098109454593214e-07
some O 0 6.280318043394573e-09
of O 0 3.286003646962854e-08
these O 0 2.356568131745007e-07
patients O 0 1.1735298357962165e-05
can O 0 1.1403457733649702e-07
transmit O 0 8.115817763609812e-05
retinoblastoma B-Disease 0 0.01610836572945118
predisposition O 0 0.00017347959510516375
to O 0 1.5822368482076854e-07
their O 0 6.414910558305564e-07
offspring O 0 2.8069560357835144e-05
. O 0 3.863718120555859e-06

To O 0 5.477720037561085e-07
determine O 0 2.3541960558759456e-07
the O 0 5.87016018016584e-08
frequency O 0 3.034869280327257e-07
and O 0 2.2605280491916346e-07
nature O 0 7.241963828619191e-08
of O 0 5.6320921260066825e-08
constitutional O 0 4.766864003613591e-05
RB1 O 0 0.14451362192630768
- O 0 0.0008215642883442342
gene O 0 1.4774127521377522e-06
mutations O 0 3.5351456517673796e-06
in O 0 1.181738980449154e-06
patients O 0 1.1776205610658508e-05
with O 0 9.125434417001088e-07
isolated O 0 2.5709345209179446e-05
unilateral B-Disease 0 5.6721532018855214e-05
retinoblastoma I-Disease 0 0.010805647820234299
, O 0 4.428140130130487e-07
we O 0 1.1555239431970676e-08
analyzed O 0 3.8395086221498786e-07
DNA O 0 5.6492153817089275e-06
from O 0 5.234639957052423e-07
peripheral O 0 0.00020594926900230348
blood O 0 2.720197880989872e-05
and O 0 2.7383528049540473e-06
from O 0 5.550384594243951e-05
tumor B-Disease 0 0.2491145133972168
tissue O 0 0.0006124962237663567
. O 0 8.862027243594639e-06

The O 0 6.833704446762567e-07
analysis O 0 8.78922946867533e-07
of O 0 5.8017094488604926e-06
tumors B-Disease 1 0.9999415874481201
from O 0 8.266083568742033e-06
54 O 0 0.000647733046207577
( O 0 3.5728106695387396e-07
71 O 0 3.792612551478669e-05
% O 0 9.720139360069879e-08
) O 0 5.030271310602075e-09
of O 0 3.941595494438843e-08
76 O 0 0.00040378610719926655
informative O 0 1.6570598745602183e-05
patients O 0 0.00033487347536720335
showed O 0 0.00011466572323115543
loss O 0 3.83739716198761e-05
of O 0 2.1101145364355034e-07
constitutional O 0 0.0004548276774585247
heterozygosity O 0 0.14538419246673584
( O 0 2.2389120204024948e-05
LOH O 1 0.999244213104248
) O 0 3.4337764986958064e-07
at O 0 1.264040520254639e-06
intragenic O 0 0.0001350952807115391
loci O 0 3.501335186228971e-06
. O 0 9.834039929046412e-07

Three O 0 1.5686413235016516e-06
of O 0 7.602594109812344e-07
13 O 0 4.5709864934906363e-05
uninformative O 1 0.7294118404388428
patients O 0 0.0010940503561869264
had O 0 2.659703568497207e-05
constitutional O 0 2.373878851358313e-05
deletions O 0 0.0002417976502329111
. O 0 8.727322892809752e-06

For O 0 1.0674859822756844e-06
39 O 0 5.5216059990925714e-06
randomly O 0 3.2132120395544916e-06
selected O 0 9.13464100449346e-05
tumors B-Disease 1 0.9996485710144043
, O 0 1.3154852922525606e-06
SSCP O 0 0.002643889980390668
, O 0 9.435556194148376e-07
hetero O 0 0.00011361856741132215
- O 0 1.2574646461871453e-05
duplex O 0 3.979212851845659e-05
analysis O 0 4.219577931507956e-08
, O 0 1.892071210818358e-08
sequencing O 0 4.3887052925128955e-07
, O 0 8.694600950320819e-08
and O 0 1.8077081165301934e-08
Southern O 0 1.5722724455713433e-08
blot O 0 2.847729319910286e-06
analysis O 0 3.3938778898345845e-08
were O 0 3.482143711153185e-07
used O 0 8.273705986994173e-08
to O 0 7.63383596336098e-08
identify O 0 5.195015546632931e-06
mutations O 0 6.0679271882690955e-06
. O 0 3.3497940421511885e-06

Mutations O 0 0.0008220121962949634
were O 0 9.74829526967369e-06
detected O 0 1.594294371898286e-05
in O 0 3.023210410901811e-07
21 O 0 9.569673238729592e-06
( O 0 1.192368301872193e-07
91 O 0 1.441357653675368e-05
% O 0 1.669967559791985e-07
) O 0 3.146916682794654e-08
of O 0 2.1963052176943165e-07
23 O 0 0.02433512918651104
tumors B-Disease 1 0.999909520149231
with O 0 0.00015812650963198394
LOH O 1 0.9995982050895691
. O 0 1.5841280401218683e-05

In O 0 9.651297659729607e-06
6 O 0 1.675778730714228e-05
( O 0 1.6534988844796317e-07
38 O 0 1.9131753106194083e-06
% O 0 4.511344897650815e-08
) O 0 1.0549860540720601e-08
of O 0 1.2963629103524e-07
16 O 0 0.020622264593839645
tumors B-Disease 1 0.999983549118042
without O 0 6.780658441130072e-05
LOH O 1 0.9987253546714783
, O 0 3.8587549511248653e-07
one O 0 7.177154515147777e-08
mutation O 0 1.336094101134222e-06
was O 0 0.0001373608101857826
detected O 0 1.6829681044328026e-05
, O 0 2.305379211975378e-07
and O 0 4.399122417453327e-07
in O 0 2.1451640463965305e-07
9 O 0 1.085886196960928e-05
( O 0 9.126351585564407e-08
56 O 0 2.5351919248350896e-06
% O 0 6.778481775882028e-08
) O 0 4.912124040856725e-09
of O 0 3.6787529467119384e-08
the O 0 0.0002176589478040114
tumors B-Disease 1 0.9999877214431763
without O 0 5.359579881769605e-05
LOH O 1 0.9992156028747559
, O 0 1.0345817145207548e-06
both O 0 2.3059683940118703e-07
mutations O 0 3.0771091132919537e-06
were O 0 3.5306036352267256e-06
found O 0 1.674513623584062e-05
. O 0 4.049264589411905e-06

Thus O 0 3.4983600926352665e-05
, O 0 7.352542183980404e-07
a O 0 1.2484906619647518e-07
total O 0 6.00938960815256e-08
of O 0 2.720833336411488e-08
45 O 0 1.2698594673565822e-06
mutations O 0 1.190378270621295e-06
were O 0 2.1625426143145887e-06
identified O 0 1.6042322386056185e-05
in O 0 5.7751462918531615e-06
tumors B-Disease 1 0.9994708895683289
of O 0 2.848671783794998e-06
36 O 0 0.005297372583299875
patients O 0 0.0005581779405474663
. O 0 1.5132683074625675e-05

Thirty O 0 5.684905772795901e-05
- O 0 0.00016483329818584025
nine O 0 2.2174426703713834e-06
of O 0 8.688616048857511e-08
the O 0 4.3757330558946705e-07
mutations O 0 6.126037533249473e-06
- O 0 0.0001905802491819486
including O 0 5.364775915950304e-06
34 O 0 2.071014023385942e-05
small O 0 2.4624566776765278e-06
mutations O 0 2.992202780660591e-06
, O 0 2.597664376935427e-07
2 O 0 2.1080356873426354e-06
large O 0 5.409595814853674e-06
structural O 0 0.008830837905406952
alterations O 0 0.0002889798197429627
, O 0 8.705251843821316e-07
and O 0 1.4756328710063826e-06
hypermethylation O 0 0.0018286320846527815
in O 0 2.642465005919803e-06
3 O 0 0.006355371791869402
tumors O 1 0.9999864101409912
- O 0 0.044707849621772766
were O 0 1.1436677596066147e-05
not O 0 8.974635079539439e-08
detected O 0 4.6015696852919064e-07
in O 0 2.621963979265729e-09
the O 0 2.0263449584945192e-08
corresponding O 0 1.2911318663100246e-06
peripheral O 0 0.00022314088710118085
blood O 0 6.868305354146287e-05
DNA O 0 8.6561034549959e-05
. O 0 4.347408776084194e-06

In O 0 9.180924280371983e-06
6 O 0 2.8077536626369692e-05
( O 0 2.056470549405276e-07
17 O 0 3.6872784221486654e-06
% O 0 8.348718694151103e-08
) O 0 4.0695842251636805e-09
of O 0 7.051192074669643e-09
the O 0 4.029488422929717e-07
36 O 0 0.0007808053051121533
patients O 0 1.4393892342923209e-05
, O 0 1.7965992071822257e-07
a O 0 7.153954015848285e-07
mutation O 0 6.460123131546425e-06
was O 0 0.00038646679604426026
detected O 0 1.0861141163331922e-05
in O 0 6.46040376750534e-08
constitutional O 0 6.545990800077561e-06
DNA O 0 0.0005950904451310635
, O 0 1.3335125004232395e-06
and O 0 2.8560796749843576e-07
1 O 0 1.2264064253031393e-07
of O 0 1.6673027403157903e-08
these O 0 5.657242496681647e-08
mutations O 0 5.36349671165226e-06
is O 0 6.800482310609368e-07
known O 0 1.7106247014453402e-06
to O 0 2.6070580361192697e-07
be O 0 2.6755722615234845e-07
associated O 0 4.6542132281501836e-07
with O 0 1.2854864053224446e-06
reduced O 0 8.485592843499035e-05
expressivity O 0 0.0016476481687277555
. O 0 1.04466853372287e-05

The O 0 3.788033154705772e-06
presence O 0 9.806449270399753e-07
of O 0 5.625039278811528e-08
a O 0 6.905532359269273e-07
constitutional O 0 1.4431347153731622e-05
mutation O 0 2.9873024686821736e-05
was O 0 0.00029541359981521964
not O 0 2.2302049274003366e-07
associated O 0 3.759390097002324e-07
with O 0 1.142406276244401e-07
an O 0 8.341825150637305e-07
early O 0 3.994108737970237e-06
age O 0 3.763755375985056e-05
at O 0 3.347373058204539e-05
treatment O 0 5.848614455317147e-05
. O 0 8.468378837278578e-06

In O 0 8.849578989611473e-06
1 O 0 1.5873461961746216e-05
patient O 0 6.099599340814166e-05
, O 0 7.490589837289008e-07
somatic O 0 0.0002763720403891057
mosaicism O 1 0.5845065116882324
was O 0 0.0005551459616981447
demonstrated O 0 3.87242425858858e-06
by O 0 4.5492434708194196e-08
molecular O 0 3.354315936121566e-07
analysis O 0 1.2533146076521007e-08
of O 0 1.2458688303240706e-08
DNA O 0 5.311687345965765e-06
and O 0 5.301013175085245e-07
RNA O 0 1.5055020412546583e-06
from O 0 1.03708782717149e-06
peripheral O 0 0.0003387269680388272
blood O 0 9.64678474701941e-05
. O 0 4.208263817417901e-06

In O 0 1.5545172573183663e-05
2 O 0 9.54119095695205e-05
patients O 0 0.00010460180783411488
without O 0 1.0958182627973656e-07
a O 0 4.0596091821498703e-07
detectable O 0 1.244995291926898e-05
mutation O 0 7.008007401054783e-07
in O 0 3.275229403243429e-07
peripheral O 0 0.005565893370658159
blood O 0 0.001850765896961093
, O 0 9.0327812358737e-06
mosaicism O 0 0.09218551963567734
was O 0 0.0007429016986861825
suggested O 0 5.7376410040888e-06
because O 0 6.814415343114888e-08
1 O 0 6.162925103581074e-08
of O 0 6.063456226002018e-08
the O 0 6.038981155143119e-06
patients O 0 0.0006190416752360761
showed O 0 0.06686156243085861
multifocal O 1 0.9984629154205322
tumors B-Disease 1 0.9999945163726807
and O 0 2.8950914838787867e-06
the O 0 1.4888125576817401e-07
other O 0 2.10281612567087e-07
later O 0 8.723338396521285e-06
developed O 0 1.4117958016868215e-05
bilateral B-Disease 0 0.00011801694927271456
retinoblastoma I-Disease 0 0.075440414249897
. O 0 1.988245094253216e-05

In O 0 2.223104729637271e-06
conclusion O 0 5.37181222171057e-07
, O 0 9.770847952950135e-08
our O 0 6.682125963664021e-09
results O 0 3.632892742189142e-08
emphasize O 0 6.209734237927478e-08
that O 0 6.583762868217491e-09
the O 0 2.9211220109459646e-08
manifestation O 0 1.5396981325466186e-06
and O 0 4.6034392653382383e-07
transmissibility O 0 1.527087079011835e-05
of O 0 1.6828502680255042e-07
retinoblastoma B-Disease 0 0.001241954741999507
depend O 0 3.352234330122883e-07
on O 0 6.229283826542087e-07
the O 0 1.265781008896738e-07
nature O 0 8.594141576168113e-08
of O 0 4.701518818706063e-08
the O 0 2.792889404190646e-07
first O 0 3.0856251669320045e-06
mutation O 0 8.744791557546705e-07
, O 0 6.812361874608541e-08
its O 0 1.1135819377727785e-08
time O 0 2.597034587381586e-08
in O 0 4.625583471806749e-08
development O 0 6.47552838017873e-08
, O 0 2.1615682044284767e-07
and O 0 9.295353464722211e-08
the O 0 3.5339780879439786e-08
number O 0 6.770108740283831e-08
and O 0 1.3076561344860238e-07
types O 0 1.4499177325433266e-07
of O 0 1.2967376505912398e-07
cells O 0 2.3311804397962987e-06
that O 0 5.8171504946358255e-08
are O 0 6.031631727410058e-08
affected O 0 2.058295223150708e-07
. O 0 1.77484395180727e-07
. O 0 1.7921003063747776e-06

Hereditary B-Disease 1 0.9999189376831055
deficiency I-Disease 1 0.9994705319404602
of I-Disease 0 1.2478948292482528e-06
the I-Disease 0 4.070393799793237e-07
fifth I-Disease 0 6.16440229350701e-05
component I-Disease 0 1.452198603146826e-06
of I-Disease 0 5.920015766491815e-08
complement I-Disease 0 1.2202970083308173e-06
in O 0 3.1884755458122527e-07
man O 0 8.843209798214957e-05
. O 0 4.278033429727657e-06

I O 0 0.0007709328201599419
. O 0 6.688814028166234e-05

Clinical O 0 0.0030219878535717726
, O 0 4.30578802479431e-05
immunochemical O 0 0.15886709094047546
, O 0 4.21853837906383e-06
and O 0 2.529398443584796e-06
family O 0 8.216733476729132e-06
studies O 0 2.4657606445543934e-06
. O 0 4.615053512679879e-06

The O 0 5.561775651585776e-06
first O 0 1.5176589840848465e-05
recognized O 0 1.5273843018803746e-05
human O 0 8.009480552573223e-06
kindred O 0 0.0026472192257642746
with O 0 0.00682395463809371
hereditary B-Disease 1 0.9999686479568481
deficiency I-Disease 1 0.9803896546363831
of I-Disease 0 4.307100596179225e-07
the I-Disease 0 9.293161156165297e-07
fifth I-Disease 0 0.0003480248269625008
component I-Disease 0 1.6117118093461613e-06
of I-Disease 0 1.293775397925856e-07
complement I-Disease 0 3.197429577994626e-06
( O 0 6.894866260154231e-07
C5 O 0 0.00341400015167892
) O 0 6.324599439722078e-07
is O 0 3.0497648140226374e-07
described O 0 2.176221642002929e-05
. O 0 3.831066351267509e-06

The O 0 5.864922513865167e-06
proband O 0 0.0008585102623328567
, O 0 7.973408742145693e-07
a O 0 2.0114931942316616e-07
20 O 0 6.894957778058597e-07
- O 0 0.00020396866602823138
year O 0 7.329185336857336e-06
- O 0 0.0022226611617952585
old O 0 0.006190698128193617
black O 0 0.003953395411372185
female O 0 0.00041731615783646703
with O 0 0.03212468698620796
systemic B-Disease 1 0.9999973773956299
lupus I-Disease 1 0.9999904632568359
erythematosus I-Disease 1 0.999993085861206
since O 0 0.0010710896458476782
age O 0 0.0001408002426614985
11 O 0 2.088296241709031e-05
, O 0 5.141921064932831e-06
lacked O 0 7.375411951215938e-05
serum O 0 0.002333997515961528
hemolytic O 0 0.026322323828935623
complement O 0 2.8418239139682555e-07
activity O 0 7.800451840012101e-08
, O 0 6.824118514714428e-08
even O 0 6.115630668546146e-08
during O 0 1.9943377083109226e-06
remission O 0 0.00013144288095645607
. O 0 4.607410119206179e-06

C5 O 0 0.24949714541435242
was O 0 0.0016779517754912376
undetectable O 0 0.002598716178908944
in O 0 5.088957664156624e-07
her O 0 1.3695042753170128e-06
serum O 0 4.311659722588956e-06
by O 0 3.8656526868408037e-08
both O 0 2.6161862365370325e-07
immunodiffusion O 0 0.003066616365686059
and O 0 6.847914482932538e-05
hemolytic O 1 0.7518841624259949
assays O 0 9.604488150216639e-05
. O 0 5.104461251903558e-06

Other O 0 7.422261205647374e-07
complement O 0 5.66555684144987e-07
components O 0 3.1436823064723285e-06
were O 0 4.5674494231207063e-07
normal O 0 4.9132228951975776e-08
during O 0 3.6404190950634074e-07
remission O 0 8.29105465527391e-06
of O 0 4.05769560529734e-06
lupus O 1 0.9156466722488403
, O 0 1.7356317130179377e-06
but O 0 4.876722528024402e-07
C1 O 0 0.00256136991083622
, O 0 8.83589962086262e-07
C4 O 0 0.014979484491050243
, O 0 2.66611232291325e-06
C2 O 0 0.003153496654704213
, O 0 3.4926401326629275e-07
and O 0 6.028544703440275e-07
C3 O 0 0.027945872396230698
levels O 0 2.9444959182001185e-06
fell O 0 0.0003097074222750962
during O 0 3.5938203382102074e-06
exacerbations O 0 0.003333749482408166
. O 0 5.140122084412724e-06

A O 0 0.00010067826951853931
younger O 0 7.569766603410244e-05
half O 0 8.282244380097836e-06
- O 0 0.008962343446910381
sister O 0 0.002136529888957739
, O 0 3.72586782759754e-06
who O 0 3.1951629352988675e-05
had O 0 7.792942051310092e-05
no O 0 6.974004463700112e-06
underlying O 0 0.11772548407316208
disease O 0 0.00434619328007102
, O 0 2.4016549104999285e-06
was O 0 0.0008533404325135052
also O 0 4.648283265851205e-06
found O 0 5.025583959650248e-06
to O 0 4.883619908468972e-07
lack O 0 2.258772610730375e-06
immunochemically O 0 0.0009676329791545868
detectable O 0 0.00013370464148465544
C5 O 0 0.0007449888507835567
. O 0 4.594339316099649e-06

By O 0 0.0005027285660617054
hemolytic O 1 0.9984221458435059
assay O 0 0.002961651189252734
, O 0 2.3628319468116388e-05
she O 0 3.8455702451756224e-05
exhibited O 0 3.283968544565141e-05
1 O 0 2.0766269699379336e-06
- O 0 0.0006976184085942805
2 O 0 1.171408143818553e-06
% O 0 1.4827149286134045e-08
of O 0 1.8358558007136594e-09
the O 0 1.400735882839399e-08
normal O 0 3.801136827519258e-08
serum O 0 1.9508611330820713e-06
C5 O 0 3.31285955326166e-05
level O 0 2.224790023319656e-07
and O 0 4.0363758557759866e-08
normal O 0 9.34537514041267e-09
concentrations O 0 7.146051217432614e-08
of O 0 1.8874781737565627e-09
other O 0 1.1377003339418934e-08
complement O 0 3.5341170701030933e-07
components O 0 2.91832911898382e-05
. O 0 4.606944912666222e-06

C5 O 0 0.008490178734064102
levels O 0 1.544471706438344e-05
of O 0 3.105061807673337e-07
other O 0 5.461877776724577e-07
family O 0 5.777592832600931e-06
members O 0 3.4826322803382936e-07
were O 0 3.2328327392860956e-07
either O 0 1.2636914625829831e-08
normal O 0 1.546739625268856e-08
or O 0 1.2639637780864632e-08
approximately O 0 5.745530984313518e-08
half O 0 2.0936945475114044e-06
- O 0 0.0038534116465598345
normal O 0 7.419487246806966e-07
, O 0 2.441504136641015e-07
consistent O 0 3.8475945984828286e-07
with O 0 2.2572482976102037e-06
autosomal O 0 0.0021340521052479744
codominant O 0 0.008636420592665672
inheritance O 0 1.799678102543112e-05
of O 0 7.212298669401207e-08
the O 0 1.2471215313780704e-06
gene O 0 1.3424350981949829e-05
determining O 0 0.0012785125290974975
C5 B-Disease 1 0.9999828338623047
deficiency I-Disease 1 0.9999226331710815
. O 0 4.483516022446565e-05

Normal O 0 0.007425307296216488
hemolytic O 1 0.9982946515083313
titers O 0 0.2948870062828064
were O 0 1.3786053386866115e-05
restored O 0 9.72627731243847e-06
to O 0 5.573977190920232e-08
both O 0 7.230203777908173e-07
homozygous O 0 0.0015266052214428782
C5 B-Disease 1 0.999976634979248
- I-Disease 1 0.9999767541885376
deficient I-Disease 1 0.9999778270721436
( O 0 2.8512527933344245e-05
C5D B-Disease 1 0.9999617338180542
) O 0 1.3608593008029857e-06
sera O 0 7.421479040203849e-06
by O 0 3.1941937095325557e-08
addition O 0 4.2948812506438117e-08
of O 0 3.514994162401308e-08
highly O 0 2.5891513359965757e-06
purified O 0 2.5952426767617e-06
human O 0 1.5414656218126765e-06
C5 O 0 0.0006494350964203477
. O 0 4.5311549001780804e-06

In O 0 2.4623016088298755e-06
specific O 0 5.852317599419621e-07
C5 O 0 0.016294268891215324
titrations O 0 0.21779309213161469
, O 0 1.0357256542192772e-05
however O 0 1.3418582511803834e-06
, O 0 2.6985739509655104e-07
it O 0 9.206407725059762e-08
was O 0 9.81531193247065e-05
noted O 0 3.872110028169118e-06
that O 0 2.4221387562306518e-08
when O 0 7.274135782608937e-08
limited O 0 3.879672405560086e-08
amounts O 0 1.3602576842686176e-08
of O 0 2.3474786559063432e-08
C5 O 0 0.0012713221367448568
were O 0 2.481911906215828e-06
assayed O 0 8.835495464154519e-06
in O 0 2.5719433693893734e-08
the O 0 3.3323246384497907e-08
presence O 0 3.339858878348423e-08
of O 0 9.389148125649172e-09
low O 0 1.9017369368157233e-06
dilutions O 0 8.044694368436467e-06
of O 0 4.067871017809921e-08
either O 0 2.748902716120938e-06
C5D B-Disease 1 0.9994638562202454
serum O 0 8.126923785312101e-05
, O 0 4.762867433782958e-08
curving O 0 3.358224489602435e-07
rather O 0 1.7224875747956503e-08
than O 0 2.8247419958660203e-09
linear O 0 1.002802108018841e-07
dose O 0 8.294624649352045e-07
- O 0 5.365113338484662e-06
response O 0 2.3858927278297415e-08
plots O 0 3.662929870529297e-08
were O 0 5.085333896204247e-07
consistently O 0 1.5408792251037084e-06
obtained O 0 2.76230821327772e-07
, O 0 9.291844094150292e-08
suggesting O 0 4.959031230100663e-07
some O 0 1.16237650615858e-08
inhibitory O 0 1.0621763976814691e-05
effect O 0 1.5275471696440945e-06
. O 0 1.2162585107944324e-06

Further O 0 4.430016815604176e-06
studies O 0 1.9225949472456705e-06
suggested O 0 2.2381532289728057e-06
that O 0 4.849003332196844e-08
low O 0 2.9897498734499095e-06
dilutions O 0 5.2187526307534426e-05
of O 0 2.004531552302069e-06
C5D B-Disease 1 0.9999110698699951
serum O 0 0.00011408679711166769
contain O 0 4.6984712298581144e-07
a O 0 1.0419772706882213e-06
factor O 0 2.352286628592992e-06
( O 0 4.990347335365186e-08
or O 0 1.1357559515090543e-07
factors O 0 3.1777597087057075e-07
) O 0 2.7086960230349177e-08
interfering O 0 5.896361585655541e-07
at O 0 4.279695815512241e-07
some O 0 8.35070590454734e-09
step O 0 3.408442239560827e-07
in O 0 1.0398574801229188e-07
the O 0 3.133562358925701e-06
hemolytic O 0 0.1101345345377922
assay O 0 3.7421739307319513e-06
of O 0 2.1354441059884266e-07
C5 O 0 0.023913564160466194
, O 0 2.9099120979481086e-07
rather O 0 9.76767644544907e-09
than O 0 5.904586153349101e-09
a O 0 7.768129250962374e-08
true O 0 7.877998200456204e-07
C5 O 0 0.0036518133711069822
inhibitor O 0 0.00012819301628042012
or O 0 2.51528558692371e-06
inactivator O 0 0.0011246770154684782
. O 0 6.201346423040377e-06

Of O 0 1.2189630069769919e-05
clinical O 0 0.0014277282170951366
interest O 0 7.693027146160603e-05
are O 0 9.913381973092328e-07
( O 0 1.7866638302166393e-07
a O 0 1.4655562381449272e-06
) O 0 3.507459567231308e-08
the O 0 3.5009364296456624e-08
documentation O 0 1.6975650396489073e-06
of O 0 2.576304723334033e-05
membranous O 1 0.9889206290245056
glomerulonephritis B-Disease 1 0.9999935626983643
, O 0 0.19660580158233643
vasculitis B-Disease 1 0.9999936819076538
, O 0 0.008673976175487041
and O 1 0.698441743850708
arthritis B-Disease 1 0.9999995231628418
in O 0 4.860225999436807e-06
an O 0 2.570531933088205e-06
individual O 0 1.3407939150056336e-06
lacking O 0 2.1312465833034366e-05
C5 O 0 0.08566154539585114
( O 0 1.6483458864513523e-07
and O 0 2.1175068809498043e-07
its O 0 6.67392541231493e-08
biologic O 0 1.568814150232356e-05
functions O 0 2.541256982624418e-08
) O 0 3.494711720009036e-08
, O 0 7.035356475171284e-08
and O 0 2.7009838277081144e-07
( O 0 1.228886219450942e-07
b O 0 3.5161588129994925e-06
) O 0 1.4279352811286117e-08
a O 0 2.3246172986546298e-07
remarkable O 0 5.2439008868532255e-06
propensity O 0 0.0018611999694257975
to O 0 4.322251697885804e-05
bacterial B-Disease 1 0.9986722469329834
infections I-Disease 1 0.9849430322647095
in O 0 1.4709469553508825e-07
the O 0 8.228003025578801e-07
proband O 0 0.008514881134033203
, O 0 6.510489356514881e-07
even O 0 3.947110016611077e-08
during O 0 4.4030507240222505e-08
periods O 0 1.719710418512932e-08
of O 0 5.375471801016829e-08
low O 0 2.195813794969581e-05
- O 0 0.00011060779070248827
dose O 0 2.6062949132210633e-07
or O 0 5.529753543953575e-09
alternate O 0 1.7942973329354572e-08
- O 0 1.2048376447637565e-05
day O 0 5.744419468101114e-06
corticosteroid O 0 0.00048754888121038675
therapy O 0 1.2797099770978093e-05
. O 0 1.6611770661256742e-06

Other O 0 8.670287456880033e-07
observations O 0 2.0006525573990075e-06
indicate O 0 1.991764293052256e-06
that O 0 9.294537761661559e-08
the O 0 1.189199338114122e-06
C5D B-Disease 1 0.9998842477798462
state O 0 3.0184389743226347e-06
is O 0 6.044657396842013e-08
compatible O 0 2.889542258799338e-07
with O 0 3.671032686725084e-07
normal O 0 1.8161793491344724e-07
coagulation O 0 1.1064513273595367e-05
function O 0 4.913785289772932e-08
and O 0 4.250564344943086e-08
the O 0 2.813022526026998e-08
capacity O 0 3.4710996033027186e-07
to O 0 2.1457037036043403e-08
mount O 0 7.067074875521939e-06
a O 0 1.0185770406678785e-05
neutrophilic O 1 0.5766147971153259
leukocytosis O 1 0.6397958397865295
during O 0 0.00031761080026626587
pyogenic B-Disease 1 0.907599687576294
infection I-Disease 0 0.006103275343775749
. O 0 5.865973662366741e-07
. O 0 4.050643383379793e-06

Susceptibility O 1 0.5825852155685425
to O 0 0.017509737983345985
ankylosing B-Disease 1 0.9999932050704956
spondylitis I-Disease 1 0.999998927116394
in O 0 0.020442573353648186
twins O 0 0.3799222707748413
: O 0 2.770021581000037e-07
the O 0 1.0740617284454856e-07
role O 0 3.7271152564244403e-07
of O 0 9.303689552098149e-08
genes O 0 7.19601530363434e-07
, O 0 9.242173177881341e-07
HLA O 0 0.00018271661247126758
, O 0 2.3856838993197016e-07
and O 0 1.4803306669364247e-07
the O 0 4.961656259183655e-07
environment O 0 1.3973349268781021e-05
. O 0 3.2892069157242076e-06

OBJECTIVE O 0 1.384238748869393e-05
To O 0 3.1419421020473237e-07
determine O 0 2.99558990946025e-07
the O 0 1.836725829207353e-07
relative O 0 4.75226897833636e-06
effects O 0 1.6492764416398131e-06
of O 0 1.282572839045315e-07
genetic O 0 1.502322902524611e-05
and O 0 6.11001541983569e-06
environmental O 0 4.2061008571181446e-05
factors O 0 8.383567546843551e-07
in O 0 2.1134144390089205e-06
susceptibility O 0 0.03119194507598877
to O 0 0.014839021489024162
ankylosing B-Disease 1 0.999998927116394
spondylitis I-Disease 1 0.9999997615814209
( O 0 0.0018100275192409754
AS B-Disease 1 0.6069732308387756
) O 0 7.850924703234341e-06
. O 0 5.5806003729230724e-06

METHODS O 0 0.00017753796419128776
Twins O 0 0.02463202178478241
with O 0 1.1313413779134862e-05
AS B-Disease 0 0.029085436835885048
were O 0 3.3605483622523025e-06
identified O 0 2.6652123779058456e-06
from O 0 6.980805977718774e-08
the O 0 4.0602787976240506e-07
Royal O 0 0.00041738615254871547
National O 0 0.0020877306815236807
Hospital O 0 0.01228635199368
for O 0 0.0016703724395483732
Rheumatic B-Disease 1 0.9997921586036682
Diseases I-Disease 0 0.024863915517926216
database O 0 6.364715954987332e-05
. O 0 4.909813651465811e-05

Clinical O 0 0.0012074146652594209
and O 0 8.931599950301461e-06
radiographic O 0 0.002367729786783457
examinations O 0 3.513354386086576e-05
were O 0 4.60423007098143e-06
performed O 0 1.0168386097575421e-06
to O 0 1.3139037946530152e-07
establish O 0 1.7556503735249862e-06
diagnoses O 0 0.003273447509855032
, O 0 3.602469587349333e-05
and O 0 0.003536852076649666
disease O 0 0.20558658242225647
severity O 0 0.0027173336129635572
was O 0 0.006161527242511511
assessed O 0 7.185951108112931e-05
using O 0 6.265717615860922e-07
a O 0 6.89146077093028e-07
combination O 0 4.5342483190324856e-07
of O 0 5.107492029310379e-08
validated O 0 5.139151198818581e-06
scoring O 0 5.997405878588324e-06
systems O 0 7.355218986049294e-05
. O 0 7.568805813207291e-06

HLA O 0 0.003795444965362549
typing O 0 0.00011085614823969081
for O 0 3.744565901797614e-06
HLA O 0 0.0013548240531235933
- O 0 0.0012758651282638311
B27 O 0 5.461582986754365e-05
, O 0 3.996464670308342e-07
HLA O 0 5.172412420506589e-05
- O 0 0.00011352304136380553
B60 O 0 1.492428327765083e-05
, O 0 9.306103265771526e-08
and O 0 1.9653055005619535e-07
HLA O 0 0.0002868130395654589
- O 0 0.003114802995696664
DR1 O 0 0.030226396396756172
was O 0 1.955650304807932e-06
performed O 0 7.983393146560047e-08
by O 0 1.2311848429646943e-08
polymerase O 0 6.931410553079331e-06
chain O 0 7.527271463914076e-06
reaction O 0 1.304464536389105e-08
with O 0 3.861928998816211e-09
sequence O 0 1.0845747411281081e-08
- O 0 3.5202351682528388e-06
specific O 0 7.0352061953826706e-09
primers O 0 7.398652996926103e-06
, O 0 2.7400145086176053e-07
and O 0 5.475453122016916e-07
zygosity O 0 0.0007025770028121769
was O 0 9.931332897394896e-06
assessed O 0 4.027320301247528e-06
using O 0 4.935538981953869e-07
microsatellite O 0 0.001652938430197537
markers O 0 0.0010700010461732745
. O 0 6.6680481722869445e-06

Genetic O 0 0.0018263887614011765
and O 0 5.412114205682883e-06
environmental O 0 7.963332791405264e-06
variance O 0 2.262900835603432e-07
components O 0 1.0733469935075846e-05
were O 0 9.707162462291308e-06
assessed O 0 6.198088522069156e-05
with O 0 2.7337449637343525e-07
the O 0 1.9030636622119346e-07
program O 0 2.622906265514757e-07
Mx O 0 1.6507085092598572e-05
, O 0 2.5274321302504177e-08
using O 0 4.717073842641639e-09
data O 0 5.823711646257834e-08
from O 0 2.535689169747002e-08
this O 0 3.254335467772762e-09
and O 0 4.851982637887886e-08
previous O 0 1.7996791257246514e-07
studies O 0 8.337691070892106e-08
of O 0 9.03893564441205e-08
twins O 0 0.0011367622064426541
with O 0 5.030628017266281e-06
AS B-Disease 0 0.11331107467412949
. O 0 1.9655784853966907e-05

RESULTS O 0 4.6624620154034346e-05
Six O 0 2.1138860120117897e-06
of O 0 2.3810652294287138e-07
8 O 0 1.4440792256209534e-05
monozygotic O 0 0.003759412094950676
( O 0 2.125726496160496e-06
MZ O 1 0.8345481753349304
) O 0 1.1375991562090348e-06
twin O 0 0.00037414123653434217
pairs O 0 6.026149640092626e-05
were O 0 0.001550512621179223
disease O 0 0.0009726843563839793
concordant O 0 0.0003442494198679924
, O 0 1.830961309678969e-06
compared O 0 7.719571840425488e-06
with O 0 2.0120438648518757e-07
4 O 0 4.4260204390411673e-07
of O 0 5.91518514170275e-08
15 O 0 1.2062009773217142e-06
B27 O 0 1.0075170393974986e-05
- O 0 2.5116774850175716e-05
positive O 0 1.728489849028847e-07
dizygotic O 0 2.1089903384563513e-05
( O 0 9.857610905328329e-08
DZ O 0 0.024318521842360497
) O 0 3.6604751585400663e-07
twin O 0 4.537311178864911e-05
pairs O 0 4.69283395432285e-06
( O 0 3.3447554415033665e-07
27 O 0 2.9767887099296786e-05
% O 0 2.3091592993296217e-07
) O 0 2.6816103115834267e-08
and O 0 3.392848668681836e-08
4 O 0 1.2977916696854663e-07
of O 0 9.952905344334795e-08
32 O 0 5.3831725381314754e-05
DZ O 0 0.30814364552497864
twin O 0 0.0006501766620203853
pairs O 0 5.5508867262688e-06
overall O 0 3.3910178899532184e-05
( O 0 1.0928167171186942e-07
12 O 0 6.740885396538943e-07
. O 0 4.28820996489776e-08
5 O 0 9.061149057743023e-07
% O 0 6.865170121272968e-07
) O 0 4.00031240133103e-07
. O 0 1.2933045354657224e-06

Nonsignificant O 0 0.07858521491289139
increases O 0 0.00025683152489364147
in O 0 5.398084681473847e-07
similarity O 0 9.301753038926108e-07
with O 0 3.044319214495772e-07
regard O 0 1.8622654351929668e-07
to O 0 1.0661058524874534e-07
age O 0 2.177961687266361e-05
at O 0 0.003578421426936984
disease O 0 0.019686797633767128
onset O 0 3.6654430005000904e-05
and O 0 1.0161038517253473e-06
all O 0 2.1225709190275666e-08
of O 0 1.6800136393158027e-07
the O 0 0.00013353227404877543
disease O 0 0.016081931069493294
severity O 0 9.081000462174416e-05
scores O 0 4.9285874410998076e-05
assessed O 0 0.003020379226654768
were O 0 1.6421761756646447e-05
noted O 0 4.346469359006733e-05
in O 0 1.3081055840302724e-05
disease O 0 0.006243978161364794
- O 0 0.006237223278731108
concordant O 0 0.03404056653380394
MZ O 1 0.9797582626342773
twins O 0 0.010773828253149986
compared O 0 2.181951276725158e-05
with O 0 5.546145985135809e-06
concordant O 0 0.029677551239728928
DZ O 1 0.9784677028656006
twins O 0 0.02365982159972191
. O 0 1.3720317838306073e-05

HLA O 0 0.12330997735261917
- O 0 0.03144965320825577
B27 O 0 0.0006105565698817372
and O 0 2.135866679964238e-06
B60 O 0 5.128468546899967e-05
were O 0 3.044704271815135e-06
associated O 0 7.719004315731581e-07
with O 0 7.188058930296393e-07
the O 0 4.5719581976300105e-05
disease O 0 0.006782269570976496
in O 0 2.355296828682185e-06
probands O 0 0.21256022155284882
, O 0 1.342972041129542e-06
and O 0 2.8074219926566e-07
the O 0 1.4565715389380784e-07
rate O 0 3.274603386671515e-06
of O 0 1.2177046073702513e-06
disease O 0 5.612375389318913e-05
concordance O 0 1.3277412108436693e-05
was O 0 0.00011437577632023022
significantly O 0 5.596280061581638e-06
increased O 0 1.7273574712817208e-06
among O 0 1.7548049981996883e-06
DZ O 0 0.3131520748138428
twin O 0 0.00023003402748145163
pairs O 0 2.65726839643321e-06
in O 0 8.001244822253284e-08
which O 0 1.511400142817365e-07
the O 0 9.217061460731202e-07
co O 0 0.02455119788646698
- O 0 0.012502296827733517
twin O 0 0.0030626393854618073
was O 0 2.684792343643494e-05
positive O 0 1.4077075505269931e-08
for O 0 8.746174451346178e-09
both O 0 5.6610740983842334e-08
B27 O 0 1.3049895642325282e-05
and O 0 4.10936900152592e-06
DR1 O 0 0.01018069963902235
. O 0 2.1344353626773227e-06

Additive O 0 7.323675527004525e-05
genetic O 0 0.0004493961750995368
effects O 0 0.00012968115333933383
were O 0 4.156750037509482e-06
estimated O 0 4.1486787267785985e-06
to O 0 4.7023078764141246e-08
contribute O 0 1.2046025688050577e-07
97 O 0 1.6787608956292388e-06
% O 0 2.3220199096840588e-08
of O 0 2.8117657091542014e-09
the O 0 3.849466168048821e-08
population O 0 8.188926869934221e-08
variance O 0 1.1342225434418651e-06
. O 0 2.6201062155450927e-06

CONCLUSION O 0 4.928136331727728e-05
Susceptibility O 0 0.001068438170477748
to O 0 2.6300704121240415e-06
AS B-Disease 0 0.007112687919288874
is O 0 2.7262339585831796e-07
largely O 0 1.49995878473419e-06
genetically O 0 2.2933912987355143e-05
determined O 0 6.687880613753805e-06
, O 0 4.675718798807793e-07
and O 0 3.7685111919927294e-07
the O 0 4.030537468224793e-07
environmental O 0 3.634408858488314e-05
trigger O 0 2.609246803331189e-05
for O 0 9.878914397631888e-07
the O 0 3.245676271035336e-05
disease O 0 0.0037081262562423944
is O 0 9.431714715901762e-07
probably O 0 6.6088491621485446e-06
ubiquitous O 0 9.409150516148657e-05
. O 0 9.575406693329569e-06

HLA O 0 0.092522531747818
- O 0 0.006058115977793932
B27 O 0 0.00012513545516412705
accounts O 0 7.405518545056111e-07
for O 0 4.606030046261367e-08
a O 0 2.83562684444405e-07
minority O 0 4.540795828233968e-07
of O 0 1.563387996839083e-08
the O 0 2.4297091272273974e-07
overall O 0 0.00013451065751723945
genetic O 0 0.0001456773024983704
susceptibility O 0 0.0001085833428078331
to O 0 1.180864614980237e-06
AS B-Disease 0 0.012899849563837051
. O 0 9.018526725412812e-06

Cell O 0 0.001010964740999043
cycle O 0 0.00013391314132604748
- O 0 0.003101266687735915
dependent O 0 6.561465852428228e-06
colocalization O 0 5.8600646298145875e-05
of O 0 2.0957710944458086e-07
BARD1 O 0 0.005012091714888811
and O 0 1.0837215995707083e-06
BRCA1 O 0 7.408043984469259e-06
proteins O 0 1.2528269088818433e-08
in O 0 5.690658166912499e-09
discrete O 0 4.779835762747098e-07
nuclear O 0 0.00046738237142562866
domains O 0 1.3432689229375683e-05
. O 0 5.238852281763684e-06

Germ O 0 0.052005864679813385
- O 0 0.0023473675828427076
line O 0 2.8339845812297426e-05
mutations O 0 2.8318941076577175e-06
of O 0 3.123678027350252e-08
the O 0 2.934072256266518e-07
BRCA1 O 0 0.0002637777361087501
gene O 0 1.0019949741035816e-06
predispose O 0 5.358394446375314e-06
women O 0 4.01868533117522e-07
to O 0 4.568878608779414e-08
early O 0 1.6724040960980346e-06
- O 0 0.1485927700996399
onset O 0 0.11941281706094742
breast B-Disease 1 0.9974724650382996
and I-Disease 1 0.9963322281837463
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999306201934814
by O 0 1.4709161177961505e-06
compromising O 0 6.019171996740624e-05
the O 0 6.654826165686245e-07
genes O 0 1.8188293324783444e-06
presumptive O 0 0.0035724909976124763
function O 0 1.2017042649858922e-07
as O 0 2.563300256497314e-07
a O 0 3.1990170100471005e-05
tumor B-Disease 0 0.07313795387744904
suppressor O 0 0.0010786517523229122
. O 0 1.1200617336726282e-05

Although O 0 7.649980034329928e-06
the O 0 2.890992334414477e-07
biochemical O 0 3.632451262092218e-05
properties O 0 1.6514815115442616e-06
of O 0 3.179551129051106e-07
BRCA1 O 0 0.00038208041223697364
polypeptides O 0 1.4784664926992264e-05
are O 0 3.175266272137378e-07
not O 0 2.667363503405795e-07
understood O 0 1.3102478533255635e-06
, O 0 6.170606781097376e-08
their O 0 2.2509953012672668e-08
expression O 0 1.0504085423690412e-07
pattern O 0 3.7071612268846366e-07
and O 0 1.669951643634704e-07
subcellular O 0 5.366797267924994e-06
localization O 0 1.9961526049883105e-05
suggest O 0 1.9036132243854809e-06
a O 0 6.91357854520902e-07
role O 0 1.061807211044652e-06
in O 0 1.2644923685911635e-07
cell O 0 6.048384966561571e-05
- O 0 0.00044601273839361966
cycle O 0 1.1158929737575818e-05
regulation O 0 8.038819032663014e-06
. O 0 2.630326207508915e-06

When O 0 0.00012296115164645016
resting O 0 0.020869499072432518
cells O 0 7.597051444463432e-05
are O 0 2.418815370219818e-07
induced O 0 3.161838685628027e-05
to O 0 1.7237192651009536e-07
proliferate O 0 2.548549855418969e-05
, O 0 5.5162725942636825e-08
the O 0 1.4631226896710814e-08
steady O 0 2.1230057427601423e-06
- O 0 7.771842319925781e-06
state O 0 4.5600156539649106e-08
levels O 0 1.2391878634332443e-08
of O 0 5.073284015111312e-09
BRCA1 O 0 3.7026493373559788e-06
increase O 0 6.999285062647687e-08
in O 0 3.275047788520169e-08
late O 0 1.2921419738631812e-06
G1 O 0 0.000338510813890025
and O 0 1.3584640612407384e-07
reach O 0 3.1666051114598304e-08
a O 0 1.4839994122439748e-08
maximum O 0 9.844815451742761e-08
during O 0 4.6185488145056297e-07
S O 0 0.00011327239917591214
phase O 0 3.5451421354082413e-06
. O 0 1.9602136944740778e-06

Moreover O 0 0.0001399391912855208
, O 0 1.4695590380142676e-06
in O 0 2.7867781682289205e-07
S O 0 0.0003163371002301574
phase O 0 9.941406460711733e-06
cells O 0 1.1615879884629976e-05
, O 0 4.939970494888257e-07
BRCA1 O 0 2.5828287107287906e-05
polypeptides O 0 1.039462176777306e-06
are O 0 2.093457318608216e-08
hyperphosphorylated O 0 2.9648785130120814e-05
and O 0 5.835264360598558e-08
accumulate O 0 4.450035362424387e-07
into O 0 5.747007758571954e-09
discrete O 0 4.2528432686594897e-07
subnuclear O 0 0.0003747502341866493
foci O 0 9.948201477527618e-05
termed O 0 5.39558932359796e-05
" O 0 1.608294155630574e-06
BRCA1 O 0 0.00012114304263377562
nuclear O 0 0.00013636023504659534
dots O 0 0.000237816377193667
. O 0 8.068565875873901e-06

" O 0 8.377604535780847e-05
BRCA1 O 0 0.006412896327674389
associates O 0 0.017214324325323105
in O 0 1.8350956452195533e-06
vivo O 0 6.502004544017836e-05
with O 0 5.658180839418492e-07
a O 0 4.827110387850553e-06
structurally O 0 0.0007192148477770388
related O 0 2.0364541342132725e-05
protein O 0 7.114239906513831e-06
termed O 0 0.00011889585584867746
BARD1 O 0 0.007682316470891237
. O 0 6.536060027428903e-06

Here O 0 7.183212801464833e-06
we O 0 9.790062449610559e-08
show O 0 6.319432799273272e-08
that O 0 4.1594137023537314e-09
the O 0 1.144451555745718e-08
steady O 0 3.5156360809196485e-06
- O 0 2.4442295398330316e-05
state O 0 8.645882587643428e-08
levels O 0 1.8412887214935836e-08
of O 0 2.270845023133461e-08
BARD1 O 0 0.0009145857766270638
, O 0 1.4385204849531874e-07
unlike O 0 3.456271002733047e-08
those O 0 4.183625446074757e-09
of O 0 8.84768951436854e-08
BRCA1 O 0 0.0004136939242016524
, O 0 1.167413415714691e-06
remain O 0 4.4712498947774293e-07
relatively O 0 4.004193598916572e-08
constant O 0 7.094661214068765e-08
during O 0 4.4658807496489317e-07
cell O 0 2.948389737866819e-05
cycle O 0 2.1151579858269542e-05
progression O 0 6.685694825137034e-05
. O 0 3.576891913326108e-06

However O 0 2.458062954246998e-05
, O 0 2.7901151042897254e-06
immunostaining O 0 0.0030196127481758595
revealed O 0 5.646259887726046e-05
that O 0 1.1746719508209935e-07
BARD1 O 0 0.0007585131679661572
resides O 0 3.6222800190444104e-06
within O 0 2.3589644015942213e-08
BRCA1 O 0 4.7756911953911185e-05
nuclear O 0 0.00023921039246488363
dots O 0 2.760796996881254e-05
during O 0 3.398241688046255e-06
S O 0 0.00023738820163998753
phase O 0 3.6354234111968253e-07
of O 0 4.879527537582362e-08
the O 0 3.1609724260306393e-07
cell O 0 7.673924847040325e-05
cycle O 0 7.968605132191442e-06
, O 0 8.530170703124895e-07
but O 0 6.418569853394729e-08
not O 0 4.487005433873037e-09
during O 0 3.594700004327933e-08
the O 0 1.2097912360786722e-07
G1 O 0 0.0012386527378112078
phase O 0 1.567910840094555e-05
. O 0 5.377176421461627e-06

Nevertheless O 0 0.00036700250348076224
, O 0 9.210776624968275e-06
BARD1 O 0 0.0016656399238854647
polypeptides O 0 1.2978901395399589e-05
are O 0 9.668865175171959e-08
found O 0 3.1970895975064195e-07
exclusively O 0 1.0429143770807059e-07
in O 0 1.3016758337869305e-08
the O 0 1.4610785470381416e-08
nuclear O 0 2.9287205052241916e-06
fractions O 0 2.578510560624636e-08
of O 0 8.809763585304609e-09
both O 0 3.3731424764482654e-08
G1 O 0 0.0002188258949900046
- O 0 4.731570152216591e-05
and O 0 1.1648231748040416e-06
S O 0 0.0009171291021630168
- O 0 8.452280599158257e-05
phase O 0 1.0998592188116163e-05
cells O 0 9.09697700990364e-06
. O 0 1.136728428718925e-06

Therefore O 0 1.18027746793814e-05
, O 0 5.419099124992499e-07
progression O 0 2.351252760490752e-06
to O 0 1.485584562033182e-07
S O 0 0.0007816755678504705
phase O 0 3.907968675775919e-06
is O 0 2.1453971044138598e-07
accompanied O 0 8.114047318485973e-07
by O 0 3.231771827927332e-08
the O 0 1.2204159460793562e-08
aggregation O 0 2.34376116736712e-07
of O 0 8.51655030942311e-08
nuclear O 0 0.0002236887376056984
BARD1 O 0 9.384330041939393e-05
polypeptides O 0 4.798584427589958e-07
into O 0 1.9198304812562128e-07
BRCA1 O 0 8.356772013939917e-05
nuclear O 0 8.450281893601641e-05
dots O 0 9.93564972304739e-05
. O 0 4.586490376823349e-06

This O 0 8.919045058064512e-07
cell O 0 5.1941413403255865e-05
cycle O 0 1.0683948858059011e-05
- O 0 0.001196892000734806
dependent O 0 5.176806098461384e-06
colocalization O 0 7.058176561258733e-05
of O 0 2.040128350699888e-07
BARD1 O 0 0.02607540227472782
and O 0 5.441950634121895e-06
BRCA1 O 0 5.9240108384983614e-05
indicates O 0 2.3231456225403235e-07
a O 0 5.434854344343876e-08
role O 0 1.3130569698205363e-07
for O 0 1.9121380034903268e-07
BARD1 O 0 0.0013020314509049058
in O 0 7.807595352460339e-07
BRCA1 O 0 0.0008565476164221764
- O 0 0.09683655947446823
mediated O 0 0.30301010608673096
tumor B-Disease 0 0.1952226459980011
suppression O 0 6.928972288733348e-05
. O 0 1.85500830411911e-05

Ethnic O 0 2.8754599043168128e-05
differences O 0 3.404548988328315e-05
in O 0 1.5829793653665547e-07
the O 0 2.2977209823693556e-07
HFE O 0 0.000550025433767587
codon O 0 1.3805656635668129e-05
282 O 0 0.0002002879191422835
( O 0 3.823383394774282e-06
Cys O 0 0.1434849351644516
/ O 0 0.0007861336343921721
Tyr O 0 0.014067455194890499
) O 0 9.878830269371974e-07
polymorphism O 0 0.00012085228809155524
. O 0 9.468996722716838e-06

Recent O 0 9.977891750168055e-05
studies O 0 1.6251868146355264e-05
have O 0 4.503789114096435e-06
shown O 0 1.1153228115290403e-05
that O 0 0.00034363463055342436
hereditary B-Disease 1 0.999998927116394
hemochromatosis I-Disease 1 1.0
( O 0 0.04075285792350769
HH B-Disease 1 0.9996747970581055
) O 0 2.0524184947134927e-05
is O 0 1.6965615259323386e-06
likely O 0 3.470259798632469e-06
to O 0 1.0969579022912512e-07
be O 0 2.3495799439388065e-07
caused O 0 1.0272522104060045e-06
by O 0 1.4693598870962887e-07
homozygosity O 0 0.0001430403790436685
for O 0 1.1182329728853801e-07
a O 0 8.556193620279373e-07
Cys282Tyr O 0 0.0003596428141463548
mutation O 0 4.2930631138915487e-07
in O 0 1.7878816649385953e-08
the O 0 2.652776629474829e-07
HFE O 0 0.0014110946794971824
gene O 0 3.701999560234981e-07
located O 0 3.757124886760721e-07
4 O 0 5.887034603802022e-06
. O 0 4.7519238250970375e-06

5 O 0 2.4860219127731398e-05
Mb O 0 0.0003670091391541064
telomeric O 0 0.0015396499074995518
to O 0 4.539735982689308e-06
HLA O 0 0.001723320921882987
- O 0 0.0007736439583823085
A O 0 2.0320003386586905e-05
. O 0 7.050481144688092e-06

Population O 0 5.257335487840464e-06
studies O 0 9.916747103488888e-07
of O 0 1.2350589884135843e-07
this O 0 1.9705073128761796e-08
polymorphism O 0 5.6376618886133656e-05
are O 0 5.7031790845485375e-08
facilitated O 0 9.275098591388087e-07
by O 0 2.770465243884246e-07
the O 0 1.3175376523122395e-07
fact O 0 2.1512896353215183e-07
that O 0 2.3300412266280546e-08
the O 0 9.318323890283864e-08
Cys282Tyr O 0 0.00038255169056355953
mutation O 0 2.9459984034474473e-06
creates O 0 1.0935565342151676e-06
a O 0 1.3434178072202485e-06
Rsal O 0 0.0005181431770324707
restriction O 0 2.008211140491767e-06
site O 0 3.1979725463315845e-06
. O 0 1.8311480971533456e-06

We O 0 3.644925300250179e-06
have O 0 1.4224799826934031e-07
studied O 0 6.816794240194213e-08
the O 0 7.625450493264907e-09
codon O 0 4.753039206661924e-07
282 O 0 2.529127596062608e-05
( O 0 4.4029795276401273e-07
Cys O 0 0.003014426212757826
/ O 0 3.5159253457095474e-05
Tyr O 0 0.0006454074173234403
) O 0 5.975294925519847e-08
polymorphism O 0 2.0260840756236576e-06
in O 0 9.457843397342458e-09
different O 0 3.207201615396116e-09
ethnic O 0 4.1494959646115603e-07
groups O 0 1.855169330156059e-06
. O 0 4.309365976951085e-06

In O 0 9.10240942175733e-06
agreement O 0 2.6006093776231864e-06
with O 0 1.6323036788890022e-07
previous O 0 2.8053452183485206e-07
observations O 0 2.6787662932292733e-07
the O 0 2.737068598435144e-07
Tyr O 0 0.0006197772454470396
allele O 0 4.267455096851336e-06
appeared O 0 4.166008693573531e-06
to O 0 1.1055214343969055e-07
be O 0 2.0036893033648084e-07
rare O 0 1.5526535435128608e-06
or O 0 7.210152830339212e-07
absent O 0 1.2359300853859168e-05
in O 0 4.78131312320329e-07
Asiatic O 0 0.0015479825669899583
( O 0 3.053431782973348e-07
Indian O 0 6.097587174735963e-06
, O 0 1.367823898590359e-07
Chinese O 0 2.030453849499736e-08
) O 0 4.85537050565199e-08
populations O 0 3.465331417373818e-07
. O 0 5.023212565902213e-07

The O 0 1.1946999620704446e-06
highest O 0 1.5753961633890867e-05
allele O 0 2.134382157237269e-06
frequency O 0 3.9116125094551535e-07
( O 0 4.3936882576645075e-08
7 O 0 2.6414267040308914e-07
. O 0 1.8219834529986656e-08
5 O 0 3.7212478787296277e-07
% O 0 8.451030453215935e-08
) O 0 5.160851301866387e-08
was O 0 2.865100668714149e-06
found O 0 7.780806186019618e-07
in O 0 5.608823698821652e-07
Swedes O 0 0.00979833584278822
. O 0 8.745812010602094e-06

Saamis O 0 0.034165624529123306
( O 0 1.6756641798565397e-06
2 O 0 3.4246920677105663e-06
% O 0 5.813445795865846e-07
) O 0 5.4139650984552645e-08
and O 0 4.55707294122476e-07
Mordvinians O 0 0.00035812650457955897
( O 0 4.767893813095725e-08
1 O 0 8.593879385898617e-08
. O 0 1.4958898120198683e-08
8 O 0 2.1003049255341466e-07
% O 0 2.9401718393273768e-08
) O 0 1.728121468147492e-08
had O 0 3.861615027744847e-07
significantly O 0 1.6414874437487015e-07
lower O 0 1.882092846017258e-07
frequencies O 0 1.2153055450880856e-08
of O 0 1.172870423005179e-08
the O 0 3.8050396256039676e-07
Tyr O 0 0.0009605806553736329
allele O 0 6.175314410938881e-06
. O 0 1.6823862551973434e-06

Comparisons O 0 5.009075721318368e-06
with O 0 5.28313648828771e-07
allele O 0 6.850107752143231e-07
frequencies O 0 1.2075977906533808e-07
based O 0 2.926772424416413e-07
on O 0 2.060417727989261e-06
prevalence O 0 8.333035657415166e-05
estimates O 0 6.090166152716847e-06
of O 0 9.433216519028065e-07
HH B-Disease 1 0.965103268623352
showed O 0 0.005480512045323849
some O 0 4.9914895328129205e-08
disagreements O 0 3.1943636713549495e-06
with O 0 5.678496250993703e-08
the O 0 4.93027094705667e-08
RFLP O 0 2.9576209271908738e-05
data O 0 4.332936214268557e-07
, O 0 4.6732580472053087e-07
particularly O 0 2.9129162726349023e-07
in O 0 3.597149316192372e-07
Finns O 0 0.0009425293537788093
. O 0 6.041942015144741e-06

The O 0 1.2834595509048086e-05
newly O 0 0.0014622037997469306
described O 0 0.0008369659190066159
HFE O 0 0.08294650167226791
marker O 0 0.00012424633314367384
provides O 0 1.3200531157053774e-07
a O 0 5.557622557716968e-07
new O 0 9.628209909351426e-07
approach O 0 1.554111150880999e-07
to O 0 9.557692415285146e-09
the O 0 1.8422021241804032e-08
screening O 0 1.773676387983869e-07
of O 0 1.5570559241950832e-07
HH B-Disease 0 0.14800946414470673
as O 0 5.339074959920254e-07
well O 0 9.274739198872339e-08
as O 0 6.293991106076646e-08
studies O 0 1.6184854345624444e-08
of O 0 1.3445383473253969e-08
the O 0 2.84297584585147e-07
relationship O 0 7.183639354479965e-07
between O 0 1.571784338239013e-07
the O 0 3.1896329346636776e-06
HFE O 0 0.034319791942834854
Tyr O 0 0.0005463639390654862
allele O 0 1.53531402702356e-06
and O 0 5.079095899418462e-07
different O 0 7.37718153231981e-07
disorders O 0 0.31694597005844116
including O 0 0.008865072391927242
cancer B-Disease 1 0.9725395441055298

Autosomal B-Disease 1 0.9980255365371704
dominant I-Disease 1 0.9967663288116455
neurohypophyseal I-Disease 1 0.9998168349266052
diabetes I-Disease 1 0.9999716281890869
insipidus I-Disease 1 0.9995689988136292
associated O 0 0.0007188448798842728
with O 0 9.295182508139987e-07
a O 0 1.4128082739262027e-06
missense O 0 8.244839409599081e-05
mutation O 0 1.2138366400904488e-06
encoding O 0 4.1256473082285083e-07
Gly23 O 0 0.000465461693238467
- O 0 0.0012240828946232796
- O 0 0.0005531976348720491
> O 0 1.5261393855325878e-05
Val O 0 0.00016285671154037118
in O 0 5.002250418328913e-07
neurophysin O 0 0.0014242612523958087
II O 0 0.005762753542512655
. O 0 7.310811724892119e-06

Autosomal B-Disease 1 0.9960882663726807
dominant I-Disease 1 0.9902141690254211
neurohypophyseal I-Disease 1 0.9996705055236816
diabetes I-Disease 1 0.999950647354126
insipidus I-Disease 1 0.9987248778343201
( O 0 8.484347199555486e-05
ADNDI B-Disease 1 0.8393298387527466
) O 0 7.976717824931256e-06
is O 0 1.0201965778833255e-05
an O 0 0.24066545069217682
inherited B-Disease 1 0.9999997615814209
disease I-Disease 1 0.999998927116394
caused O 0 0.47209542989730835
by O 0 0.0002069532056339085
progressive O 0 0.24247170984745026
degeneration O 0 0.27606824040412903
of O 0 7.251707074829028e-07
the O 0 8.424265729445324e-07
magnocellular O 0 0.00011154772801091895
neurons O 0 1.6531093933735974e-06
of O 0 2.7200135477301046e-08
the O 0 1.7883851910482917e-07
hypothalamus O 0 3.8549846976820845e-06
leading O 0 1.132886427512858e-05
to O 0 1.5608144110501598e-07
decreased O 0 1.1210984666831791e-05
ability O 0 2.348530969698004e-08
to O 0 1.4863782427099181e-09
produce O 0 7.900155196693959e-09
the O 0 4.312686030516488e-08
hormone O 0 1.98342763724213e-06
arginine O 0 6.751231012458447e-06
vasopressin O 0 1.1283190360700246e-05
( O 0 2.2646624131539284e-07
AVP O 0 0.0005511697963811457
) O 0 6.93271942964202e-07
. O 0 1.7425345504307188e-06

Affected O 0 0.00022472382988780737
individuals O 0 4.067792815476423e-06
are O 0 3.7698089272453217e-07
not O 0 3.639072474470595e-07
symptomatic O 0 5.8028261264553294e-05
at O 0 2.414114169368986e-05
birth O 0 6.20564678683877e-05
, O 0 1.1344021686454653e-06
but O 0 7.712485512456624e-07
usually O 0 3.2757809549366357e-06
develop O 0 0.0001327449135715142
diabetes B-Disease 1 0.8175257444381714
insipidus I-Disease 0 0.012185060419142246
at O 0 9.196171959047206e-06
1 O 0 3.5539401324058417e-06
- O 0 0.0035985158756375313
6 O 0 4.941858787788078e-05
yr O 0 0.040143463760614395
of O 0 3.2668754101905506e-07
age O 0 1.9703438738361e-05
. O 0 2.229551000709762e-06

The O 0 2.992282816194347e-06
genetic O 0 2.896190926549025e-05
locus O 0 2.4450127966701984e-05
of O 0 1.7136943597506615e-06
the O 0 6.964102067286149e-05
disease O 0 0.010520604439079762
is O 0 4.185144462098833e-07
the O 0 1.6048744555519079e-06
AVP O 0 0.12431593239307404
- O 0 0.11703746765851974
neurophysin O 0 0.07206075638532639
II O 0 0.15550433099269867
( O 0 9.325921723757347e-07
NPII O 0 0.004233126994222403
) O 0 1.1007158207121392e-07
gene O 0 6.72676989665888e-08
, O 0 7.052930328654838e-08
and O 0 3.423616874442814e-07
mutations O 0 1.7084335013350938e-06
that O 0 1.1089083500337438e-06
cause O 0 3.238027056795545e-05
ADNDI B-Disease 0 0.3347287178039551
have O 0 4.608566086972132e-06
been O 0 2.9913298931205645e-06
found O 0 7.045372854008747e-07
in O 0 1.407761285321385e-08
both O 0 9.232693720662155e-09
the O 0 1.8776120214170078e-08
signal O 0 2.089153952056222e-07
peptide O 0 6.802611096645705e-08
of O 0 6.57446497243086e-09
the O 0 1.4205767229213961e-07
prepro O 0 0.00018572091357782483
- O 0 0.0003804840089287609
AVP O 0 0.0020981072448194027
- O 0 0.00042431530891917646
NPII O 0 0.0005855896743014455
precursor O 0 8.817027037366643e-07
and O 0 5.158223714829546e-08
within O 0 3.724645480929212e-08
NPII O 0 0.0010094685712829232
itself O 0 1.5581433672196e-06
. O 0 1.6446681456727674e-06

An O 0 3.289588130428456e-05
affected O 0 4.2983989260392264e-05
girl O 0 0.0037774816155433655
who O 0 2.4929733626777306e-05
presented O 0 1.5480522961297538e-06
at O 0 3.1793495054444065e-06
9 O 0 3.82047846869682e-06
months O 0 6.577364501936245e-07
of O 0 1.0814332540576288e-07
age O 0 2.2243018975132145e-05
and O 0 3.2602320061414503e-06
her O 0 6.163058969832491e-06
similarly O 0 1.8363125491305254e-05
affected O 0 2.1184976048971293e-06
younger O 0 7.077117516018916e-06
brother O 0 5.849294757354073e-05
and O 0 2.7219366529607214e-06
father O 0 0.00010116485645994544
were O 0 4.803190449820249e-07
all O 0 1.336831179088449e-08
found O 0 3.39446415864586e-07
to O 0 3.341884990959443e-08
have O 0 3.9255770190038675e-08
a O 0 5.0907434712144095e-08
novel O 0 1.1730961659850436e-06
missense O 0 6.216669135028496e-05
mutation O 0 3.3466042168583954e-06
( O 0 1.1133975874599855e-07
G1758 O 0 1.845821680035442e-05
- O 0 0.001760125276632607
- O 0 0.004058880731463432
> O 0 1.6831543689477257e-05
T O 0 0.0008048482704907656
) O 0 1.943497140999284e-09
encoding O 0 1.4376277945871152e-09
the O 0 2.8947528818434876e-09
amino O 0 4.7871939301558086e-08
acid O 0 1.0874419587025841e-07
substitution O 0 2.3235571688928758e-08
Gly23 O 0 1.2957592844031751e-05
- O 0 3.0640861950814724e-05
- O 0 3.6830180761171505e-05
> O 0 2.332341409783112e-06
Val O 0 2.7926498660235666e-05
within O 0 1.9912464210847247e-07
NPII O 0 0.0008523440919816494
. O 0 2.757888296400779e-06

The O 0 6.864862371003255e-06
mutation O 0 6.123067578300834e-05
was O 0 1.9794404579442926e-05
confirmed O 0 2.0431825760169886e-06
by O 0 1.733511538759558e-07
restriction O 0 8.164999485416047e-07
endonuclease O 0 9.368548489874229e-05
analysis O 0 3.633032520156121e-06
. O 0 6.087425390433054e-06

A O 0 0.0001004516743705608
T1 O 0 0.12708914279937744
- O 0 0.000768581114243716
weighted O 0 2.6080999305122532e-05
magnetic O 0 4.907565653411439e-06
resonance O 0 2.622111196615151e-06
imaging O 0 2.5184053811244667e-05
of O 0 1.4479348919849144e-07
the O 0 2.8806875889131334e-06
fathers O 0 0.0002842799003701657
pituitary O 0 0.034403398633003235
gland O 0 4.846445517614484e-05
demonstrates O 0 7.564004249616119e-07
an O 0 1.4382834478965378e-06
attenuated O 0 0.0009024104801937938
posterior O 0 0.013050445355474949
pituitary O 0 0.12231341749429703
bright O 0 0.0001478838676121086
spot O 0 4.3412583181634545e-05
. O 0 6.3169777604343835e-06

This O 0 4.068111138622044e-06
mutation O 0 0.00015872351650614291
may O 0 9.881449841486756e-06
be O 0 7.033651883148195e-08
valuable O 0 1.2684758132763818e-07
for O 0 2.5480618504047925e-08
developing O 0 2.7368963628759957e-07
models O 0 1.7524437225802103e-06
of O 0 6.021223271091003e-06
dominantly B-Disease 1 0.9905872941017151
inherited I-Disease 1 0.9998711347579956
neurodegeneration I-Disease 1 0.9999983310699463
, O 0 4.551829260890372e-05
as O 0 7.317524364225392e-07
the O 0 1.5388967256058095e-07
early O 0 8.285958870146715e-07
age O 0 2.1846558411198203e-06
of O 0 4.2902800601041235e-07
onset O 0 0.00018004084995482117
of O 0 3.177335747750476e-05
symptoms O 0 0.0018453897209838033
suggests O 0 2.4529733764211414e-06
that O 0 6.067366342676905e-08
this O 0 5.287914817131423e-08
mutation O 0 2.404581209702883e-05
may O 0 1.2761986909026746e-05
be O 0 1.9659147199035942e-07
particularly O 0 3.8956153503022506e-07
deleterious O 0 2.2096278371463995e-06
to O 0 1.3736274340203636e-08
the O 0 1.345627964610685e-07
magnocellular O 0 0.0003317656519357115
neuron O 0 0.0005337651236914098
. O 0 6.543267545566778e-07
. O 0 4.384594376460882e-06

Frequent O 0 8.056091610342264e-05
inactivation O 0 0.002252554753795266
of O 0 4.832688318856526e-06
PTEN O 0 0.049455676227808
/ O 0 0.00020285598293412477
MMAC1 O 0 0.13425706326961517
in O 0 4.929611532134004e-05
primary O 1 0.8172985315322876
prostate B-Disease 1 0.999992847442627
cancer I-Disease 1 0.9999451637268066
. O 0 0.00038829221739433706

Sporadic B-Disease 1 0.963019073009491
prostate I-Disease 1 0.9999773502349854
carcinoma I-Disease 1 0.9999971389770508
is O 0 0.0001261446886928752
the O 0 4.538853318081237e-06
most O 0 7.136841304600239e-06
common O 0 4.931539297103882e-05
male B-Disease 0 0.02459406852722168
cancer I-Disease 0 0.016711603850126266
in O 0 3.619920505570917e-07
the O 0 6.615568395318405e-07
Western O 0 2.2853155314805917e-06
world O 0 1.0250796549371444e-05
, O 0 7.796300565132697e-07
yet O 0 1.1105916541964689e-07
many O 0 3.6186240670588177e-09
of O 0 1.8366447918083395e-08
the O 0 2.7953436187999614e-07
major O 0 4.987819920643233e-06
genetic O 0 2.6177760901191505e-06
events O 0 9.331021999514633e-08
involved O 0 1.4246211321733426e-06
in O 0 1.34346862523671e-07
the O 0 2.5262519898205937e-07
progression O 0 3.818198365479475e-06
of O 0 1.6022929116843443e-07
this O 0 1.0799033134389902e-06
often O 0 0.0006611234275624156
fatal O 1 0.9987612962722778
cancer B-Disease 1 0.7742133140563965
remain O 0 5.46273440704681e-06
to O 0 3.153111265419284e-07
be O 0 1.4252367463996052e-06
elucidated O 0 0.00022083426301833242
. O 0 2.9892964903410757e-06

Numerous O 0 3.291332541266456e-05
cytogenetic O 0 0.023148760199546814
and O 0 6.815378583269194e-05
allelotype O 0 0.058467067778110504
studies O 0 1.0880537956836633e-05
have O 0 2.2106692085799295e-06
reported O 0 4.731213994091377e-05
frequent O 0 2.011387095990358e-06
loss O 0 0.0001116767234634608
of O 0 2.6726650048658485e-07
heterozygosity O 0 0.0014131765346974134
on O 0 2.247164593427442e-05
chromosomal O 0 0.34443458914756775
arm O 0 0.06076640635728836
10q O 0 0.00011827133130282164
in O 0 6.328687959467061e-06
sporadic B-Disease 0 0.1273096650838852
prostate I-Disease 1 0.9999918937683105
cancer I-Disease 1 0.9999157190322876
. O 0 0.00011106193414889276

Deletion O 0 0.0003418202686589211
mapping O 0 9.268660505767912e-05
studies O 0 2.2611417080042884e-05
have O 0 1.4713497193952207e-06
unambiguously O 0 8.454965427517891e-05
identified O 0 1.716256156214513e-05
a O 0 8.701632623342448e-07
region O 0 4.316768240641977e-07
of O 0 2.0398793765252776e-07
chromosome O 0 0.01002428773790598
10q23 O 0 4.790967795997858e-05
to O 0 1.1625620999211606e-07
be O 0 1.766978208195269e-08
the O 0 2.7187580187160165e-08
minimal O 0 7.45054308026738e-07
area O 0 5.57969883629994e-07
of O 0 9.452524523112515e-07
loss O 0 0.0047021107748150826
. O 0 1.1785362403315958e-05

A O 0 0.00010242518328595906
new O 0 0.0001252243819180876
tumor B-Disease 0 0.018385233357548714
suppressor O 0 0.00038988643791526556
gene O 0 3.4488903111196123e-06
, O 0 1.3359386912270566e-06
PTEN O 0 0.001558107091113925
/ O 0 5.196653364691883e-05
MMAC1 O 0 0.17441293597221375
, O 0 4.843480382987764e-06
was O 0 0.00032551094773225486
isolated O 0 1.2230430911586154e-05
recently O 0 6.781861156923696e-05
at O 0 1.5139607967284974e-06
this O 0 9.330147321406912e-09
region O 0 1.1749486361622985e-07
of O 0 2.640656191488233e-07
chromosome O 0 0.014060037210583687
10q23 O 0 0.00012557437003124505
and O 0 9.902939837047597e-07
found O 0 7.150904934860591e-07
to O 0 1.7556768483473206e-08
be O 0 2.8768656790134628e-08
inactivated O 0 5.078480853626388e-07
by O 0 1.0439846320764445e-08
mutation O 0 1.2349883604656497e-07
in O 0 2.3021274841994455e-07
three O 0 0.011963510885834694
prostate B-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999303817749023
cell O 0 0.0068236119113862514
lines O 0 0.0003577132592909038
. O 0 2.1149118765606545e-05

We O 0 3.9505516724602785e-06
screened O 0 0.00013393753033597022
80 O 0 0.001606167759746313
prostate B-Disease 1 0.9998887777328491
tumors I-Disease 1 0.9999562501907349
by O 0 2.518770770620904e-06
microsatellite O 0 0.0017672063549980521
analysis O 0 2.578678731879336e-06
and O 0 1.0943746019620448e-05
found O 0 8.729597175261006e-05
chromosome O 0 0.004249379970133305
10q23 O 0 5.559306009672582e-05
to O 0 6.237189609237248e-08
be O 0 3.482003663179967e-08
deleted O 0 3.7506239891627047e-07
in O 0 1.0244136916526259e-07
23 O 0 4.3881163946934976e-06
cases O 0 6.842535185569432e-06
. O 0 4.414577233546879e-06

We O 0 1.5052996786835138e-06
then O 0 2.1299567265486985e-07
proceeded O 0 2.643742789132375e-07
with O 0 4.637816797270489e-09
sequence O 0 2.234725515748437e-09
analysis O 0 2.4301987089359045e-09
of O 0 7.097636256503392e-09
the O 0 1.0950306261747755e-07
entire O 0 3.177940016030334e-06
PTEN O 0 0.0026538153178989887
/ O 0 5.19824197908747e-06
MMAC1 O 0 0.0007455851300619543
coding O 0 1.669721859798301e-05
region O 0 1.0987331506839837e-06
and O 0 4.597385157012468e-07
tested O 0 1.8362843547947705e-06
for O 0 5.3860429005681e-08
homozygous O 0 1.9348929072293686e-06
deletion O 0 1.1612694379437016e-06
with O 0 3.979714904289722e-07
new O 0 7.946271580294706e-06
intragenic O 0 0.0049810828641057014
markers O 0 1.620312104932964e-05
in O 0 9.28118097931474e-08
these O 0 1.5151981003214132e-08
23 O 0 7.583537353639258e-06
cases O 0 1.7313220723735867e-06
with O 0 1.2676621281570988e-06
10q23 O 0 0.00047080128570087254
loss O 0 0.00012164588406449184
of O 0 1.4015409988132888e-06
heterozygosity O 0 0.004694683477282524
. O 0 1.3164429219614249e-05

The O 0 9.720693014969584e-07
identification O 0 4.332729588440998e-07
of O 0 6.339085700801661e-08
the O 0 1.363095663009517e-07
second O 0 4.687953605753137e-06
mutational O 0 3.8727674109395593e-05
event O 0 3.784711452681222e-06
in O 0 1.3016787647757155e-07
10 O 0 2.120762587765057e-07
( O 0 7.827234327351107e-08
43 O 0 2.116663017659448e-05
% O 0 6.229650352906901e-06
) O 0 3.73055154341273e-05
tumors B-Disease 1 0.9996669292449951
establishes O 0 0.00023276516003534198
PTEN O 0 0.13711926341056824
/ O 0 4.952016388415359e-05
MMAC1 O 0 0.02671184204518795
as O 0 1.06914406217129e-07
a O 0 6.381764450225091e-08
main O 0 4.233213815041381e-07
inactivation O 0 0.0001247726468136534
target O 0 1.6328921503827587e-07
of O 0 2.557005274184121e-08
10q O 0 2.034811768680811e-05
loss O 0 1.8037659174297005e-05
in O 0 1.5822895420569694e-06
sporadic B-Disease 0 0.3680172860622406
prostate I-Disease 1 0.9999980926513672
cancer I-Disease 1 0.9999392032623291
. O 0 6.711379683110863e-06
. O 0 1.3449443031277042e-05

Risk O 0 0.0027485706377774477
reversals O 0 0.00024297994968947023
in O 0 8.155209911819838e-07
predictive O 0 3.1644420232623816e-05
testing O 0 6.462640158133581e-05
for O 0 0.0010694105876609683
Huntington B-Disease 1 0.9999829530715942
disease I-Disease 1 0.9997634291648865
. O 0 0.0001402849447913468

The O 0 8.774113098297676e-07
first O 0 4.5164503603700723e-07
predictive O 0 9.486765520705376e-06
testing O 0 3.987562013207935e-05
for O 0 0.004216969478875399
Huntington B-Disease 1 0.9999979734420776
disease I-Disease 1 0.9998906850814819
( O 0 5.866489118488971e-06
HD B-Disease 0 0.012596448883414268
) O 0 1.5805915154487593e-06
was O 0 8.473597517877351e-06
based O 0 1.946911964978426e-07
on O 0 2.770145783870248e-07
analysis O 0 4.7292019189626444e-08
of O 0 1.3772667273315164e-07
linked O 0 0.00013587351713795215
polymorphic O 0 2.2046451704227366e-05
DNA O 0 0.00014528776227962226
markers O 0 6.831320933997631e-05
to O 0 7.992489514663248e-08
estimate O 0 1.2178322776890127e-06
the O 0 7.83536009407726e-08
likelihood O 0 4.890890750175458e-07
of O 0 5.729007312993417e-08
inheriting O 0 1.3099670468363911e-05
the O 0 2.5024201022461057e-07
mutation O 0 5.480264348989294e-07
for O 0 3.167149316141149e-07
HD B-Disease 0 0.0004034598241560161
. O 0 4.3163131522305775e-06

Limits O 0 1.383886319672456e-05
to O 0 1.4992581043316022e-07
accuracy O 0 4.4996278347753105e-07
included O 0 1.69884629031003e-07
recombination O 0 7.42490897209791e-07
between O 0 9.6425843310044e-08
the O 0 2.0049547799771972e-07
DNA O 0 0.00039114514947868884
markers O 0 0.001015117741189897
and O 0 1.4399743122339714e-06
the O 0 5.548889134843193e-07
mutation O 0 1.0216725968348328e-05
, O 0 8.653774443700968e-07
pedigree O 0 7.381765317404643e-05
structure O 0 3.1985123314370867e-06
, O 0 1.4142248971893423e-07
and O 0 8.936237350098963e-08
whether O 0 3.3011872346833115e-08
DNA O 0 1.1938263924093917e-06
samples O 0 1.5848010548324964e-07
were O 0 1.8488995578991307e-07
available O 0 4.9477169028477874e-08
from O 0 4.014307251054561e-07
family O 0 6.3787556427996606e-06
members O 0 1.203039346364676e-06
. O 0 3.131548737655976e-06

With O 0 1.5110513231775258e-06
direct O 0 1.7917911065978842e-07
tests O 0 3.767393650377926e-07
for O 0 1.8061744100350552e-08
the O 0 9.65469411084996e-08
HD B-Disease 0 0.006769740954041481
mutation O 0 9.561509614286479e-06
, O 0 3.6604191677724884e-07
we O 0 5.167155237018051e-08
have O 0 1.1701135349539982e-07
assessed O 0 3.1317517823481467e-06
the O 0 4.5420822658570614e-08
accuracy O 0 5.300416887621395e-07
of O 0 2.812142696484443e-08
results O 0 2.3589987563354953e-07
obtained O 0 1.6929979551605356e-07
by O 0 2.890054062731906e-08
linkage O 0 7.667426871194039e-07
approaches O 0 4.95457300075941e-07
when O 0 1.1924995533263427e-06
requested O 0 5.696633138541074e-07
to O 0 2.3952718919417748e-08
do O 0 6.493050985767468e-09
so O 0 2.4757393912722137e-09
by O 0 3.3143023880910505e-09
the O 0 2.509289842578255e-08
test O 0 7.213611752376892e-07
individuals O 0 7.514223057114577e-07
. O 0 2.9789346172037767e-06

For O 0 2.122750629496295e-06
six O 0 5.045233592682052e-06
such O 0 3.195769409103377e-07
individuals O 0 1.1477500265755225e-06
, O 0 8.788014724814275e-07
there O 0 1.6258933044355217e-07
was O 0 7.404445932479575e-05
significant O 0 8.497466410517518e-07
disparity O 0 2.9806396923959255e-06
between O 0 5.7253043195260034e-08
the O 0 7.55031067001255e-07
tests O 0 1.0626789844536688e-05
. O 0 3.4248978408868425e-06

Three O 0 4.354923021310242e-06
went O 0 1.0364707122789696e-05
from O 0 3.697987551731785e-07
a O 0 3.0601299840782303e-06
decreased O 0 0.00020294477872084826
risk O 0 9.44298881222494e-06
to O 0 3.6838297745589443e-08
an O 0 6.343319682855508e-07
increased O 0 1.953240280272439e-05
risk O 0 2.1611656848108396e-05
, O 0 1.0699070429609492e-07
while O 0 1.2657689296702301e-07
in O 0 2.855140568414072e-09
another O 0 2.7809498703845748e-08
three O 0 8.625836045439428e-08
the O 0 1.7581687643541954e-06
risk O 0 0.00037019947194494307
was O 0 0.0005208750953897834
decreased O 0 0.0002979846321977675
. O 0 4.108832399651874e-06

Knowledge O 0 2.4740115804888774e-06
of O 0 4.2991186433027906e-07
the O 0 7.879614258854417e-07
potential O 0 1.204100226459559e-05
reasons O 0 1.0623202939541443e-07
for O 0 2.7577351957575047e-08
these O 0 5.171431283201855e-09
changes O 0 1.3542361898544186e-08
in O 0 3.835548056940752e-08
results O 0 9.127707016887143e-07
and O 0 9.55942482505634e-07
impact O 0 9.402374416822568e-07
of O 0 5.959213922324125e-08
these O 0 1.214615537037389e-07
risk O 0 7.928315426397603e-06
reversals O 0 2.7406065782997757e-05
on O 0 1.614360007806681e-05
both O 0 8.027527655940503e-06
patients O 0 1.2609038094524294e-05
and O 0 2.3889668909760076e-07
the O 0 2.3099038060081512e-07
counseling O 0 1.8256520206705318e-06
team O 0 8.594860219091061e-07
can O 0 8.871968937285146e-09
assist O 0 2.390893030224106e-07
in O 0 2.3339598698157715e-08
the O 0 2.9719203098466096e-08
development O 0 4.1934065109217045e-08
of O 0 4.040473911004483e-08
strategies O 0 1.0277519777446287e-06
for O 0 9.222875974046474e-08
the O 0 3.4424292039147986e-07
prevention O 0 1.0786604434542824e-05
and O 0 1.7519055290904362e-06
, O 0 6.904841711730114e-07
where O 0 2.94030741088136e-07
necessary O 0 6.934094898269905e-08
, O 0 1.724686171655776e-07
management O 0 2.4217604277509963e-07
of O 0 4.983565560223724e-08
a O 0 3.84910345019307e-05
risk O 0 0.00015511928359046578
reversal O 0 1.0456969903316349e-05
in O 0 3.2200507149582336e-08
any O 0 4.94590279842555e-09
predictive O 0 7.461763971150503e-07
testing O 0 4.387269711969566e-07
program O 0 2.1969022157009022e-07
. O 0 1.2575102914524905e-07
. O 0 1.2089660685887793e-06

A O 0 8.657259604660794e-05
novel O 0 9.707421668281313e-06
common O 0 2.7010917165171122e-06
missense O 0 0.00015169229300227016
mutation O 0 2.4282169761136174e-05
G301C O 0 1.1262271073064767e-05
in O 0 1.8819072522546776e-08
the O 0 1.2645224956031598e-07
N O 0 0.000715188100002706
- O 0 0.009716012515127659
acetylgalactosamine O 0 0.0009024475584737957
- O 0 0.00013282772852107882
6 O 0 9.527357178740203e-06
- O 0 0.00038992060581222177
sulfate O 0 4.280894427211024e-05
sulfatase O 0 4.3773594370577484e-05
gene O 0 1.4744159670954105e-07
in O 0 1.5330944336255925e-07
mucopolysaccharidosis B-Disease 0 0.0008848085999488831
IVA I-Disease 0 0.21379795670509338
. O 0 1.7607795598451048e-05

Mucopolysaccharidosis B-Disease 1 0.9544843435287476
IVA I-Disease 1 0.9981198906898499
( O 0 0.0036354910116642714
MPS B-Disease 1 0.9998562335968018
IVA I-Disease 1 0.9999868869781494
) O 0 0.00012229301501065493
is O 0 9.020917786983773e-06
an O 0 0.0007611574837937951
autosomal B-Disease 1 0.9963858127593994
recessive I-Disease 1 0.9991055130958557
lysosomal I-Disease 1 0.9999758005142212
storage I-Disease 1 0.9999842643737793
disorder I-Disease 1 0.9997966885566711
caused O 0 0.013222840614616871
by O 0 8.361101936316118e-05
a O 0 0.04053491726517677
genetic B-Disease 1 0.999861478805542
defect I-Disease 1 0.9996668100357056
in O 0 5.110744950798107e-06
N O 0 0.0034347805194556713
- O 0 0.003375675529241562
acetylgalactosamine O 0 0.0018236881587654352
- O 0 0.0007390558603219688
6 O 0 0.00011937433009734377
- O 0 0.11660517007112503
sulfate O 0 0.004879915155470371
sulfatase O 0 0.0016113650053739548
( O 0 1.1318929864501115e-06
GALNS O 0 0.0004941741935908794
) O 0 4.964595632372948e-07
. O 0 9.37737240747083e-07

In O 0 4.063872893311782e-06
previous O 0 6.802364623581525e-06
studies O 0 2.326645244465908e-06
, O 0 4.979940513294423e-07
we O 0 4.783451856837928e-08
have O 0 5.241752987217296e-08
found O 0 4.4775271135222283e-07
two O 0 1.1580462455640372e-07
common O 0 1.5927876120258588e-06
mutations O 0 2.1803680283483118e-06
in O 0 1.8231938270218961e-07
Caucasians O 0 3.4449916711309925e-05
and O 0 3.070068487431854e-06
Japanese O 0 2.895831858040765e-05
, O 0 1.6785254501883173e-06
respectively O 0 1.2289837286516558e-05
. O 0 2.4544733605580404e-06

To O 0 1.7689141031951294e-06
characterize O 0 7.666135388717521e-06
the O 0 2.3616142641458282e-07
mutational O 0 4.249753328622319e-05
spectrum O 0 4.369221187516814e-06
in O 0 4.623608163001336e-08
various O 0 6.37729646868479e-09
ethnic O 0 1.2362021095668752e-07
groups O 0 1.8069829366140766e-07
, O 0 3.125326202280121e-07
mutations O 0 7.689798167120898e-07
in O 0 2.581985114602503e-08
the O 0 2.6644650574780826e-07
GALNS O 0 0.0010791091481223702
gene O 0 1.6475348729727557e-07
in O 0 1.0431092789531249e-07
Colombian O 0 0.000550727650988847
MPS B-Disease 1 0.9996703863143921
IVA I-Disease 1 0.9999934434890747
patients O 0 0.004746925085783005
were O 0 1.4113516954239458e-05
investigated O 0 0.0013509077252820134
, O 0 2.7594510356721003e-06
and O 0 2.108449962179293e-06
genetic O 0 2.2520489437738433e-06
backgrounds O 0 2.802002427415573e-06
were O 0 6.118190412962576e-06
extensively O 0 5.442091151053319e-06
analyzed O 0 8.963658729044255e-06
to O 0 1.0211052625663797e-07
identify O 0 2.8808966590077034e-07
racial O 0 5.706540378014324e-07
origin O 0 1.1106081956313574e-06
, O 0 3.439836575580557e-07
based O 0 4.833499360756832e-07
on O 0 1.1568159834496328e-06
mitochondrial O 0 1.7504760762676597e-05
DNA O 0 4.6428769564954564e-05
( O 0 1.9398636652567802e-07
mtDNA O 0 5.767572019976797e-07
) O 0 1.3376262586461962e-07
lineages O 0 1.5034260059110238e-06
. O 0 1.3273879631015006e-06

Three O 0 4.699565124610672e-06
novel O 0 1.0664384717529174e-05
missense O 0 0.0017225686460733414
mutations O 0 0.0004907270194962621
never O 0 1.9692392015713267e-05
identified O 0 1.7931937691173516e-05
previously O 0 1.534440161776729e-05
in O 0 1.6807940994567616e-07
other O 0 3.2907024660744355e-07
populations O 0 1.1436264912845218e-06
and O 0 1.1268491562077543e-06
found O 0 2.6276184144080617e-06
in O 0 3.142759652519089e-08
16 O 0 3.075385279771581e-07
out O 0 4.388369845287343e-08
of O 0 1.3552859456922306e-07
19 O 0 4.8015197535278276e-05
Colombian O 0 0.0003150768461637199
MPS B-Disease 1 0.9176608920097351
IVA I-Disease 1 0.9989051818847656
unrelated O 0 6.871372170280665e-05
alleles O 0 6.483072638729936e-07
account O 0 2.593577619336429e-07
for O 0 4.755750637741585e-07
84 O 0 8.526987221557647e-05
. O 0 3.7767429148516385e-06

2 O 0 1.8780039681587368e-05
% O 0 4.360918808288261e-07
of O 0 1.3856426228642249e-08
the O 0 6.17105371247817e-08
alleles O 0 1.9711507093234104e-07
in O 0 4.4444959712564014e-08
this O 0 2.751425220992587e-08
study O 0 9.2185035782677e-07
. O 0 2.5641024876676966e-06

The O 0 3.655804221125436e-06
G301C O 0 0.00012142210471211001
and O 0 1.1656200058496324e-06
S162F O 0 2.4259579731733538e-05
mutations O 0 7.424293357871647e-07
account O 0 8.072093748978659e-08
for O 0 4.3344530809008575e-07
68 O 0 0.0002085091982735321
. O 0 7.428247954521794e-06

4 O 0 5.3755295084556565e-05
% O 0 2.4876203497115057e-06
and O 0 1.0893388662225334e-06
10 O 0 2.4850287445588037e-06
. O 0 1.9325602806929965e-06

5 O 0 1.594083005329594e-05
% O 0 8.540060321138299e-07
of O 0 4.199085026357352e-07
mutations O 0 3.089274832746014e-05
, O 0 1.4301124338089721e-06
respectively O 0 1.8975026250700466e-05
, O 0 2.714867264330678e-07
whereas O 0 1.0790432014573526e-07
the O 0 5.830680649410169e-08
remaining O 0 2.0875336304015946e-06
F69V O 0 0.007211744319647551
is O 0 9.860769978331518e-08
limited O 0 3.7153078835672204e-08
to O 0 7.990032635518673e-09
a O 0 1.1737816407730861e-07
single O 0 4.977784101356519e-06
allele O 0 2.216613393102307e-05
. O 0 5.5922678257047664e-06

The O 0 2.232010274383356e-06
skewed O 0 4.2914525693049654e-05
prevalence O 0 0.00010989416477968916
of O 0 2.3620827960257884e-07
G301C O 0 1.6286619938910007e-05
in O 0 6.168676236484316e-08
only O 0 3.848526475280778e-08
Colombian O 0 7.229900074889883e-05
patients O 0 1.2276600500626955e-05
and O 0 2.1877029610095633e-07
haplotype O 0 2.500056325516198e-06
analysis O 0 6.500116711549708e-08
by O 0 2.0121071031553583e-07
restriction O 0 3.3518824693601346e-07
fragment O 0 2.6936011181533104e-06
length O 0 2.3337565835390706e-06
polymorphisms O 0 1.793691626517102e-05
in O 0 7.509724042620292e-08
the O 0 1.6486994525166665e-07
GALNS O 0 0.0024590783286839724
gene O 0 1.7466994961523596e-07
suggest O 0 8.739875312357981e-08
that O 0 2.376985364094253e-08
G301C O 0 2.477156613167608e-06
originated O 0 7.177018090942511e-08
from O 0 2.775131946464171e-08
a O 0 4.517458762620663e-07
common O 0 2.103306769640767e-06
ancestor O 0 4.4352575059747323e-05
. O 0 9.18188743526116e-06

Investigation O 0 6.130518158897758e-05
of O 0 9.242569376510801e-07
the O 0 8.947669698500249e-07
genetic O 0 1.7854568795883097e-05
background O 0 5.163864784663019e-07
by O 0 6.222443857950566e-07
means O 0 4.0814637003450116e-08
of O 0 1.257039716762165e-08
mtDNA O 0 3.642336139364488e-07
lineages O 0 6.190257977323199e-07
indicate O 0 4.438253142780013e-07
that O 0 3.386376690173165e-08
all O 0 9.62740198673373e-09
our O 0 2.8161531417936203e-07
patients O 0 4.191026164335199e-06
are O 0 2.484842731576009e-08
probably O 0 2.2529803800352965e-07
of O 0 6.375936578706387e-08
native O 0 1.639097354200203e-05
American O 0 0.0001622528361622244
descent O 0 0.036271270364522934

Low O 0 3.0655795853817835e-05
frequency O 0 1.5260998225130606e-06
of O 0 5.253824610917945e-07
BRCA1 O 0 0.00023199277347885072
germline O 0 0.0003124313661828637
mutations O 0 8.7157541202032e-06
in O 0 1.956646968892528e-07
45 O 0 3.0011940907570533e-05
German O 1 0.9827836751937866
breast B-Disease 1 0.9998158812522888
/ I-Disease 1 0.9997947812080383
ovarian I-Disease 1 0.9999994039535522
cancer I-Disease 1 0.9999697208404541
families O 0 0.0002336859906790778
. O 0 4.1986830183304846e-05

In O 0 1.5214147879305528e-06
this O 0 2.6672813291384045e-08
study O 0 3.421886063392776e-08
we O 0 8.842894416716263e-09
investigated O 0 2.7214227884542197e-06
45 O 0 1.0059953638119623e-05
German O 1 0.846147894859314
breast B-Disease 1 0.9997387528419495
/ I-Disease 1 0.9997429251670837
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999622106552124
families O 0 3.2220216326095397e-06
for O 0 3.3142930533358594e-06
germline O 0 0.006971287541091442
mutations O 0 7.875806659285445e-06
in O 0 5.751287446287279e-08
the O 0 1.3869072290617623e-06
BRCA1 O 0 0.000529802346136421
gene O 0 4.480013558350038e-06
. O 0 3.3868182072183117e-06

We O 0 1.1442265304140165e-06
identified O 0 1.5566507727271528e-06
four O 0 6.37883204035461e-08
germline O 0 0.00011712712148437276
mutations O 0 4.664825155487051e-06
in O 0 2.1883852241444401e-07
three O 0 0.0002620333689264953
breast B-Disease 1 0.999462902545929
cancer I-Disease 0 0.2536942660808563
families O 0 2.379890020165476e-06
and O 0 1.0136106993741123e-06
in O 0 1.9082774542766856e-06
one O 0 0.0029070721939206123
breast B-Disease 1 0.9999706745147705
- I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
family O 0 0.002518107881769538
. O 0 8.086947786978271e-07
among O 0 7.998755222615728e-07
these O 0 1.627242163237952e-08
were O 0 1.1393254908398376e-06
one O 0 6.665986802545376e-07
frameshift O 0 0.00039563007885590196
mutation O 0 5.983649316476658e-06
, O 0 2.421691078779986e-07
one O 0 1.3209483995524351e-07
nonsense O 0 4.1568106098566204e-05
mutation O 0 2.1078187728562625e-06
, O 0 6.165147681258532e-08
one O 0 2.5126951186393853e-08
novel O 0 1.569033258874697e-07
splice O 0 1.2784963473677635e-05
site O 0 5.6682924878259655e-06
mutation O 0 2.4190421754610725e-06
, O 0 1.9681678509186895e-07
and O 0 2.572567154857097e-07
one O 0 9.034770869220665e-07
missense O 0 0.0005985926254652441
mutation O 0 3.2956391805782914e-05
. O 0 3.594132522266591e-06

The O 0 6.040709195076488e-06
missense O 0 0.0012161690974608064
mutation O 0 0.00040960675687529147
was O 0 0.0002462497795931995
also O 0 3.90953391615767e-06
found O 0 7.857162245272775e-07
in O 0 8.603785772720585e-08
2 O 0 1.011900258163223e-05
. O 0 6.922795819264138e-06

8 O 0 3.269749504397623e-05
% O 0 4.942901909998909e-07
of O 0 3.1797021904367284e-08
the O 0 5.971956795747246e-08
general O 0 4.213072202219337e-07
population O 0 1.0534461836186892e-07
, O 0 1.6504158395491686e-07
suggesting O 0 1.6784342733444646e-06
that O 0 5.986828455206705e-08
it O 0 1.0661912597242917e-07
is O 0 1.3165118843971868e-06
not O 0 1.9967483240179718e-05
disease O 0 0.00533562246710062
associated O 0 2.0039497030666098e-05
. O 0 2.175802546844352e-05

The O 0 2.0237321223248728e-06
average O 0 3.4231845347676426e-05
age O 0 2.290733391419053e-05
of O 0 1.3489867342286743e-05
disease O 0 0.08049444109201431
onset O 0 0.0002898006059695035
in O 0 1.0015593261414324e-06
those O 0 4.3632317670017073e-07
families O 0 6.499689789052354e-06
harbouring O 1 0.6990203857421875
causative O 0 0.001207315712235868
mutations O 0 1.4634384569944814e-05
was O 0 1.3545028195949271e-05
between O 0 6.253521291910147e-07
32 O 0 0.00013664294965565205
. O 0 3.352426938363351e-05

3 O 0 5.3477706387639046e-05
and O 0 1.0420278158562724e-05
37 O 0 0.00011688031372614205
. O 0 8.573710147175007e-06

4 O 0 0.00011904809070983902
years O 0 4.0383212763117626e-05
, O 0 4.709318091045134e-07
whereas O 0 1.7731690604705364e-07
the O 0 1.7934580398559774e-07
family O 0 5.08047969560721e-06
harbouring O 0 0.0014982232823967934
the O 0 1.7947462538359105e-07
missense O 0 6.478022987721488e-05
mutation O 0 2.338325430173427e-06
had O 0 2.8227452730789082e-06
an O 0 3.677084237097006e-07
average O 0 3.986342198913917e-05
age O 0 4.907621587335598e-06
of O 0 3.5726705505112477e-07
onset O 0 2.274513644806575e-05
of O 0 1.2968924920642166e-06
51 O 0 0.0003217179619241506
. O 0 7.964753422129434e-06

2 O 0 7.050843851175159e-05
years O 0 7.583863771287724e-05
. O 0 8.258668458438478e-06

These O 0 8.099520414361905e-07
findings O 0 4.0082004488795064e-06
show O 0 1.0443908422530512e-06
that O 0 2.4598929826424865e-07
BRCA1 O 0 0.00016549567226320505
is O 0 2.9810269097652053e-07
implicated O 0 8.084673754638061e-05
in O 0 1.3079416305572522e-07
a O 0 2.654426793924358e-07
small O 0 4.275445348866924e-07
fraction O 0 8.63426521391375e-06
of O 0 0.0001369204983348027
breast B-Disease 1 0.9999054670333862
/ I-Disease 1 0.9999476671218872
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999926090240479
families O 0 2.99959192489041e-05
suggesting O 0 6.993799161136849e-06
the O 0 8.060001732701494e-08
involvement O 0 1.2359608945189393e-06
of O 0 1.8562793968612823e-07
another O 0 1.5072825590323191e-05
susceptibility O 0 0.0002864348643925041
gene O 0 1.93285700333945e-06
( O 0 1.1446981034168857e-06
s O 0 0.0007417288143187761
) O 0 1.1189685210410971e-05

Paternal O 0 0.04398932307958603
transmission O 0 0.2907998263835907
of O 0 0.40660253167152405
congenital B-Disease 1 0.9999890327453613
myotonic I-Disease 1 0.9999843835830688
dystrophy I-Disease 1 0.9999840259552002
. O 0 0.037722475826740265

We O 0 4.637377969629597e-06
report O 0 2.520760745028383e-06
a O 0 9.13594533358264e-07
rare O 0 6.361679425026523e-06
case O 0 2.165446312574204e-05
of O 0 7.46722798794508e-05
paternally O 1 0.9988228678703308
transmitted O 1 0.9998231530189514
congenital B-Disease 1 0.9999970197677612
myotonic I-Disease 1 0.9999973773956299
dystrophy I-Disease 1 0.9999979734420776
( O 0 0.10615021735429764
DM B-Disease 1 0.9999799728393555
) O 0 0.00022345683828461915
. O 0 1.8156533769797534e-05

The O 0 7.092400210240157e-06
proband O 0 0.003240378573536873
is O 0 8.475994377477036e-07
a O 0 7.941914077491674e-07
23 O 0 2.158080314984545e-05
year O 0 1.933136081788689e-05
old O 0 0.013087118975818157
, O 0 0.0010476954048499465
mentally B-Disease 1 0.9999812841415405
retarded I-Disease 1 0.9999785423278809
male O 0 0.044692717492580414
who O 1 0.6758134365081787
suffers O 1 0.9994373917579651
severe O 1 0.9911138415336609
muscular B-Disease 1 0.9996984004974365
weakness I-Disease 1 0.9972516894340515
. O 0 0.00015162114868871868

He O 0 9.921771561494097e-05
presented O 0 0.00011453578918008134
with O 0 0.0010958522325381637
respiratory O 1 0.9241763949394226
and O 0 5.180182051844895e-05
feeding O 0 0.00025633591576479375
difficulties O 0 0.0003158904146403074
at O 0 6.329320603981614e-05
birth O 0 7.238910620799288e-05
. O 0 6.124127139628399e-06

His O 0 7.308347267098725e-05
two O 0 6.547138036694378e-05
sibs O 1 0.9916286468505859
suffer O 0 0.018322018906474113
from O 0 1.6388799849664792e-05
childhood O 0 0.0023496351204812527
onset O 0 0.17815618216991425
DM B-Disease 1 0.9998542070388794
. O 0 0.000259709864621982

Their O 0 4.311766588216415e-06
late O 0 5.882757977815345e-05
father O 0 0.0001801396138034761
had O 0 4.578099833452143e-06
the O 0 4.1599793831892384e-08
adult O 0 8.618072229182872e-07
type O 0 1.5785864206918632e-06
of O 0 5.098608653497649e-06
DM B-Disease 1 0.9999940395355225
, O 0 4.673120656661922e-06
with O 0 4.610354835676844e-07
onset O 0 1.0561361705185845e-05
around O 0 1.6353918397271627e-07
30 O 0 1.0597818800306413e-06
years O 0 2.4286582629429176e-06
. O 0 2.082030505334842e-06

Only O 0 4.711114911515324e-07
six O 0 6.595013815058337e-07
other O 0 6.101555527493474e-08
cases O 0 3.0463405664704624e-07
of O 0 5.610043558590405e-07
paternal O 0 0.011528252623975277
transmission O 0 0.014464573003351688
of O 0 0.15956030786037445
congenital B-Disease 1 0.9999988079071045
DM I-Disease 1 0.9999988079071045
have O 0 0.0018700964283198118
been O 0 5.306024831952527e-05
reported O 0 0.00015453716332558542
recently O 0 7.682850264245644e-05
. O 0 2.5958565856853966e-06

We O 0 1.938810783030931e-06
review O 0 4.884365125690238e-07
the O 0 5.842101913344777e-08
sex O 0 9.16627186597907e-07
related O 0 5.575440354732564e-06
effects O 0 3.2457812721986556e-06
on O 0 4.787038960785139e-06
transmission O 0 0.0019729044288396835
of O 0 0.010690277442336082
congenital B-Disease 1 0.9999850988388062
DM I-Disease 1 0.9999746084213257
. O 0 0.0009064758778549731

Decreased O 0 0.0023551478516310453
fertility O 0 0.0002205930941272527
of O 0 2.5258739810851694e-07
males O 0 3.3738808724592673e-06
with O 0 9.868123242995352e-07
adult O 0 0.00010020798799814656
onset O 0 0.08212696760892868
DM B-Disease 1 0.9999954700469971
and O 0 0.0002023882552748546
contraction O 0 2.7814337954623625e-05
of O 0 1.3206096127760247e-07
the O 0 1.9050938249165483e-07
repeat O 0 1.6716547861506115e-06
upon O 0 1.3518186392502685e-07
male O 0 6.291135150604532e-07
transmission O 0 9.789275736693526e-07
contribute O 0 8.275883800479278e-08
to O 0 1.1063690408263938e-08
the O 0 4.794934227447811e-08
almost O 0 1.7830807053087483e-07
absent O 0 9.407997936250467e-07
occurrence O 0 1.803293656621463e-07
of O 0 1.300304148799114e-07
paternal O 0 0.0002696513547562063
transmission O 0 0.009479515254497528
of O 0 0.011447694152593613
congenital B-Disease 1 0.9999796152114868
DM I-Disease 1 0.9999544620513916
. O 0 0.00040497881127521396

Also O 0 3.2150885090231895e-05
the O 0 2.5047552298929077e-07
fathers O 0 6.703964459120471e-07
of O 0 3.574162477093523e-08
the O 0 5.654566166413133e-07
reported O 0 0.0011175365652889013
congenitally O 0 0.029398739337921143
affected O 0 8.088720278465189e-06
children O 0 2.349643182242289e-06
showed O 0 2.8938606192241423e-05
, O 0 6.91373074346302e-08
on O 0 5.178713990972028e-07
average O 0 2.0914532797178254e-05
, O 0 8.54028826324793e-07
shorter O 0 3.432850462559145e-06
CTG O 0 3.575901791919023e-05
repeat O 0 8.293279734061798e-07
lengths O 0 1.67921680258587e-05
and O 0 7.034121267679438e-07
hence O 0 1.8381134623268736e-06
less O 0 1.1194179023732431e-05
severe O 0 0.10709879547357559
clinical O 0 0.0076086451299488544
symptoms O 0 4.8294448788510635e-05
than O 0 7.371247079390741e-08
the O 0 1.1729910056601511e-06
mothers O 0 7.260798156494275e-06
of O 0 2.9895909392507747e-07
children O 0 0.0001509857684141025
with O 0 0.022547803819179535
congenital B-Disease 1 0.9999608993530273
DM I-Disease 1 0.9999477863311768
. O 0 0.0001647299068281427

We O 0 2.1515102162084077e-06
conclude O 0 3.4354607123532332e-06
that O 0 1.4733912223618972e-07
paternal O 0 3.4768509067362174e-05
transmission O 0 0.0015977267175912857
of O 0 0.022611351683735847
congenital B-Disease 1 0.9999995231628418
DM I-Disease 1 0.9999997615814209
is O 0 0.000964804959949106
rare O 0 1.920513932418544e-05
and O 0 1.2763283621097798e-06
preferentially O 0 4.25063126385794e-06
occurs O 0 5.3515947229243466e-08
with O 0 1.76367578319514e-07
onset O 0 1.0913780897681136e-05
of O 0 2.220386477347347e-06
DM B-Disease 1 0.9999710321426392
past O 0 6.565121111634653e-06
30 O 0 2.3526883978775004e-06
years O 0 5.334300681170134e-07
in O 0 2.9962695435870046e-08
the O 0 1.4675910620098875e-07
father O 0 1.815854193409905e-05
. O 0 2.9186111305534723e-07
. O 0 1.825279468903318e-06

The O 0 1.0326287338102702e-05
RB1 O 0 0.015771737322211266
gene O 0 1.1770221135520842e-05
mutation O 0 4.233050276525319e-06
in O 0 1.377294296389664e-07
a O 0 2.3988986868062057e-06
child O 0 0.0005196307320147753
with O 0 0.00043844679021276534
ectopic B-Disease 1 0.9994795918464661
intracranial I-Disease 1 0.9999089241027832
retinoblastoma I-Disease 1 0.9926794767379761
. O 0 0.00014620790898334235

The O 0 1.9034507204196416e-05
RB1 O 0 0.05464990809559822
gene O 0 1.3501811736205127e-05
mutation O 0 1.2846045137848705e-05
was O 0 1.6981357475742698e-05
investigated O 0 0.0001622007112018764
in O 0 1.7191551933137816e-06
a O 0 1.2452184819267131e-05
child O 0 0.002837564330548048
with O 0 0.0004628265160135925
ectopic B-Disease 1 0.999525785446167
intracranial I-Disease 1 0.999826967716217
retinoblastoma I-Disease 0 0.005374683532863855
using O 0 4.381854523671791e-07
DNA O 0 1.8600836483528838e-05
obtained O 0 8.879419510776643e-07
from O 0 1.0904722813620538e-07
both O 0 3.699214445873622e-08
the O 0 9.980790309782606e-07
pineal B-Disease 0 0.0004793463449459523
and I-Disease 0 0.0002522504364605993
retinal I-Disease 1 0.9139096736907959
tumours I-Disease 1 0.9998718500137329
of O 0 1.2483138789320947e-06
the O 0 9.550672984914854e-06
patient O 0 0.0003550702822394669
. O 0 1.0296130312781315e-05

A O 0 4.0564158553024754e-05
nonsense O 0 5.487613452714868e-05
mutation O 0 5.491630417964188e-06
in O 0 1.5232005523557746e-07
exon O 0 9.901553858071566e-05
17 O 0 6.908932391525013e-06
( O 0 2.504183527207715e-08
codon O 0 1.9542095230917766e-07
556 O 0 2.4133689748850884e-06
) O 0 6.2531970712598195e-09
of O 0 2.963309597703301e-09
the O 0 1.379265910372851e-07
RB1 O 0 0.011883093975484371
gene O 0 1.230839529853256e-06
was O 0 4.7597874072380364e-05
found O 0 1.211519020216656e-06
to O 0 4.579487722367048e-08
be O 0 9.27399668171347e-08
present O 0 1.1826922730051592e-07
homozygously O 0 7.242224819492549e-05
in O 0 7.303874127728704e-08
both O 0 1.1202375560515065e-07
the O 0 8.881765438673028e-07
retinal B-Disease 0 0.003633615793660283
and I-Disease 0 1.1877092219947372e-05
the I-Disease 0 4.048929622513242e-05
pineal I-Disease 0 0.13640618324279785
tumours I-Disease 1 0.9995555281639099
. O 0 2.392291571595706e-05

The O 0 1.2644806020034594e-06
same O 0 5.912714300393418e-07
mutation O 0 1.3339181350602303e-05
was O 0 5.372218583943322e-05
present O 0 5.841121151206607e-07
heterozygously O 0 0.0002542366273701191
in O 0 3.8035881999576304e-08
the O 0 6.098437665968959e-08
DNA O 0 9.304341801907867e-06
from O 0 1.0576620468327746e-07
the O 0 1.2964372331225604e-07
constitutional O 0 7.854856448830105e-06
cells O 0 8.496388659295917e-07
of O 0 6.97251607562066e-08
the O 0 3.4648892324185e-06
patient O 0 4.658888065023348e-05
, O 0 8.277231700049015e-07
proving O 0 9.021709047374316e-06
it O 0 6.937690422148535e-09
to O 0 1.0011619977490227e-08
be O 0 8.405805829170276e-09
of O 0 6.595870161163475e-08
germline O 0 0.0001797182485461235
origin O 0 3.169534693370224e-06
. O 0 5.095595042803325e-06

The O 0 2.11769770430692e-06
initial O 0 1.1055272807425354e-05
mutation O 0 2.0159663108643144e-05
was O 0 3.636035035015084e-05
shown O 0 3.565957911177975e-07
to O 0 3.3743329908020314e-08
have O 0 7.371907884134998e-08
occurred O 0 1.5664048191865731e-07
in O 0 2.9451671323954542e-08
the O 0 8.766234600443568e-07
paternally O 0 0.0006799011607654393
derived O 0 5.271287591313012e-06
RB1 O 0 0.00783410295844078
allele O 0 1.4388581803359557e-05
. O 0 2.771361096165492e-06

The O 0 6.650481736869551e-06
mutation O 0 4.8973186494549736e-05
is O 0 6.206442435541248e-07
in O 0 1.3659258968345966e-07
an O 0 5.550742230298056e-07
area O 0 4.819906962438836e-07
of O 0 3.7541873609825416e-08
the O 0 7.133414214877121e-08
gene O 0 2.362341433581605e-08
that O 0 2.1807979866395044e-09
encodes O 0 1.4877348242237076e-08
the O 0 2.029090850896864e-08
protein O 0 8.601291057175331e-08
- O 0 2.5995306714321487e-05
binding O 0 1.4072452358959708e-06
region O 0 2.9285232017173257e-07
known O 0 6.631132691836683e-07
as O 0 9.979651593994276e-08
the O 0 3.662828760297998e-07
pocket O 0 0.050196241587400436
region O 0 1.2083620504199644e-06
and O 0 1.0538958576944424e-06
has O 0 2.0206309727655025e-06
been O 0 1.8388200260233134e-06
detected O 0 1.5692817214585375e-06
in O 0 7.1688472935704795e-09
other O 0 2.6122114249460537e-08
cases O 0 8.87504256752436e-07
of O 0 2.251121259178035e-06
retinoblastoma B-Disease 0 0.03394261747598648
. O 0 1.7263512290810468e-06
. O 0 3.1983445296646096e-06

Low O 0 0.00012044709001202136
levels O 0 1.2914705393995973e-06
of O 0 6.30426342240753e-08
beta O 0 1.0470714641996892e-06
hexosaminidase O 0 6.7108754592482e-05
A O 0 1.0818887403729605e-06
in O 0 2.481864100900566e-07
healthy O 0 1.113831331167603e-06
individuals O 0 2.257290248053323e-07
with O 0 6.593371654162183e-05
apparent O 1 0.8509897589683533
deficiency O 0 0.11447304487228394
of O 0 3.1509469522461586e-07
this O 0 7.454864316969179e-07
enzyme O 0 6.129196844995022e-05
. O 0 5.492447598953731e-06

Appreciable O 0 0.0006164134829305112
beta O 0 0.00013064553786534816
hexosaminidase O 0 0.0061037554405629635
A O 0 1.7471538740210235e-05
( O 0 2.0556724678044702e-07
hex O 0 8.377733320230618e-05
A O 0 1.2419561699061887e-06
) O 0 3.5018778987705446e-08
activity O 0 3.1413872392249687e-08
has O 0 6.508329164489624e-08
been O 0 3.30457737618417e-07
detected O 0 2.1405546704045264e-06
in O 0 2.523405839838233e-07
cultured O 0 0.001700751599855721
skin O 0 0.00043817609548568726
fibroblasts O 0 9.943374607246369e-05
and O 0 0.0014402184169739485
melanoma B-Disease 1 0.9998875856399536
tissue O 0 0.07732867449522018
from O 0 7.195231319201412e-06
healthy O 0 5.706524916604394e-06
individuals O 0 4.0015294189288397e-07
previously O 0 0.00014781336358282715
reported O 0 0.0016649661120027304
as O 0 6.964361091377214e-05
having O 0 0.01389344409108162
deficiency B-Disease 0 0.006835754495114088
of I-Disease 0 7.974901450324978e-08
hex I-Disease 0 0.0017080195248126984
A I-Disease 0 6.405312547030917e-07
activity O 0 2.8129795381914846e-08
indistinguishable O 0 1.885349689700888e-07
from O 0 2.8289598219544132e-08
that O 0 2.111450569941553e-08
of O 0 7.494863325518963e-07
patients O 0 0.00021429396292660385
with O 0 0.0072871008887887
Tay B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999886751174927
Sachs I-Disease 1 0.999997615814209
disease I-Disease 1 0.6389106512069702
( O 0 4.561308742268011e-06
TSD B-Disease 0 0.05001882463693619
) O 0 1.9070694179390557e-06
. O 0 1.8618513877299847e-06

Identification O 0 1.1982955584244337e-05
and O 0 1.4353154256241396e-06
quantitation O 0 0.0003727969015017152
of O 0 4.07478268016348e-07
hex O 0 0.00040908812661655247
A O 0 1.89590252830385e-06
, O 0 1.396417559362817e-07
amounting O 0 2.165795194741804e-06
to O 0 7.993953232698914e-08
3 O 0 2.814026402120362e-06
. O 0 1.99848636839306e-06

5 O 0 2.210420097981114e-05
% O 0 4.931605872116052e-06
- O 0 0.0007673179497942328
6 O 0 6.338550156215206e-05
. O 0 3.7326610708987573e-06

9 O 0 2.0612587832147256e-05
% O 0 2.7383060796637437e-07
of O 0 4.9706830651530254e-08
total O 0 2.93323836331183e-07
beta O 0 1.522639877293841e-06
hexosaminidase O 0 6.314188794931397e-05
activity O 0 1.3615546379242005e-07
, O 0 7.85043923201556e-08
has O 0 1.1331788130064524e-07
been O 0 8.091006975519122e-08
obtained O 0 7.147141900532006e-08
by O 0 7.559534509482546e-08
cellulose O 0 0.0001221480342792347
acetate O 0 7.991284655872732e-05
gel O 0 0.0003575223672669381
electrophoresis O 0 7.479927444364876e-05
, O 0 4.6376999307540245e-07
DEAE O 0 0.00021311479213181883
- O 0 2.7521722586243413e-05
cellulose O 0 5.449648597277701e-05
ion O 0 1.85141725523863e-05
- O 0 6.713160837534815e-05
exchange O 0 3.3878291105793323e-06
chromatography O 0 5.6130178563762456e-05
, O 0 1.9059970668422466e-07
radial O 0 1.4980566447775345e-05
immunodiffusion O 0 0.0001744031033013016
, O 0 1.7644832439600577e-07
and O 0 6.460057875301572e-07
radioimmunoassay O 0 0.0011339751072227955
. O 0 3.2029352041718084e-06

Previous O 0 0.0003021596639882773
family O 0 0.0002575984108261764
studies O 0 4.180487849225756e-06
suggested O 0 1.9111341316602193e-05
that O 0 9.034006609454082e-08
these O 0 1.0128415439680793e-08
individuals O 0 3.6509646861304645e-07
may O 0 2.4558758013881743e-06
be O 0 8.580268939795133e-08
compound O 0 3.0433989195444155e-07
heterozygotes O 0 8.261152402155858e-07
for O 0 4.091861782740125e-08
the O 0 2.550804936163331e-07
common O 0 1.3608892004413065e-06
mutant O 0 0.00013331421359907836
TSD B-Disease 0 0.017163768410682678
gene O 0 1.5083315929587116e-06
and O 0 7.748166694909742e-07
a O 0 8.809085557004437e-06
rare O 0 3.234789983252995e-05
( O 0 9.230317346009542e-07
allelic O 0 7.957042544148862e-05
) O 0 4.5941811777083785e-07
mutant O 0 9.52847403823398e-06
gene O 0 8.533588697900996e-07
. O 0 1.3394941333899624e-06

Thus O 0 2.4047645638347603e-05
, O 0 6.9016090264995e-07
the O 0 5.799624247515567e-08
postulated O 0 6.681326794932829e-06
rate O 0 4.205655841360567e-06
mutant O 0 3.257813659729436e-05
gene O 0 1.1779054602811811e-06
appears O 0 2.842232902366959e-07
to O 0 6.451436718180048e-09
code O 0 6.9620549325577485e-09
for O 0 1.1302470070972959e-08
the O 0 1.217031453393247e-08
expression O 0 1.4662683511801333e-08
of O 0 1.4652171920204182e-08
low O 0 1.4240914651963976e-06
amounts O 0 4.211923254615613e-08
of O 0 2.5659655733534237e-08
hex O 0 0.0004754994879476726
A O 0 5.796024652227061e-06
. O 0 2.4144694634742336e-06

Heterozygotes O 0 0.0017634074902161956
for O 0 5.321873686625622e-06
the O 0 1.7617336425246322e-06
rare O 0 3.056250716326758e-05
mutant O 0 0.0006401964346878231
may O 0 4.390343292470789e-06
be O 0 2.5526976088485753e-08
indistinguishable O 0 2.6889838977695035e-07
from O 0 3.3625570949880057e-07
heterozygotes O 0 6.653146556345746e-06
for O 0 1.4685865323826874e-07
the O 0 1.2704784921879764e-06
common O 0 1.9583976609283127e-05
TSD B-Disease 0 0.10201379656791687
mutant O 0 0.0004458078765310347
. O 0 7.053251920297043e-06

However O 0 1.6368867363780737e-05
, O 0 2.0875148720733705e-07
direct O 0 3.0382860671807066e-08
visualization O 0 3.737566203199094e-06
and O 0 1.6343719835276715e-06
quantitation O 0 0.0004007650422863662
of O 0 2.8263045237508777e-07
hex O 0 0.0004181073745712638
A O 0 6.055603307686397e-07
by O 0 8.867997536299299e-08
the O 0 6.6889761285438e-08
methods O 0 9.140529186879576e-07
described O 0 0.00022516782337334007
may O 0 5.778385911980877e-06
prevent O 0 2.151175976905506e-06
false O 0 2.5123008526861668e-06
- O 0 0.0005850591114722192
positive O 0 6.230531539586082e-07
prenatal O 0 7.754946636850946e-06
diagnosis O 0 3.7751515264972113e-06
of O 0 3.187496417922375e-07
TSD B-Disease 0 0.03975176438689232
in O 0 9.853521078184713e-06
fetuses O 0 0.021886982023715973
having O 0 3.4029183098027715e-06
the O 0 2.3289243245017133e-07
incomplete O 0 4.77934954687953e-05
hex B-Disease 1 0.785732090473175
A I-Disease 0 0.0691148042678833
deficiency I-Disease 0 0.07744532823562622
of O 0 1.6320187512519624e-07
the O 0 2.3292827791010495e-06
type O 0 5.231249087955803e-05
described O 0 2.3172047804109752e-05
in O 0 1.7403809238203394e-07
the O 0 5.838865604346211e-07
four O 0 1.3283656699059065e-05
healthy O 0 0.00013504273374564946
individuals O 0 1.5319164958782494e-05

The O 0 3.516398282954469e-05
tumor B-Disease 0 0.04759063944220543
suppressor O 0 0.0004596092039719224
gene O 0 1.0370609743404202e-05
Smad4 O 0 0.0011164022143930197
/ O 0 6.5056694438681e-05
Dpc4 O 0 0.0015531559474766254
is O 0 2.0912669640438253e-07
required O 0 4.1937262551527965e-08
for O 0 1.2801081084035104e-07
gastrulation O 0 5.370886356104165e-05
and O 0 2.439433728795848e-06
later O 0 3.0538792543666204e-06
for O 0 5.524695438907656e-07
anterior O 0 0.0001826762018026784
development O 0 6.4215576855986e-08
of O 0 4.673962195056447e-08
the O 0 5.646564318340097e-07
mouse O 0 6.422160367947072e-05
embryo O 0 3.7401267036329955e-05
. O 0 6.145603947516065e-06

Mutations O 0 0.0004972303286194801
in O 0 8.152301234076731e-07
the O 0 2.5033489237102913e-06
SMAD4 O 0 0.2785630226135254
/ O 0 0.0007384183118119836
DPC4 O 1 0.9331061244010925
tumor B-Disease 0 0.2095470428466797
suppressor O 0 0.0002743581426329911
gene O 0 1.2295361102587776e-06
, O 0 8.438998122528574e-08
a O 0 2.2148761047446897e-07
key O 0 3.57947851625795e-06
signal O 0 7.767187071294757e-07
transducer O 0 2.916804442065768e-05
in O 0 1.0092571045561272e-07
most O 0 1.2182768216462136e-07
TGFbeta O 0 0.0011531731579452753
- O 0 0.0021263700909912586
related O 0 2.495442640793044e-05
pathways O 0 2.2935730612516636e-06
, O 0 2.7883623943125713e-07
are O 0 9.227271391409886e-09
involved O 0 1.056968343959852e-07
in O 0 2.7440826499969262e-08
50 O 0 2.933112455139053e-07
% O 0 1.9873041878781805e-07
of O 0 2.6629777494235896e-05
pancreatic B-Disease 1 0.99994957447052
cancers I-Disease 1 0.9833992719650269
. O 0 3.092269616900012e-05

Homozygous O 0 0.002420950448140502
Smad4 O 0 0.02025088667869568
mutant O 0 0.021742749959230423
mice O 0 0.005312885157763958
die O 0 0.00030664040241390467
before O 0 6.232314149201557e-07
day O 0 9.969375014406978e-07
7 O 0 5.350591436581453e-06
. O 0 1.7844615740614245e-06

5 O 0 1.2952551514899824e-05
of O 0 2.6105312826985028e-06
embryogenesis O 0 0.0004568738804664463
. O 0 1.6909752957872115e-05

Mutant O 0 0.0003896683338098228
embryos O 0 0.00012808864994440228
have O 0 2.2385718239092967e-06
reduced O 0 4.543374416243751e-06
size O 0 1.740365769364871e-05
, O 0 2.5341016680613393e-06
fail O 0 3.1683380257163662e-06
to O 0 7.7602216208561e-08
gastrulate O 0 8.170033834176138e-05
or O 0 7.851711814055307e-08
express O 0 1.0138084149957649e-07
a O 0 1.244532086275285e-07
mesodermal O 0 0.00014231835666578263
marker O 0 0.0001542827521916479
, O 0 4.987512056686683e-07
and O 0 4.7392518354172353e-07
show O 0 1.940179572557099e-06
abnormal O 0 4.609427833202062e-06
visceral O 0 7.261989139806246e-06
endoderm O 0 0.0001507913984823972
development O 0 2.229737901870976e-06
. O 0 2.9913612706877757e-06

Growth B-Disease 1 0.9989001750946045
retardation I-Disease 1 0.9998564720153809
of O 0 6.385238066286547e-06
the O 0 1.646352029638365e-05
Smad4 O 0 0.366251677274704
- O 0 0.2030745893716812
deficient O 0 0.00028972604195587337
embryos O 0 1.8971110193888308e-07
results O 0 5.084542920030799e-08
from O 0 4.04142959098408e-08
reduced O 0 1.187737325381022e-06
cell O 0 1.6524234524695203e-05
proliferation O 0 7.745101356704254e-06
rather O 0 1.0042813691768515e-08
than O 0 2.915066410480449e-08
increased O 0 6.811861226196925e-07
apoptosis O 0 1.3020532605878543e-05
. O 0 3.210813474652241e-06

Aggregation O 0 1.4723415006301366e-05
of O 0 5.67036749998806e-07
mutant O 0 0.0002087839093292132
Smad4 O 0 0.002742690034210682
ES O 0 0.00011702709161909297
cells O 0 6.0349511841195635e-06
with O 0 2.561230587616592e-07
wild O 0 1.0118500540556852e-05
- O 0 0.001263872254639864
type O 0 1.0631817531248089e-05
tetraploid O 0 0.00010518204362597317
morulae O 0 0.000701363489497453
rescues O 0 8.994611562229693e-05
the O 0 1.0914612857959582e-06
gastrulation B-Disease 0 0.001595638575963676
defect I-Disease 0 0.004119310062378645
. O 0 9.272665010939818e-06

These O 0 7.616367838636506e-07
results O 0 3.41813029081095e-06
indicate O 0 2.3907180093374336e-06
that O 0 1.9279107732472767e-07
Smad4 O 0 0.0015186265809461474
is O 0 7.701695494688465e-07
initially O 0 5.273710939945886e-06
required O 0 2.5580249030099367e-08
for O 0 1.7445410449568044e-08
the O 0 2.2062868865191376e-08
differentiation O 0 4.575593592903715e-08
of O 0 1.6528076685062842e-08
the O 0 1.0078605328089907e-07
visceral O 0 5.928280188527424e-06
endoderm O 0 8.353784505743533e-05
and O 0 7.08816173755622e-07
that O 0 2.990999092844504e-08
the O 0 1.2238081126270117e-07
gastrulation B-Disease 0 0.001208073808811605
defect I-Disease 0 0.0016374236438423395
in O 0 1.8994010986261856e-07
the O 0 1.4281797575677047e-06
epiblast O 0 0.09802422672510147
is O 0 7.016299718998198e-07
secondary O 0 5.355577741283923e-07
and O 0 1.101565999306331e-06
non O 0 1.8367749362369068e-05
- O 0 0.001341619179584086
cell O 0 9.25821004784666e-05
autonomous O 0 1.7011238924169447e-06
. O 0 4.773735781782307e-06

Rescued O 0 0.009673426859080791
embryos O 0 0.0019767330959439278
show O 0 0.0022925985977053642
severe O 0 0.47289034724235535
anterior O 1 0.575474202632904
truncations O 0 0.2965254783630371
, O 0 7.380323222605512e-05
indicating O 0 2.5671399271232076e-05
a O 0 5.703918191102275e-07
second O 0 5.097042958368547e-06
important O 0 1.1115876930034574e-07
role O 0 4.6364306172108627e-07
for O 0 1.9355192648617958e-07
Smad4 O 0 0.00017490102618467063
in O 0 1.208617845804838e-06
anterior O 0 0.0021147371735423803
patterning O 0 0.0010189402382820845
during O 0 3.677711356431246e-05
embryogenesis O 0 0.00041993564809672534
. O 0 1.6127241906360723e-05

Prevalence O 0 0.0017641530139371753
of O 0 2.1024743546149693e-06
p16 O 0 8.900857937987894e-05
and O 0 3.0524670364684425e-06
CDK4 O 0 0.002640020102262497
germline O 0 0.001878584735095501
mutations O 0 2.3201255316962488e-05
in O 0 9.54731603997061e-07
48 O 0 0.0033855331130325794
melanoma B-Disease 1 0.9998583793640137
- O 1 0.9056349992752075
prone O 0 0.22139711678028107
families O 0 5.8917130445479415e-06
in O 0 1.0653533308868646e-06
France O 0 4.37306152889505e-05
. O 0 7.054623893054668e-06

The O 0 1.5718424037913792e-05
French O 0 0.02963276579976082
Familial B-Disease 1 0.9686591029167175
Melanoma I-Disease 1 0.9998723268508911
Study O 0 9.997969027608633e-05
Group O 0 0.00020022488024551421
. O 0 1.4216503586794715e-05

Germline O 0 0.15000535547733307
mutations O 0 0.0007670314516872168
in O 0 5.217057150730398e-07
the O 0 2.706806299102027e-07
p16 O 0 7.129576260922477e-06
and O 0 6.981338174227858e-07
CDK4 O 0 0.0009603367652744055
genes O 0 4.66275196231436e-07
have O 0 1.6219024701058515e-07
been O 0 8.589083790866425e-07
reported O 0 1.185045675811125e-06
in O 0 2.373184493364988e-08
a O 0 1.7684287456631864e-07
subset O 0 1.7493662198830862e-06
of O 0 1.1207328498130664e-05
melanoma B-Disease 1 0.9983888864517212
pedigrees O 0 0.00033718193299137056
, O 0 1.4081285826250678e-06
but O 0 7.96789265677944e-08
their O 0 7.146828551185536e-08
prevalence O 0 0.00012072236859239638
is O 0 4.937450626130158e-07
not O 0 8.926969741196444e-08
well O 0 8.364129371329909e-07
known O 0 1.0812638720381074e-05
. O 0 3.945250227843644e-06

We O 0 1.0158403256355086e-06
searched O 0 6.120606485637836e-06
for O 0 3.6792442870137165e-08
such O 0 2.0099470532386476e-08
germline O 0 0.0001203956562676467
mutations O 0 2.484789320078562e-06
in O 0 1.551962043322419e-07
48 O 0 4.495701068663038e-05
French O 1 0.6168606877326965
melanoma B-Disease 1 0.9999666213989258
- O 1 0.9161970615386963
prone O 0 0.16968917846679688
families O 0 1.7732210153553751e-06
selected O 0 4.2021898138955294e-07
according O 0 4.053210034271615e-08
to O 0 3.934594872134767e-08
two O 0 2.0731076233460044e-07
major O 0 6.043048415449448e-06
criteria O 0 3.9372903870571463e-07
families O 0 2.1579120357273496e-07
with O 0 1.409779741834427e-07
at O 0 1.154794404101267e-06
least O 0 1.919280911977239e-08
three O 0 1.173031876078312e-07
affected O 0 3.770973933114874e-07
members O 0 1.4411651250156865e-07
( O 0 5.045571427331197e-08
n O 0 2.642816434672568e-05
= O 0 1.079505182133289e-05
20 O 0 3.2214671819019713e-07
) O 0 1.6286984205748922e-08
or O 0 1.7131595697605917e-08
families O 0 9.340744355768038e-08
with O 0 1.4882050436426653e-07
two O 0 1.4748211469850503e-06
affected O 0 2.8444640065572457e-06
members O 0 2.2231759544411034e-07
, O 0 8.115256378005142e-08
one O 0 1.1758046092325003e-08
of O 0 1.1219905893256055e-08
them O 0 4.47519603596902e-08
affected O 0 2.0711374304482888e-07
before O 0 6.656762252532644e-08
the O 0 4.0062332118395716e-08
age O 0 3.4379868907308264e-07
of O 0 5.169708217067637e-08
50 O 0 7.696056627537473e-07
( O 0 5.055609619830648e-08
n O 0 2.93320063065039e-05
= O 0 3.2221974834101275e-05
28 O 0 6.4400815062981565e-06
) O 0 8.954749119993721e-08
, O 0 2.41123263577947e-08
and O 0 4.952022081283758e-08
one O 0 2.549422895015141e-08
additional O 0 4.358012404281908e-07
minor O 0 3.693901453516446e-05
criterion O 0 0.0002806002157740295
. O 0 1.1677601833071094e-05

Sixteen O 0 1.0636949809850194e-05
different O 0 3.095399563335377e-07
p16 O 0 2.669199056981597e-05
germline O 0 0.0007392321713268757
mutations O 0 9.397439862368628e-05
were O 0 7.327032562898239e-06
found O 0 3.650651251518866e-06
in O 0 2.778840269002103e-07
21 O 0 1.648015677346848e-05
families O 0 1.5831319615244865e-06
, O 0 3.261894221395778e-07
while O 0 2.9108031185387517e-07
one O 0 7.879270214061762e-08
germline O 0 9.007340122479945e-05
mutation O 0 2.3579266326123616e-06
, O 0 3.742927106031857e-07
Arg24His O 0 9.966071957023814e-05
, O 0 3.480062105154502e-07
was O 0 5.027855877415277e-06
detected O 0 1.453833760933776e-06
in O 0 1.2714231445443147e-08
the O 0 2.735831685640733e-07
CDK4 O 0 0.0025349135976284742
gene O 0 1.9655881260405295e-06
. O 0 1.4438066955335671e-06

The O 0 4.595565883391828e-07
frequency O 0 2.616882284200983e-07
of O 0 3.9051968769854284e-08
p16 O 0 4.845416242460487e-06
gene O 0 2.046847811243424e-07
mutation O 0 2.241736893893176e-07
in O 0 1.239043712075727e-08
our O 0 3.94130772463086e-09
sample O 0 3.49155371281995e-08
( O 0 1.3917744290381506e-08
44 O 0 2.5309161628683796e-06
% O 0 2.0395603428369213e-07
) O 0 2.982425684194823e-08
is O 0 2.9314028537896775e-08
among O 0 7.843703286880555e-08
the O 0 1.2747855748784787e-07
highest O 0 3.792952702497132e-05
rates O 0 4.219295078655705e-06
yet O 0 1.9267748996298906e-07
reported O 0 3.7876936858083354e-06
and O 0 2.102056271269248e-07
the O 0 4.0632690456732234e-07
CDK4 O 0 0.04041019827127457
mutation O 0 6.670526886409789e-07
is O 0 1.4642003165477036e-08
the O 0 7.346582009404301e-09
second O 0 3.207006557204295e-06
mutation O 0 1.9108197193418164e-06
detected O 0 1.6930736137510394e-06
in O 0 1.1738171323827373e-08
this O 0 1.4062718989293899e-08
gene O 0 4.218081244289351e-07
worldwide O 0 3.2254129109787755e-06
. O 0 2.3330198928306345e-06

In O 0 3.5373950595385395e-06
summary O 0 3.989818651461974e-06
, O 0 7.479375767616148e-07
our O 0 1.9943739104633096e-08
results O 0 1.2565033102873713e-07
show O 0 1.299072067695306e-07
frequent O 0 4.820904564439843e-08
involvement O 0 3.700714330534538e-07
of O 0 1.3513102636864005e-08
the O 0 7.042968519499482e-08
p16 O 0 1.4046066780792898e-06
gene O 0 1.613982334447428e-07
in O 0 3.347260246755468e-07
familial B-Disease 0 0.10859649628400803
melanoma I-Disease 1 0.9995458722114563
and O 0 1.44815576277324e-05
confirm O 0 1.643269570195116e-06
the O 0 1.0400854932868242e-07
role O 0 1.9634771319942956e-07
of O 0 4.904306738495734e-09
the O 0 2.011289836900687e-07
CDK4 O 0 0.002080090343952179
gene O 0 2.647868200256198e-07
as O 0 1.953592771997137e-07
a O 0 2.4640123228891753e-05
melanoma B-Disease 1 0.998286783695221
- O 0 0.1591673195362091
predisposing O 0 0.0003609201521612704
gene O 0 6.380973900377285e-07
. O 0 1.0628593827277655e-07
. O 0 1.0276471584802493e-06

Progression O 0 0.00010318217391613871
of O 0 1.3524186215363443e-06
somatic O 0 0.00027020080597139895
CTG O 0 0.004661335609853268
repeat O 0 2.4535100237699226e-05
length O 0 5.341649284673622e-06
heterogeneity O 0 1.1529265975696035e-05
in O 0 7.364782561580796e-08
the O 0 4.2879813122453925e-07
blood O 0 0.0002715488662943244
cells O 0 3.599090996431187e-05
of O 0 0.0010359983425587416
myotonic B-Disease 1 0.9999929666519165
dystrophy I-Disease 1 0.9999924898147583
patients O 1 0.647705614566803
. O 0 7.541486411355436e-05

The O 0 4.378527137305355e-06
genetic O 0 3.783898864639923e-05
basis O 0 3.6727526548929745e-06
of O 0 0.006484032142907381
myotonic B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999992847442627
( O 0 0.19137586653232574
DM B-Disease 1 0.9999977350234985
) O 0 1.1293373972875997e-05
is O 0 1.0311002540674963e-07
the O 0 4.27039239525584e-08
expansion O 0 5.13959435011202e-07
of O 0 8.495572245692529e-08
an O 0 9.497247447143309e-06
unstable O 0 0.0030440976843237877
CTG O 0 0.00035478980862535536
repeat O 0 1.5602072380715981e-06
in O 0 2.216050454251217e-08
the O 0 2.5495687339116557e-08
34 O 0 2.1497198758879676e-06
UTR O 0 4.833905222767498e-06
of O 0 2.1899653646073602e-08
the O 0 9.762109129951568e-07
DM B-Disease 1 0.9994381070137024
protein O 0 1.3748378933087224e-06
kinase O 0 2.2526439806824783e-06
gene O 0 1.5787279039614077e-07
on O 0 1.0002954695664812e-06
chromosome O 0 0.0001608516467968002
19 O 0 6.126660446170717e-05
. O 0 8.291687663586345e-06

One O 0 1.9508777313603787e-06
of O 0 2.934374379037763e-07
the O 0 2.8259594841983926e-07
principal O 0 2.6371480998932384e-06
features O 0 9.831791913939014e-08
of O 0 9.819311230785388e-08
the O 0 1.0248264516121708e-05
DM B-Disease 1 0.9999953508377075
mutation O 0 7.526758417952806e-05
is O 0 1.8129225054508424e-07
an O 0 3.9772260151949013e-07
extraordinarily O 0 7.909171836217865e-05
high O 0 2.2554348106496036e-05
level O 0 1.0330431621241587e-07
of O 0 5.1499860376225115e-08
somatic O 0 0.0002905184810515493
mosaicism O 0 0.33268097043037415
, O 0 8.606371920905076e-06
due O 0 4.4876169340568595e-06
to O 0 1.4090296929225588e-07
an O 0 1.0169821962335845e-06
extremely O 0 4.888465355179505e-06
high O 0 1.0740350262494758e-05
degree O 0 6.465401725108677e-07
of O 0 3.299183219951374e-07
somatic O 0 0.0015391624765470624
instability O 0 4.633888602256775e-05
both O 0 1.3131472087479779e-07
within O 0 1.8024920223069785e-08
and O 0 1.7610858549232944e-07
between O 0 8.646393467870439e-08
different O 0 1.3967212453280808e-07
tissues O 0 6.094012496760115e-05
. O 0 4.658312718675006e-06

This O 0 7.531565643148497e-06
instability O 0 0.0006587301031686366
appears O 0 7.646165613550693e-06
to O 0 3.064645426320567e-08
be O 0 4.064441228024407e-09
biased O 0 1.1945616051889374e-07
towards O 0 1.9955953334260812e-08
further O 0 1.5894411120598306e-08
expansion O 0 1.2272066385321523e-07
and O 0 5.2045638909703484e-08
continuous O 0 5.241822975676769e-08
throughout O 0 1.4295785000228989e-08
the O 0 3.107597379425897e-08
life O 0 7.021561287956501e-08
of O 0 5.1749367457887274e-08
an O 0 1.2456428066798253e-06
individual O 0 8.698098667991871e-07
, O 0 1.6178918258447084e-06
features O 0 1.2571891829793458e-06
that O 0 5.648303726957238e-07
could O 0 3.7957465792715084e-06
be O 0 2.092276361054246e-07
associated O 0 1.5513184337123676e-07
with O 0 2.3585398878367414e-07
the O 0 1.262830892301281e-06
progressive O 0 0.0004905379610136151
nature O 0 1.0962714895867975e-06
of O 0 1.4635477327828994e-06
the O 0 0.0002882665430661291
disease O 0 0.045577481389045715
. O 0 2.2225634893402457e-05

Although O 0 4.074657226738054e-06
increasing O 0 5.685995461135462e-07
measured O 0 7.839356612748816e-07
allele O 0 1.3027074601268396e-06
size O 0 7.25977997717564e-06
between O 0 2.786538743748679e-06
patients O 0 4.985025952919386e-05
clearly O 0 2.052118588835583e-06
correlates O 0 1.3357055195228895e-06
with O 0 6.057618975319201e-07
an O 0 6.3323823269456625e-06
increased O 0 6.674452743027359e-05
severity O 0 0.0004528489080257714
of O 0 3.957728040404618e-05
symptoms O 0 0.0005296367453411222
and O 0 1.1353459967722301e-06
an O 0 1.9128615349472966e-06
earlier O 0 0.00010168392327614129
age O 0 1.1003900908690412e-05
of O 0 1.028869974106783e-06
onset O 0 0.00014322462084237486
, O 0 1.0549003945925506e-06
this O 0 9.395257016819869e-09
correlation O 0 6.848122779956611e-07
is O 0 1.8448750438437855e-07
not O 0 5.908889821881758e-09
precise O 0 4.11049470017133e-08
and O 0 4.905151627099258e-07
measured O 0 6.2224121393228415e-06
allele O 0 9.291699143432197e-07
length O 0 7.772731805744115e-06
cannot O 0 6.764518616364512e-07
be O 0 4.617491455860545e-08
used O 0 1.3753385985637578e-07
as O 0 7.160021908703129e-08
an O 0 6.967517407474588e-08
accurate O 0 1.137300955633691e-06
predictor O 0 2.9350139811867848e-05
of O 0 1.7393156781508878e-07
age O 0 7.289660970855039e-06
of O 0 2.289307303726673e-06
onset O 0 0.002277855994179845
. O 0 1.8793924027704634e-05

In O 0 2.5109761736530345e-06
order O 0 2.662062286162836e-07
to O 0 9.741852657896288e-09
further O 0 6.362255611236378e-09
characterize O 0 1.5585267476581066e-07
the O 0 4.467281655706756e-08
dynamics O 0 3.7693200283683836e-05
of O 0 2.93863831757335e-06
DM B-Disease 1 0.9999451637268066
CTG O 0 0.0016067734686657786
repeat O 0 5.9357757891120855e-06
somatic O 0 2.1849684344488196e-05
instability O 0 6.126993685029447e-05
, O 0 5.337038828656659e-07
we O 0 5.370388933556569e-08
have O 0 6.636529548131875e-08
studied O 0 2.1253464410619927e-07
repeat O 0 4.2354631091257033e-07
length O 0 3.7388528539850086e-07
changes O 0 2.0281390789023135e-08
over O 0 5.60431701046582e-08
time O 0 1.644864369154675e-07
in O 0 5.743356723542092e-06
111 O 1 0.9812391996383667
myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.999998927116394
patients O 0 0.00287051685154438
with O 0 1.409880837854871e-06
varying O 0 2.8436420507205185e-06
clinical O 0 0.00029525841819122434
severity O 0 0.00017607248446438462
and O 0 7.156585979828378e-06
CTG O 0 0.001527900225482881
repeat O 0 6.943292646610644e-06
size O 0 1.000324118649587e-06
over O 0 7.902146847982294e-08
time O 0 7.374660437875491e-09
intervals O 0 9.026028813252651e-09
of O 0 5.127860802645046e-09
1 O 0 4.685878991494974e-07
- O 0 7.579589873785153e-05
7 O 0 5.942822554061422e-06
years O 0 4.4790053834731225e-06
. O 0 2.0342022253316827e-06

We O 0 6.611900516872993e-06
have O 0 9.086400041269371e-07
found O 0 2.703540360471379e-07
a O 0 2.957145284199214e-08
direct O 0 1.088188472664342e-08
progression O 0 5.150776587470318e-07
of O 0 3.3992805015259364e-08
the O 0 2.9224213449197123e-07
size O 0 8.46486545924563e-06
heterogeneity O 0 5.8237669691152405e-06
over O 0 8.265848805422138e-07
time O 0 8.953144003953639e-08
related O 0 6.892531700941618e-07
to O 0 3.720356644976164e-08
initial O 0 6.965981924622611e-07
CTG O 0 7.96415624790825e-05
repeat O 0 7.864786653044575e-07
size O 0 1.0308627906852053e-06
and O 0 3.8979784733328415e-08
the O 0 1.402163274377699e-08
time O 0 1.666012217071966e-08
interval O 0 1.0498477109877058e-07
and O 0 6.088105664048271e-08
always O 0 6.526525542227546e-09
biased O 0 4.626739524837831e-08
towards O 0 1.4820816574001583e-08
further O 0 3.990735919501276e-08
expansion O 0 1.4856329926260514e-06
. O 0 1.0432798944748356e-06

Attempts O 0 1.3470788871927653e-05
to O 0 2.105458918322256e-07
mathematically O 0 5.852580216014758e-06
model O 0 2.1874996036785888e-06
the O 0 4.319420270348928e-07
dynamics O 0 0.0008875727071426809
have O 0 1.340446260655881e-06
proved O 0 5.961503120488487e-06
only O 0 4.2243129882990615e-08
partially O 0 2.554623642936349e-05
successful O 0 2.25091093852825e-06
suggesting O 0 2.63671290667844e-06
that O 0 1.9157440078743093e-08
individual O 0 2.194363979413083e-08
specific O 0 2.1284819240463548e-08
genetic O 0 3.829072284133872e-06
and O 0 3.4460201732144924e-06
/ O 0 6.602230132557452e-05
or O 0 3.2764744446467375e-06
environmental O 0 6.577946624020115e-05
factors O 0 8.413490490966069e-07
also O 0 1.7740299540491833e-07
play O 0 5.265089697559233e-08
a O 0 1.4609649667818303e-07
role O 0 6.271534402912948e-07
in O 0 2.510257672838634e-07
somatic O 0 0.00015093151887413114
mosaicism O 0 0.016331836581230164
. O 0 9.349778906653228e-07
. O 0 3.1751922051626025e-06

Aspartylglucosaminuria B-Disease 1 0.9906138181686401
among O 0 7.020893099252135e-05
Palestinian O 0 0.00019726756727322936
Arabs O 0 0.00018090712546836585
. O 0 1.263805097551085e-05

Aspartylglucosaminuria B-Disease 1 0.9996761083602905
( O 0 0.015625786036252975
AGU B-Disease 1 0.9998664855957031
) O 0 2.068712274194695e-05
is O 0 2.554196271375986e-06
a O 0 4.740824442706071e-05
rare O 0 0.05014316737651825
disorder B-Disease 0 0.23607245087623596
of I-Disease 0 1.1239202649448998e-05
glycoprotein I-Disease 0 0.38752448558807373
metabolism I-Disease 0 0.011164693161845207
caused O 0 9.59899480221793e-05
by O 0 2.442371169308899e-06
the O 0 9.868646156974137e-05
deficiency B-Disease 0 0.038289666175842285
of I-Disease 0 1.7567982979471708e-07
the I-Disease 0 8.453032023680862e-06
lysosomal I-Disease 1 0.5328963994979858
enzyme I-Disease 0 0.00043150747660547495
aspartylglucosaminidase I-Disease 0 0.005393315572291613
( O 0 9.330236707683071e-07
AGA O 0 0.00014938019739929587
) O 0 5.698796030628728e-07
. O 0 1.1652842886178405e-06

AGU B-Disease 1 0.9998563528060913
is O 0 0.014118502847850323
inherited O 1 0.9920073747634888
as O 0 9.357521776109934e-05
an O 0 0.0014562883879989386
autosomal O 1 0.986315131187439
recessive O 1 0.9603792428970337
trait O 0 0.03214680030941963
and O 0 2.7728474378818646e-05
occurs O 0 2.7485279474603885e-07
with O 0 3.6663516311818967e-07
a O 0 1.540796915833198e-06
high O 0 4.833615093957633e-05
frequency O 0 7.106781936272455e-07
in O 0 3.5421442134975223e-07
Finland O 0 3.3517746487632394e-05
because O 0 3.195345499307223e-08
of O 0 9.527787447893843e-09
a O 0 1.5036927152323187e-06
founder O 0 0.0023559133987873793
effect O 0 4.699426426668651e-06
. O 0 1.8345094758842606e-06

While O 0 9.30427631828934e-05
very O 0 3.7470167626452167e-06
few O 0 2.3602528926858213e-06
patients O 0 6.0861311794724315e-05
with O 0 5.3405343351187184e-05
AGU B-Disease 1 0.9999921321868896
have O 0 1.6872523701749742e-05
been O 0 1.5425024457726977e-06
reported O 0 3.011475200764835e-06
from O 0 1.6758258425397798e-07
non O 0 8.798204362392426e-06
- O 0 0.002094440395012498
Finnish O 0 0.019546374678611755
origin O 0 1.7173100559375598e-06
, O 0 2.2219453512661858e-06
we O 0 4.950491074851016e-06
diagnosed O 0 0.1842932552099228
the O 0 1.879265073512215e-05
disorder O 0 0.014088204130530357
in O 0 2.647608198458329e-06
8 O 0 8.565240568714216e-05
patients O 0 6.595620561711257e-06
originating O 0 7.893319775575947e-08
from O 0 1.4641059919995314e-07
3 O 0 4.854990947933402e-06
unrelated O 0 0.00016184552805498242
families O 0 2.693691158128786e-06
, O 0 1.7067742419385468e-07
all O 0 4.601023118055991e-09
Palestinian O 0 5.87089914461103e-07
Arabs O 0 2.0382206855629192e-07
from O 0 1.3450923930236058e-08
the O 0 1.3653159491866518e-08
region O 0 6.022665388627502e-08
of O 0 8.605295676034075e-08
Jerusalem O 0 3.3910440834006295e-05
. O 0 6.49035655442276e-06

The O 0 1.6634086932754144e-05
clinical O 0 0.0026264898478984833
diagnosis O 0 0.0899805948138237
of O 0 0.002275188686326146
AGU B-Disease 1 0.9999977350234985
is O 0 0.0005460536922328174
often O 0 8.930977855925448e-06
difficult O 0 4.622140750143444e-06
, O 0 1.5268539073076681e-06
in O 0 3.068842886477796e-07
particular O 0 1.528526496485938e-07
early O 0 7.43773625799804e-07
in O 0 1.047319670988145e-07
the O 0 1.7813879082950734e-07
course O 0 1.016296778288961e-06
of O 0 7.01556359672395e-07
the O 0 0.00018209988775197417
disease O 0 0.008635968901216984
, O 0 7.444896255037747e-07
and O 0 5.633708610730537e-07
most O 0 3.1868665928413975e-08
of O 0 5.3726836313217063e-08
the O 0 2.1804969946970232e-05
patients O 0 0.0006204885430634022
are O 0 6.786949597881176e-06
diagnosed O 0 0.2143777757883072
after O 0 2.5306192128482508e-06
the O 0 2.2929708620722522e-07
age O 0 1.4830961845291313e-06
of O 0 9.217107788117573e-08
5 O 0 5.456408416648628e-06
years O 0 9.652292646933347e-06
. O 0 5.137113021191908e-06

However O 0 2.9088518203934655e-05
, O 0 2.088963583446457e-06
since O 0 1.739572439873882e-06
these O 0 6.910922678571296e-08
patients O 0 2.474516577422037e-06
excrete O 0 4.770618033944629e-07
early O 0 3.9651592231848554e-08
large O 0 3.963593897537976e-08
amounts O 0 2.252339470487641e-08
of O 0 1.4985284124691134e-08
aspartylglucosamine O 0 7.861355697968975e-05
in O 0 9.527246191964878e-08
urine O 0 8.650911240692949e-07
, O 0 3.879642562765184e-08
biochemical O 0 7.93706817603379e-07
screening O 0 2.0768180775121436e-07
is O 0 2.2560973533813922e-08
easy O 0 4.4284099942615285e-08
by O 0 2.5824192562140524e-07
urine O 0 5.676336513715796e-06
chromatography O 0 0.00026981980772688985
. O 0 2.424073670681537e-07
. O 0 1.1993632824669476e-06

Detection O 0 4.557428474072367e-05
of O 0 1.3520033235181472e-06
heterozygous O 0 5.7249471865361556e-05
carriers O 0 2.9208575142547488e-05
of O 0 7.411763931486348e-07
the O 0 0.0002413807378616184
ataxia B-Disease 1 0.999993085861206
- I-Disease 1 0.9999680519104004
telangiectasia I-Disease 1 0.9999797344207764
( O 0 8.019317647267599e-06
ATM O 0 0.0005911345360800624
) O 0 1.0816147266723419e-07
gene O 0 2.809151489202577e-08
by O 0 4.597024982899711e-08
G2 O 0 0.00016715934907551855
phase O 0 6.857076186861377e-06
chromosomal O 0 0.0087656918913126
radiosensitivity O 0 0.000794390041846782
of O 0 2.4805867724353448e-06
peripheral O 0 0.04959762841463089
blood O 0 0.002172797219827771
lymphocytes O 0 0.002364899730309844
. O 0 3.4564138786663534e-06

In O 0 0.0027731340378522873
ataxia B-Disease 1 0.9999402761459351
- I-Disease 1 0.9999386072158813
telangiectasia I-Disease 1 0.9999833106994629
( O 0 0.002015677746385336
A B-Disease 1 0.999526858329773
- I-Disease 1 0.9999957084655762
T I-Disease 1 0.9999991655349731
) O 0 0.00014147972979117185
patients O 0 6.890131044201553e-05
, O 0 3.88882625657061e-07
mutations O 0 6.737928970323992e-07
in O 0 2.910371854625282e-08
a O 0 3.849363849894871e-07
single O 0 5.879790933249751e-06
gene O 0 1.049657043949992e-06
, O 0 2.663641964772978e-07
ATM O 0 6.952946569072083e-05
, O 0 6.040970106369059e-07
result O 0 2.4204314286180306e-06
in O 0 5.714164217351936e-05
an O 1 0.9596821069717407
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999997615814209
that O 0 1.7598376871319488e-05
embraces O 0 5.4548789194086567e-05
a O 0 2.519052031857427e-06
variety O 0 4.946306262354483e-07
of O 0 3.870028137953341e-07
clinical O 0 1.7860391380963847e-05
features O 0 9.422927178093232e-06
and O 0 9.173538273898885e-06
manifests O 0 2.3719983801129274e-05
extreme O 0 2.1271451259963214e-05
radiosensitivity O 0 0.000671402201987803
and O 0 7.429966331073956e-07
a O 0 4.1961428109971166e-07
strong O 0 5.060549597146746e-07
pre O 0 3.423151792958379e-05
- O 0 0.00019110667926725
disposition O 0 1.9748171325773e-05
to O 0 1.2453755289243418e-06
malignancy B-Disease 0 0.008853022940456867
. O 0 5.110662186780246e-06

Heterozygotes O 0 0.0010362856555730104
for O 0 1.256061523235985e-06
the O 0 5.953884851805924e-07
ATM O 0 0.0016466836677864194
gene O 0 5.288044121698476e-06
have O 0 1.8213899011243484e-07
no O 0 3.380904090022341e-08
clinical O 0 6.10492634223192e-07
expression O 0 1.0015003937269285e-07
of O 0 7.498574063902197e-07
A B-Disease 1 0.9931749701499939
- I-Disease 1 0.9999779462814331
T I-Disease 1 0.9999978542327881
but O 0 0.000150182269862853
may O 0 8.399780199397355e-05
be O 0 9.903886530082673e-05
cancer B-Disease 0 0.30047154426574707
prone O 0 0.0006196771282702684
with O 0 3.1803185152057267e-07
a O 0 1.91473054655944e-06
moderate O 0 5.180286098038778e-05
increase O 0 1.5274728184522246e-06
in O 0 4.294340527621898e-08
in O 0 3.402998629553622e-07
vitro O 0 0.0001330106024397537
radiosensitivity O 0 0.0009027175838127732
. O 0 4.3650061343214475e-06

We O 0 5.816967586724786e-06
performed O 0 7.753326826787088e-06
a O 0 1.518679368928133e-06
blind O 0 4.963376704836264e-05
chromosomal O 0 0.0001531368907308206
analysis O 0 3.2134403227246366e-07
on O 0 3.456796321188449e-06
G2 O 0 0.008579375222325325
- O 0 0.0013891655253246427
phase O 0 1.197887922899099e-05
lymphocytes O 0 0.00028345687314867973
from O 0 2.0195605543449346e-07
7 O 0 3.332819460410974e-06
unrelated O 0 0.0007066873949952424
A B-Disease 1 0.9900604486465454
- I-Disease 1 0.9999886751174927
T I-Disease 1 0.9999986886978149
patients O 0 0.00031327607575803995
, O 0 2.90421468207569e-07
13 O 0 4.6843338168400805e-06
obligate O 0 2.2034702851669863e-05
A B-Disease 1 0.9395222663879395
- I-Disease 1 0.9999525547027588
T I-Disease 1 0.999994158744812
heterozygotes O 0 0.0007983429823070765
( O 0 9.949108914497629e-08
parents O 0 5.8643855993523175e-08
of O 0 5.769789979126472e-08
the O 0 1.1037532203772571e-05
patients O 0 3.6782446841243654e-05
) O 0 9.469906103731773e-08
, O 0 1.2843341323787172e-07
and O 0 1.889759886353204e-07
14 O 0 6.249181296880124e-07
normal O 0 2.608437554840748e-08
controls O 0 6.484600589828915e-08
following O 0 5.700547234255282e-08
X O 0 5.305706145009026e-05
- O 0 1.528501888969913e-05
irradiation O 0 1.5217152338209416e-07
with O 0 2.153210232336278e-08
1 O 0 1.8843466875750892e-07
Gy O 0 1.1056285075028427e-05
in O 0 8.707558230014456e-09
order O 0 5.948751269357899e-09
to O 0 2.6606441494436694e-09
evaluate O 0 5.7048108459412106e-08
this O 0 1.1590374215941779e-09
cytogenetic O 0 3.10130235448014e-06
method O 0 3.846846041710705e-08
as O 0 4.650592799748665e-08
a O 0 3.882966836954438e-08
tool O 0 4.7414806658707676e-07
for O 0 1.5271867326305255e-08
detection O 0 3.514605850796215e-07
of O 0 1.1424597090581301e-07
ATM O 0 0.011685870587825775
carriers O 0 0.00011298630124656484
. O 0 2.0774134554812917e-06

Both O 0 6.215217581484467e-05
A B-Disease 1 0.6233149766921997
- I-Disease 1 0.9994251728057861
T I-Disease 1 0.9999487400054932
homozygotes O 0 0.0027405715081840754
and O 0 1.1909518207176006e-06
heterozygotes O 0 1.8728173017734662e-05
showed O 0 8.495168913214002e-06
significantly O 0 3.6695698213407013e-07
increased O 0 7.611170360632968e-08
levels O 0 1.5133668540556755e-08
of O 0 4.0339056539551166e-08
radiation O 0 0.0006347658345475793
- O 0 0.03661227226257324
induced O 0 0.0338948629796505
chromatid O 1 0.6579955220222473
damage O 0 0.013051385059952736
relative O 0 2.9882930903113447e-06
to O 0 2.0721602211892787e-08
that O 0 6.303527921858176e-09
of O 0 3.093250811048165e-08
normal O 0 2.675197094959003e-07
controls O 0 3.1516583476332016e-06
. O 0 1.6992900100376573e-06

These O 0 7.600564799759013e-07
results O 0 8.05720162588841e-07
show O 0 3.7859857116018247e-07
that O 0 1.1138750366512795e-08
the O 0 4.8181924228174466e-08
G2 O 0 0.007706903386861086
- O 0 0.0019892544951289892
phase O 0 9.666054211265873e-06
chromosomal O 0 0.03695215657353401
radiosensitivity O 0 0.021114839240908623
assay O 0 3.5010132705792785e-05
can O 0 6.666673613153762e-08
be O 0 1.637963542577836e-08
used O 0 2.2143940014984764e-08
for O 0 6.914624872678132e-09
the O 0 1.0203532241348512e-08
detection O 0 1.3151239954822813e-06
of O 0 2.946203494502697e-06
A B-Disease 1 0.9248206615447998
- I-Disease 1 0.9995372295379639
T I-Disease 1 0.9998927116394043
heterozygotes O 0 0.0026138094253838062
. O 0 6.557718734256923e-06

In O 0 6.550624675583094e-06
combination O 0 1.4865986486256588e-05
with O 0 1.016276314658171e-06
molecular O 0 5.797903941129334e-05
genetic O 0 3.689085497171618e-05
analyses O 0 1.0543047210376244e-05
, O 0 2.0776333258254454e-06
this O 0 4.4104048413373675e-08
test O 0 2.8227803340996616e-05
may O 0 6.52927951705351e-07
be O 0 7.749109798282916e-09
of O 0 8.292850850466493e-09
value O 0 2.1921535164892703e-07
in O 0 7.784192490589703e-08
studies O 0 7.757913067507616e-08
of O 0 2.469987236963789e-07
familial B-Disease 0 0.00016634365601930767
and I-Disease 0 2.9908798751421273e-05
sporadic I-Disease 0 0.0002955006202682853
cancers I-Disease 0 0.14910736680030823
aimed O 0 1.2019043424515985e-05
at O 0 1.3526765769711346e-06
determination O 0 1.986769859740889e-07
of O 0 7.868348639306078e-09
the O 0 6.965776577771976e-08
potential O 0 5.918830083828652e-07
involvement O 0 3.173549885104876e-07
of O 0 6.701784371898611e-08
ATM O 0 0.0054389238357543945
mutations O 0 2.723631951084826e-05
in O 0 1.2848630831285845e-05
tumor B-Disease 1 0.7818854451179504
risk O 0 3.372995342942886e-05
or O 0 1.0793972649025818e-07
development O 0 2.928615003838786e-07
. O 0 2.695238094929664e-07
. O 0 1.910810397021123e-06

Ataxia B-Disease 1 0.9998565912246704
- I-Disease 1 0.9995922446250916
telangiectasia I-Disease 1 0.9998528957366943
: O 0 3.353735110067646e-06
identification O 0 9.84967755357502e-07
and O 0 4.826553094972041e-07
detection O 0 2.8100841973355273e-06
of O 0 9.259341027245682e-07
founder O 0 0.016628656536340714
- O 0 0.01793668605387211
effect O 0 1.52456948399049e-06
mutations O 0 2.8868373647128465e-07
in O 0 4.107687079368816e-09
the O 0 1.6985344686304416e-08
ATM O 0 5.561123907682486e-05
gene O 0 1.238956883753417e-07
in O 0 2.813644961463524e-08
ethnic O 0 9.31816089178028e-07
populations O 0 6.03507760388311e-06
. O 0 2.793933617795119e-06

To O 0 4.6951967647146375e-07
facilitate O 0 1.9935777118007536e-07
the O 0 3.1154549162693e-08
evaluation O 0 3.174551821416571e-08
of O 0 3.1645402742697115e-08
ATM O 0 0.0002595479891169816
heterozygotes O 0 1.5535748389083892e-05
for O 0 5.235618232291017e-07
susceptibility O 0 2.5836663553491235e-05
to O 0 4.4396415432856884e-07
other O 0 8.009954399312846e-06
diseases O 0 0.0074673984199762344
, O 0 9.906907507684082e-07
such O 0 9.591312846168876e-07
as O 0 0.023308448493480682
breast B-Disease 1 0.9998311996459961
cancer I-Disease 1 0.7985114455223083
, O 0 3.439719421294285e-06
we O 0 1.1734649518757578e-07
have O 0 1.2387252468215593e-07
attempted O 0 1.0048744115920272e-05
to O 0 8.099731019228784e-08
define O 0 2.9428264269881765e-07
the O 0 2.0517786936125049e-07
most O 0 2.0988952087463986e-07
common O 0 4.471202998956869e-07
mutations O 0 4.372103603600408e-07
and O 0 7.676529634181861e-08
their O 0 6.270290242582632e-08
frequencies O 0 1.944519908647635e-06
in O 0 6.005863906466402e-05
ataxia B-Disease 1 0.9999539852142334
- I-Disease 1 0.9998629093170166
telangiectasia I-Disease 1 0.9999808073043823
( O 0 0.00010434866999275982
A B-Disease 1 0.9980437755584717
- I-Disease 1 0.9999810457229614
T I-Disease 1 0.9999897480010986
) O 0 3.8789590917076566e-07
homozygotes O 0 3.873975401802454e-06
from O 0 2.7930379786766935e-08
10 O 0 5.946950665247641e-08
ethnic O 0 2.621415831072227e-07
populations O 0 6.2566696215071715e-06
. O 0 2.2326339603750966e-06

Both O 0 2.859060259652324e-06
genomic O 0 6.259704241529107e-05
mutations O 0 3.8508140278281644e-05
and O 0 4.614960573690041e-07
their O 0 5.3590820670024186e-08
effects O 0 3.8951029068812204e-07
on O 0 1.891586549618296e-07
cDNA O 0 2.427507297397824e-06
were O 0 6.047625902283471e-06
characterized O 0 2.240232061012648e-05
. O 0 8.034696293179877e-06

Protein O 0 2.0750390831381083e-05
- O 0 4.2661216866690665e-05
truncation O 0 2.4030290660448372e-05
testing O 0 4.739383143714804e-07
of O 0 7.974092497420315e-09
the O 0 9.807496148539485e-09
entire O 0 3.16478185879987e-08
ATM O 0 6.628219580306904e-06
cDNA O 0 3.764391180993698e-07
detected O 0 2.1827420368936146e-06
92 O 0 3.186866024407209e-06
( O 0 7.264402768214495e-08
66 O 0 2.1874806407140568e-05
% O 0 2.0774795927991363e-07
) O 0 1.962121309873055e-08
truncating O 0 2.5657168407633435e-06
mutations O 0 5.097526241115702e-07
in O 0 1.600099430731916e-08
140 O 0 4.1414111251469876e-07
mutant O 0 1.2258175047463737e-05
alleles O 0 1.5508791193497018e-06
screened O 0 3.0182663977029733e-05
. O 0 2.7999831218039617e-06

The O 0 7.176324288593605e-06
haplotyping O 0 0.008016201667487621
of O 0 1.3947174920758698e-05
patients O 0 0.00013359682634472847
with O 0 8.636559414298972e-07
identical O 0 0.0002710220287553966
mutations O 0 4.500238719629124e-05
indicates O 0 4.0820900721882936e-06
that O 0 3.650904645269293e-08
almost O 0 4.588210700262607e-09
all O 0 1.2728225140534732e-09
of O 0 9.970039904771966e-09
these O 0 1.0792918558877318e-08
represent O 0 5.465884669320076e-07
common O 0 1.618357941879367e-06
ancestry O 0 0.00010142806422663853
and O 0 3.264264023528085e-06
that O 0 1.510803571136421e-07
very O 0 8.708243370847413e-08
few O 0 1.816219139527675e-07
spontaneously O 0 5.841310667165089e-06
recurring O 0 3.463184111751616e-05
ATM O 0 0.0009017165284603834
mutations O 0 9.885087820293847e-06
exist O 0 5.351370759854035e-07
. O 0 1.9976916973973857e-06

Assays O 0 8.374585740966722e-05
requiring O 0 7.990865015017334e-06
minimal O 0 1.4249649211706128e-06
amounts O 0 1.741360335927311e-07
of O 0 1.3298375733938883e-08
genomic O 0 7.194394584075781e-06
DNA O 0 0.00014391310105565935
were O 0 2.7495084395923186e-06
designed O 0 6.927511549292831e-06
to O 0 2.0088663177375565e-08
allow O 0 2.2521332354585866e-08
rapid O 0 1.8421182801375835e-07
screening O 0 1.4308530182916002e-07
for O 0 5.366722888311415e-08
common O 0 1.8864305673105264e-07
ethnic O 0 1.215305474033812e-06
mutations O 0 2.3050342861097306e-05
. O 0 3.846567324217176e-06

These O 0 2.631061022384529e-07
rapid O 0 3.0914720809960272e-06
assays O 0 1.6286403479170986e-05
detected O 0 1.3985507393954322e-05
mutations O 0 1.8374457795289345e-06
in O 0 9.55091721266399e-08
76 O 0 5.9721965953940526e-05
% O 0 1.5923563978503807e-07
of O 0 3.287477738922462e-07
Costa O 0 0.013992957770824432
Rican O 0 0.3172953724861145
patients O 0 9.648716513765976e-05
( O 0 6.761217719031265e-08
3 O 0 4.835265485780837e-07
) O 0 1.7396068585640023e-08
, O 0 9.166262415760684e-09
50 O 0 2.5122973923430436e-08
% O 0 1.609284616677087e-08
of O 0 1.231168909043845e-07
Norwegian O 1 0.7515648007392883
patients O 0 0.0002687009982764721
( O 0 1.041789019495809e-07
1 O 0 5.913097993470728e-07
) O 0 4.9574843785649136e-08
, O 0 4.942972609001117e-08
25 O 0 1.8442223392867163e-07
% O 0 1.7263820595303514e-08
of O 0 1.1635503938123293e-07
Polish O 1 0.7519513964653015
patients O 0 0.0005449274322018027
( O 0 1.0389335614036099e-07
4 O 0 1.8585623138278606e-06
) O 0 8.874004464587415e-08
, O 0 6.572636834789591e-08
and O 0 1.5085907989487168e-07
14 O 0 8.40725022044353e-07
% O 0 4.1473825262983155e-08
of O 0 3.040686351596378e-07
Italian O 0 0.2939378321170807
patients O 0 0.0005833313334733248
( O 0 1.800407005703164e-07
1 O 0 2.5431493213545764e-06
) O 0 1.42389424695466e-07
, O 0 1.209907907195884e-07
as O 0 9.267029810189342e-08
well O 0 1.564371530093922e-07
as O 0 2.4831686573634215e-07
in O 0 6.115747055446263e-07
patients O 0 1.45956983033102e-06
of O 0 1.2432651885774249e-07
Amish O 0 0.0013175593921914697
/ O 0 1.074774900189368e-05
Mennonite O 0 0.00010749624198069796
and O 0 3.64317384082824e-06
Irish O 0 5.218409569351934e-05
English O 0 9.562178320265957e-07
backgrounds O 0 1.1455191270215437e-05
. O 0 5.9272001635690685e-06

Additional O 0 9.333795787824783e-06
mutations O 0 9.127482189796865e-05
were O 0 4.989223270968068e-06
observed O 0 9.235837978849304e-07
in O 0 7.792540657192149e-08
Japanese O 0 5.196854090172565e-06
, O 0 4.5602723730553407e-07
Utah O 0 8.862509275786579e-06
Mormon O 0 3.5572696788221947e-07
, O 0 2.99608089449066e-08
and O 0 1.926642596572492e-07
African O 0 3.2204732178797713e-06
American O 0 0.00010569510777713731
patients O 0 6.0311402194201946e-05
. O 0 5.238307949184673e-06

These O 0 2.954341766780999e-07
assays O 0 3.5806633604806848e-06
should O 0 2.980315727540983e-08
facilitate O 0 2.2760353601825045e-08
screening O 0 3.724677810623689e-07
for O 0 5.431418230728013e-07
A B-Disease 1 0.6397746205329895
- I-Disease 1 0.999249279499054
T I-Disease 1 0.9999430179595947
heterozygotes O 0 2.5162615202134475e-05
in O 0 4.319123547702475e-08
the O 0 1.5423435684169817e-07
populations O 0 9.789573596208356e-07
studied O 0 2.2431877368944697e-06
. O 0 3.190601773894741e-07
. O 0 1.4366877394422772e-06

The O 0 3.370204285602085e-05
von B-Disease 1 0.9709669947624207
Hippel I-Disease 1 0.996846616268158
- I-Disease 1 0.9917819499969482
Lindau I-Disease 1 0.9982441663742065
tumor I-Disease 0 0.4987151026725769
suppressor O 0 0.00035481344093568623
gene O 0 2.270560571560054e-06
is O 0 2.2941621935501644e-08
required O 0 7.339187035881878e-09
for O 0 3.472400322834801e-08
cell O 0 6.967085482756374e-06
cycle O 0 9.240578151548107e-07
exit O 0 1.8912667201220756e-06
upon O 0 4.838822178498958e-07
serum O 0 2.8533719159895554e-05
withdrawal O 0 5.44848899153294e-06
. O 0 1.968837068488938e-06

The O 0 5.102855084260227e-06
inactivation O 0 0.0008054533391259611
of O 0 4.285381010049605e-07
the O 0 5.144133410794893e-06
von B-Disease 1 0.9966017007827759
Hippel I-Disease 1 0.9988693594932556
- I-Disease 1 0.9909571409225464
Lindau I-Disease 1 0.9625222682952881
( I-Disease 0 5.296108611219097e-06
VHL I-Disease 0 0.004570348188281059
) I-Disease 0 2.033135388046503e-06
tumor I-Disease 0 0.0009991489350795746
suppressor O 0 0.00014943817222956568
gene O 0 6.577367003046675e-06
predisposes O 0 0.00024661701172590256
affected O 0 4.963378160027787e-06
individuals O 0 1.3942324983418075e-07
to O 0 1.1448144476844391e-07
the O 0 1.1225715752516408e-05
human O 0 0.26793962717056274
VHL B-Disease 1 0.9999659061431885
cancer I-Disease 1 0.9999891519546509
syndrome I-Disease 1 0.9991768002510071
and O 0 7.179569365689531e-06
is O 0 3.160208507324569e-06
associated O 0 4.501749572227709e-06
with O 0 2.0792585928575136e-05
sporadic B-Disease 1 0.5257880687713623
renal I-Disease 1 0.9999939203262329
cell I-Disease 1 0.9999369382858276
carcinomas I-Disease 1 0.9999984502792358
( O 0 0.0015099893789738417
RCC B-Disease 1 0.9955484867095947
) O 0 1.2691532901953906e-05
and O 0 3.98526644858066e-05
brain B-Disease 0 0.01154396589845419
hemangioblastomas I-Disease 0 0.02152566984295845
. O 0 6.582876267202664e-06

VHL O 0 0.44589105248451233
- O 0 0.0054716747254133224
negative O 0 1.8289059880771674e-05
786 O 0 0.0005473052733577788
- O 0 0.003971220925450325
0 O 0 1.7138027033070102e-05
RCC B-Disease 0 0.03551648184657097
cells O 0 1.2712318493868224e-05
are O 0 1.1742709915552041e-07
tumorigenic O 0 0.0002715305017773062
in O 0 4.872139243161655e-07
nude O 0 0.016748368740081787
mice O 0 0.00025146716507151723
which O 0 7.978781013662228e-08
is O 0 4.772579487166695e-08
suppressed O 0 4.770600412484782e-07
by O 0 1.3585204960975261e-08
the O 0 6.080469461267057e-08
reintroduction O 0 1.7201167793245986e-05
of O 0 4.696509222412715e-06
VHL B-Disease 0 0.003217877121642232
. O 0 4.041710326418979e-06

Remarkably O 0 0.0014124620938673615
, O 0 3.568894499039743e-06
this O 0 3.222151789827876e-08
occurs O 0 4.642138051735856e-08
without O 0 3.440912266228224e-08
affecting O 0 1.6993729445857753e-07
the O 0 7.073717966932236e-08
growth O 0 1.5661659062971012e-06
rate O 0 1.2232286508151446e-06
and O 0 3.84409219122972e-07
cell O 0 1.605279067007359e-05
cycle O 0 2.55864097198355e-06
profile O 0 3.384002638995298e-06
of O 0 2.2149306388996592e-08
these O 0 1.9314876809062298e-08
cells O 0 5.679681862602592e-07
in O 0 4.483243642994239e-08
culture O 0 9.462211210120586e-07
. O 0 3.6499898214970017e-06

The O 0 5.682305072696181e-06
786 O 0 0.0006735636852681637
- O 0 0.0026355176232755184
0 O 0 6.635341378569137e-06
cell O 0 3.942983676097356e-05
line O 0 9.499186489847489e-06
, O 0 2.5304453288299555e-07
like O 0 4.163873938978213e-07
many O 0 7.095066507645242e-07
cancer B-Disease 0 0.029495591297745705
cells O 0 2.8554197797348024e-06
, O 0 1.903644459844145e-07
fails O 0 3.689839047638088e-07
to O 0 5.8661950852467726e-09
exit O 0 1.1244783593156171e-07
the O 0 4.232603956211278e-08
cell O 0 2.8247516183910193e-06
cycle O 0 3.3503454233141383e-07
upon O 0 2.715320306378999e-07
serum O 0 2.391541056567803e-05
withdrawal O 0 9.116153705690522e-06
. O 0 1.952556885953527e-06

Here O 0 1.1108824764960445e-05
, O 0 9.30029841583746e-07
it O 0 1.694599482959802e-08
is O 0 1.1382212505850475e-08
shown O 0 3.7737002855919854e-08
that O 0 4.2740406769326e-09
reintroduction O 0 2.2008026689945837e-07
of O 0 1.3243549368269214e-08
the O 0 1.808274276982047e-07
wild O 0 1.6855959984241053e-05
- O 0 0.028684498742222786
type O 0 2.133880479959771e-05
VHL B-Disease 0 8.443275146419182e-05
gene O 0 1.6333844143900933e-07
restores O 0 1.3243469538792851e-06
the O 0 4.618830473646085e-08
ability O 0 1.5041401013604627e-07
of O 0 3.016252492216154e-07
VHL O 0 0.007687752600759268
- O 0 0.03099018894135952
negative O 0 8.227985381381586e-05
RCC B-Disease 1 0.9945236444473267
cancer I-Disease 0 0.07159582525491714
cells O 0 9.90153353086498e-07
to O 0 1.3781097152332222e-08
exit O 0 4.997777409698756e-07
the O 0 1.5197427671864716e-07
cell O 0 1.640991285967175e-05
cycle O 0 1.3912668919147109e-06
and O 0 1.2642584579225513e-07
enter O 0 1.1520341303139503e-07
G0 O 0 1.648891338845715e-05
/ O 0 5.850721436218009e-07
quiescence O 0 1.0708686204452533e-05
in O 0 2.1844651598712517e-07
low O 0 1.9178602087777108e-05
serum O 0 8.013713522814214e-05
. O 0 1.2493165968407993e-06

Both O 0 3.388141340110451e-05
VHL O 0 0.05008035525679588
- O 0 0.004291917197406292
positive O 0 1.918944235512754e-06
and O 0 3.5904531614505686e-06
VHL O 0 0.0009830063208937645
- O 0 0.0005968234036117792
negative O 0 3.7415318274724996e-06
RCC B-Disease 0 0.02733776532113552
cells O 0 2.6936063477478456e-06
exit O 0 4.816667455997958e-07
the O 0 8.769297465960335e-08
cell O 0 9.82126766757574e-06
cycle O 0 6.559661756000423e-07
by O 0 2.7939762503592647e-07
contact O 0 2.4533710529794917e-06
inhibition O 0 9.086416866921354e-06
. O 0 2.972521315314225e-06

The O 0 5.90986701354268e-06
cyclin O 0 0.0006361459963954985
- O 0 0.0003824214800260961
dependent O 0 2.692137286430807e-06
kinase O 0 1.653318940952886e-05
inhibitor O 0 9.425929420103785e-06
, O 0 1.2582742670019798e-07
p27 O 0 2.269181550218491e-06
, O 0 1.637113911101551e-08
accumulates O 0 1.437330183762242e-07
upon O 0 3.3325029846764664e-08
serum O 0 3.950721293222159e-06
withdrawal O 0 9.158460443359218e-07
, O 0 9.601328088137961e-08
only O 0 6.297494969942363e-09
in O 0 1.4874112608254109e-08
the O 0 1.2301150320581655e-07
presence O 0 3.418957703615888e-07
of O 0 3.914497028745245e-07
VHL B-Disease 0 0.00979685690253973
, O 0 1.0795347407110967e-06
as O 0 1.1944375444272737e-07
a O 0 2.3658455461372796e-07
result O 0 1.3511149177247717e-07
of O 0 2.1204911604399967e-08
the O 0 6.491418247378533e-08
stabilization O 0 1.312167455580493e-06
of O 0 4.698462063856823e-08
the O 0 5.274538352750824e-07
protein O 0 3.225637328796438e-06
. O 0 1.5606507304255501e-06

We O 0 1.7719413563099806e-06
propose O 0 7.504685981984949e-06
that O 0 1.5723540514045453e-07
the O 0 9.376373810709993e-08
loss O 0 2.7785281417891383e-05
of O 0 8.816473950901127e-08
wild O 0 2.825136652973015e-05
- O 0 0.03849828615784645
type O 0 3.141796696581878e-05
VHL B-Disease 0 0.00028609720175154507
gene O 0 1.0622027701856496e-07
results O 0 7.650803013348195e-08
in O 0 1.7364541804454348e-08
a O 0 9.686789326224243e-08
specific O 0 4.924763175040425e-08
cellular O 0 0.0032355973962694407
defect O 0 0.0008256644941866398
in O 0 1.5442981293745106e-06
serum O 0 0.00023297317966353148
- O 0 0.002283048816025257
dependent O 0 3.839505097857909e-06
growth O 0 6.452017373703711e-07
control O 0 1.543295411465806e-07
, O 0 6.94551829383272e-08
which O 0 5.85242965200905e-08
may O 0 1.6642295577184996e-06
initiate O 0 2.1646636014338583e-05
tumor B-Disease 0 0.02050458826124668
formation O 0 4.5156328269513324e-05
. O 0 8.515934496244881e-06

This O 0 1.3734173762713908e-06
is O 0 7.419041594403097e-07
corrected O 0 1.4365410606842488e-05
by O 0 4.443250389840614e-08
the O 0 2.4588931779589984e-08
reintroduction O 0 2.143782694474794e-06
of O 0 1.434841720993063e-07
wild O 0 3.97807452827692e-05
- O 0 0.16206255555152893
type O 0 0.0002571566728875041
VHL B-Disease 0 0.013066798448562622
, O 0 3.4330666949244915e-06
implicating O 0 0.009871076792478561
VHL B-Disease 0 0.002330000512301922
as O 0 8.810606999531956e-08
the O 0 4.249510610065954e-08
first O 0 1.1406614248699043e-05
tumor B-Disease 0 0.0031898103188723326
suppressor O 0 2.8138758352724835e-05
involved O 0 9.012731538859953e-07
in O 0 4.6080511850732364e-08
the O 0 5.479110143369326e-08
regulation O 0 2.9719211624978925e-07
of O 0 1.1322573811867187e-07
cell O 0 3.0471817808574997e-05
cycle O 0 4.212809471937362e-06
exit O 0 1.5226823052216787e-05
, O 0 9.286967497246224e-07
which O 0 2.238261345155479e-07
is O 0 5.7063452629790845e-08
consistent O 0 6.259225671101376e-08
with O 0 3.6168799510960525e-08
its O 0 8.010666618929463e-08
gatekeeper O 0 2.2031174012226984e-05
function O 0 2.342420124534783e-08
in O 0 4.424880728493008e-08
the O 0 9.426432370673865e-06
kidney O 0 0.26107925176620483
. O 0 1.1269576134509407e-06
. O 0 3.350627821419039e-06

Piebaldism B-Disease 1 0.9995941519737244
with O 0 0.2131933569908142
deafness B-Disease 1 0.9999860525131226
: O 0 3.69255690202408e-06
molecular O 0 2.572204903117381e-05
evidence O 0 5.4750480558141135e-06
for O 0 1.021472940010426e-06
an O 0 8.459480886813253e-05
expanded O 0 0.47681924700737
syndrome O 1 0.9993143081665039
. O 0 3.6646459193434566e-05

In O 0 5.541927293961635e-06
a O 0 4.965257630829001e-06
South O 0 1.3731797480431851e-05
African O 0 6.103143277869094e-06
girl O 0 1.565793718327768e-05
of O 0 2.8161261411696614e-07
Xhosa O 0 0.023786425590515137
stock O 0 0.00034857948776334524
with O 0 1.5590156181133352e-05
severe O 0 0.0637904480099678
piebaldism B-Disease 1 0.7783424258232117
and O 0 0.05823809280991554
profound O 1 0.9783016443252563
congenital O 1 0.9999994039535522
sensorineural B-Disease 1 0.9999984502792358
deafness I-Disease 1 0.9999998807907104
we O 0 0.0005660407477989793
identified O 0 0.00022713774524163455
a O 0 3.575881919459789e-07
novel O 0 8.291887638733897e-07
missense O 0 3.609266286730417e-06
substitution O 0 1.4521137359224667e-07
at O 0 7.83239215706999e-07
a O 0 4.5266529014043044e-07
highly O 0 4.872505883213307e-07
conserved O 0 2.3263118009708705e-07
residue O 0 3.3485724770798697e-07
in O 0 6.542691277644508e-09
the O 0 1.5562923394440986e-08
intracellular O 0 2.361855877097696e-06
kinase O 0 1.2965389259989024e-06
domain O 0 2.6606914005355975e-08
of O 0 2.345710647944088e-08
the O 0 5.027981728744635e-07
KIT O 0 0.0013815606944262981
proto O 0 0.0017819707281887531
- O 0 0.0008081918931566179
oncogene O 0 0.00018794483912643045
, O 0 5.041089252699749e-07
R796G O 0 1.8744882254395634e-05
. O 0 5.591796821136086e-07

Though O 0 9.206225513480604e-05
auditory B-Disease 0 0.004561206791549921
anomalies I-Disease 1 0.7386204600334167
have O 0 1.8906495824921876e-05
been O 0 5.951063030806836e-06
observed O 0 1.520199361948471e-06
in O 0 2.584109211056784e-07
mice O 0 3.8776455767219886e-05
with O 0 3.6626963719754713e-06
dominant O 0 0.0007250416092574596
white O 0 0.007131179329007864
spotting O 1 0.5085276961326599
( O 0 3.267384090577252e-05
W O 1 0.9826951622962952
) O 0 1.9645051452243933e-06
due O 0 1.0770584140118444e-06
to O 0 3.3103745522566896e-07
KIT O 0 0.26227879524230957
mutations O 0 0.00045113489613868296
, O 0 0.0013656215742230415
deafness B-Disease 1 0.9999979734420776
is O 0 1.1333661859680433e-05
not O 0 1.602169135139775e-07
typical O 0 4.779976734425873e-07
in O 0 8.234596862166654e-07
human O 0 1.7850823496701196e-05
piebaldism B-Disease 0 0.008556967601180077
. O 0 1.037408128468087e-05

Thus O 0 4.2770385334733874e-05
, O 0 1.2907945574625046e-06
the O 0 4.1006211404237547e-07
occurrence O 0 2.487477831891738e-05
of O 0 0.00016028745449148118
sensorineural B-Disease 1 0.9999945163726807
deafness I-Disease 1 0.9999996423721313
in O 0 5.428507211036049e-05
this O 0 5.344179498933954e-07
patient O 0 9.46031286730431e-06
extends O 0 9.971200825020787e-07
considerably O 0 4.591526874264673e-07
the O 0 1.315470576912503e-08
phenotypic O 0 8.967702456175175e-07
range O 0 7.004867370596912e-07
of O 0 1.9870350342898746e-07
piebaldism B-Disease 0 0.0020864487159997225
due O 0 2.0442582808755105e-06
to O 0 1.1367431085318458e-07
KIT O 0 0.0005702298367395997
gene O 0 3.9397772866323066e-07
mutation O 0 2.8847844646406884e-07
in O 0 6.950567410513031e-08
humans O 0 1.8882934682551422e-07
and O 0 7.497651495214086e-07
tightens O 0 0.00015470966172870249
the O 0 1.6761902088546776e-07
clinical O 0 4.451942913874518e-06
similarity O 0 5.718853230973764e-07
between O 0 8.338857924172771e-07
piebaldism B-Disease 0 0.0055990745313465595
and O 0 2.759793460427318e-07
the O 0 3.8101010346736075e-08
various O 0 6.184545497944782e-08
forms O 0 4.39516088590608e-06
of O 0 0.005972648039460182
Waardenburg B-Disease 1 0.9999773502349854
syndrome I-Disease 1 0.9998069405555725
. O 0 2.238449951619259e-06
. O 0 1.1015682503057178e-05

Cycloheximide O 0 0.004486293066293001
facilitates O 0 1.7253507394343615e-05
the O 0 3.448008385475987e-07
identification O 0 2.2280195821622328e-07
of O 0 8.206845336644619e-08
aberrant O 0 4.49870276497677e-05
transcripts O 0 9.995449545385782e-06
resulting O 0 5.845913619850762e-06
from O 0 1.884235274474122e-07
a O 0 2.5144768756035774e-07
novel O 0 4.807691311725648e-07
splice O 0 4.0838029235601425e-05
- O 0 0.00010142778046429157
site O 0 1.951501189978444e-06
mutation O 0 6.072536393730843e-07
in O 0 8.541961449282098e-08
COL17A1 O 0 0.000426349084591493
in O 0 1.9478144963613886e-07
a O 0 4.989527951693162e-06
patient O 0 4.873065699939616e-05
with O 0 5.669325037160888e-05
generalized O 0 0.0095085883513093
atrophic B-Disease 1 0.9985858201980591
benign I-Disease 1 0.5398240685462952
epidermolysis I-Disease 1 0.9772884249687195
bullosa I-Disease 1 0.9122252464294434
. O 0 0.00010813665721798316

Patients O 0 0.011974139139056206
with O 0 4.8054225771920756e-05
generalized O 0 0.02119637094438076
atrophic B-Disease 1 0.9997386336326599
benign I-Disease 1 0.9976192116737366
epidermolysis I-Disease 1 0.9980389475822449
bullosa I-Disease 1 0.9950920343399048
often O 0 6.818629481131211e-05
show O 0 9.718851288198493e-06
decreased O 0 2.2594151232624426e-05
expression O 0 6.844375377568213e-08
of O 0 9.527300193212795e-08
type O 0 0.00013596175995189697
XVII O 1 0.9849838614463806
collagen O 0 0.002540576970204711
, O 0 6.428874144148722e-07
a O 0 5.702297585230554e-07
transmembrane O 0 8.206373604480177e-05
hemidesmosomal O 0 4.556659041554667e-05
protein O 0 1.2208063537855196e-07
encoded O 0 1.073265138984425e-07
by O 0 5.281061135065102e-07
COL17A1 O 0 0.0009439600398764014
. O 0 3.0766982490604278e-06

This O 0 1.324958361692552e-06
report O 0 1.4626868960476713e-06
documents O 0 1.3557554439103114e-06
a O 0 6.757774144716677e-07
novel O 0 1.6811512750791735e-06
splice O 0 8.923157292883843e-05
- O 0 0.0009553431300446391
site O 0 4.423279733600793e-06
mutation O 0 3.9747004620949156e-07
in O 0 7.479148678157799e-08
COL17A1 O 0 0.0008901063119992614
in O 0 3.216009361040051e-07
a O 0 4.64582353743026e-06
patient O 0 2.814584513544105e-05
with O 0 9.925850463332608e-06
generalized O 0 0.003771324874833226
atrophic B-Disease 1 0.999225378036499
benign I-Disease 1 0.5065538287162781
epidermolysis I-Disease 1 0.8963830471038818
bullosa I-Disease 1 0.8495005965232849
, O 0 1.0723902050813194e-05
and O 0 9.022087965604442e-07
applies O 0 4.510888800268731e-07
a O 0 3.363390987942694e-07
new O 0 8.982065082818735e-07
methodology O 0 9.769960342964623e-07
to O 0 8.813632490500822e-08
define O 0 5.010935524296656e-07
and O 0 2.261177058926478e-07
characterize O 0 4.758590819164965e-07
the O 0 2.391045050842422e-08
resulting O 0 3.9244622485057334e-07
mRNA O 0 2.1413417528037826e-07
splice O 0 1.3000232684134971e-05
variants O 0 4.728038675239077e-06
. O 0 2.4899773052311502e-06

Mutational O 0 0.0007096680346876383
analysis O 0 4.564185019262368e-06
of O 0 8.496437544636137e-07
COL17A1 O 0 0.027819417417049408
identified O 0 0.0001296522095799446
a O 0 6.456698429246899e-06
maternally O 0 0.1039554700255394
inherited O 0 0.24142076075077057
G O 0 0.1063028946518898
- O 0 0.001654867548495531
to O 0 1.7053796455002157e-06
- O 0 0.08444640785455704
T O 0 0.09476520121097565
transversion O 0 3.9051879866747186e-05
at O 0 2.6425655619277677e-07
the O 0 2.999768966560623e-08
- O 0 1.4114767509454396e-05
1 O 0 6.002847641184417e-08
position O 0 4.173649159611159e-08
of O 0 4.561738364827761e-08
exon O 0 0.00011279544560238719
32 O 0 2.2121954316389747e-05
. O 0 2.8596657557500293e-06

This O 0 3.7813779840689676e-07
acceptor O 0 3.399671413717442e-06
splice O 0 0.00014381595246959478
- O 0 0.0011831935262307525
site O 0 1.2352114026725758e-05
mutation O 0 1.791857584976242e-06
led O 0 1.9065001879425836e-06
to O 0 1.3374865659443458e-08
the O 0 2.8456929257458796e-08
formation O 0 7.32594571672962e-07
of O 0 5.0768196757644546e-08
aberrant O 0 1.991144563362468e-05
transcripts O 0 5.498338396137115e-06
present O 0 3.043355434328987e-07
at O 0 3.6761900901183253e-06
extremely O 0 5.7756533351494e-06
low O 0 1.6869016690179706e-05
levels O 0 4.136459665460279e-06
. O 0 2.1504865799215622e-06

Based O 0 8.578002962167375e-06
on O 0 5.204916533330106e-07
our O 0 3.950197680069323e-08
recent O 0 1.5697023059146886e-07
finding O 0 2.299856447507409e-07
that O 0 7.110809718824385e-08
cycloheximide O 0 0.00023884121037553996
stabilized O 0 4.935246761306189e-05
mutant O 0 7.212267973955022e-06
COL17A1 O 0 2.1277741325320676e-05
transcripts O 0 3.6461523222897085e-07
in O 0 6.439808686309334e-08
keratinocytes O 0 1.173964119516313e-05
homozygous O 0 3.815122454398079e-06
for O 0 6.762275006622076e-08
a O 0 1.4277821946961922e-06
frameshift O 0 0.001113510224968195
mutation O 0 5.544495706999442e-06
, O 0 3.4737655596472905e-07
the O 0 2.42274921902208e-07
effects O 0 1.4223975313143455e-06
of O 0 2.7622466092225295e-08
the O 0 3.4146822258662723e-07
splice O 0 9.30404567043297e-05
- O 0 0.00024226609093602747
site O 0 1.637781338104105e-06
mutation O 0 4.215861082457195e-08
on O 0 1.3079922922543119e-08
splicing O 0 4.591294455735806e-08
of O 0 2.2739570226804062e-08
COL17A1 O 0 8.143875311361626e-05
transcripts O 0 9.403800049767597e-07
were O 0 2.325797083813086e-07
determined O 0 2.8005700869471184e-08
using O 0 1.2267405757881988e-08
reverse O 0 2.2328129034576705e-06
transcriptase O 0 0.00011784387606894597
polymerase O 0 1.8416651073493995e-05
chain O 0 2.1409712189779384e-06
reaction O 0 8.67099725354592e-09
of O 0 9.047897986391717e-10
total O 0 1.5885136761539798e-08
RNA O 0 5.163913741057513e-08
from O 0 1.123656723223121e-08
keratinocytes O 0 6.671710366390471e-07
incubated O 0 5.314437316883414e-07
for O 0 4.539951348192517e-08
2 O 0 1.4760663589186152e-06
. O 0 1.8776461274683243e-06

5 O 0 4.3767249735537916e-05
h O 0 0.0002738670737016946
in O 0 1.927559623027264e-07
the O 0 1.6434813687737915e-07
presence O 0 5.552939228437026e-07
or O 0 7.605162721802117e-08
absence O 0 2.185194603043783e-07
of O 0 2.093309525719178e-08
10 O 0 5.297596885611711e-07
microg O 0 9.327250154456124e-05
cycloheximide O 0 6.703130202367902e-05
per O 0 1.8298004533789936e-06
ml O 0 0.00010396994912298396
. O 0 1.8757561974780401e-06

Using O 0 3.0279563816293376e-06
this O 0 1.1345650818839204e-07
approach O 0 4.5086869704391574e-07
, O 0 1.538287790481263e-07
an O 0 1.7370314253639663e-07
abnormally O 0 1.4011645362188574e-05
spliced O 0 2.3074668206390925e-05
transcript O 0 0.00010021869820775464
was O 0 0.00019535535830073059
identified O 0 4.276295385352569e-06
that O 0 9.367897568779426e-09
contains O 0 7.2045551746668934e-09
an O 0 1.2574568941658981e-08
extra O 0 1.8572171356368017e-08
264 O 0 2.6907255801233987e-07
bases O 0 4.4854846947828264e-08
upstream O 0 3.372068135831796e-08
from O 0 4.71094141474282e-09
exon O 0 2.2212568637769436e-06
32 O 0 5.757300982622837e-07
, O 0 5.550414527988323e-08
resulting O 0 1.2322260545261088e-07
in O 0 2.59474219888034e-08
a O 0 7.608346095366869e-07
premature O 0 3.105440191575326e-05
termination O 0 5.3314292927097995e-06
codon O 0 6.708677915412409e-07
27 O 0 4.2571628000587225e-06
bp O 0 2.125368882843759e-05
downstream O 0 3.565012889339414e-07
from O 0 1.5320591018053165e-08
the O 0 5.157131965916051e-08
cryptic O 0 6.956415745662525e-06
splice O 0 2.1860065317014232e-05
site O 0 9.862151273409836e-06
. O 0 2.809494617395103e-06

Three O 0 1.4883784160701907e-06
other O 0 1.522493278116599e-07
splice O 0 2.675116411410272e-05
variants O 0 1.1207092939002905e-05
, O 0 7.307865530492563e-07
including O 0 3.7734704960712406e-07
one O 0 7.608688434856958e-08
derived O 0 9.966602476652042e-08
from O 0 2.1039971542791136e-08
the O 0 1.717311093329954e-08
skipping O 0 6.062809347895382e-07
of O 0 3.022073968850236e-08
exon O 0 2.5107028704951517e-05
32 O 0 3.6930111946276156e-06
, O 0 2.2976968239163398e-07
were O 0 1.6314303366016247e-06
also O 0 3.391818381714984e-06
identified O 0 1.268703090318013e-05
. O 0 4.1839457480818965e-06

These O 0 4.587303124026221e-07
results O 0 1.1307752174616326e-06
indicate O 0 3.277535256529518e-07
the O 0 4.510415863023809e-08
usefulness O 0 2.246077656309353e-06
of O 0 3.5598625913735304e-07
cycloheximide O 0 0.014946473762392998
treatment O 0 3.925984856323339e-06
in O 0 2.5039781803570804e-08
evaluating O 0 5.749312208536139e-07
the O 0 4.828542543577896e-08
abnormal O 0 7.390589189526509e-07
processing O 0 1.8625762265855883e-07
of O 0 1.210900180126373e-08
mRNA O 0 6.103068983520643e-08
due O 0 9.115199617326653e-08
to O 0 8.772037318749426e-09
splice O 0 1.020182935462799e-05
- O 0 0.00020610210776794702
site O 0 6.4572523115202785e-06
mutations O 0 3.854745500575518e-06
, O 0 1.2075786344212247e-06
because O 0 1.4545755675499095e-06
( O 0 2.074260692097596e-07
i O 0 5.402184228842088e-07
) O 0 7.62674545740083e-09
aberrant O 0 2.585825029655098e-07
splicing O 0 1.1448406667113886e-07
often O 0 1.6038944394836108e-08
generates O 0 4.5951843219427246e-08
a O 0 3.5131918707520526e-07
premature O 0 1.87024397746427e-05
termination O 0 5.615639111056225e-06
codon O 0 2.3234192667587195e-06
, O 0 7.223821398838481e-07
( O 0 8.78944206306187e-08
ii O 0 0.00014513642236124724
) O 0 5.3235169161780505e-08
transcripts O 0 8.821248798085435e-07
with O 0 8.112252203318349e-07
premature O 0 4.509229984250851e-05
termination O 0 5.416182830231264e-06
codons O 0 9.494481787442055e-07
can O 0 2.167690382748333e-08
occur O 0 7.432586102140704e-09
at O 0 2.41918201027147e-07
low O 0 7.150535566324834e-06
or O 0 9.328198871116911e-07
undetectable O 0 0.00021924376778770238
levels O 0 3.6893430888085277e-07
due O 0 8.409963214717209e-08
to O 0 6.511256867014481e-09
nonsense O 0 1.1075840120611247e-06
- O 0 3.646134928203537e-06
mediated O 0 8.182234978448832e-07
mRNA O 0 2.4096143746987764e-08
decay O 0 1.7896597626076982e-07
, O 0 1.0682044404575208e-07
and O 0 3.3255059861403424e-07
( O 0 2.1416727236100996e-07
iii O 0 0.005662860814481974
) O 0 7.470195129144486e-08
the O 0 2.921796138366517e-08
levels O 0 2.0263064115511042e-08
of O 0 2.957397660097172e-09
these O 0 1.3591573422289116e-09
transcripts O 0 4.979556251782924e-07
can O 0 2.7571040561724658e-08
be O 0 1.7544250496825953e-08
increased O 0 1.7209926284067478e-07
by O 0 3.1670523981119914e-07
cycloheximide O 0 0.0003953542618546635
. O 0 2.118289557984099e-06

A O 0 4.526066186372191e-05
deletion O 0 0.00035792679409496486
mutation O 0 4.215307853883132e-05
in O 0 6.796923344154493e-07
COL17A1 O 0 0.015459546819329262
in O 0 1.7526195961181656e-07
five O 0 6.762390398762363e-07
Austrian O 0 0.0019191907485947013
families O 0 4.117123808100587e-06
with O 0 9.031385161506478e-06
generalized O 0 0.007138509303331375
atrophic B-Disease 1 0.9996902942657471
benign I-Disease 0 0.49140703678131104
epidermolysis I-Disease 1 0.6059408187866211
bullosa I-Disease 0 0.15488360822200775
represents O 0 7.976337656145915e-06
propagation O 0 3.1365291874863033e-07
of O 0 1.5028253130822122e-07
an O 0 2.678768851183122e-06
ancestral O 0 4.9377515097148716e-05
allele O 0 2.2371703380485997e-05
. O 0 4.004234142485075e-06

Patients O 0 0.024907676503062248
with O 0 8.591450023232028e-05
generalized O 0 0.04173924773931503
atrophic B-Disease 1 0.9997994303703308
benign I-Disease 1 0.9973389506340027
epidermolysis I-Disease 1 0.9975442290306091
bullosa I-Disease 1 0.9953147172927856
, O 0 5.5350144975818694e-05
a O 0 3.907204245479079e-06
usually O 0 2.859227379303775e-07
nonlethal O 0 1.6858710296219215e-05
form O 0 2.804162875236216e-07
of O 0 1.912812422233401e-06
junctional B-Disease 1 0.5401103496551514
epidermolysis I-Disease 1 0.8461370468139648
bullosa I-Disease 1 0.6094890832901001
, O 0 1.1014757546945475e-05
have O 0 1.946548167097717e-07
generalized O 0 1.656093218116439e-06
blistering B-Disease 0 0.0039046548772603273
, O 0 0.0004913798184134066
nail B-Disease 1 0.9999511241912842
dystrophy I-Disease 1 0.9998284578323364
, O 0 0.0010952354641631246
patchy B-Disease 1 0.7565486431121826
alopecia I-Disease 1 0.9999661445617676
, O 0 0.0018604720244184136
and O 0 0.011930447071790695
dental B-Disease 1 0.9982166886329651
abnormalities I-Disease 1 0.9974242448806763
. O 0 7.607127918163314e-05

Skin B-Disease 1 0.9897562861442566
fragility I-Disease 1 0.8255161643028259
in O 0 1.2308781151659787e-05
most O 0 3.178373617629404e-06
cases O 0 5.868593871127814e-05
is O 0 4.988933142158203e-06
due O 0 9.626845894672442e-06
to O 0 3.005983728598949e-07
mutations O 0 7.44289422982547e-07
in O 0 8.305752530191057e-09
the O 0 2.083828398724563e-08
gene O 0 6.739265501209957e-08
encoding O 0 4.0482001395503175e-07
type O 0 0.0002626797358971089
XVII O 1 0.9468969106674194
collagen O 0 0.0020295444410294294
( O 0 1.7211204976774752e-06
COL17A1 O 0 0.006913426797837019
) O 0 7.222863587230677e-07
. O 0 1.2795323982572882e-06

Recently O 0 0.004025665577501059
, O 0 2.4226183086284436e-06
we O 0 9.069884043810816e-08
reported O 0 1.2016782875434728e-06
five O 0 1.6115613732381462e-07
Austrian O 0 0.00016242680430877954
families O 0 1.7895008568302728e-06
with O 0 5.504177352122497e-06
generalized O 0 0.002122289501130581
atrophic B-Disease 1 0.9994271993637085
benign I-Disease 1 0.6228379011154175
epidermolysis I-Disease 1 0.9454934597015381
bullosa I-Disease 1 0.797785222530365
who O 0 0.00016085655079223216
share O 0 1.2996238183404785e-06
the O 0 5.7966161648437264e-08
same O 0 2.773285814328119e-07
COL17A1 O 0 0.0014378593768924475
mutation O 0 1.2967581824341323e-05
. O 0 2.4505438886990305e-06

Affected O 0 0.00015982304466888309
individuals O 0 3.248618213547161e-06
in O 0 1.8594225537071907e-07
three O 0 5.169718519937305e-07
families O 0 2.6589743811200606e-06
are O 0 2.4809625642774336e-07
homozygous O 0 4.0159102354664356e-06
for O 0 2.0502042730186076e-07
4003delTC O 0 4.927924965159036e-05
, O 0 1.1757389017930109e-07
whereas O 0 6.949798603272939e-08
those O 0 2.5116170476735533e-08
in O 0 1.8340891472234944e-08
two O 0 1.1054434168045191e-07
others O 0 2.200847802669159e-06
are O 0 2.0058307370618422e-07
compound O 0 2.977162466777372e-06
heterozygotes O 0 5.5483375035692006e-05
. O 0 2.5549538804625627e-06

To O 0 2.0496190700214356e-06
determine O 0 3.042907792405458e-06
if O 0 1.1239294650522424e-07
the O 0 5.719563134221062e-08
occurrence O 0 4.647108085009677e-07
of O 0 1.0314385434639917e-07
4003delTC O 0 0.00040051143150776625
in O 0 3.0761890457142727e-07
these O 0 4.9259558210223986e-08
unrelated O 0 2.5767541956156492e-05
families O 0 2.6821635401574895e-06
signifies O 0 1.8686821476876503e-06
propagation O 0 9.747245854896391e-08
of O 0 7.395172474389256e-08
an O 0 5.883274525331217e-07
ancestral O 0 4.120269750274019e-06
allele O 0 1.5227444691845449e-06
or O 0 9.93024542594867e-08
a O 0 4.6737841330468655e-07
mutational O 0 2.9646353141288273e-05
hot O 0 7.43932150726323e-06
spot O 0 8.77928778209025e-06
, O 0 5.725466962758219e-07
haplotypes O 0 1.1416082088544499e-05
were O 0 1.4127288068266353e-06
determined O 0 5.374374154598627e-07
for O 0 1.050378415357045e-07
polymorphisms O 0 2.715521986829117e-05
both O 0 7.24083122349839e-08
within O 0 5.67188216393788e-08
and O 0 5.005842922400916e-06
flanking O 0 0.031376224011182785
COL17A1 O 0 0.2907799184322357
. O 0 1.0026593372458592e-05

Five O 0 3.0798062653047964e-05
intragenic O 0 0.01585429534316063
polymorphisms O 0 0.0013324965257197618
were O 0 1.8452566337145981e-06
chosen O 0 1.793059425381216e-07
based O 0 2.1709722375362617e-07
on O 0 5.581157438427908e-07
their O 0 4.914483611173637e-07
informativeness O 0 0.0009409949416294694
. O 0 3.233509687561309e-06

One O 0 1.2980383417016128e-06
of O 0 1.419209070263605e-07
these O 0 2.4913347829169652e-08
, O 0 1.1359141183220345e-07
not O 0 2.3517495506553132e-08
previously O 0 9.540895916870795e-06
reported O 0 2.9460119549185038e-05
, O 0 6.052260914657381e-07
was O 0 2.5465067665209062e-05
2988 O 0 2.5462539269938134e-05
A O 0 9.629862915971898e-07
or O 0 5.13128782131389e-07
C O 0 5.960459020570852e-05
that O 0 2.3172550100980516e-08
introduces O 0 2.2325328075112338e-07
a O 0 6.313420897186006e-08
new O 0 3.8082345099610393e-07
restriction O 0 1.2682313865752803e-07
site O 0 1.8043155591840332e-07
for O 0 9.951310886435749e-08
Eco0109 O 0 1.688184420345351e-05
I O 0 2.5322633518953808e-06
. O 0 6.594976298401889e-07

All O 0 2.871647382107767e-07
the O 0 2.5583574370102724e-07
4003delTC O 0 7.167678268160671e-05
alleles O 0 2.781401235552039e-06
showed O 0 9.061202035809401e-06
the O 0 2.9647923227571482e-08
same O 0 3.917513780038462e-08
haplotype O 0 1.736860440360033e-06
for O 0 1.9552247820797675e-08
these O 0 7.447273020488865e-09
five O 0 5.732936756430718e-07
polymorphic O 0 0.00032056617783382535
markers O 0 0.0006664333050139248
. O 0 1.1352105502737686e-05

Fourteen O 0 6.642792868660763e-05
microsatellite O 0 0.017042985185980797
polymorphisms O 0 0.01972060464322567
were O 0 1.170888208434917e-05
selected O 0 7.79676895490411e-07
based O 0 6.935503051863634e-07
on O 0 8.457697049379931e-07
their O 0 1.930630304514125e-07
high O 0 9.706190030556172e-05
heterozygosity O 0 0.0001051301951520145
and O 0 1.0589418764084257e-07
their O 0 5.774531963709251e-09
location O 0 2.1263797833626086e-08
within O 0 8.391852546196787e-09
10q23 O 0 1.0435482181492262e-05
- O 0 9.780236723599955e-05
q25 O 0 1.3474771549226716e-05
near O 0 3.493243866614648e-06
COL17A1 O 0 0.0005110467318445444
. O 0 2.59036164607096e-06

Three O 0 5.722345576941734e-06
families O 0 6.276970907492796e-06
shared O 0 8.228786100517027e-06
microsatellite O 0 0.017748458310961723
polymorphisms O 0 0.016791140660643578
covering O 0 0.00026900862576439977
at O 0 3.1449770176550373e-05
most O 0 4.6518968588316056e-07
19 O 0 0.00014208961511030793
cM O 0 0.001268779393285513
, O 0 2.728176866639842e-07
whereas O 0 1.4381637924998358e-07
the O 0 8.520172656290015e-08
others O 0 5.482371534526465e-07
shared O 0 3.8432600035775977e-07
smaller O 0 3.7796186802552256e-07
regions O 0 2.9588491656795668e-08
consistent O 0 1.1653371956299452e-07
with O 0 2.815438904235634e-07
cross O 0 2.4255696189356968e-05
- O 0 0.00040727423038333654
over O 0 9.481360621066415e-07
events O 0 9.030527081677064e-08
during O 0 3.072482854804548e-07
passage O 0 1.1161660751213276e-07
of O 0 1.497359747304472e-08
this O 0 6.445753708561597e-09
mutation O 0 5.984728090879798e-08
through O 0 1.056784437736269e-08
several O 0 6.660496865151799e-08
generations O 0 4.857338808506029e-06
. O 0 2.63101105701935e-06

These O 0 8.642475677334005e-07
results O 0 6.459512860601535e-06
indicate O 0 1.957871063495986e-06
that O 0 1.0103453007559438e-07
4003delTC O 0 5.622349999612197e-05
occurs O 0 4.8588354673029244e-08
on O 0 1.3420498135019443e-07
a O 0 1.7102644278566004e-07
single O 0 2.8101214866183e-06
ancestral O 0 8.621289453003556e-06
allele O 0 3.7860902466491098e-06
. O 0 1.6788459333838546e-07
. O 0 1.9099231849395437e-06

The O 0 4.7782909859961364e-06
haptoglobin O 0 0.0008300154004245996
- O 0 0.0006082231411710382
gene O 0 2.011532842516317e-06
deletion O 0 8.872301805240568e-06
responsible O 0 4.5133988351153675e-06
for O 0 3.0685698675370077e-06
anhaptoglobinemia B-Disease 0 0.013863288797438145
. O 0 8.789894309302326e-06

We O 0 1.3148683137842454e-05
have O 0 1.0796520655276254e-06
found O 0 4.0187353533838177e-07
an O 0 5.926760593411018e-08
allelic O 0 8.740808880247641e-06
deletion O 0 1.06594734461396e-05
of O 0 2.3309463870191394e-07
the O 0 1.959501787496265e-06
haptoglobin O 0 0.0019178732763975859
( O 0 2.6400618935440434e-07
Hp O 0 5.949768819846213e-06
) O 0 2.572767776598539e-08
gene O 0 2.497862894301761e-08
from O 0 1.5771803418829222e-08
an O 0 5.513895118269829e-08
individual O 0 1.0958245155734403e-07
with O 0 2.346908786421409e-06
anhaptoglobinemia B-Disease 0 0.010455075651407242
. O 0 5.208583388593979e-06

The O 0 4.658237230614759e-06
Hp O 0 0.00014222828031051904
gene O 0 3.9676065171079244e-06
cluster O 0 3.418570486246608e-06
consists O 0 5.126464586169277e-08
of O 0 3.7042838130219025e-08
coding O 0 6.2118465393723454e-06
regions O 0 4.275754861282621e-08
of O 0 7.570959859037885e-09
the O 0 1.6075122744041437e-07
alpha O 0 5.71990676689893e-06
chain O 0 6.798531558160903e-06
and O 0 9.979251558434044e-08
beta O 0 1.7223273118815996e-07
chain O 0 5.898560857531265e-07
of O 0 9.371507125877088e-09
the O 0 2.806410179800878e-07
haptoglobin O 0 7.799528975738212e-05
gene O 0 3.445618403929984e-07
( O 0 4.767120742599218e-08
Hp O 0 4.5464776121662e-06
) O 0 1.597543963782755e-08
and O 0 9.478466900247895e-09
of O 0 5.2730264599176735e-09
the O 0 6.29809804308934e-08
alpha O 0 1.7409532802048489e-06
chain O 0 2.8280185233597877e-06
and O 0 4.78336943388058e-08
beta O 0 9.251223787032359e-08
chain O 0 1.9684286201027135e-07
of O 0 3.781306823213981e-09
the O 0 1.3647526486693096e-07
haptoglobin O 0 0.00015654737944714725
- O 0 0.0007455648155882955
related O 0 2.3278029402717948e-05
gene O 0 1.938431751113967e-06
( O 0 1.9956569019541348e-07
Hpr O 0 3.8640133425360546e-05
) O 0 4.471902315117404e-08
, O 0 1.7212101965924376e-08
in O 0 1.7202648194825088e-08
tandem O 0 5.232171588431811e-06
from O 0 1.116866670258787e-07
the O 0 1.8886898089931492e-07
5 O 0 3.9696733438177034e-06
side O 0 2.356371442147065e-05
. O 0 7.912017281341832e-06

Southern O 0 1.8735658159130253e-05
blot O 0 0.0002832493919413537
and O 0 7.24653602901526e-07
PCR O 0 3.396147440071218e-05
analyses O 0 7.3808864726743195e-06
have O 0 4.6567133722419385e-06
indicated O 0 6.705437044729479e-06
that O 0 3.452778685186786e-08
the O 0 3.500903034137082e-08
individual O 0 4.231861439052409e-08
with O 0 5.568589358517784e-07
anhaptoglobinemia B-Disease 0 0.00938131008297205
was O 0 4.5417051296681166e-05
homozygous O 0 4.946339799971611e-07
for O 0 1.9035351073171114e-08
the O 0 7.89337946116575e-08
gene O 0 1.0238100855985977e-07
deletion O 0 1.594964260220877e-06
and O 0 2.709376190068724e-07
that O 0 1.1672464772516378e-08
the O 0 1.620456124840075e-08
gene O 0 1.5897161631528434e-07
deletion O 0 8.449299457424786e-06
was O 0 7.538808858953416e-06
included O 0 4.343660293670837e-07
at O 0 1.2772878790201503e-06
least O 0 3.588425201428436e-08
from O 0 3.1959977775386506e-08
the O 0 8.304947130000073e-08
promoter O 0 5.425567360362038e-05
region O 0 1.198607151309261e-07
of O 0 4.864881830712875e-08
Hp O 0 1.1995808563369792e-05
to O 0 2.4775553697509167e-07
Hpr O 0 9.95382470136974e-06
alpha O 0 2.6606107894622255e-07
but O 0 9.783450494182944e-09
not O 0 3.1461826477396926e-09
to O 0 1.3500066842198066e-08
Hpr O 0 1.642805727897212e-05
beta O 0 7.686799108341802e-07
( O 0 1.0192391641794529e-07
Hpdel O 0 4.05441242037341e-05
) O 0 2.4711181367820245e-07
. O 0 6.321180308077601e-07

In O 0 6.563700026163133e-06
addition O 0 4.2499013943597674e-06
, O 0 5.914000666962238e-07
we O 0 6.319107370700294e-08
found O 0 2.994738395045715e-07
seven O 0 2.3446644092928182e-07
individuals O 0 8.129199358108963e-08
with O 0 1.1204015208932105e-06
hypohaptoglobinemia B-Disease 0 0.0028009391389787197
in O 0 1.482854088408203e-07
three O 0 4.05916011914087e-07
families O 0 2.9000709673709935e-06
, O 0 6.36381173535483e-07
and O 0 1.6107026112877065e-07
the O 0 5.121597723700688e-08
genotypes O 0 7.64962067023589e-07
of O 0 1.9465549172537067e-08
six O 0 3.070977072638925e-07
of O 0 4.286844301759629e-08
the O 0 1.4032701756150345e-07
seven O 0 1.2343094795141951e-06
individuals O 0 2.3331459431119583e-07
were O 0 1.1940495596718392e-06
found O 0 1.1442592722232803e-06
to O 0 4.121186947259048e-08
be O 0 3.05403744960131e-07
Hp2 O 0 0.00021274185564834625
/ O 0 6.12079820712097e-05
Hpdel O 0 0.00039611238753423095
. O 0 3.3679209536785493e-06

The O 0 6.93817628416582e-06
phenotypes O 0 0.00022914788860362023
and O 0 3.848134383588331e-06
genotypes O 0 5.0557377107907087e-05
in O 0 1.354151493160316e-07
one O 0 3.826129812978252e-08
of O 0 1.5861219893054113e-08
these O 0 4.828557997882399e-09
three O 0 1.3067858617432648e-07
families O 0 2.696582441785722e-06
showed O 0 9.363733988720924e-05
the O 0 6.824157026130706e-07
father O 0 6.983380444580689e-05
to O 0 3.074722485507664e-07
be O 0 3.6443304907152196e-07
hypohaptoglobinemic B-Disease 0 0.0004557757347356528
( O 0 2.2008948974416853e-07
Hp2 O 0 0.0001410984550602734
) O 0 4.131040043375833e-08
and O 0 2.964648899705935e-07
Hp2 O 0 7.20869647921063e-05
/ O 0 6.52216158414376e-06
Hpdel O 0 6.935080455150455e-05
, O 0 9.808228895735738e-08
the O 0 8.985202981648399e-08
mother O 0 1.2600479749380611e-05
to O 0 6.104593808231584e-08
be O 0 9.164237724235136e-08
Hp2 O 0 3.102673144894652e-05
- O 0 2.7841511837323196e-05
1 O 0 4.1944863937715127e-07
and O 0 6.286618940976041e-07
Hp1 O 0 7.206544978544116e-05
/ O 0 3.86590409107157e-06
Hp2 O 0 7.727142656221986e-05
, O 0 6.662109797161975e-08
one O 0 3.529315062422711e-09
of O 0 6.107142347389072e-09
the O 0 8.970151554876793e-08
two O 0 3.361553240210924e-07
children O 0 1.2286569699426764e-06
to O 0 2.1504855851617322e-07
be O 0 4.544075125068048e-07
hypohaptoglobinemic B-Disease 0 0.0006892308010719717
( O 0 2.2682353062464244e-07
Hp2 O 0 3.432039375184104e-05
) O 0 6.92708894689531e-08
and O 0 3.7055139046060503e-07
Hp2 O 0 0.0003268421278335154
/ O 0 8.025645001907833e-06
Hpdel O 0 0.00027516655973158777
, O 0 1.412048362681162e-07
and O 0 6.978609690122539e-08
the O 0 4.48683650233761e-08
other O 0 1.256115069736552e-07
child O 0 8.89862985786749e-06
to O 0 6.272934172102396e-08
be O 0 1.4442387907820375e-07
Hp1 O 0 2.9984219509060495e-05
and O 0 1.4056437294129864e-06
Hp1 O 0 0.0002343928936170414
/ O 0 3.679831024783198e-06
Hpdel O 0 0.00012503599282354116
, O 0 8.669876194744575e-08
showing O 0 1.0111084520758595e-06
an O 0 8.966303255419916e-08
anomalous O 0 9.051252163772006e-06
inheritance O 0 1.0935797035926953e-05
of O 0 5.83481892135751e-07
Hp O 0 0.00019419575983192772
phenotypes O 0 1.1555453966138884e-05
in O 0 9.598691264045556e-08
the O 0 3.7285195730873966e-07
child O 0 3.333881250000559e-05
with O 0 6.194685283844592e-06
Hp1 O 0 0.007985853590071201
. O 0 5.515584689419484e-06

The O 0 9.786151167645585e-06
Hp2 O 0 0.009925484657287598
/ O 0 0.00021452333021443337
Hpdel O 0 0.010113494470715523
individuals O 0 5.2131999837001786e-06
had O 0 1.908873673528433e-05
an O 0 1.1307816976113827e-06
extremely O 0 1.271980090677971e-05
low O 0 1.3938160009274725e-05
level O 0 1.931528856857767e-07
of O 0 6.693123566492432e-08
Hp O 0 3.495495184324682e-05
( O 0 6.273065622508511e-08
mean O 0 8.421648090006784e-08
+ O 0 3.7685543929910637e-07
/ O 0 7.843888170100399e-07
- O 0 2.8143673262093216e-05
SD O 0 0.00016180523380171508
= O 0 2.8672354801528854e-06
0 O 0 1.2834856022436725e-07
. O 0 1.4783998913969754e-08
049 O 0 5.526757831830764e-06
+ O 0 4.770986947733036e-07
/ O 0 5.937503715358616e-07
- O 0 1.4731126611877698e-05
0 O 0 2.8343453095658333e-07
. O 0 1.6247426515292318e-08
043 O 0 3.971661044488428e-06
mg O 0 6.105006377765676e-06
/ O 0 4.66576778990202e-07
ml O 0 6.886927167215617e-06
; O 0 5.550710824309135e-08
n O 0 6.8408776314754505e-06
= O 0 1.0147839930141345e-05
6 O 0 2.3919587874843273e-06
) O 0 3.9277715302432625e-08
, O 0 3.6850313023251147e-08
compared O 0 2.4513124685654475e-07
with O 0 4.745538362271873e-08
the O 0 1.4747168108897313e-07
level O 0 5.817045121148112e-07
( O 0 1.9431459108432136e-08
1 O 0 7.471363971944811e-08
. O 0 1.012096184638267e-08
64 O 0 9.505126854492119e-07
+ O 0 9.582664688423392e-07
/ O 0 2.504853000573348e-07
- O 0 4.121032361581456e-06
1 O 0 1.1062090266023006e-07
. O 0 3.4592699815760852e-09
07 O 0 5.609492177427455e-07
mg O 0 1.4369137488756678e-06
/ O 0 1.7631006699048157e-07
ml O 0 8.146636218953063e-07
) O 0 2.0686801160962887e-09
obtained O 0 1.548546180174526e-08
from O 0 2.5240117551561525e-08
52 O 0 1.2209105989313684e-05
healthy O 0 8.460576736979419e-07
volunteers O 0 9.191246022055566e-07
having O 0 7.887658739491599e-07
phenotype O 0 2.397650177954347e-06
Hp2 O 0 2.411435889371205e-05
, O 0 6.160868792903784e-08
whereas O 0 2.926816122794662e-08
the O 0 2.6221403714998814e-08
serum O 0 4.633098797057755e-06
Hp O 0 1.9636265733424807e-06
level O 0 3.431029327316537e-08
of O 0 1.1852978154536231e-08
an O 0 9.772860920520543e-08
individual O 0 5.220491061663779e-08
with O 0 1.2451249631340033e-06
Hp1 O 0 0.000920813181437552
/ O 0 7.300430297618732e-06
Hpdel O 0 0.0001257563999388367
was O 0 1.4121298590907827e-05
0 O 0 3.427488763918518e-06
. O 0 1.5482117987630772e-06

50 O 0 2.121438410540577e-05
mg O 0 0.00026458498905412853
/ O 0 3.196132092853077e-05
ml O 0 0.0004070301365572959
, O 0 7.756017339488608e-07
which O 0 5.843729056209668e-08
was O 0 1.192905756397522e-06
approximately O 0 3.257659741962016e-08
half O 0 7.745050112362151e-08
the O 0 2.1908091341060754e-08
level O 0 9.47496445746765e-08
of O 0 5.47049552324097e-08
Hp O 0 6.270018729992444e-06
in O 0 2.589042651379714e-07
control O 0 6.236048193386523e-07
sera O 0 5.262758349999785e-06
from O 0 2.774983798303765e-08
the O 0 1.423539828238063e-07
Hp1 O 0 0.0005798678030259907
phenotype O 0 1.2587339369929396e-05
( O 0 5.480228537635412e-08
1 O 0 3.4920006442007434e-07
. O 0 4.3499362334387115e-08
26 O 0 2.2695667212246917e-06
+ O 0 9.13063217922172e-07
/ O 0 4.528751276211551e-07
- O 0 5.141906513017602e-06
0 O 0 1.3764933726179152e-07
. O 0 3.3095961526896645e-09
33 O 0 2.536908993988618e-07
mg O 0 3.485171419015387e-06
/ O 0 4.1591434296606167e-07
ml O 0 4.399702902446734e-06
; O 0 5.0554742614394854e-08
n O 0 3.298096089565661e-06
= O 0 3.638243470049929e-06
9 O 0 7.509651709369791e-07
) O 0 8.298325582245525e-09
, O 0 7.085570796760976e-09
showing O 0 3.92119261505286e-07
a O 0 1.866137608885765e-07
gene O 0 2.5115241442108527e-07
- O 0 5.497921665664762e-05
dosage O 0 8.482515113428235e-06
effect O 0 6.047835086064879e-07
. O 0 1.3471756119542988e-06

The O 0 2.8356100756354863e-06
other O 0 6.585976279893657e-07
allele O 0 6.7533173933043145e-06
( O 0 5.010080030842801e-07
Hp2 O 0 0.0002647432265803218
) O 0 5.879326181457145e-08
of O 0 3.712615992412793e-08
individuals O 0 2.2252420706081466e-07
with O 0 2.5338456453027902e-06
Hp2 O 0 0.01830509677529335
/ O 0 0.00012317969230934978
Hpdel O 0 0.01504433061927557
was O 0 0.0002803863026201725
found O 0 3.0660423817607807e-06
to O 0 1.9152953711909504e-07
have O 0 1.974479033606258e-07
, O 0 6.640378558131488e-08
in O 0 1.1183178827423035e-08
all O 0 9.433738235031797e-09
exons O 0 2.5808608370425645e-06
, O 0 1.8464238848991954e-07
no O 0 2.1064465727249626e-08
mutation O 0 1.2036528573844407e-07
, O 0 1.782773928482584e-08
by O 0 3.515476620918889e-08
DNA O 0 4.247162451065378e-06
sequencing O 0 9.149624020210467e-06
. O 0 4.8099750529218e-06

On O 0 3.931567334802821e-06
the O 0 6.630203586155403e-08
basis O 0 2.5294770722439353e-08
of O 0 4.52986554932977e-08
the O 0 3.115306981271715e-07
present O 0 2.3008765026588662e-07
study O 0 2.64840849695247e-07
, O 0 8.516078509046565e-08
the O 0 1.4330183262245555e-08
mechanism O 0 8.559689490539313e-08
of O 0 9.048319782323233e-08
anhaptoglobinemia B-Disease 0 0.00020268176740501076
and O 0 2.2729429360879294e-07
the O 0 3.0734671696563964e-08
mechanism O 0 1.2285205741591199e-07
of O 0 7.197841256356696e-08
anomalous O 0 2.883522211050149e-05
inheritance O 0 1.934395550051704e-05
of O 0 7.081904414008022e-07
Hp O 0 0.00047740060836076736
phenotypes O 0 2.5114188247243874e-05
were O 0 2.19810635826434e-06
well O 0 6.369118068505486e-07
explained O 0 6.202298209245782e-06
. O 0 1.1448737495811656e-06

However O 0 2.4510731236659922e-05
, O 0 4.425066890689777e-07
the O 0 9.012493507043473e-08
mechanism O 0 4.275318872259959e-07
of O 0 9.78114712779643e-07
hypohaptoglobinemia B-Disease 0 0.2119881808757782
remains O 0 0.0003400007262825966
unknown O 0 0.00012518295261543244

ATM O 0 0.016666289418935776
mutations O 0 0.001891413819976151
and O 0 2.3998116375878453e-05
phenotypes O 0 0.0032188224140554667
in O 0 0.0005455709178932011
ataxia B-Disease 1 0.9999946355819702
- I-Disease 1 0.9999840259552002
telangiectasia I-Disease 1 0.9999910593032837
families O 0 0.001616826979443431
in O 0 1.3260935247672023e-06
the O 0 1.6311191757267807e-06
British O 0 0.000537090701982379
Isles O 0 8.716137017472647e-06
: O 0 2.3351040212560292e-08
expression O 0 8.01006727613185e-09
of O 0 5.813953318778431e-09
mutant O 0 2.4508733531547477e-06
ATM O 0 1.6492718714289367e-05
and O 0 2.187022971611441e-07
the O 0 3.6911097822667216e-07
risk O 0 2.555227911216207e-05
of O 0 7.098338392097503e-05
leukemia B-Disease 1 0.9999514818191528
, O 0 0.43148699402809143
lymphoma B-Disease 1 0.9999992847442627
, O 0 0.0010320894652977586
and O 0 0.04205585643649101
breast B-Disease 1 0.9993749260902405
cancer I-Disease 1 0.5689414739608765
. O 0 2.026531183219049e-05

We O 0 1.0332121291867224e-06
report O 0 1.8964291825795954e-07
the O 0 1.3649070318422218e-08
spectrum O 0 2.531920131332299e-07
of O 0 4.840548228912667e-08
59 O 0 3.176871905452572e-05
ATM O 0 0.003394858445972204
mutations O 0 1.7131180356955156e-05
observed O 0 8.691914445080329e-06
in O 0 1.891749707283452e-05
ataxia B-Disease 1 0.9999722242355347
- I-Disease 1 0.9999690055847168
telangiectasia I-Disease 1 0.9999878406524658
( O 0 0.0001723275490803644
A B-Disease 1 0.9995124340057373
- I-Disease 1 0.9999947547912598
T I-Disease 1 0.9999985694885254
) O 0 2.7142998078488745e-05
patients O 0 7.090418421284994e-06
in O 0 5.5081663674627634e-08
the O 0 1.5276986005119397e-06
British O 0 0.0003898752620443702
Isles O 0 0.0003253648173995316
. O 0 1.4729426766280085e-05

Of O 0 1.6156452602444915e-06
51 O 0 8.269785030279309e-05
ATM O 0 0.004803869873285294
mutations O 0 0.0001587292499607429
identified O 0 4.43545650341548e-05
in O 0 2.120760598245397e-07
families O 0 1.103422846426838e-06
native O 0 1.8159556702812552e-06
to O 0 6.716322076272263e-08
the O 0 3.325369846152171e-07
British O 0 0.00020302471239119768
Isles O 0 3.730619209818542e-05
, O 0 1.0964847660943633e-06
11 O 0 1.7708651967041078e-06
were O 0 3.0875826269038953e-06
founder O 0 0.00029854991589672863
mutations O 0 4.305841230234364e-06
, O 0 1.44629396459095e-07
and O 0 9.682023005552765e-08
2 O 0 7.653488864889368e-08
of O 0 1.2211262223615904e-08
these O 0 1.8785613065119833e-08
11 O 0 1.6783302498879493e-06
conferred O 0 6.112929440860171e-06
a O 0 3.361133451562637e-07
milder O 0 1.2904331924801227e-05
clinical O 0 1.2861159120802768e-05
phenotype O 0 1.059034821082605e-05
with O 0 4.6405622811107605e-07
respect O 0 1.1826381296486943e-07
to O 0 8.986951627321105e-08
both O 0 1.5964343447194551e-06
cerebellar B-Disease 0 0.11227317154407501
degeneration I-Disease 1 0.5780183672904968
and O 0 3.173353979946114e-05
cellular O 0 0.0034513003192842007
features O 0 1.9505467207636684e-05
. O 0 5.546108695853036e-06

We O 0 4.913114935334306e-06
report O 0 1.3247940842120443e-06
, O 0 1.0040882614248403e-07
in O 0 3.835570439036928e-08
two O 0 8.903357411327306e-07
A B-Disease 1 0.9832234978675842
- I-Disease 1 0.9999805688858032
T I-Disease 1 0.9999946355819702
families O 0 2.1159969037398696e-05
, O 0 3.223827320653072e-07
an O 0 3.181802128437994e-07
ATM O 0 0.0040976968593895435
mutation O 0 6.614650374103803e-06
( O 0 9.674048584429329e-08
7271T O 0 1.8304028344573453e-05
- O 0 0.0009599417098797858
- O 0 0.0021180894691497087
> O 0 8.934888683143072e-06
G O 0 0.0020465448033064604
) O 0 9.036643433546487e-08
that O 0 9.202527451179776e-08
may O 0 5.893989509786479e-07
be O 0 5.870361619031428e-08
associated O 0 4.754018334551802e-08
with O 0 5.4771355451066484e-08
an O 0 9.343984856968746e-07
increased O 0 6.473279790952802e-05
risk O 0 1.7015237972373143e-05
of O 0 1.1362514669599477e-05
breast B-Disease 1 0.9974473714828491
cancer I-Disease 0 0.15335772931575775
in O 0 2.3091064349500812e-07
both O 0 9.211648261953087e-07
homozygotes O 0 0.0006161465425975621
and O 0 1.0577196917438414e-05
heterozygotes O 0 0.00020057341316714883
( O 0 4.6178089974091563e-07
relative O 0 7.430841378663899e-06
risk O 0 1.864763726189267e-05
12 O 0 1.6983066188913654e-06
. O 0 8.363254266896547e-08
7 O 0 5.674457952409284e-06
; O 0 2.4372616280743387e-06
P O 0 0.0034091609995812178
= O 0 2.961081190733239e-05
. O 0 2.5477950771346514e-07
0025 O 0 0.00013550980656873435
) O 0 4.613433546296619e-08
, O 0 2.573052348964211e-08
although O 0 3.4063681653151434e-08
there O 0 1.242044067595316e-08
is O 0 8.508513360538927e-08
a O 0 2.5973226911446545e-06
less O 0 9.688102727523074e-05
severe O 0 0.40901950001716614
A B-Disease 1 0.9971891045570374
- I-Disease 1 0.9999712705612183
T I-Disease 1 0.9999938011169434
phenotype O 0 4.065043685841374e-05
in O 0 4.592065039332738e-08
terms O 0 3.477251908634571e-08
of O 0 1.8412395164091322e-08
the O 0 2.1596723343009216e-07
degree O 0 1.16434393930831e-05
of O 0 2.809955367411021e-05
cerebellar B-Disease 1 0.9700251817703247
degeneration I-Disease 1 0.9966607093811035
. O 0 0.00016000252799130976

This O 0 1.4866504898236599e-06
mutation O 0 2.0981155103072524e-05
( O 0 4.0514598254048906e-07
7271T O 0 8.363899542018771e-05
- O 0 0.009571094065904617
- O 0 0.030932942405343056
> O 0 4.3097643356304616e-05
G O 0 0.008913708850741386
) O 0 4.548089549416545e-08
also O 0 1.7866101487129527e-08
allows O 0 2.1609234401864796e-09
expression O 0 4.561222510801599e-09
of O 0 3.773237722271006e-09
full O 0 1.222864227656828e-07
- O 0 2.246213443868328e-05
length O 0 2.1019250198150985e-06
ATM O 0 2.7221882191952318e-05
protein O 0 5.3017711110214805e-08
at O 0 3.836945694501992e-08
a O 0 3.1787926957349555e-08
level O 0 4.764693883885229e-08
comparable O 0 4.3920209691350465e-07
with O 0 3.224851141681029e-08
that O 0 3.71762567397127e-08
in O 0 1.853898083936656e-07
unaffected O 0 1.5344490748248063e-05
individuals O 0 9.085256351681892e-07
. O 0 4.466968221095158e-06

In O 0 6.42445775156375e-06
addition O 0 3.0096980481175706e-06
, O 0 5.472414841278805e-07
we O 0 2.581153069058928e-08
have O 0 3.2987138354201306e-08
studied O 0 6.671532446489437e-07
18 O 0 1.8699263819144107e-05
A B-Disease 1 0.9834064841270447
- I-Disease 1 0.9999911785125732
T I-Disease 1 0.9999992847442627
patients O 0 0.0016416257712990046
, O 0 1.7142961894478503e-07
in O 0 5.4201439780854344e-08
15 O 0 3.699821604641329e-07
families O 0 6.114336201790138e-07
, O 0 5.153954589331988e-06
who O 0 0.003803485771641135
developed O 0 0.13036586344242096
leukemia B-Disease 1 0.9997963309288025
, O 0 0.05128305405378342
lymphoma B-Disease 1 0.9999994039535522
, O 0 0.00027723133098334074
preleukemic O 0 0.34874171018600464
T O 1 0.596741259098053
- O 0 0.0037059832829982042
cell O 0 0.010150044225156307
proliferation O 0 0.015900831669569016
, O 0 3.996546729467809e-05
or O 0 0.10473071038722992
Hodgkin B-Disease 1 0.9999988079071045
lymphoma I-Disease 1 0.9999996423721313
, O 0 2.3611179130966775e-05
mostly O 0 1.2225149248479283e-06
in O 0 2.0207062334520742e-06
childhood O 0 0.00012397070531733334
. O 0 1.4490315152215771e-05

A O 0 6.572285201400518e-05
wide O 0 1.0939582352875732e-05
variety O 0 1.7465744406308659e-07
of O 0 8.789005789822113e-08
ATM O 0 0.0038260878063738346
mutation O 0 9.428536941413768e-06
types O 0 9.999673693528166e-07
, O 0 2.0102619657791365e-07
including O 0 1.9544886527000926e-06
missense O 0 0.0006934395059943199
mutations O 0 2.300694541190751e-05
and O 0 1.0198716609011171e-06
in O 0 1.0437754554004641e-06
- O 0 0.009274228475987911
frame O 0 0.004521011374890804
deletions O 0 4.4827676902059466e-05
, O 0 2.2384947442333214e-06
were O 0 2.4571315861976473e-06
seen O 0 2.2507028916152194e-06
in O 0 1.2396199622344284e-07
these O 0 6.708095838803274e-07
patients O 0 3.735268910531886e-05
. O 0 2.451834234307171e-06

We O 0 2.503885980331688e-06
also O 0 5.761283432548225e-07
show O 0 5.994907326112298e-08
that O 0 7.119153266899048e-09
25 O 0 8.473627843841314e-08
% O 0 3.773230616843648e-09
of O 0 4.384703267135137e-09
all O 0 1.330279388866984e-07
A B-Disease 1 0.9281991124153137
- I-Disease 1 0.9999786615371704
T I-Disease 1 0.9999974966049194
patients O 0 4.712220834335312e-05
carried O 0 1.223257868332439e-06
in O 0 2.1029325125709875e-07
- O 0 0.0011634068796411157
frame O 0 0.0011997043620795012
deletions O 0 0.00010479030606802553
or O 0 2.4424621187790763e-06
missense O 0 0.0002508639299776405
mutations O 0 5.848284217790933e-06
, O 0 1.2117808978473477e-07
many O 0 3.669423875862776e-09
of O 0 3.177259344511185e-08
which O 0 6.369920129145612e-07
were O 0 2.1568908778135665e-05
also O 0 4.326063390180934e-06
associated O 0 1.709367580815524e-07
with O 0 3.400421988430935e-08
expression O 0 3.3274279331863e-08
of O 0 5.063406760541511e-08
mutant O 0 3.4975459129782394e-05
ATM O 0 0.0005177687271498144
protein O 0 2.7855423923028866e-06
. O 0 6.35509650237509e-07

The O 0 6.361715804814594e-06
DMPK O 0 0.003170662559568882
gene O 0 6.963285613892367e-06
of O 0 8.61073931446299e-06
severely O 1 0.9772903919219971
affected O 0 0.11611752212047577
myotonic B-Disease 1 0.9999977350234985
dystrophy I-Disease 1 0.9999995231628418
patients O 1 0.8843014240264893
is O 0 1.2693227290583309e-05
hypermethylated O 0 0.046133823692798615
proximal O 0 0.0004926944966427982
to O 0 1.1572292635264603e-07
the O 0 1.2957708861449646e-07
largely O 0 1.3994240362080745e-06
expanded O 0 2.931280050688656e-06
CTG O 0 0.00028977380134165287
repeat O 0 1.3677166862180457e-05
. O 0 1.8678233573155012e-06

Using O 0 2.589843006717274e-06
methylation O 0 8.355170575669035e-05
- O 0 0.004581069108098745
sensitive O 0 6.555240543093532e-05
restriction O 0 1.489894998485397e-06
enzymes O 0 2.7856910946866265e-06
, O 0 1.6008756631435972e-07
we O 0 1.0768099301117218e-08
characterized O 0 9.323799332605631e-08
the O 0 1.1475203898214659e-08
methylation O 0 1.4497243228106527e-06
pattern O 0 6.813127697569143e-07
on O 0 9.324276675215515e-07
the O 0 2.551461761868268e-07
5 O 0 2.3568472897750326e-06
side O 0 6.306897830654634e-07
of O 0 4.0325133454643947e-08
the O 0 2.320853838000403e-07
CTG O 0 0.00010704973828978837
repeat O 0 9.572817134539946e-07
in O 0 1.329586485354639e-08
the O 0 3.941565651643941e-08
DMPK O 0 0.00011660948803182691
gene O 0 3.916154156513585e-08
of O 0 1.4253583202616937e-08
normal O 0 3.911302215442447e-08
individuals O 0 1.632193935563464e-08
and O 0 2.4200357984227594e-07
of O 0 3.0878891266183928e-06
patients O 0 0.0016433711862191558
affected O 0 4.833812636206858e-05
with O 0 0.05084514245390892
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999977350234985
, O 0 1.7582862710696645e-05
showing O 0 1.888757287815679e-05
expansions O 0 2.7160065201314865e-06
of O 0 3.3733549287262576e-08
the O 0 4.6989686097731465e-07
repetitive O 0 6.429219502024353e-05
sequence O 0 1.1529918992891908e-06
. O 0 4.114207513339352e-06

The O 0 1.8990220951309311e-06
gene O 0 1.3799976841255557e-06
segment O 0 1.0281224831487634e-06
analyzed O 0 9.326669214715366e-07
corresponds O 0 8.421584141160565e-08
to O 0 8.417630148471744e-09
the O 0 4.0579827498277155e-08
genomic O 0 9.326819053967483e-06
SacI O 0 0.00016605271957814693
- O 0 2.42116475419607e-05
HindIII O 0 1.2614883416972589e-05
fragment O 0 7.158096195780672e-07
carrying O 0 5.441989969767747e-07
exons O 0 1.3132890899214544e-06
11 O 0 1.567241611155623e-06
- O 0 5.2982537454226986e-05
15 O 0 3.6959145290893503e-06
. O 0 1.4844065390207106e-06

There O 0 2.2373508272721665e-06
is O 0 1.0529420535476675e-07
constitutive O 0 6.2754747887083795e-06
methylation O 0 4.344515673437854e-06
in O 0 2.976839823531918e-07
intron O 0 0.00019844969210680574
12 O 0 2.2967074073676486e-06
at O 0 3.9485902902924863e-07
restriction O 0 3.7764220195413145e-08
sites O 0 6.805645380580927e-09
of O 0 1.0199446620617891e-08
SacII O 0 2.1130368622834794e-05
and O 0 3.898704221683147e-07
HhaI O 0 4.3116346205351874e-05
, O 0 3.9297500364909865e-08
localized O 0 2.8517467853816925e-07
1 O 0 2.216509500385655e-07
, O 0 1.0366690617047425e-07
159 O 0 1.0333902537240647e-05
- O 0 6.021990702720359e-05
1 O 0 4.1755245661079243e-07
, O 0 3.709678253471793e-08
232 O 0 1.346144358649326e-06
bp O 0 2.149958163499832e-05
upstream O 0 3.8888739339881795e-08
of O 0 4.258376318233559e-09
the O 0 6.102370520011391e-08
CTG O 0 0.00016239198157563806
repeat O 0 1.5747928046039306e-06
, O 0 5.6965472339243206e-08
whereas O 0 1.2138258398408652e-07
most O 0 6.006169428474095e-08
, O 0 3.0207522172531753e-07
if O 0 5.917441825431524e-08
not O 0 9.190719296725547e-09
all O 0 3.5461571457062746e-09
, O 0 2.2046840797429468e-08
of O 0 3.510637336390232e-09
the O 0 1.4956043514757766e-08
other O 0 4.849222801084352e-09
sites O 0 1.530312587760818e-08
of O 0 3.1506882436360684e-08
SacII O 0 0.0003701497334986925
, O 0 8.142403089550498e-07
HhaI O 0 5.448043157230131e-05
, O 0 6.544153308141176e-08
and O 0 1.9843800203034334e-07
HpaII O 0 9.389557089889422e-05
in O 0 4.7702407357519405e-08
this O 0 8.48431369604441e-09
region O 0 1.405358034389792e-07
are O 0 2.984901215086211e-08
unmethylated O 0 4.116883792448789e-05
, O 0 2.2230190666050476e-07
in O 0 4.9015508096772464e-08
normal O 0 9.302057435434108e-08
individuals O 0 1.1498838858869931e-07
and O 0 1.7699032639484358e-07
most O 0 2.2925219056446622e-08
of O 0 8.798583905900159e-08
the O 0 1.9529235942172818e-05
patients O 0 0.00012772981426678598
. O 0 3.705093376993318e-06

In O 0 2.721381406445289e-06
a O 0 6.211380991771875e-07
number O 0 1.2477455868520337e-07
of O 0 5.463586489895533e-07
young O 0 0.000521992682479322
and O 0 0.00015538201841991395
severely O 1 0.8697625994682312
affected O 0 4.4266336772125214e-05
patients O 0 2.3560927729704417e-05
, O 0 3.5485786042954715e-07
however O 0 1.6462549012885574e-07
, O 0 3.786173152775518e-08
complete O 0 4.8943295638537165e-08
methylation O 0 6.395771947609319e-07
of O 0 8.04633089046547e-08
these O 0 1.564208318427518e-08
restriction O 0 2.2963037338286085e-07
sites O 0 2.3762244438785274e-07
was O 0 1.1738230568880681e-05
found O 0 5.480938511936984e-07
in O 0 3.328183240114413e-08
the O 0 3.8742822994208836e-07
mutated O 0 1.393853199260775e-05
allele O 0 7.060062216623919e-06
. O 0 2.7793566914624535e-06

In O 0 3.7562326724582817e-06
most O 0 1.098400517207665e-07
of O 0 5.161796323704948e-08
these O 0 1.3693170330952853e-07
patients O 0 3.140080298180692e-05
, O 0 2.166223680433177e-07
the O 0 6.762648752101086e-08
onset O 0 8.425587111560162e-06
of O 0 1.2480614941523527e-06
the O 0 0.015733426436781883
disease O 1 0.9422048330307007
was O 1 0.9909952282905579
congenital O 1 0.9999440908432007
. O 0 0.00016342574963346124

Preliminary O 0 2.521392161725089e-05
in O 0 3.0878450161253568e-06
vivo O 0 0.00011673442350002006
footprinting O 0 0.0010105661349371076
data O 0 1.1357791436239495e-06
gave O 0 5.641337565975846e-07
evidence O 0 1.5251002594141028e-07
for O 0 2.5337552500559468e-08
protein O 0 5.453347640127504e-08
- O 0 1.4021844435774256e-05
DNA O 0 7.775192898407113e-06
contact O 0 1.1777353847719496e-07
in O 0 2.9731621609130343e-08
normal O 0 4.266582109835326e-08
genes O 0 7.58469340667034e-08
at O 0 3.601594471547287e-07
an O 0 7.288356869139534e-07
Sp1 O 0 0.000901959661860019
consensus O 0 2.683601678654668e-07
binding O 0 2.8205852231621975e-07
site O 0 1.4449456386955717e-07
upstream O 0 4.16739638353647e-08
of O 0 1.808245109202744e-09
the O 0 4.029284284001733e-08
CTG O 0 3.9797669160179794e-05
repeat O 0 8.874594072949549e-07
and O 0 6.945531794144699e-08
for O 0 5.068643815775431e-08
a O 0 3.927633542843978e-07
significant O 0 5.890494207960728e-07
reduction O 0 1.3838987342751352e-06
of O 0 1.560870366290601e-08
this O 0 3.2328675292347953e-09
interaction O 0 5.473268949174326e-09
in O 0 2.0211070150821797e-08
cells O 0 8.243163307497525e-08
with O 0 3.91599748184035e-08
a O 0 2.603428129077656e-06
hypermethylated O 0 0.011207505129277706
DMPK O 0 0.002325922716408968
gene O 0 5.787612167296174e-07
. O 0 9.399795430908853e-08
. O 0 7.08215452505101e-07

The O 0 0.00012871147191617638
hemochromatosis B-Disease 1 0.9997915625572205
gene O 0 4.456226452020928e-05
product O 0 3.6299052226240747e-06
complexes O 0 7.528338414886093e-07
with O 0 6.500798122033302e-08
the O 0 6.352509274165641e-08
transferrin O 0 6.130676774773747e-05
receptor O 0 5.889932594982383e-07
and O 0 1.1108055275599327e-07
lowers O 0 3.5089235552732134e-06
its O 0 3.806170045805857e-09
affinity O 0 4.3953733097623626e-08
for O 0 2.4112878804771753e-08
ligand O 0 1.1066823617511545e-06
binding O 0 1.2914705393995973e-06
. O 0 1.274221858693636e-06

We O 0 5.023044195695547e-06
recently O 0 6.685313564958051e-05
reported O 0 3.708183157868916e-06
the O 0 1.737289068159953e-08
positional O 0 6.266380978559027e-07
cloning O 0 2.0231800590408966e-06
of O 0 1.957067929936329e-08
a O 0 7.126708396754111e-07
candidate O 0 8.213889486796688e-06
gene O 0 2.800562469928991e-06
for O 0 0.00023310762480832636
hereditary B-Disease 1 0.9999936819076538
hemochromatosis I-Disease 1 0.9999994039535522
called O 1 0.5720378756523132
HFE O 1 0.8227329254150391
. O 0 4.4323864131001756e-05

The O 0 3.077147312069428e-06
gene O 0 4.620655090548098e-06
product O 0 3.4808829241228523e-06
, O 0 3.8636264321212366e-07
a O 0 4.4002678123433725e-07
member O 0 9.874901252260315e-07
of O 0 3.603342690894351e-08
the O 0 5.603230874839937e-07
major O 0 2.9469843866536394e-05
histocompatibility O 0 0.11056980490684509
complex O 0 3.4531651181168854e-05
class O 0 4.128009095438756e-05
I O 0 1.5681709555792622e-05
- O 0 0.0003805840970017016
like O 0 2.720234306252678e-06
family O 0 5.311596396495588e-06
, O 0 5.972276539978338e-07
was O 0 1.286686438106699e-05
found O 0 1.2644081834878307e-06
to O 0 3.2035412544928477e-08
have O 0 1.009609391644517e-07
a O 0 3.604395146794559e-07
mutation O 0 8.534955782124598e-07
, O 0 5.263242428554804e-07
Cys O 0 0.00032385546364821494
- O 0 8.636084385216236e-05
282 O 0 0.00014865408593323082
- O 0 0.005081437062472105
- O 0 0.0021477737464010715
> O 0 1.3270576346258167e-05
Tyr O 0 0.00013647601008415222
( O 0 7.806137602983654e-08
C282Y O 0 2.4316966573678656e-06
) O 0 8.7215861199752e-09
, O 0 6.8010646003813235e-09
in O 0 5.615999221220136e-09
85 O 0 3.9537411566925584e-07
% O 0 7.126070045160304e-08
of O 0 2.8237531068953103e-07
patient O 0 3.8070560549385846e-05
chromosomes O 0 0.00013727763143833727
. O 0 7.935108442325145e-06

This O 0 1.0211143717242521e-06
mutation O 0 7.799269951647148e-06
eliminates O 0 2.0669791410909966e-05
the O 0 2.9434946213768853e-07
ability O 0 4.996633720111276e-07
of O 0 1.0064793087849466e-07
HFE O 0 0.002341932151466608
to O 0 1.47873066680404e-07
associate O 0 2.0983100057492265e-06
with O 0 1.0926589766313555e-06
beta2 O 0 0.054337624460458755
- O 0 0.0474923737347126
microglobulin O 0 0.01713673025369644
( O 0 1.6780136036231852e-07
beta2m O 0 5.659521048073657e-05
) O 0 2.0576900183755242e-08
and O 0 3.52823974480998e-08
prevents O 0 1.3832469676344772e-06
cell O 0 3.725300484802574e-05
- O 0 0.0018811855698004365
surface O 0 0.0001819155877456069
expression O 0 4.717126103059854e-06
. O 0 5.902122211409733e-06

A O 0 3.474014374660328e-05
second O 0 2.2945814635022543e-05
mutation O 0 1.4341291716846172e-05
that O 0 3.298840169918549e-07
has O 0 1.061673629010329e-06
no O 0 1.1386038778482543e-07
effect O 0 1.3007679910970182e-07
on O 0 2.92650361188862e-06
beta2m O 0 0.039485864341259
association O 0 8.986693501356058e-06
, O 0 2.207340685345116e-06
H63D O 0 0.007259155157953501
, O 0 1.2160346614109585e-06
was O 0 1.856353264884092e-05
found O 0 9.639989002607763e-07
in O 0 3.615438615156563e-08
eight O 0 1.3857091119007237e-07
out O 0 6.213679881739154e-08
of O 0 9.726000627097164e-08
nine O 0 2.8160477086203173e-05
patients O 0 6.804635631851852e-06
heterozygous O 0 1.5251541185534734e-07
for O 0 1.5851027157509634e-08
the O 0 2.154143317056878e-07
C282Y O 0 6.777515955036506e-05
mutant O 0 3.643619129434228e-05
. O 0 2.8272095278225606e-06

In O 0 3.024077841473627e-06
this O 0 9.081724527959523e-08
report O 0 1.1206109320482938e-06
, O 0 5.425915361456646e-08
we O 0 3.640472368005021e-09
demonstrate O 0 1.5733764513470305e-08
in O 0 4.912283024793851e-09
cultured O 0 3.1926824703987222e-06
293 O 0 7.62094032324967e-06
cells O 0 2.926464503616444e-06
overexpressing O 0 4.382016049930826e-05
wild O 0 5.16097315994557e-06
- O 0 0.0010055223247036338
type O 0 5.707515811081976e-06
or O 0 1.6699642912954005e-07
mutant O 0 2.7100610168417916e-05
HFE O 0 0.00023323077766690403
proteins O 0 1.4218588262338017e-07
that O 0 2.18555875619586e-08
both O 0 2.0471517814257822e-08
the O 0 1.8322315042951232e-07
wild O 0 9.044797479873523e-06
- O 0 0.006912352982908487
type O 0 7.615462436660891e-06
and O 0 6.4290666159649845e-06
H63D O 0 0.15984158217906952
HFE O 0 0.0018159030005335808
proteins O 0 2.2702954538544873e-07
form O 0 8.211731028495706e-08
stable O 0 7.99450731392426e-07
complexes O 0 1.8593959794088732e-07
with O 0 2.3207540778003022e-07
the O 0 1.8019028402704862e-06
transferrin O 0 0.040574006736278534
receptor O 0 5.941714334767312e-05
( O 0 1.595798153175565e-06
TfR O 0 0.0004555340565275401
) O 0 6.935549095032911e-07
. O 0 1.864241085058893e-06

The O 0 4.017798801214667e-06
C282Y O 0 0.0001791845861589536
mutation O 0 1.429950225428911e-05
nearly O 0 1.4782498283238965e-06
completely O 0 3.140565695503028e-06
prevents O 0 1.6973546053122845e-06
the O 0 9.998780114983674e-08
association O 0 7.708727594035736e-07
of O 0 2.766169160395293e-08
the O 0 3.265193129209365e-07
mutant O 0 0.0001198305471916683
HFE O 0 0.0009712137398310006
protein O 0 4.4628791329159867e-07
with O 0 1.4912411927525682e-07
the O 0 3.1810905056772754e-06
TfR O 0 0.0019281978020444512
. O 0 3.544337687344523e-06

Studies O 0 4.934047410642961e-06
on O 0 7.125117463147035e-06
cell O 0 0.0014231826644390821
- O 0 0.0048563783057034016
associated O 0 2.8049969387211604e-06
transferrin O 0 9.234295248461422e-06
at O 0 1.4168506368150702e-07
37 O 0 8.803877449281572e-07
degrees O 0 3.128624257442425e-07
C O 0 8.127303590299562e-05
suggest O 0 1.9851351851229992e-07
that O 0 1.10901625660631e-08
the O 0 5.343578024508133e-08
overexpressed O 0 6.182456854730844e-05
wild O 0 4.976454874849878e-06
- O 0 0.00022061140043660998
type O 0 7.278997600224102e-06
HFE O 0 0.00013893772847950459
protein O 0 2.2828314172329556e-07
decreases O 0 1.965815528137682e-07
the O 0 5.933974200900138e-09
affinity O 0 8.764448011788772e-08
of O 0 1.4438802153904362e-08
the O 0 3.1947274692356586e-07
TfR O 0 0.00010365859634475783
for O 0 9.46939678669878e-07
transferrin O 0 0.0003594625450205058
. O 0 1.9350775346538285e-06

The O 0 6.981670594541356e-06
overexpressed O 0 0.0018860471900552511
H63D O 0 0.0076802377589046955
protein O 0 2.8416279747034423e-06
does O 0 6.39542463432008e-08
not O 0 3.323400221688644e-08
have O 0 4.4367293838831756e-08
this O 0 1.1642359076802222e-08
effect O 0 1.7120007100857038e-07
, O 0 6.845028366342376e-08
providing O 0 2.7935920243749024e-08
the O 0 1.8450890593157965e-08
first O 0 1.8268556800649094e-07
direct O 0 2.394623166424026e-08
evidence O 0 5.119312618262484e-07
for O 0 1.0253246074398703e-07
a O 0 7.755144793009094e-07
functional O 0 1.1490008091641357e-06
consequence O 0 4.680805147927458e-07
of O 0 3.9597626511067574e-08
the O 0 2.0888621747872094e-06
H63D O 0 0.09239361435174942
mutation O 0 1.696015715424437e-05
. O 0 3.7968977721902775e-06

Addition O 0 1.040927236317657e-05
of O 0 1.7643667433731025e-06
soluble O 0 0.00011220060696359724
wild O 0 1.5980162061168812e-05
- O 0 0.014495430514216423
type O 0 9.038771531777456e-05
HFE O 0 0.006483918055891991
/ O 0 4.8824382247403264e-05
beta2m O 0 0.002486727200448513
heterodimers O 0 0.00011830934090539813
to O 0 3.1223439123095886e-07
cultured O 0 0.00010467824904480949
cells O 0 3.4068862078129314e-06
also O 0 3.078219776853075e-07
decreased O 0 1.7861897276816308e-06
the O 0 6.761126769561088e-08
apparent O 0 5.545447493204847e-06
affinity O 0 4.875006993643183e-07
of O 0 3.416128180333544e-08
the O 0 2.2041758995783312e-07
TfR O 0 9.686263183539268e-06
for O 0 8.448464150490054e-09
its O 0 1.2046158737177848e-08
ligand O 0 5.032812850913615e-07
under O 0 2.8098594384573516e-07
steady O 0 1.8353357518208213e-05
- O 0 0.00043328566243872046
state O 0 2.4158468932000687e-06
conditions O 0 9.501546855972265e-07
, O 0 1.3996703351892847e-08
both O 0 4.776064876921282e-09
in O 0 2.759339956526219e-08
293 O 0 3.3323554816888645e-05
cells O 0 1.0648412853697664e-06
and O 0 2.264046941036213e-07
in O 0 1.1340787295921473e-06
HeLa O 0 0.005944246891885996
cells O 0 2.093340845021885e-05
. O 0 1.763969635248941e-06

Furthermore O 0 3.77260657842271e-05
, O 0 3.6161216598884494e-07
at O 0 2.087934944938752e-07
4 O 0 5.198581334298069e-07
degrees O 0 5.066015660304402e-07
C O 0 0.0004344654153101146
, O 0 2.71469900781085e-07
the O 0 1.5704014799666766e-07
added O 0 5.206487912801094e-06
soluble O 0 2.9058458039799007e-06
complex O 0 1.5204473413632513e-07
of O 0 3.832210779819434e-07
HFE O 0 0.015357942320406437
/ O 0 3.3030581107595935e-05
beta2m O 0 0.0005636810092255473
inhibited O 0 2.2954679934628075e-06
binding O 0 5.43443974265756e-08
of O 0 1.055318143983186e-08
transferrin O 0 6.469450454460457e-06
to O 0 3.365976297686757e-08
HeLa O 0 0.00013384305930230767
cell O 0 2.8741547794197686e-05
TfR O 0 2.2041260308469646e-05
in O 0 2.3697694473412412e-08
a O 0 4.5648366153727693e-07
concentration O 0 7.15408896212466e-05
- O 0 0.00011049974273191765
dependent O 0 2.1278196982166264e-06
manner O 0 1.7239096905541373e-06
. O 0 3.1241836495610187e-06

Scatchard O 0 0.00029960976098664105
plots O 0 5.81991935177939e-06
of O 0 2.842840274297487e-07
these O 0 1.8012306313153204e-08
data O 0 3.1767174846208945e-07
indicate O 0 4.568251199543738e-07
that O 0 1.1688059409209473e-08
the O 0 4.511224105385736e-08
added O 0 1.0620300372465863e-06
heterodimer O 0 9.27144537854474e-06
substantially O 0 3.390799747648998e-06
reduced O 0 1.9219885416532634e-07
the O 0 9.198786621311683e-09
affinity O 0 1.7315338141088432e-07
of O 0 6.365741711533701e-08
TfR O 0 0.00010387680231360719
for O 0 7.145655445128796e-07
transferrin O 0 0.0003591295680962503
. O 0 2.680598754523089e-06

These O 0 4.5164159701016615e-07
results O 0 1.4716766827405081e-06
establish O 0 6.874735163364676e-07
a O 0 5.558825932894251e-07
molecular O 0 2.9015125619480386e-05
link O 0 1.6372256141039543e-05
between O 0 1.4541332120643347e-06
HFE O 0 0.04770800471305847
and O 0 1.5989301118679577e-06
a O 0 4.773972364091605e-07
key O 0 4.877229457633803e-06
protein O 0 1.4775831402857875e-07
involved O 0 6.027481163073389e-07
in O 0 1.0476459237906965e-06
iron O 0 0.281756728887558
transport O 0 3.5484536056173965e-05
, O 0 3.194486737356783e-07
the O 0 1.5889264659563196e-07
TfR O 0 0.00023707494256086648
, O 0 2.419013469534548e-07
and O 0 1.3563629863710958e-07
raise O 0 1.1470202707641874e-06
the O 0 5.911597966701265e-08
possibility O 0 6.413026767404517e-07
that O 0 1.0318262155806224e-07
alterations O 0 1.3435302207653876e-05
in O 0 1.1756425521980418e-07
this O 0 3.8605026730920144e-08
regulatory O 0 5.370826784201199e-06
mechanism O 0 2.20251286009443e-06
may O 0 6.648286330346309e-07
play O 0 5.613763320866383e-08
a O 0 1.8731627449142252e-07
role O 0 7.303991651497199e-07
in O 0 6.710636313300711e-08
the O 0 1.178460479422938e-06
pathogenesis O 0 0.004787543322890997
of O 0 0.00446378393098712
hereditary B-Disease 1 0.9999974966049194
hemochromatosis I-Disease 1 0.9999994039535522
. O 0 0.00026004534447565675
. O 0 2.9810758860548958e-05

Genomic O 0 0.0003675995103549212
organization O 0 4.5036431401968e-06
of O 0 1.1911409814047147e-07
the O 0 1.0392005833637086e-06
UBE3A O 0 0.006762944161891937
/ O 0 1.6582551324972883e-05
E6 O 0 0.0048117870464921
- O 0 0.021429339423775673
AP O 0 0.00010108539572684094
gene O 0 2.934279166311171e-07
and O 0 2.1251945270250872e-07
related O 0 8.03305647423258e-06
pseudogenes O 0 0.0002949860936496407
. O 0 7.253724561451236e-06

The O 0 2.3629913812328596e-06
UBE3A O 0 0.0003889082872774452
gene O 0 6.953616775717819e-07
encodes O 0 1.0440945885648034e-07
the O 0 3.144288385215077e-08
E6 O 0 0.0001580273237777874
- O 0 0.000624828040599823
AP O 0 3.220200596842915e-05
ubiquitin O 0 8.110117050819099e-06
- O 0 1.553191032144241e-05
protein O 0 4.0241232568405394e-08
ligase O 0 7.441759066750819e-07
and O 0 4.7133980274338683e-07
has O 0 6.206122975527251e-07
recently O 0 7.970314982230775e-06
been O 0 3.3364591445206315e-07
shown O 0 7.049231953715207e-08
to O 0 2.5350216148467553e-08
be O 0 3.9322773659478116e-07
mutated O 0 0.00017831534205470234
in O 1 0.6022243499755859
Angelman B-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999998807907104
patients O 1 0.550153911113739
who O 0 0.0033797682262957096
lack O 0 1.3116571608406957e-05
15q11 O 0 0.0001100929148378782
- O 0 0.0001497501361882314
q13 O 0 1.5927593267406337e-05
deletions O 0 6.587090410903329e-06
or O 0 1.808653451007558e-06
chromosome O 0 0.00040859528235159814
15 O 0 1.3446068805933464e-05
paternal O 0 0.0004390360845718533
uniparental B-Disease 0 0.22547027468681335
disomy I-Disease 0 0.01831282302737236
. O 0 1.0738988748926204e-05

Previous O 0 1.0244386430713348e-05
UBE3A O 0 0.00021471281070262194
cDNA O 0 4.323411303630564e-06
analysis O 0 1.230115458383807e-06
has O 0 9.531887030789221e-07
shown O 0 1.1135016819707744e-07
a O 0 7.165063209413347e-08
coding O 0 2.5134365841950057e-06
region O 0 4.2847194237083386e-08
of O 0 8.119015681984365e-09
approximately O 0 5.733614329983538e-07
2 O 0 6.23227106189006e-06
. O 0 2.3270490601134952e-06

6 O 0 9.641872748034075e-05
kb O 0 0.0033612423576414585
and O 0 2.348919679207029e-06
a O 0 1.027412849907705e-06
3 O 0 7.5682432907342445e-06
- O 0 0.027334969490766525
untranslated O 0 0.00647694943472743
region O 0 4.844607701670611e-06
( O 0 1.5972247524587146e-07
UTR O 0 1.438704475731356e-05
) O 0 4.473375891933529e-09
of O 0 7.98124411005574e-09
< O 0 1.218924580825842e-06
50 O 0 2.2833060597804433e-07
bp O 0 1.6448893802589737e-05
, O 0 1.1154355661346926e-08
whereas O 0 5.638947531139138e-09
Northern O 0 2.2423467527232788e-09
analysis O 0 1.2918171421461011e-08
has O 0 5.627002863661801e-08
indicated O 0 4.900504180227472e-08
mRNA O 0 1.7441742494739287e-09
sizes O 0 1.932342641453033e-08
of O 0 3.912120849491885e-09
5 O 0 2.5414468041162763e-07
- O 0 3.491404277156107e-05
8 O 0 3.073630750805023e-06
kb O 0 0.0010530329309403896
. O 0 2.6224038265354466e-06

We O 0 1.1777639201682177e-06
have O 0 4.085973870360249e-08
analyzed O 0 5.00835035666114e-08
additional O 0 5.116898460499897e-09
cDNA O 0 1.2076000643901352e-07
clones O 0 2.2517267552757403e-06
and O 0 7.108315003279131e-08
provide O 0 1.0872630795688565e-08
evidence O 0 8.928758177262353e-08
for O 0 2.3763460532677527e-08
an O 0 1.0577650044751863e-07
additional O 0 6.386866857610585e-07
0 O 0 1.3492298421624582e-05
. O 0 4.260367404640419e-06

5 O 0 1.922857882163953e-05
kb O 0 0.000842988898511976
of O 0 7.699330240029667e-07
5 O 0 3.485171419015387e-06
- O 0 0.0006509175873361528
UTR O 0 6.6120526753366e-05
and O 0 1.3033060497491533e-07
> O 0 3.394713701254659e-07
2 O 0 2.0335937733761966e-07
kb O 0 7.751393422950059e-05
of O 0 5.4625601819680014e-08
3 O 0 3.1951860819390276e-06
- O 0 0.002144723432138562
UTR O 0 0.00038795697037130594
. O 0 2.882908120227512e-06

We O 0 3.1671147553424817e-06
have O 0 4.560985757962044e-07
established O 0 3.7151092868725755e-08
the O 0 1.5966971744774128e-08
genomic O 0 3.6805715808441164e-06
organization O 0 5.936246338933415e-07
of O 0 1.8870711926410877e-07
UBE3A O 0 0.0007644449360668659
and O 0 4.37652545315359e-08
the O 0 1.6298973282147244e-09
sequence O 0 4.982982915180401e-09
of O 0 6.119002193827328e-08
intron O 0 0.00043775353697128594
- O 0 0.0003277011273894459
exon O 0 0.00010939002095256001
borders O 0 3.614491561165778e-06
. O 0 2.293925263074925e-06

We O 0 6.161789769976167e-06
have O 0 8.626179806014989e-07
also O 0 7.600406348728939e-08
mapped O 0 1.2754242106893798e-06
two O 0 9.590273464255006e-08
highly O 0 8.263437507594062e-07
homologous O 0 8.633981565253634e-07
processed O 0 3.7938900732115144e-06
pseudogenes O 0 1.629905091249384e-05
, O 0 1.2805479627786553e-06
UBE3AP1 O 0 0.004049343056976795
and O 0 2.0097838842048077e-06
UBE3AP2 O 0 0.001406763563863933
, O 0 5.799048707899601e-08
to O 0 3.7201353109139745e-09
chromosomes O 0 4.795025461135083e-07
2 O 0 4.2709791614470305e-07
and O 0 6.91112006734329e-07
21 O 0 7.69020971347345e-06
, O 0 2.3696254913829762e-07
respectively O 0 3.940137048630277e-06
, O 0 1.0823267615478471e-07
and O 0 8.085684299885543e-08
determined O 0 3.0074690471337817e-07
their O 0 6.780330608080476e-08
genomic O 0 1.2120819519623183e-05
organization O 0 3.0241756121540675e-06
. O 0 1.892950308501895e-06

These O 0 9.179858011520992e-07
results O 0 3.1157751436694525e-06
will O 0 1.977032155764391e-07
form O 0 2.757603745351389e-08
the O 0 7.165730675495752e-09
basis O 0 1.152075412846898e-08
for O 0 3.022494965421174e-08
studies O 0 3.484980126700066e-08
of O 0 6.617241155026932e-08
mutation O 0 7.859560469114513e-07
and O 0 4.0977903381644865e-07
imprinting O 0 3.1269413739209995e-05
of O 0 5.688637429557275e-06
UBE3A O 0 0.006994697730988264
. O 0 4.880923825112404e-06

Mutation O 0 0.00036770853330381215
spectrum O 0 8.476948278257623e-05
and O 0 8.63848163135117e-06
genotype O 0 0.00031836176640354097
- O 0 0.007038981653749943
phenotype O 0 6.0897538787685335e-05
analyses O 0 1.3574058357335161e-05
in O 0 4.359000740805641e-05
Cowden B-Disease 1 0.9992130994796753
disease I-Disease 0 0.15320412814617157
and O 0 8.752953726798296e-05
Bannayan B-Disease 1 0.996777355670929
- I-Disease 1 0.9999724626541138
Zonana I-Disease 1 0.9999821186065674
syndrome I-Disease 1 0.9998608827590942
, O 0 4.999983957532095e-06
two O 0 7.136291969800368e-05
hamartoma B-Disease 1 0.9985741376876831
syndromes I-Disease 1 0.8549428582191467
with O 0 6.269429286476225e-05
germline O 1 0.7036302089691162
PTEN O 1 0.8219585418701172
mutation O 0 0.0001341809256700799
. O 0 7.822859515727032e-06

The O 0 0.0005539276171475649
tumour B-Disease 1 0.999864935874939
suppressor O 0 0.09435787051916122
gene O 0 0.00015305980923585594
PTEN O 0 0.01180694904178381
, O 0 4.4693021550301637e-07
which O 0 1.9662536487885518e-08
maps O 0 3.680771385461412e-07
to O 0 7.532432277912449e-07
10q23 O 0 0.00014271587133407593
. O 0 2.2554879706149222e-06

3 O 0 9.796217455004808e-06
and O 0 2.3511310587309708e-07
encodes O 0 6.542244079810189e-08
a O 0 3.134647741376284e-08
403 O 0 3.5491302696755156e-07
amino O 0 1.1466708826901595e-07
acid O 0 3.502400147681328e-07
dual O 0 3.0292767405626364e-07
specificity O 0 5.478336788655724e-07
phosphatase O 0 0.00035272265085950494
( O 0 2.9368203868784803e-08
protein O 0 4.971697720179691e-08
tyrosine O 0 2.3686861823080108e-06
phosphatase O 0 0.0007194749778136611
; O 0 6.796864795433066e-07
PTPase O 0 0.0001437444007024169
) O 0 9.130076961127997e-08
, O 0 2.1049169163234183e-07
was O 0 1.3355627743294463e-05
shown O 0 1.4116191096036346e-06
recently O 0 6.608666808460839e-06
to O 0 2.5704968820150498e-08
play O 0 4.3799662563515085e-08
a O 0 1.0275055473130124e-07
broad O 0 2.290486690981197e-06
role O 0 2.3254362986335764e-06
in O 0 5.64816389214684e-07
human O 0 2.827069147315342e-05
malignancy B-Disease 0 0.0900021567940712
. O 0 1.3495117855200078e-05

Somatic O 0 0.008222516626119614
PTEN O 0 0.11270652711391449
deletions O 0 0.0004522699164226651
and O 0 8.491540029353928e-06
mutations O 0 2.0053797925356776e-05
were O 0 1.8793713252307498e-06
observed O 0 4.926078531752864e-07
in O 0 2.3775641011525295e-07
sporadic B-Disease 0 8.368280396098271e-05
breast I-Disease 1 0.6187151670455933
, I-Disease 0 0.0005215716082602739
brain I-Disease 0 0.2422109991312027
, I-Disease 0 0.003675479907542467
prostate I-Disease 1 0.9996782541275024
and I-Disease 1 0.8911200165748596
kidney I-Disease 1 0.999968409538269
cancer I-Disease 1 0.5183717012405396
cell O 0 0.0013670112239196897
lines O 0 0.0001287217892240733
and O 0 3.0943126603233395e-06
in O 0 2.2458711157469224e-07
several O 0 8.431281912635313e-07
primary O 0 0.006566504016518593
tumours B-Disease 1 0.9998865127563477
such O 0 3.3704143334034598e-06
as O 0 0.0013028527610003948
endometrial B-Disease 1 0.9998537302017212
carcinomas I-Disease 1 0.9999960660934448
, O 1 0.9967740178108215
malignant B-Disease 1 0.9999995231628418
melanoma I-Disease 1 0.9999995231628418
and O 1 0.9997770190238953
thyroid B-Disease 1 0.9999878406524658
tumours I-Disease 1 0.9999809265136719
. O 0 0.00031988354749046266

In O 0 4.478749360714573e-06
addition O 0 8.392516065214295e-06
, O 0 6.2888166212360375e-06
PTEN O 0 0.0691651925444603
was O 0 0.0004979812074452639
identified O 0 7.919217750895768e-06
as O 0 9.018993551990206e-08
the O 0 1.6116536016852478e-07
susceptibility O 0 1.0240009942208417e-05
gene O 0 1.1257605336822962e-07
for O 0 2.8460519274631224e-07
two O 0 0.0006918140570633113
hamartoma B-Disease 1 0.9998408555984497
syndromes I-Disease 1 0.9999245405197144
Cowden B-Disease 1 0.9999251365661621
disease I-Disease 1 0.7691192030906677
( O 0 7.285368610610021e-07
CD B-Disease 0 0.0004469899577088654
; O 0 3.2261854357784614e-05
MIM O 0 0.050959598273038864
158350 O 0 0.0001322118187090382
) O 0 6.532194163355598e-08
and O 0 6.280344564402185e-07
Bannayan B-Disease 0 0.005110142752528191
- I-Disease 0 0.29253703355789185
Zonana I-Disease 1 0.8727381229400635
( I-Disease 0 7.336076350838994e-07
BZS I-Disease 0 0.0001089450015570037
) I-Disease 0 3.645268620289244e-08
or I-Disease 0 1.415207151467257e-07
Ruvalcaba I-Disease 0 0.0004349786613602191
- I-Disease 0 0.02011074684560299
Riley I-Disease 0 0.014415277168154716
- I-Disease 1 0.9970190525054932
Smith I-Disease 1 0.9993155002593994
syndrome I-Disease 1 0.9958842396736145
( O 0 4.596780399879208e-06
MIM O 0 0.020464427769184113
153480 O 0 0.0001827021624194458
) O 0 5.891955083825451e-07
. O 0 1.0215371730737388e-06

Constitutive O 0 0.00011236677528358996
DNA O 0 0.00022327156329993159
from O 0 1.7865918380266521e-06
37 O 0 7.737977284705266e-06
CD B-Disease 0 1.3891554772271775e-05
families O 0 1.64348443831841e-06
and O 0 7.439630280714482e-07
seven O 0 1.6553304931221646e-06
BZS B-Disease 0 0.0005276831216178834
families O 0 1.412255983268551e-06
was O 0 4.969828751200112e-06
screened O 0 3.7168219932937063e-06
for O 0 1.5895326441750512e-06
germline O 0 0.002999761374667287
PTEN O 0 0.01943303644657135
mutations O 0 3.604387165978551e-05
. O 0 6.0712036429322325e-06

PTEN O 1 0.5468049049377441
mutations O 0 0.001162326312623918
were O 0 1.2209769010951277e-05
identified O 0 2.0922989278915338e-05
in O 0 1.7254248518838722e-07
30 O 0 2.657390041349572e-07
of O 0 6.42230517655662e-08
37 O 0 3.316355650895275e-05
( O 0 2.1294326302268018e-07
81 O 0 1.7560727428644896e-05
% O 0 1.7064878932160354e-07
) O 0 3.753457278321548e-08
CD B-Disease 0 9.123005838773679e-06
families O 0 3.161336053381092e-06
, O 0 4.874169690083363e-07
including O 0 1.5771704511280404e-06
missense O 0 0.0002398685901425779
and O 0 6.860045232315315e-06
nonsense O 0 3.1615461921319366e-05
point O 0 5.753816822107183e-06
mutations O 0 2.373932602495188e-06
, O 0 1.2027338414100086e-07
deletions O 0 4.936282948619919e-06
, O 0 3.187177526342566e-07
insertions O 0 3.599239789764397e-06
, O 0 3.9902573689687415e-07
a O 0 4.0060581341094803e-07
deletion O 0 1.5105633792700246e-05
/ O 0 3.925827968487283e-06
insertion O 0 1.6174012671399396e-06
and O 0 6.309015248007199e-07
splice O 0 4.099715442862362e-05
site O 0 2.7416705052019097e-05
mutations O 0 1.4340334018925205e-05
. O 0 2.1625589852192206e-06

These O 0 1.8102737158187665e-06
mutations O 0 5.188869181438349e-05
were O 0 1.9970632365584606e-06
scattered O 0 1.1496846354930312e-06
over O 0 1.0475229146322818e-06
the O 0 2.868707440484286e-07
entire O 0 1.7713668967189733e-06
length O 0 1.2454489478841424e-05
of O 0 3.3631708902248647e-06
PTEN O 0 0.19262981414794922
, O 0 8.670336910654441e-07
with O 0 3.3742625760169176e-07
the O 0 3.1438273140338424e-07
exception O 0 2.385920652159257e-07
of O 0 2.446001623468419e-08
the O 0 1.3075612059765263e-07
first O 0 1.1398362858017208e-06
, O 0 5.517161412171845e-07
fourth O 0 1.123001038649818e-05
and O 0 1.3139793964001e-06
last O 0 6.641342679358786e-06
exons O 0 2.8358312192722224e-05
. O 0 4.65459561382886e-06

A O 0 2.71157859970117e-05
hot O 0 1.7791238860809244e-05
spot O 0 6.552836566697806e-06
for O 0 8.653171903461043e-07
PTEN O 0 0.0017332275165244937
mutation O 0 1.714935251584393e-06
in O 0 1.4719994112510904e-07
CD B-Disease 0 0.0007559619261883199
was O 0 0.0027349006850272417
identified O 0 1.561137287353631e-05
in O 0 9.931988387279489e-08
exon O 0 2.4747554562054574e-05
5 O 0 2.454828802456177e-07
that O 0 3.748232835221188e-09
contains O 0 3.181945373853523e-09
the O 0 5.5088914763246066e-08
PTPase O 0 3.4956818126374856e-05
core O 0 2.6675033950596116e-06
motif O 0 9.41256644182431e-07
, O 0 3.43528547830374e-08
with O 0 2.9332989370800533e-08
13 O 0 4.0051449445854814e-07
of O 0 7.351701469815453e-08
30 O 0 1.4595432276109932e-06
( O 0 3.916639812473477e-08
43 O 0 1.5990216297723236e-06
% O 0 7.314790195778187e-08
) O 0 1.2115632053166792e-08
CD B-Disease 0 3.737002771231346e-06
mutations O 0 2.43984777625883e-06
identified O 0 2.174611836380791e-06
in O 0 3.6288277271978586e-08
this O 0 7.625992282100924e-08
exon O 0 0.0004970564041286707
. O 0 7.495415957237128e-06

Seven O 0 5.657443125528516e-06
of O 0 5.458383611767204e-07
30 O 0 4.237703251419589e-06
( O 0 6.861839096927724e-08
23 O 0 8.729745786695275e-06
% O 0 1.248547931709254e-07
) O 0 3.199474107873357e-08
were O 0 9.405175660504028e-08
within O 0 2.3196815579495933e-09
the O 0 7.30509981394789e-08
core O 0 3.567033490980975e-05
motif O 0 8.720367986825295e-06
, O 0 1.300243326340933e-07
the O 0 1.0361728897123612e-07
majority O 0 1.0352054005124955e-06
( O 0 2.607756144357154e-08
five O 0 5.775669364993519e-08
of O 0 4.973642120376098e-08
seven O 0 1.7485455146015738e-06
) O 0 2.844086743891694e-08
of O 0 8.182802879730389e-09
which O 0 5.68449962656814e-08
were O 0 1.1618532198554021e-06
missense O 0 6.130606197984889e-05
mutations O 0 6.442821813834598e-06
, O 0 4.942251052852953e-07
possibly O 0 2.520347152312752e-06
pointing O 0 1.645551310502924e-05
to O 0 4.152321508854584e-08
the O 0 5.3114174392021596e-08
functional O 0 4.6816802523608203e-07
significance O 0 4.912979179039212e-08
of O 0 3.2081086231983136e-08
this O 0 7.397218126925509e-08
region O 0 3.138469992336468e-06
. O 0 3.4213492199342e-06

Germline O 0 0.20394471287727356
PTEN O 1 0.5613887906074524
mutations O 0 0.0027018350083380938
were O 0 1.9732075088541023e-05
identified O 0 1.3306616892805323e-05
in O 0 4.7128313696020996e-08
four O 0 1.109990179770648e-07
of O 0 1.3919741093104676e-07
seven O 0 7.703848496021237e-06
( O 0 6.272551331676368e-07
57 O 0 3.513890624162741e-05
% O 0 8.028775368984498e-07
) O 0 5.094201469546533e-07
BZS B-Disease 0 9.251821029465646e-05
families O 0 3.2895047752390383e-06
studied O 0 2.251463411084842e-05
. O 0 4.320040261518443e-06

Interestingly O 0 0.0013343341415748
, O 0 9.979790775105357e-06
none O 0 5.362824708754488e-07
of O 0 1.6569394745147292e-08
these O 0 2.7833378268837805e-08
mutations O 0 4.2747342376969755e-06
was O 0 1.9802258975687437e-05
observed O 0 4.1094605762737046e-07
in O 0 2.3780737379297534e-08
the O 0 2.442272659664013e-07
PTPase O 0 0.0004460318887140602
core O 0 3.319355164421722e-05
motif O 0 1.241135487362044e-05
. O 0 2.8806985028495546e-06

It O 0 6.3721831793372985e-06
is O 0 8.381056773032469e-07
also O 0 4.890540594715276e-07
worthy O 0 2.7946481395701994e-07
of O 0 9.961926394908005e-08
note O 0 1.369459710076626e-06
that O 0 1.494252899192361e-08
a O 0 4.969233202700707e-08
single O 0 5.230597821537231e-07
nonsense O 0 9.041425073519349e-06
point O 0 3.6931169233866967e-06
mutation O 0 1.361292902402056e-06
, O 0 1.986121986874423e-07
R233X O 0 6.985826530581107e-06
, O 0 2.6916163164969475e-07
was O 0 6.12640542385634e-06
observed O 0 2.1938811300969974e-07
in O 0 1.6276084480182362e-08
the O 0 3.1217123108717715e-08
germline O 0 1.9127568521071225e-05
DNA O 0 8.114983756968286e-06
from O 0 6.059421764348372e-08
two O 0 1.4559245187228953e-07
unrelated O 0 4.681191421695985e-05
CD B-Disease 0 0.0002530957863200456
families O 0 7.470333002856933e-06
and O 0 2.294063278895919e-06
one O 0 7.442458354489645e-06
BZS B-Disease 0 0.011583360843360424
family O 0 2.3307082301471382e-05
. O 0 3.867699888360221e-06

Genotype O 0 0.03346077352762222
- O 0 0.16136804223060608
phenotype O 0 0.001198135199956596
studies O 0 6.217607278813375e-06
were O 0 6.4871637732721865e-06
not O 0 6.130345298061002e-08
performed O 0 4.766561687574722e-07
on O 0 2.844445532446116e-07
this O 0 1.1594536886150308e-08
small O 0 4.366711721104366e-07
group O 0 2.4188807401515078e-06
of O 0 5.753469736191619e-07
BZS B-Disease 0 0.0038646026514470577
families O 0 9.323546692030504e-06
. O 0 5.960968792351196e-06

However O 0 2.996207149408292e-05
, O 0 3.999723048764281e-06
genotype O 0 7.630675099790096e-05
- O 0 0.0009133787825703621
phenotype O 0 1.2165160114818718e-05
analysis O 0 2.0780304055278975e-07
inthe O 0 8.254068234236911e-05
group O 0 6.286664302024292e-06
of O 0 1.4068504583519825e-07
CD B-Disease 0 0.00035585954901762307
families O 0 7.272884431586135e-06
revealed O 0 1.1732634447980672e-05
two O 0 4.529330155378375e-08
possible O 0 1.0361807767367281e-07
associations O 0 2.149845279575402e-08
worthy O 0 9.764290354041805e-08
of O 0 9.731210504071441e-09
follow O 0 2.161967493918837e-08
- O 0 6.18728699919302e-06
up O 0 1.0277838669026096e-07
in O 0 1.042096542391846e-08
independent O 0 2.434895804981352e-07
analyses O 0 4.001638444606215e-06
. O 0 7.135038231353974e-06

The O 0 4.145716502534924e-06
first O 0 1.8637114408193156e-05
was O 0 0.0010605191346257925
an O 0 5.902577868255321e-06
association O 0 6.233053863979876e-05
noted O 0 4.294883183320053e-06
in O 0 2.894511297313329e-08
the O 0 7.834971427200799e-08
group O 0 6.491876547443098e-07
of O 0 3.229233414003829e-08
CD B-Disease 0 7.207713497336954e-05
families O 0 1.3940206372353714e-05
with O 0 0.0005122650181874633
breast B-Disease 1 0.9973184466362
disease I-Disease 0 0.02037239819765091
. O 0 9.185916496790014e-06

A O 0 0.00010884729272220284
correlation O 0 6.954598211450502e-05
was O 0 0.00024099761503748596
observed O 0 2.721144937822828e-06
between O 0 8.109856253213366e-08
the O 0 1.0593252000035136e-06
presence O 0 3.3242804420297034e-06
/ O 0 9.394663720740937e-06
absence O 0 1.2940818123752251e-06
of O 0 5.407308378835296e-08
a O 0 9.24227697396418e-06
PTEN O 0 0.1390107274055481
mutation O 0 3.1476272397412686e-06
and O 0 2.909201839429443e-07
the O 0 1.980738488782663e-07
type O 0 1.317564419878181e-05
of O 0 1.648429133638274e-05
breast O 0 0.39170709252357483
involvement O 0 0.00027622634661383927
( O 0 3.1880908863968216e-06
unaffected O 0 0.0001536886702524498
versus O 0 0.052684005349874496
benign O 0 0.4318419098854065
versus O 1 0.9790472388267517
malignant O 1 0.9990400671958923
) O 0 1.076091757568065e-05
. O 0 4.6773966460023075e-06

Specifically O 0 3.2190462661674246e-05
and O 0 5.579677804234962e-07
more O 0 1.4316059449015484e-08
directly O 0 1.2304047913858085e-07
, O 0 3.232558469790092e-07
an O 0 3.139957698294893e-06
association O 0 0.0004237029352225363
was O 0 0.005233942996710539
also O 0 3.6253350117476657e-06
observed O 0 1.7911298755279859e-07
between O 0 2.116563457832399e-08
the O 0 6.175363154170554e-08
presence O 0 4.426163968673791e-08
of O 0 2.0731167893472957e-08
a O 0 5.140176199347479e-06
PTEN O 0 0.09250572323799133
mutation O 0 5.647729994961992e-05
and O 0 0.03949287161231041
malignant B-Disease 1 0.9999779462814331
breast I-Disease 1 0.999915361404419
disease I-Disease 1 0.621283233165741
. O 0 7.04945923644118e-05

Secondly O 0 0.009455608204007149
, O 0 1.7471322280471213e-05
there O 0 6.250945148167375e-07
appeared O 0 1.5042397535580676e-05
to O 0 1.2985444186597306e-07
be O 0 8.418822261546666e-08
an O 0 8.127654496092873e-07
interdependent O 0 0.0011011972092092037
association O 0 7.538076260971138e-06
between O 0 4.2642960806915653e-07
mutations O 0 3.577649067665334e-06
upstream O 0 1.3150036011211341e-06
and O 0 1.006940095749087e-07
within O 0 4.137961973071924e-09
the O 0 9.643596143860123e-08
PTPase O 0 0.00017456944624427706
core O 0 6.435489012801554e-06
motif O 0 1.1199304026376922e-06
, O 0 3.903737066934809e-08
the O 0 2.69200839397854e-08
core O 0 3.3619585337874014e-06
motif O 0 7.612911190335581e-07
containing O 0 2.01702945901161e-07
the O 0 3.118736913165776e-08
majority O 0 1.946009717812558e-07
of O 0 6.794052609393475e-08
missense O 0 0.00011671359970932826
mutations O 0 1.4064741662878077e-05
, O 0 2.3203115517844708e-07
and O 0 1.3207355209488014e-07
the O 0 9.989306448687785e-08
involvement O 0 2.4299858978338307e-06
of O 0 1.2180792907656723e-07
all O 0 2.457121581755928e-07
major O 0 7.765836198814213e-05
organ O 0 0.06270614266395569
systems O 0 0.0007513421587646008
( O 0 1.0163917067984585e-06
central O 0 1.8084655266648042e-06
nervous O 0 5.032744229538366e-05
system O 0 4.913893008051673e-06
, O 0 0.0002169238869100809
thyroid O 1 0.9966855645179749
, O 0 0.00015416965470649302
breast O 1 0.6240400075912476
, O 0 0.002358262427151203
skin O 1 0.7748899459838867
and O 1 0.5615752935409546
gastrointestinal O 1 0.9999569654464722
tract O 1 0.9941229224205017
) O 0 2.9923265174147673e-05
. O 0 2.0215818949509412e-05

However O 0 3.6544726754073054e-05
, O 0 7.76130093527172e-07
these O 0 8.637076831519153e-09
observations O 0 1.949260166611566e-07
would O 0 1.9203744727747107e-07
need O 0 1.9450220989369882e-08
to O 0 2.8706171661951885e-08
be O 0 6.073514668969437e-08
confirmed O 0 3.2373711178479425e-07
by O 0 1.851452324785896e-08
studying O 0 9.445372484151449e-08
a O 0 3.901638123693374e-08
larger O 0 7.51402282617164e-08
number O 0 1.0216736789914194e-08
of O 0 4.054044921986133e-08
CD B-Disease 0 4.369168163975701e-05
families O 0 1.140224230766762e-05
. O 0 4.16054990637349e-06

Molecular O 0 0.4299470782279968
defects O 1 0.9990149736404419
leading O 0 0.0006117142038419843
to O 0 7.271201525327342e-07
human O 0 1.7619000800550566e-06
complement B-Disease 0 2.65888938884018e-05
component I-Disease 0 0.4203151762485504
C6 I-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999822378158569
in O 0 9.328706482847338e-07
an O 0 2.8510908123280387e-06
African O 0 4.2134677642025054e-05
- O 0 0.011999620124697685
American O 0 0.00010933496378129348
family O 0 2.8729984478559345e-05
. O 0 4.779840310220607e-06

Complement B-Disease 0 0.002692208392545581
component I-Disease 1 0.8870012760162354
C6 I-Disease 1 0.9999926090240479
deficiency I-Disease 1 0.9999914169311523
( O 0 3.6505472962744534e-05
C6D B-Disease 1 0.8739902377128601
) O 0 2.5052782802958973e-05
was O 0 0.08192995935678482
diagnosed O 1 0.6224043965339661
in O 0 1.5320932789109065e-07
a O 0 1.3913291923017823e-06
16 O 0 2.0000301446998492e-05
- O 0 0.014676101505756378
year O 0 1.6754511307226494e-05
- O 0 0.0014764961088076234
old O 0 0.001383428811095655
African O 0 5.629177849186817e-06
- O 0 7.793179975124076e-05
American O 0 1.5624225852661766e-05
male O 0 2.0250261513865553e-05
with O 0 6.325205322355032e-05
meningococcal B-Disease 1 0.9996997117996216
meningitis I-Disease 1 0.9984602928161621
. O 0 5.7891847973223776e-05

The O 0 7.686662138439715e-05
patients O 0 0.0019895457662642
father O 0 0.0002161906595574692
and O 0 1.4790213072046754e-06
two O 0 2.079903197227395e-06
brothers O 0 0.07495127618312836
also O 0 0.00016269342449959368
had O 0 0.00030752658494748175
C6D B-Disease 0 0.04984697327017784
, O 0 4.6881316961844277e-07
but O 0 4.157504562840586e-08
gave O 0 1.4796123082305712e-07
no O 0 1.557117812467368e-08
history O 0 9.411240853296476e-08
of O 0 4.925345365336398e-06
meningitis B-Disease 1 0.9982596039772034
or O 0 8.357260412594769e-06
other O 0 1.9782590243266895e-05
neisserial B-Disease 1 0.8009170293807983
infection I-Disease 0 0.005547753535211086
. O 0 4.627711405191803e-06

By O 0 1.571140046507935e-06
using O 0 6.677700525870023e-07
exon O 0 7.485679088858888e-05
- O 0 4.0119088225765154e-05
specific O 0 5.898510835322668e-08
polymerase O 0 2.6443392926012166e-05
chain O 0 6.322383705992252e-05
reaction O 0 8.090148071460135e-07
( O 0 3.9414754127165e-08
PCR O 0 8.113381227303762e-06
) O 0 2.227169204616075e-08
/ O 0 1.5800277708422072e-07
single O 0 2.646202119649388e-07
- O 0 2.9974302378832363e-05
strand O 0 1.175869874714408e-05
conformation O 0 3.263688313381863e-06
polymorphism O 0 3.7562582292594016e-05
as O 0 7.436020155182632e-08
a O 0 3.236534240613764e-08
screening O 0 1.6656792922731256e-07
step O 0 6.718192224752784e-08
and O 0 2.865681025809863e-09
nucleotide O 0 1.660656856472542e-08
sequencing O 0 1.822779438498401e-08
of O 0 7.121285339195538e-09
target O 0 2.8128113171987934e-07
exons O 0 9.260833166990778e-07
, O 0 7.42482413329526e-08
we O 0 1.1450891790332207e-08
determined O 0 1.5251991669629206e-07
that O 0 8.259606332217118e-09
the O 0 7.919106081999416e-08
proband O 0 0.0008744142251089215
was O 0 1.0570098311291076e-05
a O 0 1.3392831021974416e-07
compound O 0 1.9140026097375085e-07
heterozygote O 0 9.958048394764774e-07
for O 0 1.609435074101384e-08
two O 0 6.754862624802627e-07
C6 O 1 0.7112936973571777
gene O 0 7.403255040117074e-06
mutations O 0 5.23950166098075e-06
. O 0 2.0868687897745986e-06

The O 0 1.8339688949708943e-06
first O 0 1.5791089253980317e-06
, O 0 4.854842927670688e-07
1195delC O 0 2.282869172631763e-05
located O 0 1.505414530811322e-07
in O 0 5.394720048457202e-08
exon O 0 4.362898107501678e-05
7 O 0 9.66149218584178e-06
, O 0 2.3529254633558594e-07
is O 0 3.786440316844164e-08
a O 0 1.4965411310186028e-07
novel O 0 1.160695887847396e-06
mutation O 0 1.0499683185116737e-06
, O 0 7.77607525037638e-08
while O 0 8.37736777725695e-08
the O 0 3.1756353990886055e-08
second O 0 1.1601945288930438e-06
, O 0 2.660478628513374e-07
1936delG O 0 1.69294435181655e-06
in O 0 2.254110142985155e-08
exon O 0 1.6090036297100596e-05
12 O 0 1.8489802187104942e-06
, O 0 3.686603236019437e-07
has O 0 5.399680844675459e-07
been O 0 7.073730330375838e-07
described O 0 1.6845889376781997e-06
before O 0 9.265240805689245e-07
to O 0 3.670308217351703e-07
cause O 0 3.0853368571115425e-06
C6D B-Disease 0 0.0014078932581469417
in O 0 2.1520612847325538e-07
an O 0 1.2413415788614657e-06
unrelated O 0 0.0011613656533882022
African O 0 1.6561421944061294e-05
- O 0 0.0003302991099189967
American O 0 6.986572770983912e-06
individual O 0 9.776493925528484e-07
. O 0 5.952198080194648e-06

Both O 0 2.449377097946126e-05
mutations O 0 0.00018877530237659812
result O 0 8.903526577341836e-06
in O 0 1.8409081121717463e-06
premature O 0 0.00030111600062809885
termination O 0 9.006841719383374e-05
codons O 0 1.1591082511586137e-05
and O 0 7.185425602074247e-06
C6 O 0 0.3365333080291748
null O 0 0.0002127576881321147
alleles O 0 1.5613009963999502e-05
. O 0 3.6233820992492838e-06

Allele O 0 8.920070104068145e-05
- O 0 7.60738184908405e-05
specific O 0 1.705999608248021e-07
PCR O 0 9.323123231297359e-05
indicated O 0 9.915197551890742e-06
that O 0 2.2449368586308083e-08
the O 0 3.6939969305649356e-08
probands O 0 0.00017523120914120227
two O 0 1.4585915550924256e-06
brothers O 0 0.010118379257619381
also O 0 3.1511073757428676e-05
inherited O 0 0.0005273653077892959
the O 0 2.572137987044698e-07
1195delC O 0 6.411048525478691e-05
mutation O 0 4.281516794435447e-07
from O 0 4.1595825450713164e-08
their O 0 5.8162406446626846e-08
heterozygous O 0 1.5258291341524455e-06
mother O 0 3.910045052180067e-06
and O 0 3.807478421435917e-08
the O 0 3.677434179394368e-08
1936delG O 0 1.5992984117474407e-05
mutation O 0 1.7462681967117533e-07
from O 0 2.4763641803815517e-08
their O 0 8.985306010345084e-08
homozygous O 0 1.2139815225964412e-05
father O 0 9.199592568620574e-06
. O 0 2.0981588022550568e-07
. O 0 1.3551672282119398e-06

PAX6 O 0 0.26792868971824646
mutations O 0 0.003426313167437911
reviewed O 0 0.0005960392882116139
. O 0 6.171777204144746e-05

Mutations O 0 0.0013591554015874863
in O 0 6.118452802184038e-06
PAX6 O 0 0.005503151100128889
are O 0 2.4675574650245835e-07
responsible O 0 8.899290833142004e-07
for O 0 1.1273725704086246e-06
human O 0 2.3349819457507692e-05
aniridia B-Disease 1 0.9999583959579468
and O 0 2.3148129912442528e-05
have O 0 1.5801920199010056e-06
also O 0 1.3907786069466965e-06
been O 0 1.7283082343055867e-06
found O 0 6.885567927383818e-06
in O 0 3.7594793411699357e-06
patients O 0 5.4991909564705566e-05
with O 0 7.882487989263609e-05
Peters B-Disease 1 0.9999910593032837
anomaly I-Disease 1 0.9999774694442749
, O 0 0.02783103473484516
with O 1 0.9657666683197021
congenital B-Disease 1 0.9999996423721313
cataracts I-Disease 1 0.9999971389770508
, O 0 0.01084719505161047
with O 0 0.005846063140779734
autosomal B-Disease 1 0.6374693512916565
dominant I-Disease 0 0.1405337154865265
keratitis I-Disease 1 0.980844259262085
, O 0 8.043103298405185e-05
and O 0 2.230455902463291e-05
with O 0 0.00029108684975653887
isolated B-Disease 0 0.2403043955564499
foveal I-Disease 1 0.9999043941497803
hypoplasia I-Disease 1 0.9998230338096619
. O 0 0.00012283648538868874

No O 0 2.523709781598882e-06
locus O 0 9.50589219428366e-06
other O 0 2.092320272595316e-07
than O 0 1.829969988875746e-07
chromosome O 0 0.00028676248621195555
11p13 O 0 7.793818804202601e-05
has O 0 1.964501279871911e-06
been O 0 1.8101080740962061e-06
implicated O 0 0.0021467183250933886
in O 0 1.4528201973007526e-05
aniridia B-Disease 1 0.999971866607666
, O 0 2.1326008209143765e-05
and O 0 1.1651348359009717e-05
PAX6 O 0 0.1355571299791336
is O 0 2.1906646452407585e-06
clearly O 0 2.36221194427344e-06
the O 0 1.8346845820360613e-07
major O 0 6.884248250571545e-06
, O 0 7.001714834586892e-07
if O 0 3.9759811443218496e-08
not O 0 7.054393513783452e-09
only O 0 7.3749282236690306e-09
, O 0 1.7954258169083914e-07
gene O 0 1.9669106166020356e-07
responsible O 0 3.3987278129643528e-06
. O 0 3.3283217817370314e-06

Twenty O 0 1.549601620354224e-05
- O 0 0.00011341117351548746
eight O 0 2.1369812657212606e-06
percent O 0 6.630116786254803e-06
of O 0 6.755339398978322e-08
identified O 0 1.343113854090916e-05
PAX6 O 0 0.00041582935955375433
mutations O 0 2.5656017896835692e-06
are O 0 2.7057456009060843e-07
C O 0 0.016630366444587708
- O 0 0.392623633146286
T O 0 0.15635325014591217
changes O 0 1.0136633932233963e-07
at O 0 5.471621875585697e-07
CpG O 0 1.958696338988375e-05
dinucleotides O 0 6.48983332212083e-05
, O 0 9.995633831749728e-08
20 O 0 5.248335810392746e-08
% O 0 8.890196134814232e-09
are O 0 1.5418964993685336e-09
splicing O 0 1.4046639762455015e-07
errors O 0 5.915419751545414e-05
, O 0 1.788762205023886e-07
and O 0 3.7702111654880355e-08
more O 0 2.2949795397408934e-09
than O 0 9.627658670297023e-09
30 O 0 1.4198656117514474e-07
% O 0 1.9921232663477895e-08
are O 0 9.023223057624818e-09
deletion O 0 1.4455247310252162e-06
or O 0 1.6407626901582262e-07
insertion O 0 3.2051902962848544e-06
events O 0 8.683925329933118e-07
. O 0 3.107513748545898e-06

There O 0 2.231933422081056e-06
is O 0 3.319935331091983e-07
a O 0 1.3926951396570075e-06
noticeably O 0 0.00019653969502542168
elevated O 0 0.0002930622431449592
level O 0 2.281221185285176e-07
of O 0 6.425441512192265e-08
mutation O 0 6.822855880272982e-07
in O 0 3.056070596585414e-08
the O 0 8.570406606622782e-08
paired O 0 1.4528201973007526e-05
domain O 0 5.408911647464265e-07
compared O 0 1.0601281246636063e-05
with O 0 1.9169728204815328e-07
the O 0 1.3171494117614202e-07
rest O 0 7.662588785706248e-08
of O 0 1.6126184831932733e-08
the O 0 3.794813210333814e-07
gene O 0 1.8590851595945423e-06
. O 0 2.6106085897481535e-06

Increased O 0 7.530886068707332e-05
mutation O 0 1.2805205187760293e-05
in O 0 1.3482316774116043e-07
the O 0 2.545730524161627e-07
homeodomain O 0 0.0001754226250341162
is O 0 1.9345189627983927e-07
accounted O 0 3.1621136713511078e-06
for O 0 4.7879790798788235e-08
by O 0 8.805164242176033e-08
the O 0 2.778071745979105e-07
hypermutable O 0 0.0002485457807779312
CpG O 0 1.3992858839628752e-05
dinucleotide O 0 2.2329755665850826e-05
in O 0 5.4733760634917417e-08
codon O 0 1.0292163779013208e-06
240 O 0 2.4857586140569765e-06
. O 0 1.0430162546981592e-06

Very O 0 4.075550805282546e-06
nearly O 0 2.115697043336695e-06
all O 0 6.267791263780964e-08
mutations O 0 4.124696715734899e-06
appear O 0 1.8143821307603503e-06
to O 0 1.3129534863765002e-06
cause O 0 2.3048320144880563e-05
loss O 0 4.310220538172871e-05
of O 0 7.508048582849369e-08
function O 0 1.497351220791643e-08
of O 0 2.2315276737572276e-08
the O 0 2.3027621409710264e-07
mutant O 0 8.788591367192566e-05
allele O 0 1.973167854885105e-06
, O 0 1.2667518944908807e-07
and O 0 6.320276924043355e-08
more O 0 1.8797539080850356e-09
than O 0 7.955694769634647e-09
80 O 0 5.026802085694726e-08
% O 0 4.747564119611525e-09
of O 0 6.446786660063708e-09
exonic O 0 2.8469055905588903e-05
substitutions O 0 4.936038635605655e-07
result O 0 9.608326223542463e-08
in O 0 1.230158375165047e-07
nonsense O 0 2.2489910406875424e-05
codons O 0 1.3936617506260518e-05
. O 0 2.103868382619112e-06

In O 0 4.608517883752938e-06
a O 0 1.6208848592214053e-06
gene O 0 8.022812494345999e-07
with O 0 1.7796168094719178e-07
such O 0 1.0224187718677058e-07
extraordinarily O 0 9.911604865919799e-05
high O 0 1.1854959666379727e-05
sequence O 0 3.652952784705121e-08
conservation O 0 1.0498537506009598e-07
throughout O 0 6.372238292584598e-09
evolution O 0 1.1271388444811237e-07
, O 0 4.665269557335705e-07
there O 0 6.035878641341696e-08
are O 0 1.827195603709697e-07
presumed O 0 0.003530287416651845
undiscovered O 0 0.03178175911307335
missense O 0 0.0002552426012698561
mutations O 0 2.679540921235457e-05
, O 0 1.6622992404791148e-07
these O 0 5.2309534481764786e-09
are O 0 3.2326536114624105e-08
hypothesized O 0 1.7071826050596428e-06
to O 0 2.03653147679006e-08
exist O 0 8.998525480308217e-09
in O 0 2.7664015078698867e-08
as O 0 2.4466694981128967e-07
- O 0 0.00024332098837476224
yet O 0 1.284228005715704e-06
unidentified O 0 8.550356142222881e-05
phenotypes O 0 5.3388630476547405e-06
. O 0 3.5667201814248983e-07
. O 0 2.0314125777076697e-06

Genetic O 0 0.00104113994166255
heterogeneity O 0 0.00041608273750171065
and O 0 9.8707514553098e-06
penetrance O 0 0.0002640907478053123
analysis O 0 1.8845911142761906e-07
of O 0 1.1971162905410893e-07
the O 0 1.0356230859542848e-06
BRCA1 O 0 0.00034475885331630707
and O 0 2.329144990653731e-06
BRCA2 O 0 0.00016961940855253488
genes O 0 2.9238954084576108e-06
in O 0 1.6424581190221943e-05
breast B-Disease 1 0.9979852437973022
cancer I-Disease 1 0.6679688096046448
families O 0 2.9755057767033577e-05
. O 0 1.5120594071049709e-05

The O 0 0.018307160586118698
Breast B-Disease 1 0.9999171495437622
Cancer I-Disease 1 0.9998169541358948
Linkage O 0 0.02937939576804638
Consortium O 0 0.005232980474829674
. O 0 4.911284122499637e-05

The O 0 1.9823382899630815e-06
contribution O 0 6.049789135431638e-06
of O 0 7.895681619629613e-07
BRCA1 O 0 0.0005824706749990582
and O 0 7.788254151819274e-06
BRCA2 O 0 0.010211069136857986
to O 0 0.0011401060037314892
inherited B-Disease 1 0.9999982118606567
breast I-Disease 1 0.9999963045120239
cancer I-Disease 1 0.9999974966049194
was O 1 0.6502505540847778
assessed O 0 0.01777644455432892
by O 0 5.7793727137323e-06
linkage O 0 4.351405004854314e-05
and O 0 3.7534973671426997e-06
mutation O 0 5.680342383129755e-07
analysis O 0 7.214981678771437e-08
in O 0 1.2165098439709254e-07
237 O 0 4.500225986703299e-05
families O 0 1.5678696172471973e-06
, O 0 1.3452751090881065e-07
each O 0 6.639818916909235e-09
with O 0 4.3147018402578396e-08
at O 0 3.7742694303233293e-07
least O 0 6.600523683175652e-09
four O 0 1.4147767046779336e-07
cases O 0 5.46795672562439e-06
of O 0 0.0002545597089920193
breast B-Disease 1 0.9995693564414978
cancer I-Disease 0 0.24581731855869293
, O 0 3.033812845387729e-07
collected O 0 1.3212713838584023e-06
by O 0 3.497930947560235e-06
the O 0 0.001913274871185422
Breast B-Disease 1 0.999976396560669
Cancer I-Disease 1 0.9989162683486938
Linkage O 0 0.00033295515459030867
Consortium O 0 0.0005839170189574361
. O 0 1.5180643458734266e-05

Families O 0 0.00013486127136275172
were O 0 9.956101166608278e-06
included O 0 2.4011235382204177e-06
without O 0 1.7589826484254445e-07
regard O 0 6.876302904856857e-08
to O 0 9.064104133926776e-09
the O 0 3.081285271377965e-08
occurrence O 0 1.928732217493234e-06
of O 0 1.5688845451222733e-05
ovarian B-Disease 1 0.9994876384735107
or I-Disease 0 1.46723386933445e-05
other I-Disease 0 2.618931648612488e-05
cancers I-Disease 1 0.6281707286834717
. O 0 2.1889476556680165e-05

Overall O 0 0.01807616651058197
, O 0 0.0031094916630536318
disease O 0 0.41709813475608826
was O 0 0.0026959520764648914
linked O 0 0.0013241431443020701
to O 0 1.4230921578928246e-06
BRCA1 O 0 0.00018421474669594318
in O 0 2.1682679118839587e-07
an O 0 3.400932087060937e-07
estimated O 0 1.3636338735523168e-05
52 O 0 3.692886821227148e-05
% O 0 1.6868672503278503e-07
of O 0 7.579877348007358e-08
families O 0 1.181397578875476e-06
, O 0 2.62084085989045e-07
to O 0 4.766220840224378e-08
BRCA2 O 0 5.099625013826881e-06
in O 0 1.533743088089068e-08
32 O 0 7.771061518724309e-07
% O 0 1.7068483515458865e-08
of O 0 4.841628964413758e-08
families O 0 1.6656872503517661e-06
, O 0 6.852629894638085e-07
and O 0 2.659976416907739e-07
to O 0 4.4993313963459514e-08
neither O 0 1.8639924803665053e-07
gene O 0 1.8549584979155043e-08
in O 0 1.3644671170709444e-08
16 O 0 8.789749585957907e-07
% O 0 1.1633751029194173e-07
( O 0 2.5668908776310673e-08
95 O 0 9.487901024840539e-07
% O 0 3.8854528838783153e-07
confidence O 0 1.3928638509241864e-06
interval O 0 7.097150955814868e-07
[ O 0 1.6409253476012964e-06
CI O 0 0.00018564920173957944
] O 0 2.699526078231429e-07
6 O 0 2.0130859468281415e-07
% O 0 5.4298496365845494e-08
- O 0 0.00010793236288009211
28 O 0 5.191677246330073e-06
% O 0 6.356908954785467e-08
) O 0 2.018221678667942e-08
, O 0 3.829575945246688e-08
suggesting O 0 6.491939075203845e-07
other O 0 1.6945017478064983e-07
predisposition O 0 0.00019127783889416605
genes O 0 3.5559708067012252e-06
. O 0 2.6980794700648403e-06

The O 0 5.8264504332328215e-06
majority O 0 1.0525497600610834e-05
( O 0 2.941227421615622e-07
81 O 0 2.056985795206856e-05
% O 0 1.1910125863323628e-07
) O 0 7.431480320008177e-09
of O 0 2.4046283186862638e-08
the O 0 6.034546095179394e-05
breast B-Disease 1 0.999879002571106
- I-Disease 1 0.9999984502792358
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999895095825195
families O 0 4.338543658377603e-05
were O 0 5.3002037020633e-05
due O 0 5.761943157267524e-06
to O 0 8.422377391070768e-07
BRCA1 O 0 0.0006892317323945463
, O 0 7.418128689096193e-07
with O 0 5.561143439081206e-07
most O 0 6.9754281639689e-07
others O 0 1.9195647382730385e-06
( O 0 8.668487083696164e-08
14 O 0 1.5864901570239454e-06
% O 0 2.591901306914224e-07
) O 0 1.1586560333398666e-07
due O 0 9.184533951156482e-07
to O 0 7.82965173584671e-07
BRCA2 O 0 0.00014538795221596956
. O 0 2.7923963443754474e-06

Conversely O 0 0.0003904246259480715
, O 0 2.0081977254449157e-06
the O 0 9.674270273762886e-08
majority O 0 3.023043007033266e-07
of O 0 4.7547800363645365e-08
families O 0 8.157621209647914e-07
with O 0 2.8932806799275568e-06
male B-Disease 0 3.57949138560798e-05
and I-Disease 0 3.3917971450136974e-05
female I-Disease 0 0.1671302169561386
breast I-Disease 1 0.9952815175056458
cancer I-Disease 0 0.46331197023391724
were O 0 2.6166198949795216e-05
due O 0 7.933950655569788e-06
to O 0 7.199529932222504e-07
BRCA2 O 0 0.00011727106175385416
( O 0 1.9331358203089621e-07
76 O 0 0.0001102460955735296
% O 0 1.234328351529257e-06
) O 0 1.154587380369776e-06
. O 0 2.6258296657033497e-06

The O 0 6.956475317565491e-06
largest O 0 0.0003900819574482739
proportion O 0 2.5170078515657224e-05
( O 0 2.559450535954966e-07
67 O 0 2.2589820218854584e-05
% O 0 9.573934534046202e-08
) O 0 6.931764939821505e-09
of O 0 2.4669638776231295e-08
families O 0 1.573759845996392e-06
due O 0 2.7540036171558313e-06
to O 0 4.445827173071848e-08
other O 0 5.901886979131632e-08
genes O 0 5.077009177512082e-07
was O 0 0.00018253638700116426
found O 0 6.874709015392e-06
in O 0 1.4216784904874658e-07
families O 0 5.407807748269988e-07
with O 0 2.76537093668594e-07
four O 0 7.041450089673162e-07
or O 0 1.9454735422641534e-07
five O 0 2.109370029756974e-07
cases O 0 5.503461011358013e-07
of O 0 3.120640030829236e-06
female O 0 0.47046613693237305
breast B-Disease 1 0.9933955073356628
cancer I-Disease 0 0.052437759935855865
only O 0 4.269227815711929e-07
. O 0 3.3253900255658664e-06

These O 0 1.227854681928875e-06
estimates O 0 2.1492569430847652e-05
were O 0 5.438682364911074e-06
not O 0 1.7203049651470792e-07
substantially O 0 7.25135168977431e-06
affected O 0 1.447450301839126e-07
either O 0 2.0478390538869462e-08
by O 0 1.1005583644418948e-07
changing O 0 3.358768765338027e-07
the O 0 1.0955528040312856e-07
assumed O 0 2.58976137956779e-06
penetrance O 0 8.47683895699447e-06
model O 0 6.136651791166514e-07
for O 0 5.880783646716736e-07
BRCA1 O 0 0.00010900994675466791
or O 0 1.3621520622564276e-07
by O 0 9.484710261631335e-08
including O 0 1.6383311276513268e-06
or O 0 8.130228366098891e-07
excluding O 0 0.0003426930634304881
BRCA1 O 0 0.00024713625316508114
mutation O 0 2.1804180505569093e-06
data O 0 4.97968767376733e-06
. O 0 6.099197889852803e-06

Among O 0 3.912364263669588e-05
those O 0 2.0372754079289734e-06
families O 0 1.6605117707513273e-05
with O 0 0.0007896740571595728
disease O 0 0.23273663222789764
due O 0 4.236739914631471e-05
to O 0 1.3531797549148905e-06
BRCA1 O 0 0.002584086498245597
that O 0 2.9795779710184433e-07
were O 0 3.1698341445007827e-06
tested O 0 6.864403985673562e-06
by O 0 4.3581493969213625e-08
one O 0 1.5601083092064982e-08
of O 0 5.07942221616986e-09
the O 0 1.5145161569307675e-08
standard O 0 1.8660912814993935e-07
screening O 0 1.0642225589663212e-07
methods O 0 6.81813361325112e-08
, O 0 1.1130727983754696e-07
mutations O 0 5.319238880474586e-07
were O 0 1.1891733038282837e-06
detected O 0 2.7567102733883075e-06
in O 0 1.3213876215445453e-08
the O 0 1.2379287817054774e-08
coding O 0 4.680510414800665e-07
sequence O 0 2.0300587877386533e-08
or O 0 1.6660440138593913e-08
splice O 0 7.758014817227377e-07
sites O 0 6.928807039230378e-08
in O 0 1.228733292890638e-08
an O 0 7.34588496698052e-08
estimated O 0 7.206445843621623e-06
63 O 0 7.560446829302236e-05
% O 0 6.64053061427694e-08
( O 0 6.162840904266886e-09
95 O 0 2.059116042119058e-07
% O 0 1.070237729550172e-07
CI O 0 0.00014968530740588903
51 O 0 3.0026453714526724e-06
% O 0 8.129726580818897e-08
- O 0 8.600507135270163e-05
77 O 0 1.8025759345619008e-05
% O 0 2.7428015414443507e-07
) O 0 1.584949274047176e-07
. O 0 6.86778264480381e-07

The O 0 1.9899223389074905e-06
estimated O 0 2.136602961400058e-05
sensitivity O 0 4.576903847919311e-06
was O 0 1.0218303941655904e-05
identical O 0 5.61232866402861e-07
for O 0 1.5271604425493024e-08
direct O 0 7.249810085596664e-09
sequencing O 0 5.651337460221839e-07
and O 0 7.651401290331705e-08
other O 0 1.2113945402347781e-08
techniques O 0 1.2922614587296266e-06
. O 0 2.1915946035733214e-06

The O 0 2.2649267066299217e-06
penetrance O 0 0.0003316217625979334
of O 0 1.6560411495447624e-06
BRCA2 O 0 0.007190727163106203
was O 0 5.5301708925981075e-05
estimated O 0 6.388804081325361e-07
by O 0 2.9612545304757987e-08
maximizing O 0 4.005026710274251e-07
the O 0 4.1994571375880696e-08
LOD O 0 5.8101413742406294e-05
score O 0 9.816368446990964e-07
in O 0 2.8764219450749806e-07
BRCA2 O 0 0.00020083232084289193
- O 0 0.0011645578779280186
mutation O 0 3.1321940241468837e-06
families O 0 4.3743642663685023e-07
, O 0 1.054642453368615e-07
over O 0 8.274842144828654e-08
all O 0 1.8794320766346573e-08
possible O 0 4.897434564554715e-07
penetrance O 0 9.474985563429072e-05
functions O 0 2.979114697154728e-07
. O 0 2.8046142688253894e-06

The O 0 1.447584281777381e-06
estimated O 0 1.0280745300406124e-05
cumulative O 0 3.474550976534374e-05
risk O 0 0.00042812476749531925
of O 0 2.585093170637265e-05
breast B-Disease 1 0.9991874098777771
cancer I-Disease 1 0.6265775561332703
reached O 0 3.455273326835595e-05
28 O 0 2.3043925466481596e-05
% O 0 7.169670368512016e-08
( O 0 1.0943161043996952e-08
95 O 0 2.4808511511764664e-07
% O 0 4.402765227951022e-07
CI O 0 0.0003036830748897046
9 O 0 1.0146620752493618e-06
% O 0 6.222123971610927e-08
- O 0 1.0294902494933922e-05
44 O 0 1.2744345667670132e-06
% O 0 3.415183513766351e-08
) O 0 2.12468420635048e-09
by O 0 1.4693927852249544e-08
age O 0 5.148434070179064e-07
50 O 0 1.8869488371819898e-07
years O 0 3.702808157868276e-07
and O 0 1.434806193856275e-07
84 O 0 1.8555603674030863e-05
% O 0 4.159201694164949e-08
( O 0 7.78108688592738e-09
95 O 0 1.471584027967765e-07
% O 0 2.2786662157159299e-07
CI O 0 0.00047647496103309095
43 O 0 1.9961967154813465e-06
% O 0 6.528108542624977e-08
- O 0 9.657171176513657e-06
95 O 0 4.03016088057484e-07
% O 0 2.3184485442584446e-08
) O 0 2.507551943864428e-09
by O 0 2.106342122942806e-08
age O 0 6.541058610309847e-07
70 O 0 8.492281722283224e-07
years O 0 1.8985041378982714e-06
. O 0 1.433895363334159e-06

The O 0 0.00027986016357317567
corresponding O 1 0.9041087031364441
ovarian B-Disease 1 0.9999986886978149
cancer I-Disease 1 0.9999946355819702
risks O 1 0.504679799079895
were O 0 8.516341767972335e-05
0 O 0 3.215343167539686e-05
. O 0 4.662352239392931e-06

4 O 0 3.0516455808538012e-05
% O 0 8.45735826260352e-07
( O 0 4.338965098327208e-08
95 O 0 3.374417190116219e-07
% O 0 2.4630105599499075e-07
CI O 0 0.0011820518411695957
0 O 0 5.862372063347721e-07
% O 0 8.397268658200119e-08
- O 0 2.0579120246111415e-05
1 O 0 3.475521737072995e-07
% O 0 2.3267592297315787e-08
) O 0 2.3335715582106786e-09
by O 0 1.656247405890099e-08
age O 0 3.062688165300642e-07
50 O 0 2.863757515569887e-07
years O 0 2.3442105145932146e-07
and O 0 1.7060288826087344e-07
27 O 0 5.304842943587573e-06
% O 0 2.233043261412604e-08
( O 0 3.349937438557049e-09
95 O 0 7.910561805601901e-08
% O 0 1.2762268397636944e-07
CI O 0 0.0001097302811103873
0 O 0 3.7346404724303284e-07
% O 0 5.0690690756027834e-08
- O 0 0.00015022924344521016
47 O 0 4.117272692383267e-05
% O 0 6.955209386205752e-08
) O 0 3.21040238837611e-09
by O 0 1.2453151398972295e-08
age O 0 9.435448760086729e-07
70 O 0 7.281339549081167e-07
years O 0 2.9183488550188486e-06
. O 0 1.195234403894574e-06

The O 0 6.8175227170286234e-06
lifetime O 0 0.0005399359506554902
risk O 0 0.0007017025491222739
of O 0 4.8364825488533825e-05
breast B-Disease 1 0.9999072551727295
cancer I-Disease 1 0.9864006042480469
appears O 0 3.212284718756564e-05
similar O 0 3.2540771144340397e-07
to O 0 2.725394097069511e-07
the O 0 1.7142500610134448e-06
risk O 0 3.8067948480602354e-05
in O 0 1.5667783372919075e-06
BRCA1 O 0 0.002117694588378072
carriers O 0 4.7880763304419816e-05
, O 0 6.625348305533407e-07
but O 0 1.060081586956585e-07
there O 0 3.017443361841288e-08
was O 0 7.1290119194600265e-06
some O 0 6.163781485213349e-09
suggestion O 0 1.9521344540862628e-07
of O 0 3.0808564588369336e-08
a O 0 3.2634859508107184e-06
lower O 0 0.0005328356637619436
risk O 0 1.0611143807182088e-05
in O 0 1.2631521428829728e-07
BRCA2 O 0 1.3610328096547164e-05
carriers O 0 2.62775870396581e-06
< O 0 7.720616963524662e-07
50 O 0 8.702331655285889e-08
years O 0 1.5914196183075546e-07
of O 0 9.657198063450778e-08
age O 0 2.291491546202451e-05
. O 0 4.4744797378371e-06

Eye B-Disease 1 0.9572824835777283
movement I-Disease 0 0.002166420454159379
abnormalities I-Disease 1 0.7740260362625122
correlate O 0 3.440726868575439e-05
with O 0 3.280966484453529e-05
genotype O 0 0.01767781935632229
in O 0 0.0002450017782393843
autosomal O 1 0.9574215412139893
dominant O 1 0.8962223529815674
cerebellar B-Disease 1 0.9995889067649841
ataxia I-Disease 1 0.9997192025184631
type I-Disease 0 0.2600959837436676
I I-Disease 0 0.006364997010678053
. O 0 1.8652974176802672e-05

We O 0 5.635774414258776e-06
compared O 0 5.418090586317703e-05
horizontal O 0 0.0004134908667765558
eye O 0 0.015558012761175632
movements O 0 3.3144383451144677e-06
( O 0 6.747651326577397e-08
visually O 0 5.1285319386806805e-06
guided O 0 2.9551118132076226e-05
saccades O 0 0.0057223462499678135
, O 0 5.587608939094935e-06
antisaccades O 0 0.0027675668243318796
, O 0 4.872645718023705e-07
and O 0 1.8191191486494063e-07
smooth O 0 2.2781910047342535e-06
pursuit O 0 3.4759625123115256e-05
) O 0 1.771499142932953e-07
in O 0 4.3516042325109083e-08
control O 0 2.1836571306721453e-07
subjects O 0 8.246597644756548e-07
( O 0 1.5460825864010985e-07
n O 0 2.924692671513185e-05
= O 0 2.2702990463585593e-05
14 O 0 4.314432317187311e-06
) O 0 2.0724198179777886e-07
and O 0 3.7414031339721987e-06
patients O 0 3.35396543960087e-06
with O 0 8.5596077781247e-08
three O 0 5.086628789285896e-07
forms O 0 1.3009382655582158e-06
of O 0 2.3982009224710055e-05
autosomal O 1 0.7215917706489563
dominant O 0 0.10093871504068375
cerebellar B-Disease 1 0.8155056238174438
ataxias I-Disease 1 0.9748960137367249
type I-Disease 0 0.004579796921461821
I I-Disease 0 0.0005321425851434469
spinocerebellar B-Disease 0 0.04085168614983559
ataxias I-Disease 0 0.003358646295964718
1 I-Disease 0 1.3282591453389614e-06
and I-Disease 0 4.7169140771075035e-07
2 I-Disease 0 2.8216122700541746e-06
( O 0 3.8960837400736636e-07
SCA1 B-Disease 0 0.00045717053581029177
, O 0 2.470048343639064e-07
n O 0 6.537026365549536e-06
= O 0 4.740829808724811e-06
11 O 0 5.927161623731081e-07
; O 0 1.7603586854875175e-07
SCA2 B-Disease 0 0.0001639498514123261
, O 0 2.066098971909014e-07
n O 0 1.0245431440125685e-05
= O 0 5.069995950179873e-06
10 O 0 1.154845747919353e-07
) O 0 5.022335969329106e-08
and O 0 2.472082542226417e-06
SCA3 B-Disease 1 0.9993969202041626
/ O 0 0.0001495850010542199
Machado B-Disease 0 0.009619896300137043
- I-Disease 0 0.10397233814001083
Joseph I-Disease 0 0.303606241941452
disease I-Disease 0 0.025186507031321526
( O 0 6.3063957895792555e-06
MJD B-Disease 1 0.9998867511749268
) O 0 8.608666348663974e-07
( O 0 1.0967068675427072e-07
n O 0 2.727512583078351e-05
= O 0 3.769887916860171e-05
16 O 0 2.7746614250645507e-06
) O 0 1.891505263529325e-07
. O 0 8.852413770910061e-07

In O 0 4.612035354512045e-06
SCA1 B-Disease 0 0.000706253747921437
, O 0 1.2165386920059973e-07
saccade O 0 2.104625082210987e-06
amplitude O 0 3.476171457350574e-07
was O 0 7.971500963321887e-06
significantly O 0 8.482422231281816e-07
increased O 0 3.1404351830133237e-07
, O 0 5.536320557553154e-08
resulting O 0 6.115182031862787e-07
in O 0 5.315045541465224e-07
hypermetria B-Disease 0 0.006980986334383488
. O 0 7.061503310978878e-06

The O 0 2.4946311896201223e-06
smooth O 0 1.583264020155184e-05
pursuit O 0 0.00012171852722531185
gain O 0 0.0006468428182415664
was O 0 0.0006213868618942797
decreased O 0 0.0003210316936019808
. O 0 4.943387011735467e-06

In O 0 9.230121577274986e-06
SCA2 B-Disease 0 0.0016757851699367166
, O 0 4.1473833789495984e-07
saccade O 0 1.0123364518221933e-05
velocity O 0 4.644609816750744e-06
was O 0 2.458639573887922e-05
markedly O 0 7.924610690679401e-05
decreased O 0 0.00012127850641263649
. O 0 3.9406145333487075e-06

The O 0 1.6823028090584558e-06
percentage O 0 1.7431730157113634e-05
of O 0 1.9476696877518407e-07
errors O 0 0.000116561001050286
in O 0 1.588812779118598e-06
antisaccades O 0 0.04875285178422928
was O 0 0.0002653969859238714
greatly O 0 1.4857264432066586e-06
increased O 0 3.9446268829124165e-07
and O 0 2.351261088051615e-07
was O 0 7.192727480287431e-06
significantly O 0 4.307400445213716e-07
correlated O 0 6.406296506611397e-07
with O 0 5.234819582256023e-07
age O 0 4.6027602365938947e-05
at O 0 0.002388065680861473
disease O 0 0.02203413099050522
onset O 0 0.0004255937528796494
. O 0 1.7970249245991e-05

In O 0 6.370895334839588e-06
addition O 0 2.66669962911692e-06
, O 0 2.702138033328083e-07
a O 0 1.0874585143483273e-07
correlation O 0 1.578602990548461e-07
between O 0 1.324176110983899e-07
smooth O 0 4.1841335587378126e-06
pursuit O 0 0.0001333969848928973
gain O 0 5.776424222858623e-05
and O 0 1.333691415084104e-07
the O 0 9.12237929640014e-09
number O 0 1.600096410925289e-08
of O 0 1.0843413633665477e-07
trinucleotide O 0 0.00044844040530733764
repeats O 0 5.938182312092977e-06
was O 0 2.3888263967819512e-05
found O 0 4.25407824877766e-06
. O 0 3.1501076591666788e-06

In O 0 5.8669873396866024e-05
SCA3 B-Disease 1 0.9992289543151855
, O 0 2.2395312043954618e-05
gaze B-Disease 0 0.001279516494832933
- I-Disease 0 0.043053265661001205
evoked I-Disease 0 0.0028296324890106916
nystagmus I-Disease 0 0.062317077070474625
was O 0 0.0003299742820672691
often O 0 1.8558439762728085e-07
present O 0 4.626404148666552e-08
as O 0 1.2611660338279762e-07
was O 0 4.550937319436343e-06
saccade O 0 8.297232852783054e-06
hypometria O 0 5.984779272694141e-05
and O 0 6.97719855224932e-08
smooth O 0 1.1574688585369586e-07
pursuit O 0 2.6570987756713293e-06
gain O 0 2.4006540115806274e-05
was O 0 7.739634747849777e-05
markedly O 0 3.282452962594107e-05
decreased O 0 5.865320417797193e-05
. O 0 1.7578416873220704e-06

Three O 0 6.100891368987504e-06
major O 0 1.1742574315576348e-05
criteria O 0 2.6153728072131344e-07
, O 0 2.2784547581977677e-08
saccade O 0 7.060277766868239e-07
amplitude O 0 6.530549256922313e-08
, O 0 4.0600497186460416e-08
saccade O 0 7.747930226287281e-07
velocity O 0 7.296521289390512e-07
, O 0 5.067213493248346e-08
and O 0 6.35189110198553e-08
presence O 0 3.579647867013591e-08
of O 0 3.7106193673253074e-08
gaze B-Disease 0 0.0003781548875849694
- I-Disease 0 0.00691960146650672
evoked I-Disease 0 0.0005901909898966551
nystagmus I-Disease 0 0.0025818089488893747
, O 0 3.726102590917435e-07
permitted O 0 3.6925314361724304e-08
the O 0 2.264728671264038e-08
correct O 0 4.943283897773654e-07
assignment O 0 2.655244486504671e-07
of O 0 1.1573988878410546e-08
90 O 0 6.778636674198424e-08
% O 0 1.614680655848133e-08
of O 0 1.577002883834666e-08
the O 0 5.105085847390001e-07
SCA1 B-Disease 0 0.008799032308161259
, O 0 1.7495702309133776e-07
90 O 0 4.3386751968910175e-08
% O 0 7.401745438784246e-09
of O 0 1.801969418124827e-08
the O 0 4.908164896733069e-07
SCA2 B-Disease 0 0.03506571799516678
, O 0 2.7453319262349396e-07
and O 0 1.0176210452073065e-07
93 O 0 2.1411528905446175e-06
% O 0 5.304097783209727e-08
of O 0 9.01156553823057e-08
the O 0 4.073161107953638e-06
patients O 0 3.1641855457564816e-05
with O 0 7.355301931966096e-06
SCA3 B-Disease 1 0.9996548891067505
to O 0 2.5613405796320876e-07
their O 0 1.1762715956820102e-07
genetically O 0 8.31863235362107e-06
confirmed O 0 2.468702405167278e-05
patient O 0 2.761346422630595e-06
group O 0 3.4801660149241798e-06
and O 0 1.824661580940301e-06
, O 0 1.1916880566786858e-06
therefore O 0 2.4798106323942193e-07
, O 0 7.996947601895954e-07
may O 0 1.3384253634285415e-06
help O 0 4.069706847076304e-07
orient O 0 7.111054583219811e-05
diagnoses O 0 1.771363167790696e-05
of O 0 5.225188033364248e-07
SCA1 B-Disease 0 0.04390169680118561
, O 0 2.2218712274479913e-06
SCA2 B-Disease 0 0.0021775104105472565
, O 0 5.621552645607153e-07
and O 0 1.4586834140573046e-06
SCA3 B-Disease 1 0.9931535720825195
at O 0 2.3550430796603905e-06
early O 0 5.222218533162959e-07
clinical O 0 5.500323254636896e-07
stages O 0 2.2557881607099262e-07
of O 0 4.480397421957605e-07
the O 0 0.00014539585390593857
diseases O 0 0.0857124924659729
. O 0 3.106864824076183e-06
. O 0 1.2078979125362821e-05

Genetic O 0 9.59391618380323e-05
basis O 0 1.0278832860421971e-06
and O 0 2.405411805739277e-06
molecular O 0 0.00017820486391428858
mechanism O 0 0.0001379255554638803
for O 0 0.006631467957049608
idiopathic B-Disease 1 0.9999905824661255
ventricular I-Disease 1 0.9999086856842041
fibrillation I-Disease 1 0.9999035596847534
. O 0 0.0011998111149296165

Ventricular B-Disease 1 0.9972180128097534
fibrillation I-Disease 1 0.996480405330658
causes O 0 0.00038475083420053124
more O 0 9.767177289177198e-08
than O 0 8.31883539831324e-08
300 O 0 4.678497873555898e-07
, O 0 2.4666891818014847e-07
000 O 0 1.7238111240658327e-06
sudden O 0 7.696182365179993e-06
deaths O 0 2.9247150905575836e-06
each O 0 7.042968519499482e-08
year O 0 4.759684486543847e-07
in O 0 2.098478546486149e-08
the O 0 2.9071938456581847e-07
USA O 0 5.174543912289664e-05
alone O 0 8.55900452734204e-06
. O 0 1.165426624538668e-06

In O 0 1.990300233956077e-06
approximately O 0 5.050958975516551e-07
5 O 0 1.33053356421442e-06
- O 0 0.0002509696641936898
12 O 0 2.2545718820765615e-06
% O 0 2.040100355316099e-08
of O 0 7.080004582604715e-09
these O 0 7.988600003727697e-09
cases O 0 2.1863379515707493e-06
, O 0 1.135037337007816e-06
there O 0 9.90045876392287e-08
are O 0 9.797179245651932e-08
no O 0 4.4373263108354877e-07
demonstrable O 0 0.00909363105893135
cardiac O 0 0.3737562298774719
or O 0 7.730563993391115e-06
non O 0 0.0038054881151765585
- O 1 0.9882384538650513
cardiac O 1 0.946740448474884
causes O 0 3.639152510004351e-06
to O 0 4.642705064838992e-08
account O 0 9.971679304499048e-08
for O 0 8.025700282132675e-08
the O 0 1.1215502127015498e-07
episode O 0 3.027990942428005e-06
, O 0 4.7096057187445695e-07
which O 0 9.859810745638242e-08
is O 0 2.777722443170205e-07
therefore O 0 1.046460624820611e-06
classified O 0 0.007277245633304119
as O 0 0.4324987232685089
idiopathic B-Disease 1 0.9999969005584717
ventricular I-Disease 1 0.9999850988388062
fibrillation I-Disease 1 0.999990701675415
( O 0 0.0013817229773849249
IVF B-Disease 1 0.99972003698349
) O 0 1.6520218196092173e-05
. O 0 3.867080067720963e-06

A O 0 1.8032327716355212e-05
distinct O 0 1.1094499541286496e-06
group O 0 4.434193215274718e-06
of O 0 4.183542841929011e-06
IVF B-Disease 1 0.9999858140945435
patients O 0 0.07716425508260727
has O 0 3.259964069002308e-05
been O 0 5.7458878472971264e-06
found O 0 2.962485723401187e-06
to O 0 8.181354615999226e-08
present O 0 1.4918443014266813e-07
with O 0 6.745296445842541e-07
a O 0 9.849988600763027e-06
characteristic O 0 6.40644648228772e-05
electrocardiographic O 0 0.02740946225821972
pattern O 0 5.860729652340524e-05
. O 0 7.28137183614308e-06

Because O 0 4.835680101678008e-06
of O 0 1.0741580069861811e-07
the O 0 1.3496004669377726e-07
small O 0 2.490466215476772e-07
size O 0 1.981485866053845e-06
of O 0 3.744761656321316e-08
most O 0 7.875154039993504e-08
pedigrees O 0 2.5986555556301028e-06
and O 0 1.1906514885140496e-07
the O 0 1.7585800549113628e-07
high O 0 0.0009301095269620419
incidence O 0 0.0004662261053454131
of O 0 1.5500954759772867e-06
sudden B-Disease 0 0.0028225856367498636
death I-Disease 0 0.00031813172972761095
, O 0 2.8133044907008298e-06
however O 0 1.3605617255052493e-07
, O 0 5.510804257369273e-08
molecular O 0 4.309238647692837e-06
genetic O 0 3.835973075183574e-06
studies O 0 1.39343100613587e-07
of O 0 6.181750791256491e-07
IVF B-Disease 1 0.9986358284950256
have O 0 2.4188620955101214e-06
not O 0 2.935616194577051e-08
yet O 0 1.271760794452348e-07
been O 0 8.326913985001738e-07
done O 0 8.69682082793588e-07
. O 0 2.311771140739438e-06

Because O 0 0.0004643721622414887
IVF B-Disease 1 0.9998030066490173
causes O 1 0.8738321661949158
cardiac O 1 0.9995928406715393
rhythm O 0 0.2895181179046631
disturbance O 0 0.021094439551234245
, O 0 2.1472610569617245e-06
we O 0 6.186409251540681e-08
investigated O 0 1.4604785064875614e-05
whether O 0 5.960895919088216e-07
malfunction O 0 8.613894897280261e-05
of O 0 3.552766614234315e-08
ion O 0 2.0500123355304822e-05
channels O 0 4.852213805861538e-06
could O 0 7.6105834523332305e-06
cause O 0 2.0879178919130936e-06
the O 0 1.414506982655439e-06
disorder O 0 0.00015921522572170943
by O 0 3.712446812187409e-07
studying O 0 2.1347527763282415e-06
mutations O 0 5.514162921826937e-07
in O 0 2.1638529190681766e-08
the O 0 3.7844841926926165e-07
cardiac O 0 0.0004921841900795698
sodium O 0 4.100998467038153e-06
channel O 0 3.655424052340095e-06
gene O 0 1.7305229675912415e-06
SCN5A O 0 0.0004214511136524379
. O 0 3.8069740639912197e-06

We O 0 4.107394488528371e-06
have O 0 7.311023182410281e-07
now O 0 2.504633300759451e-07
identified O 0 5.693689786312461e-07
a O 0 1.29840074691856e-07
missense O 0 5.9440375480335206e-05
mutation O 0 2.134516535079456e-06
, O 0 9.645269472002838e-08
a O 0 3.512803345984139e-07
splice O 0 0.0003926068893633783
- O 0 0.19280678033828735
donor O 0 0.00010578787623671815
mutation O 0 4.841147983825067e-06
, O 0 2.4810194076962944e-07
and O 0 2.179469049679028e-07
a O 0 5.161048761692655e-07
frameshift O 0 0.00021133472910150886
mutation O 0 9.996527978728409e-07
in O 0 2.4339016135854763e-08
the O 0 6.529553786549513e-08
coding O 0 7.808512236806564e-06
region O 0 3.6097407019042294e-07
of O 0 1.494053947226348e-07
SCN5A O 0 0.005659382324665785
in O 0 9.961792812873682e-08
three O 0 2.2571687168237986e-06
IVF B-Disease 1 0.9690886735916138
families O 0 2.423523437755648e-05
. O 0 7.138039563869825e-06

We O 0 1.1367327488187584e-06
show O 0 2.4725559910621087e-07
that O 0 4.105885409444454e-09
sodium O 0 3.2243217873428875e-08
channels O 0 6.177752531755232e-09
with O 0 4.4106891472495136e-09
the O 0 1.9579491805643556e-08
missense O 0 1.9382878235774115e-05
mutation O 0 9.421111826668493e-06
recover O 0 4.783462645718828e-05
from O 0 2.5745848120095616e-07
inactivation O 0 0.0006674894248135388
more O 0 1.494717416505864e-08
rapidly O 0 3.0770164016757917e-07
than O 0 5.784950296572333e-09
normal O 0 1.2587503483985074e-08
and O 0 2.3111326186153747e-08
that O 0 1.2248164260597605e-08
the O 0 1.036736350101819e-07
frameshift O 0 0.0002489845792297274
mutation O 0 2.6756897568702698e-06
causes O 0 1.6579738826294488e-07
the O 0 2.072405180797432e-08
sodium O 0 8.471807859677938e-07
channel O 0 2.862951760107535e-07
to O 0 3.266843506821715e-08
be O 0 1.3655287034453067e-07
non O 0 5.500247425516136e-06
- O 0 0.000331102724885568
functional O 0 9.525139830657281e-06
. O 0 2.4854693947418127e-06

Our O 0 1.6907436020119349e-06
results O 0 2.0819213659706293e-06
indicate O 0 1.227852180818445e-06
that O 0 4.287057109308989e-08
mutations O 0 5.627093742077705e-07
in O 0 1.7169418242701795e-07
cardiac O 0 0.0005216036806814373
ion O 0 3.331520201754756e-05
- O 0 0.00027593685081228614
channel O 0 1.1535528301465092e-06
genes O 0 3.937710602031075e-08
contribute O 0 1.2963389472986364e-08
to O 0 3.124462910619741e-09
the O 0 3.167692597116911e-08
risk O 0 7.135760711207695e-07
of O 0 1.5541023401510756e-07
developing O 0 4.262551010469906e-05
IVF B-Disease 1 0.869053065776825
. O 0 1.2025036539853318e-06
. O 0 1.5556622656731633e-06

Molecular O 0 0.0003547048836480826
heterogeneity O 0 0.0006466686609201133
in O 0 1.231253827427281e-05
mucopolysaccharidosis B-Disease 0 0.017206726595759392
IVA I-Disease 1 0.8499135971069336
in O 0 1.141117354563903e-05
Australia O 0 5.994763796479674e-06
and O 0 1.9858869393374334e-07
Northern O 0 8.773380244520013e-08
Ireland O 0 6.135609851298796e-07
: O 0 1.8428522707836237e-08
nine O 0 1.275130756539511e-07
novel O 0 5.740294568568061e-07
mutations O 0 1.4732985391674447e-06
including O 0 1.5675825579819502e-06
T312S O 0 0.00011239966988796368
, O 0 1.677714323022883e-07
a O 0 1.3068469684185402e-07
common O 0 2.5837522343863384e-07
allele O 0 6.229901714505104e-07
that O 0 1.3823631661580293e-07
confers O 0 8.133470146276522e-06
a O 0 1.4773657312616706e-05
mild O 0 0.0015901452861726284
phenotype O 0 0.0007361615425907075
. O 0 1.489391434006393e-05

Mucopolysaccharidosis B-Disease 1 0.8264434337615967
IVA I-Disease 1 0.9967178702354431
( O 0 0.004179905168712139
MPS B-Disease 1 0.9998168349266052
IVA I-Disease 1 0.9999774694442749
) O 0 0.00012450154463294894
is O 0 9.18773002922535e-06
an O 0 0.0015835976228117943
autosomal B-Disease 1 0.9938216209411621
recessive I-Disease 1 0.9992318153381348
lysosomal I-Disease 1 0.999977707862854
storage I-Disease 1 0.9999909400939941
disorder I-Disease 1 0.9998711347579956
caused O 0 0.009860600344836712
by O 0 4.73938234790694e-05
a O 0 0.030601024627685547
genetic B-Disease 1 0.9999260902404785
defect I-Disease 1 0.9992247819900513
in O 0 2.59652006207034e-06
N O 0 0.013518794439733028
- O 0 0.04064404219388962
acetylgalactosamine O 0 0.010677078738808632
- O 0 0.0015465004835277796
6 O 0 8.718424942344427e-05
- O 0 0.05482681840658188
sulfate O 0 0.006770171225070953
sulfatase O 0 0.002360184909775853
( O 0 1.0757752306744806e-06
GALNS O 0 0.0007592595065943897
) O 0 2.902102380630822e-07
. O 0 1.1307968179607997e-06

Previous O 0 3.4815227991202846e-05
studies O 0 4.2760916585393716e-06
of O 0 3.1430765830009477e-06
patients O 0 6.39280115137808e-05
from O 0 5.154644213689608e-07
a O 0 2.300932010257384e-06
British O 0 0.0009694785694591701
- O 0 0.07049340009689331
Irish O 0 0.00041884498205035925
population O 0 2.0566274372413318e-07
showed O 0 8.60166983329691e-06
that O 0 5.2175842313317844e-08
the O 0 1.0194063548851773e-07
I113F O 0 1.7910146198119037e-05
mutation O 0 6.070909535083047e-07
is O 0 3.992670016828015e-08
the O 0 8.161062936551389e-08
most O 0 1.2728661147320963e-07
common O 0 1.8148564606690343e-07
single O 0 3.365853444847744e-06
mutation O 0 1.5247819646901917e-05
among O 0 9.387156751472503e-05
MPS B-Disease 1 0.9997914433479309
IVA I-Disease 1 0.9999959468841553
patients O 0 0.006279776804149151
and O 0 1.9357660221430706e-06
produces O 0 8.62801698531257e-06
a O 0 0.00012156715092714876
severe O 0 0.06482302397489548
clinical O 0 0.0017615685937926173
phenotype O 0 0.0020607176702469587
. O 0 2.5065904992516153e-05

We O 0 2.122868181686499e-06
studied O 0 1.3291158211359289e-05
mutations O 0 3.355507487867726e-06
in O 0 4.530980390882178e-08
the O 0 1.436070959925928e-07
GALNS O 0 0.0006190516287460923
gene O 0 4.902167916043254e-08
from O 0 4.697351130289462e-08
23 O 0 4.8585293370706495e-06
additional O 0 1.0664516594260931e-05
MPS B-Disease 1 0.9996563196182251
IVA I-Disease 1 0.9999964237213135
patients O 0 0.0053212582133710384
( O 0 2.534490590733185e-07
15 O 0 5.681436618942826e-07
from O 0 3.80986165282593e-07
Australia O 0 1.608099410077557e-06
, O 0 5.7189957658465573e-08
8 O 0 7.140914703995804e-08
from O 0 3.8677029579048394e-08
Northern O 0 8.702713927277728e-08
Ireland O 0 2.4827500055835117e-06
) O 0 7.629775211626111e-08
, O 0 2.3110709790330475e-08
with O 0 3.246785595933943e-08
various O 0 1.6281121872907534e-07
clinical O 0 0.0006542051560245454
phenotypes O 0 0.008312479592859745
( O 0 3.070482853217982e-05
severe O 0 0.01749209314584732
, O 0 3.329039145683055e-06
16 O 0 1.9374932890059426e-05
cases O 0 4.813168743567076e-06
; O 0 1.364192371511308e-06
intermediate O 0 6.140694495115895e-06
, O 0 8.579595487390179e-07
4 O 0 8.787848855718039e-06
cases O 0 3.9536280382890254e-05
; O 0 3.7481288018170744e-05
mild O 0 0.0005919553805142641
, O 0 1.7373242826579371e-06
3 O 0 8.965813321992755e-06
cases O 0 1.3821914762957022e-05
) O 0 1.9513058759912383e-06
. O 0 3.728576530193095e-06

We O 0 5.724152742914157e-06
found O 0 3.992132860730635e-06
two O 0 1.615970575130632e-07
common O 0 3.310636600417638e-07
mutations O 0 1.1025055073332624e-06
that O 0 1.7353617209892036e-08
together O 0 7.313646221973613e-08
accounted O 0 6.176415809022728e-06
for O 0 6.661741736024851e-08
32 O 0 1.1083988056270755e-06
% O 0 1.4656253100042704e-08
of O 0 6.3695408947239684e-09
the O 0 1.0874896361201536e-07
44 O 0 2.8249805836821906e-06
unrelated O 0 8.416609489358962e-06
alleles O 0 2.9036030468887475e-07
in O 0 1.0273683415107371e-07
these O 0 2.800236984512594e-07
patients O 0 2.404299084446393e-05
. O 0 3.0978144422988407e-06

One O 0 3.4067106753354892e-06
is O 0 1.768069495255986e-07
the O 0 1.1223719553754563e-07
T312S O 0 0.00015740653907414526
mutation O 0 7.944861863506958e-06
, O 0 2.2715040870480152e-07
a O 0 1.6979068107048079e-07
novel O 0 4.163504740972712e-07
mutation O 0 6.727629511260602e-07
found O 0 3.082872979121021e-07
exclusively O 0 2.1839964858827443e-07
in O 0 1.0155149539059494e-06
milder O 0 0.0007554066251032054
patients O 0 0.0001551734167151153
. O 0 4.663713298214134e-06

The O 0 2.1044643290224485e-06
other O 0 2.688822462459939e-07
is O 0 9.30613950345105e-08
the O 0 1.0681596052108944e-07
previously O 0 3.5565342841437086e-05
described O 0 2.7934809622820467e-05
I113F O 0 1.1387799531803466e-05
that O 0 4.559015920335696e-08
produces O 0 7.083194759616163e-07
a O 0 2.849113843694795e-05
severe O 0 0.023690419271588326
phenotype O 0 0.0006465429905802011
. O 0 2.274897815368604e-05

The O 0 3.1885560929367784e-06
I113F O 0 0.0001008158506010659
and O 0 1.1584786534513114e-06
T312S O 0 1.548626460134983e-05
mutations O 0 2.4061919248197228e-06
accounted O 0 7.863483006076422e-06
for O 0 2.79202396313849e-07
8 O 0 3.791119752349914e-06
( O 0 7.10561707251145e-08
18 O 0 9.59277713263873e-07
% O 0 1.281266008845705e-07
) O 0 5.409330583461269e-08
and O 0 2.518823407626769e-07
6 O 0 3.349059170432156e-06
( O 0 2.3569494800312896e-08
14 O 0 3.0250504323703353e-07
% O 0 1.410136807322715e-08
) O 0 1.9973802611872316e-09
of O 0 5.4701896345932255e-09
44 O 0 1.9111766960122623e-06
unrelated O 0 1.0221033335255925e-05
alleles O 0 5.555651796385064e-07
, O 0 8.173032597369456e-07
respectively O 0 1.8145577996619977e-05
. O 0 4.00464705307968e-06

The O 0 2.737762770266272e-06
relatively O 0 8.890910066838842e-06
high O 0 0.00011426416313042864
residual O 0 0.00018619842012412846
GALNS O 0 0.002831854857504368
activity O 0 4.1453270682723087e-07
seen O 0 2.9886300012549327e-07
when O 0 1.311392150427082e-08
the O 0 3.399486470101465e-09
T312S O 0 3.410868032460712e-07
mutant O 0 1.291811457804215e-07
cDNA O 0 3.473764920158828e-08
is O 0 2.0029512270980376e-08
overexpressed O 0 1.6009655610105256e-06
in O 0 2.961525602529491e-08
mutant O 0 1.2590040569193661e-05
cells O 0 2.9957212177578185e-07
provides O 0 9.974280956726034e-09
an O 0 3.688012739644364e-08
explanation O 0 3.620248278934923e-08
for O 0 7.724013073584501e-08
the O 0 1.5775809742990532e-06
mild O 0 0.0005305955419316888
phenotype O 0 0.00011676981375785545
in O 0 7.477873623429332e-06
patients O 0 2.089427835016977e-05
with O 0 1.8873232932037354e-07
this O 0 3.257116532040527e-07
mutation O 0 2.0728753952425905e-05
. O 0 1.0805093552335165e-05

The O 0 4.80031928873359e-07
distribution O 0 3.6311507756181527e-07
and O 0 9.922217714120052e-08
relative O 0 8.193050859972573e-08
frequencies O 0 9.00589114394279e-09
of O 0 8.35301605661698e-09
the O 0 1.4582171559140988e-07
I113F O 0 1.4613757230108604e-05
and O 0 3.561682433428359e-07
T312S O 0 1.223807248607045e-05
mutations O 0 3.294652515251073e-07
in O 0 5.2818467821680315e-08
Australia O 0 6.933935310371453e-07
corresponded O 0 3.408968609619478e-07
to O 0 3.316371532946505e-08
those O 0 2.1746766165620102e-08
observed O 0 1.4940212622605031e-07
in O 0 2.5424109040272924e-08
Northern O 0 1.2252515091404348e-07
Ireland O 0 3.6105193430557847e-06
and O 0 8.411484486714471e-07
are O 0 6.944127761698837e-08
unique O 0 5.4937814297773e-08
to O 0 1.4365157063878087e-08
these O 0 3.037472939837471e-09
two O 0 1.0909882064424892e-07
populations O 0 1.071748783942894e-06
, O 0 2.6818923970495234e-07
suggesting O 0 1.1764819873860688e-06
that O 0 2.8102553173425804e-08
both O 0 1.1780656450355309e-07
mutations O 0 1.929907966768951e-06
were O 0 8.87710939423414e-06
probably O 0 2.0600716652552364e-06
introduced O 0 2.628648303470982e-07
to O 0 3.4456540731753194e-08
Australia O 0 2.0625473950985906e-07
by O 0 2.2985728875823952e-08
Irish O 0 1.663940679463849e-06
migrants O 0 4.083306066604564e-07
during O 0 5.0005997564994686e-08
the O 0 4.358290439654411e-08
19th O 0 3.867795840051258e-06
century O 0 8.477089068037458e-06
. O 0 5.126927590026753e-06

Haplotype O 0 0.00025936466408893466
analysis O 0 2.5439230739721097e-06
using O 0 1.2631801382667618e-06
6 O 0 5.592630714090774e-06
RFLPs O 0 3.8400699850171804e-05
provides O 0 1.6154753978980807e-08
additional O 0 1.6990270523820072e-08
data O 0 4.705546885475087e-08
that O 0 8.571905851795236e-09
the O 0 3.441312657059825e-08
I113F O 0 1.0657440725481138e-05
mutation O 0 4.832084528061387e-07
originated O 0 7.16088308649887e-08
from O 0 9.310488735536637e-08
a O 0 1.8066347138301353e-06
common O 0 7.002281563472934e-06
ancestor O 0 5.908327511860989e-05
. O 0 1.3311972907104064e-05

The O 0 2.1707953692384763e-06
other O 0 3.4991546726814704e-07
9 O 0 2.0888201106572524e-06
novel O 0 1.4677368653792655e-06
mutations O 0 8.928065653890371e-06
identified O 0 7.184130936366273e-06
in O 0 1.4472887244210142e-07
these O 0 1.8277026470059354e-07
23 O 0 0.004549158737063408
patients O 0 7.468865078408271e-05
were O 0 5.505791591531306e-07
each O 0 2.3658268233361923e-08
limited O 0 8.912440563335622e-08
to O 0 2.263286447146129e-08
a O 0 2.587334790860041e-07
single O 0 1.0385555469838437e-05
family O 0 3.6210345569998026e-05
. O 0 1.1294989235466346e-05

These O 0 4.941261408930586e-07
data O 0 4.965727384842467e-07
provide O 0 6.848672029491354e-08
further O 0 5.6403589354658834e-08
evidence O 0 2.1938286920430983e-07
for O 0 3.052924668622836e-08
extensive O 0 5.333914145921881e-07
allelic O 0 5.282805432216264e-05
heterogeneity O 0 0.00043617055052891374
in O 0 3.638771522673778e-05
MPS B-Disease 1 0.9988393187522888
IVA I-Disease 1 0.9999076128005981
in O 0 2.2158525098348036e-05
British O 0 0.036602433770895004
- O 1 0.9306076169013977
Irish O 0 0.3751565217971802
patients O 0 6.410913920262828e-05
and O 0 1.6593121188179794e-07
provide O 0 1.9575459475618118e-08
evidence O 0 1.7233855942322407e-07
for O 0 2.516066466284883e-08
their O 0 2.947510502337991e-08
transmission O 0 2.5138992896245327e-06
to O 0 7.043344396606699e-08
Australia O 0 2.3541218752143322e-07
by O 0 1.1571465563520178e-07
British O 0 1.672179132583551e-05
- O 0 0.0004276756662875414
Irish O 0 3.653298699646257e-05
migrants O 0 2.2688852823193884e-06
. O 0 1.2382693626022956e-07
. O 0 1.2359456604826846e-06

Identification O 0 6.469839263445465e-06
of O 0 7.70539770655887e-07
constitutional O 0 9.161691559711471e-05
WT1 O 0 0.08155056834220886
mutations O 0 6.96133283781819e-05
, O 0 9.42891801969381e-07
in O 0 1.096882215279038e-06
patients O 0 3.672202365123667e-05
with O 0 1.0557333553151693e-05
isolated O 0 0.032683927565813065
diffuse B-Disease 1 0.9966700673103333
mesangial I-Disease 1 0.9999991655349731
sclerosis I-Disease 1 0.9999994039535522
, O 0 0.00014141418796498328
and O 0 1.5790877796462155e-06
analysis O 0 2.630019935168093e-07
of O 0 1.1555325727385934e-06
genotype O 0 0.0006915319245308638
/ O 0 7.587240543216467e-05
phenotype O 0 2.7775849957833998e-05
correlations O 0 4.68787311547203e-06
by O 0 1.6398945490436745e-07
use O 0 3.301665785215846e-08
of O 0 2.958747735704037e-08
a O 0 6.563460033248703e-07
computerized O 0 0.000510470534209162
mutation O 0 7.66902303439565e-06
database O 0 9.528347618470434e-06
. O 0 7.324168109335005e-06

Constitutional O 0 0.00017409154679626226
mutations O 0 2.457598748151213e-05
of O 0 7.772575827402761e-08
the O 0 4.4620918515647645e-07
WT1 O 0 0.00036964015453122556
gene O 0 1.7955184716811345e-07
, O 0 1.1887595796622463e-08
encoding O 0 6.567599086793052e-08
a O 0 7.761990673316177e-06
zinc O 1 0.7678184509277344
- O 0 0.003277887823060155
finger O 0 7.607991574332118e-05
transcription O 0 1.0248548960589687e-06
factor O 0 3.620124289227533e-07
involved O 0 1.218238935507543e-06
in O 0 4.894001904176548e-06
renal O 1 0.9681500792503357
and O 0 3.9731457945890725e-05
gonadal O 1 0.631766676902771
development O 0 3.4509992019593483e-06
, O 0 1.4496636140393093e-06
are O 0 5.8490371657171636e-08
found O 0 1.596388642610691e-06
in O 0 1.6113017409224994e-07
most O 0 1.2108167766200495e-06
patients O 0 7.420388556056423e-06
with O 0 1.0251314961351454e-05
Denys B-Disease 1 0.9997392296791077
- I-Disease 1 0.9999853372573853
Drash I-Disease 1 0.9999849796295166
syndrome I-Disease 1 0.9999561309814453
( O 0 2.0353747459012084e-05
DDS B-Disease 1 0.9999680519104004
) O 0 2.4382588890148327e-06
, O 0 1.541299639029603e-06
or O 0 3.4868255170295015e-05
diffuse B-Disease 1 0.993638813495636
mesangial I-Disease 1 0.9999980926513672
sclerosis I-Disease 1 0.9999992847442627
( O 0 0.0008826286066323519
DMS B-Disease 1 0.9957489967346191
) O 0 3.851783731079195e-06
associated O 0 3.929341346520232e-06
with O 0 6.85100394548499e-06
pseudohermaphroditism B-Disease 1 0.9999207258224487
and O 0 0.00014720855688210577
/ O 0 0.001993467565625906
or O 0 0.00577141297981143
Wilms B-Disease 1 0.9999011754989624
tumor I-Disease 1 0.7504549622535706
( O 0 1.2731437891488895e-05
WT B-Disease 1 0.9967569708824158
) O 0 2.370995844103163e-06
. O 0 2.141465529348352e-06

Most O 0 2.016643156821374e-05
mutations O 0 0.0008137046243064106
in O 0 0.00012711550516542047
DDS B-Disease 1 0.9999951124191284
patients O 0 0.3982572853565216
lie O 0 0.00011741507478291169
in O 0 7.597839726258826e-07
exon O 0 0.0001261157012777403
8 O 0 1.0613780432322528e-06
or O 0 6.061872426244008e-08
exon O 0 1.262940168089699e-05
9 O 0 6.754688115506724e-07
, O 0 5.341356512644779e-08
encoding O 0 5.717904514312977e-07
zinc O 0 0.04873621463775635
finger O 0 0.00011073992936871946
2 O 0 2.262860562041169e-06
or O 0 4.311064003559295e-06
zinc O 0 0.30071187019348145
finger O 0 0.00010980031220242381
3 O 0 2.009931677093846e-06
, O 0 5.336952426659991e-07
respectively O 0 6.541148195537971e-06
, O 0 7.732267448545826e-08
with O 0 7.0104540839111e-08
a O 0 1.5476684893656056e-06
hot O 0 2.2772333977627568e-05
spot O 0 2.7840607799589634e-05
( O 0 2.172330795247035e-07
R394W O 0 2.2374831587512745e-06
) O 0 8.524737360460222e-09
in O 0 1.8063845530491562e-08
exon O 0 5.047461672802456e-05
9 O 0 1.0481591743882746e-05
. O 0 1.480478999837942e-06

We O 0 1.191166461467219e-06
analyzed O 0 1.3963579021947226e-06
a O 0 8.26783761453953e-08
series O 0 1.361896266871554e-07
of O 0 3.169633089328272e-07
24 O 0 0.00013555167242884636
patients O 0 1.7780890630092472e-05
, O 0 1.6643106448555045e-07
10 O 0 3.9346480207314016e-07
with O 0 7.75540502218064e-06
isolated B-Disease 0 0.008149181492626667
DMS I-Disease 1 0.9958831071853638
( O 0 1.1854506738018245e-05
IDMS B-Disease 0 0.3742384612560272
) O 0 4.2723067394945247e-07
, O 0 9.61437649493746e-08
10 O 0 4.5573986540148326e-07
with O 0 6.770212621631799e-06
DDS B-Disease 1 0.9999840259552002
, O 0 1.8471229850547388e-05
and O 0 1.2116935295125586e-06
4 O 0 7.740929504507221e-06
with O 0 0.00010933662269962952
urogenital B-Disease 1 0.9967578053474426
abnormalities I-Disease 1 0.9924037456512451
and O 0 1.8767670553643256e-05
/ O 0 0.00024000104167498648
or O 0 5.3043808293296024e-05
WT B-Disease 1 0.9990038275718689
. O 0 1.7820089851738885e-05

We O 0 3.0128021535347216e-06
report O 0 4.003841240773909e-06
WT1 O 0 0.00019720419368240982
heterozygous O 0 5.256728854874382e-06
mutations O 0 6.399356152542168e-06
in O 0 4.0103432752403023e-07
16 O 0 0.0003121369518339634
patients O 0 9.982402843888849e-05
, O 0 5.212958740230533e-07
4 O 0 8.562576567783253e-07
of O 0 2.41348317331358e-07
whom O 0 8.441769750788808e-05
presented O 0 2.0241823222022504e-05
with O 0 2.9868580895708874e-05
IDMS B-Disease 1 0.8048705458641052
. O 0 3.8163729186635464e-05

One O 0 8.589062417740934e-06
male O 0 2.2913538487046026e-05
and O 0 5.367894004848495e-07
two O 0 8.831434570311103e-07
female O 0 0.006726951338350773
IDMS B-Disease 1 0.9899925589561462
patients O 0 0.0001359598245471716
with O 0 6.1884911701781675e-06
WT1 O 0 0.4100433886051178
mutations O 0 0.0008102136198431253
underwent O 0 0.006328478455543518
normal O 0 7.4089198278670665e-06
puberty O 0 0.00011664584599202499
. O 0 3.4573897664813558e-06

Two O 0 7.845531945349649e-05
mutations O 0 0.003430123906582594
associated O 0 5.258934834273532e-05
with O 0 2.4026783648878336e-05
IDMS B-Disease 1 0.9520501494407654
are O 0 1.4738675702119508e-07
different O 0 2.875185423079074e-09
from O 0 1.7446316746827506e-07
those O 0 5.916505187997245e-07
described O 0 8.062808774411678e-05
in O 0 4.507441553869285e-05
DDS B-Disease 1 0.9999669790267944
patients O 0 0.006955270189791918
. O 0 2.3109814719646238e-05

No O 0 1.7371952708344907e-05
WT1 O 0 0.003977085929363966
mutations O 0 0.0001227248867508024
were O 0 5.351086656446569e-06
detected O 0 1.5156962945184205e-05
in O 0 6.942670438547793e-08
the O 0 1.4555369887148117e-07
six O 0 8.643572982691694e-06
other O 0 3.6792403989238665e-05
IDMS B-Disease 1 0.9969556331634521
patients O 0 0.00023675349075347185
, O 0 4.0470382600688026e-07
suggesting O 0 2.7048320134781534e-06
genetic O 0 1.510608967691951e-06
heterogeneity O 0 9.741381290950812e-06
of O 0 1.1455596222731401e-06
this O 0 1.1482600712042768e-05
disease O 0 0.00532193947583437
. O 0 2.1068495698273182e-05

We O 0 2.2105639345681993e-06
analyzed O 0 2.158747156499885e-05
genotype O 0 0.00013915731688030064
/ O 0 9.381913696415722e-05
phenotype O 0 0.00016864149074535817
correlations O 0 0.00013707359903492033
, O 0 8.925086376621039e-07
on O 0 6.519076123367995e-07
the O 0 6.64329249389084e-08
basis O 0 2.8482235236992892e-08
of O 0 1.2218815470532718e-07
the O 0 4.0405132040177705e-07
constitution O 0 4.783128133567516e-07
of O 0 4.387415941664585e-08
a O 0 6.918347139617254e-07
WT1 O 0 0.00031582778319716454
mutation O 0 5.184471092434251e-07
database O 0 1.2061936160989717e-07
of O 0 1.4482360199963296e-07
84 O 0 0.0002703747304622084
germ O 0 0.005641710478812456
- O 0 0.001241685007698834
line O 0 2.8879087039968e-05
mutations O 0 1.4496607718683663e-06
, O 0 3.1112861620385956e-08
to O 0 2.74093769903061e-09
compare O 0 8.616726177024248e-08
the O 0 1.7239404570545958e-08
distribution O 0 8.148774810479154e-08
and O 0 3.4884791944023164e-07
type O 0 9.293586344938376e-07
of O 0 3.873861089687125e-07
mutations O 0 7.209181603684556e-06
, O 0 1.2993668008220993e-07
according O 0 6.740666691484876e-08
to O 0 2.3849871411130152e-08
the O 0 8.80086616916742e-08
different O 0 5.072706130704319e-07
symptoms O 0 3.3029005862772465e-05
. O 0 2.5324350190203404e-06

This O 0 5.385002168623032e-06
demonstrated O 0 9.9173717899248e-05
( O 0 3.738617522230925e-07
1 O 0 8.614020998720662e-07
) O 0 3.5023990818672246e-08
the O 0 6.904625138304255e-08
association O 0 1.2439915053619188e-06
between O 0 5.647065393077355e-08
mutations O 0 6.395827085725614e-07
in O 0 3.971486961518167e-08
exons O 0 4.005892151326407e-06
8 O 0 2.215198037447408e-06
and O 0 1.2596266287800972e-06
9 O 0 2.6277204597136006e-05
and O 0 2.3101858459995128e-05
DMS B-Disease 1 0.8871681690216064
; O 0 1.4231342220227816e-06
( O 0 9.140095613702215e-08
2 O 0 1.6953291606114362e-06
) O 0 1.3984485747187136e-07
among O 0 1.9567212348192697e-06
patients O 0 9.660957402957138e-06
with O 0 5.238212906988338e-06
DMS B-Disease 1 0.7923912405967712
, O 0 3.4717388075478084e-07
a O 0 6.976240740641515e-08
higher O 0 9.662320366032873e-08
frequency O 0 1.82189303643554e-08
of O 0 1.2934838089506684e-08
exon O 0 1.745926601870451e-05
8 O 0 1.101226644095732e-06
mutations O 0 3.55518068317906e-07
among O 0 2.412116657524166e-07
46 O 0 3.766279769479297e-05
, O 0 1.0605548595776781e-05
XY O 1 0.9910502433776855
patients O 0 7.479535997845232e-05
with O 0 1.6258481991826557e-06
female O 0 4.101404920220375e-05
phenotype O 0 4.582205747283297e-06
than O 0 1.2152133876952576e-07
among O 0 1.3116256241119117e-06
46 O 0 0.0003409223281778395
, O 0 0.00014237535651773214
XY O 1 0.9969645142555237
patients O 0 0.0001739961444400251
with O 0 3.8491657505801413e-07
sexual O 0 2.822968781401869e-06
ambiguity O 0 2.75001184490975e-06
or O 0 4.012801582575776e-06
male O 0 7.273258233908564e-05
phenotype O 0 4.1044841054826975e-05
; O 0 1.1989333188466844e-06
and O 0 2.9729690140811726e-06
( O 0 3.4290999906261277e-07
3 O 0 1.8562877812655643e-06
) O 0 9.462575434326936e-08
statistically O 0 1.5013943084341008e-06
significant O 0 1.8263540368934628e-07
evidence O 0 3.932798335881671e-07
that O 0 6.101043936723727e-08
mutations O 0 3.109103658971435e-07
in O 0 2.1715885978323968e-08
exons O 0 1.4797280982747907e-06
8 O 0 8.68938457188051e-07
and O 0 9.415298762860402e-08
9 O 0 8.017771619961422e-07
preferentially O 0 3.860219521811814e-07
affect O 0 2.151518962989485e-08
amino O 0 5.035400008068791e-08
acids O 0 4.1411063023133465e-08
with O 0 3.903094736301682e-09
different O 0 1.157082540892418e-09
functions O 0 1.63909490424885e-08
. O 0 1.1239936981155552e-07
. O 0 7.9117893392322e-07

The O 0 1.827267260523513e-05
185delAG O 0 0.005059832241386175
BRCA1 O 0 0.005451091565191746
mutation O 0 1.055342818290228e-05
originated O 0 5.087530894343217e-07
before O 0 1.8672307078304584e-07
the O 0 1.603322452581324e-08
dispersion O 0 1.8412838471704163e-06
of O 0 9.356846675245833e-08
Jews O 0 8.401327136198233e-07
in O 0 5.5664553855194754e-08
the O 0 2.0236922182448325e-07
diaspora O 0 1.2705057997663971e-05
and O 0 1.212610186485108e-06
is O 0 1.0822235196883412e-07
not O 0 2.0037308701148504e-08
limited O 0 1.4852233221063216e-07
to O 0 3.0305133691399533e-07
Ashkenazim O 0 0.00028438103618100286
. O 0 4.0631211959407665e-06

The O 0 3.693402277349378e-06
185delAG O 0 0.0007618486997671425
mutation O 0 2.230464269814547e-05
in O 0 6.676738735222898e-07
BRCA1 O 0 0.00035673315869644284
is O 0 5.652959771396127e-07
detected O 0 8.873833394318353e-06
in O 0 6.286504827812678e-08
Ashkenazi O 0 6.196971662575379e-05
Jews O 0 5.057499947724864e-07
both O 0 1.4898196809554065e-07
in O 0 1.7058090406862902e-06
familial B-Disease 0 0.3853699266910553
breast I-Disease 1 0.9998477697372437
and I-Disease 1 0.9997535347938538
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999909400939941
and O 0 1.529524161014706e-05
in O 0 2.009558528470734e-07
the O 0 2.6330189939471893e-07
general O 0 4.7534335863019805e-06
population O 0 2.5886797629937064e-06
. O 0 6.161766123113921e-06

All O 0 1.4113417137195938e-06
tested O 0 9.864722960628569e-05
Ashkenazi O 0 0.0008805134566500783
mutation O 0 1.1266416549915448e-05
carriers O 0 7.2116777118935715e-06
share O 0 3.0813771445536986e-07
the O 0 1.147321349037611e-08
same O 0 1.2739792332183697e-08
allelic O 0 2.733557266765274e-06
pattern O 0 5.949412411609956e-07
at O 0 4.979679602001852e-07
the O 0 9.744175031300983e-07
BRCA1 O 0 0.00035514950286597013
locus O 0 8.466833241982386e-05
. O 0 7.120253485481953e-06

Our O 0 1.2344413562459522e-06
previous O 0 1.665569698161562e-06
study O 0 4.4813759814132936e-07
showed O 0 2.500101618352346e-05
that O 0 2.5096490219311818e-08
this O 0 1.6197732932710096e-08
Ashkenazi O 0 0.0002782770898193121
mutation O 0 8.42372355691623e-06
also O 0 8.166604175130487e-07
occurs O 0 2.0276981871347743e-08
in O 0 2.9483146590791875e-08
Iraqi O 0 7.747900667709473e-07
Jews O 0 7.257851279973693e-07
with O 0 1.3686042166227708e-07
a O 0 5.260618536340189e-07
similar O 0 8.233787980316265e-07
allelic O 0 0.00020766715169884264
pattern O 0 5.612129461951554e-05
. O 0 1.0871306585613638e-05

We O 0 1.04853643279057e-06
extended O 0 2.3953273853294377e-07
our O 0 9.022017799509285e-09
analysis O 0 8.569682741210727e-09
to O 0 4.396972563824875e-09
other O 0 7.342939589705111e-09
non O 0 8.258300567831611e-07
- O 0 1.382221671519801e-05
Ashkenazi O 0 1.7019206097756978e-06
subsets O 0 6.347011094476329e-08
354 O 0 3.270372701535962e-07
of O 0 2.4981583024441534e-08
Moroccan O 0 1.77695164893521e-05
origin O 0 8.870365775237588e-08
, O 0 5.3878924433092834e-08
200 O 0 9.117773913658311e-08
Yemenites O 0 4.791693299921462e-06
and O 0 3.1898164110089056e-08
150 O 0 8.316646216144363e-08
Iranian O 0 7.568911541966372e-07
Jews O 0 1.6873962067620596e-06
. O 0 1.3326517773748492e-06

Heteroduplex O 0 0.001062282477505505
analysis O 0 1.423484491169802e-06
complemented O 0 1.7450955738240737e-06
by O 0 2.95561175533976e-08
direct O 0 9.79682113211311e-09
DNA O 0 6.523030720018141e-07
sequencing O 0 9.86339955488802e-07
of O 0 2.030225942917241e-07
abnormally O 0 8.645544585306197e-05
migrating O 0 4.6971717893029563e-07
bands O 0 9.813915085032932e-07
were O 0 7.566507633782749e-07
employed O 0 1.144920588558307e-05
. O 0 2.878570285247406e-06

Four O 0 4.57070109405322e-06
of O 0 4.821745847038983e-07
Moroccan O 0 0.0007224903092719615
origin O 0 6.6195593717566226e-06
( O 0 1.7968356758046866e-07
1 O 0 3.5459498803902534e-07
. O 0 4.041152124045766e-08
1 O 0 2.512398680210026e-07
% O 0 4.634176065110296e-08
) O 0 1.4210204568598783e-08
and O 0 1.249780865464345e-07
none O 0 2.9749319452321288e-08
of O 0 7.886213460039926e-09
the O 0 9.294024039263604e-08
Yemenites O 0 4.7785793867660686e-05
or O 0 1.2414038508268277e-07
Iranians O 0 1.1686620382533874e-06
was O 0 2.618897269712761e-06
a O 0 1.2069345700638223e-07
carrier O 0 8.379000064451247e-06
of O 0 3.8239264199546597e-08
the O 0 8.894675715964695e-07
185delAG O 0 0.00040342024294659495
mutation O 0 7.71210397942923e-06
. O 0 1.6364416524083936e-06

BRCA1 O 0 0.021500181406736374
allelic O 0 0.0004997972282581031
patterns O 0 6.662242958554998e-05
were O 0 1.0478483090992086e-05
determined O 0 1.6308734984704643e-06
for O 0 7.099209398120365e-08
four O 0 2.1327370802737278e-07
of O 0 9.72882006067266e-08
these O 0 4.633769279394073e-08
individuals O 0 1.2016252526336757e-07
and O 0 1.1484668505090667e-07
for O 0 3.990400898601365e-08
12 O 0 2.7053636131313397e-07
additional O 0 6.773957750283444e-08
non O 0 1.7942516024049837e-06
- O 0 6.052238677511923e-05
Ashkenazi O 0 4.09996609960217e-05
185delAG O 0 1.0361188287788536e-05
mutation O 0 6.60035027522099e-07
carriers O 0 7.1232761911232956e-06
who O 0 4.430535409483127e-05
had O 0 0.016928620636463165
breast B-Disease 1 0.9949114918708801
/ I-Disease 1 0.9994520545005798
ovarian I-Disease 1 0.9999979734420776
cancer I-Disease 1 0.9999256134033203
. O 0 7.281516445800662e-05

Six O 0 9.816940291784704e-05
non O 0 0.0002452347835060209
- O 0 0.01582038216292858
Ashkenazi O 0 0.0026740054599940777
individuals O 0 2.6891865445577423e-07
shared O 0 4.922199536849803e-07
the O 0 2.5157578420476057e-07
common O 0 1.2971930800631526e-06
Ashkenazi O 0 0.0007709353812970221
haplotype O 0 3.153130455757491e-05
, O 0 4.300758860154019e-07
four O 0 1.1165593605255708e-06
had O 0 2.3226826669997536e-05
a O 0 4.402479873988341e-07
closely O 0 3.6956571420887485e-06
related O 0 1.0934253623418044e-05
pattern O 0 2.2495574739878066e-05
, O 0 3.4392107863823185e-06
and O 0 8.66663356191566e-07
the O 0 5.05406717365986e-07
rest O 0 1.6360687595806667e-06
( O 0 1.583743483024591e-07
n O 0 8.695210271980613e-05
= O 0 4.5850178139517084e-05
6 O 0 4.503346644924022e-06
) O 0 4.774391015871515e-08
displayed O 0 9.766336006578058e-07
a O 0 2.538990599987301e-07
distinct O 0 7.337957868003286e-07
BRCA1 O 0 0.00017755574663169682
allelic O 0 0.00016343663446605206
pattern O 0 8.07695250841789e-05
. O 0 1.0790965461637825e-05

We O 0 1.5385297729153535e-06
conclude O 0 3.100734602412558e-06
that O 0 2.687452749228214e-08
the O 0 7.204516094816427e-08
185delAG O 0 0.00014928975724615157
BRCA1 O 0 9.900071745505556e-05
mutation O 0 1.2763380254909862e-06
occurs O 0 3.1299400404805056e-08
in O 0 2.562615186718631e-08
some O 0 4.598805247724158e-08
non O 0 1.972212703549303e-05
- O 0 0.006858393084257841
Ashkenazi O 0 0.0012781041441485286
populations O 0 2.1195474175783602e-07
at O 0 2.861619918803626e-07
rates O 0 3.8403067037506844e-07
comparable O 0 1.7153674036762823e-07
with O 0 2.421450595591068e-08
that O 0 1.5548769383144645e-08
of O 0 3.204287111202575e-07
Ashkenazim O 0 0.000679338292684406
. O 0 5.988946668367134e-06

The O 0 1.7241776504306472e-06
majority O 0 1.6763179928602767e-06
of O 0 7.584620931311292e-08
Jewish O 0 4.48120999863022e-06
185delAG O 0 0.00023678895377088338
mutation O 0 4.305816673877416e-06
carriers O 0 1.1755098967114463e-05
have O 0 1.5194471814083954e-07
a O 0 2.1173633513171808e-07
common O 0 3.2536300409446994e-07
allelic O 0 7.08078732714057e-05
pattern O 0 1.9210176105843857e-05
, O 0 8.959282808973512e-07
supporting O 0 3.784155296671088e-06
the O 0 6.669274057458097e-07
founder O 0 0.0002581028384156525
effect O 0 4.686737042902678e-07
notion O 0 2.510633407837304e-07
, O 0 1.9501007386679703e-07
but O 0 4.464504854695406e-08
dating O 0 4.7662754809607577e-07
the O 0 1.111668197495419e-07
mutations O 0 8.588878586124338e-07
origin O 0 6.910831018558383e-08
to O 0 2.302447299484811e-08
an O 0 1.0998364530223625e-07
earlier O 0 1.4416409612749703e-06
date O 0 1.7597812984604388e-07
than O 0 3.293150285799129e-08
currently O 0 3.7812408208992565e-06
estimated O 0 1.5390245607704856e-05
. O 0 3.731212245838833e-06

However O 0 3.420175562496297e-05
, O 0 3.5791430263998336e-07
the O 0 1.6426753290943452e-08
different O 0 2.0573907022480853e-09
allelic O 0 3.6978710795665393e-06
pattern O 0 3.591234190025716e-06
at O 0 2.063703504973091e-06
the O 0 9.230247428604343e-07
BRCA1 O 0 0.000190319653484039
locus O 0 1.8598691895022057e-05
even O 0 3.062180269353121e-07
in O 0 2.845443347609944e-08
some O 0 7.233042609300355e-09
Jewish O 0 2.048553824351984e-06
mutation O 0 9.008056622406002e-06
carriers O 0 2.133036105078645e-05
, O 0 1.1961284371864167e-06
might O 0 5.034156629335484e-07
suggest O 0 1.419154784798593e-07
that O 0 6.981949240980612e-09
the O 0 3.856396091350689e-08
mutation O 0 6.772820597689133e-07
arose O 0 3.370898582488735e-07
independently O 0 2.2369786734088848e-07
. O 0 1.737106032351221e-07
. O 0 1.9900476218026597e-06

Crystal O 0 0.013610908761620522
structure O 0 2.183431206503883e-05
of O 0 1.4979246998336748e-06
the O 0 2.8976690373383462e-05
hemochromatosis B-Disease 1 0.9999779462814331
protein O 0 4.1010414861375466e-05
HFE O 0 0.0010276903631165624
and O 0 4.295937969800434e-07
characterization O 0 7.388559311038989e-07
of O 0 1.3026419942718803e-08
its O 0 2.1347471346189195e-08
interaction O 0 3.0909507842125095e-08
with O 0 6.21112576482119e-07
transferrin O 0 0.0018222035141661763
receptor O 0 1.3584535736299586e-05
. O 0 1.1426453738749842e-06

HFE O 0 0.3657473921775818
is O 0 1.320712090091547e-05
an O 0 9.555976248520892e-06
MHC O 0 0.011261330917477608
- O 0 0.030306100845336914
related O 0 2.615732046251651e-05
protein O 0 2.6383401063867495e-07
that O 0 2.4840087320399107e-08
is O 0 3.3059762927223346e-08
mutated O 0 3.439114948378119e-07
in O 0 9.259927225002684e-08
the O 0 1.5450668797711842e-05
iron B-Disease 1 0.9993453621864319
- I-Disease 1 0.9997299313545227
overload I-Disease 1 0.9997242093086243
disease I-Disease 1 0.9977351427078247
hereditary B-Disease 1 0.9999752044677734
hemochromatosis I-Disease 1 0.9999973773956299
. O 0 0.007172350771725178

HFE O 0 0.004697727970778942
binds O 0 1.4065706636756659e-05
to O 0 1.1096234402430127e-06
transferrin O 0 0.0004052588192280382
receptor O 0 2.1781568648293614e-05
( O 0 2.7152506731908943e-07
TfR O 0 0.00010695393575588241
) O 0 1.9950473273411262e-08
and O 0 6.250110828887045e-08
reduces O 0 6.487550763267791e-07
its O 0 1.5394611807550973e-08
affinity O 0 2.523275952626136e-07
for O 0 3.6044912121724337e-07
iron O 0 0.004224270582199097
- O 0 2.345225220778957e-05
loaded O 0 6.846764881629497e-05
transferrin O 0 5.3010531701147556e-05
, O 0 2.4929420305852545e-07
implicating O 0 0.0002352288574911654
HFE O 0 0.01307026855647564
in O 0 7.693716725043487e-06
iron O 0 0.16159792244434357
metabolism O 0 9.162110654870048e-05
. O 0 2.4117953216773458e-06

The O 0 9.594839866622351e-06
2 O 0 2.0009669242426753e-05
. O 0 1.2255055480636656e-05

6 O 0 0.00036163139156997204
A O 0 0.00014169453061185777
crystal O 0 0.0486268550157547
structure O 0 1.2600839909282513e-05
of O 0 8.281218697447912e-07
HFE O 0 0.0357758030295372
reveals O 0 1.0622422450978775e-05
the O 0 3.9177905364340404e-08
locations O 0 3.1262979405255464e-07
of O 0 9.535938261251431e-06
hemochromatosis B-Disease 1 0.9999961853027344
mutations O 0 0.0003459800500422716
and O 0 4.226358669257024e-06
a O 0 5.9534380852710456e-05
patch O 0 0.3818552792072296
of O 0 1.9541012079571374e-06
histidines O 0 0.03934783115983009
that O 0 5.159828333489713e-07
could O 0 4.513255760230095e-07
be O 0 1.9840085130340412e-08
involved O 0 4.020571395813022e-07
in O 0 5.077188234281493e-07
pH O 0 0.00013631653564516455
- O 0 0.0003224780084565282
dependent O 0 2.256658490296104e-06
interactions O 0 5.663611659656453e-07
. O 0 2.4215303255914478e-06

We O 0 4.200248895358527e-06
also O 0 1.9127285213471623e-06
demonstrate O 0 1.0244308441542671e-06
that O 0 5.101372835270013e-07
soluble O 0 3.390480924281292e-05
TfR O 0 0.00026959014940075576
and O 0 1.1238098522881046e-06
HFE O 0 0.004540159832686186
bind O 0 1.1840022125397809e-05
tightly O 0 4.942892246617703e-06
at O 0 6.394510023710609e-07
the O 0 4.328979130718835e-08
basic O 0 1.3519075992007856e-07
pH O 0 6.136458523542387e-07
of O 0 8.640999027420548e-09
the O 0 7.243178856697341e-08
cell O 0 0.00011665407510008663
surface O 0 3.6248973628971726e-05
, O 0 1.0202013527305098e-06
but O 0 6.769036531295569e-08
not O 0 3.439899698420845e-09
at O 0 5.608177033877837e-08
the O 0 5.560216109756766e-08
acidic O 0 2.5043134428415215e-06
pH O 0 1.8214608417110867e-06
of O 0 8.927225536581318e-08
intracellular O 0 5.040601536165923e-05
vesicles O 0 0.0001591621112311259
. O 0 2.3459847398044076e-06

TfR O 0 0.2633698582649231
HFE O 0 0.0421200767159462
stoichiometry O 0 0.0004682729486376047
( O 0 3.324686076666694e-06
2 O 0 2.13622934097657e-06
1 O 0 1.2243174296600046e-06
) O 0 2.6071244718650632e-08
differs O 0 1.0947757544954584e-07
from O 0 3.0622678082181665e-07
TfR O 0 0.00022160224034450948
transferrin O 0 4.090959555469453e-05
stoichiometry O 0 1.8102323338098358e-06
( O 0 1.1421514756193574e-07
2 O 0 7.804043775649916e-07
2 O 0 1.4052577625989215e-06
) O 0 3.454445263173511e-08
, O 0 2.1945396611044998e-08
implying O 0 1.8181913219450507e-07
a O 0 9.793420296944078e-09
different O 0 3.539938342456139e-10
mode O 0 8.438399312638012e-09
of O 0 1.0699086949728098e-08
binding O 0 2.5404776238246995e-07
for O 0 3.00259159757843e-07
HFE O 0 0.00040455051930621266
and O 0 1.0357969131291611e-06
transferrin O 0 0.0001468056725570932
to O 0 5.879858235857682e-07
TfR O 0 0.00023782295465935022
, O 0 1.530756890133489e-07
consistent O 0 7.157237291721685e-08
with O 0 2.4265176534754573e-08
our O 0 2.444718916194688e-08
demonstration O 0 1.1208728665224044e-06
that O 0 8.59143725051581e-08
HFE O 0 0.00016661464178469032
, O 0 5.298137466525077e-07
transferrin O 0 8.159584103850648e-05
, O 0 8.206241091102129e-07
and O 0 1.2163559404143598e-06
TfR O 0 0.00033101465669460595
form O 0 2.741221862834209e-07
a O 0 1.2555129842439783e-06
ternary O 0 2.3956794393598102e-05
complex O 0 3.061833558604121e-05
. O 0 1.1120197086711414e-05

Identification O 0 5.069202870799927e-06
of O 0 2.841273669673683e-07
three O 0 5.025891596233123e-07
novel O 0 5.98442511545727e-06
mutations O 0 3.1052443318912992e-06
and O 0 3.799575267748878e-07
a O 0 4.625782423772762e-07
high O 0 5.616287126031239e-06
frequency O 0 6.160669130395036e-08
of O 0 1.9567506726048123e-08
the O 0 1.9152076902173576e-07
Arg778Leu O 0 0.00017673165712039918
mutation O 0 1.0748318572950666e-06
in O 0 4.439133363121073e-07
Korean O 0 0.0004857309686485678
patients O 0 4.328447539592162e-05
with O 0 2.4119464796967804e-05
Wilson B-Disease 0 0.29453808069229126
disease I-Disease 0 0.0030310882721096277
. O 0 9.613065230951179e-06

Four O 0 1.4259872841648757e-05
mutations O 0 0.00016642459377180785
- O 0 0.0016216046642512083
- O 0 0.006866947747766972
R778L O 0 7.310669025173411e-05
, O 0 3.7646859141204914e-07
A874V O 0 2.5319204723928124e-06
, O 0 5.198472052825309e-08
L1083F O 0 1.3226984947323217e-06
, O 0 3.897183020740158e-08
and O 0 1.2772217417023057e-07
2304delC O 0 3.226637272746302e-05
- O 0 4.493673623073846e-05
- O 0 2.29075740207918e-05
in O 0 4.159836208827983e-08
the O 0 9.269857770277667e-08
copper O 0 0.0018612054409459233
- O 0 9.561208571540192e-06
transporting O 0 2.5100924176513217e-05
enzyme O 0 3.526387672536657e-06
, O 0 4.1063421463150007e-07
P O 0 0.00010363834735471755
- O 0 0.0001488949783379212
type O 0 6.131449481472373e-06
ATPase O 0 0.0002843609545379877
( O 0 4.241518354319851e-07
ATP7B O 0 0.0007936444017104805
) O 0 3.561777006666489e-08
, O 0 3.1861556948342695e-08
were O 0 3.4673576010391116e-07
identified O 0 4.95421272717067e-06
in O 0 1.2023500630675699e-06
Korean O 0 0.01889636553823948
Patients O 0 0.00011986504250671715
with O 0 2.5021696274052374e-05
Wilson B-Disease 1 0.6228790283203125
disease I-Disease 0 0.011238952167332172
. O 0 1.1735566658899188e-05

Arg778Leu O 0 0.06917566061019897
, O 0 5.3133694564166944e-06
the O 0 2.5212074206137913e-07
most O 0 1.452298050708123e-07
frequently O 0 6.74056366278819e-07
reported O 0 2.442641516609001e-06
mutation O 0 1.277331449500707e-07
of O 0 1.843748798080469e-08
this O 0 4.324720492832057e-08
enzyme O 0 6.8694594119733665e-06
, O 0 5.69543828987662e-07
was O 0 0.000146240257890895
found O 0 1.1116593441329314e-06
in O 0 2.59162593607698e-08
six O 0 1.1981316561104904e-07
of O 0 9.479374796228512e-08
eight O 0 1.7779009795049205e-05
unrelated O 0 0.0399448499083519
patients O 0 7.665624434594065e-05
studied O 0 1.942625431183842e-06
, O 0 8.613751845132356e-08
an O 0 3.4938452131427766e-08
allele O 0 1.9840470599774562e-07
frequency O 0 8.911472093586781e-08
of O 0 2.3073233990089648e-07
37 O 0 9.298317309003323e-05
. O 0 5.185793725104304e-06

5 O 0 2.953404327854514e-05
% O 0 3.6470355553319678e-06
, O 0 4.126324029130046e-07
which O 0 8.416991903459348e-08
is O 0 2.880060989696176e-08
considerably O 0 4.7261949021049077e-07
higher O 0 1.3420638822481123e-07
than O 0 8.341616286600129e-09
those O 0 6.894449899874644e-09
in O 0 1.727627108039087e-08
other O 0 9.913686938034516e-08
Asian O 0 6.534152817039285e-06
populations O 0 2.3911079551908188e-06
. O 0 1.1195641036465531e-06

The O 0 2.0125805804127594e-06
novel O 0 1.7119629092121613e-06
single O 0 7.446813583555922e-07
nucleotide O 0 6.336702426779084e-06
deletion O 0 1.585291829542257e-05
, O 0 1.0112261179529014e-06
2304delC O 0 8.129187335725874e-05
, O 0 7.062729423523706e-07
was O 0 9.290049092669506e-06
found O 0 6.906639100634493e-07
in O 0 9.780040244322663e-08
one O 0 3.01737986774242e-06
patient O 0 0.0001457381440559402
. O 0 2.1623367501888424e-05

Since O 0 1.1498029380163644e-05
a O 0 8.283825536636868e-07
mutation O 0 9.370560292154551e-07
at O 0 2.418478288745973e-07
cDNA O 0 9.213730436385958e-07
nucleotide O 0 1.2802934179489966e-05
2302 O 0 0.000113655834866222
( O 0 8.533850603953397e-08
2302insC O 0 2.1925830878899433e-05
) O 0 1.4957434757434385e-07
had O 0 5.69261555938283e-06
been O 0 6.568152457475662e-06
previously O 0 0.0007173861376941204
described O 0 0.00019198314112145454
, O 0 3.9711846966383746e-07
this O 0 9.332603134737383e-09
region O 0 4.839228395780992e-08
of O 0 2.0616971241338433e-08
the O 0 9.995136451834696e-07
ATP7B O 0 0.21011248230934143
gene O 0 2.853030082405894e-06
may O 0 1.5325346112149418e-06
be O 0 1.5159560007305117e-07
susceptible O 0 6.470222160714911e-06
to O 0 6.480692604782234e-08
gene O 0 1.1218470490348409e-06
rearrangements O 0 0.0017175046959891915
causing O 0 0.010859317146241665
Wilson B-Disease 0 0.28585290908813477
disease I-Disease 0 0.012077992781996727
. O 0 8.81654068507487e-06

Disruption O 0 0.00015221594367176294
of O 0 1.5929076369047834e-07
splicing O 0 2.021052978307125e-06
regulated O 0 1.3022155371800181e-06
by O 0 1.5952230114635313e-07
a O 0 4.610566008977912e-07
CUG O 0 0.0026986119337379932
- O 0 0.00022571613953914493
binding O 0 6.8125318648526445e-06
protein O 0 7.745677066850476e-06
in O 0 3.03260276268702e-05
myotonic B-Disease 1 0.9998782873153687
dystrophy I-Disease 1 0.9999179840087891
. O 0 0.0001724419416859746

Myotonic B-Disease 1 0.9998883008956909
dystrophy I-Disease 1 0.9999792575836182
( O 0 0.15665671229362488
DM B-Disease 1 0.9999852180480957
) O 0 0.00013514963211491704
is O 0 7.3439896368654445e-06
caused O 0 3.174776793457568e-05
by O 0 5.900063229091757e-07
a O 0 1.362568241347617e-06
CTG O 0 0.0004816836444661021
expansion O 0 8.029916216401034e-07
in O 0 2.4896104733329594e-08
the O 0 4.434444988987707e-08
3 O 0 2.1966477561363718e-06
untranslated O 0 7.625458965776488e-05
region O 0 9.472867645854421e-08
of O 0 2.000225407527978e-08
the O 0 3.0198268632375402e-06
DM B-Disease 1 0.9997997879981995
gene O 0 1.149840227299137e-05
. O 0 3.798074885708047e-06

One O 0 1.5858774986554636e-06
model O 0 3.83349333787919e-06
of O 0 3.250303961976897e-06
DM B-Disease 1 0.9999842643737793
pathogenesis O 0 0.34642764925956726
suggests O 0 1.2363485438982025e-05
that O 0 1.2292777284983458e-07
RNAs O 0 3.140464059470105e-06
from O 0 1.9669926132337423e-08
the O 0 6.330384216823859e-09
expanded O 0 1.0242554537853721e-07
allele O 0 9.042005189030533e-08
create O 0 3.140716486882411e-08
a O 0 2.4060972236839007e-07
gain O 0 1.0024834409705363e-05
- O 0 9.54400165937841e-05
of O 0 2.790072812786093e-07
- O 0 0.0005757375620305538
function O 0 9.768277209332155e-08
mutation O 0 1.2471245725009794e-07
by O 0 3.226056932703614e-08
the O 0 3.071176024604938e-08
inappropriate O 0 3.3755955541892035e-07
binding O 0 5.489926735435802e-08
of O 0 1.043204367334738e-08
proteins O 0 2.4124840791728275e-08
to O 0 7.872596796687503e-09
the O 0 7.767877718833915e-08
CUG O 0 0.000560877553652972
repeats O 0 1.303968110732967e-05
. O 0 2.9837253805453656e-06

Data O 0 1.3354519978747703e-05
presented O 0 4.215299850329757e-05
here O 0 6.274944439610408e-07
indicate O 0 4.036334360080218e-07
that O 0 7.750617925239567e-09
the O 0 3.105422763383103e-08
conserved O 0 9.1405030389069e-07
heterogeneous O 0 3.7820118450326845e-05
nuclear O 0 0.0032626744359731674
ribonucleoprotein O 0 0.00030593256815336645
, O 0 6.64439426145691e-07
CUG O 0 0.0004929903661832213
- O 0 2.282708192069549e-05
binding O 0 3.52772929090861e-07
protein O 0 1.0662136418204682e-07
( O 0 3.0168042286504715e-08
CUG O 0 0.00017699440650176257
- O 0 0.0010037744650617242
BP O 0 0.05267343670129776
) O 0 1.669129972015071e-07
, O 0 2.171823183516608e-07
may O 0 1.5204300041204988e-07
mediate O 0 6.473765097325668e-06
the O 0 4.2648815679058316e-07
trans O 0 0.00017904794367495924
- O 0 0.004108290188014507
dominant O 0 3.644222942966735e-06
effect O 0 1.6436217720183777e-08
of O 0 3.9847098953771365e-09
the O 0 1.500116155739306e-07
RNA O 0 9.672785381553695e-06
. O 0 1.921647253766423e-06

CUG O 0 0.46583980321884155
- O 1 0.5788059234619141
BP O 1 0.7974436283111572
was O 0 0.0001456786849303171
found O 0 1.3011318742428557e-06
to O 0 2.9439426896260557e-08
bind O 0 2.441224751237314e-07
to O 0 9.80777770109853e-09
the O 0 3.327346007608867e-07
human O 0 5.008074003853835e-05
cardiac O 1 0.8570545315742493
troponin O 1 0.8928270936012268
T O 0 0.4595617353916168
( O 0 2.018249318780363e-07
cTNT O 0 8.973743206297513e-06
) O 0 3.043668783675457e-08
pre O 0 2.4747196221142076e-06
- O 0 4.897980488749454e-06
messenger O 0 3.2792110005175346e-07
RNA O 0 2.1432290608913718e-08
and O 0 3.2340272682063187e-09
regulate O 0 1.2746938615748604e-08
its O 0 1.8630883502623874e-09
alternative O 0 4.215475613023045e-08
splicing O 0 1.7317860283583286e-06
. O 0 1.0625649338180665e-06

Splicing O 0 2.403874896117486e-05
of O 0 1.92079914995702e-06
cTNT O 0 0.0014819876523688436
was O 0 0.00010452183778397739
disrupted O 0 0.0002514570951461792
in O 0 9.731585123518016e-06
DM B-Disease 1 0.9999868869781494
striated O 1 0.9930709004402161
muscle O 0 0.004849205259233713
and O 0 7.416784342240135e-07
in O 0 1.239287712451187e-07
normal O 0 3.0174581411301915e-07
cells O 0 9.659950137574924e-07
expressing O 0 1.0800232530527865e-07
transcripts O 0 2.5427948457945604e-07
that O 0 4.7029537597609306e-08
contain O 0 3.190756956428231e-07
CUG O 0 0.00038128026062622666
repeats O 0 7.116499091353035e-06
. O 0 1.197235405925312e-06

Altered O 0 0.00013958309136796743
expression O 0 1.1266459978287457e-06
of O 0 8.631102588196882e-08
genes O 0 2.612399043755431e-07
regulated O 0 2.8401899498931016e-07
posttranscriptionally O 0 1.1982704563706648e-05
by O 0 5.164800427337468e-07
CUG O 0 0.006199913565069437
- O 0 0.013027581386268139
BP O 0 0.02344023622572422
therefore O 0 3.309882288249355e-07
may O 0 2.7205641117689083e-07
contribute O 0 1.2219526013268478e-07
to O 0 5.819159127895546e-07
DM B-Disease 1 0.9996823072433472
pathogenesis O 0 0.0025943750515580177
. O 0 4.881529207523272e-07
. O 0 1.6867896874828148e-06

Identification O 0 9.316284376836848e-06
of O 0 4.4740011162502924e-07
a O 0 1.4641299230788718e-06
novel O 0 5.804066859127488e-06
nonsense O 0 0.00011245714995311573
mutation O 0 2.0340178252808983e-06
and O 0 1.6099039612527122e-07
a O 0 1.0242632697554654e-07
missense O 0 2.2927727059141034e-06
substitution O 0 2.854793557105495e-08
in O 0 1.2559898898700794e-08
the O 0 6.81743159702819e-08
vasopressin O 0 1.3449917787511367e-05
- O 0 0.00026741932379081845
neurophysin O 0 0.0005792861920781434
II O 0 0.0004823710769414902
gene O 0 6.06014936010979e-08
in O 0 4.896082206329311e-09
two O 0 4.13636982443677e-08
Spanish O 0 6.210863375599729e-06
kindreds O 0 0.0003268001019023359
with O 0 8.253272972069681e-05
familial B-Disease 1 0.9205541014671326
neurohypophyseal I-Disease 1 0.9990139007568359
diabetes I-Disease 1 0.9992098808288574
insipidus I-Disease 1 0.96221923828125
. O 0 8.303780487040058e-05

Familial B-Disease 1 0.9975402355194092
neurohypophyseal I-Disease 1 0.9995298385620117
diabetes I-Disease 1 0.999915599822998
insipidus I-Disease 1 0.9993426203727722
( O 0 0.004059996455907822
FNDI B-Disease 1 0.999975323677063
) O 0 2.797140768961981e-05
is O 0 2.612551043057465e-06
an O 0 6.963391206227243e-05
autosomal B-Disease 1 0.9942544102668762
dominant I-Disease 1 0.9992596507072449
disease I-Disease 1 0.9984765648841858
caused O 0 0.1807575225830078
by O 0 0.07834585011005402
deficiency O 1 0.9647887945175171
in O 0 4.6339241066561954e-07
the O 0 4.1737157516763546e-06
antidiuretic O 0 0.024304654449224472
hormone O 0 1.2118543054384645e-05
arginine O 0 3.0497254556394182e-05
vasopressin O 0 3.127272429992445e-05
( O 0 1.687007085138248e-07
AVP O 0 9.089517698157579e-05
) O 0 5.854737583632641e-09
encoded O 0 8.156375130852211e-09
by O 0 1.3926958253307475e-08
the O 0 2.634980660332076e-07
AVP O 0 0.012883658520877361
- O 0 0.006879857275635004
neurophysin O 0 0.021406536921858788
II O 0 0.016770552843809128
( O 0 6.060728310330887e-07
AVP O 0 0.006085794419050217
- O 0 0.011345341801643372
NPII O 0 0.004118414595723152
) O 0 5.9464287716082254e-08
gene O 0 7.057411011146542e-08
on O 0 1.0172664133278886e-06
chromosome O 0 0.00034857168793678284
20p13 O 0 8.567731856601313e-05
. O 0 2.8917388590343762e-06

In O 0 3.7835204693692503e-06
this O 0 9.640469755822778e-08
study O 0 2.6966699806507677e-07
, O 0 1.3741586712967546e-07
we O 0 7.96445487338815e-09
analyzed O 0 2.5158081484732975e-07
two O 0 7.169519733452034e-08
families O 0 3.537337249781558e-07
with O 0 1.4270960946305422e-06
FNDI B-Disease 1 0.9693687558174133
using O 0 5.6359393596494556e-08
direct O 0 8.423428177195547e-09
automated O 0 3.0253902423282852e-06
fluorescent O 0 4.0946993067336734e-06
, O 0 1.3073668014840223e-07
solid O 0 3.9744807622810185e-07
phase O 0 3.8166479043866275e-07
, O 0 7.942522728399126e-08
single O 0 1.6601778440872295e-07
- O 0 9.026408406498376e-06
stranded O 0 4.587662090216327e-07
DNA O 0 1.0061031474606352e-07
sequencing O 0 7.508450039495074e-08
of O 0 2.0124289790146577e-08
PCR O 0 1.2495223018049728e-05
- O 0 2.8255462893866934e-05
amplified O 0 2.0004785255878232e-05
AVP O 0 0.0002457909577060491
- O 0 0.00015403844008687884
NPII O 0 0.0006506970967166126
DNA O 0 5.006416904507205e-05
. O 0 2.3316408714890713e-06

In O 0 2.9310535865079146e-06
one O 0 1.901519794955675e-07
of O 0 7.918094269143694e-08
the O 0 7.894536793173756e-07
families O 0 7.0506157499039546e-06
, O 0 5.163685727893608e-06
affected O 0 8.105887445708504e-07
individuals O 0 5.3126228749533766e-08
presented O 0 1.097721451515099e-06
a O 0 2.572464268268959e-07
novel O 0 1.9384447114134673e-06
nonsense O 0 1.7098067473853007e-05
mutation O 0 5.000104010832729e-07
in O 0 2.589985470535794e-08
exon O 0 9.887030500976834e-06
3 O 0 3.0038688692002324e-07
of O 0 1.7645902516960632e-08
the O 0 9.521306054693923e-08
gene O 0 1.415507995261578e-07
, O 0 1.551982187208978e-08
consisting O 0 7.096799947703403e-08
in O 0 4.946056364474316e-08
a O 0 1.5982075183273992e-06
G O 0 0.01237788237631321
to O 0 6.053876973055594e-07
T O 0 0.0012768349843099713
transition O 0 1.214553009276642e-07
at O 0 4.424893802479346e-07
nucleotide O 0 2.6690581762522925e-06
2101 O 0 1.51023787111626e-05
, O 0 6.042882461088084e-08
which O 0 8.785482563666847e-09
produces O 0 3.8343706876275974e-08
a O 0 4.525841035274425e-08
stop O 0 2.120685849149595e-07
signal O 0 8.518596672502099e-08
in O 0 2.1608089539881803e-08
codon O 0 1.3894371022615815e-06
82 O 0 2.940303056675475e-05
( O 0 2.6405098196846666e-07
Glu O 0 0.0010515704052522779
) O 0 5.459789775841273e-08
of O 0 1.9552031460534636e-07
NPII O 0 0.0066437553614377975
. O 0 4.557656666293042e-06

The O 0 8.09916491562035e-06
premature O 0 0.00019251475168857723
termination O 0 3.818502591457218e-05
eliminates O 0 1.6805015548015945e-05
part O 0 1.7377240624227852e-07
of O 0 2.8928722528576145e-08
the O 0 4.5456442876457004e-07
C O 0 0.0020247329957783222
- O 0 0.0014376018662005663
terminal O 0 7.283371814992279e-06
domain O 0 4.268502706850086e-08
of O 0 1.0072282208284378e-07
NPII O 0 0.006274072453379631
, O 0 9.032162751054784e-08
including O 0 3.467542342150409e-08
a O 0 8.556196462450316e-08
cysteine O 0 3.344283072692633e-07
residue O 0 6.956933589208347e-07
in O 0 2.832771883731766e-08
position O 0 6.761564463886316e-07
85 O 0 2.546415771575994e-06
, O 0 2.370463931811173e-07
which O 0 7.617328634523801e-08
could O 0 4.1536651451679063e-07
be O 0 3.7904793970255923e-08
involved O 0 2.3970687834662385e-07
in O 0 4.165870848282793e-08
the O 0 1.1916635855868662e-07
correct O 0 3.421708242967725e-06
folding O 0 0.00014040754467714578
of O 0 1.5594930857787404e-07
the O 0 3.1074841899680905e-06
prohormone O 0 0.013395526446402073
. O 0 1.2354811588011216e-05

In O 0 4.190578692941926e-06
the O 0 1.113629537030647e-06
second O 0 4.663226718548685e-05
family O 0 3.319921233924106e-05
, O 0 1.0616599155355289e-07
a O 0 6.299083565863839e-08
G279A O 0 7.736810516689729e-07
substitution O 0 2.111732477771966e-08
at O 0 5.0068416612703e-07
position O 0 1.2645903098018607e-06
- O 0 2.8029058739775792e-05
1 O 0 7.028140203146904e-08
of O 0 3.555551186806838e-09
the O 0 2.5293516614510736e-08
signal O 0 5.357999270927394e-07
peptide O 0 1.5980383523128694e-06
was O 0 4.396611529955408e-06
observed O 0 1.1631343710405417e-07
in O 0 1.5740427627974896e-08
all O 0 1.810662020318432e-08
affected O 0 7.942679758343729e-07
individuals O 0 1.1117207350253011e-06
. O 0 4.447686478670221e-06

This O 0 1.118012733059004e-06
missense O 0 0.00047549992450512946
mutation O 0 5.328112092684023e-05
, O 0 1.002527369564632e-06
which O 0 4.465135248210572e-07
replaces O 0 0.002180103911086917
Ala O 0 0.00946205947548151
with O 0 5.388880708778743e-06
Thr O 0 0.06882470846176147
, O 0 1.9442934444668936e-06
is O 0 1.9563707098768646e-07
frequent O 0 2.7222376957070082e-06
among O 0 0.0007044465746730566
FNDI B-Disease 1 0.9999980926513672
patients O 0 0.004282169044017792
and O 0 2.8970498533453792e-06
is O 0 4.0462359152115823e-07
thought O 0 2.68935082203825e-07
to O 0 2.446804359124144e-08
reduce O 0 3.1368909958473523e-07
the O 0 1.345556821519267e-08
efficiency O 0 2.526946047964884e-07
of O 0 2.6847832401699634e-08
cleavage O 0 1.9686121959239244e-05
by O 0 4.180843973244919e-07
signal O 0 3.846780145977391e-06
peptidases O 0 5.184219844522886e-05
. O 0 2.7024833570976625e-07
. O 0 1.2015190122838248e-06

Genetic O 0 0.0003955060092266649
heterogeneity O 0 0.00019403804617468268
of O 0 1.9722878278116696e-05
Saethre B-Disease 1 0.9818398356437683
- I-Disease 1 0.999923586845398
Chotzen I-Disease 1 0.9999474287033081
syndrome I-Disease 1 0.9999501705169678
, O 0 1.3941536053607706e-05
due O 0 3.3378896659996826e-06
to O 0 1.2681709904427407e-07
TWIST O 0 3.839256532955915e-05
and O 0 9.525902896712068e-06
FGFR O 0 0.04891909658908844
mutations O 0 1.9806433556368575e-05
. O 0 2.0827258140343474e-06

Thirty O 0 6.681469676550478e-05
- O 0 0.0018121196189895272
two O 0 8.323608199134469e-06
unrelated O 0 0.028542116284370422
patients O 0 4.735167749458924e-05
with O 0 1.980194497264165e-07
features O 0 2.65726589532278e-06
of O 0 7.42353176974575e-06
Saethre B-Disease 1 0.9864864349365234
- I-Disease 1 0.9999253749847412
Chotzen I-Disease 1 0.9999624490737915
syndrome I-Disease 1 0.9994568228721619
, O 0 5.9871081248275004e-06
a O 0 4.327052374719642e-05
common O 0 0.000500133668538183
autosomal B-Disease 1 0.5773499011993408
dominant I-Disease 0 0.41672483086586
condition I-Disease 0 0.004954989533871412
of O 0 6.175740418257192e-05
craniosynostosis B-Disease 1 0.999409556388855
and O 0 0.12008583545684814
limb B-Disease 1 0.9732383489608765
anomalies I-Disease 1 0.6352079510688782
, O 0 1.6464006193928071e-06
were O 0 1.7499219211458694e-06
screened O 0 4.871381406701403e-06
for O 0 3.0797289696238295e-07
mutations O 0 8.832596449792618e-07
in O 0 1.245743419531209e-07
TWIST O 0 8.494369103573263e-05
, O 0 2.0880174815829378e-06
FGFR2 O 0 0.0028738845139741898
, O 0 4.7234686917363433e-07
and O 0 9.700393093226012e-07
FGFR3 O 0 0.003972242120653391
. O 0 5.5628524933126755e-06

Nine O 0 3.9792812458472326e-05
novel O 0 1.2561342373373918e-05
and O 0 2.171312871723785e-06
three O 0 1.2635415487238788e-06
recurrent O 0 0.0007884995429776609
TWIST O 0 0.0012753820046782494
mutations O 0 5.7635264965938404e-05
were O 0 3.1219083211908583e-06
found O 0 2.9358961910475045e-06
in O 0 1.098609985206167e-07
12 O 0 4.022760094812838e-06
families O 0 1.0314565770386253e-05
. O 0 6.538042271131417e-06

Seven O 0 7.961164374137297e-05
families O 0 3.338096939842217e-05
were O 0 1.5771398466313258e-05
found O 0 2.0020402189402375e-06
to O 0 7.020383208100611e-08
have O 0 7.981490313113682e-08
the O 0 1.0172620079629269e-07
FGFR3 O 0 0.005828557536005974
P250R O 0 2.326859612367116e-05
mutation O 0 8.322159033014032e-07
, O 0 6.837799304548753e-08
and O 0 9.774315401500644e-08
one O 0 6.800392782224662e-08
individual O 0 1.2377711300359806e-07
was O 0 0.00015931090456433594
found O 0 2.537707814553869e-06
to O 0 6.048555434290392e-08
have O 0 9.265580303008392e-08
an O 0 5.792962838313542e-07
FGFR2 O 0 0.004217257257550955
VV269 O 0 1.235518811881775e-05
- O 0 1.3698720067623071e-05
270 O 0 5.995798801450292e-06
deletion O 0 7.915939931990579e-05
. O 0 4.961617378285155e-06

To O 0 2.0995069007767597e-06
date O 0 3.2594734875601716e-06
, O 0 9.486230112543126e-08
our O 0 4.504154826889817e-09
detection O 0 4.258419608049735e-07
rate O 0 4.0903915987655637e-07
for O 0 5.269168568133864e-08
TWIST O 0 1.2536665053630713e-05
or O 0 9.134690799328382e-07
FGFR O 0 0.004191039130091667
mutations O 0 1.439839707018109e-06
is O 0 5.923132917473595e-08
68 O 0 1.257741496374365e-05
% O 0 7.673880020320212e-08
in O 0 2.321417724715502e-08
our O 0 3.1217604146149824e-07
Saethre B-Disease 0 0.13525177538394928
- I-Disease 1 0.9992708563804626
Chotzen I-Disease 1 0.9999052286148071
syndrome I-Disease 1 0.9999687671661377
patients O 0 0.00015530530072283
, O 0 2.1043568665390922e-07
including O 0 1.911399607479325e-07
our O 0 5.3224709972710116e-08
five O 0 5.38379026693292e-06
patients O 0 3.5530018067220226e-05
elsewhere O 0 6.02819966388779e-07
reported O 0 2.680187208170537e-06
with O 0 3.5727319414036174e-07
TWIST O 0 0.0004693033988587558
mutations O 0 5.721551860915497e-05
. O 0 3.867935902235331e-06

More O 0 2.483715775269957e-07
than O 0 4.33858424742084e-08
35 O 0 2.3804477677913383e-07
different O 0 7.836104209957284e-09
TWIST O 0 1.837665149651002e-05
mutations O 0 5.047851573181106e-06
are O 0 1.6408267811129917e-07
now O 0 1.2513889942056267e-06
known O 0 1.8353650830249535e-06
in O 0 6.655454853898846e-08
the O 0 4.727628208911483e-07
literature O 0 7.637733688170556e-06
. O 0 9.101837349589914e-06

The O 0 3.286670335000963e-06
most O 0 4.628663816674816e-07
common O 0 2.849680527106102e-07
phenotypic O 0 5.637934918922838e-06
features O 0 2.5445174287597183e-06
, O 0 1.4837271464784862e-06
present O 0 2.1978431163915957e-07
in O 0 9.252953248051199e-08
more O 0 9.229225383933226e-09
than O 0 1.891688761190835e-08
a O 0 2.123130258269157e-07
third O 0 3.223014346076525e-06
of O 0 1.8217338038084563e-07
our O 0 7.342221124417847e-07
patients O 0 2.7258097361482214e-06
with O 0 2.7467226004773693e-07
TWIST O 0 8.371040894417092e-05
mutations O 0 2.6587918000586797e-06
, O 0 8.494810543879794e-08
are O 0 1.193860832415794e-08
coronal B-Disease 0 5.0736121920635924e-05
synostosis I-Disease 0 0.0005891821347177029
, O 0 3.106374037997739e-07
brachycephaly B-Disease 0 4.713182715931907e-05
, O 0 5.037916821493127e-07
low B-Disease 0 3.687105345306918e-05
frontal I-Disease 1 0.7014383673667908
hairline I-Disease 1 0.9999395608901978
, O 0 0.002234895946457982
facial B-Disease 1 0.9222868084907532
asymmetry I-Disease 0 0.03778408467769623
, O 0 0.0017179183196276426
ptosis B-Disease 1 0.9993813037872314
, O 0 0.0006853394443169236
hypertelorism B-Disease 1 0.707577109336853
, O 0 1.991871977224946e-05
broad B-Disease 0 0.0002725370868574828
great I-Disease 0 0.0002538331027608365
toes I-Disease 0 0.05285819247364998
, O 0 1.1185171615579748e-06
and O 0 4.0513737076253165e-06
clinodactyly B-Disease 0 0.0016040722839534283
. O 0 6.689717793051386e-06

Significant O 0 2.9603836082969792e-05
intra O 0 0.00041999464156106114
- O 0 0.0065929098054766655
and O 0 2.560520442784764e-06
interfamilial O 0 0.00030035051167942584
phenotypic O 0 8.643020919407718e-06
variability O 0 3.0457405955530703e-05
is O 0 1.7430168952614622e-07
present O 0 3.9227927572937915e-08
for O 0 9.21093956662844e-08
either O 0 3.1986022008823056e-07
TWIST O 0 0.00011922646081075072
mutations O 0 1.1243865628784988e-05
or O 0 2.595416162876063e-06
FGFR O 0 0.05769243463873863
mutations O 0 6.279865192482248e-05
. O 0 4.67109339297167e-06

The O 0 1.8769264897855464e-06
overlap O 0 6.158464657346485e-06
in O 0 9.743673672346631e-07
clinical O 0 1.7310301700490527e-05
features O 0 1.8688318732529297e-06
and O 0 1.637017703615129e-06
the O 0 9.57477141128038e-07
presence O 0 1.144102157013549e-06
, O 0 9.071129625226604e-08
in O 0 1.815655714665354e-08
the O 0 5.103557398911107e-08
same O 0 2.1460355981162138e-07
genes O 0 9.990754534783264e-08
, O 0 3.194876185830253e-08
of O 0 2.571310808718863e-08
mutations O 0 2.812124648698955e-07
for O 0 1.0009252093823306e-08
more O 0 3.84789311524969e-09
than O 0 2.9376382215673402e-08
one O 0 7.521858265135961e-07
craniosynostotic B-Disease 0 0.16269834339618683
condition I-Disease 0 5.671222970704548e-05
- O 0 4.30515174230095e-05
such O 0 1.4699736539114383e-07
as O 0 1.2321702342887875e-06
Saethre B-Disease 0 0.0002060488477582112
- I-Disease 0 0.0006402175058610737
Chotzen I-Disease 0 0.00010091770673170686
, I-Disease 0 3.4978600638169155e-07
Crouzon I-Disease 0 6.744403071934357e-05
, I-Disease 0 2.7221392429055413e-07
and I-Disease 0 6.564701834577136e-06
Pfeiffer I-Disease 0 0.1960839033126831
syndromes I-Disease 0 0.05075468868017197
- O 0 0.00031167545239441097
support O 0 9.837172001425643e-07
the O 0 1.00035116190611e-07
hypothesis O 0 8.020196560210024e-07
that O 0 6.846529743143037e-08
TWIST O 0 1.090259956981754e-05
and O 0 2.0202801351842936e-06
FGFRs O 0 5.516760575119406e-05
are O 0 1.060489740467574e-08
components O 0 1.880759583627878e-07
of O 0 1.9671050566216763e-08
the O 0 3.221598987579455e-08
same O 0 1.6107556177757942e-08
molecular O 0 4.0869176132218854e-07
pathway O 0 2.05015325605018e-07
involved O 0 2.2392454468445067e-07
in O 0 1.6950101766610715e-08
the O 0 4.3041726627279786e-08
modulation O 0 1.1417652103773435e-06
of O 0 7.56184408601257e-06
craniofacial O 1 0.9971127510070801
and O 0 0.00031009918893687427
limb O 0 0.012767016887664795
development O 0 6.990425731601135e-07
in O 0 3.803302206506487e-07
humans O 0 1.3845905186826712e-06
. O 0 2.368692406662376e-07
. O 0 2.2533488390763523e-06

Mutation O 0 6.254357140278444e-05
analysis O 0 3.2725490655138856e-06
of O 0 2.0395562387420796e-05
UBE3A O 1 0.9955506324768066
in O 1 0.8990247845649719
Angelman B-Disease 1 0.9999923706054688
syndrome I-Disease 1 0.999996542930603
patients O 1 0.7016405463218689
. O 0 0.0001047263722284697

Angelman B-Disease 1 0.9999935626983643
syndrome I-Disease 1 0.999997615814209
( O 0 0.030120791867375374
AS B-Disease 1 0.9801294207572937
) O 0 8.482766133965924e-06
is O 0 1.7523200313007692e-06
caused O 0 1.3959123862150591e-05
by O 0 2.429584810670349e-06
chromosome O 0 0.009368612430989742
15q11 O 0 0.00021620406187139452
- O 0 0.00015898510173428804
q13 O 0 6.372426469170023e-06
deletions O 0 1.1052637773900642e-06
of O 0 1.7105189442645496e-07
maternal O 0 8.964189328253269e-05
origin O 0 9.00797090253036e-07
, O 0 4.885357043349359e-07
by O 0 1.9680901459651068e-06
paternal O 0 0.0022517775651067495
uniparental B-Disease 1 0.7446655035018921
disomy I-Disease 1 0.5810505747795105
( O 0 1.2235167559992988e-05
UPD B-Disease 1 0.9993473887443542
) O 0 5.2921535598216e-07
15 O 0 3.8588467532463255e-07
, O 0 5.991912388481069e-08
by O 0 3.6737401387654245e-07
imprinting O 0 0.07718418538570404
defects O 1 0.9868358373641968
, O 0 1.372678980260389e-06
and O 0 3.229172307328554e-07
by O 0 6.728528205712792e-07
mutations O 0 1.156010966951726e-06
in O 0 8.227157621831793e-08
the O 0 9.568382211000426e-07
UBE3A O 0 0.004901973996311426
gene O 0 3.3647461350483354e-06
. O 0 1.5599216567352414e-06

UBE3A O 0 0.005695609841495752
encodes O 0 1.2166251508460846e-05
a O 0 2.588632924016565e-06
ubiquitin O 0 3.453053068369627e-05
- O 0 0.00015937077114358544
protein O 0 2.1133871541678673e-07
ligase O 0 1.2606336667886353e-06
and O 0 1.3000165210996784e-07
shows O 0 1.1227525646972936e-06
brain O 0 0.0001080664515029639
- O 0 7.925940008135512e-05
specific O 0 2.977436110995768e-07
imprinting O 0 0.0002724716323427856
. O 0 8.96806250239024e-06

Here O 0 3.1431848128704587e-06
we O 0 1.1171607638971182e-07
describe O 0 5.173733370611444e-07
UBE3A O 0 0.00014125557208899409
coding O 0 2.136252442141995e-05
- O 0 0.00043410068610683084
region O 0 9.341375175608846e-07
mutations O 0 4.150637778366217e-06
detected O 0 3.5407024370215368e-06
by O 0 1.4426777283915726e-07
SSCP O 0 9.535587741993368e-05
analysis O 0 1.0166316144477605e-07
in O 0 2.4187852432078216e-07
13 O 0 1.9368320863577537e-05
AS B-Disease 0 0.04862091317772865
individuals O 0 6.990625820435525e-07
or O 0 1.110872972276411e-06
families O 0 1.091352169169113e-05
. O 0 1.7244097762159072e-05

Two O 0 1.3187373042455874e-06
identical O 0 6.506692443508655e-06
de O 0 3.905617631971836e-06
novo O 0 3.7151246488065226e-06
5 O 0 6.512321419904765e-07
- O 0 2.667901208042167e-05
bp O 0 1.625076765776612e-05
duplications O 0 6.053011247786344e-07
in O 0 2.2377207642421126e-08
exon O 0 9.658110684540588e-06
16 O 0 9.856178166955942e-07
were O 0 8.263216386694694e-07
found O 0 4.116542640986154e-06
. O 0 5.197181053517852e-06

Among O 0 2.1021834982093424e-05
the O 0 6.423689455914428e-07
other O 0 1.540148986123313e-07
11 O 0 2.7194716949452413e-06
unique O 0 3.02137721064355e-07
mutations O 0 3.93081791116856e-06
, O 0 3.9854197098065924e-07
8 O 0 3.2397140330431284e-06
were O 0 1.6769911326264264e-06
small O 0 3.201812717179564e-07
deletions O 0 6.042956556484569e-06
or O 0 7.014801326477027e-07
insertions O 0 8.038993109948933e-05
predicted O 0 0.0006402934668585658
to O 0 8.190065159396909e-07
cause O 0 6.133987881185021e-06
frameshifts O 0 0.00029415113385766745
, O 0 1.867688297352288e-07
1 O 0 3.497546572361898e-07
was O 0 8.613818863523193e-06
a O 0 1.7182293277073768e-07
mutation O 0 4.224538656671939e-07
to O 0 1.9414047258692335e-08
a O 0 8.449967481283238e-08
stop O 0 1.580728650196761e-07
codon O 0 1.3126964404364116e-07
, O 0 6.254535378502624e-08
1 O 0 1.3242834029369988e-07
was O 0 1.8042569536191877e-06
a O 0 1.8161759385293408e-07
missense O 0 2.9444447136484087e-05
mutation O 0 1.9224135030526668e-06
, O 0 1.9595206879330362e-07
and O 0 5.241342933004489e-07
1 O 0 5.3520207075052895e-06
was O 0 0.0004984817351214588
predicted O 0 3.6997113056713715e-05
to O 0 1.881938374026504e-07
cause O 0 2.4750545435381355e-07
insertion O 0 3.271227342338534e-07
of O 0 9.001018241860947e-08
an O 0 1.3458040939440252e-06
isoleucine O 0 0.0051413350738584995
in O 0 3.6373688772073365e-07
the O 0 1.6458874085856223e-07
hect O 0 2.093536386382766e-05
domain O 0 3.817251581494929e-08
of O 0 9.2023491049531e-09
the O 0 1.5302022404739546e-07
UBE3A O 0 0.00032790485420264304
protein O 0 1.4967821471145726e-07
, O 0 2.0571564007809684e-08
which O 0 3.3478932959241092e-09
functions O 0 2.4982380608662424e-09
in O 0 2.0798021083123786e-08
E2 O 0 6.776708323741332e-05
binding O 0 6.223565947038878e-07
and O 0 1.5010033393991762e-07
ubiquitin O 0 1.2798125681001693e-05
transfer O 0 1.990972123167012e-06
. O 0 4.293789970688522e-06

Eight O 0 1.2019226232951041e-05
of O 0 6.355696768878261e-07
the O 0 6.340029017337656e-07
cases O 0 1.993441765080206e-05
were O 0 7.484186789952219e-05
familial O 0 0.0026757479645311832
, O 0 3.831176400126424e-06
and O 0 4.367873884802975e-07
five O 0 9.771152917892323e-07
were O 0 5.38823314855108e-06
sporadic O 0 2.5307632313342765e-05
. O 0 5.249479727353901e-06

In O 0 6.409182788047474e-06
two O 0 3.662402832560474e-06
familial O 0 0.012337129563093185
cases O 0 0.00018171135161537677
and O 0 6.457277322624577e-06
one O 0 9.624244512451696e-07
sporadic O 0 1.9690101908054203e-05
case O 0 7.133012695703655e-05
, O 0 7.455649210896809e-06
mosaicism O 0 0.00301163736730814
for O 0 2.733468363658176e-06
UBE3A O 0 0.018927892670035362
mutations O 0 9.601997589925304e-06
was O 0 6.400614802259952e-05
detected O 0 9.709866390039679e-06
in O 0 9.690965185882305e-08
the O 0 7.740936212030647e-07
mother O 0 3.291809844085947e-05
of O 0 7.392747392032106e-08
three O 0 8.45211252453737e-06
AS B-Disease 1 0.8649759888648987
sons O 0 0.03141262009739876
, O 0 4.5305267803996685e-07
in O 0 5.607963160514373e-08
the O 0 4.0621455354994396e-07
maternal O 0 7.171471952460706e-05
grandfather O 0 0.00012772933405358344
of O 0 5.0464375789260885e-08
two O 0 1.8648154309630627e-06
AS B-Disease 0 0.10145141184329987
first O 0 7.4788008532777894e-06
cousins O 0 0.00030354526825249195
, O 0 3.907220502696873e-07
and O 0 1.699392413456735e-07
in O 0 1.0233864600195375e-07
the O 0 6.479777994172764e-07
mother O 0 2.8884265702799894e-05
of O 0 2.757914785433968e-07
an O 0 2.2971844373387285e-05
AS B-Disease 1 0.8868575096130371
daughter O 0 0.22513869404792786
. O 0 2.2165901100379415e-05

The O 0 9.154487088380847e-07
frequencies O 0 7.779217980896647e-07
with O 0 1.5577927570120664e-07
which O 0 7.422006831347971e-08
we O 0 1.8688584901838112e-08
detected O 0 8.818860237624904e-07
mutations O 0 2.1577906750280818e-07
were O 0 3.3208664262929233e-07
5 O 0 5.778291551905568e-07
( O 0 3.31499308003913e-08
14 O 0 6.052116532373475e-07
% O 0 3.6826001803547115e-08
) O 0 4.83610662627143e-09
of O 0 6.321045908919132e-09
35 O 0 1.8945451074614539e-06
in O 0 8.018356112415859e-08
sporadic O 0 2.730774212977849e-06
cases O 0 1.037217316479655e-05
and O 0 4.5405072341964114e-06
8 O 0 7.798541446391027e-06
( O 0 9.41590911907042e-08
80 O 0 3.147526115299115e-07
% O 0 2.938663712370726e-08
) O 0 3.725439068347214e-09
of O 0 7.3233303865549715e-09
10 O 0 2.72724037131411e-07
in O 0 1.704558911796994e-07
familial O 0 0.0001082188609871082
cases O 0 3.111630576313473e-05
. O 0 4.213275587972021e-06
. O 0 1.3055071576673072e-05

The O 0 0.00011201726010767743
hemochromatosis B-Disease 1 0.9998088479042053
845 O 1 0.9283106923103333
G O 1 0.9486591815948486
- O 0 0.04495502635836601
- O 0 0.003897357964888215
> O 0 3.983078386227135e-06
A O 0 6.453549872276199e-07
and O 0 8.007305751789318e-08
187 O 0 5.061561296315631e-06
C O 0 0.0002466463774908334
- O 0 0.0012450222857296467
- O 0 0.0009930997621268034
> O 0 7.001393441896653e-06
G O 0 0.0004513723833952099
mutations O 0 4.220153471123922e-07
: O 0 2.4048759428296762e-08
prevalence O 0 6.784056949982187e-06
in O 0 1.021196709416472e-07
non O 0 1.456276913813781e-05
- O 0 0.021231481805443764
Caucasian O 0 0.003449301701039076
populations O 0 1.4525319784297608e-05
. O 0 3.343426669744076e-06

Hemochromatosis B-Disease 1 0.99556964635849
, O 0 0.0012187683023512363
the O 0 0.02408413030207157
inherited B-Disease 1 0.9999983310699463
disorder I-Disease 1 0.9999955892562866
of I-Disease 0 0.004435162991285324
iron I-Disease 1 0.9997050166130066
metabolism I-Disease 0 0.0015837785322219133
, O 0 2.495687795089907e-06
leads O 0 8.62208707985701e-06
, O 0 2.146650786016835e-06
if O 0 8.341252168975188e-07
untreated O 0 0.0017216613050550222
, O 0 6.286595066740119e-07
to O 0 8.507083180120389e-07
progressive O 0 0.05180669575929642
iron B-Disease 1 0.9879480004310608
overload I-Disease 0 0.005055710207670927
and O 0 1.0915020538959652e-05
premature B-Disease 0 0.00035644369199872017
death I-Disease 0 4.7027486289152876e-05
. O 0 5.949082606093725e-06

The O 0 0.00014719254977535456
hemochromatosis B-Disease 1 0.9999067783355713
gene O 0 0.00026251349481754005
, O 0 7.1401227614842355e-06
HFE O 0 0.04037458449602127
, O 0 9.168325050268322e-06
recently O 0 0.002630164846777916
has O 0 9.019507160701323e-06
been O 0 1.8243072190671228e-05
identified O 0 4.902187720290385e-05
, O 0 3.811940700870764e-07
and O 0 1.985190181130747e-07
characterization O 0 1.2468693739720038e-06
of O 0 3.412070981312354e-08
this O 0 1.7652936890044657e-08
gene O 0 2.559694678438973e-07
has O 0 7.511069952670368e-07
shown O 0 3.3296697665718966e-07
that O 0 2.3076001554045433e-08
it O 0 4.673014863953995e-09
contains O 0 6.714576894495394e-09
two O 0 1.7765663073987525e-07
mutations O 0 2.110083414663677e-06
that O 0 4.2727386073693197e-08
result O 0 1.2169809338047344e-07
in O 0 8.942150131474591e-09
amino O 0 7.10804357595407e-08
acid O 0 1.4185609131800447e-07
substitutions O 0 9.75404823577719e-09
- O 0 7.351743391836862e-08
cDNA O 0 4.276937559666294e-08
nucleotides O 0 2.7162761284671433e-07
845 O 0 1.488855923525989e-05
G O 0 0.0009950556559488177
- O 0 0.0003078932932112366
- O 0 0.00022694618382956833
> O 0 1.0758911912489566e-06
A O 0 8.484461773150542e-07
( O 0 1.0295025276718661e-07
C282Y O 0 1.6154189097505878e-06
) O 0 4.165837008685003e-09
and O 0 2.8119549355665185e-08
187 O 0 5.547182354348479e-06
C O 0 0.00023011848679743707
- O 0 0.0009360485710203648
- O 0 0.002605974907055497
> O 0 5.028460145695135e-05
G O 0 0.004857172723859549
( O 0 3.336083693739056e-07
H63D O 0 0.0005086190067231655
) O 0 4.727245084268361e-07
. O 0 1.2090317795809824e-06

Although O 0 0.013072002679109573
hemochromatosis B-Disease 1 0.9999397993087769
is O 0 9.90951739368029e-05
common O 0 4.711070232588099e-06
in O 0 7.118285907381505e-07
Caucasians O 0 0.00018732741591520607
, O 0 1.004430828288605e-06
affecting O 0 5.497019515132706e-07
> O 0 9.070764463103842e-06
= O 0 8.215785783249885e-05
1 O 0 6.473298981291009e-07
/ O 0 1.1827379466922139e-06
300 O 0 1.4150896276987623e-07
individuals O 0 1.6185349949182637e-08
of O 0 8.104611204373668e-09
northern O 0 1.403879252848128e-07
European O 0 1.7427240663892007e-06
origin O 0 2.1089296353693499e-07
, O 0 1.8615605767990928e-07
it O 0 7.765107312707187e-08
has O 0 8.922669394451077e-07
not O 0 7.956077752169222e-08
been O 0 5.098391397950763e-07
recognized O 0 6.799186280659342e-08
in O 0 4.171691259102772e-08
other O 0 3.385634954611305e-07
populations O 0 5.1514380174921826e-06
. O 0 3.870637101499597e-06

The O 0 2.2033386812836397e-06
present O 0 2.6047294454656367e-07
study O 0 1.3351295535812824e-07
used O 0 1.9206602530630335e-07
PCR O 0 1.3903654689784162e-05
and O 0 5.664541049554828e-07
restriction O 0 4.843050760428014e-07
- O 0 3.229879439459182e-05
enzyme O 0 5.107530682835204e-07
digestion O 0 1.2198312049349624e-07
to O 0 1.4994825381364763e-09
analyze O 0 8.278516538950953e-09
the O 0 5.833244443032015e-10
frequency O 0 3.30327054598456e-09
of O 0 1.7667615148653226e-09
the O 0 4.7251084822619305e-08
845 O 0 0.00022890287800692022
G O 0 0.0043567088432610035
- O 0 0.0001110898083425127
- O 0 2.395960473222658e-05
> O 0 2.247658130727359e-07
A O 0 1.1003317013091873e-07
and O 0 1.656679273764894e-07
187 O 0 7.048047336866148e-06
C O 0 0.00016933128063101321
- O 0 0.0001566381542943418
- O 0 9.882726590149105e-05
> O 0 1.513897245786211e-06
G O 0 6.706844578729942e-05
mutations O 0 1.4485011945453152e-07
in O 0 2.134046894752828e-08
HLA O 0 1.8409837139188312e-05
- O 0 8.154874194588047e-06
typed O 0 5.568047072301852e-07
samples O 0 9.111810328477077e-08
from O 0 3.7151092868725755e-08
non O 0 1.1361495353412465e-06
- O 0 7.417533925035968e-05
Caucasian O 0 3.2124778954312205e-05
populations O 0 3.811773297002219e-07
, O 0 2.4454605451751377e-08
comprising O 0 3.338865894875198e-07
Australian O 0 3.771549017983489e-05
Aboriginal O 0 6.391744591383031e-06
, O 0 3.613019430304121e-07
Chinese O 0 1.6081155962410776e-08
, O 0 9.448219628893639e-08
and O 0 6.595461172764772e-07
Pacific O 0 5.495379809872247e-05
Islanders O 0 0.0009672932792454958
. O 0 3.5912237308366457e-06

Results O 0 7.74044674471952e-05
showed O 0 9.593183494871482e-05
that O 0 1.0145627982183214e-07
the O 0 1.6267355817944917e-07
845 O 0 0.006856496911495924
G O 0 0.3248279094696045
- O 0 0.0186977069824934
- O 0 0.0007150927558541298
> O 0 1.5903606254141778e-06
A O 0 1.9385852283448912e-06
mutation O 0 3.451197017056984e-06
was O 0 4.298956264392473e-05
present O 0 1.2361125811821694e-07
in O 0 3.434388062828475e-08
these O 0 1.2160290552287734e-08
populations O 0 1.11225993748576e-07
( O 0 4.741356196547031e-09
allele O 0 2.2516092101909635e-08
frequency O 0 3.0378455306845353e-08
0 O 0 3.225734133138758e-07
. O 0 1.5829938249112274e-08
32 O 0 9.269899123864889e-07
% O 0 1.5403576014705322e-07
) O 0 4.435409550751501e-08
, O 0 7.906971433158105e-08
and O 0 2.7188366402697284e-07
, O 0 7.112410003173864e-07
furthermore O 0 9.55926111601002e-07
, O 0 1.2742421517941693e-07
it O 0 7.51405124788107e-08
was O 0 3.779289545491338e-05
always O 0 3.1641062037124357e-07
seen O 0 2.3623644551662437e-07
in O 0 6.3779168613109505e-09
conjunction O 0 1.1671712485394892e-07
with O 0 9.625429129300755e-07
HLA O 0 0.005890998989343643
haplotypes O 0 8.057067316258326e-05
common O 0 6.669922640867298e-07
in O 0 1.0843910303037774e-07
Caucasians O 0 1.2562923984660301e-05
, O 0 2.714768925216049e-07
suggesting O 0 7.457737183358404e-07
that O 0 7.294560333548361e-08
845 O 0 0.0004483936063479632
G O 0 0.05874943360686302
- O 0 0.007555556949228048
- O 0 0.0007874441798776388
> O 0 2.873158791771857e-06
A O 0 1.0277990440954454e-05
may O 0 3.910175564669771e-06
have O 0 1.0065387812119297e-07
been O 0 9.697899372440588e-08
introduced O 0 4.33410143330093e-08
into O 0 2.925720776758567e-09
these O 0 4.812789722308253e-09
populations O 0 7.400873869300995e-08
by O 0 2.0601372341388924e-07
Caucasian O 0 5.197104110266082e-05
admixture O 0 0.00014141203428152949
. O 0 1.1470747267594561e-05

187 O 0 0.0005571937072090805
C O 0 0.005010864231735468
- O 0 0.004766426514834166
- O 0 0.0019375024130567908
> O 0 2.3336930098594166e-05
G O 0 0.0008061819826252759
was O 0 3.75298191102047e-06
present O 0 1.5276906850658634e-08
at O 0 6.01656893195468e-08
an O 0 2.184708591812523e-08
allele O 0 6.517807094041927e-08
frequency O 0 3.172505458337582e-08
of O 0 5.23826493292745e-08
2 O 0 1.191668889077846e-05
. O 0 5.135403171152575e-06

68 O 0 0.0019196659559383988
% O 0 3.2189809644478373e-06
in O 0 6.736951974062322e-08
the O 0 3.090714884024237e-08
two O 0 1.7675351671186945e-07
populations O 0 1.5003780617917073e-06
analyzed O 0 2.861126631614752e-05
( O 0 2.3670889959248598e-07
Australian O 0 3.438962085056119e-05
Aboriginal O 0 7.190210453700274e-06
and O 0 1.8831228771887254e-06
Chinese O 0 2.579544400305167e-07
) O 0 1.8811506663496402e-07
. O 0 8.81778362327168e-07

In O 0 1.9887254438799573e-06
the O 0 4.5839050244467217e-07
Australian O 0 3.113408456556499e-05
Aboriginal O 0 2.1143982849025633e-06
samples O 0 1.437879859622626e-07
, O 0 4.6579874179997205e-08
187 O 0 4.218144113110611e-06
C O 0 0.0001805929496185854
- O 0 0.0003053448745049536
- O 0 0.00020437025523278862
> O 0 5.135555056767771e-06
G O 0 0.004133171867579222
was O 0 3.6428893508855253e-05
found O 0 8.783364364717272e-07
to O 0 9.026445724202858e-08
be O 0 3.421165786221536e-07
associated O 0 3.058042068460054e-07
with O 0 1.3692455240743584e-06
HLA O 0 0.0067441463470458984
haplotypes O 0 0.00013015713193453848
common O 0 7.149827752073179e-07
in O 0 1.8747462604551401e-07
Caucasians O 0 3.8486923585878685e-05
, O 0 9.714743782751611e-07
suggesting O 0 2.0460372525121784e-06
that O 0 3.055406239127478e-08
it O 0 2.1321591603395973e-08
was O 0 1.873337396318675e-06
introduced O 0 3.070795457915665e-07
by O 0 1.5206212822249654e-07
recent O 0 1.8527258589529083e-06
admixture O 0 8.958197577157989e-05
. O 0 1.0979959370160941e-05

In O 0 9.274718308915908e-07
the O 0 6.758806136986095e-08
Chinese O 0 1.6704541749845703e-08
samples O 0 5.7280349352595294e-08
analyzed O 0 2.8287664122217393e-07
, O 0 1.8296658410577038e-08
187 O 0 1.944143377841101e-06
C O 0 7.206826558103785e-05
- O 0 0.0002819561050273478
- O 0 0.0011297630844637752
> O 0 8.757312571106013e-06
G O 0 0.003617236390709877
was O 0 4.591852848534472e-05
present O 0 2.7154601411893964e-07
in O 0 4.967176892023417e-07
association O 0 2.919189455496962e-06
with O 0 6.035217552380345e-07
a O 0 9.074552735910402e-07
wide O 0 5.739731932408176e-06
variety O 0 1.8070467433517479e-07
of O 0 6.626511321883299e-07
HLA O 0 0.014588231220841408
haplotypes O 0 0.00011823084787465632
, O 0 2.8093023729525157e-07
showing O 0 1.5608352441631723e-06
this O 0 2.3973470320015622e-08
mutation O 0 3.637361771779979e-07
to O 0 4.846802781344195e-08
be O 0 1.7682583575151511e-07
widespread O 0 7.273469577739888e-07
and O 0 4.818725756194908e-06
likely O 0 2.2143954083730932e-06
to O 0 2.5433324779555733e-08
predate O 0 1.2757393506035442e-06
the O 0 5.585436113619835e-09
more O 0 4.191788693930221e-09
genetically O 0 4.132471076445654e-07
restricted O 0 7.840981197659858e-08
845 O 0 6.438987475121394e-05
G O 0 0.0015798505628481507
- O 0 0.0003643945965450257
- O 0 0.000262257584836334
> O 0 4.0863201320462395e-06
A O 0 3.1626143481844338e-06
mutation O 0 6.815650522185024e-06
. O 0 1.4454971051236498e-06

Genotype O 0 0.011326760984957218
- O 0 0.05260608717799187
phenotype O 0 0.0019193744519725442
correlations O 0 0.001197759760543704
in O 0 0.00011921258555958048
attenuated B-Disease 1 0.8374739289283752
adenomatous I-Disease 1 0.9998314380645752
polyposis I-Disease 1 0.9996737241744995
coli I-Disease 1 0.9994872808456421
. O 0 0.0003557398449629545

Germ O 0 0.04585389047861099
- O 0 0.004119333811104298
line O 0 3.1015606509754434e-05
mutations O 0 2.553278136474546e-06
of O 0 6.289143072990555e-08
the O 0 4.1490393414278515e-06
tumor B-Disease 0 0.049365874379873276
suppressor O 0 0.00025933573488146067
APC O 0 0.00029668203205801547
are O 0 5.504463729266718e-07
implicated O 0 0.0010831971885636449
in O 0 0.00010094841127283871
attenuated B-Disease 1 0.992653489112854
adenomatous I-Disease 1 0.9999855756759644
polyposis I-Disease 1 0.9999740123748779
coli I-Disease 1 0.9999878406524658
( O 0 0.0014940063701942563
AAPC B-Disease 1 0.9999204874038696
) O 0 3.5283555916976184e-06
, O 0 4.618654543264711e-07
a O 0 1.821196860873897e-06
variant O 0 0.0002834017504937947
of O 0 0.001389689976349473
familial B-Disease 1 0.9999754428863525
adenomatous I-Disease 1 0.9999420642852783
polyposis I-Disease 1 0.9999732971191406
( O 0 0.0006226890254765749
FAP B-Disease 0 0.039004478603601456
) O 0 8.871134014043491e-06
. O 0 6.4891623878793325e-06

AAPC B-Disease 1 0.9996235370635986
is O 0 5.6151005992433056e-05
recognized O 0 4.2868264245043974e-06
by O 0 1.6431459926025127e-07
the O 0 9.500298858711176e-08
occurrence O 0 8.544810157218308e-07
of O 0 1.0675261563619642e-07
< O 0 2.0149111151113175e-05
100 O 0 1.4409112054636353e-06
colonic B-Disease 0 0.04293058440089226
adenomas I-Disease 0 0.010656902566552162
and O 0 4.4631087803281844e-07
a O 0 4.5102351009518316e-07
later O 0 1.6232505004154518e-05
onset O 0 0.0011795081663876772
of O 1 0.5014590620994568
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
( O 0 2.512269702492631e-06
age O 0 5.4628958423563745e-06
> O 0 3.689494405989535e-06
40 O 0 3.5377120184421074e-06
years O 0 3.5527709769667126e-06
) O 0 5.162633556210494e-07
. O 0 1.6645676623738836e-06

The O 0 1.9915132725145668e-06
aim O 0 2.1667581222573062e-06
of O 0 2.2156402934569996e-08
this O 0 6.7152043925489124e-09
study O 0 1.2646249558656564e-07
was O 0 6.768792445654981e-06
to O 0 6.767190541268064e-08
assess O 0 2.673457856872119e-06
genotype O 0 3.2454165193485096e-05
- O 0 0.002891284879297018
phenotype O 0 4.810263999388553e-05
correlations O 0 7.581151294289157e-05
in O 0 1.7226477211806923e-05
AAPC B-Disease 1 0.9987004995346069
families O 0 2.9370970878517255e-05
. O 0 5.642054475174518e-06

By O 0 4.095777057955274e-06
protein O 0 2.255206254631048e-06
- O 0 5.679471360053867e-05
truncation O 0 8.432693721260875e-05
test O 0 9.235749530489556e-06
( O 0 6.627598736486107e-08
PTT O 0 5.893618435948156e-06
) O 0 9.78630598780228e-09
assay O 0 2.8572594601428136e-07
, O 0 1.5191336188991045e-08
the O 0 6.170427724327965e-09
entire O 0 1.3055526437710796e-07
coding O 0 5.816468274133513e-06
region O 0 1.9525998595781857e-07
of O 0 1.582882092066029e-08
the O 0 1.3890408467887028e-07
APC B-Disease 0 5.367993799154647e-05
gene O 0 2.080344501109721e-07
was O 0 1.6770326283221948e-06
screened O 0 3.498611704344512e-06
in O 0 1.7616703473777306e-07
affected O 0 6.616982091145474e-07
individuals O 0 2.006601675930142e-07
from O 0 1.7444499462726526e-06
11 O 0 0.0015499235596507788
AAPC B-Disease 1 0.9998801946640015
kindreds O 0 0.000447501108283177
, O 0 4.18247907418845e-07
and O 0 6.536169649962176e-08
their O 0 3.991832286942554e-08
phenotypic O 0 3.173055347360787e-06
differences O 0 6.376073997671483e-06
were O 0 6.23080904915696e-06
examined O 0 0.00021802201808895916
. O 0 9.671844964032061e-06

Five O 0 8.329524462169502e-06
novel O 0 1.6852971384651028e-05
germ O 0 0.0059256404638290405
- O 0 0.004044973757117987
line O 0 4.316563354223035e-05
APC B-Disease 0 0.0002584895119071007
mutations O 0 2.62193361777463e-06
were O 0 5.842915129505855e-07
identified O 0 1.5857201560720569e-06
in O 0 6.169429411784222e-08
seven O 0 4.659338628698606e-06
kindreds O 0 0.0014623368624597788
. O 0 9.196619430440478e-06

Mutations O 0 0.0025020025204867125
were O 0 1.8782207916956395e-05
located O 0 1.5535496231677826e-06
in O 0 2.273818111575565e-08
three O 0 2.8675907870479023e-08
different O 0 1.783956649070717e-09
regions O 0 2.8771564686280726e-08
of O 0 2.4448308266755703e-08
the O 0 6.18185708844976e-07
APC B-Disease 0 0.0007890937849879265
gene O 0 5.685105861630291e-07
( O 0 2.3392500381191894e-08
1 O 0 2.0493224894835294e-07
) O 0 1.5263537989085307e-08
at O 0 7.350845976361597e-08
the O 0 2.2737966176578084e-08
5 O 0 1.4726481367688393e-07
end O 0 8.290751196682322e-08
spanning O 0 5.607320758826972e-07
exons O 0 3.652625764516415e-06
4 O 0 1.3745927844865946e-06
and O 0 3.909859458417486e-07
5 O 0 1.3866228982806206e-06
, O 0 1.797233295519618e-07
( O 0 7.09097891515853e-09
2 O 0 6.334771285310126e-08
) O 0 3.4370533086303112e-09
within O 0 1.0129338479103467e-09
exon O 0 1.6478050383739173e-05
9 O 0 5.640328254230553e-06
, O 0 2.0829074287576077e-07
and O 0 2.9446877647387737e-07
( O 0 3.2260874860412514e-08
3 O 0 2.389828352988843e-07
) O 0 1.1421313672599354e-08
at O 0 3.419902583345902e-08
the O 0 1.6997075746871815e-08
3 O 0 4.6657589791720966e-07
distal O 0 1.229033023264492e-05
end O 0 3.3798667686824047e-07
of O 0 2.2130935306563515e-08
the O 0 2.7128848500979075e-07
gene O 0 8.96910535175266e-07
. O 0 1.5889188489381922e-06

Variability O 0 0.0006411715876311064
in O 0 7.93557774159126e-07
the O 0 1.3895058259549842e-07
number O 0 9.300511010224e-07
of O 0 0.00180700677447021
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999990463256836
was O 1 0.56461101770401
most O 0 5.738172148994636e-06
apparent O 0 7.334340625675395e-05
in O 0 4.795821268999134e-07
individuals O 0 1.3005980292746244e-07
with O 0 1.607311219231633e-06
mutations O 0 2.2790493403590517e-06
in O 0 1.8547612512520573e-07
region O 0 4.857751605413796e-07
1 O 0 3.369540308995056e-06
, O 0 2.4759308416832937e-06
and O 0 3.1473959097638726e-05
upper O 0 0.2274608165025711
- O 1 0.9981659054756165
gastrointestinal O 1 0.9696643352508545
manifestations O 0 2.0483432308537886e-05
were O 0 3.588464096537791e-06
more O 0 2.2909293306838663e-07
severe O 0 4.9448055506218225e-05
in O 0 6.338687796869635e-08
them O 0 1.885306488702554e-07
. O 0 2.6774584966915427e-06

In O 0 5.552602488023695e-06
individuals O 0 1.2440460750440252e-06
with O 0 7.347173323069001e-07
mutations O 0 6.6533366407384165e-06
in O 0 1.6481273235058325e-07
either O 0 6.40195423784462e-07
region O 0 1.723125706121209e-06
2 O 0 3.4985482670890633e-06
or O 0 7.42140514375933e-07
region O 0 3.1101473041417194e-07
3 O 0 6.892860255902633e-07
, O 0 8.124145978172237e-08
the O 0 3.0285541186003684e-08
average O 0 1.1088787914559362e-06
number O 0 5.064227792672682e-08
of O 0 4.002098137334542e-07
adenomas B-Disease 0 0.0512741394340992
tended O 0 3.5260379718238255e-06
to O 0 2.6401517416729803e-08
be O 0 2.9839277715382195e-08
lower O 0 1.493881654823781e-06
than O 0 1.9484271973624345e-08
those O 0 1.3321121983267403e-08
in O 0 5.116110557423781e-08
individuals O 0 5.0324040046234586e-08
with O 0 3.793217615566391e-07
mutations O 0 2.2736699065717403e-06
in O 0 1.1506418218232284e-07
region O 0 4.7564401484123664e-07
1 O 0 1.361886234008125e-06
, O 0 9.64983996709634e-07
although O 0 5.935759759267967e-07
age O 0 2.2599597286898643e-06
at O 0 6.92776256983052e-06
diagnosis O 0 0.00021545066556427628
was O 0 7.07372892065905e-05
similar O 0 3.396628699192661e-06
. O 0 1.4062768968869932e-05

In O 0 8.167030500771943e-06
all O 0 3.0212095225579105e-06
AAPC B-Disease 1 0.9992561936378479
kindreds O 0 0.0018507959321141243
, O 0 7.675174629184767e-07
a O 0 1.7149486097878253e-07
predominance O 0 1.2821920790884178e-05
of O 0 8.065289307523926e-07
right O 0 0.003159376559779048
- O 1 0.9995681643486023
sided O 1 0.9999836683273315
colorectal B-Disease 1 0.9999998807907104
adenomas I-Disease 1 0.999990701675415
and O 0 0.022907044738531113
rectal B-Disease 1 0.9998816251754761
polyp I-Disease 1 0.9984790682792664
sparing O 0 0.0009031915687955916
was O 0 0.00030888355104252696
observed O 0 1.0969838513119612e-05
. O 0 2.3616262296854984e-06

No O 0 0.00021099791047163308
desmoid B-Disease 1 0.9919943809509277
tumors I-Disease 1 0.9999734163284302
were O 0 2.077718272630591e-05
found O 0 2.857212393791997e-06
in O 0 9.113548316008746e-08
these O 0 1.5007285014689842e-07
kindreds O 0 0.0002977264521177858
. O 0 1.0290416867064778e-05

Our O 0 2.0272786969144363e-06
data O 0 1.2115074241592083e-06
suggest O 0 1.9418105239310535e-06
that O 0 1.4008098503381916e-07
, O 0 2.050271859843633e-06
in O 0 1.0019291039498057e-05
AAPC B-Disease 1 0.9999556541442871
families O 0 1.4892251783749089e-05
, O 0 2.5284936100433697e-07
the O 0 3.6268762215740935e-08
location O 0 7.270931945413395e-08
of O 0 2.4763121331261573e-08
the O 0 2.0292650333431084e-06
APC B-Disease 0 0.01558380015194416
mutation O 0 2.906999179685954e-05
may O 0 4.211130544717889e-06
partially O 0 1.6327068806276657e-05
predict O 0 5.251440029496734e-07
specific O 0 3.5834734291029235e-08
phenotypic O 0 6.117676548456075e-06
expression O 0 2.2637780148215825e-06
. O 0 2.5828624075074913e-06

This O 0 2.9033915325271664e-06
should O 0 5.289529667606985e-07
help O 0 2.9793790190524305e-07
in O 0 1.3278099508795549e-08
the O 0 2.280337341176164e-08
design O 0 7.926705052341276e-07
of O 0 2.940385854799388e-07
tailored O 0 0.0026841836515814066
clinical O 0 0.0002957867400255054
- O 0 0.05245586112141609
management O 0 9.925253834808245e-06
protocols O 0 1.1945097639909363e-06
in O 0 2.2089858831009224e-08
this O 0 3.3116420716794437e-09
subset O 0 1.8290593573055958e-07
of O 0 2.132140480171074e-06
FAP B-Disease 0 0.05173692852258682
patients O 0 9.155202860711142e-05
. O 0 3.7521371609727794e-07
. O 0 2.5781819203984924e-06

Wilms B-Disease 1 0.9986631870269775
' I-Disease 0 0.08934483677148819
tumor I-Disease 0 0.031052477657794952
1 O 0 1.7481338545621838e-06
and O 0 9.401181841894868e-07
Dax O 0 0.18084542453289032
- O 0 0.00010977936472045258
1 O 0 1.3357866635033133e-07
modulate O 0 2.487503820702841e-07
the O 0 2.3035367391344153e-08
orphan O 0 7.710477075306699e-05
nuclear O 0 4.600175452651456e-05
receptor O 0 1.589196244822233e-06
SF O 0 0.0070296465419232845
- O 0 2.2829803128843196e-05
1 O 0 8.086825431519173e-08
in O 0 1.4428836792035327e-08
sex O 0 2.1625660906465782e-07
- O 0 4.472107775654877e-06
specific O 0 2.0050421767336957e-08
gene O 0 1.77858680672216e-07
expression O 0 4.511176996402355e-07
. O 0 8.472494528177776e-07

Products O 0 4.781278039445169e-05
of O 0 1.3086320223010262e-06
steroidogenic O 0 0.014551968313753605
factor O 0 1.0672125426935963e-05
1 O 0 3.4855404464906314e-06
( O 0 3.411674640574347e-07
SF O 0 0.25175899267196655
- O 0 0.01022642944008112
1 O 0 3.984723662142642e-06
) O 0 1.2427103968093434e-07
and O 0 1.2445239917724393e-05
Wilms B-Disease 1 0.999384880065918
tumor I-Disease 0 0.059211861342191696
1 O 0 4.782384621648816e-06
( O 0 5.698959171240858e-07
WT1 O 0 0.00018552197434473783
) O 0 8.492575176433093e-08
genes O 0 6.50203872964994e-08
are O 0 2.479647820408104e-09
essential O 0 9.650695353968786e-09
for O 0 3.4317032771014055e-08
mammalian O 0 4.357353191153379e-06
gonadogenesis O 0 5.475428406498395e-05
prior O 0 3.0248139637478744e-07
to O 0 5.8901463262373e-08
sexual O 0 1.7987438241107157e-06
differentiation O 0 7.959552021929994e-06
. O 0 4.701259513240075e-06

In O 0 8.186947525246069e-06
males O 0 1.2264232282177545e-05
, O 0 1.924598336700001e-06
SF O 1 0.5417140126228333
- O 0 0.0030845412984490395
1 O 0 8.97360564522387e-07
participates O 0 3.187475385857397e-07
in O 0 3.379298618710891e-08
sexual O 0 1.5600137714955054e-07
development O 0 1.8829449999202552e-08
by O 0 5.528006141730657e-08
regulating O 0 1.0576798104011687e-06
expression O 0 1.9102602166753968e-08
of O 0 7.2170984743991085e-09
the O 0 2.087417243501477e-07
polypeptide O 0 0.00022876719594933093
hormone O 0 3.7638812500517815e-05
Mullerian O 0 8.433842594968155e-05
inhibiting O 0 2.6680741939344443e-05
substance O 0 5.535213404073147e-06
( O 0 5.618406362373207e-07
MIS O 0 0.0015915100229904056
) O 0 9.578407116350718e-07
. O 0 1.928570554809994e-06

Here O 0 1.2707215319096576e-05
, O 0 6.593813282051997e-07
we O 0 1.474044175608924e-08
show O 0 4.123608476902518e-08
that O 0 2.2579484948437312e-08
WT1 O 0 8.038119995035231e-05
- O 0 0.00015285008703358471
KTS O 0 0.0019983781967312098
isoforms O 0 6.758097725878542e-08
associate O 0 6.734343855896441e-07
and O 0 1.7943509078577335e-07
synergize O 0 8.920078107621521e-05
with O 0 3.2830330383148976e-06
SF O 1 0.7983868718147278
- O 0 0.0003041147720068693
1 O 0 2.547114945627982e-07
to O 0 1.8804362511559702e-08
promote O 0 4.7395502633662545e-07
MIS O 0 0.0003810793277807534
expression O 0 1.6671381217747694e-06
. O 0 1.0252175570713007e-06

In O 0 8.564286872569937e-06
contrast O 0 3.684897819766775e-05
, O 0 2.56757721217582e-06
WT1 O 0 0.002698719734326005
missense O 0 0.0007489070412702858
mutations O 0 0.00022325706959236413
, O 0 2.390091367487912e-06
associated O 0 2.576267206677585e-06
with O 0 2.943760136986384e-06
male B-Disease 0 0.00030717847403138876
pseudohermaphroditism I-Disease 1 0.9987370371818542
in O 0 3.9969127101358026e-05
Denys B-Disease 1 0.9992889165878296
- I-Disease 1 0.9999258518218994
Drash I-Disease 1 0.9999300241470337
syndrome I-Disease 1 0.9997531771659851
, O 0 4.856611667491961e-06
fail O 0 3.823241058853455e-06
to O 0 4.4819955746788764e-08
synergize O 0 6.601940549444407e-05
with O 0 1.5775825659147813e-06
SF O 1 0.775950014591217
- O 0 0.0022262237034738064
1 O 0 5.53707195649622e-06
. O 0 2.0378079170768615e-06

Additionally O 0 7.85252996138297e-05
, O 0 1.8087397393173887e-06
the O 0 4.893120717497368e-07
X O 0 0.012568973004817963
- O 0 0.1494673788547516
linked O 0 0.0008406341657973826
, O 0 6.415681355065317e-07
candidate O 0 1.3307227391123888e-06
dosage O 0 4.164173788012704e-06
- O 0 2.24572722800076e-05
sensitive O 0 2.2488038666779175e-06
sex O 0 9.005514698401385e-07
- O 0 2.3997497919481248e-05
reversal O 0 6.075784767745063e-06
gene O 0 8.528334660695691e-08
, O 0 1.0943833217424981e-07
Dax O 0 0.10632625222206116
- O 0 0.0001931726437760517
1 O 0 9.012834993882279e-07
, O 0 1.0389395299625903e-07
antagonizes O 0 4.184308636467904e-06
synergy O 0 3.722770713920909e-07
between O 0 1.9232537340485578e-07
SF O 1 0.545714795589447
- O 0 0.0019831745885312557
1 O 0 2.2031222215446178e-06
and O 0 7.038630087663478e-07
WT1 O 0 0.0008767587132751942
, O 0 1.8628729492320417e-07
most O 0 1.8177210847625247e-08
likely O 0 3.718427166177207e-08
through O 0 3.0616467139310544e-09
a O 0 2.4348718596911567e-08
direct O 0 1.9170052212302835e-08
interaction O 0 5.3783640652227405e-08
with O 0 1.6633205177640775e-06
SF O 1 0.9346199035644531
- O 0 0.004047877620905638
1 O 0 8.021695975912735e-06
. O 0 1.8190947912444244e-06

We O 0 2.133954922101111e-06
propose O 0 4.348457878222689e-06
that O 0 1.28741220351003e-07
WT1 O 0 0.00011252504191361368
and O 0 1.059001988323871e-06
Dax O 0 0.2073407769203186
- O 0 0.0001740387815516442
1 O 0 3.7323084711715637e-07
functionally O 0 2.0116269752179505e-06
oppose O 0 2.1584082787740044e-07
each O 0 8.404218654334272e-09
other O 0 8.244653848521466e-09
in O 0 4.883233373220719e-08
testis O 0 1.6826361388666555e-05
development O 0 1.8911547883249114e-08
by O 0 1.3561805189965526e-07
modulating O 0 3.762050982913934e-05
SF O 0 0.0767933800816536
- O 0 7.206373265944421e-05
1 O 0 1.0552747653491679e-06
- O 0 9.564310312271118e-05
mediated O 0 4.4098091166233644e-05
transactivation O 0 0.00011729466496035457
. O 0 3.4712155638771947e-07
. O 0 1.1448912573541747e-06

A O 0 5.828025678056292e-05
mouse O 0 0.0002393139584455639
model O 0 0.00018474861280992627
for O 0 0.00043130634003318846
Prader B-Disease 1 0.9999868869781494
- I-Disease 1 0.9999921321868896
Willi I-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.9999529123306274
imprinting O 0 0.13597045838832855
- O 1 0.8497594594955444
centre O 0 0.0054925475269556046
mutations O 0 0.0002575262333266437
. O 0 1.3029401088715531e-05

Imprinting O 0 0.0002260939363623038
in O 0 1.5380896911665332e-06
the O 0 4.620905826868693e-07
15q11 O 0 7.100938091753051e-05
- O 0 0.0007709306082688272
q13 O 0 2.1232193830655888e-05
region O 0 6.920776485230817e-08
involves O 0 6.706567035053013e-08
an O 0 1.344235016631501e-07
imprinting O 0 0.00011088638711953536
centre O 0 4.4397478632163256e-05
( O 0 7.356961191362643e-07
IC O 0 0.0009165704250335693
) O 0 2.422975455829146e-07
, O 0 5.8041834449795715e-08
mapping O 0 3.499034733067674e-07
in O 0 1.0090857927025354e-07
part O 0 1.0522734328333172e-07
to O 0 2.9760499842268473e-08
the O 0 1.1774859842716978e-07
promoter O 0 1.7730853869579732e-05
and O 0 6.789817064145609e-08
first O 0 2.1508157033167663e-07
exon O 0 3.7640176742570475e-05
of O 0 1.0593696515570628e-06
SNRPN O 0 0.010272154584527016
. O 0 3.2141408610186772e-06

Deletion O 0 0.00026538356905803084
of O 0 1.2599737146956613e-06
this O 0 1.7181638156671397e-07
IC O 0 0.0004583819245453924
abolishes O 0 0.00012470947694964707
local O 0 4.6229862959989987e-07
paternally O 0 3.161603308399208e-05
derived O 0 7.617488506639347e-08
gene O 0 7.592451822802104e-08
expression O 0 3.37012018292171e-08
and O 0 3.1589263471687445e-07
results O 0 1.2662251720030326e-05
in O 0 0.0025569042190909386
Prader B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999985694885254
Willi I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.999991774559021
( O 0 0.0009632398723624647
PWS B-Disease 1 0.9998706579208374
) O 0 1.151374090113677e-05
. O 0 8.344868547283113e-06

We O 0 3.709420980158029e-06
have O 0 3.109877582119225e-07
created O 0 1.715218616027414e-07
two O 0 5.110970491273292e-08
deletion O 0 4.268766497261822e-05
mutations O 0 1.0988203030137811e-05
in O 0 9.631423836253816e-07
mice O 0 0.0001932898157974705
to O 0 1.1490457154650358e-06
understand O 0 1.1244541383348405e-05
PWS B-Disease 1 0.9996209144592285
and O 0 1.3410830206339597e-06
the O 0 4.953004761887314e-08
mechanism O 0 1.3027343470639607e-07
of O 0 6.181420530992909e-08
this O 0 1.9176860632796888e-07
IC O 0 0.006582838948816061
. O 0 1.1960260962950997e-05

Mice O 0 0.022809607908129692
harbouring O 0 0.018377743661403656
an O 0 8.073699973465409e-06
intragenic O 0 0.0077032651752233505
deletion O 0 0.0001356027350993827
in O 0 1.2077191513526486e-06
Snrpn O 0 0.0013257646933197975
are O 0 3.87848189120632e-07
phenotypically O 0 2.9992028430569917e-05
normal O 0 1.586075626391903e-07
, O 0 1.4125534164577402e-07
suggesting O 0 7.668333523724868e-07
that O 0 4.2355353002676566e-08
mutations O 0 5.573631369770737e-07
of O 0 3.7179134437792527e-07
SNRPN O 0 0.07976424694061279
are O 0 1.26257646115846e-07
not O 0 3.3013261457881526e-08
sufficient O 0 9.428830338720218e-08
to O 0 3.2872549127205275e-07
induce O 0 5.800125654786825e-05
PWS B-Disease 1 0.9832649827003479
. O 0 1.133977002609754e-05

Mice O 0 0.0016357148997485638
with O 0 8.021902431210037e-07
a O 0 7.525022169829754e-07
larger O 0 4.977048888576974e-07
deletion O 0 3.88206308343797e-06
involving O 0 5.52742267245776e-06
both O 0 1.646532609811402e-06
Snrpn O 0 0.0013583078980445862
and O 0 1.2404600511217723e-06
the O 0 2.6026189061667537e-06
putative O 0 0.0806911364197731
PWS O 1 0.999935507774353
- O 0 0.3076225519180298
IC O 0 0.017273960635066032
lack O 0 1.7569921055837767e-06
expression O 0 4.977922429816317e-08
of O 0 1.3638713269870095e-08
the O 0 4.6899563699298596e-07
imprinted O 0 0.0006956701981835067
genes O 0 1.4267775441112462e-06
Zfp127 O 0 5.646545105264522e-05
( O 0 3.377835966489329e-08
mouse O 0 1.7620966445974773e-06
homologue O 0 1.5339061292252154e-06
of O 0 2.381996466738201e-07
ZNF127 O 0 0.018613459542393684
) O 0 3.813926241491572e-07
, O 0 2.3442552787855675e-07
Ndn O 0 0.0003411177603993565
and O 0 3.104379857177264e-06
Ipw O 0 0.0006071233074180782
, O 0 6.921072781551629e-07
and O 0 7.360069957940141e-07
manifest O 0 7.3921364673879e-06
several O 0 1.6969194405191956e-07
phenotypes O 0 5.6101871450664476e-05
common O 0 5.916633654123871e-06
to O 0 3.102229311480187e-05
PWS B-Disease 1 0.999920129776001
infants O 0 0.18177063763141632
. O 0 1.6880991097423248e-05

These O 0 5.097652433505573e-07
data O 0 1.2545507388495025e-06
demonstrate O 0 1.195492018268851e-06
that O 0 2.8989756373221098e-08
both O 0 2.4918101360071887e-08
the O 0 7.169861504507935e-08
position O 0 5.418535806711589e-07
of O 0 2.2490254991680558e-08
the O 0 1.6483143383538845e-07
IC O 0 0.0006222364027053118
and O 0 7.604145935147244e-07
its O 0 6.65140689193322e-08
role O 0 2.0692067437266815e-07
in O 0 8.485478986131056e-09
the O 0 1.1887913764496716e-08
coordinate O 0 2.2060140736357425e-07
expression O 0 3.060451447822743e-08
of O 0 1.4880185972288018e-08
genes O 0 1.691990689778322e-07
is O 0 3.937778103590972e-08
conserved O 0 2.3241253188643896e-07
between O 0 1.6519291534677905e-07
mouse O 0 0.00010851917613763362
and O 0 4.863280992140062e-06
human O 0 2.5635349629737902e-06
, O 0 1.0205624221271137e-06
and O 0 7.841868523428275e-07
indicate O 0 5.322014544617559e-07
that O 0 4.991109037177921e-08
the O 0 1.115627554781895e-07
mouse O 0 2.0980955014238134e-05
is O 0 8.793617212177196e-08
a O 0 9.4202562195278e-08
suitable O 0 2.568311572304083e-07
model O 0 1.3763359447693801e-06
system O 0 1.1239009154451196e-06
in O 0 1.2223325995819323e-07
which O 0 6.798382656825197e-08
to O 0 2.6312536149930565e-08
investigate O 0 4.4031432366864465e-07
the O 0 4.497538341752261e-08
molecular O 0 3.1971978842193494e-06
mechanisms O 0 2.1267334204821964e-07
of O 0 2.8279995234470334e-08
imprinting O 0 1.4657095562142786e-05
in O 0 9.214083718234178e-08
this O 0 6.254783802006614e-09
region O 0 2.4970150391823154e-08
of O 0 8.739804435720089e-09
the O 0 8.639536019927618e-08
genome O 0 8.320902452396695e-06
. O 0 3.092888505307201e-07
. O 0 9.738072321852087e-07

Mutations O 0 0.00010235059016849846
of O 0 2.535254566282674e-07
the O 0 1.84004818493122e-07
ATM O 0 0.0003225428517907858
gene O 0 2.8707597721222555e-06
detected O 0 8.953517863119487e-06
in O 0 9.110591463468154e-07
Japanese O 0 0.21520288288593292
ataxia B-Disease 1 0.999992847442627
- I-Disease 1 0.9999942779541016
telangiectasia I-Disease 1 0.9999982118606567
patients O 0 0.08627339452505112
: O 0 2.578358930804825e-07
possible O 0 1.8938699497539346e-07
preponderance O 0 6.839254183432786e-06
of O 0 1.2856351538914623e-08
the O 0 2.675540855534564e-08
two O 0 3.289133587713877e-07
founder O 0 0.0009136894950643182
mutations O 0 3.2339230529032648e-06
4612del165 O 0 7.836142685846426e-06
and O 0 1.726298478388344e-06
7883del5 O 0 6.717469659633934e-05
. O 0 1.7970772887565545e-06

The O 0 7.788299626554362e-06
ATM O 0 0.0050811548717319965
( O 0 5.560158570006024e-06
A O 1 0.8397409915924072
- O 1 0.9998974800109863
T O 1 0.9999887943267822
, O 0 3.745108642760897e-06
mutated O 0 2.8815063615184044e-06
) O 0 2.0854269422443394e-08
gene O 0 2.0307364678728845e-08
on O 0 3.001818242864829e-07
human O 0 2.389108885836322e-06
chromosome O 0 0.00041194268851540983
11q22 O 0 0.00026193022495135665
. O 0 6.678549198113615e-06

3 O 0 0.00012016077380394563
has O 0 3.149404437863268e-05
recently O 0 0.0003570276312530041
been O 0 3.217986659365124e-06
identified O 0 3.175404344801791e-06
as O 0 2.8288409836818573e-08
the O 0 2.340486204843728e-08
gene O 0 6.824483023137873e-08
responsible O 0 2.8908186777698575e-07
for O 0 2.542712138620118e-07
the O 0 2.3403457817039452e-05
human O 0 0.21129566431045532
recessive B-Disease 1 0.999275267124176
disease I-Disease 1 0.9998407363891602
ataxia B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999921321868896
telangiectasia I-Disease 1 0.9999971389770508
( O 0 0.0049956622533500195
A B-Disease 1 0.9995806813240051
- I-Disease 1 0.999976634979248
T I-Disease 1 0.9999794960021973
) O 0 7.701145477767568e-06
. O 0 3.992848178313579e-06

In O 0 5.1648480621224735e-06
order O 0 5.318923967934097e-07
to O 0 3.84929705887771e-08
define O 0 1.855652840276889e-07
the O 0 3.909169166149695e-08
types O 0 3.6633565514421207e-07
of O 0 2.9807931696268497e-06
disease O 0 0.004970450419932604
- O 0 0.008662790060043335
causing O 0 8.229139348259196e-05
ATM O 0 0.004060511477291584
mutations O 0 8.987190085463226e-06
in O 0 3.5737818393499765e-07
Japanese O 0 0.00041879023774527013
A B-Disease 1 0.9923689365386963
- I-Disease 1 0.9999922513961792
T I-Disease 1 0.9999991655349731
patients O 0 0.0005631616804748774
as O 0 1.014855570247164e-06
well O 0 1.8485170016901975e-07
as O 0 9.746130302801248e-08
to O 0 1.8599894957560537e-08
look O 0 8.46705248136459e-08
for O 0 2.7323210360918893e-08
possible O 0 1.1366498853249141e-07
mutational O 0 9.679669346951414e-06
hotspots O 0 5.852267349837348e-06
, O 0 1.936303846150622e-07
reverse O 0 4.038392944494262e-06
- O 0 7.606374765600776e-06
transcribed O 0 5.712061579288275e-07
RNA O 0 1.7684793363059725e-07
derived O 0 2.8731149015470692e-08
from O 0 3.012227622889441e-08
ten O 0 3.7096438632033824e-07
patients O 0 3.1615529678674648e-06
belonging O 0 6.619973760280118e-07
to O 0 3.429276063116049e-08
eight O 0 6.610214882130094e-07
unrelated O 0 8.448525477433577e-05
Japanese O 0 0.00038928588037379086
A B-Disease 1 0.9549322128295898
- I-Disease 1 0.9998182654380798
T I-Disease 1 0.9999874830245972
families O 0 1.4412050404644106e-05
was O 0 2.6314140995964408e-05
analyzed O 0 4.719110620499123e-06
for O 0 3.473215599569812e-07
mutations O 0 3.1464065841646516e-07
by O 0 9.709370196731015e-09
the O 0 3.4735329279556026e-08
restriction O 0 2.1634490110500337e-07
endonuclease O 0 1.532493843114935e-05
fingerprinting O 0 5.8976878790417686e-05
method O 0 4.198815076961182e-06
. O 0 4.220119990350213e-06

As O 0 1.5700985386501998e-05
has O 0 6.10726556260488e-06
been O 0 1.4704504565088428e-06
reported O 0 6.1447130974556785e-06
by O 0 2.589166285815736e-07
others O 0 5.2761156439373735e-06
, O 0 6.568557182617951e-07
mutations O 0 9.033245191858441e-07
that O 0 2.3605396748394014e-08
lead O 0 2.411234163446352e-06
to O 0 5.509753009391716e-08
exon O 0 4.062764855916612e-05
skipping O 0 3.021719749085605e-05
or O 0 1.372532324239728e-06
premature O 0 5.333422450348735e-06
protein O 0 8.590077271719565e-08
truncation O 0 4.747566890728194e-06
were O 0 2.62953608398675e-06
also O 0 3.5159337130608037e-07
predominant O 0 2.234155829228257e-07
in O 0 2.018025391237188e-08
our O 0 1.7661264450907765e-07
mutants O 0 2.7885354938916862e-05
. O 0 2.1030480183981126e-06

Six O 0 3.989978267782135e-06
different O 0 5.8548188519580435e-08
mutations O 0 5.538101959245978e-06
were O 0 3.4004267490672646e-06
identified O 0 6.980551916058175e-06
on O 0 4.627463283668476e-07
12 O 0 3.718413665865228e-07
of O 0 1.8126591783129697e-08
the O 0 2.8089030479350185e-07
16 O 0 7.431925496348413e-06
alleles O 0 2.595267460492323e-06
examined O 0 6.397221295628697e-05
. O 0 4.657126282836543e-06

Four O 0 1.2886611330031883e-05
were O 0 5.774375495093409e-06
deletions O 0 1.7559856132720597e-05
involving O 0 7.768863724777475e-05
a O 0 3.448978895903565e-05
loss O 0 0.0009238061611540616
of O 0 4.045177703915215e-08
a O 0 1.487741059236214e-07
single O 0 5.95118308410747e-07
exon O 0 3.7467452784767374e-05
exon O 0 4.6875615225872025e-05
7 O 0 2.2659485239273636e-06
, O 0 1.0987567122811015e-07
exon O 0 8.231391802837607e-06
16 O 0 4.261799801952293e-07
, O 0 3.253400038261134e-08
exon O 0 3.607920689319144e-06
33 O 0 6.561000418514595e-07
or O 0 4.621024629614112e-08
exon O 0 1.6048748875618912e-05
35 O 0 2.713396725084749e-06
. O 0 1.102432975130796e-06

The O 0 6.581683464901289e-06
others O 0 2.4578066586400382e-06
were O 0 7.581034822123911e-08
minute O 0 1.8989918260103877e-07
deletions O 0 4.960566911904607e-06
, O 0 2.5674887638160726e-07
4649delA O 0 6.063663477107184e-06
in O 0 6.19116704569933e-08
exon O 0 1.8997821825905703e-05
33 O 0 5.1183783398300875e-06
and O 0 2.786448476399528e-07
7883del5 O 0 2.7350747586751822e-06
in O 0 6.743534441966403e-08
exon O 0 6.085202767280862e-05
55 O 0 2.6671736122807488e-05
. O 0 2.779142050712835e-06

The O 0 3.416517301957356e-06
mutations O 0 3.947171353502199e-05
4612del165 O 0 7.611945329699665e-05
and O 0 1.596271431481e-06
7883del5 O 0 2.9617871405207552e-05
were O 0 2.2306312530417927e-06
found O 0 4.906723347630759e-07
in O 0 9.037863790695155e-09
more O 0 1.8292390935314984e-09
than O 0 6.584856215852142e-09
two O 0 8.617120528242594e-08
unrelated O 0 6.038575520506129e-05
families O 0 3.16480804940511e-06
; O 0 6.501275606751733e-07
44 O 0 7.1979634412855376e-06
% O 0 2.2312664782475622e-07
( O 0 1.3108895302593737e-08
7 O 0 1.566966574273465e-07
of O 0 3.632920453355837e-08
16 O 0 1.7309092754658195e-06
) O 0 8.906149595588886e-09
of O 0 3.6136307279832636e-09
the O 0 3.117582636491534e-08
mutant O 0 2.2544927560375072e-05
alleles O 0 8.345517130692315e-07
had O 0 7.958974492794368e-07
one O 0 3.840216589168222e-09
of O 0 8.102941428944632e-09
the O 0 1.1293962387526335e-07
two O 0 2.3793543277861318e-06
mutations O 0 3.075488348258659e-05
. O 0 2.128542291757185e-06

The O 0 6.27945564701804e-06
4612del165 O 0 0.00025098404148593545
mutations O 0 1.0043590009445325e-05
in O 0 2.1750127032760247e-08
three O 0 3.6848064155492466e-08
different O 0 7.690933223614138e-09
families O 0 8.46296529743995e-07
were O 0 1.2090305290257675e-06
all O 0 2.74565312707864e-08
ascribed O 0 1.1483434718684293e-06
to O 0 1.4615579857490957e-08
the O 0 1.3014008004574862e-07
same O 0 2.297158516739728e-06
T O 1 0.5421555042266846
- O 0 0.003690243000164628
- O 0 0.0001472381700295955
> O 0 2.3023184780868178e-07
A O 0 2.2238751284930913e-08
substitution O 0 4.448157397973773e-09
at O 0 3.416095140096331e-08
the O 0 9.32639299122684e-09
splice O 0 3.7685470033466117e-06
donor O 0 9.666723599366378e-07
site O 0 2.3997813514142763e-07
in O 0 1.3205062998622452e-07
intron O 0 0.0002682313206605613
33 O 0 5.177387356525287e-05
. O 0 2.7785220026999013e-06

Microsatellite O 0 0.0037765633314847946
genotyping O 0 0.001158211030997336
around O 0 1.6433730252174428e-06
the O 0 3.6799184499614057e-07
ATM O 0 0.0003591436252463609
locus O 0 0.0002618942526169121
also O 0 2.0305880752857774e-05
indicated O 0 6.58689577903715e-06
that O 0 6.387926987372339e-08
a O 0 1.648122406550101e-06
common O 0 9.235404831997585e-06
haplotype O 0 0.0013815126148983836
was O 0 0.0006500416784547269
shared O 0 3.170794116158504e-07
by O 0 5.3375678987777064e-08
the O 0 6.631708515669743e-08
mutant O 0 8.587473530496936e-06
alleles O 0 2.0659471999806556e-07
in O 0 6.781068151440195e-08
both O 0 5.948907642050472e-07
mutations O 0 1.4775713680137414e-05
. O 0 2.2593671928916592e-06

This O 0 7.989697792254447e-07
suggests O 0 1.924322987179039e-06
that O 0 2.468790150089717e-08
these O 0 2.769282358983105e-09
two O 0 3.634369534211146e-07
founder O 0 0.014062106609344482
mutations O 0 7.026720413705334e-05
may O 0 1.0659000508894678e-06
be O 0 1.590420595221076e-08
predominant O 0 2.2158437218422478e-07
among O 0 1.4234571210636204e-07
Japanese O 0 6.357700385706266e-06
ATM O 0 0.00027894083177670836
mutant O 0 5.627086648019031e-05
alleles O 0 4.13791167375166e-06
. O 0 2.6020431960205315e-06

W474C O 0 0.0003317963273730129
amino O 0 6.6843736021837685e-06
acid O 0 3.2450261642225087e-06
substitution O 0 1.4349224386478454e-07
affects O 0 1.942305232205399e-07
early O 0 2.684645039607858e-08
processing O 0 3.434132622714969e-08
of O 0 1.921822256889527e-09
the O 0 6.698510190972229e-09
alpha O 0 5.351267873265897e-08
- O 0 2.4100103246382787e-07
subunit O 0 5.936883429313866e-09
of O 0 8.730507872201088e-09
beta O 0 3.4219456779283064e-07
- O 0 2.448134546284564e-05
hexosaminidase O 0 1.8094580809702165e-05
A O 0 1.5557438359792286e-07
and O 0 1.7934374341166404e-07
is O 0 3.726905504208844e-07
associated O 0 2.118148131557973e-06
with O 0 6.704298357362859e-06
subacute O 1 0.7709529995918274
G B-Disease 0 0.328624963760376
( I-Disease 0 1.7479004554843414e-06
M2 I-Disease 0 0.017267415300011635
) I-Disease 0 2.369040885241702e-06
gangliosidosis I-Disease 0 0.0004970672889612615
. O 0 2.9471702873706818e-06

Mutations O 0 0.000758358568418771
in O 0 4.668767701332399e-07
the O 0 2.7265900826023426e-07
HEXA O 0 0.005801527760922909
gene O 0 3.84258925123504e-07
, O 0 3.994252484318395e-09
encoding O 0 1.9782413485103234e-09
the O 0 8.143923757586435e-09
alpha O 0 9.705319570230131e-08
- O 0 4.0927722011474543e-07
subunit O 0 4.253465579751037e-09
of O 0 8.05277622362155e-09
beta O 0 4.601499483669613e-07
- O 0 9.026506450027227e-05
hexosaminidase O 0 9.921099990606308e-05
A O 0 6.828948357906484e-07
( O 0 3.357243727464265e-08
Hex O 0 3.514453783282079e-05
A O 0 1.44879834351741e-06
) O 0 3.5228065797809904e-08
, O 0 1.920892245266259e-08
that O 0 3.927162595118716e-09
abolish O 0 4.795290919901163e-07
Hex O 0 1.019676165014971e-05
A O 0 4.846248202738934e-07
enzyme O 0 4.484510554902954e-06
activity O 0 2.6798675207828637e-06
cause O 0 0.002867872826755047
Tay B-Disease 1 0.9999963045120239
- I-Disease 1 0.9999898672103882
Sachs I-Disease 1 0.9999992847442627
disease I-Disease 1 0.8390092253684998
( O 0 4.546850959741278e-06
TSD B-Disease 0 0.20909483730793
) O 0 4.3095658952552185e-07
, O 0 4.5049216623738175e-07
the O 0 2.028348035310046e-06
fatal O 0 0.4067157506942749
infantile B-Disease 0 0.022509777918457985
form I-Disease 0 1.909112825160264e-06
of I-Disease 0 2.463562850607559e-06
G I-Disease 0 0.328806608915329
( I-Disease 0 4.0708056303628837e-07
M2 I-Disease 0 0.00444774841889739
) I-Disease 0 4.7368300215566705e-07
gangliosidosis I-Disease 0 0.0001868965628091246
, I-Disease 0 4.5147709215598297e-07
Type I-Disease 0 1.1211603805350023e-06
1 I-Disease 0 3.009353576999274e-06
. O 0 3.491035840852419e-06

Less O 0 0.002251074882224202
severe O 1 0.8358383178710938
, O 0 8.42251829453744e-05
subacute O 1 0.9303818345069885
( O 0 2.7724614483304322e-05
juvenile O 1 0.9963899254798889
- O 1 0.9985215067863464
onset O 1 0.7609872817993164
) O 0 5.824958498124033e-05
and O 0 0.009932605549693108
chronic O 1 0.9974671602249146
( O 0 1.6012587593650096e-06
adult O 0 4.037201142637059e-05
- O 1 0.6645158529281616
onset O 0 0.0007797523867338896
) O 0 2.2485950523787324e-07
variants O 0 6.021792842147988e-07
are O 0 2.2517602360494493e-07
characterized O 0 4.434167749423068e-06
by O 0 6.333454507512215e-07
a O 0 1.1896440810232889e-06
broad O 0 6.834819942014292e-06
spectrum O 0 6.40160360489972e-05
of O 0 1.641480935177242e-06
clinical O 0 4.4076023186789826e-05
manifestations O 0 8.54571771924384e-06
and O 0 3.137443627565517e-06
are O 0 1.9149611318880488e-07
associated O 0 5.383699885896931e-07
with O 0 8.387614229832252e-07
residual O 0 8.819780487101525e-05
levels O 0 2.0999483751893422e-07
of O 0 2.377624674920753e-08
Hex O 0 4.105929110664874e-05
A O 0 1.4295751498138998e-06
enzyme O 0 4.162284312769771e-06
activity O 0 5.787816235169885e-07
. O 0 7.672166475458653e-07

We O 0 3.7320594401535345e-06
identified O 0 1.630004589969758e-05
a O 0 2.5685321816126816e-06
1422 O 0 0.048533421009778976
G O 0 0.15708805620670319
- O 0 0.03500404953956604
- O 0 0.022015871480107307
> O 0 2.0835876057390124e-05
C O 0 8.241664181696251e-05
( O 0 1.7315494815761667e-08
amino O 0 9.880783835569673e-08
acid O 0 6.689192559861112e-07
W474C O 0 4.543061038475571e-07
) O 0 1.074364042175091e-09
substitution O 0 1.894514989331242e-09
in O 0 3.678140902962923e-09
the O 0 8.8945544263197e-09
first O 0 4.1344381429553323e-07
position O 0 2.961498353215575e-07
of O 0 3.9096985204878365e-08
exon O 0 4.125324994674884e-05
13 O 0 8.692160804457671e-07
of O 0 3.8245904221412275e-08
HEXA O 0 0.0002326542162336409
of O 0 7.999474860298506e-08
a O 0 2.001652546823607e-06
non O 0 2.148699786630459e-05
- O 0 0.0005482701817527413
Jewish O 0 2.9017617634963244e-05
proband O 0 0.0037415276747196913
who O 0 6.547039902216056e-06
manifested O 0 1.368895709674689e-06
a O 0 5.693059961231484e-07
subacute O 0 0.002518173772841692
variant O 0 1.9029172108275816e-05
of O 0 4.227297722536605e-06
G B-Disease 1 0.5664395093917847
( I-Disease 0 1.7291323501922307e-06
M2 I-Disease 0 0.010532117448747158
) I-Disease 0 1.012286475088331e-06
gangliosidosis I-Disease 0 0.00029958892264403403
. O 0 3.876646587741561e-06

On O 0 5.668330231856089e-06
the O 0 4.061204492700199e-07
second O 0 3.342932541272603e-05
maternally O 0 0.11492513120174408
inherited O 0 0.10928530991077423
allele O 0 8.384212378587108e-06
, O 0 3.8701907101312827e-07
we O 0 3.532131742645106e-08
identified O 0 1.1003637609974248e-06
the O 0 4.0667933376425935e-07
common O 0 0.00015728081052657217
infantile O 1 0.9874738454818726
disease O 0 0.37334248423576355
- O 0 0.007491184864193201
causing O 0 5.348734703147784e-05
4 O 0 2.0804209270863794e-06
- O 0 0.0002493689826223999
bp O 0 0.00016957348270807415
insertion O 0 1.5390610315080266e-06
, O 0 2.7039658334615524e-07
+ O 0 3.4829781725420617e-06
TATC O 0 0.00022588687716051936
1278 O 0 5.404153489507735e-05
, O 0 2.8067947965837448e-08
in O 0 2.2657225429156824e-08
exon O 0 2.846495590347331e-05
11 O 0 5.036859420215478e-06
. O 0 1.9947808596043615e-06

Pulse O 0 0.000130167551105842
- O 0 0.00026695316773839295
chase O 0 2.7340962333255447e-05
analysis O 0 9.970556646976547e-08
using O 0 1.287027941998531e-07
proband O 0 0.00013218105596024543
fibroblasts O 0 1.4031154933036305e-05
revealed O 0 1.3555223631556146e-05
that O 0 1.1869267346753531e-08
the O 0 1.3207904991929809e-08
W474C O 0 2.126937033608556e-06
- O 0 1.1861706070703804e-06
containing O 0 2.7385455680928317e-08
alpha O 0 6.03669576548782e-08
- O 0 2.9624075637002534e-07
subunit O 0 1.0939070982374233e-08
precursor O 0 2.84951198636918e-07
was O 0 1.063108243215538e-06
normally O 0 2.0693558866469175e-08
synthesized O 0 4.170594252173032e-07
, O 0 2.856078928914485e-08
but O 0 1.0190715826752239e-08
not O 0 2.494614514958471e-09
phosphorylated O 0 2.7073124897469825e-07
or O 0 3.966997397242267e-08
secreted O 0 4.3230383539594186e-07
, O 0 3.9249108851890924e-08
and O 0 5.6686051408405547e-08
the O 0 1.0700804864427482e-07
mature O 0 3.29463819070952e-06
lysosomal O 0 0.0001834505092119798
alpha O 0 1.0112993322763941e-06
- O 0 6.885679340484785e-06
subunit O 0 1.9109877769096784e-07
was O 0 4.59767943539191e-06
not O 0 2.0109446552396548e-07
detected O 0 3.389234962014598e-06
. O 0 8.294165354527649e-07

When O 0 5.205246452533174e-06
the O 0 2.1543692696468497e-07
W474C O 0 6.044939254934434e-06
- O 0 4.547136541077634e-06
containing O 0 7.446680427847241e-08
alpha O 0 9.421459878922178e-08
- O 0 6.692976626254676e-07
subunit O 0 7.883058827928835e-08
was O 0 7.773295692459214e-06
transiently O 0 4.388368324725889e-05
co O 0 0.00013181152462493628
- O 0 8.38886116980575e-05
expressed O 0 1.2720408903987845e-07
with O 0 9.484906193790721e-09
the O 0 9.463004602139335e-09
beta O 0 7.042942229418259e-08
- O 0 8.512901672474982e-07
subunit O 0 9.704131720411624e-09
to O 0 1.94830707123117e-09
produce O 0 1.0690356155862446e-08
Hex O 0 6.642558673775056e-06
A O 0 7.643217827535409e-07
( O 0 5.103080624735412e-08
alphabeta O 0 3.42152634402737e-05
) O 0 4.1854157473153464e-08
in O 0 1.5153287336033827e-07
COS O 0 0.18254424631595612
- O 0 0.00012818323739338666
7 O 0 8.084856744972058e-06
cells O 0 6.170783422021486e-07
, O 0 2.117306330262636e-08
the O 0 5.115990742154963e-09
mature O 0 4.138524545282962e-08
alpha O 0 7.24106570260119e-08
- O 0 8.724475151211664e-07
subunit O 0 7.893891762478233e-08
was O 0 3.3726391848176718e-06
present O 0 3.626184508220831e-08
, O 0 6.658540030457516e-08
but O 0 1.0995907295807683e-08
its O 0 4.398121422610757e-09
level O 0 9.2894161696222e-08
was O 0 1.3160876051188097e-06
much O 0 1.593873477645502e-08
lower O 0 4.086036540229543e-07
than O 0 2.307163349257735e-09
that O 0 1.9275194773626936e-09
from O 0 2.7039404049133964e-09
normal O 0 3.5925189489915965e-09
alpha O 0 8.944915919073537e-08
- O 0 1.7538213796797208e-06
subunit O 0 1.7413354669315595e-07
transfections O 0 1.284191785089206e-05
, O 0 1.7465954016415708e-08
although O 0 3.40834227507969e-09
higher O 0 1.2708727403776265e-08
than O 0 2.1068553568426296e-09
in O 0 3.420272731702312e-09
those O 0 1.697825169344469e-08
cells O 0 1.9931026429276244e-07
transfected O 0 2.0272977963031735e-06
with O 0 1.2260060522351068e-08
an O 0 5.6677944115790524e-08
alpha O 0 9.015172963700024e-07
- O 0 2.1124284103279933e-05
subunit O 0 8.785249292486697e-07
associated O 0 3.3709898161760066e-06
with O 0 5.106218850414734e-06
infantile O 0 0.13276387751102448
TSD B-Disease 0 0.3725471496582031
. O 0 1.8607366655487567e-05

Furthermore O 0 6.0351794672897086e-05
, O 0 1.1182260095665697e-06
the O 0 7.14297172521583e-08
precursor O 0 8.378012807952473e-07
level O 0 2.557863787444603e-08
of O 0 4.6006194409642376e-09
the O 0 1.0308304432271598e-08
W474C O 0 1.0088180033562821e-06
alpha O 0 8.139004847862452e-08
- O 0 1.4141440942694317e-06
subunit O 0 7.797640222406699e-08
was O 0 3.006333145094686e-06
found O 0 1.9884492985511315e-07
to O 0 1.282096651067377e-08
accumulate O 0 1.4256188478611875e-06
in O 0 6.20737505840907e-09
comparison O 0 1.7403667840198978e-08
to O 0 1.326746046359517e-09
the O 0 1.5892159810348971e-09
normal O 0 6.289560428029972e-09
alpha O 0 7.579733107831998e-08
- O 0 1.708342324491241e-06
subunit O 0 1.21157171406594e-07
precursor O 0 1.456607833461021e-06
levels O 0 6.524761033688264e-07
. O 0 3.494106124435348e-07

We O 0 1.126139068219345e-06
conclude O 0 2.109954493789701e-06
that O 0 4.896084604411044e-08
the O 0 1.632322295108679e-07
1422 O 0 0.010773594491183758
G O 0 0.027300652116537094
- O 0 0.004798611160367727
- O 0 0.0053424471989274025
> O 0 1.9285085727460682e-05
C O 0 0.00013459920592140406
mutation O 0 5.329592340785894e-07
is O 0 3.182523755640432e-08
the O 0 1.022627387214925e-07
cause O 0 8.479486837131844e-07
of O 0 4.4792696485274064e-07
Hex B-Disease 1 0.5762594938278198
A I-Disease 0 0.22327348589897156
enzyme I-Disease 1 0.9999430179595947
deficiency I-Disease 1 0.9991669654846191
in O 0 2.2284658030002902e-07
the O 0 1.8029841157840565e-06
proband O 0 0.004008704796433449
. O 0 5.719001364923315e-06

The O 0 1.6028294567149715e-06
resulting O 0 4.58866088592913e-06
W474C O 0 1.1344204722263385e-05
substitution O 0 1.4071001430693286e-07
clearly O 0 3.378384292318515e-07
interferes O 0 1.0536210481859598e-07
with O 0 1.6066593389041373e-08
alpha O 0 2.4327744085894665e-07
- O 0 1.3290587048686575e-06
subunit O 0 2.438901880452704e-08
processing O 0 3.306008409253991e-07
, O 0 5.2863015298498794e-08
but O 0 8.322513345149218e-09
because O 0 1.5314388646103794e-09
the O 0 2.4092088324323413e-09
base O 0 1.1952739953358105e-07
substitution O 0 1.6599800289895938e-07
falls O 0 0.00022300668933894485
at O 0 1.854881475082948e-07
the O 0 1.65059290679892e-08
first O 0 2.155511822365952e-07
position O 0 7.543992808223265e-08
of O 0 2.0811949497101523e-08
exon O 0 5.953846266493201e-05
13 O 0 1.68533290434425e-06
, O 0 4.4993488046429775e-08
aberrant O 0 1.1043639460694976e-06
splicing O 0 2.663456598384073e-06
may O 0 1.065966102942184e-06
also O 0 1.6882964359865582e-07
contribute O 0 1.5243644213569496e-07
to O 0 1.573588690462202e-07
Hex B-Disease 0 0.023245474323630333
A I-Disease 0 0.004445447586476803
deficiency I-Disease 0 0.036153897643089294
in O 0 3.184582197945929e-08
this O 0 4.233475792148056e-08
proband O 0 0.0003147787065245211
. O 0 2.49745852443084e-07
. O 0 1.2695373925453168e-06

Two O 0 5.840892754349625e-06
frequent O 0 4.253795850672759e-05
missense O 0 0.004708182066679001
mutations O 0 0.008298219181597233
in O 0 0.0044683669693768024
Pendred B-Disease 1 0.9999432563781738
syndrome I-Disease 1 0.9999724626541138
. O 0 0.0005111467908136547

Pendred B-Disease 1 0.9999086856842041
syndrome I-Disease 1 0.9999912977218628
is O 0 0.24787305295467377
an O 1 0.9956790804862976
autosomal B-Disease 1 0.9999986886978149
recessive I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999998807907104
characterized O 1 0.943896472454071
by O 0 0.02222444862127304
early O 1 0.5556594133377075
childhood O 1 0.9987493753433228
deafness B-Disease 1 0.9999986886978149
and O 1 0.9873915314674377
goiter B-Disease 1 0.9999881982803345
. O 0 0.0010048489784821868

A O 0 5.988399061607197e-05
century O 0 1.4204388207872398e-05
after O 0 6.2091044128465e-06
its O 0 5.250348422691786e-08
recognition O 0 3.7123547258488543e-07
as O 0 2.228823632322019e-06
a O 0 0.0018964920891448855
syndrome O 1 0.9606456160545349
by O 0 3.259650611653342e-06
Vaughan O 0 0.04357333853840828
Pendred O 0 0.0036649901885539293
, O 0 1.0376062391515006e-06
the O 0 5.795107426820323e-06
disease O 0 0.002106321509927511
gene O 0 1.5188168163149385e-06
( O 0 4.682358678564924e-07
PDS O 0 0.001309873885475099
) O 0 2.9011891911068233e-07
was O 0 7.405797077808529e-06
mapped O 0 1.91809067473514e-05
to O 0 1.2308324812693172e-06
chromosome O 0 0.0020248116925358772
7q22 O 0 0.00030106378835625947
- O 0 0.0007593196351081133
q31 O 0 0.00011248705413891003
. O 0 2.6065138172270963e-06

1 O 0 2.9423450541798957e-05
and O 0 6.342730102915084e-06
, O 0 2.763303882602486e-06
recently O 0 8.52254088385962e-05
, O 0 1.9651594129754812e-07
found O 0 1.2591350184720795e-07
to O 0 4.875989390029645e-09
encode O 0 1.362769381785256e-07
a O 0 3.025970272574341e-06
putative O 0 0.0007684390875510871
sulfate O 0 0.013804526999592781
transporter O 0 0.017127875238656998
. O 0 1.1561825886019506e-05

We O 0 1.3742350120082847e-06
performed O 0 2.7046824015997117e-06
mutation O 0 2.1584740750313358e-07
analysis O 0 1.7617283631921055e-08
of O 0 4.048666824019165e-08
the O 0 4.670923203775601e-07
PDS B-Disease 0 0.0035549707245081663
gene O 0 2.137213414243888e-06
in O 0 1.5137284208321944e-06
patients O 0 3.2580376227997476e-06
from O 0 2.443181301714503e-07
14 O 0 5.817255896545248e-06
Pendred B-Disease 0 4.42520686192438e-05
families O 0 1.5127139363357855e-07
originating O 0 2.9373243393138182e-08
from O 0 2.536932264263214e-08
seven O 0 2.00812365847014e-07
countries O 0 2.1101541847201588e-08
and O 0 2.511588945708354e-07
identified O 0 2.0163342924206518e-06
all O 0 1.4358532496316911e-07
mutations O 0 5.26081112184329e-06
. O 0 1.8744901808531722e-06

The O 0 8.48508807393955e-06
mutations O 0 4.9112699343822896e-05
include O 0 6.241152732400224e-07
three O 0 1.5988753432338854e-07
single O 0 1.7584873148734914e-06
base O 0 3.854253009194508e-06
deletions O 0 6.271023266890552e-06
, O 0 8.84760567032572e-08
one O 0 1.1408490152575723e-08
splice O 0 3.5661660149344243e-06
site O 0 1.0837329682544805e-06
mutation O 0 3.143110802739102e-07
and O 0 1.2039181740419735e-07
10 O 0 7.611067758261925e-07
missense O 0 0.0002311947609996423
mutations O 0 2.3803826479706913e-05
. O 0 2.7493222205521306e-06

One O 0 1.0214348549197894e-05
missense O 0 0.0013195467181503773
mutation O 0 0.00013149692676961422
( O 0 7.08168897745054e-07
L236P O 0 0.00013999045768287033
) O 0 7.857439641156816e-07
was O 0 2.0007550119771622e-05
found O 0 9.59810222411761e-07
in O 0 6.469047519885862e-08
a O 0 7.35481421543227e-07
homozygous O 0 1.2415924175002147e-05
state O 0 1.7872790181172604e-07
in O 0 3.390241687384332e-08
two O 0 3.323210648886743e-07
consanguineous O 0 0.0020956078078597784
families O 0 8.181834346032701e-06
and O 0 1.3908688742958475e-06
in O 0 1.2923079850679642e-07
a O 0 4.1866292121994775e-07
heterozygous O 0 1.1307730574117159e-06
state O 0 1.03111403859657e-07
in O 0 1.231363366827054e-08
five O 0 1.0329919319929104e-07
additional O 0 2.1540446937251545e-07
non O 0 1.3824747838953044e-05
- O 0 0.00040173891466110945
consanguineous O 0 0.000606878544203937
families O 0 1.2368083844194189e-05
. O 0 5.34639866600628e-06

Another O 0 2.8533228032756597e-05
missense O 0 0.0024318171199411154
mutation O 0 0.00024267575645353645
( O 0 9.66058451012941e-07
T416P O 0 0.00017415349429938942
) O 0 8.947115475166356e-07
was O 0 7.304277824005112e-05
found O 0 2.670051117092953e-06
in O 0 1.0170389685981718e-07
a O 0 1.064668708750105e-06
homozygous O 0 1.205357057187939e-05
state O 0 3.5468428905005567e-07
in O 0 2.3643433166853356e-07
one O 0 6.944225674487825e-07
family O 0 6.068552465876564e-06
and O 0 6.775352403565194e-07
in O 0 1.1355631812648426e-07
a O 0 4.2783165099535836e-07
heterozygous O 0 1.1943309345952002e-06
state O 0 2.6030159006040776e-07
in O 0 4.619209192924245e-08
four O 0 5.38539495664736e-07
families O 0 6.026088158250786e-06
. O 0 6.023623427608982e-06

Pendred B-Disease 1 0.8595261573791504
patients O 0 0.011657818220555782
in O 0 8.052193152252585e-07
three O 0 1.4260076568461955e-06
non O 0 4.9612950533628464e-05
- O 0 0.01798788458108902
consanguineous O 0 0.0029326332733035088
families O 0 5.165783932170598e-06
were O 0 3.423261659918353e-06
shown O 0 1.142938188536391e-07
to O 0 8.849069921268438e-09
be O 0 1.4811886828169918e-08
compound O 0 9.554597824035227e-08
heterozygotes O 0 1.940422180268797e-06
for O 0 1.1734213245517822e-07
L236P O 0 1.234159844898386e-05
and O 0 1.1660447398753604e-06
T416P O 0 6.180600030347705e-05
. O 0 2.015719246628578e-06

In O 0 6.713012226100545e-06
total O 0 4.768630333273904e-06
, O 0 4.662263108912157e-07
one O 0 6.451635670146061e-08
or O 0 4.3049933395877815e-08
both O 0 1.0002018768773269e-08
of O 0 9.737189721192863e-09
these O 0 1.7989474798696392e-08
mutations O 0 1.962430360435974e-06
were O 0 1.3041156989856972e-06
found O 0 1.0912219750025542e-06
in O 0 3.644962731641499e-08
nine O 0 3.001211723585584e-07
of O 0 3.9845296839757793e-08
the O 0 1.5890537952145678e-07
14 O 0 2.976873020088533e-06
families O 0 8.629413059679791e-07
analyzed O 0 1.6245143342530355e-05
. O 0 4.496072961046593e-06

The O 0 8.00260124833585e-07
identification O 0 3.8674383517900424e-07
of O 0 4.410741638594118e-08
two O 0 3.7794924878653546e-07
frequent O 0 6.377022600645432e-06
PDS B-Disease 0 0.006954515818506479
mutations O 0 3.3358976452291245e-06
will O 0 1.6859079465803006e-08
facilitate O 0 3.437159890040675e-08
the O 0 2.1259445759369555e-07
molecular O 0 0.0005205641500651836
diagnosis O 0 0.005941153038293123
of O 0 0.011183534748852253
Pendred B-Disease 1 0.9999921321868896
syndrome I-Disease 1 0.9999808073043823
. O 0 0.0002291994751431048

Insertional O 0 0.007970361039042473
mutation O 0 5.186573980608955e-05
by O 0 7.612925969624484e-07
transposable O 0 0.0002586707123555243
element O 0 4.511427960096626e-06
, O 0 5.16730324306991e-07
L1 O 0 0.0007972904713824391
, O 0 3.535627399742225e-07
in O 0 2.646085484059313e-08
the O 0 6.798907179472735e-07
DMD B-Disease 1 0.9993440508842468
gene O 0 5.24505878729542e-07
results O 0 5.928597488491505e-07
in O 0 9.76860974333249e-07
X B-Disease 1 0.9254005551338196
- I-Disease 1 0.999251663684845
linked I-Disease 1 0.997829258441925
dilated I-Disease 1 0.9989068508148193
cardiomyopathy I-Disease 1 0.9997220635414124
. O 0 3.8449357816716656e-05

X B-Disease 1 0.9788954257965088
- I-Disease 1 0.9994537234306335
linked I-Disease 1 0.9997950196266174
dilated I-Disease 1 0.9999054670333862
cardiomyopathy I-Disease 1 0.9999898672103882
( O 0 0.00010569773439783603
XLDCM B-Disease 1 0.7990837693214417
) O 0 5.784030463473755e-07
is O 0 9.033455228291132e-08
a O 0 1.0800639529406908e-06
clinical O 0 1.9842731489916332e-05
phenotype O 0 1.5659161363146268e-05
of O 0 4.3485675860210904e-07
dystrophinopathy B-Disease 0 0.11568978428840637
which O 0 2.051453293461236e-06
is O 0 5.04616878060915e-07
characterized O 0 3.254727062085294e-06
by O 0 1.4479667242994765e-06
preferential O 0 0.0003255043993704021
myocardial B-Disease 1 0.9966585636138916
involvement I-Disease 0 4.81192946608644e-05
without O 0 1.8009066593549505e-07
any O 0 6.715809064417044e-08
overt O 0 1.4503171769320033e-05
clinical O 0 0.00047226142487488687
signs O 0 0.0022727942559868097
of O 0 0.00611412338912487
skeletal B-Disease 1 0.9999926090240479
myopathy I-Disease 1 0.999995231628418
. O 0 0.000932976312469691

To O 0 2.2465062556875637e-06
date O 0 2.468635784680373e-06
, O 0 1.7820283915170876e-07
several O 0 5.568398719901779e-08
mutations O 0 1.6825064221848152e-06
in O 0 4.260743367012765e-07
the O 0 0.0006160216871649027
Duchenne B-Disease 1 0.999985933303833
muscular I-Disease 1 0.9999740123748779
dystrophy I-Disease 1 0.9999401569366455
gene O 0 0.0005022421246394515
, O 0 0.0005531691713258624
DMD O 1 0.9999933242797852
, O 0 0.0001966924755834043
have O 0 3.041216359633836e-06
been O 0 3.066036470045219e-06
identified O 0 2.7401412808103487e-05
in O 0 2.839081844285829e-06
patients O 0 1.6154963304870762e-05
with O 0 2.4320675038325135e-06
XLDCM B-Disease 0 0.48298418521881104
, O 0 1.1120441740786191e-06
but O 0 3.858021813130108e-08
a O 0 8.562171416315323e-08
pathogenic O 0 1.4702932560339832e-07
correlation O 0 4.4426233358763056e-08
of O 0 1.5691087540403714e-08
these O 0 2.624822315056008e-08
cardiospecific O 0 0.0015048834029585123
mutations O 0 5.040328687755391e-06
in O 0 1.1339629963913467e-06
DMD O 1 0.9996603727340698
with O 0 1.4706117781315697e-06
the O 0 3.84571285394486e-06
XLDCM B-Disease 1 0.6646320223808289
phenotype O 0 0.0007373730186372995
has O 0 8.30234512250172e-06
remained O 0 1.6004731151042506e-05
to O 0 1.2944099125888897e-07
be O 0 4.47587041207953e-07
elucidated O 0 0.00015382867422886193
. O 0 3.1900253816274926e-06

We O 0 5.741275799664436e-06
report O 0 8.16872272935143e-07
here O 0 1.9515736582320642e-08
the O 0 5.227991373146779e-09
identification O 0 3.29069500537571e-08
of O 0 1.8262628742604647e-08
a O 0 1.7367399607337575e-07
unique O 0 3.509159540726614e-08
de O 0 5.449333002616186e-07
novo O 0 4.3031633367718314e-07
L1 O 0 1.352481558569707e-05
insertion O 0 3.623277962105931e-07
in O 0 3.8593025664113156e-08
the O 0 1.8457619432865613e-07
muscle O 0 1.1154163075843826e-05
exon O 0 1.4059055502002593e-05
1 O 0 5.09592211983545e-07
in O 0 8.81507617123134e-07
DMD O 1 0.9993245601654053
in O 0 3.816596745309653e-07
three O 0 3.543533239280805e-06
XLDCM B-Disease 1 0.9037172198295593
patients O 0 1.2402267202560324e-05
from O 0 3.7918027828709455e-08
two O 0 2.8226250492480176e-07
unrelated O 0 0.00012902887829113752
Japanese O 0 0.00017959027900360525
families O 0 2.4058450435404666e-05
. O 0 1.0220760486845393e-05

The O 0 1.9323483684274834e-06
insertion O 0 3.943874980905093e-05
was O 0 3.2260253647109494e-05
a O 0 8.113149760902161e-07
5 O 0 2.0202917312417412e-06
- O 0 0.0001625509321456775
truncated O 0 7.663581413908105e-07
form O 0 2.1395123894762946e-08
of O 0 8.290826691847997e-09
human O 0 9.572491421749874e-08
L1 O 0 4.176706715952605e-05
inversely O 0 1.302167493122397e-05
integrated O 0 2.250155375804752e-06
in O 0 3.878015064628926e-08
the O 0 3.2157114304709467e-08
5 O 0 1.6973059473457397e-06
- O 0 0.0014645532937720418
untranslated O 0 0.000668010616209358
region O 0 2.469548974204372e-07
in O 0 3.3002304888896106e-08
the O 0 2.7298216309645795e-07
muscle O 0 3.294328780611977e-05
exon O 0 4.52008425781969e-05
1 O 0 2.213428388131433e-06
, O 0 3.6404679804036277e-07
which O 0 1.1747100359116303e-07
affected O 0 7.250601896657827e-08
the O 0 5.0640927895528876e-08
transcription O 0 7.141629225770885e-07
or O 0 1.6965796589829552e-07
the O 0 2.387957920291228e-07
stability O 0 1.1006439990524086e-06
of O 0 9.636112707767097e-08
the O 0 3.7673755741707282e-06
muscle O 0 9.169060649583116e-05
form O 0 4.990575774854733e-08
of O 0 6.488942716487145e-08
dystrophin O 0 1.5907346096355468e-05
transcripts O 0 2.6446327865414787e-06
but O 0 9.986106164205921e-08
not O 0 4.500101624671515e-09
that O 0 3.408140658578418e-09
of O 0 1.6462728069654986e-08
the O 0 1.7273114281124435e-06
brain O 0 0.00435717822983861
or O 0 2.6144975890929345e-06
Purkinje O 0 0.19782844185829163
cell O 0 0.0028924262151122093
form O 0 3.590720098145539e-06
, O 0 7.581390036648372e-06
probably O 0 1.1264558452239726e-05
due O 0 4.554948134227743e-07
to O 0 1.555775774875201e-08
its O 0 2.422055445094884e-08
unique O 0 3.381433089089114e-08
site O 0 2.0006763179480913e-07
of O 0 4.745303172626336e-08
integration O 0 1.5501485904678702e-05
. O 0 8.963436812337022e-06

We O 0 2.5277417989855167e-06
speculate O 0 2.0766526631632587e-06
that O 0 1.1632015350926395e-08
this O 0 9.080954321838419e-10
insertion O 0 8.178936639069434e-08
of O 0 2.6695005317378673e-08
an O 0 1.3197559667332825e-07
L1 O 0 7.062903023324907e-05
sequence O 0 2.999577475293336e-07
in O 0 3.4936304018629016e-06
DMD O 1 0.999932050704956
is O 0 1.4470143696598825e-06
responsible O 0 1.1206365115867811e-06
for O 0 4.227424099667587e-08
some O 0 2.912474927896369e-09
of O 0 3.90982357600933e-09
the O 0 3.5870158399120555e-08
population O 0 2.3097181056641602e-08
of O 0 9.123845501335381e-08
Japanese O 0 0.0009465600596740842
patients O 0 4.795364020537818e-06
with O 0 4.2240071707055904e-07
XLDCM B-Disease 0 0.012847869656980038
. O 0 6.246773978091369e-07
. O 0 1.4837512480880832e-06

Severe O 1 0.6545594930648804
early O 0 0.0008443437982350588
- O 1 0.9987713694572449
onset O 1 0.9992687106132507
obesity B-Disease 1 0.9999924898147583
, O 0 0.4568116068840027
adrenal B-Disease 1 0.9999620914459229
insufficiency I-Disease 1 0.9999796152114868
and O 0 0.002031537238508463
red O 0 0.3781195878982544
hair O 1 0.8754492402076721
pigmentation O 0 0.005314402282238007
caused O 0 4.2603729525581e-05
by O 0 7.707566510362085e-06
POMC O 0 0.28428950905799866
mutations O 0 3.369864134583622e-05
in O 0 1.2099176274205092e-06
humans O 0 3.750638143174001e-06
. O 0 3.0782950943830656e-06

Sequential O 0 1.0822377589647658e-05
cleavage O 0 0.00012199844786664471
of O 0 1.7385428918714751e-07
the O 0 6.570355282065066e-08
precursor O 0 1.64016023518343e-06
protein O 0 2.515501194011449e-07
pre O 0 1.8020567949861288e-05
- O 0 0.0012711453018710017
pro O 0 0.0005014230264350772
- O 0 0.016661204397678375
opiomelanocortin O 0 0.0027375028003007174
( O 0 8.508642679316836e-08
POMC O 0 1.8542370526120067e-05
) O 0 3.080038224467785e-09
generates O 0 4.035066059060455e-09
the O 0 1.9204819068363577e-08
melanocortin O 0 0.00020057646906934679
peptides O 0 1.3156836757843848e-05
adrenocorticotrophin O 0 0.0001242473954334855
( O 0 2.2805814126058976e-07
ACTH O 0 1.4560741874447558e-05
) O 0 2.6238963002356286e-08
, O 0 6.299804766740635e-08
melanocyte O 0 0.0001624246360734105
- O 0 0.000966921856161207
stimulating O 0 5.322915967553854e-05
hormones O 0 4.603202796715777e-06
( O 0 3.402900716764634e-08
MSH O 0 1.9269604308647104e-05
) O 0 4.1063552558284755e-09
alpha O 0 4.244196460945204e-08
, O 0 5.9437836874565164e-09
beta O 0 1.352555756284346e-08
and O 0 2.331979587211208e-08
gamma O 0 1.4600470876757754e-07
as O 0 1.8194274531424526e-08
well O 0 3.2204114930323158e-09
as O 0 5.733978181154953e-09
the O 0 2.366914664264641e-08
opioid O 0 2.6320993129047565e-05
- O 0 2.05994783755159e-05
receptor O 0 1.989673819480231e-06
ligand O 0 1.7408652865924523e-06
beta O 0 3.0640985642094165e-06
- O 0 0.00022791788796894252
endorphin O 0 0.000572837539948523
. O 0 2.1755577108706348e-06

While O 0 2.8733600629493594e-05
a O 0 1.9742483345908113e-06
few O 0 1.1050976667092982e-07
cases O 0 6.83068151374755e-07
of O 0 6.948943337192759e-06
isolated O 0 0.30871686339378357
ACTH B-Disease 1 0.9952074885368347
deficiency I-Disease 1 0.9856228828430176
have O 0 2.900043455156265e-06
been O 0 1.881643220258411e-05
reported O 0 8.096562669379637e-05
( O 0 1.1297685205136077e-06
OMIM O 0 0.016987808048725128
201400 O 0 8.268230885732919e-05
) O 0 1.8633775766829785e-07
, O 0 4.032606284454232e-07
an O 0 1.6515161405550316e-05
inherited O 1 0.9754272699356079
POMC O 1 0.9976716637611389
defect O 1 0.7210953831672668
has O 0 1.0421192200738005e-05
not O 0 2.0731590666400734e-07
been O 0 3.0539404178853147e-06
described O 0 5.216806130192708e-06
so O 0 1.6601478591837804e-07
far O 0 1.0093376658915076e-06
. O 0 2.191690782638034e-06

Recent O 0 3.946918877772987e-05
studies O 0 3.0741700811631745e-06
in O 0 2.0435867043033795e-07
animal O 0 7.398516004286648e-07
models O 0 5.233030151430285e-06
elucidated O 0 3.92343063140288e-05
a O 0 1.6362733390451467e-07
central O 0 3.549339311348376e-08
role O 0 1.1628726070966877e-07
of O 0 2.812475230484779e-08
alpha O 0 4.765338871948188e-06
- O 0 0.0004235281085129827
MSH O 0 7.868023385526612e-05
in O 0 8.167895693134142e-09
the O 0 6.170345123734933e-09
regulation O 0 8.838261322807739e-08
of O 0 9.902060504884957e-09
food O 0 3.941249460126528e-08
intake O 0 1.7667153073830377e-08
by O 0 2.1184241028038286e-09
activation O 0 2.4899476258610775e-08
of O 0 1.0804040329048803e-08
the O 0 5.853255515830824e-07
brain O 0 0.0003711065510287881
melanocortin O 0 0.00020609326020348817
- O 0 4.208459722576663e-05
4 O 0 3.191026507920469e-06
- O 0 0.0005814716569148004
receptor O 0 3.0168619105097605e-06
( O 0 1.2529623916179844e-07
MC4 O 0 0.0008626841008663177
- O 0 0.004035815596580505
R O 0 0.008678709156811237
; O 0 2.710484920953604e-07
refs O 0 3.519778829286224e-06
3 O 0 9.020935181069945e-07
- O 0 4.7093773900996894e-05
5 O 0 4.824519237445202e-07
) O 0 8.682614627275598e-09
and O 0 1.0693924856752801e-08
the O 0 1.2437721963465265e-08
linkage O 0 1.7583497537998483e-06
of O 0 1.1029399047401967e-06
human O 0 0.0004382773768156767
obesity B-Disease 1 0.9923651814460754
to O 0 5.642166343022836e-07
chromosome O 0 8.914041245589033e-05
2 O 0 1.980830347747542e-06
in O 0 8.16881851051221e-08
close O 0 5.718449642699852e-07
proximity O 0 1.3780498875348712e-07
to O 0 1.8778413490849744e-08
the O 0 1.939203428946712e-07
POMC O 0 0.0002991142973769456
locus O 0 6.841765298304381e-06
, O 0 2.8398596896295203e-07
led O 0 1.0560298733253148e-06
to O 0 2.1392347449022964e-08
the O 0 6.932891949418263e-08
proposal O 0 6.875993676658254e-07
of O 0 5.172815065179748e-08
an O 0 1.2620746474567568e-06
association O 0 3.5937002849095734e-06
of O 0 4.921584491057729e-07
POMC O 0 0.013654585927724838
with O 0 7.365719284280203e-06
human O 0 0.0003321232507005334
obesity B-Disease 1 0.99825519323349
. O 0 2.6322046323912218e-05

The O 0 1.5981344176907442e-06
dual O 0 5.436379524326185e-06
role O 0 3.2162455454454175e-07
of O 0 4.294570032925549e-08
alpha O 0 3.6577257560566068e-06
- O 0 0.00032682251185178757
MSH O 0 0.0001757730497047305
in O 0 2.747009908432574e-08
regulating O 0 3.1132930189414765e-07
food O 0 3.3743329908020314e-08
intake O 0 6.749041148168544e-08
and O 0 3.0289122321391915e-08
influencing O 0 3.9496135286754e-06
hair O 0 0.002492871368303895
pigmentation O 0 3.0238150429795496e-05
predicts O 0 6.344391294987872e-05
that O 0 1.1808765520981979e-07
the O 0 6.709253739245469e-07
phenotype O 0 0.00012030820653308183
associated O 0 3.05074718198739e-06
with O 0 3.0843425520288292e-06
a O 0 0.0007806311477907002
defect O 0 0.15679191052913666
in O 0 6.039683739800239e-06
POMC O 0 0.06298036873340607
function O 0 7.918786764093966e-07
would O 0 7.473707341887348e-07
include O 0 2.1804366042488255e-05
obesity B-Disease 1 0.9984753727912903
, O 0 7.940900104586035e-06
alteration O 0 0.00010698677215259522
in O 0 5.864407739863964e-06
pigmentation O 0 0.01716804876923561
and O 0 0.011625281535089016
ACTH B-Disease 1 0.9903871417045593
deficiency I-Disease 1 0.858640730381012
. O 0 1.4022191862750333e-05

The O 0 2.02389992409735e-06
observation O 0 1.0454078619659413e-05
of O 0 8.66279890487931e-07
these O 0 1.0675449857444619e-06
symptoms O 0 3.4172840969404206e-05
in O 0 1.0137213735106343e-07
two O 0 1.4804196553086513e-06
probands O 0 0.03894016891717911
prompted O 0 4.748381797980983e-06
us O 0 2.403297116870817e-07
to O 0 2.9871436435513488e-09
search O 0 1.1844729641552476e-08
for O 0 7.504526422508206e-08
mutations O 0 2.04518940449816e-07
within O 0 1.2968262019796839e-08
their O 0 4.7542314973725297e-07
POMC O 0 0.0030840719118714333
genes O 0 3.664160203697975e-06
. O 0 1.4878631873216364e-06

Patient O 0 0.0032848669216036797
1 O 0 6.106467481004074e-05
was O 0 0.00028584094252437353
found O 0 5.421805781224975e-06
to O 0 5.201794905929091e-08
be O 0 2.0483469143073307e-08
a O 0 8.085191183226925e-08
compound O 0 2.4916397478591534e-07
heterozygote O 0 3.632866309999372e-06
for O 0 4.481072224393756e-08
two O 0 1.9288303576558974e-07
mutations O 0 1.9941380742238835e-06
in O 0 1.8896915321420238e-07
exon O 0 0.00016254239017143846
3 O 0 6.784729521314148e-06
( O 0 9.694070968180313e-08
G7013T O 0 4.17101000493858e-06
, O 0 1.2584459341269394e-07
C7133delta O 0 1.892024010885507e-05
) O 0 1.49003787086599e-08
which O 0 4.00309163595125e-09
interfere O 0 6.142656161500781e-09
with O 0 2.4073485427322794e-09
appropriate O 0 1.5786842944010004e-09
synthesis O 0 7.614796793120604e-09
of O 0 2.3422948913776054e-08
ACTH O 0 1.8023627490038052e-05
and O 0 2.2312622149911476e-07
alpha O 0 6.194862180564087e-06
- O 0 0.00039581392775289714
MSH O 0 0.001149078831076622
. O 0 1.456278710065817e-06

Patient O 0 0.0019055468728765845
2 O 0 2.342931657040026e-05
was O 0 5.3389656386571005e-05
homozygous O 0 5.985555617371574e-06
for O 0 4.863128211241019e-08
a O 0 6.201129281180329e-07
mutation O 0 1.5957585901560378e-06
in O 0 1.5940352682264347e-07
exon O 0 0.0002827669377438724
2 O 0 1.0438140634505544e-05
( O 0 3.3619605233070615e-07
C3804A O 0 7.967610144987702e-06
) O 0 3.437383000459704e-08
which O 0 1.1190459048293633e-07
abolishes O 0 6.152714922791347e-05
POMC O 0 0.0011981935240328312
translation O 0 3.908106464223238e-06
. O 0 2.9339366847125348e-06

These O 0 9.011218935484067e-07
findings O 0 2.621581188577693e-06
represent O 0 1.5988447898962477e-07
the O 0 5.086017296207501e-08
first O 0 3.66582355582068e-07
examples O 0 1.7681183805962064e-07
of O 0 6.89361684180767e-07
a O 0 0.006820678245276213
genetic B-Disease 1 0.9993785619735718
defect I-Disease 1 0.9989016056060791
within O 0 3.272535025189427e-07
the O 0 2.878661007343908e-06
POMC O 0 0.02705428935587406
gene O 0 4.561342166198301e-07
and O 0 1.1413924738690184e-07
define O 0 6.516900157294003e-07
a O 0 6.785098776163068e-06
new O 0 0.012964893132448196
monogenic B-Disease 1 0.9997956156730652
endocrine I-Disease 1 0.9999221563339233
disorder I-Disease 0 0.11406440287828445
resulting O 0 2.278827923873905e-05
in O 0 2.7657056307361927e-06
early O 0 0.00024070734798442572
- O 1 0.9969692826271057
onset O 1 0.9640164375305176
obesity B-Disease 1 0.999983549118042
, O 0 0.017054907977581024
adrenal B-Disease 1 0.9998325109481812
insufficiency I-Disease 1 0.9999023675918579
and O 0 0.0006620093481615186
red O 0 0.02207689918577671
hair O 0 0.24907249212265015
pigmentation O 0 0.00041472725570201874
. O 0 7.362772294072784e-07
. O 0 8.36269828141667e-06

A O 0 0.000136451271828264
European O 0 0.00010292471415596083
multicenter O 1 0.754924476146698
study O 0 9.780554682947695e-05
of O 0 0.0011536478996276855
phenylalanine B-Disease 1 0.9999791383743286
hydroxylase I-Disease 1 0.9999837875366211
deficiency I-Disease 1 0.9999823570251465
: O 0 3.8078820807641023e-07
classification O 0 1.50954917899071e-06
of O 0 1.078403286669527e-07
105 O 0 4.6360368287423626e-05
mutations O 0 4.3513236960279755e-06
and O 0 1.6687417314642516e-07
a O 0 2.024923873022999e-07
general O 0 1.9159074327035341e-07
system O 0 1.630842518807185e-07
for O 0 2.9162825398998393e-07
genotype O 0 1.791877548384946e-05
- O 0 2.8510163247119635e-05
based O 0 9.266584584111115e-07
prediction O 0 4.453505425772164e-06
of O 0 1.2512673492892645e-06
metabolic O 0 0.1112184226512909
phenotype O 0 0.0003286052669864148
. O 0 8.835074368107598e-06

Phenylketonuria B-Disease 1 0.9721059203147888
( O 0 0.0002419950906187296
PKU B-Disease 0 0.24436582624912262
) O 0 1.3300019418238662e-05
and O 0 0.0009404714801348746
mild B-Disease 1 0.9398648738861084
hyperphenylalaninemia I-Disease 1 0.999997615814209
( O 0 0.02680264413356781
MHP B-Disease 1 0.9999909400939941
) O 0 1.2765213796228636e-05
are O 0 4.200180683255894e-06
allelic B-Disease 0 0.292843759059906
disorders I-Disease 1 0.9975639581680298
caused O 0 0.00025837001157924533
by O 0 2.7497180781210773e-06
mutations O 0 2.3129973669711035e-06
in O 0 2.0612292317423453e-08
the O 0 9.430125658127508e-08
gene O 0 8.932443620324193e-07
encoding O 0 3.0027654247533064e-06
phenylalanine O 0 0.008928759954869747
hydroxylase O 0 0.3623577356338501
( O 0 3.526613727444783e-05
PAH O 1 0.5450584888458252
) O 0 8.363268193534168e-07
. O 0 8.48097499783762e-07

Previous O 0 4.956168413627893e-05
studies O 0 1.3091626897221431e-05
have O 0 9.925452104653232e-07
suggested O 0 1.620121338419267e-06
that O 0 1.26858168414401e-08
the O 0 4.446404133773285e-08
highly O 0 5.722847618017113e-06
variable O 0 4.434204311110079e-05
metabolic O 0 0.09107299894094467
phenotypes O 0 0.000753195898141712
of O 0 0.005166436545550823
PAH B-Disease 1 0.9999793767929077
deficiency I-Disease 1 0.9018665552139282
correlate O 0 1.5710360457887873e-05
with O 0 8.213780529331416e-05
PAH O 1 0.9900031089782715
genotypes O 0 0.0007317535928450525
. O 0 6.326624315988738e-06

We O 0 4.721023287856951e-06
identified O 0 1.1770714991143905e-05
both O 0 2.0890422547381604e-07
causative O 0 6.041201777406968e-05
mutations O 0 1.7368607586831786e-05
in O 0 1.6859823972481536e-06
686 O 0 0.46560412645339966
patients O 0 0.00019634340424090624
from O 0 1.7042565048086544e-07
seven O 0 1.1853812793560792e-06
European O 0 5.038868039264344e-06
centers O 0 2.0357390440040035e-06
. O 0 1.7569954025020706e-06

On O 0 2.10348525797599e-06
the O 0 4.643289486239155e-08
basis O 0 1.2809648453071532e-08
of O 0 7.771860488503535e-09
the O 0 4.394903641014025e-08
phenotypic O 0 5.886810185984359e-07
characteristics O 0 2.841430024602687e-08
of O 0 2.178658142781842e-08
297 O 0 0.00038714235415682197
functionally O 0 0.006890349555760622
hemizygous O 0 0.37959274649620056
patients O 0 1.359426914859796e-05
, O 0 3.968957429378861e-08
105 O 0 1.3865499681742222e-07
of O 0 2.3786045133533662e-08
the O 0 3.084602440139861e-07
mutations O 0 3.1176627999229822e-06
were O 0 9.862779961622437e-07
assigned O 0 6.723210503878363e-07
to O 0 9.005822754204473e-09
one O 0 2.81698331328073e-09
of O 0 2.0453709836942835e-09
four O 0 4.6420140620284656e-08
arbitrary O 0 9.262475941795856e-07
phenotype O 0 3.183963417541236e-05
categories O 0 2.1444497178890742e-05
. O 0 8.772324690653477e-06

We O 0 2.226563310614438e-06
proposed O 0 1.0534594366617966e-05
and O 0 1.743706548040791e-06
tested O 0 8.185448677977547e-06
a O 0 2.4743576076957652e-08
simple O 0 1.6256942458880985e-08
model O 0 2.311499258667027e-07
for O 0 3.5519533980732376e-08
correlation O 0 1.3339725057903706e-07
between O 0 1.6533238067495404e-07
genotype O 0 9.585675798007287e-06
and O 0 1.016125224850839e-06
phenotypic O 0 1.240356777998386e-05
outcome O 0 1.6993410099530593e-05
. O 0 1.16944311230327e-05

The O 0 3.735107384272851e-06
observed O 0 1.0589630619506352e-05
phenotype O 0 3.851600195048377e-05
matched O 0 3.081483009736985e-05
the O 0 7.679963118789601e-07
predicted O 0 9.13112162379548e-05
phenotype O 0 1.256174891750561e-05
in O 0 2.206447362596009e-07
79 O 0 9.63747879723087e-05
% O 0 1.1229672480794761e-07
of O 0 1.0012998075126234e-07
the O 0 1.8108800077243359e-06
cases O 0 3.0385284844669513e-05
, O 0 2.5676063160062768e-06
and O 0 9.872774171526544e-07
in O 0 6.726782686428123e-08
only O 0 7.835864401783965e-09
5 O 0 1.5199920255781763e-07
of O 0 1.043395840838457e-07
184 O 0 0.00241484004072845
patients O 0 0.00028090833802707493
was O 0 1.981196692213416e-05
the O 0 1.881286948446359e-07
observed O 0 1.227695406669227e-06
phenotype O 0 4.560668003250612e-07
more O 0 1.8700985204844756e-09
than O 0 4.10311384868578e-09
one O 0 1.7584016021032767e-08
category O 0 2.290953347028335e-07
away O 0 3.639106438413364e-08
from O 0 2.0145950685446223e-08
that O 0 6.151686449129556e-08
expected O 0 1.881336743281281e-06
. O 0 2.2596602775593055e-06

Among O 0 9.786496775632259e-06
the O 0 4.5320348363020457e-07
seven O 0 2.2424262624554103e-06
contributing O 0 1.6939384295255877e-05
centers O 0 4.937205630994868e-07
, O 0 8.933390915899508e-08
the O 0 6.555521991913338e-08
proportion O 0 2.0912041236442747e-06
of O 0 1.7085671970562544e-06
patients O 0 3.06573165289592e-05
for O 0 5.18971489782416e-07
whom O 0 8.454160706605762e-06
the O 0 3.070865659537958e-07
observed O 0 1.231723672390217e-05
phenotype O 0 2.0723497073049657e-05
did O 0 2.8701691690002917e-07
not O 0 1.9669851525350168e-08
match O 0 5.612339464278193e-07
the O 0 3.007928057741083e-07
predicted O 0 0.00030981109011918306
phenotype O 0 8.532386345905252e-06
was O 0 6.173706424306147e-06
4 O 0 2.2237325083551696e-06
% O 0 4.601244825153117e-07
- O 0 0.0006935872952453792
23 O 0 2.125912214978598e-05
% O 0 1.0366809277684297e-07
( O 0 5.78629908432049e-08
P O 0 4.3110714614158496e-05
< O 0 1.638368644307775e-06
. O 0 9.44421927329131e-08
0001 O 0 5.805218734167283e-06
) O 0 9.9457091451427e-09
, O 0 2.5968017069999405e-08
suggesting O 0 6.385727715496614e-07
that O 0 6.571396227172954e-08
differences O 0 2.527044955513702e-07
in O 0 1.7458226864164317e-08
methods O 0 7.013370861841395e-08
used O 0 1.3712811153254734e-07
for O 0 9.72833760215508e-08
mutation O 0 7.789329288243607e-07
detection O 0 4.405341314850375e-06
or O 0 2.040479785136995e-06
phenotype O 0 6.088952432037331e-05
classification O 0 9.435961692361161e-05
may O 0 1.1912780792044941e-05
account O 0 1.5862556779211445e-07
for O 0 5.681919645894595e-08
a O 0 2.328857817701646e-07
considerable O 0 2.5144433379864495e-07
proportion O 0 4.63341592649158e-07
of O 0 2.144910240531317e-07
genotype O 0 0.0002271641860716045
- O 0 0.03244764730334282
phenotype O 0 0.00033168596564792097
inconsistencies O 0 0.00046240317169576883
. O 0 1.2703628271992784e-05

Our O 0 2.8172753445687704e-06
data O 0 1.2474033610487822e-06
indicate O 0 1.0253965001538745e-06
that O 0 8.683711882895295e-08
the O 0 2.4907751594582805e-06
PAH O 1 0.994034469127655
- O 0 0.02480422705411911
mutation O 0 6.4585578911646735e-06
genotype O 0 4.403299953992246e-06
is O 0 2.326257764195816e-08
the O 0 1.5977054346194564e-08
main O 0 3.5832550793202245e-07
determinant O 0 3.455089199633221e-06
of O 0 5.381082246458391e-07
metabolic O 0 0.002192295854911208
phenotype O 0 3.741464752238244e-05
in O 0 1.1381558806533576e-06
most O 0 2.1906183974351734e-05
patients O 0 0.002786497352644801
with O 0 0.1263219714164734
PAH B-Disease 1 0.9999730587005615
deficiency I-Disease 1 0.9882164597511292
. O 0 1.022156993712997e-05

In O 0 5.759351097367471e-06
the O 0 7.161851840464806e-07
present O 0 4.71619472364182e-07
study O 0 3.707055213908461e-07
, O 0 8.380547455999476e-08
the O 0 3.376683110900558e-08
classification O 0 1.0667379228834761e-06
of O 0 3.6612885878639645e-07
105 O 0 0.008260800503194332
PAH O 1 0.9953161478042603
mutations O 0 4.128761065658182e-05
may O 0 4.022842006179417e-07
allow O 0 1.1783505726725707e-08
the O 0 1.9983492194342034e-08
prediction O 0 3.429250625686109e-07
of O 0 1.456237619379408e-08
the O 0 1.0011871864890054e-07
biochemical O 0 1.8962289686896838e-05
phenotype O 0 2.322650516362046e-06
in O 0 2.136445687028754e-08
> O 0 9.816620831770706e-07
10 O 0 3.7470201164069294e-07
, O 0 1.1129750987493026e-07
000 O 0 6.240890684239275e-07
genotypes O 0 8.52570155984722e-06
, O 0 5.984437052575231e-07
which O 0 1.0935065120065701e-06
may O 0 2.319476152479183e-06
be O 0 2.5607683085127064e-08
useful O 0 1.222377488119264e-08
for O 0 1.3940938181633555e-08
the O 0 1.7898167925523012e-07
management O 0 1.2758829370795866e-06
of O 0 5.804283205179672e-07
hyperphenylalaninemia B-Disease 1 0.9991580247879028
in O 0 1.756910205585882e-05
newborns O 0 0.0038192877545952797
. O 0 6.283014045038726e-06

Somatic O 0 0.0014827654231339693
instability O 0 0.0001383002381771803
of O 0 2.435625106045336e-07
the O 0 7.29074770333682e-07
CTG O 0 0.0005530531634576619
repeat O 0 4.337370228313375e-06
in O 0 9.53540890691329e-08
mice O 0 9.276513992517721e-07
transgenic O 0 1.872549660220102e-06
for O 0 6.126138032414019e-07
the O 0 0.0006436797557398677
myotonic B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.999998927116394
region O 0 0.000943459162954241
is O 0 6.4429814301547594e-06
age O 0 5.97902835579589e-05
dependent O 0 5.674106432707049e-06
but O 0 2.629500954753894e-07
not O 0 1.3866894299496835e-08
correlated O 0 1.8187445505191135e-07
to O 0 6.9451577822121635e-09
the O 0 1.6026804772195646e-08
relative O 0 2.972309403048712e-07
intertissue O 0 1.095031348086195e-05
transcription O 0 3.790707694406592e-07
levels O 0 1.4327646624678891e-07
and O 0 6.698691663586942e-07
proliferative O 0 0.008277114480733871
capacities O 0 3.658298010122962e-05
. O 0 2.6150987650908064e-06

A O 0 0.0002511358179617673
( O 0 4.87814122607233e-06
CTG O 0 0.001318040769547224
) O 0 8.587011848248949e-07
nexpansion O 0 0.0001342620817013085
in O 0 7.084194919571019e-08
the O 0 6.309087297040605e-08
3 O 0 8.768251063884236e-06
- O 0 0.11200571805238724
untranslated O 0 0.0340377502143383
region O 0 2.8917086183355423e-06
( O 0 1.2108590397019725e-07
UTR O 0 1.2269319995539263e-05
) O 0 6.539846442166208e-09
of O 0 6.635666682797137e-09
the O 0 9.353765335617936e-07
DM O 1 0.9999080896377563
protein O 0 3.9372298488160595e-06
kinase O 0 2.0860888980678283e-05
gene O 0 6.646929477938102e-07
( O 0 1.9336502532496525e-07
DMPK O 0 0.0016758848214522004
) O 0 6.385916861972873e-08
is O 0 1.637104496410302e-08
responsible O 0 1.3568522945206496e-06
for O 0 9.36509168241173e-05
causing O 1 0.9944121241569519
myotonic B-Disease 1 0.9999960660934448
dystrophy I-Disease 1 0.9999973773956299
( O 0 0.01810433156788349
DM B-Disease 1 0.9999648332595825
) O 0 2.162559212592896e-05
. O 0 4.4788730519940145e-06

Major O 0 0.0025661501567810774
instability O 0 0.0018661675276234746
, O 0 3.694395445563714e-06
with O 0 5.729050371883204e-07
very O 0 5.9432203158849006e-08
large O 0 2.3237174673340633e-07
expansions O 0 1.142789187724702e-06
between O 0 9.552812230140262e-08
generations O 0 2.188129656133242e-06
and O 0 1.2372169067020877e-06
high O 0 3.599495903472416e-05
levels O 0 6.526191498323897e-08
of O 0 2.565197299020383e-08
somatic O 0 5.68461291550193e-05
mosaicism O 0 0.03906714916229248
, O 0 1.1300292044325033e-06
is O 0 1.865198129280543e-07
observed O 0 1.7461710513089201e-06
in O 0 1.7481938812125009e-06
patients O 0 6.58658318570815e-05
. O 0 7.773976903990842e-06

There O 0 1.3899956684326753e-05
is O 0 4.951460255142592e-07
a O 0 2.715939331210393e-07
good O 0 5.632651323139726e-08
correlation O 0 8.261500994422022e-08
between O 0 1.3173666957300156e-07
repeat O 0 9.35092793952208e-06
size O 0 8.792190783424303e-06
( O 0 5.459821394993014e-08
at O 0 2.6717094669947983e-07
least O 0 1.8821262770529756e-08
in O 0 1.3678422305929416e-07
leucocytes O 0 0.0011984941083937883
) O 0 2.3587962516558036e-07
, O 0 2.3535268667274067e-07
clinical O 0 6.348908755171578e-06
severity O 0 4.984664701623842e-05
and O 0 6.886034498165827e-06
age O 0 1.6683878129697405e-05
of O 0 3.993427526438609e-06
onset O 0 0.0017006737180054188
. O 0 2.0439410945982672e-05

The O 0 1.485091070208e-05
trinucleotide O 0 0.008874458260834217
repeat O 0 0.00021866528550162911
instability O 0 0.00016075980965979397
mechanisms O 0 6.3694074015074875e-06
involved O 0 1.3708023288927507e-05
in O 0 5.378750756790396e-06
DM B-Disease 1 0.9999817609786987
and O 0 5.477700324263424e-05
other O 0 7.530086804763414e-06
human O 0 0.003691074438393116
genetic B-Disease 1 0.9999486207962036
diseases I-Disease 1 0.9999527931213379
are O 0 7.4613612923712935e-06
unknown O 0 3.824960731435567e-05
. O 0 8.788217201072257e-06

We O 0 1.9386259282327956e-06
studied O 0 5.605210844805697e-06
somatic O 0 6.67199565214105e-05
instability O 0 8.212276588892564e-05
by O 0 5.602541932603344e-07
measuring O 0 3.989395554526709e-05
the O 0 6.730074346705806e-07
CTG O 0 0.000383745355065912
repeat O 0 1.6834999314596644e-06
length O 0 7.171885840762116e-07
at O 0 2.2930539955723361e-07
several O 0 1.2651360847826254e-08
ages O 0 2.0884488094452536e-07
in O 0 2.0119992782952068e-08
various O 0 1.5929252583646303e-08
tissues O 0 4.1517762383591617e-07
of O 0 4.6020083743769646e-08
transgenic O 0 9.882461745291948e-05
mice O 0 2.1454419766087085e-05
carrying O 0 9.324097845819779e-06
a O 0 1.426728658771026e-06
( O 0 2.899861328842235e-07
CTG O 0 9.688378486316651e-05
) O 0 7.065357010560547e-08
55expansion O 0 3.0514476748066954e-05
surrounded O 0 1.982047251658514e-06
by O 0 2.4710326229637758e-08
45 O 0 2.2426735313274548e-07
kb O 0 5.6678713008295745e-05
of O 0 5.97030549442934e-08
the O 0 4.351948632574931e-07
human O 0 1.240479923581006e-05
DM B-Disease 1 0.9999480247497559
region O 0 1.422552145413647e-06
, O 0 5.657123836044775e-08
using O 0 6.117286943663203e-08
small O 0 6.216038173079141e-07
- O 0 0.001443556509912014
pool O 0 5.492230775416829e-05
PCR O 0 6.395269156200811e-05
. O 0 1.1656288734229747e-06

These O 0 2.891377562264097e-06
mice O 0 0.0004033363948110491
have O 0 8.209818815885228e-07
been O 0 5.987331519463623e-07
shown O 0 1.3805635035168962e-07
to O 0 2.423497313941425e-08
reproduce O 0 3.350533859247662e-07
the O 0 1.8129529877342065e-08
intergenerational O 0 7.714691309956834e-05
and O 0 1.6239281421803753e-06
somatic O 0 6.400590064004064e-05
instability O 0 6.21297249381314e-06
of O 0 6.028388099821314e-08
the O 0 2.421649583084218e-07
55 O 0 9.66961306403391e-06
CTG O 0 9.528471127850935e-05
repeat O 0 1.5496964351768838e-06
suggesting O 0 4.6731869929317327e-07
that O 0 3.274283955079227e-09
surrounding O 0 1.881017297478138e-08
sequences O 0 1.9348911806105207e-08
and O 0 1.9357665337338403e-07
the O 0 4.4392773901336113e-08
chromatin O 0 7.116526830941439e-06
environment O 0 9.304281434197037e-07
are O 0 3.697761030707625e-08
involved O 0 5.555879170060507e-07
in O 0 1.2741282944261911e-06
instability O 0 8.351586438948289e-05
mechanisms O 0 1.6259076801361516e-05
. O 0 9.580640835338272e-06

As O 0 5.590716227743542e-06
observed O 0 2.9220248052297393e-06
in O 0 2.049480229970868e-08
some O 0 1.3790766306698288e-09
of O 0 1.1000165223151726e-08
the O 0 5.483427685248898e-07
tissues O 0 1.939188405231107e-05
of O 0 0.00013783642498310655
DM B-Disease 1 0.9999996423721313
patients O 0 0.146006241440773
, O 0 1.4004961030877894e-06
there O 0 1.406614416055163e-07
is O 0 1.4187111219143844e-07
a O 0 9.822342690313235e-07
tendency O 0 8.244120976996783e-07
for O 0 1.338488857527409e-07
repeat O 0 2.8996066703257384e-06
length O 0 1.2862749372288818e-06
and O 0 3.81239146918233e-07
somatic O 0 1.6047708413680084e-05
mosaicism O 0 0.0015368529129773378
to O 0 1.4703508099955798e-07
increase O 0 3.4316124697397754e-07
with O 0 1.1212722483833204e-07
the O 0 1.118356678375676e-07
age O 0 5.813867005599604e-07
of O 0 8.657384142907176e-08
the O 0 2.145357484550914e-06
mouse O 0 0.00024922730517573655
. O 0 8.390506991418079e-06

Furthermore O 0 0.00024016106908675283
, O 0 3.2119894513016334e-06
we O 0 5.1905953313280406e-08
observed O 0 1.0839236352921944e-07
no O 0 4.620766880236715e-09
correlation O 0 1.93455527153219e-08
between O 0 6.770106253384256e-09
the O 0 5.8833418137282933e-08
somatic O 0 2.4603965357528068e-05
mutation O 0 6.991998816374689e-06
rate O 0 1.5545649148407392e-05
and O 0 1.1063752936024684e-05
tissue O 0 0.006229836028069258
proliferation O 0 0.0025101008359342813
capacity O 0 4.353517579147592e-05
. O 0 3.1435863547812914e-06

The O 0 1.142904807238665e-06
somatic O 0 9.541628242004663e-05
mutation O 0 3.432055746088736e-05
rates O 0 3.0808560040895827e-06
in O 0 2.9577829963045588e-08
different O 0 1.7888298842194672e-08
tissues O 0 1.7340438716928475e-05
were O 0 4.1560247154848184e-06
also O 0 1.1963167025896837e-06
not O 0 1.6665175905927754e-08
correlated O 0 3.1439563485946564e-07
to O 0 8.511007898448497e-09
the O 0 6.180358980145684e-08
relative O 0 2.8887041025882354e-06
inter O 0 9.257248166250065e-05
- O 0 0.1638047993183136
tissue O 0 0.00020902931282762438
difference O 0 2.0826134061735502e-07
in O 0 9.94396387454799e-09
transcriptional O 0 1.000511389293024e-07
levels O 0 1.694774098837115e-08
of O 0 1.269178873108956e-09
the O 0 9.253178667734119e-09
three O 0 1.7184260059366352e-07
genes O 0 7.074391419337189e-07
( O 0 2.441227309191163e-07
DMAHP O 0 0.0009611634304746985
, O 0 1.1074140502387309e-06
DMPK O 0 0.0017699920572340488
and O 0 1.654648713156348e-06
59 O 0 0.00011884597915923223
) O 0 4.1312450349551e-08
surrounding O 0 5.9317819989246345e-08
the O 0 9.619071761335363e-08
repeat O 0 5.763328317698324e-06
. O 0 2.7986939699076174e-07
. O 0 1.4165508446239983e-06

A O 0 2.3813521693227813e-05
novel O 0 5.644562406814657e-06
missense O 0 0.00036331667797639966
mutation O 0 7.085171091603115e-05
in O 0 5.269809662422631e-06
patients O 0 3.091667895205319e-05
from O 0 5.536219873647497e-07
a O 0 8.446995707345195e-06
retinoblastoma B-Disease 0 0.02028137445449829
pedigree O 0 0.0013763371389359236
showing O 0 6.031657903804444e-05
only O 0 1.5426805077822792e-07
mild O 0 7.426604952343041e-06
expression O 0 7.726149675590932e-08
of O 0 1.2902219737043197e-07
the O 0 3.2015526812756434e-05
tumor B-Disease 0 0.18561968207359314
phenotype O 0 0.00010784492042148486
. O 0 4.4265034375712276e-06

We O 0 3.6298808936408022e-06
have O 0 1.5528652852481173e-07
used O 0 2.029911705392351e-08
single O 0 6.028331256402453e-08
strand O 0 5.714896360586863e-06
conformation O 0 1.4846613112240448e-06
polymorphism O 0 4.201927822578e-06
analysis O 0 6.824860321330561e-08
to O 0 2.88659443015149e-08
study O 0 5.101970756982155e-08
the O 0 4.262539121668851e-08
27 O 0 4.194041139271576e-06
exons O 0 5.863434466846229e-07
of O 0 3.4405772453283134e-08
the O 0 8.898425107872754e-07
RB1 O 0 0.010935856960713863
gene O 0 4.248862239819573e-07
in O 0 5.227545329944405e-08
individuals O 0 1.1996510806966398e-07
from O 0 4.1712425513651397e-07
a O 0 7.881419151090086e-06
family O 0 0.00011106702004326507
showing O 0 0.0011640831362456083
mild O 0 2.8679203751380555e-05
expression O 0 5.021416527029032e-08
of O 0 4.879592552242684e-08
the O 0 8.672174772073049e-06
retinoblastoma B-Disease 0 0.17739102244377136
phenotype O 0 0.0007026165840215981
. O 0 1.233940838574199e-05

In O 0 6.737851890648017e-06
this O 0 4.791468768416962e-07
family O 0 1.861331293184776e-05
affected O 0 1.5517180145252496e-06
individuals O 0 9.134289484791225e-07
developed O 0 0.0005137561820447445
unilateral B-Disease 1 0.6158215403556824
tumors I-Disease 1 0.9999984502792358
and O 0 0.00034853644319809973
, O 0 8.333592631970532e-06
as O 0 5.519534624909284e-07
a O 0 4.582659300922387e-07
result O 0 1.6623151566363958e-07
of O 0 2.3926784109562504e-08
linkage O 0 5.344807959772879e-06
analysis O 0 5.334870820661308e-07
, O 0 1.8481835013517411e-06
unaffected O 0 9.397494977747556e-06
mutation O 0 2.6265183805662673e-06
carriers O 0 6.491743533842964e-06
were O 0 1.505344130237063e-06
also O 0 1.384096890433284e-06
identified O 0 1.4579879916709615e-06
within O 0 1.4190866259866652e-08
the O 0 5.86199234930973e-07
pedigree O 0 0.0004328962822910398
. O 0 6.336919796012808e-06

A O 0 2.2347354388330132e-05
single O 0 3.783282181757386e-06
band O 0 4.969037490809569e-06
shift O 0 3.7704273836425273e-07
using O 0 2.1033035579876014e-07
SSCP O 0 0.0017466206336393952
was O 0 1.3460926311381627e-05
identified O 0 1.1027622122128378e-06
in O 0 3.483425103922855e-08
exon O 0 0.00015342496044468135
21 O 0 6.671292794635519e-06
which O 0 3.5094540606905866e-08
resulted O 0 5.862892180630297e-07
in O 0 2.9438306015094895e-08
a O 0 1.9971056985923497e-07
missense O 0 6.392915111064212e-06
mutation O 0 2.673735650660092e-07
converting O 0 1.4642305359302554e-06
a O 0 4.774596163770184e-06
cys O 0 0.1897619068622589
- O 0 0.014926438219845295
- O 0 0.00022164618712849915
> O 0 1.0682731499400688e-06
arg O 0 8.25825918582268e-06
at O 0 3.408230782042665e-07
nucleotide O 0 1.452895276088384e-06
position O 0 3.838139548406616e-07
28 O 0 6.491914064099547e-07
in O 0 1.519765469026879e-08
the O 0 2.009742559039296e-07
exon O 0 0.0007534411270171404
. O 0 1.2055800652888138e-05

The O 0 4.606329639500473e-06
mutation O 0 2.237934313598089e-05
destroyed O 0 3.7226553104119375e-05
an O 0 1.0522177262828336e-06
NdeI O 0 0.0004786477657034993
restriction O 0 2.4992552880576113e-06
enzyme O 0 3.998628926638048e-06
site O 0 4.5599085751746316e-06
. O 0 2.719272060858202e-06

Analysis O 0 3.7070692542329198e-06
of O 0 4.6521452645720274e-07
all O 0 3.0439767328971357e-07
family O 0 1.7967764506465755e-05
members O 0 4.963171136296296e-07
demonstrated O 0 1.207000650538248e-06
that O 0 6.230516991223567e-09
the O 0 2.3380858138466465e-08
missense O 0 2.451180807838682e-05
mutation O 0 7.834215466573369e-06
co O 0 0.00011418704525567591
- O 0 0.00011105081648565829
segregated O 0 1.2385884474497288e-05
with O 0 4.1623683500802144e-05
patients O 0 0.0013052534777671099
with O 0 0.0026811002753674984
tumors B-Disease 1 0.9999961853027344
or O 0 2.945730921055656e-05
who O 0 0.0010174966882914305
, O 0 8.91679178494087e-07
as O 0 1.7752485348410119e-07
a O 0 1.4098093004122347e-07
result O 0 4.1923666316279196e-08
of O 0 1.2260131576624644e-08
linkage O 0 3.0944543141231406e-06
analysis O 0 2.2844612885819515e-06
had O 0 0.0003695580817293376
been O 0 3.2870336781343212e-06
predicted O 0 5.5622476793359965e-06
to O 0 1.1368912034015466e-08
carry O 0 9.760268682157403e-08
the O 0 3.2683149697732006e-07
predisposing O 0 0.00010408699745312333
mutation O 0 1.1635404007392935e-05
. O 0 3.7156523831072263e-06

These O 0 3.529250136580231e-07
observations O 0 1.2081546856279601e-06
point O 0 9.63883053373138e-07
to O 0 4.8434575461442364e-08
another O 0 4.3139286276527855e-07
region O 0 1.4394949232610088e-07
of O 0 2.7759682552641607e-08
the O 0 5.3361685559139e-07
RB1 O 0 0.006146163679659367
gene O 0 1.5034331113383814e-07
where O 0 1.3797910014545778e-07
mutations O 0 1.94273880538276e-07
only O 0 6.261037910348932e-09
modify O 0 2.6947265041599167e-07
the O 0 1.7024037290980232e-08
function O 0 4.172986400874379e-09
of O 0 5.657811552595149e-09
the O 0 8.83993038769404e-08
gene O 0 3.003685264957312e-07
and O 0 4.3699279217435105e-07
raise O 0 1.9632016119430773e-06
important O 0 3.281951066469446e-08
questions O 0 1.637458098002753e-07
for O 0 2.1731803201419098e-07
genetic O 0 1.0995939192071091e-05
counseling O 0 3.195109911757754e-06
in O 0 2.423728915346146e-07
families O 0 5.015271540287358e-07
with O 0 4.2283073753424105e-07
these O 0 8.702945564209585e-08
distinctive O 0 1.3792839126836043e-05
phenotypes O 0 2.5050992917385884e-05
. O 0 3.1665030064687016e-07
. O 0 3.458115315879695e-06

Maternal B-Disease 0 0.12318364530801773
disomy I-Disease 1 0.8460413813591003
and O 0 0.15622302889823914
Prader B-Disease 1 0.999992847442627
- I-Disease 1 0.9999978542327881
Willi I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.999984622001648
consistent O 0 1.8242479200125672e-05
with O 0 2.923864713011426e-06
gamete O 0 0.0005849905428476632
complementation O 0 0.2563261389732361
in O 0 1.1452877970441477e-06
a O 0 2.8757356176356552e-06
case O 0 1.8365542928222567e-05
of O 0 2.4100663722492754e-06
familial O 0 0.0037459845189005136
translocation O 0 0.012185956351459026
( O 0 1.541167307550495e-06
3 O 0 7.247846951941028e-06
; O 0 1.7564057088748086e-06
15 O 0 2.7049377422372345e-06
) O 0 7.549967051545536e-08
( O 0 1.2510885660788063e-08
p25 O 0 9.869515906757442e-07
; O 0 1.1323783155603451e-07
q11 O 0 3.5887721878680168e-06
. O 0 3.05186489413245e-08
2 O 0 4.776254058924678e-07
) O 0 3.700266404393915e-07
. O 0 8.904622177396959e-07

Maternal B-Disease 1 0.712980329990387
uniparental I-Disease 1 0.9921601414680481
disomy I-Disease 1 0.9865072965621948
( I-Disease 0 0.00032585373264737427
UPD I-Disease 1 0.9996178150177002
) I-Disease 0 2.9797188290103804e-06
for I-Disease 0 7.908115549071226e-07
chromosome I-Disease 0 0.0003436900151427835
15 I-Disease 0 1.7755003227648558e-06
is O 0 7.04536020634805e-08
responsible O 0 3.5544277920962486e-07
for O 0 9.588590899056726e-08
an O 0 4.4804355070482416e-07
estimated O 0 1.3936963114247192e-05
30 O 0 7.609500016769744e-07
% O 0 1.700404794746646e-08
of O 0 3.5303738599168355e-08
cases O 0 2.799676076392643e-05
of O 0 0.002415179740637541
Prader B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999984502792358
Willi I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999877214431763
( O 0 0.00035820863558910787
PWS B-Disease 1 0.9998840093612671
) O 0 2.8405273042153567e-05
. O 0 8.325347153004259e-06

We O 0 3.088212906732224e-06
report O 0 1.0945227586489636e-06
on O 0 5.665237949870061e-07
an O 0 2.638417981870589e-07
unusual O 0 4.63109216752855e-07
case O 0 1.5748393025205587e-06
of O 0 4.2200690586469136e-07
maternal B-Disease 0 0.00015212831203825772
disomy I-Disease 0 0.0006225703982636333
15 I-Disease 0 2.8121271498093847e-06
in O 0 3.601107664508163e-06
PWS B-Disease 1 0.9999358654022217
that O 0 1.13867270101764e-06
is O 0 1.2202744414935296e-07
most O 0 3.9144815389136056e-08
consistent O 0 1.8921367939128686e-07
with O 0 1.316819151497839e-07
adjacent O 0 2.3882159894128563e-06
- O 0 0.00011211760283913463
1 O 0 1.1901070138264913e-06
segregation O 0 5.298758765093226e-07
of O 0 1.0181607734693898e-07
a O 0 1.4859680049994495e-05
paternal O 0 0.016320733353495598
t O 0 0.2525409460067749
( O 0 1.8267267876126425e-07
3 O 0 1.1532667940628016e-06
; O 0 3.706531686020753e-07
15 O 0 9.102305966735003e-07
) O 0 1.8888945518824585e-08
( O 0 5.558219218215754e-09
p25 O 0 3.4011557659141545e-07
; O 0 4.784966378679201e-08
q11 O 0 1.608310981282557e-06
. O 0 4.066464942553694e-09
2 O 0 6.742942559867515e-08
) O 0 2.6259576735299106e-09
with O 0 2.975645285729911e-09
simultaneous O 0 1.4157402006276243e-07
maternal O 0 1.926850382005796e-05
meiotic O 0 0.0006577899330295622
nondisjunction O 0 0.001037979731336236
for O 0 9.907832918543136e-07
chromosome O 0 0.00010487266990821809
15 O 0 8.83488064573612e-06
. O 0 5.003484602639219e-06

The O 0 6.345348083414137e-05
patient O 0 0.0014039488742128015
( O 0 4.0837644519342575e-06
J O 0 0.1501496583223343
. O 0 1.4344533383336966e-06
B O 0 0.00021253546583466232
. O 0 7.041773386617933e-08
) O 0 1.7819580477862473e-08
, O 0 1.2286115236292972e-08
a O 0 7.812736413370658e-08
17 O 0 3.070039156227722e-06
- O 0 0.00033556533162482083
year O 0 1.0097842277900781e-05
- O 0 0.003115525236353278
old O 0 0.01026704628020525
white O 0 0.0010459168115630746
male O 0 8.247782716352958e-06
with O 0 2.1173373170313425e-05
PWS B-Disease 1 0.9999572038650513
, O 0 1.3066332030575722e-05
was O 0 5.064732249593362e-05
found O 0 7.189882467173447e-07
to O 0 3.8528817469796195e-08
have O 0 1.0034028008476525e-07
47 O 0 3.6736212223331677e-06
chromosomes O 0 2.424987542326562e-06
with O 0 3.0444297749454563e-07
a O 0 4.961844297213247e-06
supernumerary O 0 0.22010962665081024
, O 0 1.5394913134514354e-05
paternal O 0 0.0005939617403782904
der O 0 0.28007230162620544
( O 0 2.1723288057273749e-07
15 O 0 4.5259966441335564e-07
) O 0 8.200051304640965e-09
consisting O 0 1.9372619064483843e-08
of O 0 2.906394591661865e-08
the O 0 8.041081400733674e-07
short O 0 7.301632285816595e-05
arm O 0 0.02258405275642872
and O 0 1.78331663391873e-06
the O 0 1.10417022369802e-06
proximal O 0 0.018800951540470123
long O 0 0.0022358265705406666
arm O 0 0.014598512090742588
of O 0 9.358307124784915e-07
chromosome O 0 0.002792601939290762
15 O 0 6.404521172953537e-06
, O 0 9.952257187251234e-07
and O 0 3.7215359043329954e-06
distal O 0 0.0224443431943655
chromosome O 1 0.5329807996749878
arm O 1 0.5438752174377441
3p O 0 0.40827658772468567
. O 0 2.0843885067733936e-05

The O 0 7.483387889806181e-05
t O 0 0.14118902385234833
( O 0 3.472815137683938e-07
3 O 0 1.0207473906120867e-06
; O 0 1.327243239757081e-07
15 O 0 1.2940793112647953e-06
) O 0 7.72379209479368e-08
was O 0 3.6577744140231516e-06
present O 0 5.3841013425426354e-08
in O 0 3.830657036019147e-08
the O 0 7.133659352120958e-08
balanced O 0 1.1347127610861207e-06
state O 0 5.270666179058026e-07
in O 0 1.5678440945521288e-07
the O 0 7.223859938676469e-06
patients O 0 0.0001614429202163592
father O 0 8.308944961754605e-05
and O 0 2.06175604944292e-06
a O 0 6.848959856142756e-06
sister O 0 0.0005182713503018022
. O 0 5.6552312344138045e-06

Fluorescent O 0 5.755958045483567e-05
in O 0 3.407213569062151e-07
situ O 0 3.750023097381927e-06
hybridization O 0 1.8951432139147073e-06
analysis O 0 1.2782408020939329e-06
demonstrated O 0 1.0883225513680372e-05
that O 0 1.7154704323729675e-07
the O 0 4.040800831717206e-06
PWS B-Disease 1 0.9999382495880127
critical O 0 2.5993100280174986e-05
region O 0 2.35614834309672e-06
resided O 0 1.1443299626989756e-05
on O 0 6.607069167330337e-07
the O 0 1.2040754882036708e-07
derivative O 0 1.6992955352179706e-05
chromosome O 0 0.00020762914209626615
3 O 0 6.274540737649659e-06
and O 0 1.6564928273510304e-06
that O 0 1.625837597885038e-07
there O 0 7.787949130033667e-08
was O 0 1.722342312859837e-05
no O 0 4.3440330443900166e-08
deletion O 0 1.7861897276816308e-06
of O 0 3.327234878724994e-07
the O 0 1.791641625459306e-05
PWS B-Disease 1 0.9999707937240601
region O 0 1.7459846048950567e-06
on O 0 4.1842025666483096e-07
the O 0 7.424427650448706e-08
normal O 0 5.456323393104867e-08
pair O 0 6.929149662937562e-07
of O 0 6.909881733463408e-08
15s O 0 2.6827292458619922e-05
present O 0 4.2584846937643306e-07
in O 0 8.225335363931663e-07
J O 0 0.0048443335108459
. O 0 1.1452153557911515e-05

B O 0 0.010659418068826199
. O 0 0.00020053017942700535

Methylation O 0 1.3934065464127343e-05
analysis O 0 8.254332328760938e-07
at O 0 9.57279098656727e-07
exon O 0 1.5206331227091141e-05
alpha O 0 3.6799957570110564e-07
of O 0 1.0739282352290047e-08
the O 0 6.538427044233686e-08
small O 0 1.820984948608384e-06
nuclear O 0 0.0073753949254751205
ribonucleoprotein O 0 0.004518946632742882
- O 0 0.0014436340425163507
associated O 0 2.463748614900396e-06
polypeptide O 0 6.180510808917461e-06
N O 0 7.267614273587242e-05
( O 0 3.1124648103286745e-07
SNRPN O 0 0.00048232555855065584
) O 0 6.932270224524473e-08
gene O 0 7.766143994558661e-08
showed O 0 2.501222525097546e-06
a O 0 6.401544965228823e-07
pattern O 0 3.5759812817559578e-06
characteristic O 0 2.8079523417545715e-07
of O 0 1.598897547694378e-08
only O 0 1.3487919225951828e-08
the O 0 2.929735671841627e-07
maternal O 0 6.248664431041107e-05
chromosome O 0 0.00011263722262810916
15 O 0 3.0583473744627554e-06
in O 0 1.5636676380381687e-06
J O 0 0.014626791700720787
. O 0 1.2501553101174068e-05

B O 0 0.008363882079720497
. O 0 0.00014843992539681494

Maternal B-Disease 0 0.025753352791070938
disomy I-Disease 0 0.3336116373538971
was O 0 0.0006159630138427019
confirmed O 0 6.0235083765292075e-06
by O 0 8.799640482948234e-08
polymerase O 0 2.251905607408844e-05
chain O 0 1.4923502021702006e-05
reaction O 0 3.4751831634594055e-08
analysis O 0 6.155287390896547e-09
of O 0 8.83724649014539e-09
microsatellite O 0 2.9701704988838173e-05
repeats O 0 5.099539066577563e-07
at O 0 1.3568714507528057e-07
the O 0 1.7757557202457974e-08
gamma O 0 8.990086257654184e-07
- O 0 3.613886292441748e-05
aminobutyric O 0 6.347538146656007e-05
acid O 0 1.576274257786281e-06
receptor O 0 3.115265201358852e-07
beta3 O 0 4.283226189727429e-06
subunit O 0 1.9308180299049127e-07
( O 0 5.375133227403239e-08
GABRB3 O 0 3.2029911380959675e-05
) O 0 3.691024730301251e-08
locus O 0 3.676996811918798e-06
. O 0 2.77114963864733e-06

A O 0 0.0006155886221677065
niece O 0 0.46969249844551086
( O 0 5.918620445299894e-06
B O 0 0.00038393394788727164
. O 0 3.323109467601171e-07
B O 0 1.980705746973399e-05
. O 0 1.4247984125859148e-08
) O 0 4.164788514060547e-09
with O 0 7.775092569772823e-09
45 O 0 2.726059733504371e-07
chromosomes O 0 2.173660277549061e-06
and O 0 1.5901269989626599e-07
the O 0 9.79420846647372e-08
derivative O 0 5.484941539179999e-06
3 O 0 1.6293374756060075e-06
but O 0 4.543763054698502e-08
without O 0 3.861967812213152e-08
the O 0 2.7841616656587576e-07
der O 0 0.05602419003844261
( O 0 2.7980135541838536e-07
15 O 0 5.248256229606341e-07
) O 0 5.612404052612874e-08
demonstrated O 0 6.370563596647116e-07
a O 0 3.3597169135646254e-07
phenotype O 0 5.04579656990245e-06
consistent O 0 2.711095135055075e-07
with O 0 1.515057022061228e-07
that O 0 1.6695837246061274e-07
reported O 0 3.493223857731209e-06
for O 0 2.974149992951425e-07
haploinsufficiency O 0 0.0001047793120960705
of O 0 1.9336594903052173e-07
distal O 0 0.0008306594099849463
3 O 0 3.364129224792123e-05
p O 0 0.0007199805113486946
. O 0 5.178011178941233e-06

Uniparental B-Disease 1 0.9991031885147095
disomy I-Disease 1 0.9994854927062988
associated O 0 0.0008107480243779719
with O 0 2.483654498064425e-06
unbalanced O 0 0.00018660914793144912
segregation O 0 6.758097697456833e-06
of O 0 2.5303125994469156e-07
non O 0 2.8495076549006626e-05
- O 0 0.006232989951968193
Robertsonian O 0 0.002151401713490486
translocations O 0 0.000264136353507638
has O 0 6.485963695013197e-06
been O 0 7.877932148403488e-06
reported O 0 5.913062341278419e-05
previously O 0 4.003596041002311e-05
but O 0 6.043355256224459e-07
has O 0 1.546918952044507e-06
not O 0 7.804008816947317e-08
, O 0 8.811061036340107e-08
to O 0 9.21896781136411e-09
our O 0 4.31337499051665e-09
knowledge O 0 2.539803212187053e-08
, O 0 1.2379788927319169e-07
been O 0 7.383712841146917e-07
observed O 0 1.8687715908072278e-07
in O 0 1.6314158912678067e-08
a O 0 3.3002785926328215e-07
case O 0 8.63128479977604e-06
of O 0 3.132904748781584e-05
PWS B-Disease 1 0.9997653365135193
. O 0 0.00010300827125320211

Furthermore O 0 0.0001965775591088459
, O 0 2.2295614598988323e-06
our O 0 1.7475808533617965e-07
findings O 0 1.1087254279118497e-06
are O 0 1.7710911848212163e-08
best O 0 2.3838872209580586e-07
interpreted O 0 3.224337774554442e-07
as O 0 3.2222992274455464e-08
true O 0 4.3600035581903285e-08
gamete O 0 8.719146535440814e-06
complementation O 0 0.002435030648484826
resulting O 0 3.591842687455937e-05
in O 0 5.916582722420571e-06
maternal B-Disease 0 0.018605610355734825
UPD I-Disease 1 0.9994982481002808
15 I-Disease 0 0.00010831601684913039
and O 0 0.00027221895288676023
PWS B-Disease 1 0.9986649751663208

Schwartz B-Disease 1 0.8953437209129333
- I-Disease 1 0.9993496537208557
Jampel I-Disease 1 0.999777615070343
syndrome I-Disease 1 0.9998388290405273
type I-Disease 0 7.101195660652593e-05
2 I-Disease 0 1.1333294423820917e-05
and O 0 0.00010026744712376967
Stuve B-Disease 1 0.9858549237251282
- I-Disease 1 0.9999439716339111
Wiedemann I-Disease 1 0.9999899864196777
syndrome I-Disease 1 0.9995514750480652
: O 0 2.4114908114825084e-07
a O 0 1.0265725904901046e-06
case O 0 7.259911399160046e-06
for O 0 4.414242766870302e-07
" O 0 1.3479389053827617e-06
lumping O 0 5.533890362130478e-05
" O 0 1.0757455584098352e-06
. O 0 6.016282441123622e-07

Recent O 0 7.939920760691166e-05
studies O 0 9.675590263213962e-06
demonstrated O 0 5.099459940538509e-06
the O 0 3.5880969306845145e-08
existence O 0 4.006179565863022e-08
of O 0 2.3639369572947544e-08
a O 0 1.7215373873114004e-06
genetically O 0 1.7931219190359116e-05
distinct O 0 1.7005677932502294e-07
, O 0 5.790394652649411e-07
usually O 0 7.649154554201232e-08
lethal O 0 4.62809879309134e-07
form O 0 2.4496900508097497e-08
of O 0 1.0192002264375333e-07
the O 0 1.6955435057752766e-05
Schwartz B-Disease 1 0.8865705132484436
- I-Disease 1 0.9998594522476196
Jampel I-Disease 1 0.9999431371688843
syndrome I-Disease 1 0.9997685551643372
( O 0 3.574917400328559e-06
SJS B-Disease 0 0.08196242153644562
) O 0 1.5331880831581657e-07
of O 0 7.924573992568185e-07
myotonia B-Disease 1 0.9208884835243225
and O 0 0.00799333956092596
skeletal B-Disease 1 0.9996028542518616
dysplasia I-Disease 1 0.9997479319572449
, O 0 1.2680692634603474e-05
which O 0 4.0542312262914493e-07
we O 0 4.550280721105082e-07
called O 0 3.799323530984111e-05
SJS B-Disease 0 0.059388626366853714
type I-Disease 0 6.148288775875699e-06
2 I-Disease 0 3.2180632842937484e-06
. O 0 2.7485855298436945e-06

This O 0 0.00020243592734914273
disorder O 1 0.7466928958892822
is O 0 1.853568846854614e-06
reminiscent O 0 1.519488068879582e-05
of O 0 7.948021902848268e-07
another O 0 0.00021983010810799897
rare O 0 0.00689194118604064
condition O 0 0.0001811525726225227
, O 0 2.9891568829043536e-06
the O 0 2.0227700588293374e-05
Stuve B-Disease 1 0.9982001781463623
- I-Disease 1 0.999987006187439
Wiedemann I-Disease 1 0.9999934434890747
syndrome I-Disease 1 0.9999558925628662
( O 0 1.0296188520442229e-05
SWS B-Disease 0 0.1766197681427002
) O 0 6.151394131848065e-07
, O 0 4.9998746476376255e-08
which O 0 1.2877432453706206e-08
comprises O 0 1.7195276313941577e-07
campomelia B-Disease 0 0.00044096630881540477
at O 0 4.6396826292038895e-06
birth O 0 1.1753597391361836e-05
with O 0 6.984298670431599e-05
skeletal B-Disease 1 0.9987441301345825
dysplasia I-Disease 1 0.9986792206764221
, O 0 0.00013728968042414635
contractures B-Disease 1 0.8848304748535156
, O 0 3.446516529947985e-06
and O 0 1.6538315321668051e-06
early B-Disease 0 6.0063694036216475e-06
death I-Disease 0 0.00010293177183484659
. O 0 6.597356787096942e-06

To O 0 2.4409832803939935e-06
test O 0 1.8832000705515384e-06
for O 0 8.155585362601414e-08
possible O 0 3.561754056136124e-07
nosologic O 0 0.0005454513011500239
identity O 0 3.392601229279535e-06
between O 0 1.8310363429918652e-06
these O 0 3.427044475756702e-06
disorders O 1 0.5124210715293884
, O 0 3.532001301209675e-06
we O 0 5.5194089298993276e-08
reviewed O 0 8.638676263217349e-07
the O 0 6.60934489360443e-08
literature O 0 7.05858269611781e-08
and O 0 2.400264520474593e-07
obtained O 0 2.485988375156012e-07
a O 0 4.983840895533831e-08
follow O 0 2.904072715637085e-08
- O 0 1.7607828340260312e-05
up O 0 2.3577976548949664e-07
of O 0 1.1401355415330272e-08
the O 0 2.2234212693206246e-08
only O 0 9.541736289975233e-09
two O 0 6.427280823118053e-07
surviving O 0 0.025972019881010056
patients O 0 2.1991418179823086e-05
, O 0 1.5687160725974536e-07
one O 0 7.876175089904791e-08
with O 0 3.1395086352858925e-06
SJS B-Disease 0 0.19388964772224426
type I-Disease 0 1.762454530762625e-06
2 I-Disease 0 8.577779340157576e-07
at O 0 2.38818188336154e-06
age O 0 3.969642875745194e-06
10 O 0 2.2129549392957415e-07
years O 0 2.540831189890014e-07
and O 0 5.664001534455565e-08
another O 0 1.2029163087845518e-07
with O 0 6.380596460076049e-07
SWS B-Disease 0 0.0013936236500740051
at O 0 4.034632183902431e-06
age O 0 2.1050764189567417e-06
7 O 0 3.0673818400828168e-06
years O 0 1.707117576188466e-06
. O 0 1.1083776598752593e-06

Patients O 0 0.08129988610744476
reported O 0 0.00045153117389418185
as O 0 1.7909316056829994e-06
having O 0 6.5020276451832615e-06
either O 0 1.1007994544343092e-05
neonatal O 1 0.9956949949264526
SJS B-Disease 1 0.9963271021842957
or O 0 1.7875949197332375e-05
SWS B-Disease 0 0.009897634387016296
presented O 0 2.9945695132482797e-06
a O 0 2.082468455455455e-07
combination O 0 6.490366217803967e-07
of O 0 3.201409981556935e-07
a O 0 0.0005032372428104281
severe O 0 0.16746605932712555
, O 0 7.615859794896096e-05
prenatal O 0 0.03653841093182564
- O 1 0.9895703792572021
onset O 1 0.9614385366439819
neuromuscular B-Disease 1 0.9999818801879883
disorder I-Disease 1 0.998854398727417
( O 0 9.570495603838935e-05
with O 0 0.4147894084453583
congenital B-Disease 1 0.9999980926513672
joint I-Disease 1 0.988516092300415
contractures I-Disease 1 0.9999855756759644
, O 1 0.584722101688385
respiratory O 1 0.7313615679740906
and O 0 0.00014922613627277315
feeding O 0 0.002090665278956294
difficulties O 0 0.002012119395658374
, O 0 4.229806108924095e-06
tendency O 0 6.746301096427487e-06
to O 0 6.314251663752657e-07
hyperthermia B-Disease 0 0.23782585561275482
, O 0 1.842636493165628e-06
and O 0 9.15262774014991e-07
frequent O 0 3.629088269008207e-06
death O 0 0.0001621151895960793
in O 0 2.8536339868878713e-06
infancy O 0 5.6121400120900944e-05
) O 0 3.530118064531962e-08
with O 0 5.002955916211249e-08
a O 0 3.782676571972843e-07
distinct O 0 1.15729164917866e-06
campomelic B-Disease 0 0.1061006635427475
- I-Disease 1 0.7385364174842834
metaphyseal I-Disease 1 0.94044029712677
skeletal I-Disease 1 0.9752801656723022
dysplasia I-Disease 1 0.9700884222984314
. O 0 1.7654541807132773e-05

The O 0 3.852680038107792e-06
similarity O 0 2.743434379226528e-06
of O 0 8.615609203843633e-08
the O 0 3.4579298358039523e-07
clinical O 0 1.582243748998735e-05
and O 0 2.7941332518821582e-06
radiographic O 0 0.044517938047647476
findings O 0 7.301444566110149e-05
is O 0 8.179449082490464e-07
so O 0 1.3528917008898134e-07
extensive O 0 2.1601431399176363e-06
that O 0 2.8742331323883263e-06
these O 0 1.6885471723071532e-06
disorders O 0 0.06362579762935638
appear O 0 1.460935891373083e-06
to O 0 5.8505655431417836e-08
be O 0 7.233887089341806e-08
a O 0 2.5597972808100167e-07
single O 0 4.1277667151007336e-06
entity O 0 1.1772960533562582e-05
. O 0 8.367580448975787e-06

The O 0 1.275104409614869e-06
follow O 0 3.6527163160826603e-07
- O 0 2.7079424398834817e-05
up O 0 3.5586606372817187e-07
observation O 0 1.547339394392111e-07
of O 0 1.9199472234276982e-08
an O 0 1.9742662971111713e-07
identical O 0 4.973565410182346e-06
and O 0 5.387305463955272e-07
unique O 0 2.517247992273042e-07
pattern O 0 4.042011369165266e-06
of O 0 8.95348330232082e-06
progressive O 1 0.9980356097221375
bone B-Disease 1 0.9999874830245972
dysplasia I-Disease 1 0.9990419745445251
in O 0 3.0866613087709993e-06
the O 0 2.9494194677681662e-06
two O 0 0.00016916717868298292
patients O 0 0.00036921369610354304
( O 0 1.1605271765802172e-07
one O 0 3.089533606726036e-07
with O 0 1.702799454506021e-05
SJS B-Disease 1 0.8787797093391418
type I-Disease 0 1.2694935321633238e-05
2 I-Disease 0 2.3919130853755632e-06
, O 0 2.8892389991597156e-07
one O 0 1.7342490821192769e-07
with O 0 7.895283488323912e-06
SWS B-Disease 0 0.08423367142677307
) O 0 2.7029088300878357e-07
surviving O 0 6.4411506173200905e-06
beyond O 0 7.560211656709726e-07
infancy O 0 9.717888133309316e-06
adds O 0 6.734325097568217e-07
to O 0 1.1121046306072913e-08
the O 0 2.4132480902494535e-08
evidence O 0 2.1865601240733668e-07
in O 0 2.3862430253984712e-08
favor O 0 1.709194776822187e-07
of O 0 6.997282753218315e-08
identity O 0 6.052772732800804e-06
. O 0 7.634966095793061e-06

The O 0 4.667174835049082e-06
hypothesis O 0 1.9030714611290023e-05
that O 0 1.0578955880191643e-06
SWS B-Disease 0 0.018161168321967125
and O 0 8.945411536842585e-05
SJS B-Disease 1 0.9600388407707214
type I-Disease 0 3.2011284929467365e-05
2 I-Disease 0 2.988928827107884e-06
are O 0 4.237119455297034e-08
the O 0 2.538811259000795e-07
same O 0 1.5135367902985308e-05
disorder O 0 0.0529729425907135
should O 0 2.321046395081794e-07
be O 0 6.098865856785096e-09
testable O 0 3.299494011343995e-08
by O 0 1.6769666544291795e-08
molecular O 0 1.0694495813368121e-06
methods O 0 4.7633989197493065e-07
. O 0 3.1813831924409897e-07
. O 0 2.0959998892067233e-06

A O 0 5.886355211259797e-05
mouse O 0 0.00018212731811217964
model O 0 0.00010606383148115128
of O 0 0.00031780858989804983
severe O 1 0.9995962977409363
von B-Disease 1 0.9999995231628418
Willebrand I-Disease 1 0.9999979734420776
disease I-Disease 1 0.9999942779541016
: O 0 0.0006152278510853648
defects O 1 0.9983008503913879
in O 0 8.24863018351607e-05
hemostasis O 1 0.9891881346702576
and O 0 0.07866846770048141
thrombosis B-Disease 1 0.9994977712631226
. O 0 9.958330338122323e-05

von B-Disease 1 0.9978311657905579
Willebrand I-Disease 1 0.9975751042366028
factor I-Disease 0 0.002737643662840128
( I-Disease 0 5.764807792729698e-05
vWf I-Disease 0 0.16724637150764465
) I-Disease 0 0.006431539077311754
deficiency I-Disease 1 0.9993744492530823
causes O 1 0.7345397472381592
severe O 1 0.999795138835907
von B-Disease 1 0.9999992847442627
Willebrand I-Disease 1 0.9999961853027344
disease I-Disease 1 0.9999867677688599
in O 0 8.944865840021521e-05
humans O 0 4.595698555931449e-05
. O 0 1.7217365893884562e-05

We O 0 6.988385621298221e-07
generated O 0 2.8918526595589356e-07
a O 0 4.559281023830408e-07
mouse O 0 7.638767783646472e-06
model O 0 1.6840973557918915e-06
for O 0 5.067242341283418e-07
this O 0 3.8992357076494955e-07
disease O 0 1.1313251889077947e-05
by O 0 2.942247512294216e-08
using O 0 2.733184487624385e-07
gene O 0 3.939859709589655e-07
targeting O 0 2.7585615498537663e-06
. O 0 2.091407395710121e-06

vWf B-Disease 0 0.30210110545158386
- I-Disease 1 0.97966468334198
deficient I-Disease 1 0.931187093257904
mice O 0 0.0010590037563815713
appeared O 0 2.1249310520943254e-05
normal O 0 2.189126462326385e-07
at O 0 1.8270035297973664e-06
birth O 0 1.2250193321960978e-05
; O 0 1.8771220311464276e-07
they O 0 1.0642713021979944e-07
were O 0 3.5494451822160045e-07
viable O 0 9.580544428899884e-07
and O 0 1.2958194020029623e-06
fertile O 0 1.378700017085066e-05
. O 0 7.136038220778573e-06

Neither O 0 0.0006038199062459171
vWf O 0 0.007738375570625067
nor O 0 0.00024099463189486414
vWf O 0 0.0018611664418131113
propolypeptide O 0 0.01402982883155346
( O 0 6.836130069132196e-06
von B-Disease 1 0.9541388154029846
Willebrand I-Disease 1 0.9977397918701172
antigen O 0 0.18061670660972595
II O 0 0.32872316241264343
) O 0 4.947845013703045e-07
were O 0 2.4585420987932594e-07
detectable O 0 8.459640525870782e-07
in O 0 1.0810513373371577e-08
plasma O 0 1.688289012236055e-05
, O 0 1.0611128118398483e-06
platelets O 0 0.00040825403993949294
, O 0 1.4724108154950954e-07
or O 0 1.4417534544008959e-07
endothelial O 0 0.0009611917776055634
cells O 0 4.829126964978059e-07
of O 0 1.6283506099057377e-08
the O 0 4.486639966216899e-07
homozygous O 0 4.67494573967997e-05
mutant O 0 9.989125101128593e-05
mice O 0 0.00010143707186216488
. O 0 2.74836270364176e-06

The O 0 6.509466857096413e-06
mutant O 0 0.0024682634975761175
mice O 0 0.018468370661139488
exhibited O 0 0.06978421658277512
defects O 1 0.9916784763336182
in O 0 7.2443090175511315e-06
hemostasis O 0 0.10350244492292404
with O 0 1.3552716154663358e-05
a O 0 0.0001473787851864472
highly O 0 0.015039400197565556
prolonged O 1 0.8197112679481506
bleeding O 1 0.9873773455619812
time O 0 1.3976142554383841e-06
and O 0 7.938620910863392e-06
spontaneous O 0 0.00017508673772681504
bleeding O 0 0.4785199761390686
events O 0 5.374118572376574e-08
in O 0 3.4364390444352466e-08
approximately O 0 5.13445961303205e-08
10 O 0 2.300490251627707e-07
% O 0 1.5544594589300686e-07
of O 0 1.563317141517473e-06
neonates O 0 0.033055104315280914
. O 0 9.205507922160905e-06

As O 0 6.420696990971919e-06
in O 0 5.259188355921651e-07
the O 0 1.8407149582344573e-06
human O 0 0.0001479089551139623
disease O 0 0.0010337003041058779
, O 0 4.282819645595737e-07
the O 0 2.790685016407224e-07
factor O 0 2.527086280679214e-06
VIII O 0 0.001273800851777196
level O 0 6.153517801976705e-07
in O 0 4.1435317399418636e-08
these O 0 3.80055666937551e-08
mice O 0 3.4465727367205545e-05
was O 0 3.8131056498968974e-05
reduced O 0 5.145320756128058e-06
strongly O 0 3.445477148034115e-07
as O 0 4.149130816699653e-08
a O 0 1.0129502214795139e-07
result O 0 1.7410482655577653e-07
of O 0 3.9251652594884945e-08
the O 0 5.757311782872421e-07
lack O 0 4.026327076189773e-07
of O 0 8.964489950358256e-08
protection O 0 4.786591489391867e-06
provided O 0 5.00330941122229e-07
by O 0 4.5234523895487655e-06
vWf O 0 0.00034573080483824015
. O 0 3.762801043194486e-06

Defective O 1 0.9926694631576538
thrombosis B-Disease 1 0.9988491535186768
in O 0 2.735290581767913e-05
mutant O 0 0.0076940665021538734
mice O 0 0.002890751464292407
was O 0 0.00012583124043885618
also O 0 2.2679464564134832e-06
evident O 0 1.556861434437451e-06
in O 0 5.413273029830634e-08
an O 0 1.5519799489993602e-07
in O 0 4.07937079671683e-07
vivo O 0 5.9024539950769395e-05
model O 0 6.310336175374687e-06
of O 0 4.923391679767519e-05
vascular B-Disease 1 0.9999198913574219
injury I-Disease 1 0.7399480938911438
. O 0 4.315913247410208e-05

In O 0 3.03537808576948e-06
this O 0 3.0403150219626696e-08
model O 0 9.755417522683274e-07
, O 0 1.0496474800447686e-07
the O 0 1.0844385656127997e-07
exteriorized O 0 0.0013608256122097373
mesentery O 0 0.001485112588852644
was O 0 0.00016015087021514773
superfused O 0 0.0002166282938560471
with O 0 1.0031002375399112e-06
ferric O 0 0.002451652893796563
chloride O 0 3.254205694247503e-06
and O 0 6.896912196907579e-08
the O 0 2.676280885793858e-08
accumulation O 0 1.0429017720525735e-06
of O 0 1.104499247617241e-07
fluorescently O 0 0.03633466362953186
labeled O 0 0.00054385099792853
platelets O 0 0.0010238273534923792
was O 0 8.463719495921396e-06
observed O 0 3.4800027037817927e-07
by O 0 3.3687678069327376e-07
intravital O 0 0.00019473809516057372
microscopy O 0 1.831558984122239e-05
. O 0 3.5423843200987903e-06

We O 0 1.6309387547153165e-06
conclude O 0 2.8321614991000388e-06
that O 0 2.3484412636776142e-08
these O 0 1.1657157905631266e-08
mice O 0 5.0461812861613e-06
very O 0 5.013970394429634e-08
closely O 0 1.8715570604399545e-06
mimic O 0 0.014298913069069386
severe O 0 0.3811008334159851
human O 0 0.028690682724118233
von B-Disease 1 0.9999996423721313
Willebrand I-Disease 1 0.9999964237213135
disease I-Disease 1 0.9999823570251465
and O 0 5.763878652942367e-05
will O 0 2.3433997284882935e-06
be O 0 9.73342366705765e-08
very O 0 6.652267625639752e-09
useful O 0 1.1451765757897192e-08
for O 0 2.258120623821469e-08
investigating O 0 3.3954497666854877e-06
the O 0 8.644612137231888e-08
role O 0 3.617018649038073e-07
of O 0 5.031713001812932e-08
vWf O 0 3.606107839004835e-06
in O 0 2.3280954053461755e-08
normal O 0 3.948262161657112e-08
physiology O 0 2.7838320875162026e-06
and O 0 4.208430084418069e-07
in O 0 2.2171805085235974e-06
disease O 0 7.274604286067188e-05
models O 0 1.433900797565002e-05
. O 0 1.2386607295411523e-06
. O 0 6.603953806916252e-06

Oral O 0 0.0005922940908931196
contraceptives O 0 0.005518173798918724
and O 0 6.657608537352644e-06
the O 0 5.750706350227119e-06
risk O 0 0.0007561618112958968
of O 0 0.0027662876527756453
hereditary B-Disease 1 0.9999920129776001
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999707937240601
. O 0 0.0001848270185291767

Hereditary B-Disease 1 0.9998095631599426
Ovarian I-Disease 1 0.9999667406082153
Cancer I-Disease 1 0.9995976090431213
Clinical O 0 0.01748507097363472
Study O 0 9.784986468730494e-05
Group O 0 0.00044757217983715236
. O 0 2.820993358909618e-05

BACKGROUND O 0 0.00017839149222709239
Women O 0 2.249394492537249e-05
with O 0 3.4295292152819457e-06
mutations O 0 1.5132640328374691e-05
in O 0 1.4187624230999063e-07
either O 0 2.6137522013414127e-07
the O 0 1.1262281987001188e-06
BRCA1 O 0 0.00041834337753243744
or O 0 4.771068802256195e-07
the O 0 1.171153371615219e-06
BRCA2 O 0 0.0010438109748065472
gene O 0 7.609173167111294e-07
have O 0 1.9564714648367953e-07
a O 0 5.471402459988894e-07
high O 0 0.00048003814299590886
lifetime O 0 0.0012877867557108402
risk O 0 0.0036113588139414787
of O 0 0.028089899569749832
ovarian B-Disease 1 0.999998927116394
cancer I-Disease 1 0.9998923540115356
. O 0 0.00012736325152218342

Oral O 0 0.001363603281788528
contraceptives O 1 0.5692639946937561
protect O 0 0.14549925923347473
against O 1 0.9979105591773987
ovarian B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999955892562866
in O 0 2.928432331827935e-05
general O 0 2.0037203285028227e-05
, O 0 2.732602979449439e-06
but O 0 3.1743095973979507e-07
it O 0 4.542168596799456e-08
is O 0 1.5817782639260258e-07
not O 0 1.1952157308314781e-07
known O 0 9.525643918095739e-07
whether O 0 7.435792781507189e-07
they O 0 3.4954126704178634e-07
also O 0 3.181642796334927e-06
protect O 0 6.127100277808495e-06
against O 0 1.7161235518869944e-05
hereditary B-Disease 0 0.014536816626787186
forms I-Disease 0 5.257455268292688e-05
of I-Disease 1 0.6939626336097717
ovarian I-Disease 1 0.999998927116394
cancer I-Disease 1 0.9999464750289917
. O 0 0.00010999627556884661

METHODS O 0 1.0927205948974006e-05
We O 0 2.757157346877648e-07
enrolled O 0 1.0962988199025858e-05
207 O 0 0.0002419696975266561
women O 0 4.0002189052756876e-05
with O 0 0.004765958525240421
hereditary B-Disease 1 0.9999946355819702
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999943971633911
and O 0 3.0065455575822853e-05
161 O 0 0.00011390472354833037
of O 0 4.5107256596566003e-07
their O 0 4.783556732945726e-07
sisters O 0 1.4869289771013428e-05
as O 0 1.1595780335937889e-07
controls O 0 1.3853048130840762e-07
in O 0 1.0439926256822218e-08
a O 0 4.4619469008466695e-07
case O 0 1.1427518984419294e-05
- O 0 0.0013026566011831164
control O 0 4.75805518362904e-06
study O 0 3.736553935596021e-06
. O 0 4.296070983400568e-06

All O 0 9.40121765324875e-07
the O 0 2.2160370463097934e-06
patients O 0 8.337217877851799e-06
carried O 0 8.018574817469926e-07
a O 0 3.3383466302439047e-07
pathogenic O 0 1.8158309558202745e-06
mutation O 0 1.0991315093633602e-06
in O 0 1.132638587364454e-07
either O 0 2.400102403044002e-06
BRCA1 O 0 0.0012432512594386935
( O 0 3.769266072595201e-07
179 O 0 0.00029083609115332365
women O 0 3.221573570044711e-05
) O 0 4.4627853412748664e-07
or O 0 9.3807170742366e-07
BRCA2 O 0 0.00013758114073425531
( O 0 4.131493938075437e-07
28 O 0 4.3632640881696716e-05
women O 0 1.602192787686363e-05
) O 0 3.897205829161976e-07
. O 0 1.0009691777668195e-06

The O 0 1.3058147487754468e-05
control O 0 1.7438564100302756e-05
women O 0 2.785284550554934e-06
were O 0 1.081028472071921e-06
enrolled O 0 4.667424491344718e-06
regardless O 0 1.295345839480433e-07
of O 0 8.014625052510382e-08
whether O 0 7.932021048873139e-07
or O 0 4.14634740764086e-07
not O 0 1.003381768782674e-07
they O 0 1.811702219356448e-07
had O 0 1.7222829455931787e-06
either O 0 5.019214199819544e-07
mutation O 0 8.826972589304205e-06
. O 0 2.5355304842378246e-06

Lifetime O 0 0.0002415759809082374
histories O 0 3.625471072155051e-05
of O 0 3.2904995350691024e-06
oral O 0 0.0002181806630687788
- O 0 0.07362527400255203
contraceptive O 0 0.0003263461694587022
use O 0 1.4112607971128455e-07
were O 0 2.496013280506304e-07
obtained O 0 2.5976146389439236e-07
by O 0 3.108480939317815e-07
interview O 0 1.637783134356141e-05
or O 0 1.0655712401330675e-07
by O 0 1.4913349843936885e-07
written O 0 4.545557530377664e-08
questionnaire O 0 8.906797006602574e-07
and O 0 3.3506296404084424e-07
were O 0 1.2877920880782767e-06
compared O 0 3.0168879675329663e-05
between O 0 1.6692841882104403e-06
patients O 0 1.850827902671881e-05
and O 0 1.288659404963255e-06
control O 0 1.4032060562385595e-06
women O 0 7.736566658422817e-07
, O 0 1.475106472526022e-07
after O 0 1.2856311286668642e-06
adjustment O 0 4.987882675777655e-07
for O 0 3.6926582680507636e-08
year O 0 2.7084485054729157e-07
of O 0 5.852675144524255e-08
birth O 0 5.9899234656768385e-06
and O 0 1.931965016410686e-06
parity O 0 2.7532276362762786e-05
. O 0 4.007749339507427e-06

RESULTS O 0 2.494428917998448e-05
The O 0 5.244678504823241e-07
adjusted O 0 0.00021957118588034064
odds O 0 0.0034996450413018465
ratio O 0 0.00012516434071585536
for O 1 0.5953854322433472
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999977350234985
associated O 0 6.57076234347187e-05
with O 0 7.200106892923941e-07
any O 0 4.824703481176584e-08
past O 0 3.8125187984405784e-07
use O 0 9.759970964751119e-08
of O 0 2.9960270353512897e-07
oral O 0 8.104480366455391e-05
contraceptives O 0 0.0016549589345231652
was O 0 1.8541717508924194e-05
0 O 0 7.58734995542909e-06
. O 0 3.560144477887661e-06

5 O 0 4.4115466153016314e-05
( O 0 4.849451897825929e-07
95 O 0 1.1730827509381925e-06
percent O 0 1.922056617331691e-05
confidence O 0 2.2876704406371573e-06
interval O 0 2.0871962647106557e-07
, O 0 2.8091674764141317e-08
0 O 0 1.0878734713060112e-07
. O 0 2.850210956140131e-09
3 O 0 2.2833710033864918e-08
to O 0 7.652478650754801e-09
0 O 0 1.9862905276113452e-07
. O 0 1.1574120328816662e-08
8 O 0 3.08593826048309e-07
) O 0 7.447091832091246e-08
. O 0 4.651484175610676e-07

The O 0 2.2607253413298167e-05
risk O 0 0.0004082830564584583
decreased O 0 2.4776765712886117e-05
with O 0 2.04024701133676e-07
increasing O 0 6.788177984162758e-07
duration O 0 4.400339150834043e-07
of O 0 5.380251977271655e-08
use O 0 5.090564627607819e-07
( O 0 1.5660432950426184e-07
P O 0 1.7254214981221594e-05
for O 0 1.6517842027496954e-07
trend O 0 1.0459217492098105e-06
, O 0 1.424493376589453e-07
< O 0 4.51056649808379e-07
0 O 0 2.066376794118696e-07
. O 0 1.1525480125840204e-08
001 O 0 5.997520474920748e-06
) O 0 1.3937960119392301e-08
; O 0 2.4447175395181375e-09
use O 0 2.3629891376941714e-09
for O 0 1.5092446403741633e-08
six O 0 2.463411874487065e-07
or O 0 9.734333161759423e-08
more O 0 3.791057778812501e-08
years O 0 5.157607574801659e-06
was O 0 9.538962331134826e-05
associated O 0 1.89514906878685e-07
with O 0 1.0605504030536395e-08
a O 0 1.2678457039783098e-07
60 O 0 6.106393470872717e-07
percent O 0 2.082143328152597e-05
reduction O 0 1.3786802810500376e-05
in O 0 2.492058456482482e-06
risk O 0 3.720330641954206e-05
. O 0 4.01561510443571e-06

Oral O 0 0.000603823340497911
- O 0 0.01163959689438343
contraceptive O 0 0.0014265017816796899
use O 0 4.904991783405421e-06
protected O 0 0.016945436596870422
against O 1 0.9931603670120239
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999710321426392
both O 0 1.813423750718357e-06
for O 0 1.1864274256367935e-06
carriers O 0 1.0692970136005897e-05
of O 0 5.5152625577647996e-08
the O 0 4.691755293606548e-06
BRCA1 O 0 0.0171342883259058
mutation O 0 1.553287438582629e-05
( O 0 5.094070729683153e-07
odds O 0 0.00029944442212581635
ratio O 0 1.8507180357119069e-06
, O 0 2.6431300170770555e-07
0 O 0 3.803378092470666e-07
. O 0 7.969941151486637e-09
5 O 0 3.697324046925132e-08
; O 0 1.8143921920454886e-08
95 O 0 3.3216454653484107e-07
percent O 0 8.584509487263858e-06
confidence O 0 1.7748693892372103e-07
interval O 0 6.889982984148446e-08
, O 0 3.573440210402623e-08
0 O 0 6.512066619279722e-08
. O 0 3.8698559912120345e-09
3 O 0 2.7031939353605594e-08
to O 0 1.2691190320879286e-08
0 O 0 2.3242670010859e-07
. O 0 1.8371773435887917e-08
9 O 0 5.191922127778525e-07
) O 0 6.886248904436343e-09
and O 0 7.99963917330615e-09
for O 0 2.7765507226718e-08
carriers O 0 7.651021292076621e-07
of O 0 1.644183100779628e-08
the O 0 1.0885102028623805e-06
BRCA2 O 0 0.0010964511893689632
mutation O 0 2.9031371013843454e-06
( O 0 2.546636324041174e-07
odds O 0 3.158776962663978e-05
ratio O 0 5.538057621379266e-07
, O 0 1.0921479542957968e-07
0 O 0 5.724102152271371e-07
. O 0 1.4665257452861624e-08
4 O 0 1.2316844788529124e-07
; O 0 3.572281670471966e-08
95 O 0 5.760563794865448e-07
percent O 0 1.1564824490051251e-05
confidence O 0 2.5459732455601625e-07
interval O 0 6.211701020220062e-08
, O 0 3.146430316292026e-08
0 O 0 8.436552434432087e-08
. O 0 3.6321563534613688e-09
2 O 0 3.900343159557451e-08
to O 0 6.0849800753715044e-09
1 O 0 6.583125866654882e-08
. O 0 1.4217552468664962e-08
1 O 0 2.4581507318544027e-07
) O 0 1.4431111594603863e-07
. O 0 7.048296879474947e-07

CONCLUSIONS O 0 0.00018003587319981307
Oral O 0 0.0002139932184945792
- O 0 0.004916096571832895
contraceptive O 0 0.0005970255006104708
use O 0 6.675172699033283e-07
may O 0 1.0981947298205341e-06
reduce O 0 1.2603727554960642e-06
the O 0 9.846220336839906e-07
risk O 0 0.000348196888808161
of O 0 0.01429238822311163
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999885559082031
in O 0 5.23346398040303e-06
women O 0 3.72875092580216e-06
with O 0 9.918147725329618e-07
pathogenic O 0 3.4162110296165338e-06
mutations O 0 9.655813073550235e-07
in O 0 3.791781111317505e-08
the O 0 1.0170879249926656e-06
BRCA1 O 0 0.0006076304125599563
or O 0 1.7163445590995252e-05
BRCA2 O 0 0.0013088899431750178
gene O 0 4.6501532779075205e-05

A O 0 0.0001274947280762717
Japanese O 0 0.0005380899528972805
family O 0 0.00015406485181301832
with O 0 4.2142430174862966e-05
adrenoleukodystrophy B-Disease 1 0.9999566078186035
with O 0 1.3323976872925414e-06
a O 0 3.214414903141005e-07
codon O 0 1.2297929288251908e-06
291 O 0 2.652643706824165e-05
deletion O 0 1.2355953913356643e-05
: O 0 1.2223523526699864e-07
a O 0 9.038286634677206e-07
clinical O 0 2.1016501705162227e-05
, O 0 3.3185976917593507e-06
biochemical O 0 0.0001936521293828264
, O 0 3.3396090657333843e-06
pathological O 0 0.00023543644056189805
, O 0 2.0282068362575956e-06
and O 0 5.62815830562613e-06
genetic O 0 2.9312375772860833e-05
report O 0 1.7510137695353478e-05
. O 0 8.946228263084777e-06

We O 0 2.0268648768251296e-06
report O 0 1.5499225582971121e-06
a O 0 7.83769678491808e-07
Japanese O 0 7.76090455474332e-05
family O 0 7.426126103382558e-05
with O 0 0.002593521261587739
adrenoleukodystrophy B-Disease 1 0.9999984502792358
( O 0 0.022316880524158478
ALD B-Disease 1 0.9999967813491821
) O 0 2.70356576947961e-06
with O 0 1.5921862939194398e-07
a O 0 3.7764550597785274e-07
three O 0 5.756521659350256e-07
base O 0 1.0462636055308394e-05
pair O 0 5.287038584356196e-05
deletion O 0 2.229588062618859e-05
( O 0 2.4627826178402756e-07
delGAG O 0 1.8530567103880458e-05
291 O 0 1.5683879610151052e-05
) O 0 4.40235368159847e-08
in O 0 5.912477973879504e-08
the O 0 7.56780991650885e-06
ALD B-Disease 1 0.9999371767044067
gene O 0 2.0784556909347884e-05
. O 0 6.778876468160888e-06

A O 0 3.143552748952061e-05
variety O 0 1.0954374829452718e-06
of O 0 3.6149700122223294e-07
phenotypes O 0 5.710481127607636e-05
were O 0 2.064219415842672e-06
observed O 0 2.5504547807031486e-07
within O 0 1.0459019428310512e-08
this O 0 7.273234814419993e-08
family O 0 1.5507413991144858e-05
. O 0 7.76998967921827e-06

While O 0 2.1253768863971345e-05
the O 0 2.062847670458723e-06
proband O 0 0.05179675668478012
( O 0 2.0625427623599535e-06
patient O 0 1.725884067127481e-05
1 O 0 4.532978437055135e-06
) O 0 1.3645188801092445e-06
was O 0 5.204499029787257e-05
classified O 0 6.256982305785641e-05
as O 0 5.303513717080932e-06
having O 0 6.528384801640641e-06
a O 0 1.3249482435639948e-06
rare O 0 3.867205577989807e-06
intermediate O 0 1.0848498277482577e-06
type O 0 9.798158089324716e-07
of O 0 3.683415741306817e-07
adult O 0 0.00031949099502526224
cerebral O 0 0.190619558095932
and O 0 4.741747034131549e-05
cerebello O 1 0.6095942258834839
- O 1 0.7523397207260132
brain O 0 0.1291624754667282
stem O 0 0.00011367479601176456
forms O 0 2.5252936097786005e-07
, O 0 1.1457017308202921e-06
his O 0 1.1838182217616122e-05
younger O 0 0.0005443475674837828
brother O 0 0.004986391868442297
( O 0 6.249300668059732e-07
patient O 0 5.183974735700758e-06
2 O 0 2.3528946258011274e-06
) O 0 3.0168942544150923e-07
and O 0 4.538212579063838e-06
nephew O 0 0.24635836482048035
( O 0 1.5699462210250203e-06
patient O 0 1.2305741620366462e-05
3 O 0 3.5087091418972705e-06
) O 0 4.002132527602953e-07
had O 0 1.2815784430131316e-05
a O 0 4.7624791477574036e-05
childhood O 0 0.12253294140100479
ALD B-Disease 1 0.9999829530715942
type O 0 0.004994174465537071
. O 0 4.2071955249411985e-05

Another O 0 0.0004983083344995975
nephew O 1 0.646351158618927
( O 0 1.4405167348741088e-05
patient O 0 9.341981785837561e-05
4 O 0 7.086140158207854e-06
) O 0 6.204382430041733e-08
of O 0 1.7683055375528056e-07
patient O 0 1.4309188372862991e-05
1 O 0 1.036289813782787e-05
was O 0 0.0010237360838800669
classified O 0 3.1829953513806686e-05
as O 0 2.2082545001467224e-06
having O 0 6.327529263217002e-06
an O 0 1.80876213562442e-06
adolescent O 0 0.0005609515937976539
form O 0 2.911521278292639e-06
. O 0 6.281576133915223e-06

The O 0 1.7821248547988944e-06
tau O 0 6.901780579937622e-06
level O 0 3.92288313832978e-07
in O 0 3.66150487707273e-08
the O 0 1.595060155068495e-07
cerebrospinal O 0 0.01732701249420643
fluid O 0 0.0069570220075547695
( O 0 1.3800102351524401e-05
CSF O 1 0.9981774091720581
) O 0 6.173702900014177e-07
in O 0 4.511396696216252e-07
patient O 0 7.378261670965003e-06
1 O 0 3.4809727367246523e-06
was O 0 0.00035227014450356364
as O 0 1.4234884702091222e-06
high O 0 5.1552120567066595e-05
as O 0 2.4510134721822396e-07
that O 0 5.3807955424645115e-08
of O 0 1.3241802889751852e-06
patients O 0 0.0002703922800719738
with O 0 0.0014483608538284898
Alzheimers B-Disease 1 0.9999802112579346
disease I-Disease 0 0.38906508684158325
( O 0 9.954251254384872e-07
AD B-Disease 0 0.0001786328648449853
) O 0 1.7963711798074655e-06
. O 0 2.230314294138225e-06

His O 0 0.00020416887127794325
brain O 0 0.004459564574062824
magnetic O 0 4.417802483658306e-05
resonance O 0 5.5394975788658485e-05
image O 0 0.00016222079284489155
( O 0 4.843919214181369e-06
MRI O 0 0.09165434539318085
) O 0 5.268784661893733e-06
showed O 0 0.012577720917761326
abnormalities B-Disease 0 0.4227263033390045
in I-Disease 0 3.055517368011351e-07
the I-Disease 0 8.552554504603904e-07
bilateral I-Disease 0 0.00024460264830850065
cerebellar I-Disease 0 0.11677374690771103
hemispheres I-Disease 0 0.0014549077022820711
and O 0 0.0008143142331391573
brain O 0 0.12314128875732422
stem O 0 0.0018157181330025196
, O 0 9.43128270591842e-07
but O 0 1.8093160747412185e-07
not O 0 4.7351047527399714e-08
in O 0 1.560827769253592e-07
the O 0 1.5711470041424036e-05
cerebral O 1 0.9288621544837952
white O 0 0.007589960005134344
matter O 0 6.211523100319027e-07
, O 0 2.8756869596691104e-07
where O 0 1.8943720192510227e-07
marked O 0 1.1119179816887481e-06
reductions O 0 4.706472282123286e-06
of O 0 5.985778273043252e-08
the O 0 7.379267572105164e-06
cerebral O 1 0.7650789022445679
blood O 0 0.00046558285248465836
flow O 0 9.874204351945082e-07
and O 0 5.207194817558047e-07
oxygen O 0 6.292802936513908e-07
metabolism O 0 6.612004881390021e-07
were O 0 2.946853783214465e-07
clearly O 0 9.924394817062421e-08
demonstrated O 0 5.906560218704726e-08
by O 0 9.270932466165505e-09
positron O 0 2.5926852686097845e-05
emission O 0 3.641617468019831e-06
tomography O 0 2.426633727736771e-05
( O 0 5.705979901904357e-07
PET O 0 6.15027456660755e-05
) O 0 4.460794116312172e-07
. O 0 1.1713410685842973e-06

In O 0 5.828976281918585e-05
patients O 0 0.0005193130346015096
2 O 0 6.0103748182882555e-06
and O 0 1.7556754983161227e-06
3 O 0 1.7759779211701243e-06
, O 0 1.1223313833852444e-07
the O 0 5.4480974398529725e-08
autopsy O 0 4.1629322367953137e-05
findings O 0 1.2363155292405281e-05
showed O 0 0.0019994075410068035
massive O 0 0.005718087777495384
demyelination B-Disease 1 0.9976255297660828
of I-Disease 0 8.055932994466275e-06
the I-Disease 0 0.00027153361588716507
cerebral I-Disease 1 0.992095947265625
white I-Disease 0 0.002377307042479515
matter I-Disease 0 2.5323356567241717e-07
with O 0 9.705633630119337e-08
sparing O 0 8.203596166822535e-07
of O 0 8.229198300568896e-08
the O 0 1.1583682635318837e-06
U O 0 0.02170695550739765
- O 0 0.05744118615984917
fibers O 0 0.00035827793180942535
, O 0 1.0574139253094472e-07
compatible O 0 1.580989419380785e-07
with O 0 5.5367749496326724e-08
the O 0 1.0061184241294541e-07
findings O 0 1.322095613431884e-06
of O 0 1.3708814776691725e-06
childhood O 0 0.017178203910589218
ALD B-Disease 1 0.9998695850372314
. O 0 5.545803651330061e-05

Oleic O 0 0.04247481748461723
and O 0 5.909808896831237e-05
erucic O 0 0.22992520034313202
acids O 0 1.9038647224078886e-05
( O 0 2.0966467673133593e-07
Lorenzos O 0 0.00012920299195684493
Oil O 0 1.7594149539945647e-05
) O 0 5.770153421735813e-08
were O 0 1.9811749041309668e-07
administered O 0 2.4407546561633353e-07
to O 0 4.3915855485465727e-07
patients O 0 3.400731657166034e-06
1 O 0 5.44290344350884e-07
and O 0 4.4799529064221133e-07
4 O 0 2.272423671456636e-06
, O 0 2.3220603395657236e-07
but O 0 2.461497494721243e-08
sufficient O 0 3.822292882205147e-08
effectiveness O 0 1.15244006337889e-06
was O 0 3.369039177414379e-06
not O 0 4.806462072792783e-08
obtained O 0 1.4829802239546552e-06
. O 0 3.3227081530640135e-06

The O 0 6.843723440397298e-06
findings O 0 1.5163873285928275e-05
in O 0 3.6740485143127444e-07
this O 0 4.383024787557588e-08
family O 0 4.193905169813661e-06
suggest O 0 9.962246849681833e-07
that O 0 1.2110899660910945e-07
delGAG291 O 0 2.6355251975473948e-05
is O 0 3.244173285565921e-08
part O 0 4.887398219466377e-08
of O 0 6.815884034949704e-08
the O 0 1.1815394600489526e-06
cause O 0 2.7906128252652707e-06
of O 0 4.4509948793347576e-07
Japanese O 0 0.005644825287163258
ALD B-Disease 1 0.9998914003372192
with O 0 2.75883780886943e-06
phenotypic O 0 4.511475344770588e-05
variations O 0 3.187296533724293e-05
. O 0 6.881970421090955e-06

Moreover O 0 0.0003481064341031015
, O 0 2.7054434212914202e-06
although O 0 1.2298674789690267e-07
the O 0 3.8309494243549125e-08
scale O 0 4.141555564274313e-06
of O 0 6.90253116886197e-08
the O 0 2.423414571239846e-07
study O 0 6.213981578184757e-07
is O 0 3.995706663317833e-07
limited O 0 6.985493996580772e-07
, O 0 3.8560031612178136e-07
there O 0 1.576668928748859e-08
is O 0 2.676464738726736e-08
a O 0 3.329298010612547e-07
possibility O 0 5.352434072847245e-06
that O 0 4.506829895944975e-07
PET O 0 0.0001541509700473398
can O 0 2.717524978379515e-07
detect O 0 1.3474900697474368e-05
an O 0 1.226623339789512e-06
insidious B-Disease 0 0.023065365850925446
lesion I-Disease 0 0.317609041929245
which O 0 6.328177164505178e-07
is O 0 3.838047746285156e-07
undetectable O 0 6.128304448793642e-06
by O 0 4.562703992405659e-08
computed O 0 4.3459244807309005e-06
tomogram O 0 0.0018727686256170273
( O 0 3.908386929651897e-07
CT O 0 0.018832961097359657
) O 0 1.1009068856537851e-07
or O 0 1.4624231425841572e-07
MRI O 0 0.00015864150191191584
analysis O 0 1.8526927192397125e-07
, O 0 5.329130203790555e-07
and O 0 2.411313744232757e-07
that O 0 1.014214134897884e-08
the O 0 3.05120124721725e-08
higher O 0 4.97816927236272e-07
level O 0 3.719136287827496e-08
of O 0 1.3025401202071407e-08
tau O 0 2.9839054604963167e-07
reflects O 0 1.555755169135864e-08
the O 0 2.7962132609360424e-09
process O 0 8.39098834859442e-09
of O 0 2.2067041527407127e-07
neuronal B-Disease 0 0.024320943281054497
degeneration I-Disease 1 0.9805986881256104
in O 0 0.0009867812041193247
ALD B-Disease 1 0.9999560117721558
. O 0 0.00014535868831444532

Lorenzos O 0 0.17146654427051544
Oil O 0 0.0006091162213124335
should O 0 4.5155417183195823e-07
be O 0 2.2941797794828744e-08
given O 0 4.712388701477721e-09
in O 0 5.908720623892805e-09
the O 0 2.0557404667442825e-08
early O 0 4.761296281685645e-07
stage O 0 8.40999655338237e-06
. O 0 3.13155851472402e-07
. O 0 2.183052174586919e-06

Nonsense O 0 0.0005341521464288235
mutation O 0 0.000134616406285204
in O 0 4.6680378318342264e-07
exon O 0 5.349438652046956e-05
4 O 0 7.400632853205025e-07
of O 0 8.177345733884067e-08
human O 0 2.6449455958754697e-07
complement O 0 1.1010996558979969e-06
C9 O 0 0.021616540849208832
gene O 0 1.6968430145425373e-06
is O 0 8.558448882922676e-08
the O 0 2.5944186177184747e-07
major O 0 1.4163902051222976e-05
cause O 0 2.2250308120419504e-06
of O 0 8.494671419612132e-07
Japanese O 0 0.0007286757463589311
complement B-Disease 0 0.0010099471546709538
C9 I-Disease 1 0.9983861446380615
deficiency I-Disease 1 0.8075718283653259
. O 0 8.084255568974186e-06

Deficiency B-Disease 1 0.9918462634086609
of I-Disease 0 1.3539671499529504e-06
the I-Disease 0 1.071701831278915e-06
ninth I-Disease 0 0.0001255655224667862
component I-Disease 0 1.8284904399479274e-06
of I-Disease 0 2.6942356612380536e-07
human I-Disease 0 1.1380255955373286e-06
complement I-Disease 0 2.6505285859457217e-06
( O 0 5.624909817925072e-07
C9 O 0 0.017662541940808296
) O 0 2.0199399841658305e-07
is O 0 2.127373832649937e-08
the O 0 1.241035789689704e-07
most O 0 2.237092530776863e-06
common O 0 0.0006860016728751361
complement B-Disease 1 0.9994229078292847
deficiency I-Disease 1 0.9999711513519287
in O 0 1.1677051361402846e-06
Japan O 0 9.154024155577645e-05
but O 0 7.69045072956942e-07
is O 0 7.571084665869421e-07
rare O 0 2.034431190622854e-06
in O 0 7.056374329295068e-08
other O 0 1.7643654359744687e-07
countries O 0 2.388791529028822e-07
. O 0 3.5505322557582986e-06

We O 0 1.1984668617515126e-06
studied O 0 1.0279167099724873e-06
the O 0 1.0566292729663473e-08
molecular O 0 7.128666084099677e-07
basis O 0 5.2251330373565e-08
of O 0 5.299089934851509e-06
C9 B-Disease 1 0.9998408555984497
deficiency I-Disease 1 0.616901159286499
in O 0 7.18572934488293e-08
four O 0 1.1959607491007773e-06
Japanese O 0 0.0007695866515859962
C9 B-Disease 1 0.9667784571647644
- I-Disease 1 0.9808134436607361
deficient I-Disease 1 0.8787683844566345
patients O 0 0.00023897559731267393
who O 0 7.210642070276663e-05
had O 0 0.0016497878823429346
suffered O 1 0.711184561252594
from O 0 0.0027367621660232544
meningococcal B-Disease 1 0.9999192953109741
meningitis I-Disease 1 0.9995484948158264
. O 0 0.00012173269351478666

Direct O 0 1.187872044283722e-06
sequencing O 0 2.4202765871450538e-06
of O 0 1.9899611913842818e-07
amplified O 0 1.9577793864300475e-05
C9 O 0 0.00023111124755814672
cDNA O 0 9.455590088691679e-07
and O 0 3.8350879094650736e-07
DNA O 0 1.80723345692968e-05
revealed O 0 5.6915355344244745e-06
a O 0 1.1046087422528217e-07
nonsense O 0 4.102954790141666e-06
substitution O 0 9.277393786533139e-08
( O 0 6.62220358549348e-08
CGA O 0 2.7641059205052443e-05
- O 0 0.001370087149553001
- O 0 0.0003495503915473819
> O 0 4.988695309293689e-06
TGA O 0 6.473755638580769e-05
) O 0 9.624206320779649e-09
at O 0 1.1022238233238113e-08
codon O 0 1.696708196163854e-08
95 O 0 2.265661969147459e-08
in O 0 3.580820751025726e-09
exon O 0 1.2972078593520564e-06
4 O 0 1.5217514715004654e-07
in O 0 5.897494936846215e-09
the O 0 1.9953937169248093e-08
four O 0 9.969213351723738e-06
C9 B-Disease 1 0.9560314416885376
- I-Disease 1 0.8570642471313477
deficient I-Disease 0 0.02088354527950287
individuals O 0 1.2180332760181045e-06
. O 0 1.30841726786457e-06

An O 0 5.340507868822897e-06
allele O 0 8.978931873571128e-06
- O 0 3.0974399123806506e-05
specific O 0 6.938725505278853e-08
polymerase O 0 3.627297337516211e-05
chain O 0 4.4651038479059935e-05
reaction O 0 6.964806402720569e-07
system O 0 2.548465829477209e-07
designed O 0 5.6972266975208186e-06
to O 0 4.4106240437713495e-08
detect O 0 2.852537591024884e-06
exclusively O 0 3.471055975978743e-08
only O 0 4.970737599307995e-09
one O 0 3.223521005679686e-09
of O 0 6.434526689247377e-09
the O 0 4.131654662842266e-08
normal O 0 4.1968068131836844e-08
and O 0 2.470401625487284e-07
mutant O 0 1.1080035619670525e-05
alleles O 0 4.636067956198531e-07
indicated O 0 2.5105164240812883e-06
that O 0 5.5280136024293824e-09
all O 0 2.3270998461555337e-09
the O 0 3.69532848765175e-08
four O 0 4.2315168684581295e-06
patients O 0 1.215698375744978e-05
were O 0 7.362141332123429e-07
homozygous O 0 9.79073206508474e-07
for O 0 1.5284776111457177e-08
the O 0 6.020334097911473e-08
mutation O 0 2.4991837221932656e-07
in O 0 5.094813815276211e-08
exon O 0 5.4825814004288986e-05
4 O 0 2.1101800484757405e-06
and O 0 2.2127943566374597e-07
that O 0 3.629665101811952e-08
the O 0 2.751698069403119e-08
parents O 0 1.7195898749378102e-07
of O 0 7.774235655233497e-08
patient O 0 2.084786274281214e-06
2 O 0 1.1091580063293804e-06
were O 0 2.1808091332786717e-06
heterozygous O 0 5.1992979024362285e-06
. O 0 2.0601562482625013e-06

The O 0 4.850709956372157e-06
common O 0 2.261371946588042e-06
mutation O 0 1.100877057069738e-06
at O 0 2.8079440994588367e-07
codon O 0 3.068948331019783e-07
95 O 0 2.4026073219829414e-07
in O 0 2.5596451180831536e-08
exon O 0 1.5661238649045117e-05
4 O 0 5.798037364002084e-06
might O 0 2.8817211727982794e-07
be O 0 3.466879228142261e-09
responsible O 0 6.185984346984696e-08
for O 0 9.582100091165557e-08
most O 0 2.37135077441053e-06
Japanese O 0 0.019574293866753578
C9 B-Disease 1 0.9992901086807251
deficiency I-Disease 1 0.565828800201416
. O 0 4.466481016152102e-07
. O 0 2.413424226688221e-06

BRCA1 O 0 0.010817836970090866
required O 0 2.0015743302792544e-06
for O 0 2.895144461945165e-07
transcription O 0 1.0549644684942905e-05
- O 0 0.004323398694396019
coupled O 0 0.00013714261876884848
repair O 0 0.0016697380924597383
of O 0 8.749747735237179e-07
oxidative O 0 0.018044237047433853
DNA O 0 0.018477363511919975
damage O 0 0.017309095710515976
. O 0 3.864993777824566e-05

The O 0 0.00042695875163190067
breast B-Disease 1 0.9993739724159241
and I-Disease 1 0.9990187883377075
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
susceptibility O 0 0.16187696158885956
gene O 0 3.9150138036347926e-05
BRCA1 O 0 0.00036401732359081507
encodes O 0 4.465357960725669e-06
a O 0 2.6091149265994318e-05
zinc O 1 0.5769284963607788
finger O 0 0.0001621269475435838
protein O 0 6.460070522962269e-08
of O 0 2.3584783903629614e-08
unknown O 0 2.152226443286054e-06
function O 0 5.549117076952825e-07
. O 0 4.073992840858409e-06

Association O 0 7.723295857431367e-05
of O 0 2.944831010154303e-07
the O 0 8.065212000474276e-07
BRCA1 O 0 0.0001181453189929016
protein O 0 1.1629446561300938e-07
with O 0 2.459137249388732e-08
the O 0 1.0503664782390842e-07
DNA O 0 0.0001750981027726084
repair O 0 0.010333222337067127
protein O 0 1.929348627527361e-06
Rad51 O 0 0.00010110293806064874
and O 0 3.2687233897377155e-07
changes O 0 2.1516500581242326e-08
in O 0 4.035296541360367e-09
the O 0 5.0759552117085605e-09
phosphorylation O 0 6.625311499419695e-08
and O 0 4.727849045593757e-07
cellular O 0 4.224797885399312e-05
localization O 0 1.7137205077233375e-06
of O 0 1.8137589208322424e-08
the O 0 5.638111133521306e-08
protein O 0 1.0450428788999488e-07
after O 0 1.3061606978226337e-06
exposure O 0 6.166218895486963e-07
to O 0 1.116406167511741e-08
DNA O 0 1.6079113265732303e-05
- O 0 0.0019000336760655046
damaging O 0 0.00019770933431573212
agents O 0 2.7755083920055768e-06
are O 0 1.2763993417763686e-08
consistent O 0 4.815023046944589e-08
with O 0 8.221793024176804e-08
a O 0 4.737363212825585e-07
role O 0 9.639584277465474e-07
for O 0 4.6494176331179915e-07
BRCA1 O 0 3.869806096190587e-05
in O 0 2.8897184733978065e-07
DNA O 0 0.00034532297286204994
repair O 0 0.060371629893779755
. O 0 3.0012541174073704e-05

Here O 0 9.258173122361768e-06
, O 0 4.629493730590184e-07
it O 0 1.4338220388765421e-08
is O 0 1.3114896724175651e-08
shown O 0 5.972867711534491e-08
that O 0 2.9346251650963495e-08
mouse O 0 3.67429711332079e-05
embryonic O 0 0.0003009650681633502
stem O 0 0.006362084299325943
cells O 0 9.87526509561576e-05
deficient B-Disease 0 0.001895724213682115
in I-Disease 0 5.620850060950033e-07
BRCA1 I-Disease 0 0.0006337511003948748
are O 0 3.345533912124665e-07
defective O 0 0.001026066835038364
in O 0 2.90789813561787e-07
the O 0 4.218210278850165e-07
ability O 0 2.9651832278432266e-07
to O 0 1.0472932743255114e-08
carry O 0 5.069804132062927e-08
out O 0 6.713196398777654e-08
transcription O 0 4.852079769079864e-07
- O 0 0.0001724675967125222
coupled O 0 1.7163445590995252e-05
repair O 0 0.0006474663387052715
of O 0 2.1328287402866408e-07
oxidative O 0 0.006885156035423279
DNA O 0 0.1445041000843048
damage O 0 0.27939969301223755
, O 0 6.663795375061454e-06
and O 0 1.965029696293641e-06
are O 0 1.057621759059657e-07
hypersensitive O 0 1.33707289933227e-05
to O 0 9.052462246472714e-08
ionizing O 0 1.6400650565628894e-05
radiation O 0 2.8068807296222076e-06
and O 0 1.1686927336995723e-07
hydrogen O 0 4.0304094000020996e-06
peroxide O 0 0.00031726097222417593
. O 0 1.776896056071564e-06

These O 0 6.675732606709062e-07
results O 0 1.052313109539682e-06
suggest O 0 1.058710040524602e-06
that O 0 1.421631026232717e-07
BRCA1 O 0 2.4627577658975497e-05
participates O 0 5.144075885255006e-07
, O 0 1.5033801048502937e-07
directly O 0 1.1154998702522789e-07
or O 0 2.0906247755192453e-07
indirectly O 0 5.859499651705846e-06
, O 0 2.675197094959003e-07
in O 0 8.127835116056303e-08
transcription O 0 4.28674047725508e-06
- O 0 0.0023167964536696672
coupled O 0 6.542033224832267e-05
repair O 0 0.0017048652516677976
of O 0 5.310506026035e-07
oxidative O 0 0.01705162040889263
DNA O 0 0.042822275310754776
damage O 0 0.005907964892685413
. O 0 9.771814575287863e-07
. O 0 5.324102403392317e-06

Truncation O 0 0.0017213465180248022
mutations O 0 0.0006480683223344386
in O 0 7.590517157041177e-07
the O 0 3.807428470281593e-07
transactivation O 0 0.00026955187786370516
region O 0 1.476601369176933e-06
of O 0 2.3772511781317007e-07
PAX6 O 0 0.007420255336910486
result O 0 3.5615742035588482e-06
in O 0 5.608571882476099e-07
dominant O 0 4.8745438107289374e-05
- O 0 0.005076216068118811
negative O 0 6.89546459398116e-06
mutants O 0 3.310194006189704e-05
. O 0 1.7545389709994197e-06

PAX6 O 0 0.07508547604084015
is O 0 5.322533979779109e-06
a O 0 7.586298806927516e-07
transcription O 0 3.3650380828476045e-06
factor O 0 5.163333298696671e-07
with O 0 1.8462120721096653e-08
two O 0 5.148787352027284e-08
DNA O 0 7.418517634505406e-05
- O 0 0.0016256836242973804
binding O 0 2.654138143043383e-06
domains O 0 1.6987406752377865e-06
( O 0 1.3345591298730142e-07
paired O 0 1.549437547510024e-05
box O 0 9.008852066472173e-05
and O 0 1.062102455762215e-05
homeobox O 0 0.00031421438325196505
) O 0 4.2393587307287817e-08
and O 0 6.928172524567344e-08
a O 0 2.99915711821086e-07
proline O 0 3.869153078994714e-05
- O 0 5.634974513668567e-05
serine O 0 5.9116878219356295e-06
- O 0 2.015157042478677e-05
threonine O 0 1.6889121980057098e-05
( O 0 1.4158537453567988e-07
PST O 0 9.417956607649103e-05
) O 0 4.4640110274940525e-08
- O 0 9.730434612720273e-06
rich O 0 6.431842507481633e-07
transactivation O 0 2.070711889246013e-05
domain O 0 1.0673769565983093e-06
. O 0 1.6534781934751663e-06

PAX6 O 0 0.20472346246242523
regulates O 0 0.003096742555499077
eye O 0 0.015595603734254837
development O 0 4.128691671212437e-06
in O 0 4.2093373053830874e-07
animals O 0 4.211609621052048e-07
ranging O 0 3.3899170830409275e-06
from O 0 8.897729912860086e-07
jellyfish O 0 4.367571364127798e-06
to O 0 9.989169491575467e-09
Drosophila O 0 3.3581788017045255e-08
to O 0 3.168647211282405e-08
humans O 0 2.990566088101332e-07
. O 0 6.485342396445049e-07

Heterozygous O 0 0.00024200566986110061
mutations O 0 0.00012363295536488295
in O 0 2.430953713883355e-07
the O 0 2.08908019772025e-07
human O 0 2.0191400835756212e-06
PAX6 O 0 0.001519370125606656
gene O 0 1.4865726143398206e-06
result O 0 4.781481379723118e-07
in O 0 5.2615963141988686e-08
various O 0 8.073125457030983e-08
phenotypes O 0 6.819383997935802e-05
, O 0 4.765880021295743e-06
including O 0 0.0002840252418536693
aniridia B-Disease 1 0.9999909400939941
, O 0 0.02899661660194397
Peters B-Disease 1 0.9999830722808838
anomaly I-Disease 1 0.9999299049377441
, O 0 0.002973113674670458
autosomal B-Disease 0 0.2507103979587555
dominant I-Disease 0 0.12424112856388092
keratitis I-Disease 1 0.9905573129653931
, O 0 0.0003293985209893435
and O 0 0.0045693423599004745
familial B-Disease 1 0.9648439288139343
foveal I-Disease 1 0.9994275569915771
dysplasia I-Disease 1 0.9991446733474731
. O 0 0.00013307263725437224

It O 0 4.2455876609892584e-06
is O 0 8.962487640928885e-07
believed O 0 2.6529917249717982e-06
that O 0 3.656519753647558e-09
the O 0 1.0982345699517282e-08
mutated O 0 2.9127303946552274e-07
allele O 0 1.6230272592565598e-07
of O 0 3.0945667361947926e-08
PAX6 O 0 8.390909351874143e-05
produces O 0 3.7468163327503134e-07
an O 0 1.6312796446982247e-07
inactive O 0 1.0306210242561065e-05
protein O 0 5.141898213878449e-07
and O 0 2.641202627273742e-06
aniridia B-Disease 1 0.9998575448989868
is O 0 1.0525747711653821e-05
caused O 0 7.29350431356579e-05
due O 0 2.164816351069021e-06
to O 0 5.845389523528866e-07
genetic O 0 4.4978962250752375e-05
haploinsufficiency O 0 0.004635120276361704
. O 0 9.231830517819617e-06

However O 0 1.926703225763049e-05
, O 0 2.581845706117747e-07
several O 0 4.6100382178337895e-08
truncation O 0 0.00016525285900570452
mutations O 0 0.00010308893979527056
have O 0 2.073035830107983e-06
been O 0 5.6595690693939105e-06
found O 0 1.6318909956680727e-06
to O 0 4.360602545716574e-08
occur O 0 1.0325837962454898e-08
in O 0 1.4376202450705478e-08
the O 0 5.14875864610076e-07
C O 0 0.031552884727716446
- O 0 0.013092946261167526
terminal O 0 2.06097374757519e-05
half O 0 1.306397194866804e-07
of O 0 1.1307369618407392e-07
PAX6 O 0 0.0006907928618602455
in O 0 9.993210596803692e-07
patients O 0 5.2356058404257055e-06
with O 0 1.5420258705489687e-06
Aniridia B-Disease 1 0.997492790222168
resulting O 0 2.9112602533132304e-06
in O 0 1.660021240468268e-07
mutant O 0 5.7950846894527785e-06
proteins O 0 6.697644749920073e-08
that O 0 1.8062364048887503e-08
retain O 0 1.4469878806266934e-07
the O 0 3.4472446230893183e-08
DNA O 0 5.713128484785557e-05
- O 0 0.0010133117903023958
binding O 0 2.584646381365019e-06
domains O 0 1.1928681260542362e-06
but O 0 1.8098975829161645e-07
have O 0 1.710758681383595e-07
lost O 0 4.099833404325182e-06
most O 0 2.754437788965447e-09
of O 0 5.343982589778307e-09
the O 0 2.7653365464175295e-07
transactivation O 0 0.00010484526865184307
domain O 0 4.571407316689147e-06
. O 0 2.4233831936726347e-06

It O 0 5.08746188643272e-06
is O 0 6.141212338661717e-07
not O 0 2.6766995731009047e-08
clear O 0 5.552500326189147e-08
whether O 0 7.113183642104559e-08
such O 0 8.504051152158354e-08
mutants O 0 0.00028802204178646207
really O 0 1.911020035549882e-06
behave O 0 3.1888313856143213e-07
as O 0 1.1738466554334082e-07
loss O 0 1.478983904235065e-05
- O 0 2.1303058019839227e-05
of O 0 2.2478660355318425e-07
- O 0 0.0006363539723679423
function O 0 3.135449446745042e-07
mutants O 0 1.2608268662006594e-05
as O 0 1.8113428268407006e-07
predicted O 0 5.8387427088746335e-06
by O 0 1.2437221812433563e-06
haploinsufficiency O 0 0.0012283021351322532
. O 0 3.184001116096624e-06

Contrary O 0 1.0536252375459298e-05
to O 0 1.5898146443760197e-07
this O 0 5.077601450409475e-09
theory O 0 2.3859609399323745e-08
, O 0 2.0313059678755963e-08
our O 0 3.061144671079319e-09
data O 0 1.9653730021218507e-07
showed O 0 6.307881449174602e-06
that O 0 6.040598687917509e-09
these O 0 2.82739387458264e-09
mutants O 0 5.353215328796068e-06
are O 0 2.899025375313613e-08
dominant O 0 1.6111569038912421e-06
- O 0 1.5239039385051001e-05
negative O 0 4.8003510499938784e-08
in O 0 1.7361431403628558e-08
transient O 0 9.25750441638229e-07
transfection O 0 0.0001367455261060968
assays O 0 2.1105495761730708e-05
when O 0 4.104556978745677e-07
they O 0 3.2311248787664226e-08
are O 0 9.875465778463877e-09
coexpressed O 0 8.39615040604258e-06
with O 0 9.123218802642441e-08
wild O 0 7.021165401965845e-06
- O 0 0.0029053697362542152
type O 0 3.9844839193392545e-05
PAX6 O 0 0.0020055158529430628
. O 0 6.93863285050611e-06

We O 0 3.810403086390579e-06
found O 0 3.0168332614266546e-06
that O 0 2.071543647730323e-08
the O 0 1.0726429167107199e-07
dominant O 0 2.8850430680904537e-05
- O 0 0.011843914166092873
negative O 0 3.164403324262821e-06
effects O 0 1.5997750324459048e-06
result O 0 3.930079728320379e-08
from O 0 2.170619772812188e-08
the O 0 2.017590539082903e-08
enhanced O 0 1.010741129903181e-06
DNA O 0 1.060846170730656e-05
binding O 0 9.477627713749825e-07
ability O 0 3.151962246761286e-08
of O 0 3.995715314175641e-09
these O 0 2.8674103091930192e-08
mutants O 0 4.105768312001601e-05
. O 0 3.0049857286940096e-06

Kinetic O 0 0.00011059587268391624
studies O 0 5.348459126253147e-06
of O 0 3.2124688686963054e-07
binding O 0 2.716835297178477e-06
and O 0 7.632102665411367e-07
dissociation O 0 2.5532548534101807e-05
revealed O 0 1.0633014426275622e-05
that O 0 5.657261326064145e-09
various O 0 2.9185862615577207e-09
truncation O 0 2.9103250199113972e-05
mutants O 0 0.00012813483772333711
have O 0 3.0484011404041667e-07
3 O 0 5.898144763705204e-07
- O 0 2.7495780159370042e-05
5 O 0 3.0224032343539875e-07
- O 0 1.1962336429860443e-05
fold O 0 6.229830660231528e-07
higher O 0 1.0886642343166386e-07
affinity O 0 2.863731829449989e-08
to O 0 6.155531084850452e-10
various O 0 6.697970511559959e-10
DNA O 0 3.0215521746868035e-06
- O 0 9.186915121972561e-06
binding O 0 1.1249996134665707e-07
sites O 0 2.6841433964364114e-08
when O 0 6.088256299108252e-08
compared O 0 2.663560678684007e-07
with O 0 2.0038838144387228e-08
the O 0 4.633734107528653e-08
wild O 0 6.044558631401742e-06
- O 0 0.0036232396960258484
type O 0 6.018580825184472e-05
PAX6 O 0 0.0020735720172524452
. O 0 6.034053058101563e-06

These O 0 4.765307437537558e-07
results O 0 1.1351760349498363e-06
provide O 0 1.011475276868623e-07
a O 0 3.873746834415215e-07
new O 0 4.1348721424583346e-07
insight O 0 3.626551858815219e-07
into O 0 5.62596946807048e-09
the O 0 1.5573167644333807e-08
role O 0 7.473217067399673e-08
of O 0 2.520461528376927e-08
mutant O 0 2.4554854462621734e-05
PAX6 O 0 0.00043816922698169947
in O 0 6.597511514883081e-07
causing O 0 0.000200024907826446
aniridia B-Disease 1 0.9886931777000427
. O 0 6.941934884707734e-07
. O 0 2.428750804028823e-06

Reversal O 0 0.16967613995075226
of O 0 0.034717973321676254
severe O 1 0.9999483823776245
hypertrophic B-Disease 1 0.9999799728393555
cardiomyopathy I-Disease 1 0.9999948740005493
and O 0 0.0004077415796928108
excellent O 0 0.00024359443341381848
neuropsychologic O 0 0.1798422932624817
outcome O 0 2.429442247375846e-05
in O 0 6.325588515210256e-07
very B-Disease 0 7.555129855063569e-07
- I-Disease 0 0.008976389653980732
long I-Disease 0 6.625906826229766e-05
- I-Disease 0 0.004584875423461199
chain I-Disease 0 0.00015723104297649115
acyl I-Disease 0 3.820403799181804e-05
- I-Disease 0 0.00034216520725749433
coenzyme I-Disease 0 2.0085131836822256e-05
A I-Disease 0 0.0002070496993837878
dehydrogenase I-Disease 0 0.035161830484867096
deficiency I-Disease 0 0.09374354779720306
. O 0 2.587290282463073e-06

Very B-Disease 0 3.392602957319468e-05
- I-Disease 0 0.051749296486377716
long I-Disease 0 0.0001596134970895946
- I-Disease 0 0.0027663246728479862
chain I-Disease 0 5.4737894970458e-05
acyl I-Disease 0 8.821376468404196e-06
- I-Disease 0 2.0464394765440375e-05
coenzyme I-Disease 0 1.5836392321944004e-06
A I-Disease 0 3.6573767374648014e-06
dehydrogenase I-Disease 0 5.2379389671841636e-05
( I-Disease 0 1.493081185799383e-06
VLCAD I-Disease 1 0.7136232256889343
) I-Disease 0 0.00014921363617759198
deficiency I-Disease 0 0.13650624454021454
is O 0 5.152992343937512e-07
a O 0 3.256254058214836e-05
disorder O 0 0.005194018129259348
of O 0 8.228795991271909e-07
fatty O 0 4.571086901705712e-05
acid O 0 2.375227950324188e-06
beta O 0 1.8409170365885075e-07
oxidation O 0 2.752620105184178e-07
that O 0 1.1831581048227235e-07
reportedly O 0 3.941216709790751e-05
has O 0 2.60989622802299e-07
high O 0 5.384662927099271e-06
rates O 0 6.070869176255655e-07
of O 0 1.501826716321375e-07
morbidity O 0 0.026236431673169136
and O 0 2.7660942578222603e-05
mortality O 0 0.0005131830694153905
. O 0 7.1623967414780054e-06

We O 0 1.2147446568633313e-06
describe O 0 6.41117992472573e-07
the O 0 3.2789852610903836e-08
outcome O 0 1.0888574308864918e-07
of O 0 1.129820326184472e-08
a O 0 2.677481631963019e-07
5 O 0 2.292119006597204e-06
- O 0 0.0013727025361731648
year O 0 1.3441479495668318e-05
- O 0 0.0025412258692085743
old O 0 0.004318298771977425
girl O 0 0.0005342985386960208
with O 0 0.0055014886893332005
VLCAD B-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.9999929666519165
who O 0 0.0014820046490058303
was O 0 7.043895311653614e-05
first O 0 1.842661049522576e-06
seen O 0 2.3955610686243745e-06
at O 0 5.447805619951396e-07
5 O 0 4.5554475036624353e-07
months O 0 3.4352339639553975e-07
of O 0 1.606316857305501e-07
age O 0 0.00010027701500803232
with O 0 0.019453363493084908
severe O 1 0.9994010925292969
hypertrophic B-Disease 1 0.9999364614486694
cardiomyopathy I-Disease 1 0.9999920129776001
, O 0 0.25576281547546387
hepatomegaly B-Disease 1 0.9999974966049194
, O 0 0.28452742099761963
encephalopathy B-Disease 1 0.9989516735076904
, O 0 1.896445974125527e-05
and O 0 7.821381586836651e-05
hypotonia B-Disease 0 0.39441969990730286
. O 0 4.134915434406139e-05

Biochemical O 0 0.02808358520269394
studies O 0 0.011870596557855606
indicated O 1 0.9922590851783752
VLCAD B-Disease 1 0.9999972581863403
deficiency I-Disease 1 0.9999974966049194
caused O 0 0.005792892538011074
by O 0 4.577178970066598e-06
a O 0 2.2378062567440793e-05
stable O 0 5.39559950993862e-05
yet O 0 4.298316980566597e-06
inactive O 0 9.461506124353036e-05
enzyme O 0 3.229516005376354e-05
. O 0 2.1465443751367275e-06

Molecular O 0 0.0003989871474914253
genetic O 0 8.936595259001479e-05
analysis O 0 1.0735686828411417e-06
of O 0 5.006301648791123e-07
her O 0 4.3665691919159144e-05
VLCAD O 0 0.17377375066280365
gene O 0 3.651591441666824e-06
revealed O 0 2.322777800145559e-05
a O 0 2.0379884517751634e-06
T1372C O 0 0.00030061660800129175
( O 0 3.482449528746656e-07
F458L O 0 9.704514923214447e-06
) O 0 5.382858958569159e-08
missense O 0 6.492647571576526e-06
mutation O 0 3.1368363124784082e-06
and O 0 2.2583742520509986e-06
a O 0 2.1559326341957785e-05
1668 O 0 0.4862504303455353
ACAG O 0 0.05761626362800598
1669 O 0 0.00073832186171785
splice O 0 5.483878339873627e-05
site O 0 1.094703475246206e-05
mutation O 0 7.80327263782965e-06
. O 0 1.9817960037471494e-06

After O 0 0.00010267015022691339
initial O 0 2.7015967134502716e-05
treatment O 0 2.3535374566563405e-05
with O 0 8.012956413949723e-07
intravenous O 0 1.5843441360630095e-05
glucose O 0 1.0932271834462881e-05
and O 0 7.474462790924008e-07
carnitine O 0 0.00020634473185054958
, O 0 1.971729801653055e-07
the O 0 1.0781318593444666e-07
patient O 0 7.831616130715702e-06
has O 0 1.3196090549172368e-06
thrived O 0 6.465133083111141e-06
on O 0 1.232473437084991e-06
a O 0 1.2143750609538984e-06
low O 0 7.038027251837775e-05
- O 0 0.00116001907736063
fat O 0 2.939538035207079e-06
diet O 0 2.5895607436154933e-08
supplemented O 0 1.860805554088074e-08
with O 0 9.112241627917683e-09
medium O 0 1.15961938718101e-06
- O 0 0.00010580522939562798
chain O 0 9.598152246326208e-06
triglyceride O 0 4.482740678213304e-06
oil O 0 2.4690407371963374e-06
and O 0 1.196231806943615e-07
carnitine O 0 3.839128476101905e-05
and O 0 1.0477172907030763e-07
avoidance O 0 1.6039135743994848e-06
of O 0 1.8854377970001224e-07
fasting O 0 6.928965376573615e-06
. O 0 1.3844980912836036e-06

Her O 0 0.004281449131667614
ventricular O 1 0.9273182153701782
hypertrophy O 1 0.5803330540657043
resolved O 0 0.00033310215803794563
significantly O 0 1.6435596990049817e-05
over O 0 1.5942433719828841e-06
1 O 0 4.302208708395483e-06
year O 0 7.453516900568502e-06
, O 0 3.9409644614352146e-07
and O 0 2.2958795398153597e-06
cognitively O 0 0.018344391137361526
, O 0 6.946312396394205e-07
she O 0 9.745151601237012e-07
is O 0 8.360682812735831e-09
in O 0 7.4211685685554585e-09
the O 0 1.0836322417162592e-07
superior O 0 7.547710265498608e-05
range O 0 2.2175950107339304e-06
for O 0 1.4424978189708781e-06
age O 0 6.126760126790032e-05
. O 0 7.4597392085706815e-06

Clinical O 0 0.0019456484587863088
recognition O 0 0.00013328445493243635
of O 0 0.014681951142847538
VLCAD B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999986886978149
is O 0 2.2900410840520635e-05
important O 0 5.258195301394153e-07
because O 0 1.886824776420326e-07
it O 0 1.921977066388081e-08
is O 0 3.4166362183896126e-08
one O 0 1.8161511405878628e-08
of O 0 2.161002754519359e-08
the O 0 1.998273546632845e-07
few O 0 5.066198696113133e-07
directly O 0 4.526726479525678e-05
treatable O 1 0.9270364046096802
causes O 0 8.478831296088174e-05
of O 0 0.00020274383132345974
cardiomyopathy B-Disease 1 0.9999613761901855
in O 0 7.354039553320035e-06
children O 0 9.500246051175054e-06
. O 0 1.0512097787795938e-06
. O 0 5.6322169257327914e-06

Cloning O 0 0.00047955839545466006
of O 0 2.266188403154956e-06
a O 0 3.584134447010001e-06
novel O 0 1.7077802567655453e-06
member O 0 4.390321066694014e-07
of O 0 1.4779883095172863e-08
the O 0 1.9332428280449676e-07
low O 0 5.098012479720637e-05
- O 0 0.0011553289368748665
density O 0 8.306709787575528e-06
lipoprotein O 0 0.022202249616384506
receptor O 0 5.414356564870104e-05
family O 0 9.27476958167972e-06
. O 0 4.168914074398344e-06

A O 0 1.0640094842528924e-05
gene O 0 1.172289898931922e-06
encoding O 0 1.3662334197306336e-07
a O 0 5.611954065898317e-07
novel O 0 3.1715971999801695e-06
transmembrane O 0 6.574735743924975e-05
protein O 0 1.1441970855230466e-06
was O 0 1.1455780622782186e-05
identified O 0 3.041080844923272e-07
by O 0 4.907226180961288e-09
DNA O 0 2.0706575298845564e-07
sequence O 0 3.868977582754951e-09
analysis O 0 4.58920856871714e-09
within O 0 4.350016791221378e-09
the O 0 1.0884624543905375e-06
insulin B-Disease 0 0.00166602386161685
- I-Disease 1 0.9685884118080139
dependent I-Disease 1 0.6620574593544006
diabetes I-Disease 1 0.999993085861206
mellitus I-Disease 1 0.9999881982803345
( O 0 4.576796345645562e-05
IDDM B-Disease 0 0.14451919496059418
) O 0 2.132830729806301e-07
locus O 0 1.0362285138398875e-05
IDDM4 O 0 0.0010661687701940536
on O 0 1.1046294275729451e-05
chromosome O 0 0.001506286789663136
11q13 O 0 0.00025290210032835603
. O 0 3.2394882509834133e-06

Based O 0 1.2994431017432362e-05
on O 0 3.341603360240697e-06
its O 0 3.3647705777184456e-07
chromosomal O 0 0.011661883443593979
position O 0 2.1632586140185595e-05
, O 0 1.8712522376063134e-07
this O 0 4.977815493134585e-09
gene O 0 4.6878902537628164e-08
is O 0 1.0849015907865578e-08
a O 0 6.402478902600706e-08
candidate O 0 2.0000678091491864e-07
for O 0 1.686103274778361e-07
conferring O 0 5.057637463323772e-05
susceptibility O 0 0.0006480665178969502
to O 0 4.62971038359683e-05
diabetes B-Disease 1 0.8753790855407715
. O 0 5.588449494098313e-05

The O 0 3.0596397664339747e-06
gene O 0 3.7916113342362223e-06
, O 0 2.941392835964507e-07
termed O 0 9.291502465202939e-06
low O 0 1.1456545507826377e-05
- O 0 8.459956734441221e-05
density O 0 1.4077512560106697e-06
lipoprotein O 0 0.001076347311027348
receptor O 0 4.975785941496724e-06
related O 0 2.2870096927363193e-06
protein O 0 3.3987822689596214e-07
5 O 0 1.0237237120236387e-06
( O 0 2.802743210850167e-07
LRP5 O 0 0.0005546783795580268
) O 0 4.393965014060086e-08
, O 0 1.1960625379003886e-08
encodes O 0 3.0417130147952776e-08
a O 0 9.125219690986341e-08
protein O 0 2.702632073692257e-08
of O 0 2.587570868683997e-08
1615 O 0 6.741740799043328e-05
amino O 0 2.085913024529873e-07
acids O 0 6.904598137680296e-08
that O 0 1.4936223369232948e-09
contains O 0 3.7051581802671762e-09
conserved O 0 4.409782405900842e-08
modules O 0 4.91761056764517e-07
which O 0 1.798608337821861e-07
are O 0 2.042997415685477e-08
characteristic O 0 3.435868833889799e-08
of O 0 9.731637717891317e-09
the O 0 3.038558986645512e-07
low O 0 0.00010344610927859321
- O 0 0.009724480099976063
density O 0 1.6096051695058122e-05
lipoprotein O 0 0.06457267701625824
( O 0 3.3385899769200478e-06
LDL O 0 0.0008557505789212883
) O 0 6.532568477268796e-07
receptor O 0 4.302130946598481e-06
family O 0 5.153138317837147e-06
. O 0 2.5878973701765062e-06

These O 0 5.77890318709251e-07
modules O 0 4.781896677741315e-06
include O 0 5.428336748991569e-07
a O 0 2.2982797531767574e-07
putative O 0 6.617179678869434e-06
signal O 0 4.563761422105017e-07
peptide O 0 2.5997411512435065e-07
for O 0 1.569240559717855e-08
protein O 0 3.1887090301552234e-08
export O 0 1.363793842301675e-07
, O 0 2.914299201961512e-08
four O 0 5.151847517481656e-07
epidermal O 0 0.0043722535483539104
growth O 0 4.178717790637165e-05
factor O 0 2.40379745264363e-06
( O 0 1.9697451136835298e-07
EGF O 0 8.70075891725719e-05
) O 0 8.454610167518695e-08
repeats O 0 4.0234635889646597e-07
with O 0 1.7664295626218518e-07
associated O 0 1.2441516901162686e-06
spacer O 0 1.6404310372308828e-05
domains O 0 1.809804302865814e-06
, O 0 1.4755089239315566e-07
three O 0 3.187493575751432e-07
LDL O 0 0.0009138078894466162
- O 0 0.0023455906193703413
receptor O 0 8.976363460533321e-06
( O 0 1.041550561353688e-07
LDLR O 0 0.00029539078241214156
) O 0 1.918446379534089e-08
repeats O 0 1.6625941157144553e-07
, O 0 5.8825566640052784e-08
a O 0 8.886046742873077e-08
single O 0 1.6956201989160036e-06
transmembrane O 0 2.027006667049136e-05
spanning O 0 3.0826222428004257e-06
domain O 0 1.417852445229073e-06
, O 0 3.033399025298422e-07
and O 0 3.354044224579411e-07
a O 0 1.1234734529352863e-06
cytoplasmic O 0 2.6787358365254477e-05
domain O 0 6.449436568800593e-06
. O 0 2.7308992684993427e-06

The O 0 5.262319291432505e-07
encoded O 0 1.0267331163049676e-06
protein O 0 5.239838856141432e-07
has O 0 1.464385235294685e-07
a O 0 7.068067020554736e-08
unique O 0 1.131645319674135e-07
organization O 0 2.3243069335876498e-07
of O 0 2.0296316449730512e-07
EGF O 0 0.0017810480203479528
and O 0 1.2704804248642176e-05
LDLR O 0 0.031132806092500687
repeats O 0 3.1607419259671587e-06
; O 0 2.047874971822239e-07
therefore O 0 5.8501750999084834e-08
, O 0 5.305043941916665e-07
LRP5 O 0 0.03664982318878174
likely O 0 4.8101492211571895e-06
represents O 0 4.3560058315961214e-07
a O 0 1.3693275491277745e-07
new O 0 2.520036730402353e-07
category O 0 2.1827223406489793e-07
of O 0 8.711150201179407e-08
the O 0 4.923504093312658e-06
LDLR O 0 0.29631730914115906
family O 0 4.6151904825819656e-05
. O 0 8.563069968658965e-06

Both O 0 6.225320703379111e-06
human O 0 6.092437160987174e-06
and O 0 2.5296999410784338e-06
mouse O 0 0.0005213308031670749
LRP5 O 0 0.36990049481391907
cDNAs O 0 0.0024656690657138824
have O 0 2.3370882900053402e-06
been O 0 3.581564897103817e-06
isolated O 0 8.37962716104812e-07
and O 0 6.592951962147708e-08
the O 0 2.3005158666933312e-08
encoded O 0 1.3022996370182227e-07
mature O 0 1.258862454278642e-07
proteins O 0 3.811843729550901e-09
are O 0 2.1884984935383045e-09
95 O 0 1.3828102396473696e-07
% O 0 9.817362922603934e-08
identical O 0 4.275145784049528e-06
, O 0 7.209815180431178e-07
indicating O 0 3.493450549285626e-06
a O 0 3.019317773578223e-07
high O 0 1.7625301552470773e-05
degree O 0 7.785103548485495e-07
of O 0 1.1913999742318993e-07
evolutionary O 0 6.514366305054864e-06
conservation O 0 8.297968633996788e-06
. O 0 4.464071139409498e-07
. O 0 3.1510630833508912e-06

The O 0 4.660351805796381e-06
APC B-Disease 0 0.00021344015840440989
variants O 0 5.745279850088991e-06
I1307K O 0 2.4479759304085746e-05
and O 0 6.464582043008704e-07
E1317Q O 0 2.1745043341070414e-05
are O 0 2.2234559082789929e-07
associated O 0 2.4903643861762248e-05
with O 1 0.9564239382743835
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.004360246937721968
but O 0 2.2133799575385638e-06
not O 0 2.1639235114889743e-07
always O 0 1.542621532735211e-07
with O 0 9.370383935447535e-08
a O 0 2.382163074798882e-06
family O 0 5.563515969697619e-06
history O 0 1.3529395801015198e-05
. O 0 1.8327540601603687e-05

Classical O 1 0.7662106156349182
familial B-Disease 1 0.9998407363891602
adenomatous I-Disease 1 0.9997666478157043
polyposis I-Disease 1 0.999954342842102
( O 0 0.0014248160878196359
FAP B-Disease 0 0.12244296818971634
) O 0 2.41302609538252e-06
is O 0 3.865270343794691e-07
a O 0 8.59917690831935e-06
high O 0 0.31119707226753235
- O 1 0.998877227306366
penetrance O 1 0.9945825934410095
autosomal B-Disease 1 0.9487716555595398
dominant I-Disease 1 0.8203197717666626
disease I-Disease 0 0.10357370227575302
that O 0 4.224643532779737e-07
predisposes O 0 1.5564159184577875e-05
to O 0 6.184450995760926e-08
hundreds O 0 7.666586157029087e-07
or O 0 1.916106526778094e-07
thousands O 0 1.3796127859677654e-05
of O 0 0.023932555690407753
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
and I-Disease 1 0.9952800273895264
carcinoma I-Disease 1 0.9999998807907104
and O 0 0.00011031045141862705
that O 0 2.2421282608320325e-07
results O 0 2.652640205269563e-07
from O 0 7.55846798483617e-08
truncating O 0 1.74569522641832e-05
mutations O 0 7.446416248058085e-07
in O 0 1.9835166398252113e-08
the O 0 2.762405699741066e-07
APC B-Disease 0 0.0006207801052369177
gene O 0 2.388544089626521e-06
. O 0 2.3796583263901994e-06

A O 0 9.759787644725293e-05
variant O 0 0.00012535412679426372
of O 0 4.6913751248212066e-06
FAP B-Disease 0 0.03855143114924431
is O 0 9.688600403023884e-05
attenuated B-Disease 1 0.7317420244216919
adenomatous I-Disease 1 0.999980092048645
polyposis I-Disease 1 0.9999563694000244
coli I-Disease 1 0.9999076128005981
, O 0 9.447042430110741e-06
which O 0 2.1108571957029199e-07
results O 0 1.0391638625151245e-06
from O 0 1.3325462759894435e-06
germ O 0 0.007850553840398788
- O 0 0.002477607922628522
line O 0 3.9241567719727755e-05
mutations O 0 7.831548032299906e-07
in O 0 2.1787743165191387e-08
the O 0 6.256003359794704e-08
5 O 0 7.178434202614881e-07
and O 0 3.062957034671854e-07
3 O 0 2.637560214679979e-07
regions O 0 9.78292824527216e-09
of O 0 6.233667360078243e-09
the O 0 4.1567520270291425e-07
APC B-Disease 0 0.00037865701597183943
gene O 0 2.6332022571295965e-06
. O 0 1.6726052081139642e-06

Attenuated B-Disease 1 0.9925969839096069
adenomatous I-Disease 1 0.999762237071991
polyposis I-Disease 1 0.9998860359191895
coli I-Disease 1 0.9999749660491943
patients O 1 0.982200026512146
have O 0 2.2581141820410267e-05
" O 0 1.3296393035489018e-06
multiple O 0 8.152367809088901e-05
" O 0 0.4730564057826996
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999973773956299
( O 0 4.668243036576314e-06
typically O 0 6.494415742963611e-07
fewer O 0 1.670031224421109e-07
than O 0 2.0488158725129324e-08
100 O 0 5.7417626209144146e-08
) O 0 1.4297639516769323e-08
without O 0 5.2094271119074165e-09
the O 0 2.9307097193509435e-08
florid O 0 0.0001124604677897878
phenotype O 0 4.566292773233727e-06
of O 0 1.887425753466232e-07
classical O 0 5.796775803901255e-05
FAP B-Disease 0 0.0011336089810356498
. O 0 5.824389063491253e-06

Another O 0 2.6077839720528573e-05
group O 0 3.444124376983382e-05
of O 0 2.8084500627301168e-06
patients O 0 3.785566514125094e-05
with O 0 7.699756565671123e-07
multiple O 0 0.0001263471640413627
adenomas B-Disease 1 0.9843581914901733
has O 0 2.151406260963995e-05
no O 0 2.1050816201295675e-07
mutations O 0 6.596876573894406e-07
in O 0 4.530401298552533e-08
the O 0 3.7821388332304196e-07
APC B-Disease 0 0.001141233486123383
gene O 0 5.15793885824678e-07
, O 0 1.0438714781457747e-07
and O 0 8.788016714333935e-08
their O 0 1.382287990736586e-07
phenotype O 0 8.049082680372521e-06
probably O 0 4.1721099819369556e-07
results O 0 8.142265528476855e-08
from O 0 5.681139469970731e-08
variation O 0 6.407830142052262e-07
at O 0 1.9666756543301744e-06
a O 0 1.323103447248286e-06
locus O 0 5.438134030555375e-05
, O 0 1.055579787134775e-06
or O 0 1.8382117161763745e-07
loci O 0 4.673926525811112e-07
, O 0 1.1504071295576068e-07
elsewhere O 0 4.5118181191128315e-08
in O 0 8.089784842013614e-09
the O 0 1.5843083644995204e-07
genome O 0 2.9360946427914314e-05
. O 0 5.923979642830091e-06

Recently O 0 0.018320197239518166
, O 0 1.1456610991444904e-05
however O 0 7.525883916059684e-07
, O 0 1.533230431505217e-07
a O 0 5.473416990753321e-07
missense O 0 8.764998347032815e-05
variant O 0 2.0187673726468347e-05
of O 0 2.623436785142985e-06
APC B-Disease 0 0.01115814596414566
( O 0 1.3679065204996732e-06
I1307K O 0 3.783025749726221e-05
) O 0 7.65985674888725e-08
was O 0 4.129026365262689e-06
described O 0 1.872462235041894e-06
that O 0 4.0609943852132346e-08
confers O 0 3.3010749689310614e-07
an O 0 7.21885612620099e-07
increased O 0 7.198296952992678e-05
risk O 0 0.008059513755142689
of O 1 0.7904769778251648
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00012066747149219736
including O 0 2.245810719614383e-05
multiple O 0 0.0004002703935839236
adenomas B-Disease 1 0.8785075545310974
, O 0 6.116265012678923e-06
in O 0 1.5872044514253503e-06
Ashkenazim O 0 0.004083636216819286
. O 0 8.99036240298301e-06

We O 0 5.443725967779756e-06
have O 0 5.579528874477546e-07
studied O 0 4.5235026391310384e-07
a O 0 3.106785229078923e-08
set O 0 3.776767698582262e-08
of O 0 4.0546325408286066e-08
164 O 0 0.004005237948149443
patients O 0 4.5564895117422566e-05
with O 0 1.1176086445630062e-05
multiple O 1 0.8674564957618713
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999982118606567
and I-Disease 0 0.03973531723022461
/ I-Disease 0 0.10060550272464752
or I-Disease 0 0.05217719078063965
carcinoma I-Disease 1 0.9999978542327881
and O 0 1.925716787809506e-05
analyzed O 0 2.80702552117873e-05
codons O 0 8.795989742793608e-06
1263 O 0 0.00012353066995274276
- O 0 0.0003207184199709445
1377 O 0 0.00027491559740155935
( O 0 5.2952021434293783e-08
exon O 0 1.5907800843706354e-05
15G O 0 9.16981116461102e-06
) O 0 3.1201392580726406e-09
of O 0 8.349858027223434e-10
the O 0 1.3057838366137275e-08
APC B-Disease 0 5.126169980940176e-06
gene O 0 2.272127552771508e-08
for O 0 6.358812498774569e-08
germ O 0 0.00025859844754450023
- O 0 0.0002788424608297646
line O 0 2.3906630303827114e-05
variants O 0 4.019274001620943e-06
. O 0 3.120866267636302e-06

Three O 0 9.499919542577118e-05
patients O 0 0.0002267398522235453
with O 0 4.5700986106567143e-07
the O 0 3.039941418592207e-07
I1307K O 0 6.802489951951429e-05
allele O 0 2.0688823951786617e-06
were O 0 1.4626868960476713e-06
detected O 0 9.167644634544558e-07
, O 0 5.304742423106745e-09
each O 0 5.073361286633826e-09
of O 0 5.191892569200718e-07
Ashkenazi O 0 0.001523443846963346
descent O 0 0.0003688882279675454
. O 0 9.765547474671621e-06

Four O 0 0.00020800284983124584
patients O 0 0.0061591267585754395
had O 0 5.271764166536741e-05
a O 0 3.072007075388683e-06
germ O 0 0.024812739342451096
- O 0 0.002912971656769514
line O 0 1.856278868217487e-05
E1317Q O 0 1.3360354387259576e-05
missense O 0 3.876014488923829e-06
variant O 0 2.771768322418211e-06
of O 0 3.510378689952631e-07
APC O 0 0.0007136657950468361
that O 0 9.634979960537748e-07
was O 0 2.86127942672465e-05
not O 0 4.3976537966727847e-08
present O 0 5.340826447763902e-08
in O 0 1.4972232520449325e-07
controls O 0 4.033224286104087e-06
; O 0 3.2629520774207776e-07
one O 0 3.232370104910842e-08
of O 0 1.934931681546459e-08
these O 0 2.8592673118055245e-08
individuals O 0 4.4810980170950643e-07
had O 0 2.1129240849404596e-05
an O 0 1.48449987591448e-06
unusually O 0 2.736949682002887e-05
large O 0 5.338728783499391e-07
number O 0 7.720228012431107e-08
of O 0 4.640283464141248e-07
metaplastic B-Disease 0 0.1455041617155075
polyps I-Disease 0 0.0008425042615272105
of I-Disease 0 4.442148693328818e-08
the I-Disease 0 1.2123211945436196e-06
colorectum I-Disease 0 0.0013035080628469586
. O 0 2.9719089980062563e-06

There O 0 6.583692993444856e-06
is O 0 8.010083547560498e-07
increasing O 0 8.452399242742104e-07
evidence O 0 1.8789054365697666e-06
that O 0 1.0865794308756449e-07
there O 0 3.8264143853439236e-08
exist O 0 6.336402691431431e-08
germ O 0 0.0003393152146600187
- O 0 0.0001827051310101524
line O 0 1.0706230568757746e-06
variants O 0 4.718381063639754e-08
of O 0 8.355661051950847e-09
the O 0 2.118046040777699e-07
APC B-Disease 0 5.51727061974816e-05
gene O 0 2.3976036800377187e-07
that O 0 3.0556158492345276e-08
predispose O 0 8.846042192089953e-07
to O 0 1.4281532401128061e-08
the O 0 3.4177443097860305e-08
development O 0 5.5225047645990344e-08
of O 0 3.5656355521496153e-06
multiple O 1 0.9577117562294006
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
and I-Disease 1 0.9983730316162109
carcinoma I-Disease 1 0.9999998807907104
, O 0 0.0007108576246537268
but O 0 4.131442778998462e-07
without O 0 6.932216933819291e-08
the O 0 8.476084900621572e-08
florid O 0 0.00010344423208152875
phenotype O 0 4.018495928903576e-06
of O 0 3.3412288047429684e-08
classical O 0 1.0783292054838967e-05
FAP B-Disease 0 0.00028693885542452335
, O 0 4.346428283952264e-07
and O 0 1.2820335371088731e-07
possibly O 0 3.813991895640356e-07
with O 0 1.2146989547545672e-07
importance O 0 7.27596489014104e-06
for O 1 0.826692521572113
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
risk O 0 0.0033434899523854256
in O 0 1.543572238915658e-07
the O 0 2.4133959186656284e-07
general O 0 1.3739650057686958e-06
population O 0 2.9713572757827933e-07
. O 0 3.737348208687763e-07
. O 0 2.3165450784290442e-06

Genomic O 0 0.00021709107386413962
structure O 0 9.903676982503384e-06
of O 0 5.194096388549951e-07
the O 0 8.59197461977601e-05
human O 1 0.8178113102912903
congenital B-Disease 1 0.9999984502792358
chloride I-Disease 1 0.9998849630355835
diarrhea I-Disease 1 0.9999972581863403
( O 0 0.00026349647669121623
CLD B-Disease 1 0.7341141700744629
) O 0 5.545743988477625e-06
gene O 0 3.2460973216075217e-06
. O 0 3.4219497138110455e-06

Congenital B-Disease 1 0.9999866485595703
chloride I-Disease 1 0.999910831451416
diarrhea I-Disease 1 0.9999958276748657
( O 0 0.002413505455479026
CLD B-Disease 1 0.9984258413314819
) O 0 5.312672510626726e-05
is O 0 4.401729711389635e-06
caused O 0 2.3484615667257458e-05
by O 0 1.1554344609976397e-06
mutations O 0 3.479230372249731e-06
in O 0 4.3202852850754425e-08
a O 0 2.692014220428973e-07
gene O 0 1.6674307801167743e-07
which O 0 8.500742865180655e-08
encodes O 0 2.37652170653746e-06
an O 0 8.601606532465667e-05
intestinal O 1 0.9497658014297485
anion O 0 0.008007893338799477
transporter O 0 0.27983352541923523
. O 0 2.324433262401726e-05

We O 0 2.078122633974999e-06
report O 0 6.325522576844378e-07
here O 0 1.6289471105324083e-08
the O 0 1.0545172735021424e-08
complete O 0 2.3072398391832394e-07
genomic O 0 1.4776996067666914e-05
organization O 0 1.87804602092001e-07
of O 0 3.575908280595286e-08
the O 0 2.707653266043053e-07
human O 0 2.405505711067235e-06
CLD B-Disease 0 0.0012052847305312753
gene O 0 1.942507168450902e-07
which O 0 1.0671165284747985e-08
spans O 0 2.430446386370022e-07
approximately O 0 4.815022975890315e-07
39kb O 0 0.0008751986897550523
, O 0 1.1472965866232698e-07
and O 0 4.0475548246377e-08
comprises O 0 1.9134296280753915e-07
21 O 0 2.9228328912722645e-06
exons O 0 1.3910087545809802e-05
. O 0 3.5600528462964576e-06

All O 0 1.816340045479592e-06
exon O 0 0.0006113679264672101
/ O 0 2.4963945179479197e-05
intron O 0 0.0001244460145244375
boundaries O 0 3.469176874659752e-07
conform O 0 5.108607297188428e-07
to O 0 1.3741750848339507e-08
the O 0 3.588808894505746e-08
GT O 0 0.00017101899720728397
/ O 0 0.0002586366899777204
AG O 1 0.9917558431625366
rule O 0 6.114497864473378e-06
. O 0 4.035763140564086e-06

An O 0 1.065639821717923e-06
analysis O 0 1.2150836425917078e-07
of O 0 5.2952731977029543e-08
the O 0 4.4163735424262995e-07
putative O 0 0.0002554811944719404
promoter O 0 0.00012927519856020808
region O 0 7.137769131304594e-08
sequence O 0 1.0725934806998794e-08
shows O 0 5.232183752923447e-08
a O 0 3.501170908748463e-07
putative O 0 0.0001527451677247882
TATA O 1 0.5847941040992737
box O 0 3.670949081424624e-05
and O 0 3.76975862081963e-07
predicts O 0 6.59490387988626e-06
multiple O 0 2.718108191857027e-07
transcription O 0 3.2188645491260104e-06
factor O 0 4.538293580935715e-07
binding O 0 4.5750175559078343e-07
sites O 0 5.744254281125905e-07
. O 0 1.040964207277284e-06

The O 0 2.5486219783488195e-06
genomic O 0 8.677988807903603e-05
structure O 0 1.6083837181213312e-05
was O 0 2.1091351300128736e-05
determined O 0 1.28644018104751e-07
using O 0 1.760562717834091e-08
DNA O 0 1.8494829419068992e-06
from O 0 3.326431752270764e-08
several O 0 1.9685876040398398e-08
sources O 0 2.2749807371269526e-08
including O 0 1.3769187034995412e-07
multiple O 0 1.2054040325892856e-06
large O 0 1.1141767572553363e-05
- O 0 0.005705647636204958
insert O 0 1.2628956028493121e-05
libaries O 0 1.4369588825502433e-05
and O 0 2.8477780134039676e-08
genomic O 0 7.231976155708253e-07
DNA O 0 9.983255949919112e-06
from O 0 1.421334332007973e-06
Finnish O 0 0.039404019713401794
CLD B-Disease 1 0.7521063089370728
patients O 0 0.00022898825409356505
and O 0 1.6771174387031351e-06
controls O 0 1.544552833365742e-05
. O 0 7.212267973955022e-06

Exon O 0 0.0006900674197822809
- O 0 0.0001713255187496543
specific O 0 2.0978947645744483e-07
primers O 0 9.164567018160596e-05
developed O 0 5.2561572374543175e-06
in O 0 5.676406189536465e-08
this O 0 3.952577820598435e-09
study O 0 3.905651269064947e-08
will O 0 9.299339964741193e-09
facilitate O 0 1.8217820141330776e-08
mutation O 0 4.804115860679303e-08
screening O 0 8.690969366398349e-08
studies O 0 3.8553519488004895e-08
of O 0 2.4397189690716914e-07
patients O 0 1.0660815860319417e-05
with O 0 1.271409360015241e-06
the O 0 0.00021206079691182822
disease O 0 0.022209158167243004
. O 0 1.444569443265209e-05

Genomic O 0 1.7051444956450723e-05
sequencing O 0 4.232577794027748e-06
of O 0 2.147534274854479e-07
a O 0 1.178683078251197e-06
BAC O 0 4.409384564496577e-05
clone O 0 0.04205489158630371
H O 1 0.9996236562728882
_ O 0 9.761394721863326e-06
RG364P16 O 0 1.2844636330555659e-05
revealed O 0 3.2052698770712595e-06
the O 0 3.447080487717358e-08
presence O 0 4.69918823853277e-08
of O 0 1.5387536578259642e-08
another O 0 8.331155640917132e-07
, O 0 2.209905147765312e-07
highly O 0 2.2071967009651416e-07
homologous O 0 2.516470374303026e-07
gene O 0 5.789102885955799e-08
3 O 0 1.024060054533038e-07
of O 0 4.2428368374203274e-08
the O 0 1.0050200671685161e-06
CLD B-Disease 0 0.05943205952644348
gene O 0 1.101841235140455e-06
, O 0 8.606624390949946e-08
with O 0 8.599716494472887e-08
a O 0 3.541887565461366e-07
similar O 0 2.4649466467963066e-07
genomic O 0 2.6283345505362377e-05
structure O 0 4.582323981594527e-06
, O 0 4.086807166459039e-06
recently O 0 0.00025634909979999065
identified O 0 1.3931408830103464e-05
as O 0 5.4500947044289205e-06
the O 0 0.06138243153691292
Pendred B-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999986886978149
gene O 0 4.769947554450482e-05
( O 0 2.7895616767636966e-06
PDS B-Disease 0 0.004187712445855141
) O 0 5.788114094684715e-07
. O 0 3.396818613055075e-07
. O 0 2.7221885829931125e-06

The O 0 7.245179403980728e-06
APCI1307K O 0 0.04365750029683113
allele O 0 0.00046424116590060294
and O 0 0.0030925001483410597
cancer B-Disease 1 0.974952220916748
risk O 0 0.0002082893915940076
in O 0 3.4126671266676567e-07
a O 0 2.482226818756317e-06
community O 0 7.077104555719416e-07
- O 0 0.0005782215157523751
based O 0 1.8666659116206574e-06
study O 0 1.6747171116548998e-07
of O 0 3.602408753522468e-07
Ashkenazi O 0 0.00048155232798308134
Jews O 0 8.471827641187701e-06
. O 0 1.7320833194389706e-06

Mutations O 0 0.0007815586286596954
in O 0 3.854627721011639e-06
APC O 0 0.00354976044036448
are O 0 6.290591954893898e-06
classically O 1 0.768823504447937
associated O 0 0.0004688102344516665
with O 0 0.013136456720530987
familial B-Disease 1 0.9999885559082031
adenomatous I-Disease 1 0.9999760389328003
polyposis I-Disease 1 0.9999934434890747
( O 0 0.0006973797571845353
FAP B-Disease 0 0.029173916205763817
) O 0 1.7320072629445349e-06
, O 0 5.977432806503202e-07
a O 0 1.2478907592594624e-05
highly O 0 0.02081725187599659
penetrant O 1 0.9994049072265625
autosomal B-Disease 1 0.9999886751174927
dominant I-Disease 1 0.9998893737792969
disorder I-Disease 1 0.9999903440475464
characterized O 0 0.009537284262478352
by O 0 0.00017812568694353104
multiple O 1 0.8050824403762817
intestinal O 1 0.9999940395355225
polyps B-Disease 1 0.9992462396621704
and O 0 5.8885165344690904e-05
, O 0 4.597806309902808e-06
without O 0 2.7616492843662854e-06
surgical O 0 0.036121729761362076
intervention O 0 4.900493877357803e-06
, O 0 1.699551290812451e-07
the O 0 1.3154924261016276e-07
development O 0 1.3317636330612004e-05
of O 1 0.8211811184883118
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
( O 0 0.00012062386667821556
CRC B-Disease 0 0.36217522621154785
) O 0 5.524334028450539e-06
. O 0 6.92040612193523e-06

APC B-Disease 0 0.004534408915787935
is O 0 1.2048790267726872e-05
a O 0 0.00021804426796734333
tumour O 1 0.9999741315841675
- O 0 0.13241256773471832
suppressor O 0 0.0009095862624235451
gene O 0 1.90403090982727e-06
, O 0 9.562291580778037e-08
and O 0 2.938207899205736e-07
somatic O 0 0.0003740471147466451
loss O 0 0.01919117383658886
occurs O 0 2.100754727507592e-06
in O 0 4.082798113813624e-05
tumours B-Disease 1 0.999847412109375
. O 0 9.020930156111717e-05

The O 0 2.4953520551207475e-05
germline O 0 0.2747897207736969
T O 1 0.8125483989715576
- O 0 0.0006653071031905711
to O 0 4.075878905496211e-07
- O 0 9.354274516226724e-05
A O 0 2.1626497073157225e-06
transversion O 0 0.00012710774899460375
responsible O 0 4.791482979271677e-07
for O 0 2.1295701202461714e-08
the O 0 6.860700096922301e-08
APC O 0 1.5132466614886653e-05
I1307K O 0 1.5917793234621058e-06
allele O 0 2.730669557138299e-08
converts O 0 4.4557594947036705e-08
the O 0 2.809376375978445e-08
wild O 0 4.405583524658141e-07
- O 0 1.1572260518732946e-05
type O 0 1.1505211716666963e-07
sequence O 0 1.6827724991230752e-08
to O 0 5.317306417396139e-08
a O 0 7.319413725781487e-06
homopolymer O 1 0.8517211675643921
tract O 0 0.39358416199684143
( O 0 8.23763684820733e-07
A8 O 0 0.27361544966697693
) O 0 5.316880447026051e-07
that O 0 9.808827883261984e-08
is O 0 7.414973879349418e-07
genetically O 0 0.00030594394775107503
unstable O 0 0.004514136351644993
and O 0 5.766374215454562e-06
prone O 0 0.0010132364695891738
to O 0 3.4987277786058257e-07
somatic O 0 0.00013031420530751348
mutation O 0 2.5513270884403028e-05
. O 0 5.322173365129856e-06

The O 0 6.083020707592368e-06
I1307K O 0 0.00018362936680205166
allele O 0 2.3352780772256665e-05
was O 0 2.227704862889368e-05
found O 0 6.637839078393881e-07
in O 0 1.161911455938025e-07
6 O 0 9.779610991245136e-06
. O 0 2.241695028715185e-06

1 O 0 8.695081305631902e-06
% O 0 4.019248933673225e-07
of O 0 1.5830941890726535e-07
unselected O 0 0.0028248655144125223
Ashkenazi O 0 0.00283286115154624
Jews O 0 3.7264899219735526e-06
and O 0 5.562097840083879e-07
higher O 0 9.900541044771671e-07
proportions O 0 8.806564437691122e-07
of O 0 8.007412333199682e-08
Ashkenazim O 0 0.0002645857457537204
with O 0 1.0175032002734952e-05
family O 0 5.776115722255781e-05
or O 0 1.0492495903235977e-06
personal O 0 1.2575582331919577e-05
histories O 0 5.286556643113727e-06
of O 0 5.953674190095626e-06
CRC B-Disease 0 0.28924885392189026
( O 0 2.6193667963525513e-06
ref O 0 0.006610512267798185
. O 0 1.3733189518916333e-07
2 O 0 1.2242952607266488e-06
) O 0 2.1901328750573157e-07
. O 0 6.597134074581845e-07

To O 0 1.5386295899588731e-06
evaluate O 0 1.9467258880467853e-06
the O 0 5.239733980033634e-08
role O 0 2.0736514727559552e-07
of O 0 8.155461017622656e-08
I1307K O 0 0.00017376038886141032
in O 0 8.126600732794032e-06
cancer B-Disease 0 0.01889106258749962
, O 0 7.387573077721754e-07
we O 0 1.6306155714573833e-07
genotyped O 0 7.752457895549014e-05
5 O 0 3.281576255176333e-07
, O 0 3.0319299071379646e-07
081 O 0 0.00012191449059173465
Ashkenazi O 0 9.899345604935661e-05
volunteers O 0 1.7845380853032111e-06
in O 0 1.7245191941128724e-08
a O 0 1.7725467671425577e-07
community O 0 6.74134810196847e-07
survey O 0 3.697101419675164e-05
. O 0 4.367125711723929e-06

Risk O 0 0.0016199520323425531
of O 0 1.0113657481269911e-05
developing O 0 0.05199620500206947
colorectal B-Disease 1 0.9999988079071045
, I-Disease 0 0.04562429338693619
breast I-Disease 1 0.8995974659919739
and I-Disease 0 2.6265954147675075e-05
other I-Disease 0 5.981971753499238e-06
cancers I-Disease 0 0.2126205414533615
were O 0 1.0182799087488092e-05
compared O 0 1.6751859220676124e-05
between O 0 2.1508320457996888e-07
genotyped O 0 0.0011597472475841641
I1307K O 0 3.34929209202528e-05
carriers O 0 4.8670444812159985e-06
and O 0 4.207996653349255e-07
non O 0 4.044602519570617e-06
- O 0 0.00024373081396333873
carriers O 0 2.626275545480894e-06
and O 0 2.6735463620752853e-08
their O 0 5.502041933169721e-09
first O 0 3.440965485879133e-07
- O 0 0.00017831873265095055
degree O 0 9.51677793636918e-06
relatives O 0 2.8654845664277673e-05
. O 0 3.5903813113691285e-06

Sperm O 0 9.411841892870143e-05
DNA O 0 5.5015403631841764e-05
analysis O 0 7.720565236013499e-07
in O 0 6.614818062189443e-07
a O 0 2.8188447686261497e-05
Friedreich B-Disease 1 0.9389774799346924
ataxia I-Disease 1 0.9850183129310608
premutation O 1 0.9156187772750854
carrier O 0 0.010112854652106762
suggests O 0 1.7426609701942652e-06
both O 0 5.528417190703294e-08
meiotic O 0 6.685873813694343e-05
and O 0 4.3064557075922494e-07
mitotic O 0 5.819540092488751e-05
expansion O 0 2.0823840714001562e-06
in O 0 6.534723695494904e-08
the O 0 3.850028349461354e-07
FRDA B-Disease 0 0.0028445797506719828
gene O 0 1.7515965282655088e-06
. O 0 9.685306849860353e-07

Friedreich B-Disease 1 0.9961121678352356
ataxia I-Disease 1 0.9986469149589539
is O 0 0.0006841755821369588
usually O 0 3.098728120676242e-05
caused O 0 5.194037294131704e-05
by O 0 5.861410841134784e-07
an O 0 3.8031242866054527e-07
expansion O 0 2.5502070002403343e-06
of O 0 1.9821935381969524e-07
a O 0 2.8575339001690736e-06
GAA O 0 0.0005118635599501431
trinucleotide O 0 0.00023167204926721752
repeat O 0 4.030124728160445e-06
in O 0 6.645852579367784e-08
intron O 0 1.0820118404808454e-05
1 O 0 3.8176299455017215e-08
of O 0 1.1383645137641452e-08
the O 0 3.7137002095732896e-07
FRDA B-Disease 0 0.005212218035012484
gene O 0 2.2734770936949644e-06
. O 0 1.2376181075524073e-06

Occasionally O 0 9.980080358218402e-05
, O 0 9.583513929101173e-07
a O 0 4.498430996591196e-07
fully O 0 9.560774287820095e-07
expanded O 0 3.4842065588236437e-07
allele O 0 2.420960072413436e-06
has O 0 5.281152084535279e-07
been O 0 9.89018872132874e-07
found O 0 6.503203735519492e-07
to O 0 3.323717479020161e-08
arise O 0 3.8042159644646745e-07
from O 0 6.143783792822433e-08
a O 0 3.0120327210170217e-07
premutation O 0 4.27476734330412e-05
of O 0 5.078030085314822e-08
100 O 0 2.6297792032892175e-07
or O 0 1.2838688689953415e-07
less O 0 2.645389827193867e-07
triplet O 0 0.0001337589928880334
repeats O 0 7.495465979445726e-06
. O 0 2.1374050902522868e-06

We O 0 2.6872482976614265e-06
have O 0 2.7746247610593855e-07
examined O 0 3.5823300095216837e-06
the O 0 3.274410431686192e-08
sperm O 0 1.6798466049294802e-06
DNA O 0 2.113337814080296e-06
of O 0 6.332403756914573e-08
a O 0 3.663576535473112e-06
premutation O 0 0.02465747855603695
carrier O 0 0.0009512223768979311
. O 0 8.797936061455403e-06

This O 0 2.4770969275778043e-07
mans O 0 6.159363238111837e-06
leucocyte O 0 0.0010098278289660811
DNA O 0 0.0002915543154813349
showed O 0 2.0780888007720932e-05
one O 0 3.4179070240725196e-08
normal O 0 2.8620993575145803e-08
allele O 0 1.7255926820780587e-07
and O 0 5.861231855419646e-08
one O 0 1.4942186155053605e-08
allele O 0 2.8865724033266815e-08
of O 0 4.042491674738358e-09
approximately O 0 5.6766229050708716e-08
100 O 0 1.2235197743848403e-07
repeats O 0 1.4817687770118937e-06
. O 0 1.2285761386010563e-06

His O 0 4.0944567444967106e-05
sperm O 0 0.0001733608660288155
showed O 0 1.932481609401293e-05
an O 0 1.224124304144425e-07
expanded O 0 2.8547316333060735e-07
allele O 0 4.2549203271846636e-07
in O 0 4.29538928869988e-08
a O 0 3.9618637970306736e-07
tight O 0 6.503174972749548e-06
range O 0 1.6264144164779282e-07
centering O 0 8.162197104866209e-07
on O 0 4.112212934614945e-07
a O 0 5.740196939996167e-08
size O 0 3.115181925750221e-07
of O 0 1.6987160122994283e-08
approximately O 0 4.345947672845796e-07
320 O 0 6.006826151860878e-05
trinucleotide O 0 0.0004053001757711172
repeats O 0 8.346476533915848e-06
. O 0 1.8119492324331077e-06

His O 0 0.0006460979930125177
affected O 0 0.00018182434723712504
son O 0 0.01857886277139187
has O 0 6.589853001059964e-07
repeat O 0 3.9561288645018067e-07
sizes O 0 2.9556014169429545e-07
of O 0 3.7905589778119975e-08
1040 O 0 1.945224721566774e-05
and O 0 1.5769523997732904e-06
540 O 0 7.665492739761248e-05
. O 0 3.892223958246177e-06

These O 0 3.898823024428566e-07
data O 0 7.992335326889588e-07
suggest O 0 6.333182227535872e-07
that O 0 1.6462164964536896e-08
expansion O 0 3.644584296580433e-07
occurs O 0 2.030806101060989e-08
in O 0 1.0915519155219044e-08
two O 0 2.653677597663773e-07
stages O 0 5.4476677178172395e-06
, O 0 4.835565050598234e-07
the O 0 5.926387558474744e-08
first O 0 4.4826967382505245e-07
during O 0 1.299874980986715e-07
meiosis O 0 1.829683924370329e-07
followed O 0 4.4741462090769346e-08
by O 0 2.998012860189192e-08
a O 0 4.6134683628906714e-08
second O 0 1.3224209851614432e-06
mitotic O 0 0.0003005332255270332
expansion O 0 7.417364395223558e-05
. O 0 1.01040077424841e-05

We O 0 5.226735538599314e-06
also O 0 1.1885167623404413e-06
show O 0 1.2180177577647555e-07
that O 0 3.6301341932443165e-09
in O 0 3.7335556868356434e-09
all O 0 1.5308313505713045e-09
informative O 0 4.876550860899442e-07
carrier O 0 0.00010580362140899524
father O 0 9.354557732876856e-06
to O 0 1.0374424874726174e-07
affected O 0 2.0172103631921345e-07
child O 0 2.7889259399671573e-06
transmissions O 0 1.5367041896752198e-06
, O 0 1.6950269809967722e-07
with O 0 1.2584831665662932e-07
the O 0 2.1097119429214217e-07
notable O 0 2.2518663627124624e-06
exception O 0 1.0352365364951766e-07
of O 0 3.308676355118223e-08
the O 0 5.761727948083717e-07
premutation O 0 0.007992371916770935
carrier O 0 1.8037022528005764e-05
, O 0 2.018991729357822e-08
the O 0 5.067983810391752e-09
expansion O 0 4.783894382853759e-07
size O 0 3.5883138025383232e-06
decreases O 0 9.456010957364924e-06
. O 0 1.2065905252711673e-07
. O 0 7.890396886978124e-07

The O 0 4.363141670182813e-06
R496H O 0 0.00011019586236216128
mutation O 0 5.34398259333102e-06
of O 0 1.8935429579869378e-07
arylsulfatase O 0 0.0023689349181950092
A O 0 1.3268703696667217e-05
does O 0 5.297288225847296e-07
not O 0 1.0600244877423393e-06
cause O 0 0.00014071902842260897
metachromatic B-Disease 1 0.9995206594467163
leukodystrophy I-Disease 1 0.9996685981750488
. O 0 5.3997642680769786e-05

Deficiency B-Disease 1 0.9964075684547424
of I-Disease 0 1.691505894996226e-05
arylsulfatase I-Disease 0 0.22002801299095154
A I-Disease 0 0.00032257361453957856
( O 0 8.134214112942573e-06
ARSA O 0 0.2255130112171173
) O 0 5.650232424159185e-07
enzyme O 0 1.9064756997977383e-05
activity O 0 6.060726718715159e-06
causes O 0 0.0004751211672555655
metachromatic B-Disease 1 0.99994957447052
leukodystrophy I-Disease 1 0.9999693632125854
( O 0 0.00032679448486305773
MLD B-Disease 1 0.9996683597564697
) O 0 1.1315560186631046e-05
. O 0 6.147620297269896e-06

A O 0 1.0046090210380498e-05
number O 0 1.597977501432979e-07
of O 0 3.340674652463349e-07
ARSA O 0 0.3555522859096527
gene O 0 4.717940555565292e-06
mutations O 0 5.67055212741252e-06
responsible O 0 4.154740508965915e-06
for O 0 1.7061905964510515e-05
MLD B-Disease 1 0.9999611377716064
have O 0 1.988694566534832e-05
been O 0 9.722606591822114e-06
identified O 0 1.6173478798009455e-05
. O 0 3.3561668715265114e-06

Recently O 0 0.0010058139450848103
, O 0 5.864519039278093e-07
the O 0 7.041692384746057e-08
R496H O 0 1.7481374015915208e-05
mutation O 0 7.402496180475282e-07
of O 0 2.9475901897058066e-07
ARSA O 0 0.49810755252838135
was O 0 0.0004140170640312135
proposed O 0 2.562875579315005e-06
to O 0 8.894558334304747e-08
be O 0 6.309833366913153e-08
a O 0 3.411375359974045e-07
cause O 0 1.2980012797925156e-06
of O 0 1.96639643945673e-06
MLD B-Disease 1 0.9999510049819946
( O 0 2.884987225115765e-06
Draghia O 0 0.0004913025768473744
et O 0 1.5212554899335373e-05
al O 0 8.438009899691679e-06
. O 0 6.344613723285875e-08
, O 0 2.836911789927399e-07
1997 O 0 1.1267769878031686e-05
) O 0 3.167333488818258e-07
. O 0 9.166403174276638e-07

We O 0 5.126023552293191e-06
have O 0 5.174276225261565e-07
investigated O 0 9.047282219398767e-06
the O 0 2.71719841293816e-07
R496H O 0 3.9602164179086685e-05
mutation O 0 1.8753734138954314e-06
and O 0 5.206902073950914e-07
found O 0 1.4793753280173405e-06
this O 0 9.882512586045777e-09
mutation O 0 4.07238957222944e-07
at O 0 6.120112061580585e-07
a O 0 2.5808731152210385e-07
relatively O 0 4.2578145098559617e-07
high O 0 1.1230930795136373e-05
frequency O 0 3.4421140071572154e-07
in O 0 7.589368067328905e-08
an O 0 1.1913295594467854e-07
African O 0 5.644222369483032e-07
American O 0 8.768567454353615e-07
population O 0 6.923021089733083e-08
( O 0 6.83356162767268e-08
f O 0 9.250242146663368e-05
= O 0 7.850392648833804e-06
0 O 0 3.8351868170138914e-07
. O 0 1.8227620302013747e-08
09 O 0 2.9239758987387177e-06
, O 0 1.7114196282363991e-07
n O 0 1.1065040780522395e-05
= O 0 1.1534302757354453e-05
61 O 0 6.208192644407973e-06
subjects O 0 1.810902404031367e-06
) O 0 4.179313179974997e-07
. O 0 1.0363206683905446e-06

The O 0 1.570628592162393e-05
ARSA O 0 0.12784671783447266
enzyme O 0 3.119251050520688e-05
activity O 0 6.373997507580498e-07
in O 0 5.8660859281189914e-08
subjects O 0 4.954951577929023e-07
with O 0 4.4346992922328354e-07
and O 0 1.2583610669025802e-06
without O 0 1.758318575184603e-07
the O 0 1.3223184680555278e-07
R496H O 0 2.8525038942461833e-05
mutation O 0 1.9840028926410014e-06
was O 0 1.1024299965356477e-05
determined O 0 7.132671839826799e-07
and O 0 7.34665491108899e-07
found O 0 9.83126369646925e-07
to O 0 2.8966985254896827e-08
be O 0 1.010647920907104e-07
normal O 0 3.457801369677327e-07
. O 0 1.3409332950686803e-06

It O 0 1.5711475498392247e-06
is O 0 2.17028073734582e-07
therefore O 0 8.355441138974129e-08
concluded O 0 2.1841851776116528e-06
that O 0 1.1083121087551717e-08
the O 0 4.3395608884111425e-08
R496H O 0 1.3766203664999921e-05
mutation O 0 3.44466855040082e-07
of O 0 2.380361507903217e-07
ARSA O 0 0.20650212466716766
does O 0 1.132604054987496e-07
not O 0 1.2287309836267468e-08
negatively O 0 1.1367864516387272e-07
influence O 0 2.0853832438660902e-08
the O 0 7.394069356791988e-09
activity O 0 2.5868406083873197e-08
of O 0 2.4616579707981145e-07
ARSA O 1 0.5901541709899902
and O 0 4.315374553698348e-06
is O 0 2.5593089958420023e-07
not O 0 4.5596067366204807e-08
a O 0 1.2605133861143258e-06
cause O 0 2.522248360037338e-05
of O 0 7.46667938074097e-05
MLD B-Disease 1 0.9994319081306458

Down O 0 0.00027434740331955254
- O 0 0.0003486240457277745
regulation O 0 2.028142944254796e-06
of O 0 3.2917128578446864e-07
transmembrane O 0 0.0003115563013125211
carbonic O 0 0.0006467880448326468
anhydrases O 0 0.005932418629527092
in O 0 8.525385055691004e-05
renal B-Disease 1 0.9999498128890991
cell I-Disease 1 0.9998600482940674
carcinoma I-Disease 1 0.9999995231628418
cell O 0 0.35108187794685364
lines O 0 7.35115900170058e-05
by O 0 2.692676616788958e-06
wild O 0 3.2858133636182174e-05
- O 0 0.008535734377801418
type O 0 0.00014841303345747292
von B-Disease 1 0.9531537294387817
Hippel I-Disease 1 0.8434668779373169
- I-Disease 0 0.12804605066776276
Lindau I-Disease 0 0.11720140278339386
transgenes O 0 0.0009863924933597445
. O 0 5.277876880427357e-06

To O 0 2.513266508685774e-06
discover O 0 7.098922651493922e-06
genes O 0 6.792478188799578e-07
involved O 0 8.953824135460309e-07
in O 0 6.730126074216969e-07
von B-Disease 1 0.9862328767776489
Hippel I-Disease 1 0.9984748959541321
- I-Disease 1 0.9743520617485046
Lindau I-Disease 1 0.8341808915138245
( O 0 3.0685609999636654e-06
VHL B-Disease 0 0.00031947362003847957
) O 0 1.026412448368319e-07
- O 0 4.0740120311966166e-05
mediated O 0 9.714578482089564e-05
carcinogenesis O 0 0.044256728142499924
, O 0 7.558394372608745e-07
we O 0 2.2159939305765874e-07
used O 0 0.00011157241533510387
renal B-Disease 1 0.99989914894104
cell I-Disease 1 0.9994102716445923
carcinoma I-Disease 1 0.9999990463256836
cell O 0 0.17426326870918274
lines O 0 0.00016269637853838503
stably O 0 0.0014992778887972236
transfected O 0 0.002033101860433817
with O 0 1.3170895272196503e-06
wild O 0 4.487190381041728e-05
- O 0 0.04225888475775719
type O 0 0.00038899207720533013
VHL O 0 0.004153303802013397
- O 0 0.0014581435825675726
expressing O 0 1.8458989870850928e-05
transgenes O 0 0.00014575509703718126
. O 0 3.935559107048903e-06

Large O 0 3.7741898267995566e-05
- O 0 0.00019595980120357126
scale O 0 1.3874476280761883e-05
RNA O 0 6.600840833925758e-07
differential O 0 1.7831381455835071e-06
display O 0 1.6638566648907727e-06
technology O 0 1.1616123629210051e-05
applied O 0 3.725114652297634e-07
to O 0 8.468307832742994e-09
these O 0 1.933145421517679e-09
cell O 0 3.9140591070463415e-06
lines O 0 2.025164576480165e-06
identified O 0 1.9480648916214705e-06
several O 0 5.1024187541770516e-08
differentially O 0 9.651252184994519e-06
expressed O 0 3.128197931800969e-07
genes O 0 4.705556122530652e-08
, O 0 2.0192420180364934e-08
including O 0 5.490156951282188e-08
an O 0 3.2007810091272404e-07
alpha O 0 9.568632776790764e-06
carbonic O 0 4.837571032112464e-05
anhydrase O 0 8.344931120518595e-05
gene O 0 1.829003366538018e-07
, O 0 1.5904637962194101e-07
termed O 0 3.611398642533459e-05
CA12 O 0 0.002960957121104002
. O 0 6.477186161646387e-06

The O 0 5.265893605610472e-07
deduced O 0 2.565499016782269e-06
protein O 0 1.2424391115928302e-07
sequence O 0 5.8512352296702375e-08
was O 0 4.536036158242496e-06
classified O 0 7.462414487235947e-06
as O 0 3.2779291814222233e-07
a O 0 8.477441042487044e-07
one O 0 1.8109507209373987e-06
- O 0 0.01845025084912777
pass O 0 5.953551590209827e-05
transmembrane O 0 0.0006867069168947637
CA O 0 1.37420820465195e-05
possessing O 0 1.930529106175527e-05
an O 0 1.160856413662259e-06
apparently O 0 1.688983138592448e-05
intact O 0 2.515462938390556e-06
catalytic O 0 1.1416443612688454e-06
domain O 0 7.574963944989577e-08
in O 0 1.1061453086824713e-08
the O 0 4.955433041686774e-08
extracellular O 0 9.899938049784396e-06
CA O 0 1.806013642635662e-05
module O 0 5.939227412454784e-05
. O 0 2.61049899563659e-06

Reintroduced O 0 0.0006689808215014637
wild O 0 0.0001803941559046507
- O 0 0.07728151977062225
type O 0 0.0001470172283006832
VHL B-Disease 0 0.0038669526111334562
strongly O 0 4.366721441328991e-06
inhibited O 0 1.3699614100914914e-06
the O 0 3.833156725363551e-08
overexpression O 0 7.020690873105195e-07
of O 0 1.537116744998457e-08
the O 0 1.277339833904989e-07
CA12 O 0 0.0003851780202239752
gene O 0 8.670554763057226e-08
in O 0 1.8173256677300742e-08
the O 0 8.245079925472965e-07
parental O 0 0.0011797863990068436
renal B-Disease 1 0.9999518394470215
cell I-Disease 1 0.999651312828064
carcinoma I-Disease 1 0.9999980926513672
cell O 0 0.2514362931251526
lines O 0 0.0009264664258807898
. O 0 3.827098407782614e-05

Similar O 0 8.528059879608918e-06
results O 0 8.226613317674492e-06
were O 0 2.8443039354897337e-06
obtained O 0 1.6489445897605037e-06
with O 0 2.420089913357515e-06
CA9 O 0 0.1381862759590149
, O 0 2.8751961167472473e-07
encoding O 0 1.1070681438241081e-07
another O 0 9.195242455461994e-06
transmembrane O 0 0.01392962597310543
CA O 0 2.087296888930723e-05
with O 0 7.808743163195686e-08
an O 0 3.892436666319554e-07
intact O 0 1.2231970686116256e-05
catalytic O 0 9.348413186671678e-06
domain O 0 3.6814597024203977e-06
. O 0 2.051081764875562e-06

Although O 0 1.1755525520129595e-05
both O 0 2.7413634029471723e-07
domains O 0 2.862924475266482e-07
of O 0 4.6141106935237985e-08
the O 0 7.464753366548393e-07
VHL B-Disease 0 0.000357017241185531
protein O 0 8.937720252788495e-08
contribute O 0 1.681861050428779e-08
to O 0 3.7099738836587903e-09
regulation O 0 3.9670428719773554e-08
of O 0 2.990131875435509e-08
CA12 O 0 0.0015409814659506083
expression O 0 1.0000591998959862e-07
, O 0 1.2126382564758842e-08
the O 0 8.257416972412557e-09
elongin O 0 3.352727435412817e-05
binding O 0 2.7991958972961584e-07
domain O 0 2.1137741157417622e-07
alone O 0 9.030119372255285e-07
could O 0 3.2403642080680584e-07
effectively O 0 3.270508614150458e-06
regulate O 0 7.588218522869283e-06
CA9 O 0 0.0034871569368988276
expression O 0 4.317083039495628e-06
. O 0 1.9993938167317538e-06

We O 0 3.2149253001989564e-06
mapped O 0 0.000161150106578134
CA12 O 0 0.035005394369363785
and O 0 7.192590146587463e-06
CA9 O 0 0.007125364150851965
loci O 0 6.912702247063862e-06
to O 0 6.190186923049623e-07
chromosome O 0 0.0003098031156696379
bands O 0 3.839428973151371e-05
15q22 O 0 4.337128848419525e-05
and O 0 1.4652321169705829e-06
17q21 O 0 9.242077794624493e-05
. O 0 2.3540662823506864e-06

2 O 0 6.385909364325926e-05
respectively O 0 0.00012175428855698556
, O 0 1.6125696902236086e-06
regions O 0 1.0926329423455172e-06
prone O 0 0.00020781093917321414
to O 0 6.901885996057899e-08
amplification O 0 9.767811206984334e-06
in O 0 7.31900442474398e-08
some O 0 7.610967855953277e-08
human O 0 2.8741274945787154e-05
cancers B-Disease 0 0.07063446193933487
. O 0 9.257846613763832e-06

Additional O 0 6.58432054478908e-06
experiments O 0 2.5148796339635737e-05
are O 0 2.797650324737333e-07
needed O 0 4.4112005070928717e-07
to O 0 2.22642597691447e-08
define O 0 1.271246645728752e-07
the O 0 8.756060054793124e-08
role O 0 5.254937036625051e-07
of O 0 5.808680043628556e-07
CA O 0 0.00032046870910562575
IX O 0 0.003891559084877372
and O 0 2.7483063604449853e-05
CA O 0 0.00035071230377070606
XII O 0 0.002896970836445689
enzymes O 0 1.200221504404908e-06
in O 0 1.3124981101952926e-08
the O 0 2.346001437558698e-08
regulation O 0 1.9073044654760452e-07
of O 0 6.854813960899264e-08
pH O 0 2.4947810288722394e-06
in O 0 6.499865978781827e-09
the O 0 1.4880667364991496e-08
extracellular O 0 1.2701985951935058e-06
microenvironment O 0 6.260745522013167e-06
and O 0 5.555307680538135e-08
its O 0 2.3749459288069374e-08
potential O 0 8.191666438506218e-07
impact O 0 1.7497316093795234e-06
on O 0 9.656116890255362e-05
cancer B-Disease 0 0.2753238379955292
cell O 0 0.0012542741606011987
growth O 0 5.5866963521111757e-05
. O 0 5.400811915023951e-06

A O 0 1.1914791684830561e-05
gene O 0 9.208091000800778e-07
encoding O 0 1.2405162408413162e-07
a O 0 5.228562827142014e-07
transmembrane O 0 1.666883508733008e-05
protein O 0 1.8179711958055123e-07
is O 0 2.5296991168488603e-08
mutated O 0 3.523456371112843e-06
in O 0 3.0517830964527093e-06
patients O 0 0.0031182989478111267
with O 1 0.7015256285667419
diabetes B-Disease 1 0.999998927116394
mellitus I-Disease 1 0.9999978542327881
and O 1 0.9887856245040894
optic B-Disease 1 0.9999982118606567
atrophy I-Disease 1 0.9999762773513794
( O 1 0.8316311240196228
Wolfram B-Disease 1 0.999988317489624
syndrome I-Disease 1 0.9999961853027344
) O 0 3.184716479154304e-05
. O 0 1.217643148265779e-05

Wolfram B-Disease 1 0.9997795224189758
syndrome I-Disease 1 0.9999874830245972
( O 0 0.0013655421789735556
WFS B-Disease 1 0.9855743646621704
; O 0 0.0003849530185107142
OMIM O 1 0.9598079323768616
222300 O 0 0.14612770080566406
) O 0 3.3717583391990047e-06
is O 0 2.0817983568122145e-06
an O 0 0.0008039388339966536
autosomal B-Disease 1 0.9991657733917236
recessive I-Disease 1 0.9999347925186157
neurodegenerative I-Disease 1 0.9999929666519165
disorder I-Disease 1 0.9808304309844971
defined O 0 2.590285657788627e-05
by O 0 3.772678610403091e-05
young O 0 0.00824652798473835
- O 0 0.1935962587594986
onset O 0 0.0018459483981132507
non O 0 0.0004388896923046559
- O 1 0.7267395257949829
immune O 0 0.0012153958668932319
insulin B-Disease 0 0.00018508979701437056
- I-Disease 0 0.269528865814209
dependent I-Disease 0 0.051979225128889084
diabetes I-Disease 1 0.9999638795852661
mellitus I-Disease 1 0.9999586343765259
and O 0 0.03765852376818657
progressive O 1 0.9913950562477112
optic B-Disease 1 0.9999641180038452
atrophy I-Disease 1 0.99338299036026
. O 0 0.00010957021004287526

Linkage O 0 0.0003277442301623523
to O 0 2.343583219044376e-06
markers O 0 6.41709120827727e-05
on O 0 1.2808625797333661e-05
chromosome O 0 0.010351353324949741
4p O 1 0.9910446405410767
was O 0 0.0005409597652032971
confirmed O 0 3.8879206840647385e-06
in O 0 4.967441924463856e-08
five O 0 7.773493280183175e-07
families O 0 7.804619599482976e-06
. O 0 5.9050671552540734e-06

On O 0 1.6923083876463352e-06
the O 0 3.8107700106593256e-08
basis O 0 1.8441568272464792e-08
of O 0 3.169227369426153e-08
meiotic O 0 0.0236026830971241
recombinants O 1 0.8696126341819763
and O 0 0.01200733333826065
disease O 0 0.03449514880776405
- O 0 0.06388317048549652
associated O 0 1.890826206363272e-05
haplotypes O 0 5.122652146383189e-05
, O 0 5.673791747540236e-07
the O 0 5.002994498681801e-07
WFS B-Disease 0 0.004730162210762501
gene O 0 9.344270779365615e-07
was O 0 4.147171694057761e-06
localized O 0 5.34987009359611e-07
to O 0 6.107283923029172e-08
a O 0 4.887799036623619e-07
BAC O 0 2.664002522578812e-06
/ O 0 8.188065407921385e-07
P1 O 0 6.282656249823049e-05
contig O 0 7.3507026172592305e-06
of O 0 4.491620853031009e-09
less O 0 1.143705308237486e-08
than O 0 1.4510389334532192e-08
250 O 0 4.4388667674866156e-07
kb O 0 0.0010057493345811963
. O 0 5.149296612216858e-06

Mutations O 0 0.0010886177187785506
in O 0 1.167310870187066e-06
a O 0 1.1502088455017656e-06
novel O 0 5.32346302861697e-06
gene O 0 1.827069809223758e-06
( O 0 1.885374842913734e-07
WFS1 O 0 0.0006316949147731066
) O 0 1.3524087627558856e-08
encoding O 0 1.4009923887670084e-08
a O 0 2.461338510784117e-07
putative O 0 4.944527609040961e-05
transmembrane O 0 4.8305781092494726e-05
protein O 0 4.6884716198292153e-07
were O 0 1.1423663863752154e-06
found O 0 4.928892849420663e-07
in O 0 3.2418352446939025e-08
all O 0 2.992859648998092e-08
affected O 0 3.061126108150347e-07
individuals O 0 3.7278365283555104e-08
in O 0 5.61865896031577e-08
six O 0 1.96494711417472e-05
WFS B-Disease 0 0.03935890644788742
families O 0 5.401059297582833e-06
, O 0 3.490722235710564e-07
and O 0 1.6105873612559662e-07
these O 0 2.1156672858069214e-08
mutations O 0 2.9010225262027234e-06
were O 0 3.3526894185342826e-06
associated O 0 6.421178113669157e-07
with O 0 1.5872075209699688e-06
the O 0 0.00010643282439559698
disease O 0 0.047446683049201965
phenotype O 0 0.00018114688282366842
. O 0 1.0831785402842797e-05

WFS1 O 1 0.7956788539886475
appears O 0 0.00014476834621746093
to O 0 3.1257820864993846e-07
function O 0 7.701123649894726e-08
in O 0 3.708935736312924e-08
survival O 0 2.6454652015672764e-06
of O 0 2.526582250084175e-07
islet O 0 0.013874994590878487
beta O 0 5.941932613495737e-06
- O 0 0.0013288427144289017
cells O 0 3.145301661788835e-06
and O 0 1.227186089636234e-06
neurons O 0 1.579134004714433e-05
. O 0 2.8398702056620095e-07
. O 0 1.4474863974101027e-06

Stable O 0 9.644944657338783e-05
interaction O 0 3.9522032579952793e-07
between O 0 1.5370179085039126e-07
the O 0 9.796133326744894e-08
products O 0 1.3667068969880347e-06
of O 0 3.497886069681044e-08
the O 0 5.543642487282341e-07
BRCA1 O 0 0.00015852853539399803
and O 0 1.0740443030954339e-05
BRCA2 O 0 0.018977737054228783
tumor B-Disease 0 0.002408621832728386
suppressor O 0 1.8971912140841596e-05
genes O 0 1.332126657871413e-07
in O 0 3.313121865744506e-08
mitotic O 0 0.00014879649097565562
and O 0 4.198038368485868e-05
meiotic O 1 0.5852000117301941
cells O 0 0.00043894071131944656
. O 0 8.83295160747366e-06

BRCA1 O 0 0.38282254338264465
and O 0 3.774931246880442e-05
BRCA2 O 0 0.0008884260314516723
account O 0 2.4599592052254593e-06
for O 0 2.5204766984643356e-07
most O 0 1.9880093304891489e-07
cases O 0 6.343501013361674e-07
of O 0 5.207353979130858e-07
familial O 0 0.0034819943830370903
, O 0 8.663676453579683e-06
early O 0 3.146024027955718e-05
onset O 0 0.00570766581222415
breast B-Disease 0 0.4257161021232605
and I-Disease 0 0.0001467168185627088
/ I-Disease 0 0.07109496742486954
or I-Disease 1 0.9501738548278809
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9998639822006226
and O 0 9.903733371174894e-07
encode O 0 4.785770215676166e-07
products O 0 1.433788725080376e-06
that O 0 3.826624350722341e-09
each O 0 7.108352129137074e-09
interact O 0 1.2351273426247644e-07
with O 0 4.925805683342332e-07
hRAD51 O 0 0.00013467390090227127
. O 0 2.4279056560772005e-06

Results O 0 5.231044997344725e-05
presented O 0 1.9614795746747404e-05
here O 0 1.766948543036051e-07
show O 0 3.0001183404237963e-07
that O 0 8.500013137791029e-08
BRCA1 O 0 2.5226165234926157e-05
and O 0 3.2050313620857196e-06
BRCA2 O 0 0.00016456347657367587
coexist O 0 2.1891316919209203e-06
in O 0 8.0332810625805e-08
a O 0 5.37183268534136e-07
biochemical O 0 4.2209678213112056e-05
complex O 0 2.5192562134179752e-06
and O 0 1.0799465144373244e-06
colocalize O 0 0.0005025436403229833
in O 0 2.3479962862893444e-07
subnuclear O 0 7.582626130897552e-05
foci O 0 4.218429694446968e-06
in O 0 2.6664165986289845e-08
somatic O 0 1.0722174920374528e-05
cells O 0 3.783477268370916e-06
and O 0 1.29663135339797e-07
on O 0 1.0528456328984248e-07
the O 0 1.3459753311906297e-08
axial O 0 9.652213748267968e-07
elements O 0 5.972173511281653e-08
of O 0 1.6966556870556815e-07
developing O 0 1.0161495083593763e-05
synaptonemal O 0 0.0006144669023342431
complexes O 0 8.975823220680468e-06
. O 0 2.3552138372906484e-06

Like O 0 6.384216248989105e-05
BRCA1 O 0 0.0031570016872137785
and O 0 1.3279475751915015e-05
RAD51 O 0 0.24586336314678192
, O 0 4.195009296381613e-06
BRCA2 O 0 5.43791611562483e-05
relocates O 0 2.8174581530038267e-06
to O 0 5.409082959317857e-08
PCNA O 0 0.0003833018126897514
+ O 0 3.391911036487727e-07
replication O 0 1.7064975565972418e-07
sites O 0 1.7826071285753642e-08
following O 0 6.005550545751248e-08
exposure O 0 6.133644205874589e-07
of O 0 1.6753872955632687e-08
S O 0 0.00012253885506652296
phase O 0 1.7476737639299245e-06
cells O 0 7.1952189273361e-07
to O 0 6.261924312411793e-08
hydroxyurea O 0 2.5934343284461647e-05
or O 0 4.627957821412565e-07
UV O 0 0.00015300625818781555
irradiation O 0 7.062405529723037e-06
. O 0 9.664971685197088e-07

Thus O 0 3.9411228499375284e-05
, O 0 1.0268652658851352e-05
BRCA1 O 0 0.0003024458419531584
and O 0 4.022982466267422e-06
BRCA2 O 0 0.00017887080321088433
participate O 0 4.106674964532431e-07
, O 0 5.13195345774875e-07
together O 0 3.4983406749233836e-07
, O 0 1.5802039854406758e-07
in O 0 5.011848003277919e-08
a O 0 1.3156069371689227e-06
pathway O 0 5.969126505078748e-06
( O 0 2.1267019292281475e-06
s O 0 0.01695193536579609
) O 0 3.3993009651567263e-07
associated O 0 1.701654639418848e-07
with O 0 1.5798839569924894e-08
the O 0 1.699030249824318e-08
activation O 0 1.5254582308443787e-07
of O 0 4.388403596067292e-08
double O 0 3.251385351177305e-05
- O 0 0.0036912639625370502
strand O 0 0.0004938864149153233
break O 0 3.349595863255672e-05
repair O 0 0.00372125580906868
and O 0 9.104155651584733e-07
/ O 0 4.242224349582102e-06
or O 0 2.1117391213465453e-07
homologous O 0 6.7980845415149815e-06
recombination O 0 8.923582208808511e-05
. O 0 1.286198130401317e-05

Dysfunction O 0 0.22876489162445068
of O 0 4.374724994704593e-06
this O 0 8.318762638737098e-07
pathway O 0 1.848601459641941e-05
may O 0 8.944112778408453e-06
be O 0 6.964673815446076e-08
a O 0 3.3183781056322914e-07
general O 0 1.4412795508178533e-06
phenomenon O 0 1.4059226032259176e-06
in O 0 3.277372329080208e-08
the O 0 1.0367659797339002e-07
majority O 0 7.511671924476104e-07
of O 0 9.989896909701201e-08
cases O 0 3.4132017390220426e-06
of O 0 8.88042904989561e-06
hereditary B-Disease 1 0.9958357810974121
breast I-Disease 1 0.8791249990463257
and I-Disease 0 0.0010139085352420807
/ I-Disease 0 0.1310507208108902
or I-Disease 1 0.9768288731575012
ovarian I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999600648880005
. O 0 5.059621344116749e-06
. O 0 1.2489814253058285e-05

A O 0 3.903278411598876e-05
novel O 0 1.1474566235847306e-05
Arg362Ser O 0 0.0006152009009383619
mutation O 0 5.52610435988754e-06
in O 0 4.125874397686857e-08
the O 0 9.689708946325482e-08
sterol O 0 0.00031303692958317697
27 O 0 9.301722457166761e-05
- O 0 0.0037854358088225126
hydroxylase O 0 0.0010973842581734061
gene O 0 5.991946636640932e-07
( O 0 1.0864219746054005e-07
CYP27 O 0 0.0010132062016054988
) O 0 5.543336456526049e-08
: O 0 5.5593645242879575e-09
its O 0 1.1925454401762181e-08
effects O 0 1.2363788925995323e-07
on O 0 6.128930607474103e-08
pre O 0 1.5412231277878163e-06
- O 0 7.698728268223931e-07
mRNA O 0 8.727993439094917e-09
splicing O 0 4.061203995320284e-08
and O 0 3.905800127768089e-08
enzyme O 0 6.979121280892286e-07
activity O 0 2.3459035958239838e-07
. O 0 5.684141228812223e-07

A O 0 4.7028563130879775e-05
novel O 0 2.099927223753184e-05
C O 0 0.0002167095080949366
to O 0 1.0325605614980304e-07
A O 0 6.809802357565786e-07
mutation O 0 3.721343659890408e-07
in O 0 1.983395669924448e-08
the O 0 1.879056412690261e-07
sterol O 0 0.00038379980833269656
27 O 0 4.908614937448874e-05
- O 0 0.0014257547445595264
hydroxylase O 0 0.00015268198330886662
gene O 0 3.351620421199186e-07
( O 0 4.563887756603435e-08
CYP27 O 0 0.00013678634422831237
) O 0 3.1369864927910385e-08
was O 0 1.1389572591724573e-06
identified O 0 5.706291261731167e-08
by O 0 4.504971062857521e-09
sequencing O 0 3.8747552366658056e-07
amplified O 0 1.611411244084593e-05
CYP27 O 0 9.204750676872209e-05
gene O 0 1.0424032126366001e-07
products O 0 2.2608018923619966e-07
from O 0 6.297569399293934e-08
a O 0 1.966837089639739e-06
patient O 0 2.15575382753741e-05
with O 0 4.0792259824229404e-05
cerebrotendinous B-Disease 1 0.9999022483825684
xanthomatosis I-Disease 1 0.9997349381446838
( O 0 1.301434986089589e-05
CTX B-Disease 0 0.33452653884887695
) O 0 1.3858654028808814e-06
. O 0 2.4016319457587088e-06

The O 0 3.4783643059199676e-06
mutation O 0 1.6240341210504994e-05
changed O 0 8.724716735741822e-07
the O 0 1.0088047730505423e-07
adrenodoxin O 0 4.738880670629442e-05
cofactor O 0 3.4074346899615193e-07
binding O 0 2.868617627882486e-07
residue O 0 1.0579440186120337e-06
362Arg O 0 3.323126520626829e-06
to O 0 8.950992480549758e-08
362Ser O 0 2.281152228533756e-05
( O 0 1.0839174535703933e-07
CGT O 0 0.00031202597892843187
362Arg O 0 1.4522660421789624e-05
to O 0 1.6281168768728094e-07
AGT O 0 0.0008361305226571858
362Ser O 0 0.00017097723321057856
) O 0 4.091221939006573e-08
, O 0 3.397640568891802e-08
and O 0 3.225143530016794e-07
was O 0 5.1195562264183536e-05
responsible O 0 9.305530511483084e-06
for O 0 9.158381726592779e-05
deficiency O 0 0.04916537180542946
in O 0 3.311467011712921e-08
the O 0 1.7520382300517667e-07
sterol O 0 0.0009156137821264565
27 O 0 0.00011288667883491144
- O 0 0.0005641196039505303
hydroxylase O 0 0.00031293160282075405
activity O 0 1.9179640275979182e-07
, O 0 5.0351886216049024e-08
as O 0 5.3420286860728083e-08
confirmed O 0 2.897094475429185e-07
by O 0 1.2830164486388185e-08
expression O 0 1.2607639376938096e-08
of O 0 4.737839898183438e-09
mutant O 0 4.872487693319272e-07
cDNA O 0 7.118965328345439e-08
into O 0 8.326010458858946e-08
COS O 0 0.0017268691444769502
- O 0 3.677501081256196e-05
1 O 0 1.0105463843501639e-06
cells O 0 2.6496009013499133e-06
. O 0 9.58819555307855e-07

Quantitative O 0 2.2357840862241574e-05
analysis O 0 3.062351652260986e-06
showed O 0 8.026262366911396e-05
that O 0 5.524548640778448e-08
the O 0 1.967180196515983e-08
expression O 0 2.1332452249112066e-08
of O 0 1.2699446827468819e-08
CYP27 O 0 4.536411142908037e-05
gene O 0 6.502854699164118e-09
mRNA O 0 2.8414937069953794e-09
in O 0 2.5460977770563886e-09
the O 0 4.9273186419895865e-08
patient O 0 6.676817520201439e-06
represented O 0 7.392234692815691e-06
52 O 0 0.0001453520671930164
. O 0 7.041953267616918e-06

5 O 0 1.1032670954591595e-05
% O 0 4.144655179061374e-07
of O 0 2.43107134423326e-08
the O 0 5.657631163558108e-08
normal O 0 2.7223367737860826e-07
level O 0 1.9989895463368157e-06
. O 0 3.682316673803143e-06

As O 0 5.928608061367413e-06
the O 0 2.797463594106375e-07
mutation O 0 1.3236524409876438e-06
occurred O 0 1.7229976378985157e-07
at O 0 5.7904610883952046e-08
the O 0 4.8209294334355945e-09
penultimate O 0 1.2386655043883366e-06
nucleotide O 0 3.9183703393064206e-07
of O 0 2.5617747922979106e-08
exon O 0 4.3104875658173114e-05
6 O 0 1.081400114344433e-05
( O 0 5.639219224917724e-08
- O 0 1.283219717151951e-05
2 O 0 2.1483967316271446e-07
position O 0 5.669664915330941e-08
of O 0 6.228509263905835e-09
exon O 0 3.6957371776225045e-05
6 O 0 1.0872674465645105e-05
- O 0 0.00011755119339795783
intron O 0 5.155167673365213e-05
6 O 0 8.821341452858178e-07
splice O 0 3.835939878626959e-06
site O 0 6.461974635385559e-07
) O 0 3.019358985056897e-09
of O 0 2.6503521599607893e-09
the O 0 7.296006998558369e-08
gene O 0 1.9505954185206065e-07
, O 0 9.670728218225122e-08
we O 0 3.2179631404005704e-08
hypothesized O 0 4.304558842704864e-07
that O 0 1.1970895386070879e-08
the O 0 4.0850744653653237e-07
mutation O 0 2.7268884878139943e-05
may O 0 1.2613223589141853e-05
partially O 0 2.2002030164003372e-05
affect O 0 1.3270503806950273e-08
the O 0 1.548834949183231e-09
normal O 0 1.69547809125703e-09
splicing O 0 3.1299755676172936e-08
efficiency O 0 2.3481710798023414e-07
in O 0 1.965421247973609e-08
exon O 0 1.8378053937340155e-05
6 O 0 3.5905320601159474e-06
and O 0 1.7910957694766694e-07
cause O 0 7.604901952618093e-08
alternative O 0 7.852351657788859e-09
splicing O 0 2.1544103390169766e-07
elsewhere O 0 3.5382143437345803e-07
, O 0 2.8641744975743677e-08
which O 0 8.254346539615653e-09
resulted O 0 5.051127800470567e-07
in O 0 9.042177850915323e-08
decreased O 0 9.154888175544329e-06
transcript O 0 2.040006847892073e-06
in O 0 1.0491811508472892e-07
the O 0 1.3242698742033099e-06
patient O 0 6.717879296047613e-05
. O 0 7.061651558615267e-06

Transfection O 0 0.0027575239073485136
of O 0 2.367471461184323e-05
constructed O 0 0.0021307989954948425
minigenes O 0 0.1306149661540985
, O 0 2.813215814967407e-06
with O 0 4.106451854113402e-07
or O 0 1.3264474318930297e-07
without O 0 5.2862006327814015e-08
the O 0 1.4380046309270256e-07
mutation O 0 8.444672516816354e-07
, O 0 1.0799079319667726e-07
into O 0 9.8855153396471e-08
COS O 0 0.08956421166658401
- O 0 8.89591101440601e-05
1 O 0 9.977954960049829e-07
cells O 0 8.220308700401802e-07
confirmed O 0 2.773936387256981e-07
that O 0 4.485293914058275e-09
the O 0 3.042472940251173e-08
mutant O 0 3.222369559807703e-05
minigene O 0 0.003604533150792122
was O 0 6.624984052905347e-06
responsible O 0 1.708631032215635e-07
for O 0 2.5783041479598978e-08
a O 0 7.214348585193875e-08
mRNA O 0 3.406913862136207e-08
species O 0 1.660390935853684e-08
alternatively O 0 7.277827762663946e-08
spliced O 0 5.3148341976339e-06
at O 0 3.369128990016179e-06
an O 0 1.8011847942034365e-06
activated O 0 0.0007108739227987826
cryptic O 0 1.6662560256008874e-06
5 O 0 4.9372911092859795e-08
splice O 0 7.535190889029764e-07
site O 0 2.563236876085284e-07
88 O 0 2.157779590561404e-06
bp O 0 9.368127393827308e-06
upstream O 0 5.910651168505865e-08
from O 0 3.5004474874256175e-09
the O 0 2.9909006382666803e-09
3 O 0 3.7479559011899255e-08
end O 0 3.613508425814871e-08
of O 0 3.8263344492861506e-08
exon O 0 0.0001033187290886417
6 O 0 1.8027512851404026e-05
. O 0 1.3617681133837323e-06

Our O 0 6.855911465208919e-07
data O 0 5.868334937986219e-07
suggest O 0 3.6602622799364326e-07
that O 0 1.8179706628984604e-08
the O 0 1.0344588474708871e-07
C O 0 8.125924068735912e-05
to O 0 3.629865830134804e-08
A O 0 2.9186392680458084e-07
mutation O 0 2.4132808107424353e-07
at O 0 1.763107349006532e-07
the O 0 2.2825870971132645e-08
penultimate O 0 2.8734796160279075e-06
nucleotide O 0 3.17343193501074e-07
of O 0 2.5835911188210048e-08
exon O 0 1.4757180906599388e-05
6 O 0 4.6696138156221423e-07
of O 0 9.152722135752356e-09
the O 0 1.9538684625786118e-07
CYP27 O 0 0.002439469564706087
gene O 0 2.65182052316959e-07
not O 0 1.9816031482378094e-08
only O 0 2.5974408401907567e-08
causes O 0 3.828951776085887e-06
the O 0 5.939312177360989e-05
deficiency B-Disease 0 0.18302351236343384
in I-Disease 0 1.1972075242283609e-07
the I-Disease 0 3.5446925039650523e-07
sterol I-Disease 0 0.000702746503520757
27 I-Disease 0 8.169745706254616e-05
- I-Disease 0 0.0006624719244427979
hydroxylase I-Disease 0 0.00010700932762119919
activity I-Disease 0 2.3419157457738038e-07
, O 0 1.5003178077677148e-07
but O 0 1.1695824753132911e-07
also O 0 9.283426152251195e-07
partially O 0 8.995627467811573e-06
leads O 0 2.821497275817819e-07
to O 0 5.253911528058097e-09
alternative O 0 3.472506193702429e-08
pre O 0 6.829788503637246e-07
- O 0 2.1441351805151498e-07
mRNA O 0 2.1043171649637316e-09
splicing O 0 9.05769237391496e-09
of O 0 2.5038526807463768e-09
the O 0 4.399986153202917e-08
gene O 0 5.938052254350623e-07
. O 0 6.434210604311374e-07

To O 0 1.2373513982311124e-06
our O 0 1.2304693086662155e-07
knowledge O 0 7.90336756040233e-08
, O 0 5.75245024947435e-08
this O 0 4.413693410754149e-09
is O 0 1.813765848623916e-08
the O 0 5.668302804906489e-08
first O 0 2.5553656541887904e-06
report O 0 2.3801940187695436e-06
regarding O 0 4.2327496885263827e-07
effects O 0 9.837950756264036e-07
on O 0 3.436885549490398e-07
pre O 0 3.0116705147520406e-06
- O 0 8.689997912370018e-07
mRNA O 0 2.0918955456750155e-09
splicing O 0 5.732075702979955e-09
of O 0 2.2623702911062082e-09
a O 0 7.549664360340103e-08
mutation O 0 2.4064988224381523e-07
at O 0 2.4824490196806437e-07
the O 0 2.0798326261228794e-07
- O 0 0.00021968131477478892
2 O 0 9.695621656646836e-07
position O 0 1.0191886445909404e-07
of O 0 4.757852778425331e-09
a O 0 6.53002700801153e-08
5 O 0 2.3677256422161008e-07
splice O 0 1.1717616871464998e-05
site O 0 7.609517069795402e-06
. O 0 2.0845141079917084e-06

ATM O 0 0.007430668920278549
germline O 0 0.1337636560201645
mutations O 0 0.0008093038923107088
in O 0 1.3089080312056467e-05
classical O 0 0.008233461529016495
ataxia B-Disease 1 0.9999892711639404
- I-Disease 1 0.9999864101409912
telangiectasia I-Disease 1 0.9999954700469971
patients O 0 0.04168548062443733
in O 0 1.668611275817966e-07
the O 0 2.928391609202663e-07
Dutch O 0 0.0012696697376668453
population O 0 2.4441442292300053e-06
. O 0 5.148879154148744e-06

Germline O 0 0.009300671517848969
mutations O 0 0.00013738109555561095
in O 0 2.656782100984856e-07
the O 0 1.6546535164252418e-07
ATM O 0 0.00027458398835733533
gene O 0 8.773996000854822e-07
are O 0 3.713990182063753e-08
responsible O 0 1.8344026102568023e-06
for O 0 6.735661736456677e-05
the O 1 0.9545919895172119
autosomal B-Disease 1 0.9999990463256836
recessive I-Disease 1 0.9999997615814209
disorder I-Disease 1 1.0
ataxia B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999979734420776
telangiectasia I-Disease 1 0.9999970197677612
( O 0 0.007034114561975002
A B-Disease 1 0.9985620379447937
- I-Disease 1 0.9999630451202393
T I-Disease 1 0.9999730587005615
) O 0 1.0706215107347816e-05
. O 0 3.841805209958693e-06

In O 0 3.0681717362313066e-06
our O 0 1.928624300262527e-07
study O 0 2.4846966084624e-07
, O 0 1.5458732605111436e-07
we O 0 9.808675649480847e-09
have O 0 1.1967311586147389e-08
determined O 0 2.299550772022485e-08
the O 0 9.02837005156698e-09
ATM O 0 2.318097722309176e-05
mutation O 0 3.606509721976181e-07
spectrum O 0 6.961446388231707e-07
in O 0 4.629272964962183e-08
19 O 0 3.5601683521235827e-06
classical O 0 1.2621994756045751e-05
A B-Disease 1 0.9945486187934875
- I-Disease 1 0.9999932050704956
T I-Disease 1 0.9999992847442627
patients O 0 0.0003952312108594924
, O 0 1.7606272706416348e-07
including O 0 9.358078045806906e-08
some O 0 2.2304979196974273e-08
immigrant O 0 9.370630141347647e-05
populations O 0 1.0873916380660376e-06
, O 0 3.227903846436675e-07
as O 0 6.58566179367881e-08
well O 0 2.932023512869364e-08
as O 0 4.914525675303594e-08
12 O 0 4.331308289806657e-08
of O 0 2.4207531978959196e-08
Dutch O 0 4.915997487842105e-05
ethnic O 0 6.249837269933778e-07
origin O 0 1.8127165049008909e-06
. O 0 2.2828976398159284e-06

Both O 0 2.5034967165993294e-06
the O 0 3.400163564037939e-07
protein O 0 1.4824553318248945e-07
truncation O 0 1.4230245142243803e-05
test O 0 3.280454393461696e-06
( O 0 6.018106546434865e-08
PTT O 0 1.4287777958088554e-05
) O 0 3.329332542989505e-08
and O 0 1.2028848139777892e-08
the O 0 1.3092852135798694e-08
restriction O 0 1.480488833749405e-07
endonuclease O 0 3.1063438655110076e-05
fingerprinting O 0 0.0003979068424087018
( O 0 6.157040388643509e-07
REF O 0 0.002956902841106057
) O 0 1.6739658548203806e-08
method O 0 1.9687716346084017e-08
were O 0 3.109275610313489e-07
used O 0 1.2669741522586264e-07
and O 0 3.1999078942135384e-07
compared O 0 2.549526016082382e-06
for O 0 1.725687326370462e-08
their O 0 5.390582646924713e-09
detection O 0 1.5140965103910276e-07
efficiency O 0 7.739157013020304e-07
, O 0 3.519166824617059e-08
identifying O 0 7.972207640705165e-07
76 O 0 1.244496615981916e-05
% O 0 7.01627413945971e-08
and O 0 9.12504560801608e-08
60 O 0 5.7777519657520315e-08
% O 0 7.94526222591685e-09
of O 0 7.283907255128952e-09
the O 0 2.216938668198054e-07
mutations O 0 4.493179858400254e-06
, O 0 1.125060180129367e-06
respectively O 0 4.938514393870719e-05
. O 0 4.108491339138709e-06

Most O 0 0.00014150052447803319
patients O 0 0.0009288506698794663
were O 0 4.651888502849033e-06
found O 0 1.6186943412321853e-06
to O 0 5.654976931168676e-08
be O 0 7.980029437248959e-08
compound O 0 1.1085710411862237e-06
heterozygote O 0 0.00010222184209851548
. O 0 2.9964378427393967e-06

Seventeen O 0 7.150978490244597e-05
mutations O 0 0.00017330024274997413
were O 0 5.841628080816008e-06
distinct O 0 1.316178810384372e-07
, O 0 9.181209037478766e-08
of O 0 3.185943242556277e-08
which O 0 1.7328090962109854e-07
10 O 0 7.026156367828662e-07
were O 0 1.0695964647311484e-06
not O 0 1.8943448765185167e-07
reported O 0 1.539431104902178e-05
previously O 0 2.2596372218686156e-05
. O 0 2.963570750580402e-06

Mutations O 0 0.0024603349156677723
are O 0 6.077426633055438e-07
small O 0 6.899213644828706e-07
deletions O 0 2.819401015585754e-05
or O 0 1.517377882009896e-06
point O 0 7.538615136581939e-06
mutations O 0 1.092599723051535e-05
frequently O 0 7.794382668180333e-07
affecting O 0 1.1081725688200095e-06
splice O 0 3.171726348227821e-05
sites O 0 1.0286335054843221e-05
. O 0 7.40054429115844e-06

Moreover O 0 0.000155411078594625
, O 0 3.5102589208690915e-06
a O 0 2.7604617116594454e-06
16 O 0 2.4071783627732657e-05
. O 0 6.180870514072012e-06

7 O 0 8.666775102028623e-05
- O 0 0.0007584503036923707
kb O 0 0.0027806181460618973
genomic O 0 2.443716766720172e-05
deletion O 0 6.863697308290284e-06
of O 0 7.3261837485461e-08
the O 0 1.3918479169205966e-07
3 O 0 5.481738298840355e-07
end O 0 2.7947865532951255e-07
of O 0 2.2238031860410956e-08
the O 0 1.5364784644589236e-07
gene O 0 3.143725280096987e-07
, O 0 2.1656536830505502e-07
most O 0 1.2469985222196556e-07
likely O 0 1.9537992557161488e-06
a O 0 3.0239775128393376e-07
result O 0 1.0874087053025505e-07
of O 0 8.50258707885132e-09
recombination O 0 9.175149671136751e-07
between O 0 7.086452313842528e-08
two O 0 1.2480668942771445e-07
LINE O 0 1.456838162994245e-05
elements O 0 7.569654485450883e-07
, O 0 1.576448653395346e-06
was O 0 4.7196910600177944e-05
identified O 0 3.399932393222116e-05
. O 0 3.8361154111044016e-06

The O 0 3.183831267961068e-06
most O 0 7.972390108079708e-07
frequently O 0 3.0249111659941263e-06
found O 0 4.58151998827816e-06
mutation O 0 1.8180558072344866e-06
, O 0 6.0788755718022e-07
identified O 0 9.71618192124879e-06
in O 0 7.582162453445562e-08
three O 0 5.701840564142913e-07
unrelated O 0 0.0008671823889017105
Turkish O 0 0.0014459339436143637
A B-Disease 1 0.9969755411148071
- I-Disease 1 0.9999861717224121
T I-Disease 1 0.9999971389770508
individuals O 0 5.198752205615165e-06
, O 0 3.0175237952789757e-06
was O 0 0.0008385605178773403
previously O 0 5.9838777815457433e-05
described O 0 6.18791273154784e-06
to O 0 4.0559243075222184e-08
be O 0 2.9668175471897484e-08
a O 0 1.8136591961592785e-07
Turkish O 0 9.458239219384268e-06
A B-Disease 1 0.6757123470306396
- I-Disease 1 0.9991483688354492
T I-Disease 1 0.9999282360076904
founder O 0 0.04851856082677841
mutation O 0 2.839029548340477e-05
. O 0 2.1397627278929576e-06

The O 0 5.526942459255224e-06
presence O 0 2.4410298919974593e-06
of O 0 1.3777344065601937e-07
a O 0 4.412855560076423e-06
founder O 0 0.002580299274995923
mutation O 0 5.380013135436457e-06
among O 0 6.48782872758602e-07
relatively O 0 2.7206212394048634e-07
small O 0 1.441987222960961e-07
ethnic O 0 1.1145301215265135e-07
population O 0 1.0860863142170274e-07
groups O 0 2.9749944729928757e-08
in O 0 4.023309685408094e-08
Western O 0 2.3618734701358335e-07
Europe O 0 1.1612040680120117e-06
could O 0 1.7240053296063707e-07
indicate O 0 4.062675529326043e-08
a O 0 3.581498830840246e-08
high O 0 1.0159693374589551e-05
carrier O 0 4.008223186247051e-06
frequency O 0 1.1175848158018198e-07
in O 0 2.7570989047376315e-08
such O 0 5.77998946482694e-08
communities O 0 4.710674659236247e-07
. O 0 3.122119551335345e-06

In O 0 2.8147427656222135e-05
patients O 0 4.530851583695039e-05
of O 0 1.813181995657942e-07
Dutch O 0 0.00047715764958411455
ethnic O 0 1.0816452231665608e-06
origin O 0 1.71262911408121e-06
, O 0 2.6506270387471886e-06
however O 0 4.8147842335311e-07
, O 0 2.1294488306011772e-07
no O 0 8.810472706954897e-08
significant O 0 8.104055950752809e-07
founder O 0 0.0007442657370120287
effect O 0 9.819569868341205e-07
could O 0 2.8962105602658994e-07
be O 0 1.5166472167038592e-07
identified O 0 4.887798695563106e-06
. O 0 2.112088623107411e-06

The O 0 7.206219379440881e-06
observed O 0 1.9637089280877262e-05
genetic O 0 2.034875979006756e-05
heterogeneity O 0 3.0822295229882e-05
including O 0 3.507986548356712e-06
the O 0 1.5254973959599738e-06
relative O 0 1.0614736311254092e-05
high O 0 0.00012813336797989905
percentage O 0 6.392512659658678e-06
of O 0 3.5064630310444045e-08
splice O 0 8.407016866840422e-05
- O 0 0.0007489538402296603
site O 0 1.0092779120896012e-05
mutations O 0 4.023120709462091e-06
had O 0 1.5898465335340006e-06
no O 0 2.1247988257755424e-08
reflection O 0 4.9610601848826263e-08
on O 0 4.688042452016816e-07
the O 0 1.3266350151752704e-06
phenotype O 0 7.457336323568597e-05
. O 0 4.498281668929849e-06

All O 0 2.2396488930098712e-05
patients O 0 0.0005278402823023498
manifested O 0 3.2392748835263774e-05
classical O 0 1.1410182196414098e-05
A B-Disease 1 0.8683702945709229
- I-Disease 1 0.9996153116226196
T I-Disease 1 0.9999736547470093
and O 0 4.376719516585581e-06
increased O 0 6.929169558134163e-07
cellular O 0 9.967520782083739e-06
radioresistant O 0 2.5202576580340974e-05
DNA O 0 4.62485240859678e-06
synthesis O 0 1.4333197668747744e-06
. O 0 1.5237437764881179e-06

Determination O 0 2.5073053620872088e-05
of O 0 2.926044260220806e-07
the O 0 1.3120832420554507e-07
genomic O 0 6.594998012587894e-06
structure O 0 3.9143924368545413e-07
of O 0 2.6148034848461066e-08
the O 0 3.5419415667092835e-07
COL4A4 O 0 0.00244579603895545
gene O 0 1.02104287691418e-07
and O 0 3.959770467076851e-08
of O 0 1.0144061235450863e-07
novel O 0 6.783368735341355e-05
mutations O 0 0.0015229950658977032
causing O 0 0.12469622492790222
autosomal B-Disease 1 0.9920044541358948
recessive I-Disease 1 0.9995660185813904
Alport I-Disease 1 0.9999762773513794
syndrome I-Disease 1 0.9999128580093384
. O 0 0.00042717368341982365

Autosomal B-Disease 1 0.9995003938674927
recessive I-Disease 1 0.9998821020126343
Alport I-Disease 1 0.999983549118042
syndrome I-Disease 1 0.9999879598617554
is O 0 0.0002098258410114795
a O 0 0.0005483522545546293
progressive O 1 0.9663398861885071
hematuric B-Disease 1 0.9998615980148315
glomerulonephritis I-Disease 1 0.9999861717224121
characterized O 0 0.009353605099022388
by O 0 7.66644297982566e-05
glomerular B-Disease 1 0.9744979739189148
basement I-Disease 1 0.9154279232025146
membrane I-Disease 1 0.7825556397438049
abnormalities I-Disease 1 0.9964578747749329
and O 0 2.005417991313152e-05
associated O 0 5.3340127124101855e-06
with O 0 1.2566678151415545e-06
mutations O 0 5.911698735872051e-06
in O 0 1.4039447648883652e-07
either O 0 2.785271533412015e-07
the O 0 1.1339284355926793e-06
COL4A3 O 0 0.08976360410451889
or O 0 3.138108866096445e-07
the O 0 4.285658974367834e-07
COL4A4 O 0 0.0018184026703238487
gene O 0 2.0929068966779596e-07
, O 0 1.0402060546255143e-08
which O 0 1.6398131741368616e-09
encode O 0 1.4899781852761862e-08
the O 0 8.115566174637934e-08
alpha3 O 0 0.00010297241533407941
and O 0 2.9616553547384683e-06
alpha4 O 0 0.006539462599903345
type O 0 3.3245312806684524e-05
IV O 0 0.3629179298877716
collagen O 0 0.003772410796955228
chains O 0 0.0002141442382708192
, O 0 7.281312264240114e-07
respectively O 0 1.1732913662854116e-05
. O 0 2.4801609015412396e-06

To O 0 2.3318743842537515e-06
date O 0 2.5206741156580392e-06
, O 0 1.4559063288288598e-07
mutation O 0 2.506291423287621e-07
screening O 0 2.2967373070059693e-07
in O 0 2.1015425843984303e-08
the O 0 1.2366780488548557e-08
two O 0 1.1905208197049433e-07
genes O 0 1.6789593928479007e-06
has O 0 5.429069460660685e-06
been O 0 1.737506863719318e-05
hampered O 0 0.00030537074781022966
by O 0 3.4672387982936925e-07
the O 0 3.174285438944935e-07
lack O 0 2.1337910993679543e-07
of O 0 8.782052418609965e-08
genomic O 0 2.0647961719078012e-05
structure O 0 4.871279543294804e-06
information O 0 2.7260205115453573e-06
. O 0 5.13064014739939e-06

We O 0 9.382227290188894e-06
report O 0 1.817570478124253e-06
here O 0 2.7163270743812973e-08
the O 0 6.2047473825543875e-09
complete O 0 4.422147270588539e-08
characterization O 0 3.396235399577563e-07
of O 0 1.4235325807021582e-08
the O 0 5.1363500119805394e-08
48 O 0 3.9806943163966935e-07
exons O 0 2.4256576125480933e-07
of O 0 2.0192805649799084e-08
the O 0 4.3916566028201487e-07
COL4A4 O 0 0.006218698341399431
gene O 0 2.9132388590369374e-07
, O 0 1.9593651146010416e-08
a O 0 5.030695859886691e-08
comprehensive O 0 1.082662834051007e-06
gene O 0 1.014192775983247e-06
screen O 0 3.3795506169553846e-05
, O 0 6.521736963804869e-07
and O 0 7.579848926297927e-08
the O 0 2.2051299453096362e-08
subsequent O 0 5.1205429230094524e-08
detection O 0 3.4815758453987655e-07
of O 0 2.5346446719254345e-08
10 O 0 2.0109945353397052e-07
novel O 0 4.785313194588525e-07
mutations O 0 5.063682237960165e-07
in O 0 4.290791650873871e-07
eight O 0 0.0034586144611239433
patients O 1 0.5053871273994446
diagnosed O 1 0.9735304117202759
with O 0 0.016201047226786613
autosomal B-Disease 1 0.9991388320922852
recessive I-Disease 1 0.999778687953949
Alport I-Disease 1 0.9999784231185913
syndrome I-Disease 1 0.9999278783798218
. O 0 0.0005234365817159414

Furthermore O 0 0.00015507770876865834
, O 0 3.0505639188049827e-06
we O 0 3.6295059402391416e-08
identified O 0 2.3541106486391072e-07
a O 0 1.870263410808093e-08
glycine O 0 7.70539770655887e-07
to O 0 8.353302050068123e-09
alanine O 0 4.2292953139622114e-07
substitution O 0 1.098913493535747e-08
in O 0 6.525915363653212e-09
the O 0 3.386441349562119e-08
collagenous O 0 0.00028807780472561717
domain O 0 1.0536416539252969e-06
that O 0 1.2718032849079464e-07
is O 0 1.9109128857053292e-07
apparently O 0 2.9720195016125217e-06
silent O 0 2.1900671072216937e-06
in O 0 1.2782630953722673e-08
the O 0 3.356808164767244e-08
heterozygous O 0 1.3994988421472954e-06
carriers O 0 2.806621296258527e-06
, O 0 5.496569599472423e-08
in O 0 5.12768743021752e-08
11 O 0 4.707267180492636e-06
. O 0 3.0777898700762307e-06

5 O 0 2.1171716070966795e-05
% O 0 5.592916636487644e-07
of O 0 3.416036875591999e-08
all O 0 1.7548666519928702e-08
control O 0 8.343503736796265e-07
individuals O 0 2.872466211556457e-07
, O 0 3.3991355508078414e-07
and O 0 3.098645322552329e-07
in O 0 1.5107950446235918e-07
one O 0 1.8841993210116925e-07
control O 0 2.3442508734206058e-07
individual O 0 3.4264253656601795e-08
homozygous O 0 2.7213297926209634e-07
for O 0 5.940689717931491e-09
this O 0 3.047768259989425e-09
glycine O 0 5.261789738142397e-06
substitution O 0 5.458826422000129e-07
. O 0 2.02353317035886e-06

There O 0 1.7053347619366832e-05
has O 0 1.1741801245079841e-05
been O 0 9.72669340626453e-07
no O 0 1.8786581179597306e-08
previous O 0 5.413954795585596e-08
finding O 0 5.7563799060744714e-08
of O 0 9.710351633884784e-09
a O 0 6.680420483462512e-08
glycine O 0 1.68672056588548e-06
substitution O 0 1.177737658508704e-07
that O 0 7.320037553881775e-08
is O 0 1.224850763037466e-07
not O 0 3.838731643668325e-08
associated O 0 5.011121118059236e-08
with O 0 5.5246960783961185e-08
any O 0 9.370670994712782e-08
obvious O 0 3.094947032877826e-06
phenotype O 0 7.959877621033229e-06
in O 0 5.538696541407262e-07
homozygous O 0 3.1320323614636436e-05
individuals O 0 2.206688122896594e-06
. O 0 8.451903340755962e-06

Founder O 0 0.03444228693842888
BRCA1 O 0 0.010066276416182518
and O 0 7.744813046883792e-06
BRCA2 O 0 0.00031425696215592325
mutations O 0 6.147532531031175e-06
in O 0 3.6626158816943644e-07
French O 0 0.00043773773359134793
Canadian O 1 0.6059324741363525
breast B-Disease 1 0.9989790916442871
and I-Disease 1 0.9984190464019775
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999784231185913
families O 0 0.0001710147480480373
. O 0 3.0955910915508866e-05

We O 0 7.26928556105122e-06
have O 0 9.406320486959885e-07
identified O 0 9.623179266782245e-07
four O 0 1.5162812871949427e-07
mutations O 0 6.206442435541248e-07
in O 0 8.275817364733484e-09
each O 0 7.195724904818235e-09
of O 0 8.751769087211869e-08
the O 0 0.0002812435559462756
breast B-Disease 1 0.9995977282524109
cancer I-Disease 1 0.8392881751060486
- O 0 0.06752816587686539
susceptibility O 0 0.0002035940415225923
genes O 0 1.4338966138893738e-06
, O 0 9.646516900829738e-07
BRCA1 O 0 4.268212796887383e-05
and O 0 1.013716996567382e-06
BRCA2 O 0 4.342716056271456e-05
, O 0 1.1380046061049143e-07
in O 0 1.2424307271885482e-07
French O 0 0.00032777583692222834
Canadian O 1 0.5881775617599487
breast B-Disease 1 0.9980108141899109
cancer I-Disease 1 0.9074457287788391
and O 0 0.05530091002583504
breast B-Disease 1 0.9999072551727295
/ I-Disease 1 0.9999386072158813
ovarian I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.999976634979248
families O 0 3.5250031942268834e-05
from O 0 1.2992163647140842e-05
Quebec O 0 0.0007535408949479461
. O 0 1.548118598293513e-05

To O 0 5.149758180778008e-06
identify O 0 7.557757635368034e-05
founder O 0 0.008373462595045567
effects O 0 0.00011172582890139893
, O 0 3.1920657761475013e-07
we O 0 1.5587103163738902e-08
examined O 0 6.57249870528176e-07
independently O 0 4.401194786396445e-08
ascertained O 0 1.1848934263980482e-05
French O 0 0.00011176257976330817
Canadian O 0 0.11126351356506348
cancer B-Disease 0 0.032006215304136276
families O 0 7.136856083889143e-07
for O 0 1.1345369443915843e-07
the O 0 3.2505159452966836e-08
distribution O 0 3.0248248350517315e-08
of O 0 2.068554749712348e-08
these O 0 2.058863834975e-08
eight O 0 8.037424777285196e-06
mutations O 0 3.2054966141004115e-05
. O 0 2.266246838189545e-06

Mutations O 0 0.0007792695541866124
were O 0 7.922089025669266e-06
found O 0 1.5600777487634332e-06
in O 0 4.605116643574547e-08
41 O 0 3.108183591393754e-06
of O 0 1.1544438649480071e-07
97 O 0 9.195205348078161e-05
families O 0 1.6980580767267384e-05
. O 0 5.070953193353489e-06

Six O 0 4.887528575636679e-06
of O 0 2.371375273924059e-07
eight O 0 5.2973718993598595e-06
mutations O 0 5.62736340725678e-06
were O 0 5.56711256649578e-07
observed O 0 4.6261749275799957e-07
at O 0 5.485237011271238e-07
least O 0 1.3040668989106052e-07
twice O 0 7.5478883445612155e-06
. O 0 2.8831334475398762e-06

The O 0 1.2455712749215309e-05
BRCA1 O 0 0.002867582719773054
C4446T O 0 0.00022896619339007884
mutation O 0 2.4067054255283438e-05
was O 0 1.2287341633054893e-05
the O 0 2.6949012976729136e-07
most O 0 2.8360975079522177e-07
common O 0 4.663516790515132e-07
mutation O 0 2.5278382054239046e-06
found O 0 1.5166139064604067e-06
, O 0 6.831241705640423e-08
followed O 0 6.910303085305713e-08
by O 0 1.2059635423611326e-07
the O 0 1.916288965730928e-06
BRCA2 O 0 0.0006545280921272933
8765delAG O 0 0.00031824278994463384
mutation O 0 1.1417932910262607e-05
. O 0 3.327909098516102e-06

Together O 0 6.917806786077563e-06
, O 0 8.071152706179419e-07
these O 0 1.3929986941718653e-08
mutations O 0 1.8560488115326734e-06
were O 0 1.0574397037999006e-06
found O 0 1.7195289956362103e-06
in O 0 1.321541844845342e-07
28 O 0 2.467682634232915e-06
of O 0 8.625803360473583e-08
41 O 0 8.374369645025581e-05
families O 0 4.052927124575945e-06
identified O 0 1.3371762179303914e-05
to O 0 1.4286440830346692e-07
have O 0 5.123728215039591e-07
a O 0 1.995073944272008e-06
mutation O 0 2.3114795112633146e-05
. O 0 6.091990144341253e-06

The O 0 3.2051109428721247e-06
odds O 0 0.00011205882765352726
of O 0 7.522096012735346e-08
detection O 0 3.4345630410825834e-06
of O 0 8.24527077725179e-08
any O 0 1.1606595684554577e-08
of O 0 1.9022648345412563e-08
the O 0 8.889792724176004e-08
four O 0 5.452470759337302e-06
BRCA1 O 0 0.00319101894274354
mutations O 0 1.4017498870089184e-05
was O 0 6.183718505781144e-05
18 O 0 2.185510311392136e-05
. O 0 6.343721906887367e-06

7x O 0 0.015334811992943287
greater O 0 1.1207456736883614e-05
if O 0 1.6000834079932247e-07
one O 0 2.1186354004498753e-08
or O 0 3.1372675124430316e-08
more O 0 1.4673482873206467e-08
cases O 0 1.0825588105944917e-05
of O 0 0.10796710103750229
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999949932098389
were O 0 0.0018612089334055781
also O 0 1.2277947462280281e-05
present O 0 1.7462863866057887e-07
in O 0 1.3146107846750965e-07
the O 0 1.7840498003351968e-06
family O 0 2.8704103897325695e-05
. O 0 8.61524858919438e-06

The O 0 5.9045823945780285e-06
odds O 0 0.0001320767478318885
of O 0 9.71750822031936e-08
detection O 0 2.1127132185938535e-06
of O 0 4.310835421961201e-08
any O 0 7.700620585637807e-09
of O 0 1.515417658026763e-08
the O 0 1.0819181284205115e-07
four O 0 5.880845492356457e-06
BRCA2 O 0 0.0005711620906367898
mutations O 0 7.742797606624663e-06
was O 0 1.373084251099499e-05
5 O 0 5.264073479338549e-06
. O 0 4.125322448089719e-06

3x O 0 0.0026771060656756163
greater O 0 2.122298246831633e-05
if O 0 5.681583274963486e-07
there O 0 3.0743112944264794e-08
were O 0 1.0539003625353871e-07
at O 0 6.653932160816112e-08
least O 0 2.6318291990179432e-09
five O 0 1.262672810753429e-07
cases O 0 2.4066303012659773e-06
of O 0 8.789086132310331e-05
breast B-Disease 1 0.9993022680282593
cancer I-Disease 0 0.12073200196027756
in O 0 3.788481706124003e-07
the O 0 2.995409431605367e-06
family O 0 8.982799045043066e-05
. O 0 2.1852936697541736e-05

Interestingly O 0 0.00022505126253236085
, O 0 1.417379166923638e-06
the O 0 9.798375799618952e-08
presence O 0 7.483343722469726e-08
of O 0 7.269101587326077e-08
a O 0 0.0007925867103040218
breast B-Disease 1 0.9992247819900513
cancer I-Disease 0 0.4434060752391815
case O 0 2.465229954395909e-05
< O 0 1.1358972187736072e-05
36 O 0 1.3310449503478594e-05
years O 0 1.8961139858220122e-06
of O 0 1.8289266279225558e-07
age O 0 5.241116014076397e-05
was O 0 0.00013991717423778027
strongly O 0 1.037343508869526e-07
predictive O 0 1.4505110357276862e-07
of O 0 1.2241461178064128e-08
the O 0 1.5189023372386146e-07
presence O 0 1.3169422174996726e-07
of O 0 9.239299103569465e-09
any O 0 1.8373514931724344e-09
of O 0 5.022611215821371e-09
the O 0 9.009846735352767e-08
eight O 0 3.9861147342890035e-06
mutations O 0 7.492700206057634e-06
screened O 0 3.57104217982851e-05
. O 0 2.147715804312611e-06

Carriers O 0 0.00010723721788963303
of O 0 1.7275998231980338e-07
the O 0 1.3646264562794386e-07
same O 0 1.4998843766989012e-07
mutation O 0 1.6819320762806456e-06
, O 0 1.0453259591258757e-07
from O 0 2.3891304934409163e-08
different O 0 3.1987708037917173e-09
families O 0 2.448300904234202e-07
, O 0 2.836949590800941e-07
shared O 0 1.0112511290572002e-06
similar O 0 8.54023141982907e-07
haplotypes O 0 0.00012466858606785536
, O 0 2.082558921756572e-06
indicating O 0 5.614583642454818e-06
that O 0 3.35665468753632e-08
the O 0 5.348176301822605e-08
mutant O 0 1.3465485608321615e-05
alleles O 0 1.0091490594277275e-06
were O 0 6.929084520379547e-06
likely O 0 1.2210374507048982e-06
to O 0 1.994621356971038e-08
be O 0 1.4629440769908797e-08
identical O 0 3.4847084862121847e-07
by O 0 2.45382921093551e-07
descent O 0 4.671389251598157e-05
for O 0 3.2006221317715244e-07
a O 0 6.7369006728768e-07
mutation O 0 4.063594758463296e-07
in O 0 4.5076806287625004e-08
the O 0 7.036402394078323e-07
founder O 0 0.0009666649275459349
population O 0 2.100730625897995e-06
. O 0 5.265790605335496e-06

The O 0 8.836236133902275e-07
identification O 0 6.874636824250047e-07
of O 0 3.176523364345485e-07
common O 0 8.63731202116469e-06
BRCA1 O 0 0.005002835299819708
and O 0 1.3374300579016563e-05
BRCA2 O 0 0.0005424374830909073
mutations O 0 2.5502313292236067e-06
will O 0 2.5279723203652793e-08
facilitate O 0 6.283387676830898e-08
carrier O 0 7.480740805476671e-06
detection O 0 1.5073050008140854e-06
in O 0 3.1853056725594797e-07
French O 0 0.000201405884581618
Canadian O 0 0.25661420822143555
breast B-Disease 1 0.9962490200996399
cancer I-Disease 1 0.7395475506782532
and O 0 0.04602847993373871
breast B-Disease 1 0.9998922348022461
/ I-Disease 1 0.9999308586120605
ovarian I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999748468399048
families O 0 0.0003177964536007494
. O 0 3.451743032201193e-05

Are O 0 1.0092682714457624e-05
Dp71 O 0 0.0013212444027885795
and O 0 8.72268901730422e-06
Dp140 O 0 0.0007569476147182286
brain O 0 0.0002983543963637203
dystrophin O 0 1.1142044058942702e-05
isoforms O 0 2.970597847706813e-07
related O 0 3.2389352782047354e-06
to O 0 4.021364020445617e-06
cognitive B-Disease 0 0.06012802571058273
impairment I-Disease 1 0.9926780462265015
in O 0 0.007578080054372549
Duchenne B-Disease 1 0.9999452829360962
muscular I-Disease 1 0.9998314380645752
dystrophy I-Disease 1 0.9995638728141785
? O 0 0.0013420768082141876

Molecular O 0 0.0002601189771667123
study O 0 5.465292815642897e-06
and O 0 2.698774324016995e-06
neuropsychological O 0 0.0007164583657868207
analysis O 0 4.1019194441105356e-07
were O 0 4.5911983193036576e-07
performed O 0 2.152672919919496e-07
concurrently O 0 1.1154488532838513e-07
on O 0 6.165675131342141e-06
49 O 0 0.0034457712899893522
patients O 0 0.0003225456166546792
with O 0 0.0016749725909903646
Duchenne B-Disease 1 0.9999895095825195
muscular I-Disease 1 0.999985933303833
dystrophy I-Disease 1 0.9999808073043823
( O 0 0.005457097664475441
DMD B-Disease 1 0.9999959468841553
) O 0 1.4362643923959695e-05
in O 0 2.766127806808072e-07
order O 0 1.5224846094952227e-07
to O 0 4.1059969646539685e-08
find O 0 4.928033092710393e-08
a O 0 4.4699408618953385e-08
molecular O 0 1.2962296978002996e-06
explanation O 0 4.7801865576957425e-08
for O 0 6.375170613637238e-08
the O 0 1.2796922419511247e-06
cognitive B-Disease 0 0.05140165239572525
impairment I-Disease 1 0.6948210000991821
observed O 0 1.003445686365012e-05
in O 0 1.3472795217239764e-06
most O 0 8.795533358352259e-05
DMD B-Disease 1 0.9999790191650391
patients O 0 0.008559714071452618
. O 0 1.6674812286510132e-05

Complete O 0 3.6478045331023168e-06
analysis O 0 2.387973836448509e-07
of O 0 6.032426114188638e-08
the O 0 3.2733402122175903e-07
dystrophin O 0 4.1613839130150154e-05
gene O 0 7.163013151512132e-07
was O 0 1.1385172001610044e-05
performed O 0 8.669841236041975e-07
to O 0 2.239121066338612e-08
define O 0 8.219268465836649e-08
the O 0 2.4044540580803186e-08
localization O 0 1.1573931715247454e-06
of O 0 4.2601900673844284e-08
deletions O 0 7.474935955542605e-06
and O 0 1.0095744755744818e-06
duplications O 0 1.6790661902632564e-05
in O 0 9.169640691197856e-08
relation O 0 2.063533059981637e-07
to O 0 3.272150550515107e-08
the O 0 1.289624123046451e-07
different O 0 7.104857786544017e-07
DMD B-Disease 1 0.9997698664665222
promoters O 0 0.0006782463751733303
. O 0 9.920191587298177e-06

Qualitative O 0 2.0698884327430278e-05
analysis O 0 1.2360693517621257e-06
of O 0 9.89507924487043e-08
the O 0 2.2168669033817423e-07
Dp71 O 0 9.439489804208279e-05
transcript O 0 2.1183238914090907e-06
and O 0 1.6659652146699955e-07
testing O 0 9.958716162827841e-08
for O 0 1.0515528003907093e-08
the O 0 5.353858689716162e-09
specific O 0 1.7473242852616977e-09
first O 0 1.156722859718684e-07
exon O 0 8.95901848707581e-06
of O 0 1.7353889347759832e-07
Dp140 O 0 2.195139677496627e-05
were O 0 1.0282303719577612e-06
also O 0 2.0164426928204193e-07
carried O 0 3.468201157375006e-07
out O 0 6.273227199926623e-07
. O 0 1.7502824221082847e-06

Neuropsychological O 0 0.008578864857554436
analysis O 0 1.0683021173463203e-05
assessed O 0 0.0003636320470832288
verbal O 0 6.452799425460398e-05
and O 0 9.869594578049146e-06
visuospatial O 0 0.0007685221498832107
intelligence O 0 2.797143315547146e-05
, O 0 6.563628858202719e-07
verbal O 0 1.2329318451520521e-05
memory O 0 0.0005320719792507589
, O 0 1.3948990726930788e-06
and O 0 4.895188681075524e-07
reading O 0 8.017864274734166e-06
skills O 0 1.1192843885510229e-05
. O 0 2.8352449135127245e-06

Comparison O 0 9.139882422459777e-06
of O 0 4.3640721969495644e-07
molecular O 0 2.4936842237366363e-05
and O 0 2.552815431045019e-06
psychometric O 0 0.0006124740466475487
findings O 0 1.1521056876517832e-05
demonstrated O 0 3.4033303109026747e-06
that O 0 2.0844288073362804e-08
deletions O 0 1.6038308103816235e-06
and O 0 2.221069479446669e-07
duplications O 0 8.502649507136084e-06
that O 0 1.2202535515370982e-07
were O 0 7.726679314146168e-07
localized O 0 1.530822601125692e-06
in O 0 1.5465191438579495e-07
the O 0 2.975310167130374e-07
distal O 0 0.00040119505138136446
part O 0 8.174139338734676e-07
of O 0 6.723153234133861e-08
the O 0 4.776964601660438e-07
gene O 0 1.8583000382932369e-06
seemed O 0 9.23287075238477e-07
to O 0 2.3250468217383968e-08
be O 0 4.1249617055427734e-08
preferentially O 0 2.1474022560141748e-06
associated O 0 9.650889296608511e-07
with O 0 4.717094725492643e-06
cognitive B-Disease 0 0.0511074960231781
impairment I-Disease 1 0.831082284450531
. O 0 3.754206045414321e-05

Two O 0 5.3529497563431505e-06
altered O 0 5.211303141550161e-05
Dp71 O 0 0.00016372925892937928
transcripts O 0 5.35302115167724e-06
and O 0 1.8682281677229184e-07
two O 0 1.6555967263798266e-08
deleted O 0 5.139584118296625e-07
Dp140 O 0 7.242073252200498e-07
DNA O 0 7.006082682892156e-07
sequences O 0 2.957269451542288e-08
were O 0 5.109718017592968e-07
found O 0 5.844776183039357e-07
in O 0 6.297281629485951e-08
four O 0 1.2974421224498656e-05
patients O 0 0.00034567146212793887
with O 0 0.001837533200159669
severe O 1 0.9525664448738098
cerebral B-Disease 1 0.9992899894714355
dysfunction I-Disease 1 0.9691832065582275
. O 0 0.00010060380736831576

These O 0 9.969071470550261e-07
findings O 0 1.2483895261539146e-05
suggest O 0 1.430213387720869e-06
that O 0 1.009285544029126e-08
some O 0 7.749372255005937e-10
sequences O 0 7.309431282465084e-09
located O 0 8.557893949046047e-08
in O 0 1.879403477289543e-08
the O 0 2.1394269822394563e-07
distal O 0 0.00019360672740731388
part O 0 7.155325079111208e-07
of O 0 7.830593773405781e-08
the O 0 2.9743003437943116e-07
gene O 0 2.4087648853310384e-07
and O 0 4.355228782060294e-07
, O 0 1.9665036177229922e-07
in O 0 8.598437517548518e-08
particular O 0 7.981140726087688e-08
, O 0 2.3642621727049118e-07
some O 0 7.455704320591394e-08
DMD B-Disease 1 0.9968673586845398
isoforms O 0 3.7091839999447984e-07
expressed O 0 8.60293823734537e-07
in O 0 1.0467745426012698e-07
the O 0 1.2342092304606922e-05
brain O 0 0.26659324765205383
may O 0 4.154963971814141e-05
be O 0 2.743552443007502e-07
related O 0 8.961778235061502e-07
to O 0 2.1366987823512318e-07
the O 0 8.057039849518333e-06
cognitive B-Disease 0 0.3588876724243164
impairment I-Disease 1 0.9571478962898254
associated O 0 0.00012643405352719128
with O 0 0.0003678716020658612
DMD B-Disease 1 0.9999701976776123
. O 0 1.679690831224434e-05
. O 0 6.678230874967994e-06

I1307K O 0 0.002696077572181821
APC O 0 0.0022325750906020403
and O 0 1.1436666682129726e-05
hMLH1 O 0 0.00039132710662670434
mutations O 0 1.192762647406198e-05
in O 0 1.1932522170354787e-07
a O 0 9.705992169983801e-07
non O 0 3.161226777592674e-05
- O 0 0.0023210677318274975
Jewish O 0 1.4327704775496386e-05
family O 0 1.039872586261481e-05
with O 0 1.0495806236576755e-05
hereditary B-Disease 1 0.9473801851272583
non I-Disease 1 0.8426287770271301
- I-Disease 1 0.9999473094940186
polyposis I-Disease 1 0.9999486207962036
colorectal I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999477863311768
. O 0 0.0003960889298468828

We O 0 1.246379611075099e-06
describe O 0 8.159660183082451e-07
a O 0 5.899184998270357e-07
French O 0 0.00014131671923678368
Canadian O 0 0.01793709024786949
hereditary B-Disease 1 0.9875596165657043
non I-Disease 1 0.9422038793563843
- I-Disease 1 0.9999949932098389
polyposis I-Disease 1 0.9999970197677612
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 0.005997784901410341
HNPCC B-Disease 1 0.9990436434745789
) O 0 3.810526550296345e-06
kindred O 0 5.555908501264639e-05
which O 0 1.364541901693883e-07
carries O 0 1.2709814427580568e-06
a O 0 3.3437410706937953e-07
novel O 0 1.4123085065875784e-06
truncating O 0 8.33758240332827e-05
mutation O 0 4.593756784743164e-06
in O 0 5.178185915610811e-07
hMLH1 O 0 0.00041958631481975317
. O 0 4.651613380701747e-06

Interestingly O 0 0.0002001210377784446
, O 0 1.9829794837278314e-06
the O 0 2.6243975526085705e-07
I1307K O 0 8.27295589260757e-05
APC O 0 0.00017594511155039072
polymorphism O 0 0.00022657195222564042
, O 0 2.249580347779556e-06
associated O 0 6.017705231897708e-07
with O 0 1.3156579825590597e-07
an O 0 2.616715391923208e-06
increased O 0 0.0001886076497612521
risk O 0 0.0021774633787572384
of O 0 0.3315754234790802
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
, O 0 0.0014007451245561242
is O 0 8.415893717028666e-06
also O 0 3.4920949474326335e-06
present O 0 7.339988883359183e-08
in O 0 9.187498051232978e-08
this O 0 2.06597093210803e-07
family O 0 2.1444027879624628e-05
. O 0 1.316645102633629e-05

The O 0 5.892443368793465e-06
I1307K O 0 0.0002020629617618397
polymorphism O 0 0.000635514676105231
has O 0 5.209229584579589e-06
previously O 0 8.932162018027157e-06
only O 0 7.683927805146595e-08
been O 0 3.048364987989771e-06
identified O 0 8.579312634537928e-06
in O 0 1.555562789690157e-07
individuals O 0 2.146447002360219e-07
of O 0 3.9623097336516366e-07
self O 0 3.507245492073707e-05
- O 0 0.0536472387611866
reported O 0 0.00023645799956284463
Ashkenazi O 0 4.474055458558723e-05
Jewish O 0 2.1711141471314477e-06
origins O 0 2.670911953828181e-06
. O 0 1.528484176560596e-06

In O 0 5.7973957154899836e-06
addition O 0 4.251457994541852e-06
, O 0 4.0462742845193134e-07
in O 0 6.177766209702895e-08
this O 0 5.4735011190132354e-08
family O 0 1.7758642570697702e-05
, O 0 1.842694473452866e-06
there O 0 2.3889396061349544e-07
appears O 0 3.566917484931764e-06
to O 0 1.9450895649697486e-07
be O 0 2.0321765248354495e-07
no O 0 6.718409650829926e-08
relationship O 0 1.0898588698182721e-07
between O 0 4.4931912412948805e-08
the O 0 3.0939418138586916e-07
I1307K O 0 2.330239294678904e-05
polymorphism O 0 3.0346827770699747e-05
and O 0 4.850187451665988e-07
the O 0 1.7492082804437814e-07
presence O 0 6.980819193813659e-07
or O 0 2.769416482806264e-07
absence O 0 1.3188957836973714e-06
of O 0 5.2992263590567745e-06
cancer B-Disease 0 0.1684872955083847
. O 0 2.5407491648365976e-06
. O 0 5.6739440879027825e-06

Identification O 0 5.572256213781657e-06
of O 0 3.7184668144618627e-07
a O 0 1.7307623920714832e-06
novel O 0 2.8393551474437118e-06
mutation O 0 5.595450716100459e-07
of O 0 1.1919086162492931e-08
the O 0 2.6778823780659877e-07
CPO O 0 0.000497564091347158
gene O 0 1.6879454278750927e-07
in O 0 3.271463810960995e-08
a O 0 1.0707547062338563e-06
Japanese O 0 0.0008168856147676706
hereditary B-Disease 0 0.3062187731266022
coproporphyria I-Disease 0 0.0727006196975708
family O 0 5.247182343737222e-05
. O 0 4.305352831579512e-06

Hereditary B-Disease 1 0.9988872408866882
coproporphyria I-Disease 1 0.9965644478797913
( O 0 0.0004254704399500042
HCP B-Disease 1 0.975627601146698
) O 0 9.254359611077234e-06
is O 0 3.7061786315462086e-06
an O 0 0.0001836472365539521
autosomal B-Disease 1 0.9919243454933167
dominant I-Disease 1 0.9979800581932068
disease I-Disease 1 0.9865216016769409
characterized O 0 0.017283808439970016
by O 0 0.0015849544433876872
a O 0 0.31759271025657654
deficiency B-Disease 1 0.6610733270645142
of I-Disease 0 1.3080592680125847e-06
coproporphyrinogen I-Disease 0 0.1258496791124344
oxidase I-Disease 0 6.743425910826772e-05
( O 0 1.089301463252923e-06
CPO O 0 0.0023129628971219063
) O 0 1.0772418335136535e-07
caused O 0 2.2801681609507796e-07
by O 0 3.0983642318460625e-08
a O 0 3.100374783571169e-07
mutation O 0 5.567633252212545e-07
in O 0 4.246504303750953e-08
the O 0 5.175327260076301e-07
CPO O 0 0.0021728582214564085
gene O 0 1.5985610843927134e-06
. O 0 1.1702044275807566e-06

Only O 0 8.353965768037597e-07
11 O 0 3.3971016364375828e-06
mutations O 0 1.3174802688808995e-06
of O 0 2.6264901364925208e-08
the O 0 1.7699338172860735e-07
gene O 0 6.152925493552175e-07
have O 0 3.007093312135112e-07
been O 0 5.288160082272952e-06
reported O 0 8.098748367046937e-05
in O 0 8.169523425749503e-06
HCP B-Disease 1 0.9908745288848877
patients O 0 0.0005428926087915897
. O 0 8.745978448132519e-06

We O 0 2.1804160041938303e-06
report O 0 7.024199817351473e-07
another O 0 1.9146507668210688e-07
mutation O 0 6.648527346442279e-07
in O 0 4.6562462330257404e-08
a O 0 9.255138593289303e-07
Japanese O 0 8.744459773879498e-05
family O 0 1.7847811250248924e-05
. O 0 4.757311216962989e-06

Polymerase O 0 0.001843730453401804
chain O 0 0.0008083524880930781
reaction O 0 2.9422080842778087e-06
- O 0 3.5715427657123655e-05
single O 0 1.9333970158186276e-06
strand O 0 6.246632983675227e-05
conformational O 0 4.111760063096881e-06
polymorphism O 0 1.7863458197098225e-05
and O 0 4.952523013912469e-08
direct O 0 3.232738299274729e-09
sequence O 0 5.01873298475175e-09
analyses O 0 2.880624947465549e-07
demonstrated O 0 1.8878879473049892e-06
a O 0 2.689799600830156e-07
C O 0 1.6135594705701806e-05
to O 0 9.472037731939054e-08
T O 0 4.088821879122406e-05
substitution O 0 8.257967643032771e-09
in O 0 1.2726992792977398e-08
exon O 0 4.3055788410129026e-06
1 O 0 5.0053326816623667e-08
of O 0 4.032311373691755e-09
the O 0 3.1321615523438595e-08
CPO O 0 4.975238334736787e-05
gene O 0 1.899860713194812e-08
at O 0 3.16537338562739e-08
nucleotide O 0 1.101200496123056e-06
position O 0 9.864021421890357e-07
85 O 0 1.9895826426363783e-06
, O 0 8.264952100489609e-08
which O 0 2.9761974218445175e-08
lies O 0 4.298249507428409e-07
in O 0 2.3390267500644768e-08
the O 0 8.162946585343889e-08
putative O 0 1.6999894796754234e-05
presequence O 0 3.0497456464217976e-05
for O 0 3.219516386820942e-08
targeting O 0 2.5567206307641754e-07
to O 0 1.1359508533814733e-07
mitochondria O 0 6.409396974049741e-06
. O 0 1.467798369958473e-06

This O 0 7.084120738909405e-07
mutation O 0 2.126156459780759e-06
changes O 0 2.210393645896147e-08
the O 0 5.300868632929223e-09
codon O 0 7.716179339922746e-08
for O 0 1.0910605752201263e-08
glutamine O 0 1.2029288143367012e-07
to O 0 4.285248156321586e-09
a O 0 1.3557094113991752e-08
termination O 0 9.042003057402326e-07
codon O 0 1.0482149548352027e-07
at O 0 1.9892478064775787e-07
amino O 0 4.3281536932227027e-07
acid O 0 2.695566763577517e-06
position O 0 1.2368404895823915e-06
29 O 0 2.999583193741273e-05
. O 0 1.6588642210990656e-06

MaeI O 0 0.004582891706377268
restriction O 0 6.8877880039508455e-06
analysis O 0 9.088298043025134e-07
showed O 0 9.221666914527304e-06
two O 0 5.2244256920630505e-08
other O 0 4.391107921719595e-08
carriers O 0 5.588120529864682e-06
in O 0 5.081857068489626e-08
the O 0 7.117349127838679e-07
family O 0 2.5584462491679005e-05
. O 0 5.538281584449578e-06

The O 0 1.574700763740111e-05
C O 0 0.0885070413351059
- O 1 0.7985553741455078
T O 1 0.9125363230705261
mutation O 0 2.581557282610447e-06
is O 0 6.109147676625071e-08
located O 0 5.8112508583008093e-08
within O 0 4.169207645787765e-09
a O 0 1.0929497875622474e-06
recently O 0 0.000246745184995234
proposed O 0 1.3476959566105506e-06
putative O 0 3.3560386327735614e-06
alternative O 0 2.3286816031031776e-08
translation O 0 2.7396426460768453e-08
initiation O 0 6.747085734559732e-08
codon O 0 4.4507359575618466e-07
( O 0 8.860423150736096e-08
TIC O 0 0.00027096414123661816
- O 0 4.1337287257192656e-05
1 O 0 5.917261205468094e-07
) O 0 2.0120452859373472e-08
, O 0 1.9168151510484677e-08
supporting O 0 2.832856580425869e-07
that O 0 5.677429157913139e-07
TIC O 0 0.019263966009020805
- O 0 0.00024098865105770528
1 O 0 5.423240168056509e-07
is O 0 2.321634617885593e-08
the O 0 2.465759507686016e-08
real O 0 2.528665390855167e-06
TIC O 0 0.001101719681173563
rather O 0 4.6138382003846345e-08
than O 0 1.2279090810807247e-07
TIC O 0 0.000727913633454591
- O 0 9.95027494354872e-06
2 O 0 4.154080954776873e-07
. O 0 9.14023559062116e-08
. O 0 3.5208526583119237e-07

Human B-Disease 0 0.0002146405604435131
complement I-Disease 0 0.0006258880603127182
factor I-Disease 0 0.10536949336528778
H I-Disease 1 0.9999796152114868
deficiency I-Disease 1 0.9998024106025696
associated O 0 0.009851627983152866
with O 1 0.911958634853363
hemolytic B-Disease 1 0.9999837875366211
uremic I-Disease 1 0.999991774559021
syndrome I-Disease 1 0.9999614953994751
. O 0 0.0007424147916026413

This O 0 6.859776817691454e-07
study O 0 3.832777224488382e-07
reports O 0 4.014701744381455e-07
on O 0 7.049997634567262e-07
six O 0 4.244627689331537e-06
cases O 0 1.913513733597938e-05
of O 0 0.0003155791782774031
deficiency B-Disease 1 0.6670854687690735
in I-Disease 0 7.520660716409111e-08
the I-Disease 0 1.3962311129489535e-07
human I-Disease 0 2.4261896669486305e-07
complement I-Disease 0 1.8735987339368876e-07
regulatory I-Disease 0 1.584717892910703e-06
protein I-Disease 0 1.0608811180645716e-06
Factor I-Disease 0 2.623892214614898e-06
H I-Disease 1 0.9720306396484375
( O 0 5.040291171098943e-07
FH O 0 0.00010354440019000322
) O 0 1.9993825262076825e-08
in O 0 5.328552710182066e-09
the O 0 1.0835635499972796e-08
context O 0 3.2070012423446315e-08
of O 0 2.6339205305703217e-06
an O 1 0.798193633556366
acute B-Disease 1 0.9999771118164062
renal I-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999527931213379
. O 0 0.0005493676289916039

Five O 0 4.0380195969191846e-06
of O 0 1.7182702549689566e-07
the O 0 2.944067318821908e-07
cases O 0 3.658381501736585e-06
were O 0 4.809057372767711e-06
observed O 0 1.2587992159751593e-06
in O 0 9.808304213265728e-08
children O 0 3.926254521502415e-06
presenting O 0 0.00012912391684949398
with O 1 0.7482267618179321
idiopathic O 1 0.9999923706054688
hemolytic B-Disease 1 0.9999984502792358
uremic I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.999997615814209
( O 0 0.10053851455450058
HUS B-Disease 1 0.9999260902404785
) O 0 5.6321117881452665e-05
. O 0 2.2927573809283786e-05

Two O 0 1.2609378927663784e-06
of O 0 2.866380555133219e-07
the O 0 5.751242611040652e-07
children O 0 4.882143912254833e-06
exhibited O 0 0.000569741940125823
a O 0 0.0015609042020514607
homozygous O 1 0.9779996275901794
deficiency O 1 0.9563141465187073
characterized O 0 1.868560866569169e-05
by O 0 1.7209250700034318e-06
the O 0 8.664600841257197e-07
absence O 0 1.8226998008685769e-06
of O 0 3.485292410232432e-08
the O 0 1.4032178796696826e-07
150 O 0 1.6798402384665678e-06
- O 0 0.00033570980303920805
kD O 0 9.064555342774838e-06
form O 0 1.9283955765558858e-08
of O 0 2.761804118733835e-08
Factor O 0 2.4835030671965797e-06
H O 1 0.9617703557014465
and O 0 7.886628168307652e-07
the O 0 1.1807425437382335e-07
presence O 0 1.3953645350284205e-07
, O 0 1.8779987343009452e-08
upon O 0 1.7953174946683248e-08
immunoblotting O 0 1.4853714674245566e-05
, O 0 1.3331264092641959e-08
of O 0 2.099970863866929e-09
the O 0 3.4363278444971e-08
42 O 0 7.273577921296237e-06
- O 0 0.00020605944155249745
kD O 0 0.00011876509233843535
Factor O 0 2.1639680198859423e-06
H O 1 0.6828427314758301
- O 0 1.0422982086311094e-05
like O 0 1.0797410965324161e-07
protein O 0 1.7532240548234768e-08
1 O 0 7.540943158801383e-08
( O 0 4.1895209079712004e-08
FHL O 0 7.570618618046865e-05
- O 0 3.281072713434696e-05
1 O 0 6.791266287109465e-07
) O 0 1.5168115652386405e-08
and O 0 2.6167192856973998e-08
other O 0 5.937837954661518e-08
FH O 0 0.0011933476198464632
- O 0 0.00010773339454317465
related O 0 5.0824423851736356e-06
protein O 0 6.917871928635577e-07
( O 0 1.0464610511462524e-07
FHR O 0 0.00024074269458651543
) O 0 1.46224735431133e-07
bands O 0 5.589442025666358e-06
. O 0 2.103469341818709e-06

Southern O 0 1.4553148503182456e-05
blot O 0 0.00031590848811902106
and O 0 4.1427068708799197e-07
PCR O 0 2.4390076305280672e-06
analysis O 0 1.5049817392309706e-08
of O 0 7.53892592797456e-09
DNA O 0 4.8788201638672035e-06
of O 0 1.2662144399655517e-07
one O 0 7.527731213485822e-06
patient O 0 0.00020556982781272382
with O 0 0.00030247613904066384
homozygous O 1 0.8129041194915771
deficiency O 1 0.6446971893310547
ruled O 0 3.7747227906947955e-05
out O 0 5.84721306040592e-07
the O 0 2.906428733240318e-07
presence O 0 1.5989118651305034e-07
of O 0 1.7841346178215645e-08
a O 0 3.2547967521168175e-07
large O 0 8.686311048222706e-07
deletion O 0 1.2510120086517418e-06
of O 0 3.777084955913779e-08
the O 0 2.69168054956026e-07
FH O 0 0.0014191159280017018
gene O 0 2.0131129474521003e-07
as O 0 4.088624194764634e-08
the O 0 4.5098911982677237e-07
underlying O 0 0.0007322635501623154
defect O 0 0.0020168214105069637
for O 0 1.646892269491218e-05
the O 0 0.004929616581648588
deficiency O 1 0.8636364340782166
. O 0 2.1518164430744946e-05

The O 0 1.3437407915262156e-06
other O 0 1.982747477313751e-07
four O 0 3.174576193032408e-07
children O 0 1.9274452824902255e-06
presented O 0 7.468252533726627e-06
with O 0 1.9569359210436232e-05
heterozygous O 0 0.20224040746688843
deficiency O 1 0.7005467414855957
and O 0 4.325580903241644e-06
exhibited O 0 0.0008446536958217621
a O 0 3.7276129205565667e-06
normal O 0 9.138132099906215e-07
immunoblotting O 0 0.0002172148524550721
pattern O 0 5.816318093820882e-07
of O 0 2.313249503060888e-08
proteins O 0 2.6366793193233207e-08
of O 0 3.230730527548076e-08
the O 0 2.0364168449305e-06
FH O 0 0.07947596162557602
family O 0 5.0678052502917126e-05
. O 0 5.674988642567769e-06

Factor B-Disease 1 0.8242536783218384
H I-Disease 1 0.9999786615371704
deficiency I-Disease 1 0.9980915188789368
is O 0 8.688514867571939e-07
the O 0 1.170101768366294e-06
only O 0 2.110100831487216e-05
complement B-Disease 1 0.9984681010246277
deficiency I-Disease 1 0.9999834299087524
associated O 0 4.4136253563920036e-05
with O 0 8.226227510022e-05
HUS B-Disease 1 0.9996143579483032
. O 0 0.00010200381802860647

These O 0 2.680026227608323e-07
observations O 0 1.0150539537789882e-06
suggest O 0 1.340250605608162e-06
a O 0 3.6936484093530453e-07
role O 0 5.69504209124716e-07
for O 0 2.9427786785163335e-07
FH O 0 0.009133496321737766
and O 0 1.4442982774198754e-06
/ O 0 4.977508524461882e-06
or O 0 5.967448259980301e-07
FH O 0 0.000408645166317001
receptors O 0 1.1223938827242819e-06
in O 0 1.2564475682097509e-08
the O 0 3.231251639590482e-07
pathogenesis O 0 0.0008199703879654408
of O 0 3.415315950405784e-05
idiopathic O 1 0.9992271661758423
HUS B-Disease 1 0.9998340606689453
. O 0 1.2773080925398972e-05
. O 0 8.522352800355293e-06

Further O 0 2.6956413421430625e-06
evidence O 0 3.7208367302810075e-06
for O 0 1.312036914669079e-07
a O 0 1.682508127487381e-06
major O 0 1.6817264622659422e-05
ancient O 0 3.270139131927863e-05
mutation O 0 0.03936467692255974
underlying O 1 0.97652268409729
myotonic B-Disease 1 0.9999959468841553
dystrophy I-Disease 1 0.9999920129776001
from O 0 3.6516266845865175e-05
linkage O 0 0.0006092474213801324
disequilibrium O 0 0.028593698516488075
studies O 0 5.009859251003945e-06
in O 0 1.7308140343175182e-07
the O 0 6.354193260449392e-07
Japanese O 0 4.896207610727288e-05
population O 0 1.4811372466283501e-06
. O 0 2.042150072156801e-06

The O 0 0.12944601476192474
myotonic B-Disease 1 0.9999575614929199
dystrophy I-Disease 1 0.9999899864196777
( O 0 0.05001141503453255
DM B-Disease 1 0.999991774559021
) O 0 5.113213410368189e-05
mutation O 0 9.053522808244452e-05
is O 0 1.4540083839165163e-06
an O 0 1.4539677977154497e-05
unstable O 0 0.066681407392025
( O 0 3.6652679682447342e-06
CTG O 0 0.0016215034993365407
) O 0 1.795992830011528e-07
n O 0 1.1094733054051176e-05
repeat O 0 1.084518135030521e-05
, O 0 2.1416930451323424e-07
present O 0 4.050443180858565e-08
at O 0 2.944808557003853e-07
a O 0 6.160069432326054e-08
copy O 0 4.3010749095628853e-07
number O 0 2.5447734586236948e-08
of O 0 3.83600919917626e-08
5 O 0 7.282312139977876e-07
- O 0 3.0298277124529704e-05
37 O 0 3.8847119299134647e-07
repeats O 0 3.827056715977051e-08
on O 0 3.2044454201241024e-08
normal O 0 1.051426412601586e-08
chromosomes O 0 1.5912935680262308e-07
but O 0 6.184838419187599e-09
amplified O 0 2.3836325624415622e-07
to O 0 2.5237216760842784e-09
50 O 0 2.340874694084505e-08
- O 0 2.0873683297395473e-06
3000 O 0 4.2147360090893926e-07
copies O 0 5.025133873459708e-07
on O 0 6.8686863414768595e-06
DM B-Disease 1 0.9990897178649902
chromosomes O 0 0.0001188663809443824
. O 0 2.728639628912788e-06

Previous O 0 4.420718687470071e-05
findings O 0 2.9009066565777175e-05
in O 0 6.850395379842666e-07
Caucasian O 0 0.0001146686845459044
populations O 0 2.618492544570472e-06
of O 0 1.6961297433226719e-07
a O 0 0.00023465945560019463
DM B-Disease 1 0.9999953508377075
founder O 1 0.673948347568512
chromosome O 0 0.03145354986190796
raise O 0 1.1864300176966935e-05
a O 0 1.590114919736152e-07
question O 0 5.157072990868983e-08
about O 0 8.448673760597103e-09
the O 0 1.1684716305637721e-08
molecular O 0 3.7196903690528416e-07
events O 0 2.0727529914665865e-08
involved O 0 1.8406097979095648e-07
in O 0 1.6429792637495666e-08
the O 0 1.526162520804064e-07
expansion O 0 2.3015176338958554e-05
mutation O 0 1.1868271940329578e-05
. O 0 6.9808979787922e-06

To O 0 1.337102389697975e-06
investigate O 0 1.0838273738045245e-05
whether O 0 1.8996705648532952e-06
a O 0 2.2743010958947707e-06
founder O 0 0.0010521343210712075
chromosome O 0 0.0002109665219904855
for O 0 7.739519105598447e-07
the O 0 1.9005687136086635e-05
DM B-Disease 1 0.9999908208847046
mutation O 0 1.774396514520049e-05
exists O 0 6.707973909669818e-08
in O 0 4.708985557044798e-08
the O 0 1.4924306412922306e-07
Japanese O 0 4.956659904564731e-05
population O 0 3.5410701570981473e-07
, O 0 1.7950853248294152e-07
we O 0 4.3815955308446064e-08
genotyped O 0 1.0525366633373778e-05
families O 0 5.235198585751277e-08
using O 0 5.552246307161113e-08
polymorphic O 0 6.44077590550296e-06
markers O 0 3.812494833255187e-05
near O 0 2.459780944263912e-06
the O 0 2.272743415687728e-07
( O 0 3.297053865480848e-07
CTG O 0 0.0001435244339518249
) O 0 3.770405143654898e-08
n O 0 1.4045476746105123e-06
repeat O 0 1.2307034467085032e-06
region O 0 1.995759788542273e-07
and O 0 4.673984790315444e-07
constructed O 0 7.398291199933738e-05
haplotypes O 0 0.00022564342361874878
. O 0 6.695129741274286e-06

Six O 0 4.590839580487227e-06
different O 0 1.3919367347625666e-07
haplotypes O 0 5.8841495047090575e-05
were O 0 1.130656437453581e-05
found O 0 1.0823998309206218e-05
and O 0 2.0085763026145287e-05
DM B-Disease 1 0.9999768733978271
alleles O 0 1.860884003690444e-05
were O 0 7.132990504032932e-06
always O 0 1.2247647873664391e-06
haplotype O 0 1.5213613551168237e-05
A O 0 1.010440246318467e-05
. O 0 8.470276043226477e-06

To O 0 3.3294011245743604e-06
find O 0 8.523892915945908e-07
an O 0 7.623956577162971e-08
origin O 0 3.9635029480677986e-08
of O 0 1.5117857188329253e-08
the O 0 2.826759839535953e-07
( O 0 3.9607456869816815e-07
CTG O 0 7.468395779142156e-05
) O 0 2.16543014630588e-08
n O 0 1.3499200122168986e-06
repeat O 0 1.0770318112918176e-06
mutation O 0 4.6476398551931197e-07
and O 0 1.30135120457453e-07
to O 0 2.7149441805818242e-08
investigate O 0 4.491315053201106e-07
the O 0 2.7691042348010342e-08
mechanism O 0 4.7267310065990387e-08
of O 0 1.1884353945390558e-08
the O 0 4.654248542124151e-08
expansion O 0 1.2848882988691912e-06
mutation O 0 5.36478808044194e-07
in O 0 4.245653784096248e-08
the O 0 7.136462443213532e-08
Japanese O 0 5.121849881106755e-06
population O 0 6.508813044092676e-08
we O 0 1.6532238689137557e-08
have O 0 1.9683660923419666e-08
studied O 0 1.6518376355634246e-07
90 O 0 3.151999123929272e-07
Japanese O 0 6.725136336172e-05
DM B-Disease 1 0.996254563331604
families O 0 4.0859509908841574e-07
comprising O 0 2.3509271329658077e-07
190 O 0 2.980588533318951e-06
affected O 0 3.9343066760011425e-07
and O 0 9.070575401892711e-08
130 O 0 2.89698346023215e-06
unaffected O 0 2.2584372345590964e-05
members O 0 4.853560540141189e-07
. O 0 1.4160214050207287e-06

The O 0 4.05353011956322e-06
results O 0 4.68676489617792e-06
suggest O 0 3.3614651329116896e-06
that O 0 1.1402914168456846e-07
a O 0 9.518153092358261e-07
few O 0 2.650826900207903e-07
common O 0 5.903046371713572e-07
ancestral O 0 5.0049115998263005e-06
mutations O 0 3.817360720859142e-06
in O 0 8.22922956444927e-08
both O 0 4.0425098291052564e-07
Caucasian O 0 0.000312823336571455
and O 0 3.936313532904023e-06
Japanese O 0 6.469502113759518e-05
populations O 0 1.5609246020176215e-06
have O 0 8.752904534503614e-08
originated O 0 1.6884822429119595e-08
by O 0 1.5791217222727028e-08
expansion O 0 1.8410750612929405e-07
of O 0 2.5615499055220425e-08
an O 0 1.2061617553627002e-06
ancestral O 0 1.0226737686025444e-05
n O 0 8.830813749227673e-05
= O 0 6.790011411794694e-06
5 O 0 9.162350522728957e-08
repeat O 0 1.5414273946134927e-07
to O 0 1.195620047411694e-08
n O 0 2.9516397717088694e-06
= O 0 3.2036473385232966e-06
19 O 0 1.8114118347511976e-06
- O 0 1.8364737115916796e-05
37 O 0 1.7221021835212014e-06
copies O 0 1.8376823618382332e-06
. O 0 1.4343344219014398e-06

These O 0 2.6666234020922275e-07
data O 0 1.818380326312763e-07
support O 0 6.84233967263026e-08
multistep O 0 2.1571499928541016e-06
models O 0 1.234589717569179e-06
of O 0 7.983896210816965e-08
triplet O 0 0.0004368485533632338
repeat O 0 4.302902198105585e-06
expansion O 0 1.204521367981215e-06
that O 0 6.591128709487748e-08
have O 0 8.789223926441991e-08
been O 0 1.0360997748648515e-07
proposed O 0 1.305047305777407e-07
for O 0 1.98940142581705e-07
both O 0 1.0775890586955938e-05
DM B-Disease 1 0.9999728202819824
and O 0 0.00014922329864930362
Friedreichs B-Disease 0 0.025440853089094162
ataxia I-Disease 0 0.0022684948053210974
. O 0 9.86970462690806e-07
. O 0 2.749445457084221e-06

The O 0 1.193698835777468e-06
molecular O 0 1.4692389413539786e-05
basis O 0 1.8025543795374688e-06
of O 0 0.000491297454573214
C6 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999940395355225
in O 0 1.1995589375146665e-06
the O 0 2.7669511837302707e-07
western O 0 2.237237822555471e-06
Cape O 0 4.0113769500749186e-05
, O 0 4.5868000597693026e-07
South O 0 1.1551887837413233e-06
Africa O 0 2.116072437274852e-06
. O 0 1.4615631016567932e-06

Deficiency B-Disease 1 0.9939054846763611
of I-Disease 0 7.963620873852051e-07
the I-Disease 0 4.463023515199893e-07
sixth I-Disease 0 0.00011679453746182844
component I-Disease 0 2.064804220935912e-06
of I-Disease 0 2.3020001549411973e-07
human I-Disease 0 1.348750288343581e-06
complement I-Disease 0 1.2670119531321689e-06
( O 0 4.772584247803024e-07
C6 O 0 0.479073703289032
) O 0 4.751616131670744e-07
has O 0 8.211698059312766e-07
been O 0 2.6862130653171334e-06
reported O 0 4.443497800821206e-06
in O 0 2.3896864931316486e-08
a O 0 6.340501101931295e-08
number O 0 6.421802112299702e-08
of O 0 2.896958228859603e-08
families O 0 2.7021121695725014e-07
from O 0 7.23592918916438e-08
the O 0 8.244531102263863e-08
western O 0 1.2447558219719213e-06
Cape O 0 2.9454557079588994e-05
, O 0 5.377229399528005e-07
South O 0 1.39962435241614e-06
Africa O 0 2.2851759240438696e-06
. O 0 1.3290207334648585e-06

Meningococcal B-Disease 1 0.9993575215339661
disease I-Disease 1 0.999198853969574
is O 0 7.725506293354556e-05
endemic O 0 0.005560121964663267
in O 0 5.217186185291212e-07
the O 0 2.0890074665658176e-06
Cape O 0 0.0009851377690210938
and O 0 2.822299336457945e-07
almost O 0 1.9443099574800726e-08
all O 0 6.831694765452312e-09
pedigrees O 0 9.892179377857246e-07
of O 0 6.921324029462994e-07
total O 0 0.2336256504058838
C6 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999947547912598
( O 0 1.8782443476084154e-06
C6Q0 O 0 0.020641472190618515
) O 0 3.4821039207599824e-07
have O 0 2.1733377764121542e-07
been O 0 8.689077617418661e-07
ascertained O 0 6.289386419666698e-06
because O 0 7.409516342704592e-07
of O 0 1.2850260645791423e-05
recurrent O 1 0.9283318519592285
disease O 0 0.061822231858968735
. O 0 1.9319693819852546e-05

We O 0 3.259591721871402e-06
have O 0 1.3719169089654315e-07
sequenced O 0 1.3978420838611783e-06
the O 0 3.6587191942771824e-08
expressed O 0 5.490669963137407e-08
exons O 0 2.1296438035278697e-07
of O 0 1.58077622103292e-08
the O 0 1.6806465907848178e-07
C6 O 0 0.02367950975894928
gene O 0 8.407236862240097e-08
from O 0 2.0554228541413977e-08
selected O 0 6.540478807437466e-07
cases O 0 2.4872335870895768e-06
and O 0 2.7537830646906514e-06
have O 0 1.2930677257827483e-06
found O 0 7.002422535151709e-07
three O 0 8.965624260781624e-07
molecular O 0 0.04473993554711342
defects O 1 0.9892282485961914
leading O 0 0.00411747582256794
to O 0 3.3447820442233933e-06
total O 0 0.006659852806478739
deficiency O 0 0.46204066276550293
879delG O 0 0.00020856803166680038
, O 0 6.416526048269589e-07
which O 0 8.702514264768979e-08
is O 0 8.95669671763244e-08
the O 0 5.57182943339285e-07
common O 0 1.3366471648623701e-05
defect O 0 0.0006473090033978224
in O 0 3.95154756915872e-07
the O 0 1.6237515865213936e-06
Cape O 0 0.0004210419429000467
and O 0 3.485400611680234e-06
hitherto O 0 2.952322938654106e-05
unreported O 0 3.3158146834466606e-05
, O 0 1.1859251571877394e-06
and O 0 5.096009658700495e-07
1195delC O 0 5.70091578993015e-05
and O 0 1.0127529321835027e-06
1936delG O 0 2.4427101379842497e-05
, O 0 1.4943475434847642e-07
which O 0 5.8392725321709804e-08
have O 0 1.096545858558784e-07
been O 0 6.12404676303413e-07
previously O 0 4.90676075060037e-06
reported O 0 2.3891955152066657e-06
in O 0 1.3391847630828124e-07
African O 0 2.584710500741494e-06
- O 0 0.00030200902256183326
Americans O 0 2.015253085119184e-05
. O 0 3.6735302728629904e-06

We O 0 5.776066700491356e-06
also O 0 1.0075968930323143e-06
show O 0 6.629444726513611e-08
that O 0 4.7852011242355275e-09
the O 0 2.187143444132289e-08
879delG O 0 8.473488560412079e-05
and O 0 6.288325039349729e-06
1195delC O 0 0.20612137019634247
defects O 1 0.9855395555496216
are O 0 9.876032436295645e-07
associated O 0 2.1173684672248783e-06
with O 0 1.8343956753597013e-06
characteristic O 0 9.798318933462724e-05
C6 O 1 0.9842396974563599
/ O 0 0.0005558340344578028
C7 O 1 0.5520492196083069
region O 0 2.9686966627195943e-06
DNA O 0 0.00017982744611799717
marker O 0 0.0003037114511243999
haplotypes O 0 0.0001965417613973841
, O 0 2.6328307285439223e-06
although O 0 1.7767085580544517e-07
small O 0 2.578870521574572e-07
variations O 0 2.2746373815607512e-06
were O 0 3.7259178498061374e-06
observed O 0 4.591960987454513e-06
. O 0 2.8218948955327505e-06

The O 0 2.3597493054694496e-05
1936delG O 0 0.07847228646278381
defect O 0 0.3748488128185272
was O 0 0.00017222471069544554
observed O 0 2.12590293813264e-06
only O 0 3.5393071584621794e-08
once O 0 5.97192865825491e-07
in O 0 2.9466617590401256e-08
the O 0 3.234066241475375e-07
Cape O 0 4.6580040361732244e-05
, O 0 1.8473063789770094e-07
but O 0 2.102737539644295e-08
its O 0 3.5971073231166883e-08
associated O 0 7.492861868740874e-07
haplotype O 0 5.032595709053567e-06
could O 0 3.8032183624636673e-07
be O 0 1.10944618825215e-07
deduced O 0 1.0221462616755161e-05
. O 0 2.383271748840343e-06

The O 0 5.742298299082904e-07
data O 0 7.496672083107114e-07
from O 0 1.7576579125488934e-07
the O 0 1.6297185823077598e-07
haplotypes O 0 3.060969538637437e-05
indicate O 0 8.813579484012735e-07
that O 0 7.594143092148897e-09
these O 0 1.2526686354874528e-09
three O 0 2.0807709688597242e-07
molecular O 0 0.02247486263513565
defects O 1 0.9743116497993469
account O 0 3.3564838304300793e-06
for O 0 1.414239932273631e-06
the O 0 1.4792053661949467e-05
defects O 1 0.6915356516838074
in O 0 1.1643518860182667e-07
all O 0 8.006370677549057e-09
the O 0 2.2312750047603913e-07
38 O 0 4.352517134975642e-05
unrelated O 0 0.0003975201107095927
C6Q0 O 0 0.07650651037693024
individuals O 0 1.0173566806770395e-06
we O 0 5.845992134823064e-08
have O 0 3.5688898947228154e-08
studied O 0 1.5454516244517436e-07
from O 0 5.474325703858085e-08
the O 0 7.025760737633391e-07
Cape O 0 0.00012839511327911168
. O 0 3.547482720023254e-06

We O 0 9.461278750677593e-06
have O 0 2.1084097170387395e-06
also O 0 3.2506341085536405e-07
observed O 0 2.2573590285901446e-07
the O 0 2.0998822947149165e-07
879delG O 0 0.0009045540355145931
defect O 0 7.935173925943673e-05
in O 0 6.052572132375644e-08
two O 0 1.692025875854597e-06
Dutch O 1 0.9860777854919434
C6 B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999326467514038
deficient I-Disease 1 0.9998461008071899
kindreds O 0 0.0006072743562981486
, O 0 6.07446509093279e-07
but O 0 4.4019841993758746e-08
the O 0 8.899666426032127e-08
879delG O 0 0.0006388372858054936
defect O 0 8.17421023384668e-05
in O 0 1.0022475294135802e-07
the O 0 1.2112741387682036e-06
Cape O 0 0.003104466013610363
probably O 0 2.327878428332042e-05
did O 0 1.43178112921305e-07
not O 0 5.992127238840794e-09
come O 0 1.9790113992002034e-09
from O 0 1.7424917064801093e-09
The O 0 9.503231979124394e-09
Netherlands O 0 6.197367838467471e-06
. O 0 1.945163745631362e-07
. O 0 9.84975145001954e-07

Complement B-Disease 1 0.9795148372650146
C7 I-Disease 1 0.9999805688858032
deficiency I-Disease 1 0.9999775886535645
: O 0 2.0339907678135205e-06
seven O 0 2.015027348534204e-06
further O 0 1.1801678283518413e-06
molecular O 0 0.018096374347805977
defects O 1 0.9950657486915588
and O 0 1.4345791896630544e-05
their O 0 2.962146709251101e-06
associated O 0 2.8983295123907737e-05
marker O 0 0.0008678453741595149
haplotypes O 0 0.0008509280160069466
. O 0 1.2386498383420985e-05

Seven O 0 4.003371486760443e-06
further O 0 4.877015840065724e-07
molecular O 0 1.398737367708236e-05
bases O 0 2.0437561033759266e-05
of O 0 0.005018430296331644
C7 B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.9999943971633911
are O 0 9.979135029425379e-06
described O 0 0.00014748575631529093
. O 0 1.3936138202552684e-05

All O 0 5.591465992438316e-07
these O 0 5.627346411074541e-08
new O 0 1.4870447557768784e-06
molecular O 0 0.0004343623004388064
defects O 1 0.5166998505592346
involve O 0 1.7897193629323738e-06
single O 0 4.426402483659331e-06
- O 0 0.001173296244814992
nucleotide O 0 5.313500878401101e-06
events O 0 6.166194310708306e-08
, O 0 9.008299883817017e-08
deletions O 0 1.3564578011937556e-06
and O 0 5.911051061957551e-07
substitutions O 0 1.9591373074945295e-06
, O 0 7.683502900590611e-08
some O 0 1.1079226425181332e-09
of O 0 8.328770562116006e-09
which O 0 7.547129854401646e-08
alter O 0 2.565499016782269e-06
splice O 0 5.114479790790938e-06
sites O 0 4.1919989257621637e-07
, O 0 1.9332576073338714e-07
and O 0 3.1519809340352367e-07
others O 0 1.4417029206015286e-06
codons O 0 7.5638777161657345e-06
. O 0 1.5848100929360953e-06

They O 0 2.974727294713375e-06
are O 0 3.028738859711666e-08
distributed O 0 2.3446371955060386e-08
along O 0 3.3297961721245883e-08
the O 0 1.261421118670114e-07
C7 O 1 0.6426452398300171
gene O 0 8.924899361772987e-07
, O 0 4.516562412959502e-08
but O 0 6.927165507875088e-09
predominantly O 0 3.4945235594108226e-09
towards O 0 6.725394907647342e-09
the O 0 1.9754180513587016e-08
3 O 0 8.697019779901893e-07
end O 0 3.582446197469835e-06
. O 0 1.933426574396435e-06

All O 0 8.905878985387972e-07
were O 0 2.17629644794215e-06
found O 0 7.801774586368992e-07
in O 0 7.761257592164839e-08
compound O 0 9.704168633106747e-07
heterozygous O 0 3.910097348125419e-06
individuals O 0 1.4358904536493355e-06
. O 0 4.7206499402818736e-06

The O 0 3.804348671110347e-05
C6 O 1 0.9681708812713623
/ O 0 0.0032414537854492664
C7 O 1 0.9835194945335388
marker O 0 0.009691203944385052
haplotypes O 0 0.0018451869254931808
associated O 0 3.029888466699049e-05
with O 0 8.111021998047363e-06
most O 0 0.00012141827755840495
C7 B-Disease 1 0.9999871253967285
defects I-Disease 1 0.9998792409896851
are O 0 2.728853132794029e-06
tabulated O 0 0.002517123706638813
. O 0 7.718673487033811e-07
. O 0 4.067726877110545e-06

A O 0 4.0197868656832725e-05
genome O 0 6.852930528111756e-05
- O 0 0.00010726667096605524
wide O 0 7.977805580594577e-07
search O 0 1.203235200364361e-07
for O 0 3.267900297032611e-07
chromosomal O 0 0.013480355963110924
loci O 0 3.145766459056176e-05
linked O 0 0.040017250925302505
to O 0 4.740155418403447e-05
mental O 0 0.4479740560054779
health O 0 0.00011491496115922928
wellness O 0 3.0426490411628038e-05
in O 0 6.703862140966521e-07
relatives O 0 5.900197720620781e-06
at O 0 2.7500787837198004e-05
high O 0 0.023282628506422043
risk O 0 0.004393166396766901
for O 0 0.0013968978310003877
bipolar B-Disease 1 0.9999830722808838
affective I-Disease 1 0.9999573230743408
disorder I-Disease 1 0.974918007850647
among O 0 3.2389291391154984e-06
the O 0 5.686375175173453e-07
Old O 0 8.69664509082213e-05
Order O 0 8.075741106949863e-07
Amish O 0 0.0003938653680961579
. O 0 6.712736194458557e-06

Bipolar B-Disease 1 0.9997989535331726
affective I-Disease 1 0.9997014403343201
disorder I-Disease 1 0.9999067783355713
( O 0 0.009078442119061947
BPAD B-Disease 1 0.9999880790710449
; O 0 0.4099714756011963
manic B-Disease 1 0.9999691247940063
- I-Disease 1 0.9999960660934448
depressive I-Disease 1 0.9999970197677612
illness I-Disease 1 0.9939342141151428
) O 0 7.639422619831748e-06
is O 0 6.385472488545929e-07
characterized O 0 2.891451913455967e-06
by O 0 1.5391829322197736e-07
episodes O 0 3.716236847139953e-07
of O 0 4.98184078878694e-07
mania B-Disease 0 0.046345021575689316
and O 0 2.878104533010628e-05
/ O 0 6.208316335687414e-05
or O 0 2.908055421357858e-06
hypomania B-Disease 0 0.0016955474857240915
interspersed O 0 1.1839219951070845e-05
with O 0 3.7915430084467516e-07
periods O 0 1.1392592114134459e-06
of O 0 3.8178231989149936e-06
depression B-Disease 0 0.007134711369872093
. O 0 9.704329386295285e-06

Compelling O 0 2.9336482839426026e-05
evidence O 0 2.120406861649826e-05
supports O 0 5.2819355005340185e-06
a O 0 7.636442092007201e-07
significant O 0 4.7682121362413454e-07
genetic O 0 1.0911667231994215e-06
component O 0 1.4706272395414999e-06
in O 0 1.073248725447229e-07
the O 0 5.796776463284914e-07
susceptibility O 0 5.454155325423926e-05
to O 0 1.1141341929032933e-06
develop O 0 5.321226853993721e-05
BPAD B-Disease 1 0.9975693821907043
. O 0 1.3233040590421297e-05

To O 0 3.874635694955941e-06
date O 0 1.5330111637013033e-05
, O 0 1.0584103620203678e-06
however O 0 1.1625565576878216e-07
, O 0 5.066623742777665e-08
linkage O 0 3.140949274893501e-06
studies O 0 5.177099637876381e-07
have O 0 1.8261310685829812e-07
attempted O 0 1.2594376130437013e-05
only O 0 1.2787947589742998e-08
to O 0 5.5850556179848354e-08
identify O 0 2.7618309559329646e-06
chromosomal O 0 0.0010707898763939738
loci O 0 8.673978300066665e-06
that O 0 1.2143495951022487e-06
cause O 0 3.8210396269278135e-06
or O 0 2.2675172317576653e-07
increase O 0 1.3910890857005143e-06
the O 0 6.181456342346792e-07
risk O 0 1.4692754120915197e-05
of O 0 6.522085413962486e-07
developing O 0 0.00031684048008173704
BPAD B-Disease 1 0.9987373948097229
. O 0 1.504447754996363e-05

To O 0 1.5076111594680697e-06
determine O 0 1.088748945221596e-06
whether O 0 2.2721344805631816e-07
there O 0 4.591469604520171e-08
could O 0 4.04684527666177e-07
be O 0 3.011874980529683e-07
protective O 0 8.505090590915643e-06
alleles O 0 2.2580587710763211e-07
that O 0 1.787128951491468e-07
prevent O 0 5.583128768194001e-06
or O 0 7.881658348196652e-07
reduce O 0 1.441003132640617e-05
the O 0 9.244676562047971e-07
risk O 0 6.525527624035021e-06
of O 0 4.1950863760575885e-07
developing O 0 0.0006636104080826044
BPAD B-Disease 1 0.9999406337738037
, O 0 1.0642768302204786e-06
similar O 0 1.1124084409175339e-07
to O 0 3.715194552000867e-08
what O 0 1.3881608751376007e-08
is O 0 3.812478155396093e-08
observed O 0 2.0156026891982037e-07
in O 0 2.786060520065803e-07
other O 0 4.975650881533511e-05
genetic B-Disease 1 0.9999748468399048
disorders I-Disease 1 0.9999945163726807
, O 0 0.000133737557916902
we O 0 2.9020545753155602e-06
used O 0 0.0006578796892426908
mental O 0 0.38797715306282043
health O 0 0.0018088199431076646
wellness O 0 0.0005189671064727008
( O 0 7.117403129086597e-07
absence O 0 2.3090412923920667e-06
of O 0 9.451136406823935e-07
any O 0 0.00032922171521931887
psychiatric B-Disease 1 0.9991841912269592
disorder I-Disease 1 0.814107358455658
) O 0 1.2249469136804692e-06
as O 0 4.7277632120312774e-07
the O 0 3.31862167968211e-07
phenotype O 0 5.731439159717411e-06
in O 0 5.519577328527703e-08
our O 0 8.123495831569016e-08
genome O 0 1.3717373803956434e-05
- O 0 0.001469976152293384
wide O 0 8.048530617088545e-06
linkage O 0 8.66721438796958e-06
scan O 0 9.1235806394252e-06
of O 0 3.137506965344983e-08
several O 0 1.1109644759699222e-07
large O 0 2.8014414965582546e-06
multigeneration O 0 0.0006048246286809444
Old O 0 7.851448572182562e-06
Order O 0 4.7417838544561164e-08
Amish O 0 7.861623089411296e-06
pedigrees O 0 3.887260390911251e-06
exhibiting O 0 1.9200817405362613e-05
an O 0 1.339056098004221e-06
extremely O 0 1.4917924090696033e-05
high O 0 0.0016698860563337803
incidence O 0 0.001566620427183807
of O 0 3.913027831004001e-05
BPAD B-Disease 1 0.9998214840888977
. O 0 5.801470251753926e-05

We O 0 1.0147646207769867e-05
have O 0 1.3633598427986726e-06
found O 0 8.863445941642567e-07
strong O 0 7.64020242627339e-08
evidence O 0 7.960828440900514e-08
for O 0 2.725154324423329e-08
a O 0 3.8978973293524177e-07
locus O 0 1.0365695743530523e-05
on O 0 1.5753479601698928e-05
chromosome O 0 0.012059333734214306
4p O 1 0.6080741286277771
at O 0 4.4725770749209914e-06
D4S2949 O 0 5.251101811154513e-06
( O 0 7.201478080531842e-09
maximum O 0 1.7589256628980365e-07
GENEHUNTER O 0 0.00020745537767652422
- O 0 1.7102518540923484e-05
PLUS O 0 7.881387773522874e-07
nonparametric O 0 1.5201153473753948e-06
linkage O 0 1.0898990012719878e-06
score O 0 5.704337127099279e-07
= O 0 4.824160896532703e-06
4 O 0 3.5261751918369555e-07
. O 0 4.3034091845584044e-08
05 O 0 1.2520703421614598e-05
, O 0 2.675186863143608e-07
P O 0 0.00010621979890856892
= O 0 5.256282747723162e-06
5 O 0 1.0411216067041096e-07
. O 0 6.990477086077362e-09
22 O 0 4.3854876707882795e-07
x O 0 7.86094824434258e-06
10 O 0 5.001186309527839e-07
( O 0 3.879909016291094e-08
- O 0 2.420947748760227e-05
4 O 0 8.789775165496394e-07
) O 0 1.7521976758416713e-08
; O 0 1.6656310108942307e-08
SIBPAL O 0 3.758730963454582e-05
Pempirical O 0 3.044393906748155e-06
value O 0 1.336627164505444e-08
< O 0 1.5370031292150088e-07
3 O 0 1.3191092307351937e-07
x O 0 1.2150922884757165e-05
10 O 0 1.3011218698011362e-06
( O 0 1.4837623041330517e-07
- O 0 0.0003513448464218527
5 O 0 3.074263759117457e-06
) O 0 6.319638146123907e-08
) O 0 2.1533868022061142e-08
and O 0 1.3035322865562193e-07
suggestive O 0 3.0347441679623444e-06
evidence O 0 1.2824554573853675e-07
for O 0 1.6705179461951047e-08
a O 0 2.2378493724772852e-07
locus O 0 1.0075584214064293e-05
on O 0 2.1287400159053504e-05
chromosome O 0 0.02664935775101185
4q O 1 0.6201353669166565
at O 0 9.511577445664443e-06
D4S397 O 0 6.890258191560861e-06
( O 0 9.528078770415505e-09
maximum O 0 2.0359514962819958e-07
GENEHUNTER O 0 0.00056517927441746
- O 0 1.2495842383941635e-05
PLUS O 0 4.4832353296442307e-07
nonparametric O 0 4.106537971892976e-07
linkage O 0 8.662684081173211e-07
score O 0 5.033772367823985e-07
= O 0 3.7800364225404337e-06
3 O 0 3.741959631042846e-07
. O 0 3.930184888645272e-08
29 O 0 2.7209348445467185e-06
, O 0 1.4502316503239854e-07
P O 0 2.7454512746771798e-05
= O 0 1.0875576208491111e-06
2 O 0 7.707192395400853e-08
. O 0 1.516360192965749e-08
57 O 0 3.1702361411589663e-06
x O 0 5.051400148659013e-05
10 O 0 1.2480733175834757e-06
( O 0 1.339417110557406e-07
- O 0 3.133305290248245e-05
3 O 0 9.756849976838566e-07
) O 0 2.990474357034145e-08
; O 0 2.5232560929566716e-08
SIBPAL O 0 2.3788939870428294e-05
Pempirical O 0 2.396399622739409e-06
value O 0 2.1760831359074473e-08
< O 0 1.7761935566795728e-07
1 O 0 6.144732367374672e-08
x O 0 3.7290103591658408e-06
10 O 0 6.304312023530656e-07
( O 0 1.078259330711262e-07
- O 0 7.212279160739854e-05
3 O 0 3.379967893124558e-06
) O 0 3.992319363987917e-08
) O 0 4.059118818844354e-09
that O 0 7.931710399589065e-09
are O 0 5.450716855648352e-08
linked O 0 0.00012687475827988237
to O 0 1.173225336970063e-05
mental O 0 0.20804578065872192
health O 0 0.0004297378472983837
wellness O 0 0.0006911386153660715
. O 0 1.6085969036794268e-05

These O 0 1.0559965630818624e-06
findings O 0 9.817662430577911e-06
are O 0 1.2206574240281043e-07
consistent O 0 2.478533644989511e-07
with O 0 1.2524331793883903e-07
the O 0 2.274812231917167e-07
hypothesis O 0 1.3660005606652703e-06
that O 0 2.7988079409624333e-08
certain O 0 9.834113967599478e-09
alleles O 0 2.7516989575815387e-07
could O 0 8.764930043980712e-07
prevent O 0 1.027973553391348e-06
or O 0 9.99283145119989e-08
modify O 0 1.1358408755768323e-06
the O 0 2.9824116154486546e-07
clinical O 0 5.231553132034605e-06
manifestations O 0 3.043061497010058e-06
of O 0 3.2685004498489434e-06
BPAD B-Disease 1 0.9999459981918335
and O 0 9.11991810426116e-06
perhaps O 0 7.026598609627399e-07
other O 0 7.527678462793119e-07
related O 0 0.0020031712483614683
affective B-Disease 1 0.9916340112686157
disorders I-Disease 1 0.9807478189468384
. O 0 6.878885324113071e-05

Segregation O 0 0.0029591387137770653
distortion O 0 0.11483314633369446
in O 0 0.004301039502024651
myotonic B-Disease 1 0.9997237324714661
dystrophy I-Disease 1 0.9998699426651001
. O 0 0.001072456012479961

Myotonic B-Disease 1 0.9998462200164795
dystrophy I-Disease 1 0.9999635219573975
( O 0 0.15487216413021088
DM B-Disease 1 0.9999865293502808
) O 0 0.00023264290939550847
is O 0 1.8832013665814884e-05
an O 0 0.0004800754541065544
autosomal B-Disease 1 0.9969738721847534
dominant I-Disease 1 0.9976068735122681
disease I-Disease 1 0.9340230822563171
which O 0 7.021707915555453e-06
, O 0 1.8028516706181108e-06
in O 0 7.0302860422089e-08
the O 0 3.577430049972463e-07
typical O 0 9.636481081543025e-06
pedigree O 0 0.00019720022100955248
, O 0 1.0719946175186124e-07
shows O 0 3.370743684172339e-08
a O 0 3.4383404567961406e-08
three O 0 7.869373774838095e-08
generation O 0 2.076559394481592e-05
anticipation O 0 2.00942849915009e-05
cascade O 0 0.0002713972353376448
. O 0 4.523055395111442e-06

This O 0 2.75697311735712e-06
results O 0 1.5842020729905926e-05
in O 0 0.00014797090261708945
infertility B-Disease 1 0.9998748302459717
and O 1 0.9997630715370178
congenital B-Disease 1 0.9999997615814209
myotonic I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999996423721313
( O 0 0.010474891401827335
CDM B-Disease 0 0.4693666994571686
) O 0 5.3478197514778e-07
with O 0 2.3580652452892537e-07
the O 0 1.7237127281077846e-07
disappearance O 0 2.9396636819001287e-05
of O 0 6.677084456896409e-06
DM B-Disease 1 0.9999821186065674
in O 0 3.637348299889709e-06
that O 0 1.5702696600783383e-06
pedigree O 0 0.0002445713907945901
. O 0 6.1787782215105835e-06

The O 0 4.4968606971451663e-07
concept O 0 1.5360625127414096e-07
of O 0 1.3215974092872784e-07
segregation O 0 9.373596185469069e-06
distortion O 0 0.0011500305263325572
, O 0 1.1808264162027626e-06
where O 0 1.3975500223750714e-07
there O 0 1.3995314240844436e-08
is O 0 1.589386577904861e-08
preferential O 0 1.8533218337779545e-07
transmission O 0 4.964197728440922e-07
of O 0 9.291396985133815e-09
the O 0 2.2612153927070722e-08
larger O 0 1.6303248173699103e-07
allele O 0 1.8520532307775284e-07
at O 0 4.882516009274696e-07
the O 0 1.9363328647159506e-06
DM B-Disease 1 0.9999407529830933
locus O 0 0.00022582571546081454
, O 0 3.583061243261909e-06
has O 0 1.6775541098468238e-06
been O 0 9.994372476285207e-07
put O 0 6.817840585426893e-07
forward O 0 1.239043513123761e-06
to O 0 1.0125214089384826e-07
explain O 0 1.4309800917544635e-06
partially O 0 8.941094165493269e-06
the O 0 9.915879672917072e-08
maintenance O 0 9.274202966480516e-06
of O 0 1.5694567991886288e-06
DM B-Disease 1 0.9999488592147827
in O 0 4.94305254505889e-07
the O 0 5.128792963660089e-07
population O 0 8.786137755123491e-07
. O 0 2.5365416149725206e-06

In O 0 2.1011335320508806e-06
a O 0 1.9737929051188985e-06
survey O 0 7.590129371237708e-06
of O 0 9.777639888852718e-07
DM B-Disease 1 0.9999372959136963
in O 0 5.641391567223764e-07
Northern O 0 2.3368959034542058e-07
Ireland O 0 1.506478611190687e-06
, O 0 1.4401855708001676e-07
59 O 0 1.6132978998939507e-05
pedigrees O 0 1.7728640159475617e-05
were O 0 2.3442066776624415e-06
ascertained O 0 2.9987681045895442e-05
. O 0 3.2687810289644403e-06

Sibships O 0 0.03194859251379967
where O 0 1.1712445484590717e-05
the O 0 4.6013107635189954e-07
status O 0 1.4853281982141198e-07
of O 0 1.138151795032627e-08
all O 0 1.0389490157081127e-08
the O 0 1.9620787838903198e-07
members O 0 8.378995630664576e-07
had O 0 3.385977106518112e-05
been O 0 8.998527846415527e-06
identified O 0 6.960264727240428e-06
were O 0 5.259386398392962e-06
examined O 0 4.4782809709431604e-05
to O 0 3.361293110515362e-08
determine O 0 5.8624394227990706e-08
the O 0 4.8717158307454156e-08
transmission O 0 1.4143613498163177e-06
of O 0 1.0471160294400761e-07
the O 0 6.27292547505931e-06
DM B-Disease 1 0.9999678134918213
expansion O 0 1.1066190381825436e-05
from O 0 6.735821216352633e-07
affected O 0 5.252667278909939e-07
parents O 0 8.103145887616847e-08
to O 0 2.0837052971955927e-08
their O 0 7.160596027233623e-08
offspring O 0 3.5549808217183454e-06
. O 0 1.4149103435556754e-06

Where O 0 6.505215424112976e-06
the O 0 1.4013792224432109e-06
transmitting O 0 0.0002608991344459355
parent O 0 0.00014594871026929468
was O 0 7.606699364259839e-05
male O 0 6.798207778047072e-06
, O 0 4.080530686678685e-07
58 O 0 5.5966625950532034e-05
. O 0 3.566472059901571e-06

3 O 0 1.704430724203121e-05
% O 0 4.109727171908162e-07
of O 0 2.8256865292064504e-08
the O 0 2.2618608852553734e-07
offspring O 0 8.171557055902667e-06
were O 0 1.4883647963870317e-05
affected O 0 1.426173639629269e-06
, O 0 2.2497039253721596e-07
and O 0 3.3349672889926296e-07
in O 0 3.690004035661332e-08
the O 0 9.4707729658694e-08
case O 0 3.262004838688881e-06
of O 0 1.2733310938983777e-07
a O 0 6.365235549310455e-06
female O 0 4.5633034460479394e-05
transmitting O 0 0.0003603683435358107
parent O 0 6.3832098931015935e-06
, O 0 4.240826569912315e-07
68 O 0 1.9637782315840013e-05
. O 0 1.9882418200722896e-06

7 O 0 4.909096969640814e-05
% O 0 7.48467982703005e-06
were O 0 6.891513294249307e-06
affected O 0 6.8354652285052e-06
. O 0 2.6960631203110097e-06

Studies O 0 9.188614967570174e-06
on O 0 1.1929658967346768e-06
meiotic O 0 0.00025191783788613975
drive O 0 8.047944720601663e-05
in O 0 1.359050929750083e-05
DM B-Disease 1 0.9999877214431763
have O 0 2.918287464126479e-06
shown O 0 1.0455593013602993e-07
increased O 0 5.329104624252068e-08
transmission O 0 1.5214075688163575e-07
of O 0 9.152844704374274e-09
the O 0 5.442084116680235e-08
larger O 0 3.566430848422897e-07
allele O 0 6.786009976167406e-07
at O 0 5.301867531670723e-07
the O 0 1.472110398026416e-06
DM B-Disease 1 0.999842643737793
locus O 0 2.749328632489778e-05
in O 0 4.315418209444033e-07
non O 0 3.5646153264679015e-05
- O 0 0.186494380235672
DM O 1 0.9997177720069885
heterozygotes O 0 9.362128184875473e-05
for O 0 1.3395260793913621e-06
CTGn O 0 0.0005351055297069252
. O 0 2.0368286186567275e-06

This O 0 4.442025840489805e-07
study O 0 2.1187025822655414e-07
provides O 0 2.8417334263508565e-08
further O 0 3.5461251712831654e-08
evidence O 0 3.0052842703298666e-07
that O 0 3.265529002760559e-08
the O 0 8.178482175935642e-07
DM B-Disease 1 0.9999727010726929
expansion O 0 1.78330246853875e-05
tends O 0 1.0399719485576497e-06
to O 0 3.289490280167229e-08
be O 0 7.449975925055696e-08
transmitted O 0 2.2760020783607615e-06
preferentially O 0 7.651855412404984e-06
. O 0 1.2668185718212044e-06

Diagnosis O 0 0.16545766592025757
of O 0 0.0007817529840394855
hemochromatosis B-Disease 1 0.9996395111083984
. O 0 0.000611643074080348

If O 0 0.0007100803195498884
untreated O 1 0.9888138175010681
, O 0 0.004246944095939398
hemochromatosis B-Disease 1 0.9999939203262329
can O 0 0.004658146761357784
cause O 0 0.16048574447631836
serious O 1 0.8762985467910767
illness O 0 0.3515560030937195
and O 0 1.4502978956443258e-05
early B-Disease 0 5.215151031734422e-05
death I-Disease 0 0.001483138301409781
, O 0 4.004425591119798e-06
but O 0 5.145999466549256e-07
the O 0 1.2309967132750899e-05
disease O 0 0.0010219402611255646
is O 0 4.015903982690361e-07
still O 0 2.7042904093832476e-06
substantially O 0 1.47566743180505e-05
under O 0 1.687854455667548e-05
- O 1 0.9900941252708435
diagnosed O 1 0.965888261795044
. O 0 1.2737644283333793e-05

The O 0 4.567368250718573e-06
cornerstone O 0 0.00020261085592210293
of O 0 1.4164655226522882e-07
screening O 0 1.5746245480841026e-06
and O 0 2.646616223955789e-07
case O 0 1.8257147758049541e-06
detection O 0 4.586254362948239e-06
is O 0 6.292814447306228e-08
the O 0 1.9807341544719748e-08
measurement O 0 5.805168257211335e-07
of O 0 7.510254107501169e-08
serum O 0 1.1312475180602632e-05
transferrin O 0 5.233524007053347e-06
saturation O 0 8.069753221207066e-08
and O 0 3.2684265960369885e-08
the O 0 3.222686473236536e-08
serum O 0 9.894170943880454e-06
ferritin O 0 2.762517033261247e-05
level O 0 8.127910291477747e-07
. O 0 1.346760654996615e-06

Once O 0 0.00016333912208210677
the O 0 5.704038812837098e-06
diagnosis O 0 0.0007223353604786098
is O 0 2.8716467568301596e-06
suspected O 0 0.009008888155221939
, O 0 9.314560884376988e-06
physicians O 0 6.5392209762649145e-06
must O 0 2.2647418163046495e-08
use O 0 3.262154990579802e-08
serum O 0 1.8457388932802132e-06
ferritin O 0 8.212941793317441e-06
levels O 0 5.131067837282899e-07
and O 0 1.4828628991381265e-06
hepatic O 0 0.13059744238853455
iron O 0 0.326018363237381
stores O 0 7.110719252523268e-06
on O 0 1.6514564777025953e-05
liver O 0 0.004568435717374086
biopsy O 0 0.0002839981170836836
specimens O 0 1.5595314835081808e-05
to O 0 4.3708280372811714e-07
assess O 0 9.553709242027253e-05
patients O 0 3.31379055751313e-06
for O 0 2.5813351456349665e-08
the O 0 3.006241797720577e-07
presence O 0 8.406897791246593e-07
of O 0 1.3154112821212038e-06
iron B-Disease 1 0.759369969367981
overload I-Disease 0 0.006056706886738539
. O 0 9.667316589911934e-06

Liver O 1 0.9954297542572021
biopsy O 1 0.7678208351135254
is O 0 2.5735691451700404e-05
also O 0 3.828667104244232e-06
used O 0 2.2729146564870462e-07
to O 0 2.6477563253024528e-08
establish O 0 1.1284208767392556e-07
the O 0 1.9197700851236732e-07
presence O 0 7.549929819106183e-07
or O 0 4.042598504838679e-07
absence O 0 1.2937276778757223e-06
of O 0 1.241899326487328e-06
cirrhosis B-Disease 1 0.7508084177970886
, O 0 2.15591808228055e-06
which O 0 2.0632006680898485e-07
can O 0 2.533064957788156e-07
affect O 0 3.7312659060262376e-06
prognosis O 0 0.00018819409888237715
and O 0 4.3438981265353505e-06
management O 0 3.040189403691329e-05
. O 0 5.729231361328857e-06

A O 0 2.8462513000704348e-05
DNA O 0 0.00020567099272739142
- O 0 0.000317568687023595
based O 0 2.4415749066974968e-06
test O 0 5.375696332521329e-07
for O 0 2.9637520881919954e-08
the O 0 1.7041442390564043e-07
HFE O 0 0.0005215505370870233
gene O 0 1.4358107591760927e-07
is O 0 1.9794235583958653e-08
commercially O 0 3.7563009414043336e-07
available O 0 2.7697275584159797e-08
, O 0 9.929279798370771e-08
but O 0 1.802137816753202e-08
its O 0 7.053707395954234e-09
place O 0 1.8337814822189102e-08
in O 0 3.156619143851458e-08
the O 0 2.680869499727123e-07
diagnosis O 0 3.6112574889557436e-05
of O 0 2.6931005777441896e-05
hemochromatosis B-Disease 1 0.9999957084655762
is O 0 3.6368499422678724e-05
still O 0 7.570190973638091e-06
being O 0 9.656397196522448e-06
evaluated O 0 3.509590897010639e-05
. O 0 4.4384914872352965e-06

Currently O 0 0.00029206593171693385
, O 0 9.703243222247693e-07
the O 0 9.125794520059571e-08
most O 0 3.6699088212799325e-08
useful O 0 7.41627559364133e-08
role O 0 3.058164566027699e-07
for O 0 3.247491520141921e-08
this O 0 3.000999271307592e-08
test O 0 1.1843440006487072e-06
is O 0 1.7277260511150416e-08
in O 0 1.3172908985836784e-08
the O 0 2.8243823280149627e-08
detection O 0 4.399425506562693e-06
of O 0 1.7447930076741613e-05
hemochromatosis B-Disease 1 0.9999933242797852
in O 0 3.066182671318529e-06
the O 0 2.237801027149544e-06
family O 0 1.4057983207749203e-05
members O 0 1.0422874083815259e-06
of O 0 1.7511356418253854e-06
patients O 0 2.013097946473863e-05
with O 0 2.800295817451115e-07
a O 0 3.369453679624712e-06
proven O 0 0.0003022633900400251
case O 0 1.9711253571585985e-06
of O 0 4.60266676327592e-07
the O 0 0.00019099573546554893
disease O 0 0.018738333135843277
. O 0 2.588821189419832e-05

It O 0 1.1091632359239156e-06
is O 0 4.2928544985443295e-07
crucial O 0 4.500199793255888e-06
to O 0 5.588727617578115e-06
diagnose O 1 0.7756215929985046
hemochromatosis B-Disease 1 0.9999735355377197
before O 0 0.016749633476138115
hepatic B-Disease 1 0.9984601736068726
cirrhosis I-Disease 1 0.9978499412536621
develops O 0 0.0003350261249579489
because O 0 1.0065356036648154e-05
phlebotomy O 0 0.11183831095695496
therapy O 0 0.00011089305189670995
can O 0 3.532203436407144e-06
avert O 1 0.8297951221466064
serious O 1 0.9994474053382874
chronic O 1 0.9999951124191284
disease O 1 0.8589171767234802
and O 0 6.137092714197934e-05
can O 0 1.119908006330661e-06
even O 0 6.619715122724301e-07
lead O 0 3.537927796060103e-06
to O 0 3.280793237081525e-08
normal O 0 7.599681595138463e-08
life O 0 4.840650262849522e-07
expectancy O 0 1.2874105777882505e-05
. O 0 1.7905679783325468e-07
. O 0 1.3964616982775624e-06

Prevalence O 0 0.0008072385680861771
of O 0 7.173698008955398e-07
the O 0 4.583900761190307e-07
I1307K O 0 6.3104453147389e-05
APC B-Disease 0 5.912239066674374e-05
gene O 0 2.817520226017223e-07
variant O 0 9.332389936389518e-07
in O 0 3.529101633148457e-08
Israeli O 0 1.4590979162676376e-06
Jews O 0 1.9847037435738457e-07
of O 0 9.528423383642348e-09
differing O 0 3.04149807561771e-08
ethnic O 0 1.248252488039725e-07
origin O 0 7.930425454105716e-07
and O 0 1.0773866051749792e-05
risk O 0 0.001259017619304359
for O 0 0.17207291722297668
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999963641166687
. O 0 0.000117089381092228

BACKGROUND O 0 0.00014742712664883584
& O 0 0.00018206080130767077
AIMS O 0 3.759429819183424e-05
Israeli O 0 1.1582617844396736e-05
Jews O 0 1.0773009080367046e-06
of O 0 3.2467582400386163e-07
European O 0 3.069580998271704e-05
birth O 0 9.680751827545464e-05
, O 0 1.7287366063101217e-06
i O 0 9.942524457073887e-07
. O 0 2.6176529388521885e-08
e O 0 5.460153715830529e-07
. O 0 8.21211898482943e-09
, O 0 5.780077927397542e-08
Ashkenazim O 0 4.4997445911576506e-06
, O 0 2.1376446568410756e-07
have O 0 9.520761068415595e-08
the O 0 5.175745172891766e-06
highest O 1 0.9993975162506104
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
incidence O 0 0.004497794434428215
of O 0 2.854413310160453e-07
any O 0 8.853041322254285e-08
Israeli O 0 5.4170350267668255e-06
ethnic O 0 2.7509324809216196e-06
group O 0 6.474786641774699e-05
. O 0 6.452512025134638e-06

The O 0 5.024342499382328e-06
I1307K O 0 0.00022506112873088568
APC B-Disease 0 0.0005438404623419046
gene O 0 4.972351234755479e-06
variant O 0 4.146552237216383e-05
was O 0 7.305790495593101e-05
found O 0 3.6788101169804577e-06
in O 0 3.251440148233087e-07
6 O 0 5.0283357268199325e-05
. O 0 6.683977971988497e-06

1 O 0 1.7580046915099956e-05
% O 0 9.914543852573843e-07
of O 0 1.3630487671889568e-07
American O 0 2.4468238279951038e-06
Jews O 0 1.3211201803642325e-06
, O 0 1.728740386397476e-07
28 O 0 7.907323720246495e-07
% O 0 1.505202895657476e-08
of O 0 9.071735007637471e-08
their O 0 8.574721141485497e-05
familial O 1 0.9999375343322754
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
cases O 0 0.007176966872066259
, O 0 1.4407036360353231e-05
but O 0 6.392789941855881e-07
not O 0 6.229545590485941e-08
in O 0 1.6855565831974673e-07
non O 0 1.2571073966682889e-05
- O 0 0.0005504069849848747
Jews O 0 3.2041582016972825e-05
. O 0 5.762416094512446e-06

We O 0 7.125722277123714e-06
assessed O 0 5.4496278607985005e-05
the O 0 5.167643735148886e-07
I1307K O 0 5.943833093624562e-05
prevalence O 0 4.821056791115552e-05
in O 0 6.891310277978846e-08
Israeli O 0 1.2079241287210607e-06
Jews O 0 2.3841009522129752e-07
of O 0 1.53864210261645e-08
differing O 0 3.131426495883716e-08
ethnic O 0 8.509324800343165e-08
origin O 0 3.807900270658138e-07
and O 0 2.484557444404345e-05
risk O 0 0.0015797460218891501
for O 0 0.057653456926345825
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999570846557617
. O 0 0.00011056139919674024

METHODS O 0 6.1281994021555874e-06
DNA O 0 2.2118387278169394e-05
samples O 0 9.783068435353925e-07
from O 0 1.0291295637898656e-07
500 O 0 1.1040123126804247e-06
unrelated O 0 9.927734936354682e-06
Jews O 0 7.183446655290027e-07
of O 0 1.9727643518763216e-07
European O 0 7.2895772973424755e-06
or O 0 7.348231179094e-07
non O 0 1.0592650141916238e-05
- O 0 0.0007283934974111617
European O 0 3.6774665659322636e-06
origin O 0 1.8463957474068593e-07
, O 0 1.1391925625048316e-07
with O 0 1.1448363324007005e-07
or O 0 3.3447807368247595e-07
without O 0 1.560734119721019e-07
a O 0 9.337660458186292e-07
personal O 0 1.6908315956243314e-05
and O 0 1.2951428288943134e-05
/ O 0 3.993617428932339e-05
or O 0 1.4790452951274347e-06
family O 0 2.5372746677021496e-06
history O 0 2.7723390871869924e-07
of O 0 4.830522470911092e-07
neoplasia B-Disease 1 0.5823178291320801
, O 0 7.3864216574293096e-06
were O 0 4.51237428933382e-06
examined O 0 2.283296089444775e-05
for O 0 8.440881771321074e-08
the O 0 1.8175724392222037e-07
I1307K O 0 1.1794470083259512e-05
variant O 0 7.136679300856485e-07
by O 0 3.675863169405602e-08
the O 0 5.794449720042394e-08
allele O 0 4.5433645823322877e-07
- O 0 7.851643204048742e-06
specific O 0 2.306878421620695e-08
oligonucleotide O 0 5.459526437334716e-05
( O 0 9.060820502782008e-07
ASO O 0 0.005461296997964382
) O 0 5.908171374358062e-08
method O 0 2.9174120186326036e-07
. O 0 1.3247965853224741e-06

RESULTS O 0 5.644536577165127e-05
In O 0 6.547924158439855e-07
persons O 0 4.94652795168804e-07
at O 0 1.7197913848576718e-06
average O 0 0.0005917940870858729
risk O 0 0.009367657825350761
for O 1 0.6907649636268616
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
, O 0 0.0003075896529480815
I1307K O 0 0.00034853379474952817
was O 0 5.372034138417803e-05
found O 0 1.5348981605711742e-06
in O 0 1.6240693412328255e-07
5 O 0 8.153366252372507e-06
. O 0 4.249629910191288e-06

0 O 0 1.5829107724130154e-05
% O 0 3.3689511269585637e-07
of O 0 4.472533632338127e-08
120 O 0 5.577645083576499e-07
European O 0 9.245434284821386e-07
and O 0 3.2897042956392397e-07
1 O 0 3.043076048925286e-06
. O 0 2.7438295546744484e-06

6 O 0 3.175091478624381e-05
% O 0 5.893303978155018e-07
of O 0 1.6846198036546411e-07
188 O 0 3.766754161915742e-05
non O 0 2.85430269286735e-05
- O 0 0.0005328315892256796
European O 0 2.8368460789351957e-06
Jews O 0 1.0602145721350098e-06
( O 0 8.761673342405629e-08
P O 0 7.298451237147674e-05
= O 0 6.559488610946573e-06
0 O 0 5.232762987361639e-07
. O 0 2.3831592699252724e-08
08 O 0 1.3306680557434447e-06
) O 0 1.1561505175450293e-07
. O 0 3.2504357250218163e-07

It O 0 1.4434459671974764e-06
occurred O 0 5.8784394241229165e-06
in O 0 4.301095373193675e-07
15 O 0 6.2346607592189685e-06
. O 0 8.047010851441883e-06

4 O 0 1.4903617739037145e-05
% O 0 1.9091388026026834e-07
of O 0 2.848114810660718e-08
52 O 0 1.4751046364835929e-05
Ashkenazi O 0 0.00027846015291288495
Israelis O 0 3.967126031056978e-05
with O 0 0.00019133950991090387
familial O 1 0.9943854808807373
cancer B-Disease 1 0.9777148962020874
( O 0 4.077471658092691e-06
P O 0 0.014284679666161537
= O 0 5.02281473018229e-05
0 O 0 3.1594008760293946e-06
. O 0 2.2740030658496835e-07
02 O 0 4.6979166654637083e-05
) O 0 3.876639809163862e-08
and O 0 2.797055742576049e-07
was O 0 7.054321486066328e-06
not O 0 2.8019433884196587e-08
detected O 0 6.596681032533525e-07
in O 0 3.770786349832633e-08
51 O 0 5.147470346855698e-06
non O 0 2.5652689146227203e-06
- O 0 2.4346771169803105e-05
European O 0 2.791568647353415e-07
Jews O 0 3.8432673932220496e-07
at O 0 4.346625246398617e-06
increased O 0 4.3295749492244795e-05
cancer B-Disease 0 0.011877882294356823
risk O 0 5.054397479398176e-05
. O 0 4.524789801507723e-06

Colorectal B-Disease 1 0.9991554021835327
neoplasia I-Disease 1 0.9879658818244934
occurred O 0 0.00706368125975132
personally O 0 0.004496048670262098
or O 0 2.120935732818907e-06
in O 0 1.6951887005234312e-07
the O 0 9.740629280940993e-08
families O 0 2.2507835240048735e-07
of O 0 5.635079958210554e-08
13 O 0 1.3720781453230302e-06
of O 0 5.773720346269329e-08
20 O 0 1.8117971194442362e-06
Ashkenazi O 0 6.003109956509434e-05
I1307K O 0 1.6713245713617653e-05
carriers O 0 1.691035549811204e-06
, O 0 1.7043369382463425e-08
8 O 0 4.588020630080791e-08
of O 0 5.231674649053275e-08
whom O 0 5.056750160292722e-05
also O 0 7.049169653328136e-06
had O 0 8.872209036780987e-06
a O 0 5.724074867430318e-07
personal O 0 1.732389318931382e-05
or O 0 2.4019457214308204e-06
family O 0 2.656465085237869e-06
history O 0 3.094708631579124e-07
of O 0 1.4050942809262779e-06
noncolonic O 0 0.14112192392349243
neoplasia B-Disease 1 0.5248786807060242
. O 0 2.3283579139388166e-05

CONCLUSIONS O 0 2.975097595481202e-05
The O 0 2.73360387836874e-06
I1307K O 0 0.0003388369514141232
APC O 0 0.0013377104187384248
variant O 0 0.00015003170119598508
may O 0 8.0440190686204e-07
represent O 0 4.803630204719411e-08
a O 0 6.890658710290154e-07
susceptibility O 0 5.415146370069124e-05
gene O 0 1.2253256045369199e-06
for O 0 1.9605371562647633e-05
colorectal B-Disease 1 0.9999983310699463
, I-Disease 0 2.753668923105579e-05
or I-Disease 0 7.221548230518238e-07
other I-Disease 0 7.392548582174641e-07
, I-Disease 0 5.075552689959295e-05
cancers I-Disease 0 0.04484763741493225
in O 0 4.7234911448867933e-07
Ashkenazi O 0 0.0005461369291879237
Jews O 0 8.663743756187614e-06
, O 0 9.58279201768164e-07
and O 0 1.4561898069587187e-06
partially O 0 9.686909834272228e-06
explains O 0 1.1628071661107242e-07
the O 0 3.742833598607831e-08
higher O 0 2.778032012429321e-06
incidence O 0 0.005195040721446276
of O 0 0.0975695475935936
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999904632568359
in O 0 9.617981049814261e-06
European O 0 3.8463182136183605e-05
Israelis O 0 0.00014902395196259022
. O 0 1.092960337700788e-05

Systematic O 0 6.656357982137706e-06
analysis O 0 6.6603820414457e-07
of O 0 2.694479803722061e-07
coproporphyrinogen O 0 0.002524544484913349
oxidase O 0 0.00014800023927818984
gene O 0 3.0163786504999734e-05
defects O 0 0.4914039075374603
in O 0 7.39006418370991e-06
hereditary B-Disease 1 0.642257571220398
coproporphyria I-Disease 0 0.3136173188686371
and O 0 3.104259667452425e-05
mutation O 0 1.9946532120229676e-05
update O 0 5.686505392077379e-05
. O 0 9.422306902706623e-06

Hereditary B-Disease 1 0.9893521666526794
coproporphyria I-Disease 1 0.8741328716278076
( O 0 0.00012033538951072842
HC B-Disease 1 0.9993733763694763
) O 0 4.107432687305845e-05
is O 0 9.819956176215783e-06
an O 0 0.005927741527557373
acute O 1 0.9996886253356934
hepatic B-Disease 1 0.9999650716781616
porphyria I-Disease 1 0.9999172687530518
with O 0 0.2033163160085678
autosomal O 1 0.964097797870636
dominant O 0 0.44726794958114624
inheritance O 0 0.438638836145401
caused O 0 0.009634079411625862
by O 0 1.6565716578043066e-05
deficient B-Disease 0 0.01163502223789692
activity I-Disease 0 1.5056011193337326e-07
of I-Disease 0 3.0481251656055974e-07
coproporphyrinogen I-Disease 0 0.07939232885837555
III I-Disease 0 0.40388062596321106
oxidase I-Disease 0 4.5711476559517905e-05
( O 0 3.4624011391315435e-07
CPO O 0 0.00014572119107469916
) O 0 3.3678588806651533e-07
. O 0 6.404579835361801e-07

Clinical O 0 0.002023708773776889
manifestations O 0 0.00019768765196204185
of O 0 7.291746442206204e-06
the O 0 0.00024622041382826865
disease O 0 0.3514842092990875
are O 0 1.6803272728793672e-06
characterized O 0 0.00010012643178924918
by O 0 9.180977212963626e-05
acute O 0 0.06033923476934433
attacks O 0 0.00020390545250847936
of O 0 0.007501145824790001
neurological B-Disease 1 0.9999712705612183
dysfunction I-Disease 1 0.9578540325164795
often O 0 2.129844688170124e-05
precipitated O 0 0.0009592020069248974
by O 0 1.2505404811236076e-05
drugs O 0 4.310911026550457e-05
, O 0 3.525287581851444e-07
fasting O 0 6.898371225361188e-07
, O 0 6.769934088879381e-07
cyclical O 0 0.00033675655140541494
hormonal O 0 6.455205584643409e-05
changes O 0 5.902933253310039e-07
, O 0 4.908665232505882e-06
or O 0 0.0003772338095586747
infectious B-Disease 1 0.8315721750259399
diseases I-Disease 0 0.061346154659986496
. O 0 2.797250090225134e-05

Skin O 1 0.9983420372009277
photosensitivity O 1 0.9965914487838745
may O 0 0.0027885150630027056
also O 0 6.705852683808189e-06
be O 0 4.396630970404658e-07
present O 0 1.3015215927225654e-06
. O 0 5.5510568017780315e-06

The O 0 1.2431388540790067e-06
seven O 0 1.612835831110715e-06
exons O 0 1.3797312021779362e-05
, O 0 1.4547974558354326e-07
the O 0 7.148668856871154e-08
exon O 0 8.070193143794313e-05
/ O 0 7.833737072360236e-06
intron O 0 3.749680035980418e-05
boundaries O 0 1.7169614352496865e-07
and O 0 1.3502854301350453e-07
part O 0 2.409724686458503e-08
of O 0 1.3792930353417887e-08
3 O 0 2.824962450631574e-07
noncoding O 0 1.4691205478811753e-06
sequence O 0 2.845007784912923e-09
of O 0 2.6891433524411923e-09
the O 0 4.792858376845288e-08
CPO O 0 8.27348412713036e-05
gene O 0 4.1133180417318727e-08
were O 0 6.745013791942256e-08
systematically O 0 1.543776875223557e-06
analyzed O 0 8.628861678516841e-07
by O 0 2.5194953678919774e-08
an O 0 8.853294275468215e-08
exon O 0 3.532605478540063e-05
- O 0 8.741933925193734e-06
by O 0 1.6101404298751731e-07
- O 0 3.862804805976339e-05
exon O 0 5.418855289462954e-05
denaturing O 0 3.657387424027547e-05
gradient O 0 2.7882908398169093e-05
gel O 0 0.00022584553516935557
electrophoresis O 0 0.00020445369591470808
( O 0 3.542070032835909e-07
DGGE O 0 0.0006444313912652433
) O 0 1.6557990534238343e-08
strategy O 0 4.1187508514894944e-08
followed O 0 2.4295880862723607e-08
by O 0 6.699736765369835e-09
direct O 0 2.935637066769914e-09
sequencing O 0 3.309276337404299e-07
in O 0 2.968062595698484e-08
seven O 0 2.083990153778359e-07
unrelated O 0 2.674098504940048e-05
heterozygous O 0 3.567536623449996e-05
HC B-Disease 1 0.9995402097702026
patients O 0 0.0014631397789344192
from O 0 7.631229550497665e-07
France O 0 9.458130080020055e-06
, O 0 4.609743484706996e-07
Holland O 0 9.388742182636634e-05
, O 0 4.181553663329396e-07
and O 0 4.366316090909095e-07
Czech O 0 9.697908535599709e-05
Republic O 0 2.66671759163728e-06
. O 0 1.693277113190561e-06

Seven O 0 1.3824497727910057e-05
novel O 0 1.122622961702291e-05
mutations O 0 9.064572623174172e-06
and O 0 2.586787104519317e-07
two O 0 1.4219877186860685e-07
new O 0 9.64999071584316e-06
polymorphisms O 0 0.0004191117768641561
were O 0 4.6205230319174007e-05
detected O 0 8.658374281367287e-05
. O 0 6.024312824592926e-06

Among O 0 1.786369648471009e-05
these O 0 1.1416417322607231e-07
mutations O 0 2.115701136062853e-06
two O 0 2.3588009412378597e-07
are O 0 2.6291323251825816e-07
missense O 0 0.00011771316349040717
( O 0 3.748542383164022e-07
G197W O 0 2.0981335183023475e-05
, O 0 1.086427687368996e-06
W427R O 0 1.7331230992567725e-05
) O 0 2.7577510053333754e-08
, O 0 1.7796210727283324e-08
two O 0 4.1880191758991714e-08
are O 0 3.511654256271868e-07
nonsense O 0 3.512101829983294e-05
( O 0 2.0316204540904437e-07
Q306X O 0 1.1207616807951126e-05
, O 0 4.724622044705029e-07
Q385X O 0 6.959036909393035e-06
) O 0 2.3383220693062867e-08
, O 0 1.7677534103199832e-08
two O 0 3.6581472073748955e-08
are O 0 7.172871363536615e-08
small O 0 3.020190320057736e-07
deletions O 0 2.0261641111574136e-05
( O 0 2.475325970863196e-07
662de14bp O 0 7.806173925928306e-06
; O 0 1.0180248466440389e-07
1168del3bp O 0 4.792617619386874e-05
removing O 0 1.922631554407417e-06
a O 0 8.89559359507075e-08
glycine O 0 3.648810206868802e-06
at O 0 1.276699549634941e-06
position O 0 8.711605232747388e-07
390 O 0 1.2728864021482877e-05
) O 0 1.6540445813006954e-07
, O 0 4.022572852591111e-08
and O 0 6.844453537269146e-08
one O 0 7.265747115070553e-08
is O 0 2.987578184843187e-08
a O 0 2.777599661385466e-08
splicing O 0 7.685890182074218e-07
mutation O 0 2.221623390141758e-06
( O 0 1.1565121837975312e-07
IVS1 O 0 0.00022489382536150515
- O 0 0.00010404462227597833
15c O 0 1.2817423339583911e-05
- O 0 0.0001406069059157744
- O 0 0.0007158570806495845
> O 0 8.868334589351434e-06
g O 0 0.00012976724246982485
) O 0 1.13803020340697e-08
which O 0 3.2195883736818587e-09
creates O 0 1.280767047973086e-08
a O 0 2.5129443415039532e-08
new O 0 1.4708430740029144e-07
acceptor O 0 1.3533527862819028e-06
splice O 0 1.9038337995880283e-05
site O 0 8.692810297361575e-06
. O 0 2.1978839868097566e-06

The O 0 7.2751458901620936e-06
pathological O 0 0.0002244099450763315
significance O 0 4.408067297845264e-07
of O 0 3.3929715925751225e-08
the O 0 1.2927591797051718e-07
point O 0 3.6955407267669216e-06
mutations O 0 2.7327048428560374e-06
G197W O 0 9.524558663542848e-06
, O 0 2.073255984669231e-07
W427R O 0 4.92051913170144e-06
, O 0 6.706081023821753e-08
and O 0 4.80333710584091e-08
the O 0 6.549910125386305e-08
in O 0 3.4276416727152537e-07
- O 0 0.0008059596293605864
frame O 0 0.0006992177804931998
deletion O 0 8.775711467023939e-05
390delGly O 0 0.00011897445801878348
were O 0 1.3161302376829553e-06
assessed O 0 3.623976681410568e-06
by O 0 2.7227800458717866e-08
their O 0 1.292152251863854e-08
respective O 0 3.962233208198995e-08
expression O 0 2.66824820016609e-08
in O 0 1.084394707362435e-08
a O 0 1.2984577324459678e-07
prokaryotic O 0 1.6893897054615081e-06
system O 0 2.0850777104897134e-07
using O 0 8.303078402605024e-08
site O 0 5.171405064174905e-07
- O 0 1.3801392015011515e-05
directed O 0 1.907720616145525e-06
mutagenesis O 0 9.393927757628262e-05
. O 0 1.9590065676311497e-06

These O 0 1.7204968116857344e-06
mutations O 0 4.467029430088587e-05
resulted O 0 1.5014263226476032e-05
in O 0 4.971963676325686e-07
the O 0 5.873945383427781e-07
absence O 0 6.575943189091049e-06
or O 0 2.464556416725827e-07
a O 0 4.044287322813034e-07
dramatic O 0 9.458635759074241e-06
decrease O 0 5.3088510867382865e-06
of O 0 1.8387920874829433e-07
CPO O 0 0.0013882932253181934
activity O 0 2.447309270792175e-06
. O 0 1.5895326441750512e-06

The O 0 2.230709924333496e-06
two O 0 9.047790854310733e-07
polymorphisms O 0 0.0001441776257706806
were O 0 2.480974671925651e-06
localized O 0 5.200017312745331e-06
in O 0 6.634086275880691e-07
noncoding O 0 0.00025357090635225177
part O 0 1.7500309468232444e-07
of O 0 3.348009869341695e-08
the O 0 2.629633684136934e-07
gene O 0 2.586732819054305e-07
1 O 0 3.467291662673233e-07
) O 0 2.048624381245645e-08
a O 0 4.0231643083643576e-07
C O 0 0.0002086404274450615
/ O 0 5.934689397690818e-06
G O 0 0.0004637146193999797
polymorphism O 0 8.243544471042696e-06
in O 0 1.7955218822862662e-07
the O 0 3.8920762790439767e-07
promotor O 0 0.00043835840187966824
region O 0 2.660044913227466e-07
, O 0 3.990089325611734e-08
142 O 0 2.050670900644036e-06
bp O 0 5.178829451324418e-05
upstream O 0 1.159056139954373e-07
from O 0 3.1254641097433478e-09
the O 0 1.9675581164335654e-09
transcriptional O 0 3.6536217606908394e-08
initiation O 0 1.518354935114985e-07
site O 0 8.273199227915029e-07
( O 0 5.040607931050545e-08
- O 0 0.00010252544598188251
142C O 0 1.6978750863927417e-05
/ O 0 4.374111540528247e-06
G O 0 0.0001235845120390877
) O 0 1.71334253451505e-08
, O 0 1.7918521777460228e-08
and O 0 6.626638082707359e-08
2 O 0 4.339478323345247e-07
) O 0 1.3002267706951898e-08
a O 0 5.031856886716923e-08
6 O 0 1.828394601943728e-06
bp O 0 9.641164797358215e-05
deletion O 0 2.774023869278608e-06
polymorphism O 0 1.745232475514058e-05
in O 0 6.811036712406349e-08
the O 0 7.332837981266493e-08
3 O 0 1.363863248116104e-06
noncoding O 0 2.1360956452554092e-05
part O 0 4.808589082472281e-08
of O 0 7.273633251259071e-09
the O 0 8.642831517136074e-08
CPO O 0 0.00016522369696758687
gene O 0 4.564740763157715e-08
, O 0 2.9606217921696043e-08
574 O 0 4.340821305959253e-06
bp O 0 2.0515730284387246e-05
downstream O 0 1.7174757260818296e-07
of O 0 4.035265899204887e-09
the O 0 2.1724504861708738e-08
last O 0 5.959940949651354e-07
base O 0 9.978147375022672e-08
of O 0 7.320872352778451e-09
the O 0 7.353538933330128e-08
normal O 0 1.2255867432031664e-07
termination O 0 7.603792710142443e-06
codon O 0 1.1631814231805038e-06
( O 0 7.314859828966291e-08
+ O 0 2.0645520635298453e-06
574 O 0 3.2964027923299e-05
delATTCTT O 0 3.4173168387496844e-05
) O 0 2.549656983319437e-07
. O 0 7.847225447221717e-07

Five O 0 4.998817530577071e-05
intragenic O 0 0.0675409585237503
dimorphisms O 0 0.1997210532426834
are O 0 1.462935301788093e-06
now O 0 1.9270189568487694e-06
well O 0 3.0377938742276456e-07
characterized O 0 5.5329810493276455e-06
and O 0 6.509160925816104e-07
the O 0 3.2607962907604815e-07
high O 0 0.0001064468378899619
degree O 0 1.2333587164903292e-06
of O 0 1.1258690335580468e-07
allelic O 0 5.232516923570074e-05
heterogeneity O 0 0.00026498158695176244
in O 0 6.078178557800129e-06
HC B-Disease 1 0.9891290068626404
is O 0 3.4096165109076537e-06
demonstrated O 0 3.4224915452796267e-06
with O 0 1.1075876216182223e-07
seven O 0 2.40101314830099e-07
new O 0 3.3941989840968745e-07
different O 0 7.207317853641371e-09
mutations O 0 3.2131981697602896e-07
making O 0 6.811686148466833e-08
a O 0 3.032484841014593e-08
total O 0 4.629034933145704e-08
of O 0 2.1246327364110584e-08
nineteen O 0 8.755709131946787e-06
CPO O 0 0.013531823642551899
gene B-Disease 0 1.3966580809210427e-05
defects I-Disease 0 0.22768191993236542
reported O 0 7.757387720630504e-06
so O 0 4.0059045858242825e-08
far O 0 1.0386423099362219e-07
. O 0 1.314906654670267e-07
. O 0 1.1508255965964054e-06

Coincidence O 0 1.7269278032472357e-05
of O 0 5.066237349637959e-07
two O 0 2.5847327833616873e-07
novel O 0 3.5971775105281267e-06
arylsulfatase O 0 0.000907819950953126
A O 0 1.7865030486063915e-06
alleles O 0 4.576667151923175e-07
and O 0 2.787126334169443e-07
mutation O 0 1.2021791917504743e-06
459 O 0 4.1225095628760755e-05
+ O 0 4.910430561722023e-06
1G O 0 7.271108188433573e-05
> O 0 8.542903628949716e-07
A O 0 2.460939469983714e-07
within O 0 2.642589969070741e-08
a O 0 7.4658955782069825e-06
family O 0 0.00025050470139831305
with O 0 0.006587125360965729
metachromatic B-Disease 1 0.9999932050704956
leukodystrophy I-Disease 1 0.9999277591705322
: O 0 1.4563562444891431e-07
molecular O 0 2.885725507439929e-07
basis O 0 1.9740284074032388e-08
of O 0 2.431387429169263e-07
phenotypic O 0 2.211786159023177e-05
heterogeneity O 0 0.00027491163928061724
. O 0 1.1385649486328475e-05

In O 0 9.089033483178355e-06
a O 0 1.0487730833119713e-05
family O 0 8.984087799035478e-06
with O 0 3.3462231385783525e-07
three O 0 3.796210194195737e-06
siblings O 0 0.000417460803873837
, O 0 5.482454525918001e-07
one O 0 1.329557761664546e-07
developed O 0 1.6639916111671482e-06
classical O 0 6.59593479213072e-06
late O 0 0.0019986045081168413
infantile O 1 0.9926290512084961
metachromatic B-Disease 1 0.9999895095825195
leukodystrophy I-Disease 1 0.9999823570251465
( O 0 7.928813283797354e-05
MLD B-Disease 1 0.9998345375061035
) O 0 2.96205644190195e-06
, O 0 2.2519459434988676e-06
fatal O 0 0.0035925405099987984
at O 0 1.1699628885253333e-05
age O 0 2.6518144295550883e-05
5 O 0 4.810488462680951e-06
years O 0 5.895119102206081e-06
, O 0 8.261892503469426e-07
with O 0 9.928283361659851e-06
deficient O 0 0.09136459976434708
arylsulfatase O 0 0.013304275460541248
A O 0 1.782904473657254e-05
( O 0 6.544091206706071e-07
ARSA O 0 0.005889523774385452
) O 0 2.863196613134278e-08
activity O 0 2.748220495618625e-08
and O 0 2.518578412491479e-07
increased O 0 7.1911704253579956e-06
galactosylsulfatide O 0 0.002273912774398923
( O 0 1.0771498182293726e-06
GS O 1 0.9480993747711182
) O 0 1.4243345276554464e-06
excretion O 0 2.0511719412752427e-05
. O 0 2.517099574106396e-06

The O 0 1.2059513210260775e-06
two O 0 7.846948619771865e-07
other O 0 8.136984774864686e-07
siblings O 0 0.0004663557047024369
, O 0 1.0033500075223856e-05
apparently O 0 2.3820539354346693e-05
healthy O 0 3.5949307175542344e-07
at O 0 1.3130762681612396e-06
12 O 0 1.6296343119392986e-06
( O 0 4.977001566430772e-08
1 O 0 2.3616368594048254e-07
/ O 0 1.3751448477705708e-06
2 O 0 9.40657173487125e-07
) O 0 1.8384954003636267e-08
and O 0 6.079553571680663e-08
15 O 0 2.2747080663521047e-07
years O 0 5.107984293317713e-07
, O 0 1.6577398298522894e-07
respectively O 0 8.905835784389637e-06
, O 0 3.587419996620156e-07
and O 0 5.37408709533338e-07
their O 0 4.240668829424976e-07
father O 0 0.0004342134634498507
, O 0 2.1509545149456244e-06
apparently O 0 3.286596620455384e-05
healthy O 0 8.561866593481682e-07
as O 0 8.185616451328315e-08
well O 0 1.2112388958485099e-07
, O 0 1.5177599266280595e-07
presented O 0 6.7688179115066305e-06
ARSA O 0 0.030955368652939796
and O 0 6.1260720940481406e-06
GS O 1 0.8054271936416626
values O 0 9.909905429594801e-08
within O 0 2.2444477387750794e-09
the O 0 3.178744378828924e-08
range O 0 1.8414752958051395e-06
of O 0 7.64088053983869e-06
MLD B-Disease 1 0.9999191761016846
patients O 0 0.0015344445127993822
. O 0 5.6358171605097596e-06

Mutation O 0 0.0001274890237255022
screening O 0 3.798299530899385e-06
and O 0 1.540680898415303e-07
sequence O 0 2.4802590203876207e-08
analysis O 0 1.716241087024173e-07
disclosed O 0 3.113806451437995e-05
the O 0 4.721306723354246e-08
involvement O 0 8.629504009149969e-07
of O 0 2.9212054997174164e-08
three O 0 2.7828210136249254e-07
different O 0 1.3915334307057492e-07
ARSA O 0 0.2650628685951233
mutations O 0 3.3725330013112398e-06
being O 0 7.367325594032081e-08
the O 0 5.2276423190278365e-09
molecular O 0 1.4834199646429624e-07
basis O 0 1.6657262236208226e-08
of O 0 1.3053571024101984e-07
intrafamilial O 0 0.0007351313252002001
phenotypic O 0 3.253615795983933e-05
heterogeneity O 0 0.0002936297096312046
. O 0 6.693521299894201e-06

The O 0 1.531932684883941e-05
late O 0 0.0006609237170778215
infantile O 1 0.962967038154602
patient O 1 0.764694333076477
inherited O 1 0.9782235026359558
from O 0 3.7050915125291795e-05
his O 0 0.0002683500060811639
mother O 0 0.000683270744048059
the O 0 2.0355341234790103e-07
frequent O 0 2.3695666584444552e-07
0 O 0 1.477810201322427e-06
- O 0 0.00015816392260603607
type O 0 2.046521331067197e-06
mutation O 0 2.5651564783402137e-07
459 O 0 1.80312963493634e-05
+ O 0 3.379593863428454e-06
1G O 0 3.970320540247485e-05
> O 0 9.042589113050781e-07
A O 0 7.707573672632861e-07
, O 0 2.742228843999328e-07
and O 0 1.8357785336320376e-07
from O 0 2.122300344353789e-07
his O 0 6.163100351841422e-06
father O 0 5.054060238762759e-05
a O 0 8.12453151866066e-07
novel O 0 1.2048086546201375e-06
, O 0 1.571304864000922e-07
single O 0 3.427109049880528e-07
basepair O 0 6.729511369485408e-05
microdeletion O 0 5.506009529199218e-06
of O 0 6.636197813492117e-09
guanine O 0 6.269243613132858e-07
at O 0 2.457955439183479e-08
nucleotide O 0 1.5165748834533588e-07
7 O 0 8.73474235163485e-08
in O 0 2.809038868178959e-08
exon O 0 1.5004872693680227e-05
1 O 0 1.621639285076526e-06
( O 0 2.95258132609888e-07
7delG O 0 3.92471811210271e-05
) O 0 1.8169934890011064e-07
. O 0 6.265125875870581e-07

The O 0 1.8701796307141194e-06
two O 0 4.1929133658413775e-06
clinically O 0 0.005146447103470564
unaffected O 0 0.00023305497597903013
siblings O 0 1.40632655529771e-05
carried O 0 3.917477044979023e-07
the O 0 1.0073357969986318e-07
maternal O 0 1.2928476280649193e-05
mutation O 0 7.168781053223938e-07
459 O 0 2.9795410227961838e-05
+ O 0 4.080038706888445e-06
1G O 0 4.218770845909603e-05
> O 0 1.141484403888171e-06
A O 0 5.133333615958691e-07
and O 0 5.09510527990642e-07
, O 0 1.0214714052381169e-07
on O 0 1.6216812070979358e-07
their O 0 8.391585026856774e-08
paternal O 0 1.1953247849305626e-05
allele O 0 1.0096052847075043e-06
, O 0 5.206410591540589e-08
a O 0 2.5863915453783193e-08
novel O 0 1.2394471582410915e-07
cytosine O 0 1.0268594223816763e-06
to O 0 6.049419187803551e-09
thymidine O 0 6.744518259438337e-07
transition O 0 5.3158661472707536e-08
at O 0 2.1890971879656718e-07
nucleotide O 0 3.516668357406161e-06
2435 O 0 4.146876744925976e-05
in O 0 3.6640823708466996e-08
exon O 0 1.2417570360412356e-05
8 O 0 5.291194611345418e-07
, O 0 3.325289910094398e-08
resulting O 0 5.442821304768586e-08
in O 0 2.9472448925815797e-09
substitution O 0 5.048187201595056e-09
of O 0 1.5434743261266703e-08
alanine O 0 1.767323919921182e-05
464 O 0 4.566185089061037e-05
by O 0 1.3603324759969837e-06
valine O 0 0.0004241709248162806
( O 0 4.2584642301335407e-07
A464V O 0 1.4364738490257878e-05
) O 0 1.4372930934314354e-07
. O 0 5.629449333355296e-07

The O 0 3.567849944374757e-06
fathers O 0 1.5161617739067879e-05
genotype O 0 4.689470733865164e-05
thus O 0 2.5707133772812085e-06
was O 0 4.9934380513150245e-05
7delG O 0 0.00030807594885118306
/ O 0 0.00010775178816402331
A464V O 0 0.00019659142708405852
. O 0 2.460845962559688e-06

Mutation O 0 0.0010134020121768117
A464V O 0 0.0012162147322669625
was O 0 9.273434261558577e-05
not O 0 9.961812708070283e-08
found O 0 2.5957524485420436e-07
in O 0 7.433950344193363e-08
18 O 0 2.0709587261080742e-05
unrelated O 0 0.19034481048583984
MLD B-Disease 1 0.9999885559082031
patients O 0 0.0018522938480600715
and O 0 8.515840477230086e-07
50 O 0 1.1075070460719871e-06
controls O 0 6.934280008863425e-06
. O 0 2.6680097562348237e-06

A464V O 0 0.0043259900994598866
, O 0 1.0411496077722404e-05
although O 0 1.229996996698901e-06
clearly O 0 1.238372533407528e-06
modifying O 0 1.7917271179612726e-05
ARSA O 0 0.15781863033771515
and O 0 2.2925538360141218e-05
GS O 1 0.9998517036437988
levels O 0 7.256437675096095e-05
, O 0 3.639242777353502e-06
apparently O 0 6.839481648057699e-05
bears O 0 2.2871052351547405e-05
little O 0 1.1330405413900735e-07
significance O 0 4.5519687574824275e-08
for O 0 1.5258918040217395e-07
clinical O 0 5.980185960652307e-06
manifestation O 0 5.647351827064995e-06
of O 0 2.9313582672330085e-06
MLD B-Disease 1 0.9998414516448975
, O 0 3.960884441767121e-06
mimicking O 0 1.1158546840306371e-05
the O 0 2.6179705514550733e-07
frequent O 0 6.339319043036085e-06
ARSA O 0 0.024809323251247406
pseudodeficiency O 0 0.000971923815086484
allele O 0 1.0506852959224489e-05
. O 0 1.6901051367312903e-06

Our O 0 2.626370587677229e-06
results O 0 2.1959524474368664e-06
demonstrate O 0 9.099563271774969e-07
that O 0 1.738651533855773e-08
in O 0 1.1803750865624352e-08
certain O 0 2.1685712781049915e-08
genetic O 0 9.228858834831044e-05
conditions O 0 0.00010282876610290259
MLD B-Disease 1 0.9999392032623291
- O 0 0.3371826708316803
like O 0 2.6203981178696267e-05
ARSA O 0 0.07734931260347366
and O 0 2.5519539121887647e-06
GS O 1 0.9667060375213623
values O 0 1.562033958180109e-06
need O 0 9.072600448689627e-08
not O 0 7.182013206374904e-09
be O 0 6.820537024054829e-09
paralleled O 0 2.90410889647319e-06
by O 0 2.534100531192962e-05
clinical O 0 0.07820845395326614
disease O 0 0.03404458984732628
, O 0 7.163860118453158e-07
a O 0 1.1941975799345528e-06
finding O 0 4.354931661509909e-06
with O 0 9.438514098292217e-06
serious O 0 0.0022588646970689297
diagnostic O 0 0.0016041748458519578
and O 0 0.00014605477917939425
prognostic O 1 0.5656378269195557
implications O 0 0.0002120007120538503
. O 0 1.3039470104558859e-05

Moreover O 0 6.783969729440287e-05
, O 0 1.8950148614749196e-06
further O 0 3.9630808146284835e-07
ARSA O 0 0.01297856867313385
alleles O 0 3.5095590646960773e-06
functionally O 0 2.0142271750955842e-05
similar O 0 4.552377106392669e-07
to O 0 2.99970650985415e-07
A464V O 0 0.00011963279393967241
might O 0 9.142673889073194e-07
exist O 0 1.210219124914147e-08
which O 0 3.2691936269202415e-08
, O 0 5.497072663729341e-08
together O 0 5.490659660267738e-08
with O 0 4.1351282220603025e-07
0 O 0 2.3342650820268318e-05
- O 0 0.016827816143631935
type O 0 0.00013038059114478528
mutations O 0 3.137422390864231e-05
, O 0 8.558759873267263e-06
may O 0 7.007154636085033e-05
cause O 0 2.1159363313927315e-05
pathological O 0 0.001570102758705616
ARSA O 1 0.7973642349243164
and O 0 8.101049024844542e-05
GS O 1 0.9998353719711304
levels O 0 1.512656581326155e-05
, O 0 2.6449583856447134e-07
but O 0 4.9709200311554014e-08
not O 0 5.286583970587344e-08
clinical O 0 1.5561192867608042e-06
outbreak O 0 2.4887190193112474e-06
of O 0 4.910299935545481e-07
the O 0 0.0002314378070877865
disease O 0 0.022414326667785645
. O 0 1.9331409930600785e-06
. O 0 1.2564505595946684e-05

Human O 0 0.08337271213531494
MLH1 O 1 0.9980019927024841
deficiency O 1 0.9989056587219238
predisposes O 0 0.022290624678134918
to O 0 7.934273889986798e-05
hematological B-Disease 1 0.9981095790863037
malignancy I-Disease 1 0.9993613362312317
and O 0 0.00411174725741148
neurofibromatosis B-Disease 1 0.99847012758255
type I-Disease 0 0.00025947371614165604
1 I-Disease 0 2.0712945115519688e-05
. O 0 5.659623184328666e-06

Heterozygous O 0 0.0005971916252747178
germ O 0 0.10735243558883667
- O 0 0.020964769646525383
line O 0 8.437994256382808e-05
mutations O 0 4.732044544653036e-06
in O 0 2.609343141557474e-08
the O 0 2.0058307370618422e-07
DNA O 0 0.001081968774087727
mismatch O 1 0.8516471982002258
repair O 0 0.411782830953598
genes O 0 8.2635533544817e-06
lead O 0 3.378700421308167e-05
to O 0 1.5436369722010568e-05
hereditary B-Disease 1 0.9981569647789001
nonpolyposis I-Disease 1 0.9999327659606934
colorectal I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999592304229736
. O 0 0.00019397995492909104

The O 0 0.0004034102603327483
disease O 0 0.46370354294776917
susceptibility O 0 0.000415890448493883
of O 0 4.268586508260341e-06
individuals O 0 9.299523662775755e-05
who O 0 0.022287994623184204
constitutionally O 0 0.008469619788229465
lack O 0 2.0710044736915734e-06
both O 0 2.0189096971989784e-07
wild O 0 1.0698906407924369e-05
- O 0 0.0037196266930550337
type O 0 4.462825017981231e-06
alleles O 0 7.565389523733757e-07
is O 0 5.744105919802678e-07
unknown O 0 7.264399300765945e-06
. O 0 4.472286946111126e-06

We O 0 4.657228600990493e-06
have O 0 2.1170666286707274e-07
identified O 0 2.0677113354850007e-07
three O 0 2.1613656642216483e-08
offspring O 0 1.1342356174282031e-06
in O 0 1.033713274978254e-07
a O 0 4.125352643313818e-05
hereditary B-Disease 1 0.9998483657836914
nonpolyposis I-Disease 1 0.9999970197677612
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
family O 0 0.0989924818277359
who O 0 0.05972389131784439
developed O 0 0.0017610328504815698
hematological B-Disease 1 0.9859368205070496
malignancy I-Disease 1 0.942473292350769
at O 0 4.2914773075608537e-05
a O 0 8.765876373217907e-06
very O 0 4.736432401841739e-07
early O 0 4.059441380377393e-06
age O 0 1.0733909221016802e-05
, O 0 3.0135066708680824e-07
and O 0 1.0720334842062584e-07
at O 0 6.918993449289701e-07
least O 0 4.4853627478858016e-09
two O 0 6.785127570907434e-09
of O 0 1.621519807315508e-08
them O 0 6.385722173263275e-08
displayed O 0 3.338593160151504e-05
signs O 0 5.913136192248203e-06
of O 0 1.6679778127581812e-06
neurofibromatosis B-Disease 1 0.9305294156074524
type I-Disease 0 3.955268402933143e-05
1 I-Disease 0 3.252678652643226e-05
( O 0 4.342995453043841e-06
NF1 B-Disease 0 0.003253210335969925
) O 0 1.4821883951299242e-06
. O 0 1.9957931272074347e-06

DNA O 0 2.6351206543040462e-05
sequence O 0 2.764977864444518e-07
analysis O 0 2.0842168169110664e-07
and O 0 3.1743550721330394e-07
allele O 0 8.380417853004474e-07
- O 0 9.42550650506746e-06
specific O 0 8.897405479046938e-09
amplification O 0 9.6704798124847e-06
in O 0 7.116874911616833e-08
two O 0 5.834218086420151e-07
siblings O 0 0.000531742291059345
revealed O 0 3.777855818043463e-05
a O 0 3.2935447507043136e-06
homozygous O 0 0.00016142155800480396
MLH1 O 0 0.005750488489866257
mutation O 0 4.827538759855088e-06
( O 0 2.3939867332956055e-07
C676T O 0 3.119515531579964e-05
- O 0 0.0004964384716004133
- O 0 0.0013419348979368806
> O 0 1.9441917174845003e-05
Arg226Stop O 0 0.0003602593205869198
) O 0 5.274367254060053e-07
. O 0 8.671197520015994e-07

Thus O 0 1.1941419870709069e-05
, O 0 8.825515465105127e-07
a O 0 1.1266138244536705e-06
homozygous O 0 8.880103996489197e-05
germ O 0 0.007599886506795883
- O 0 0.009337271563708782
line O 0 0.0003678729699458927
MLH1 O 0 0.07417092472314835
mutation O 0 1.5418583643622696e-05
and O 0 7.740028195257764e-06
consequent O 0 0.3621114194393158
mismatch O 1 0.9999343156814575
repair O 1 0.999971866607666
deficiency O 1 0.9908941984176636
results O 0 2.8920560453116195e-06
in O 0 3.276085465131473e-07
a O 0 3.960990397899877e-06
mutator O 0 0.04217590019106865
phenotype O 0 0.0005840484518557787
characterized O 0 0.00014545118028763682
by O 0 0.0006345555884763598
leukemia B-Disease 1 0.9996945858001709
and O 0 0.0011181074660271406
/ O 0 0.21601302921772003
or O 1 0.9293076395988464
lymphoma B-Disease 1 0.9999998807907104
associated O 0 0.005581502337008715
with O 0 0.00027954441611655056
neurofibromatosis B-Disease 1 0.9992454051971436
type I-Disease 0 9.202819637721404e-05
1 I-Disease 0 1.1181961781403515e-05
. O 0 1.624961441848427e-06
. O 0 9.937491995515302e-06

Missense O 0 0.010754229500889778
mutations O 0 0.0014584296150133014
in O 0 2.0026932361361105e-06
the O 0 2.454084437886195e-07
most O 0 8.313664068282378e-08
ancient O 0 8.445681487501133e-08
residues O 0 3.646889297215239e-07
of O 0 3.533438786007537e-08
the O 0 4.883987685389002e-07
PAX6 O 0 0.000789809855632484
paired O 0 1.0604345334286336e-05
domain O 0 2.3460222564608557e-07
underlie O 0 5.707401214749552e-06
a O 0 7.043115601845784e-07
spectrum O 0 4.426549276104197e-05
of O 0 8.743709622649476e-05
human O 1 0.9073173403739929
congenital B-Disease 1 0.9999934434890747
eye I-Disease 1 0.9996660947799683
malformations I-Disease 1 0.9997531771659851
. O 0 0.00036083246232010424

Mutations O 0 0.0002325060631847009
of O 0 4.324605242800317e-07
the O 0 1.920875774885644e-06
human O 0 2.303430301253684e-05
PAX6 O 0 0.22237518429756165
gene O 0 0.0001133028490585275
underlie O 1 0.714628279209137
aniridia B-Disease 1 0.9999966621398926
( O 0 0.22240111231803894
congenital B-Disease 1 0.999993085861206
absence I-Disease 0 0.00018334558990318328
of I-Disease 0 1.41573093515035e-06
the I-Disease 0 3.3258758776355535e-05
iris I-Disease 1 0.8237612843513489
) O 0 2.081123511743499e-06
, O 0 1.96919222616998e-06
a O 0 4.592395998770371e-05
rare O 0 0.003734997706487775
dominant O 0 0.14561191201210022
malformation B-Disease 1 0.9997106194496155
of I-Disease 0 7.865297448006459e-06
the I-Disease 0 0.00017271954857278615
eye I-Disease 0 0.262533038854599
. O 0 4.0389604691881686e-05

The O 0 1.95052439266874e-06
spectrum O 0 1.0394035598437767e-05
of O 0 6.259356837290397e-07
PAX6 O 0 0.015552646480500698
mutations O 0 9.215324826072901e-05
in O 0 1.856101880548522e-05
aniridia B-Disease 1 0.9999908208847046
patients O 0 0.010836112312972546
is O 0 6.344057510432322e-07
highly O 0 1.325183347944403e-06
biased O 0 9.06955301616108e-06
, O 0 1.725199467728089e-07
with O 0 1.397316822249195e-07
92 O 0 2.220048918388784e-05
% O 0 4.9421334580301846e-08
of O 0 8.013337549073185e-09
all O 0 4.4913576857652515e-08
reported O 0 0.0002013743796851486
mutations O 0 4.221843028062722e-06
leading O 0 1.1235173587920144e-05
to O 0 1.2819737094105221e-07
premature O 0 4.115840056329034e-06
truncation O 0 2.529463472455973e-06
of O 0 4.897775340850785e-08
the O 0 2.0167524894532107e-07
protein O 0 5.897103960705863e-07
( O 0 2.0955706503400506e-08
nonsense O 0 6.260681857384043e-07
, O 0 2.4169883872104947e-08
splicing O 0 1.3763974493485875e-07
, O 0 3.100362633290388e-08
insertions O 0 7.83126495207398e-07
and O 0 2.965740577565157e-07
deletions O 0 5.1616279961308464e-06
) O 0 5.954305493105494e-08
and O 0 6.539025321217196e-08
just O 0 4.03509829993709e-08
2 O 0 2.2018859624495235e-07
% O 0 3.915310031743502e-08
leading O 0 3.7613125414281967e-07
to O 0 3.3616569528049922e-09
substitution O 0 3.514684099314991e-09
of O 0 3.588231933804309e-09
one O 0 2.9617176267038303e-08
amino O 0 3.4846951280087524e-07
acid O 0 7.295797672668414e-07
by O 0 4.851455059906584e-08
another O 0 6.035378419255721e-07
( O 0 5.221476726546825e-07
missense O 0 7.605495193274692e-05
) O 0 8.67560572714865e-07
. O 0 1.3425700444713584e-06

The O 0 4.547050139080966e-06
extraordinary O 0 1.4739585822098888e-05
conservation O 0 7.863293944865291e-07
of O 0 1.7298757981620838e-08
the O 0 1.0764962610210205e-07
PAX6 O 0 0.00016511032299604267
protein O 0 8.991032274252575e-08
at O 0 4.437457334915962e-08
the O 0 2.051240244327346e-08
amino O 0 3.205971381703421e-07
acid O 0 1.3956788507130113e-06
level O 0 1.558724420647195e-07
amongst O 0 7.699036359554157e-07
vertebrates O 0 9.999053872888908e-06
predicts O 0 1.9549399439711124e-05
that O 0 2.123790352470678e-07
pathological O 0 8.748380787437782e-05
missense O 0 0.0009850440546870232
mutations O 0 2.975205279653892e-05
should O 0 1.596201428810673e-07
in O 0 5.9591226175825796e-08
fact O 0 2.6951173026645847e-07
be O 0 3.176229768087069e-07
common O 0 4.6506636408594204e-07
even O 0 7.632626761733263e-07
though O 0 6.192288992679096e-07
they O 0 6.592084389467345e-08
are O 0 3.096792866585929e-08
hardly O 0 5.078340450381802e-07
ever O 0 1.034495880958275e-06
seen O 0 2.9752834507235093e-06
in O 0 4.737426479550777e-06
aniridia B-Disease 1 0.9998670816421509
patients O 0 0.0004547167045529932
. O 0 3.2942170946625993e-06

This O 0 2.0630425296985777e-06
indicates O 0 1.1249389899603557e-05
that O 0 8.689775654602272e-08
there O 0 1.490393053416028e-08
is O 0 2.121385023201583e-08
a O 0 1.7624701342811022e-07
heavy O 0 0.0001401833287673071
ascertainment O 0 0.0059208255261182785
bias O 0 2.8027456210111268e-05
in O 0 4.871019143593003e-08
the O 0 3.911041090987055e-08
selection O 0 1.8720770356139838e-07
of O 0 1.3596787766800844e-06
patients O 0 1.1648126928776037e-05
for O 0 5.163909122529731e-07
PAX6 O 0 0.002386721083894372
mutation O 0 6.18692922671471e-07
analysis O 0 4.884565285578901e-08
and O 0 2.7891525178347365e-07
that O 0 3.567957662653498e-08
the O 0 1.7690123854663398e-07
missing O 0 6.312767800409347e-05
PAX6 O 0 0.01626996323466301
missense O 0 0.0017576487734913826
mutations O 0 0.00018796509539242834
frequently O 0 7.440088211296825e-06
may O 0 9.896596566250082e-06
underlie O 0 9.535715071251616e-05
phenotypes O 0 2.6985919248545542e-05
distinct O 0 1.9798868322595808e-07
from O 0 2.1982948510412825e-06
textbook O 0 0.040447697043418884
aniridia B-Disease 1 0.9994244575500488
. O 0 3.271022069384344e-05

Here O 0 5.176524609851185e-06
we O 0 1.130394124970735e-07
present O 0 2.304784807449778e-08
four O 0 6.564030030631329e-08
novel O 0 2.1732373625127366e-06
PAX6 O 0 0.0018200029153376818
missense O 0 0.0003215947072021663
mutations O 0 1.738697028486058e-05
, O 0 2.1381644899065577e-07
two O 0 2.5391548774678085e-07
in O 0 3.03943329527101e-06
association O 0 7.737105988780968e-06
with O 0 4.435000846569892e-06
atypical O 0 0.0015890984795987606
phenotypes O 0 0.00030223545036278665
ectopia B-Disease 0 0.03438651189208031
pupillae I-Disease 0 0.024984542280435562
( O 0 3.588980348467885e-07
displaced B-Disease 0 6.956376182642998e-06
pupils I-Disease 0 8.702631021151319e-06
) O 0 7.099566118995426e-06
and O 0 0.005515688564628363
congenital B-Disease 1 0.9999744892120361
nystagmus I-Disease 0 0.44263869524002075
( O 0 9.707241588330362e-07
searching B-Disease 0 1.6108702766359784e-05
gaze I-Disease 0 0.0017136174719780684
) O 0 1.722041673701824e-07
, O 0 4.0291457281682597e-08
and O 0 3.9533709639272274e-08
two O 0 1.9191807609786338e-07
in O 0 5.553712867367722e-07
association O 0 3.073818334087264e-06
with O 0 2.0938591660524253e-07
more O 0 2.603835298486956e-07
recognizable O 0 0.0002226401848020032
aniridia B-Disease 1 0.97523432970047
phenotypes O 0 0.0001406425581080839
. O 0 2.7499829684529686e-06

Strikingly O 0 0.0009357663802802563
, O 0 1.6752359215388424e-06
all O 0 1.216581146934459e-08
four O 0 2.6530602781349444e-07
mutations O 0 1.2169940646344912e-06
are O 0 1.921280556871352e-08
located O 0 5.695526539284401e-08
within O 0 7.642297461529779e-09
the O 0 4.461610956241202e-07
PAX6 O 0 0.003291469532996416
paired O 0 2.2775113393436186e-05
domain O 0 3.762575033761095e-07
and O 0 2.0181454374323948e-07
affect O 0 6.242498074016112e-08
amino O 0 1.0452163934360215e-07
acids O 0 1.046477038357807e-07
which O 0 1.912359870459568e-08
are O 0 1.1395311361184213e-08
highly O 0 2.608403519843705e-07
conserved O 0 2.3229597445606487e-07
in O 0 1.2826885331662652e-08
all O 0 1.2110202618487165e-08
known O 0 1.0686970881579327e-06
paired O 0 3.4410545595164876e-06
domain O 0 6.770921459064994e-07
proteins O 0 8.206819757106132e-07
. O 0 1.670309757173527e-06

Our O 0 2.283047706441721e-06
results O 0 1.716990595923562e-06
support O 0 2.6902151262220286e-07
the O 0 6.956031484151026e-08
hypothesis O 0 4.6398011477322143e-07
that O 0 1.857663711746227e-08
the O 0 3.952903426807097e-08
under O 0 3.5336955761522404e-07
- O 0 2.4393064450123347e-05
representation O 0 1.5926190144455177e-07
of O 0 3.259338257066702e-07
missense O 0 0.0011221858439967036
mutations O 0 2.3720978788333014e-05
is O 0 5.724615448343684e-07
caused O 0 4.141654244449455e-06
by O 0 1.1066306342399912e-06
ascertainment O 0 0.04266636073589325
bias O 0 0.0015385403530672193
and O 0 9.218967534252442e-06
suggest O 0 1.4254637790145352e-06
that O 0 4.8750248282658504e-08
a O 0 6.15125316016929e-07
substantial O 0 2.90731782115472e-06
burden O 0 6.161427882034332e-05
of O 0 6.870940296721528e-07
PAX6 B-Disease 1 0.5127065181732178
- I-Disease 1 0.847969114780426
related I-Disease 0 0.15926474332809448
disease I-Disease 0 0.07961463183164597
remains O 0 2.3214246539282613e-05
to O 0 2.14836802570062e-07
be O 0 4.189537037291302e-07
uncovered O 0 0.0002819098881445825
. O 0 1.2953869372722693e-06
. O 0 4.777757567353547e-06

The O 0 8.782653821981512e-06
chromosomal O 0 0.009390500374138355
order O 0 4.718880575182993e-07
of O 0 7.713207139659062e-08
genes O 0 6.048510385880945e-07
controlling O 0 1.0039826520369388e-05
the O 0 4.4327921955300553e-07
major O 0 1.8355493011767976e-05
histocompatibility O 0 0.019106745719909668
complex O 0 3.092126462433953e-06
, O 0 2.2967360564507544e-06
properdin O 0 0.00892532616853714
factor O 0 2.1823132556164637e-05
B O 0 0.0007265384192578495
, O 0 3.938795543945162e-06
and O 0 0.00021785951685160398
deficiency B-Disease 0 0.003246384672820568
of I-Disease 0 1.0794647842260474e-08
the I-Disease 0 1.9171002563211914e-08
second I-Disease 0 4.6558022859244375e-07
component I-Disease 0 3.3919917541425093e-07
of I-Disease 0 8.372958859581558e-08
complement I-Disease 0 3.0320827590912813e-06
. O 0 4.062857442477252e-06

The O 0 4.344403805589536e-06
relationship O 0 3.966645635955501e-06
of O 0 6.096646387732108e-08
the O 0 7.162084614265041e-08
genes O 0 7.417350644800536e-08
coding O 0 9.965885965357302e-07
for O 0 3.8347513964254176e-07
HLA O 0 5.0079259381163865e-05
to O 0 2.0228849706427354e-08
those O 0 5.149541237869926e-09
coding O 0 3.194450357568712e-07
for O 0 1.4222818833786732e-07
properdin O 0 0.00012967336806468666
Factor O 0 6.211025151969807e-07
B O 0 1.638373578316532e-05
allotypes O 0 7.830007962184027e-05
and O 0 1.7700969010547851e-06
for O 0 1.1452962098701391e-05
deficiency B-Disease 0 0.0035165827721357346
of I-Disease 0 2.295541001728907e-08
the I-Disease 0 7.773198262839287e-08
second I-Disease 0 1.5298973039534758e-06
component I-Disease 0 1.1781581861214363e-06
of I-Disease 0 1.5062458658121614e-07
complement I-Disease 0 2.038713546426152e-06
( O 0 6.20447735855123e-07
C2 O 0 0.005709582474082708
) O 0 3.5225181704845454e-07
was O 0 1.5672590961912647e-05
studied O 0 1.4470612086370238e-06
in O 0 8.094541925629528e-08
families O 0 3.5709334156308614e-07
of O 0 5.7161278164130636e-06
patients O 0 0.0003562502097338438
with O 0 0.0003584359656088054
connective O 1 0.9977936744689941
tissue O 1 0.9988937973976135
disorders O 1 0.9678337574005127
. O 0 7.890165579738095e-05

Patients O 0 0.02213473990559578
were O 0 1.452994820283493e-05
selected O 0 1.9661206351884175e-06
because O 0 3.4492251188567025e-07
they O 0 2.7086960230349177e-08
were O 0 1.1601122196225333e-07
heterozygous O 0 3.2955230722109263e-07
or O 0 2.540967045661091e-07
homozygous O 0 5.637103095068596e-05
for O 0 0.0006986024673096836
C2 B-Disease 1 0.9999854564666748
deficiency I-Disease 1 0.9999237060546875
. O 0 3.867375198751688e-05

12 O 0 3.383252624189481e-05
families O 0 2.1463458779180655e-06
with O 0 2.7385618750486174e-07
15 O 0 8.771753527980763e-07
matings O 0 1.9368135326658376e-05
informative O 0 1.522567526990315e-05
for O 0 0.04153425991535187
C2 B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9999905824661255
were O 0 8.699381578480825e-05
found O 0 4.5625376515090466e-05
. O 0 1.544247970741708e-05

Of O 0 3.4719612358458107e-06
57 O 0 7.74333966546692e-05
informative O 0 2.0691527424787637e-06
meioses O 0 0.00025854521663859487
, O 0 7.746260877183886e-08
two O 0 1.577983610445699e-08
crossovers O 0 4.284872375137638e-06
were O 0 3.2881152947084047e-06
noted O 0 1.9752144453377696e-06
between O 0 4.4707937263410713e-07
the O 0 0.007086762692779303
C2 B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.999971866607666
gene O 0 1.0552918183748261e-06
and O 0 2.875607378882705e-07
the O 0 1.1663149734886247e-06
HLA O 0 0.014588074758648872
- O 0 0.03482384607195854
B O 0 0.0002023051056312397
gene O 0 1.1573794012065264e-07
, O 0 6.187292456161231e-09
with O 0 4.1309355935936765e-09
a O 0 2.8607457736029573e-08
recombinant O 0 6.415393727365881e-07
fraction O 0 1.7452158829200926e-07
of O 0 8.234222548253456e-08
0 O 0 7.719999302935321e-06
. O 0 3.211052444385132e-06

035 O 0 0.27484995126724243
. O 0 0.0006057359278202057

A O 0 4.859074397245422e-05
lod O 0 0.00031356714316643775
score O 0 1.3208102700446034e-06
of O 0 1.0549401707748984e-07
13 O 0 1.6450430848635733e-06
was O 0 6.91429761445761e-07
calculated O 0 4.863063196580697e-08
for O 0 2.8465026957746886e-07
linkage O 0 0.00018339139933232218
between O 0 0.01950094662606716
C2 B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999948740005493
and O 0 0.0002746900136116892
HLA O 0 0.07819613069295883
- O 0 0.029439149424433708
B O 0 2.5772902517928742e-05
at O 0 2.3196875531539263e-07
a O 0 3.2660274484896945e-08
maximum O 0 2.1331807431579364e-07
likelihood O 0 6.13330485066399e-07
value O 0 1.256776016589356e-08
of O 0 1.0691737495349685e-09
the O 0 5.245100798134672e-09
recombinant O 0 2.3078847277702152e-07
fraction O 0 1.2445772767932795e-07
of O 0 4.755469262818224e-08
0 O 0 5.074813998362515e-06
. O 0 1.5891522480160347e-06

04 O 0 0.015461410395801067
. O 0 0.00020689715165644884

18 O 0 0.00019327618065290153
families O 0 9.527929250907619e-06
with O 0 8.404180107390857e-07
21 O 0 9.476036666455911e-07
informative O 0 7.971996751621191e-08
matings O 0 5.262688318907749e-06
for O 0 1.3253092845388892e-07
both O 0 1.8826672487648466e-07
properdin O 0 0.0003925213823094964
Factor O 0 6.228458460100228e-07
B O 0 2.7876947115146322e-06
allotype O 0 2.117472467944026e-05
and O 0 6.483400056822575e-07
HLA O 0 0.00012479443103075027
- O 0 0.00037613502354361117
B O 0 2.5325161914224736e-05
were O 0 1.4361562534759287e-06
found O 0 2.807204737109714e-06
. O 0 1.155126028606901e-06

Of O 0 1.711544882709859e-06
72 O 0 2.2336869733408093e-05
informative O 0 1.91909612112795e-06
meioses O 0 0.0012544760247692466
, O 0 3.380311284217896e-07
three O 0 3.273474362686102e-07
recombinants O 0 0.003294730791822076
were O 0 4.340779923950322e-06
found O 0 5.57792247946054e-07
, O 0 2.3072391996947772e-08
giving O 0 4.944148646046642e-09
a O 0 9.349707674743968e-09
recombinant O 0 3.7307603406588896e-07
fraction O 0 2.3758029499276745e-07
of O 0 6.220996340289275e-08
0 O 0 9.521751962893177e-06
. O 0 2.524000819903449e-06

042 O 0 0.042983297258615494
. O 0 0.00041485493420623243

A O 0 3.6935492971679196e-05
lod O 0 0.00019128040003124624
score O 0 9.988883675760007e-07
of O 0 5.220471166467178e-08
16 O 0 3.7724953472206835e-07
between O 0 2.2477460959180462e-07
HLA O 0 0.001345255528576672
- O 0 0.010248146951198578
B O 0 6.475379632320255e-05
and O 0 2.478129488281411e-07
Factor O 0 2.5929890057341254e-07
B O 0 1.5555166100966744e-05
allotypes O 0 0.00012104419147362933
was O 0 2.5260692382289562e-06
calculated O 0 5.8720416973301326e-08
at O 0 4.6761556404817384e-08
a O 0 3.825648420274774e-08
maximum O 0 2.0886280083232123e-07
likelihood O 0 2.651684098964324e-07
value O 0 4.860427615938079e-09
of O 0 1.323621878768222e-09
the O 0 8.089753755768925e-09
recombinant O 0 2.5231415179405303e-07
fraction O 0 1.673572285199043e-07
of O 0 7.734583817864404e-08
0 O 0 4.6970831135695335e-06
. O 0 2.30414912039123e-06

04 O 0 0.020076628774404526
. O 0 0.00022064738732296973

A O 0 2.0341658455436118e-05
crossover O 0 3.438601561356336e-05
was O 0 0.00024209522234741598
shown O 0 6.485799985966878e-07
to O 0 2.1872102351494505e-08
have O 0 2.968130630165433e-08
occurred O 0 2.1701973551557785e-08
between O 0 7.094969500798243e-09
genes O 0 4.404352438314163e-08
for O 0 7.195686180239136e-08
Factor O 0 5.017811872676248e-07
B O 0 1.0224786819890141e-05
and O 0 2.5052379442058736e-06
HLA O 0 0.006453334353864193
- O 0 0.14925500750541687
D O 0 0.2334190458059311
, O 0 7.618171338208413e-08
in O 0 1.244173208903021e-08
which O 0 1.9222544267449848e-07
HLA O 0 0.0012927387142553926
- O 0 0.09657521545886993
D O 0 0.3066355288028717
segregared O 0 7.645023288205266e-05
with O 0 4.1753852997317153e-07
HLA O 0 0.00010960950021399185
- O 0 7.110181468306109e-05
A O 0 1.961072030098876e-06
and O 0 1.8431654780215467e-06
B O 0 6.743920675944537e-05
. O 0 2.144854306607158e-06

These O 0 5.188240379538911e-07
studies O 0 9.310130621997814e-07
suggest O 0 3.55190337586464e-07
that O 0 5.787443857485641e-09
the O 0 1.574805530424328e-08
genes O 0 3.7636798566609286e-08
for O 0 1.2101571655875887e-07
Factor O 0 5.590998625848442e-06
B O 0 0.02883581630885601
and O 1 0.5076164603233337
C2 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999895095825195
are O 0 2.192469139572495e-07
located O 0 3.080730834881251e-07
outside O 0 7.514152144949549e-08
those O 0 2.6889294346688075e-08
for O 0 4.196334657535772e-07
HLA O 0 0.001312870066612959
, O 0 2.733395660925453e-07
that O 0 5.5582618507799e-09
the O 0 9.187528959841984e-09
order O 0 1.559549112073455e-08
of O 0 4.771405315295851e-08
genese O 0 0.0007193796918727458
is O 0 2.8107518801334663e-07
HLA O 0 8.896403596736491e-05
- O 0 0.00015475525287911296
A O 0 4.782375526701799e-06
, O 0 2.68816074822098e-06
- O 0 0.0032009356655180454
B O 0 6.203168595675379e-05
, O 0 6.588576866306539e-07
- O 0 0.00490937102586031
D O 0 0.05343315377831459
, O 0 1.7841880151081568e-07
Factor O 0 2.7943707436861587e-07
B O 0 6.551066326210275e-05
allotype O 0 0.038567572832107544
, O 0 0.07169893383979797
C2 B-Disease 1 0.9999988079071045
deficiency I-Disease 1 0.9999881982803345
, O 0 4.5938307380311016e-07
that O 0 1.6777695677205884e-08
the O 0 4.7295987570805664e-08
genes O 0 3.308989278139052e-07
coding O 0 8.726042869966477e-05
for O 0 0.041931767016649246
C2 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999895095825195
and O 0 1.3721417417400517e-05
Factor O 0 3.6481665119936224e-06
B O 0 1.981807145057246e-05
allotypes O 0 2.4625205696793273e-05
are O 0 6.068915148205178e-09
approximately O 0 2.2749981454239787e-08
3 O 0 5.925302275500144e-07
- O 0 9.803479042602703e-05
- O 0 1.861709461081773e-05
5 O 0 2.3082654365680355e-07
centimorgans O 0 2.9922341582278023e-06
from O 0 5.64747182352221e-09
the O 0 2.2011505507180118e-08
HLA O 0 1.8290387743036263e-05
- O 0 1.622065065021161e-05
A O 0 6.023940954946738e-07
and O 0 1.441243739463971e-06
HLA O 0 0.0007085759425535798
- O 0 0.0018113366095349193
B O 0 1.5047891793074086e-05
loci O 0 1.732448851043955e-07
, O 0 6.831854193478648e-08
and O 0 1.8615338603922282e-07
that O 0 4.858872770796552e-08
the O 0 4.21845953724187e-07
apparent O 0 8.89300208655186e-05
lack O 0 4.290918127480836e-07
of O 0 6.954758191568544e-08
recombinants O 0 0.00011328882101224735
between O 0 5.511150646952956e-08
the O 0 6.166723665046447e-08
Factor O 0 5.671200256074371e-07
B O 0 7.037369505269453e-05
gene O 0 3.947930508729769e-06
and O 0 0.018018115311861038
C2 B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999933242797852
gene O 0 3.1698946258984506e-06
suggests O 0 6.919455586285039e-07
that O 0 1.128881077505639e-08
these O 0 1.3688954414448062e-09
two O 0 9.105416864940707e-08
genes O 0 5.705887815565802e-07
lie O 0 4.787431862496305e-06
in O 0 5.98803922002844e-08
close O 0 5.528063411475159e-07
proximity O 0 1.1205261074564987e-07
to O 0 2.7531889656984276e-08
one O 0 9.990640137402806e-08
another O 0 2.5143069706246024e-06
. O 0 2.96330540550116e-06

Distribution O 0 5.026604867452988e-06
of O 0 1.3225724160292884e-06
emerin O 0 0.004151876084506512
and O 0 5.500887255038833e-06
lamins O 0 0.0060241553001105785
in O 0 3.244489334974787e-07
the O 0 1.3861839534001774e-06
heart O 0 2.9738808734691702e-05
and O 0 4.781618372362573e-07
implications O 0 6.287341875577113e-06
for O 0 9.290864909416996e-06
Emery B-Disease 1 0.8075533509254456
- I-Disease 1 0.9983214735984802
Dreifuss I-Disease 1 0.9994768500328064
muscular I-Disease 1 0.9991528987884521
dystrophy I-Disease 1 0.9989458918571472
. O 0 0.00012784702994395047

Emerin O 0 0.015393402427434921
is O 0 2.588963752714335e-06
a O 0 6.718076406286855e-07
nuclear O 0 0.00018199121404904872
membrane O 0 4.728642579721054e-06
protein O 0 1.867650922804387e-07
which O 0 3.0025166353198074e-08
is O 0 4.923889562746808e-08
missing O 0 3.893813300237525e-06
or O 0 4.5215833210932033e-07
defective O 0 0.00035252916859462857
in O 0 3.8265388866420835e-06
Emery B-Disease 1 0.86875319480896
- I-Disease 1 0.9998573064804077
Dreifuss I-Disease 1 0.9999406337738037
muscular I-Disease 1 0.9999738931655884
dystrophy I-Disease 1 0.9999344348907471
( O 0 0.0003919207083526999
EDMD B-Disease 1 0.9999338388442993
) O 0 1.4364614798978437e-05
. O 0 4.608341896528145e-06

It O 0 3.366655846548383e-06
is O 0 6.711698574690672e-07
one O 0 1.4203666864887055e-07
member O 0 4.82951861613401e-07
of O 0 5.152058690782724e-08
a O 0 1.52792313201644e-06
family O 0 5.711376161343651e-06
of O 0 6.628799269492447e-07
lamina O 1 0.5143884420394897
- O 0 0.17989136278629303
associated O 0 3.424332817303366e-06
proteins O 0 3.204176479698617e-08
which O 0 1.964330742509901e-08
includes O 0 2.5506201950520335e-07
LAP1 O 0 0.0012447887565940619
, O 0 7.819256779839634e-07
LAP2 O 0 0.00045515119563788176
and O 0 4.721748155134264e-06
lamin O 0 0.10713610053062439
B O 0 0.005994866136461496
receptor O 0 5.447642979561351e-05
( O 0 2.8966765057703014e-06
LBR O 0 0.0063345832750201225
) O 0 9.10397318421019e-07
. O 0 1.3751119922744692e-06

A O 0 3.9277918403968215e-05
panel O 0 2.9462986276485026e-05
of O 0 2.1722436827076308e-07
16 O 0 1.58140501298476e-05
monoclonal O 0 7.445001392625272e-05
antibodies O 0 4.127475222048815e-06
( O 0 5.633628674672764e-08
mAbs O 0 5.135393621458206e-06
) O 0 6.727398726980027e-08
has O 0 3.442908393935795e-07
been O 0 3.8386519918276463e-07
mapped O 0 3.3696687751216814e-06
to O 0 3.7698587362910985e-08
six O 0 7.426948656075183e-08
specific O 0 2.8516411454404533e-09
sites O 0 1.2243516422927314e-08
throughout O 0 1.9747956603310968e-09
the O 0 9.335113126951455e-09
emerin O 0 4.097183591511566e-06
molecule O 0 4.7977060546600114e-08
using O 0 3.9432947573914134e-08
phage O 0 2.6177335712418426e-06
- O 0 4.89622425448033e-06
displayed O 0 5.798097504339239e-07
peptide O 0 6.016936282549068e-08
libraries O 0 1.553015671618141e-08
and O 0 8.649511329394954e-08
has O 0 2.7886522957487614e-07
been O 0 1.552930370962713e-07
used O 0 3.5718453972322095e-08
to O 0 1.1675737709992973e-08
localize O 0 2.365940872550709e-06
emerin O 0 3.5793207644019276e-05
in O 0 9.171232306925958e-08
human O 0 3.001223092269356e-07
and O 0 2.780125441859127e-06
rabbit O 0 0.001747635891661048
heart O 0 0.0009179949993267655
. O 0 5.8983864619222e-06

Several O 0 5.0526391532912385e-06
mAbs O 0 5.765132300439291e-05
against O 0 2.1666730845026905e-06
different O 0 6.872736690866077e-08
emerin O 0 0.0008996546384878457
epitopes O 0 0.00010528048733249307
did O 0 3.862226378714695e-07
not O 0 8.178137278491704e-09
recognize O 0 3.2340782496476095e-08
intercalated O 0 8.477210030832794e-06
discs O 0 5.991882790112868e-05
in O 0 8.133764595186221e-07
the O 0 5.203901764616603e-06
heart O 0 0.00041751412209123373
, O 0 4.253459735537035e-07
though O 0 1.2666407656070078e-07
they O 0 4.4482362682174426e-08
recognized O 0 1.2257936532478197e-07
cardiomyocyte O 0 1.5329482266679406e-05
nuclei O 0 1.2875709671789082e-06
strongly O 0 1.436058937542839e-06
, O 0 2.747827387850066e-08
both O 0 1.8363959242151395e-08
at O 0 5.8468947372603e-07
the O 0 4.816304226551438e-07
rim O 0 0.00019321612489875406
and O 0 5.124891231389483e-07
in O 0 1.2268311877505766e-07
intranuclear O 0 0.00013586120621766895
spots O 0 5.753475420533505e-07
or O 0 1.7879898450701148e-07
channels O 0 2.2817876015324146e-06
. O 0 3.134904318358167e-06

A O 0 5.404859621194191e-05
polyclonal O 0 0.0005213494296185672
rabbit O 0 0.00027468136977404356
antiserum O 0 0.0004740463336929679
against O 0 5.93302320339717e-05
emerin O 0 0.0048384410329163074
did O 0 1.3866083463653922e-06
recognize O 0 8.906527426688626e-08
both O 0 3.173201434947259e-08
nuclear O 0 4.8604324547341093e-05
membrane O 0 2.2668975816486636e-06
and O 0 4.2605401517903374e-07
intercalated O 0 0.0001164002824225463
discs O 0 0.00028574312455020845
but O 0 2.619768793010735e-07
, O 0 1.2467262422433123e-07
after O 0 3.7905164163021254e-07
affinity O 0 3.8133370594550797e-07
purification O 0 1.1094435876657371e-06
against O 0 3.821798202352511e-07
a O 0 1.2931278092764842e-07
pure O 0 9.254238761968736e-07
- O 0 0.000568566145375371
emerin O 0 0.0001631601044209674
band O 0 1.6842965351315797e-06
on O 0 8.508853710509356e-08
a O 0 7.988558081706287e-08
western O 0 2.4384002017541206e-07
blot O 0 8.653123950352892e-05
, O 0 2.1005612893532088e-07
it O 0 3.046154262165146e-08
stained O 0 0.0015444247983396053
only O 0 1.1896011287149122e-08
the O 0 1.0983292497712682e-07
nuclear O 0 0.00011747620737878606
membrane O 0 1.4576970897905994e-05
. O 0 1.1063837064284598e-06

These O 0 8.99627877970488e-07
results O 0 2.408940190434805e-06
would O 0 4.998163376512821e-07
not O 0 2.2195274951286592e-08
be O 0 3.1170358738563664e-08
expected O 0 2.211332486012907e-07
if O 0 4.8947683239930484e-08
immunostaining O 0 1.278514537261799e-05
at O 0 5.37890173291089e-07
intercalated O 0 4.29114188591484e-05
discs O 0 0.00026915769558399916
were O 0 8.224415978475008e-06
due O 0 3.7011523090768605e-07
to O 0 7.725806661085244e-09
a O 0 2.5497243427707872e-08
product O 0 6.160927767950852e-08
of O 0 1.0053469168269658e-08
the O 0 2.0551156865167286e-07
emerin O 0 0.001890887157060206
gene O 0 2.7434424509920063e-07
and O 0 6.239510526029335e-07
, O 0 3.6405754144652747e-07
therefore O 0 7.464299045523148e-08
, O 0 1.3039847601703514e-07
cast O 0 6.344311032080441e-07
some O 0 1.5704323175214085e-08
doubt O 0 1.8762594322652149e-07
upon O 0 6.05407057818752e-09
the O 0 5.2170570086218504e-08
hypothesis O 0 3.530546337060514e-06
that O 0 9.696670531411655e-06
cardiac B-Disease 1 0.9847613573074341
defects I-Disease 1 0.9989000558853149
in O 0 0.0002770175924524665
EDMD B-Disease 1 0.9999953508377075
are O 0 8.623896064818837e-06
caused O 0 9.490212505625095e-06
by O 0 2.033240775745071e-07
absence O 0 7.418298650918587e-07
of O 0 1.646776155439511e-07
emerin O 0 0.0006690174923278391
from O 0 1.2856776265834924e-06
intercalated O 0 0.0008370548603124917
discs O 0 0.0031246792059391737
. O 0 6.31620650892728e-06

Although O 0 0.0001644524309085682
emerin O 0 0.03183462843298912
was O 0 0.00014113372890278697
abundant O 0 5.048007096775109e-07
in O 0 1.7782163297397346e-08
the O 0 2.248296304685482e-08
membranes O 0 6.945921882106632e-07
of O 0 9.767121156301073e-08
cardiomyocyte O 0 0.0002078872494166717
nuclei O 0 3.693324742926052e-06
, O 0 3.100058449945209e-07
it O 0 6.165311816630492e-08
was O 0 1.4680863387184218e-05
absent O 0 7.69376697462576e-07
from O 0 2.9194509920671408e-08
many O 0 1.474660038525144e-08
non O 0 2.211402943430585e-06
- O 0 0.0004895639722235501
myocyte O 0 0.0012384698493406177
cells O 0 1.6064930150605505e-06
in O 0 5.8554441295655124e-08
the O 0 1.6810919305498828e-06
heart O 0 0.00018215111049357802
. O 0 4.397219072416192e-06

This O 0 1.6878745157100639e-07
distribution O 0 1.2741644184188772e-07
of O 0 1.939023945851659e-07
emerin O 0 0.011455942876636982
was O 0 3.372184801264666e-05
similar O 0 6.537927532690446e-08
to O 0 4.961410127179988e-08
that O 0 1.5174336454037984e-08
of O 0 6.787071527014632e-08
lamin O 0 0.005231853108853102
A O 0 1.0483511687198188e-05
, O 0 8.376758273698215e-07
a O 0 5.18376907621132e-07
candidate O 0 3.0711341878486564e-06
gene O 0 1.6673895686381002e-07
for O 0 2.75061012189326e-07
an O 0 2.056795528915245e-05
autosomal O 0 0.006672829855233431
form O 0 5.002616035199026e-06
of O 0 6.20722712483257e-05
EDMD B-Disease 1 0.9999028444290161
. O 0 7.55290748202242e-05

In O 0 4.775812612933805e-06
contrast O 0 1.6708081602700986e-05
, O 0 9.437811968382448e-06
lamin O 0 0.32616549730300903
B1 O 1 0.9892282485961914
was O 0 0.0009569108951836824
absent O 0 8.111640454444569e-06
from O 0 3.031004780496005e-07
cardiomyocyte O 0 0.00010425029176985845
nuclei O 0 2.265410557811265e-06
, O 0 2.0864341365722794e-07
showing O 0 5.5080317906686105e-06
that O 0 8.820659900266037e-07
lamin O 0 0.18618805706501007
B1 O 1 0.9096105098724365
is O 0 2.608806539683428e-07
not O 0 1.5241836237578354e-08
essential O 0 1.111267078357514e-08
for O 0 9.784272059221166e-09
localization O 0 9.498212989456079e-07
of O 0 6.887276526867936e-08
emerin O 0 0.00012665148824453354
to O 0 3.137112258855268e-08
the O 0 2.2455326131876063e-07
nuclear O 0 0.00013234413927420974
lamina O 0 0.002496164757758379
. O 0 4.988671207684092e-06

Lamin O 1 0.984545111656189
B1 O 1 0.9885079264640808
is O 0 9.982761184801348e-06
also O 0 6.978302735660691e-07
almost O 0 1.456267426647173e-07
completely O 0 2.646792609084514e-06
absent O 0 1.6566680642426945e-05
from O 0 6.0012907852069475e-06
skeletal O 1 0.5361870527267456
muscle O 0 0.0012097078142687678
nuclei O 0 0.00010440291225677356
. O 0 7.198574166977778e-06

In O 0 6.659721111645922e-05
EDMD B-Disease 1 0.9992110729217529
, O 0 1.5235258388202055e-06
the O 0 3.799469538989797e-08
additional O 0 1.20789721336223e-07
absence O 0 8.691083621670259e-07
of O 0 3.0547948881576303e-07
lamin O 0 0.3882867395877838
B1 O 1 0.930330753326416
from O 0 4.712364898296073e-05
heart O 0 0.00263445102609694
and O 0 1.5251193872245494e-05
skeletal O 1 0.6421520113945007
muscle O 0 0.0008437301148660481
nuclei O 0 2.0096720618312247e-05
which O 0 4.502972842601594e-06
already O 0 6.313273479463533e-05
lack O 0 2.0807324290217366e-06
emerin O 0 0.005518409889191389
may O 0 1.4194054074323503e-06
offer O 0 2.4449102298262915e-08
an O 0 1.3303779411444339e-08
alternative O 0 3.334810827482215e-08
explanation O 0 1.0602955846650275e-08
of O 0 3.0694835118083574e-08
why O 0 5.493780577126017e-07
these O 0 2.309431756941649e-08
tissues O 0 2.1370626654970692e-06
are O 0 2.323260517300696e-08
particularly O 0 3.1685269163972407e-07
affected O 0 6.754314654244808e-07
. O 0 3.388561538031354e-07
. O 0 3.6929866382706678e-06

Genetic O 0 0.00014149618800729513
mapping O 0 1.0252028005197644e-05
of O 0 1.0439905508974334e-06
the O 0 5.929874532739632e-06
copper B-Disease 0 0.38789796829223633
toxicosis I-Disease 0 0.01668529212474823
locus O 0 1.2273241736693308e-05
in O 0 2.575682458427764e-07
Bedlington O 0 0.0005342583172023296
terriers O 0 0.0013553660828620195
to O 0 3.567863302578189e-07
dog O 0 8.699282625457272e-05
chromosome O 0 0.00012845805031247437
10 O 0 6.902754421389545e-07
, O 0 8.722705047148338e-08
in O 0 2.7911738698094268e-08
a O 0 5.161240892448404e-07
region O 0 2.808706767609692e-06
syntenic O 0 0.001388384378515184
to O 0 2.302904817952367e-07
human O 0 1.4714156577610993e-06
chromosome O 0 0.00011288980749668553
region O 0 3.895930603903253e-06
2p13 O 0 6.014770769979805e-05
- O 0 0.00033213719143532217
p16 O 0 3.7066751247039065e-05
. O 0 1.731199859023036e-06

Abnormal O 1 0.9100853800773621
hepatic B-Disease 1 0.9988425970077515
copper I-Disease 1 0.9944934844970703
accumulation I-Disease 0 0.004992392845451832
is O 0 9.036442861543037e-06
recognized O 0 6.519276212202385e-06
as O 0 2.1000832930440083e-05
an O 0 0.1348411589860916
inherited B-Disease 1 0.9999996423721313
disorder I-Disease 1 0.999996542930603
in O 0 5.799749487778172e-05
man O 0 0.12066701054573059
, O 0 1.3401355317910202e-05
mouse O 0 0.00013542597298510373
, O 0 7.590976110805059e-06
rat O 0 0.0010671049822121859
and O 0 3.482779220576049e-06
dog O 0 7.538452337030321e-05
. O 0 3.6515671126835514e-06

The O 0 1.4994344383012503e-05
major O 0 7.28135637473315e-05
cause O 0 1.7789576304494403e-05
of O 0 4.546455784293357e-06
hepatic B-Disease 1 0.9989637136459351
copper I-Disease 1 0.9946092367172241
accumulation I-Disease 0 0.0003844868333544582
in O 0 2.714095444389386e-06
man O 0 0.0010047814575955272
is O 0 2.3302240492739656e-07
a O 0 1.3515740420189104e-06
dysfunctional O 0 0.0008788496488705277
ATP7B O 0 0.022784803062677383
gene O 0 2.71592102762952e-06
, O 0 3.7618394799210364e-06
causing O 0 0.00289240968413651
Wilson B-Disease 1 0.8374263644218445
disease I-Disease 0 0.33688366413116455
( O 0 1.4739880498382263e-05
WD B-Disease 0 0.23014970123767853
) O 0 2.7962951207882725e-06
. O 0 3.1287158890336286e-06

Mutations O 0 0.0003458666324149817
in O 0 8.405261837651778e-07
the O 0 1.0515627764107194e-06
ATP7B O 0 0.08272302895784378
genes O 0 3.3544772577442927e-06
have O 0 2.817477593453077e-07
also O 0 6.301781354522973e-07
been O 0 6.291518843681843e-07
demonstrated O 0 1.8620927448864677e-06
in O 0 1.1457668591674519e-07
mouse O 0 2.5209836167050526e-05
and O 0 1.1457649634394329e-05
rat O 0 0.0047505940310657024
. O 0 7.83045106800273e-06

The O 0 8.627276656625327e-06
ATP7B O 0 0.015671664848923683
gene O 0 2.240932735730894e-05
has O 0 3.7946499560348457e-06
been O 0 5.639540745505656e-07
excluded O 0 1.817705651774304e-06
in O 0 2.566322976349511e-08
the O 0 9.042557280736219e-08
much O 0 4.7581323769918527e-07
rarer O 0 0.00010110911534866318
human O 0 4.137420546612702e-05
copper B-Disease 1 0.9982874989509583
overload I-Disease 1 0.9100241661071777
disease O 0 0.05043264105916023
non B-Disease 0 5.753362347604707e-05
- I-Disease 0 0.23816263675689697
Indian I-Disease 0 0.015636036172509193
childhood I-Disease 0 0.0403609499335289
cirrhosis I-Disease 1 0.78676837682724
, O 0 3.395423846086487e-06
indicating O 0 2.1985610146657564e-05
genetic O 0 3.434911195654422e-05
heterogeneity O 0 0.00021417875541374087
. O 0 2.2583100871997885e-05

By O 0 7.245469532790594e-06
investigating O 0 0.00033538113348186016
the O 0 6.558467430295423e-05
common O 0 0.0045939902774989605
autosomal O 1 0.9897683262825012
recessive O 1 0.9990246295928955
copper B-Disease 1 0.9999524354934692
toxicosis I-Disease 1 0.9996894598007202
( O 0 2.077680801448878e-05
CT B-Disease 0 0.4067440629005432
) O 0 1.3753870575783367e-07
in O 0 1.3036839163760305e-07
Bedlington O 0 0.0025682381819933653
terriers O 0 0.04837893322110176
, O 0 1.4129578858046443e-06
we O 0 3.0599377254247884e-08
have O 0 4.468023107051522e-08
identified O 0 3.2419842455055914e-07
a O 0 2.582861924338431e-08
new O 0 3.027621744422504e-07
locus O 0 1.0451347407069989e-05
involved O 0 1.1239599189138971e-05
in O 0 0.00010601540270727128
progressive O 1 0.9997771382331848
liver B-Disease 1 0.9999948740005493
disease I-Disease 1 0.9996881484985352
. O 0 9.31946124183014e-05

We O 0 2.8839256174251204e-06
examined O 0 3.763899076147936e-05
whether O 0 3.679602968986728e-07
the O 0 3.470000820016139e-07
WD B-Disease 0 0.009896034374833107
gene O 0 3.3031451494025532e-06
ATP7B O 0 0.004943637643009424
was O 0 0.0002768968988675624
also O 0 2.105048451994662e-06
causative O 0 5.64007541470346e-06
for O 0 3.9049257338774623e-07
CT B-Disease 0 0.008883903734385967
by O 0 2.637187890286441e-07
investigating O 0 2.2661630282527767e-05
the O 0 2.1062191990495194e-06
chromosomal O 0 0.49604639410972595
co O 0 0.011251965537667274
- O 0 0.0001468331174692139
localization O 0 5.210690233070636e-06
of O 0 5.317747309163678e-07
ATP7B O 0 0.013132655061781406
and O 0 8.923443601815961e-07
C04107 O 0 3.0837102258374216e-06
, O 0 5.738529651466706e-09
using O 0 4.693256006049751e-09
fluorescence O 0 8.874427237515192e-08
in O 0 2.748556049425588e-08
situ O 0 2.032468501056428e-06
hybridization O 0 2.481313231328386e-06
( O 0 7.86297164268035e-07
FISH O 0 2.2587108105653897e-05
) O 0 3.915348258942686e-07
. O 0 1.0175409670409863e-06

C04107 O 0 0.0036403476260602474
is O 0 2.303793053215486e-06
an O 0 4.1112559756584233e-07
anonymous O 0 3.0192709346010815e-06
microsatellite O 0 0.0017841891385614872
marker O 0 0.00023935778881423175
closely O 0 9.756619874679018e-06
linked O 0 0.0002380480000283569
to O 0 5.494988727150485e-06
CT B-Disease 0 0.2340000718832016
. O 0 9.617577234166674e-06

However O 0 1.573840381752234e-05
, O 0 1.6620011820123182e-06
BAC O 0 1.1805474969150964e-05
clones O 0 2.1175472284085117e-05
containing O 0 4.33144259659457e-06
ATP7B O 0 0.001203600550070405
and O 0 6.050373713151203e-07
C04107 O 0 4.0696977521292865e-06
mapped O 0 2.571623099356657e-06
to O 0 1.87537860796283e-08
the O 0 9.421801649978079e-08
canine O 0 0.00033780946978367865
chromosome O 0 0.0008789899293333292
regions O 0 7.341730565713078e-07
CFA22q11 O 0 0.00033741313382051885
and O 0 2.4597386527602794e-06
CFA10q26 O 0 0.00042043469147756696
, O 0 8.617809044153546e-07
respectively O 0 3.898041541106068e-06
, O 0 1.4342616339035885e-07
demonstrating O 0 1.5876812540227547e-06
that O 0 4.430374644925905e-07
WD B-Disease 0 0.008537288755178452
cannot O 0 2.4547327370783023e-07
be O 0 1.753321043906908e-08
homologous O 0 7.414096785396396e-07
to O 0 9.558394822306582e-07
CT B-Disease 0 0.013636256568133831
. O 0 4.227995304972865e-06

The O 0 1.618810711079277e-05
copper O 0 0.029144272208213806
transport O 0 7.111291779438034e-05
genes O 0 2.8128913527325494e-06
CTR1 O 0 0.00274455058388412
and O 0 2.7822554784506792e-06
CTR2 O 0 0.04108627513051033
were O 0 8.430393791059032e-06
also O 0 5.129634246259229e-07
excluded O 0 2.4097951154544717e-06
as O 0 7.763760123680186e-08
candidate O 0 2.1244852632662514e-07
genes O 0 3.6349028675886075e-08
for O 0 1.4756736277377058e-07
CT B-Disease 0 0.01658686064183712
since O 0 7.329481377382763e-07
they O 0 2.9019078695569078e-08
both O 0 8.315183208651433e-09
mapped O 0 2.139787511623581e-06
to O 0 4.464850178464985e-07
canine O 0 0.0005966454627923667
chromosome O 0 0.0017795211169868708
region O 0 1.4019865375303198e-05
CFA11q22 O 0 0.0013625141000375152
. O 0 1.1841693776659667e-05

2 O 0 0.00013774535909760743
- O 0 0.005225253291428089
22 O 0 7.693078805459663e-05
. O 0 8.509739927831106e-06

5 O 0 0.0003882951568812132
. O 0 6.323192064883187e-05

A O 0 7.64456854085438e-06
transcribed O 0 2.9970465220685583e-06
sequence O 0 1.6248253587036743e-07
identified O 0 1.8242632222609245e-06
from O 0 2.0150677570995867e-08
the O 0 7.051248473999294e-08
C04107 O 0 1.079216872312827e-05
- O 0 2.039365608652588e-05
containing O 0 7.604472216371505e-07
BAC O 0 2.811354761433904e-06
was O 0 9.109696293307934e-06
found O 0 6.711006790283136e-07
to O 0 1.3809830612387941e-08
be O 0 1.3922496933105322e-08
homologous O 0 1.0979584885717486e-07
to O 0 1.454033871084448e-08
a O 0 1.5224337346353423e-07
gene O 0 1.7702140553410572e-07
expressed O 0 6.316648892834564e-08
from O 0 3.262640291268326e-08
human O 0 1.075532054528594e-06
chromosome O 0 0.0003510397800710052
2p13 O 0 0.00016362531459890306
- O 0 0.0011259590974077582
p16 O 0 5.9476587921381e-06
, O 0 5.465197361331775e-08
a O 0 6.859810497417129e-08
region O 0 7.418142899950908e-08
devoid O 0 1.1119990261931889e-07
of O 0 3.7233012228909956e-09
any O 0 1.1873795280337163e-08
positional O 0 4.933727268507937e-06
candidate O 0 1.439033803762868e-05
genes O 0 1.3439430404105224e-06
. O 0 1.2664502264669864e-06

Molecular O 0 3.702026151586324e-05
analysis O 0 9.961952400772134e-07
of O 0 1.077547935324219e-07
the O 0 3.272069761806051e-07
APC B-Disease 0 0.00012935449194628745
gene O 0 2.731235611008742e-07
in O 0 2.9450772487393806e-08
205 O 0 5.0011663006444e-06
families O 0 1.0804740213643527e-06
: O 0 1.032682632740034e-07
extended O 0 7.574876121907437e-07
genotype O 0 3.6664951039711013e-05
- O 0 0.0014571900246664882
phenotype O 0 1.161757518275408e-05
correlations O 0 4.035990514239529e-06
in O 0 4.3557645312830573e-07
FAP B-Disease 0 3.986901356256567e-05
and O 0 1.889111302944002e-07
evidence O 0 1.710022985434989e-07
for O 0 1.9424938102474698e-08
the O 0 2.3051981656863063e-08
role O 0 7.853808625668535e-08
of O 0 1.8486822739305353e-08
APC B-Disease 0 2.226018659712281e-05
amino O 0 3.7818864484506776e-07
acid O 0 1.7310429711869801e-06
changes O 0 6.977464295232494e-07
in O 0 0.003928723279386759
colorectal B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999916553497314
predisposition O 1 0.6379247903823853
. O 0 0.00010080344509333372

BACKGROUND O 0 4.537665518000722e-05
/ O 0 2.634753764141351e-05
AIMS O 0 9.726148164190818e-06
The O 0 2.639039848872926e-07
development O 0 2.681406613191939e-06
of O 0 0.13063426315784454
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
and O 0 6.664893589913845e-05
a O 0 3.477717655187007e-06
variable O 0 3.123194801446516e-06
range O 0 3.072071649512509e-06
of O 0 2.077662884403253e-06
extracolonic O 0 0.4686897099018097
manifestations O 0 0.0010751053923740983
in O 0 0.0008419845253229141
familial B-Disease 1 0.9999805688858032
adenomatous I-Disease 1 0.9999758005142212
polyposis I-Disease 1 0.9999957084655762
( O 0 0.0006347467424347997
FAP B-Disease 0 0.022740507498383522
) O 0 7.004820190559258e-07
is O 0 4.9181544170551206e-08
the O 0 2.2808983146660466e-08
result O 0 1.4460319164300017e-07
of O 0 7.287411563083879e-08
the O 0 2.860846961993957e-06
dominant O 0 0.0005930052138864994
inheritance O 0 0.02720757946372032
of O 0 0.07080383598804474
adenomatous B-Disease 1 0.999995231628418
polyposis I-Disease 1 0.9999815225601196
coli I-Disease 1 0.9999637603759766
( O 0 3.875342008541338e-05
APC B-Disease 0 0.0020649719517678022
) O 0 6.588978749277885e-07
gene O 0 1.1581870467125555e-06
mutations O 0 8.202233402698766e-06
. O 0 2.7929529551329324e-06

In O 0 4.558295131573686e-06
this O 0 6.096541937949951e-08
study O 0 1.1567305335802303e-07
, O 0 1.4581136298374986e-08
direct O 0 3.6358647204082217e-09
mutation O 0 3.6758354582389074e-08
analysis O 0 4.891424598696403e-09
of O 0 1.3545410126880597e-08
the O 0 1.4293949845978204e-07
APC B-Disease 0 0.0001595941575942561
gene O 0 5.927155939389195e-07
was O 0 3.6195692700857762e-06
performed O 0 2.5961983851630066e-07
to O 0 1.6637354605109067e-08
determine O 0 3.0184395427568234e-07
genotype O 0 1.361288559564855e-05
- O 0 0.0002527268370613456
phenotype O 0 3.6836302115261788e-06
correlations O 0 1.2215779179314268e-06
for O 0 2.2861954107611382e-07
nine O 0 1.7263069821638055e-05
extracolonic O 0 0.01746995560824871
manifestations O 0 2.7160454010299873e-06
and O 0 1.8139913038339728e-07
to O 0 3.342828591712532e-08
investigate O 0 9.477076332586876e-07
the O 0 1.9057407030231843e-07
incidence O 0 2.317927464901004e-05
of O 0 3.599383546770696e-07
APC B-Disease 0 0.0005956391687504947
mutations O 0 2.5032459234353155e-06
in O 0 7.913095032563433e-07
non O 0 0.0018762702820822597
- O 1 0.9987998008728027
FAP O 1 0.9989080429077148
colorectal B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999426603317261
. O 0 0.00012184998922748491

METHODS O 0 1.088745102606481e-05
The O 0 7.852981980249751e-07
APC B-Disease 0 7.112512685125694e-05
gene O 0 4.4196556814313226e-07
was O 0 1.4374414831763715e-06
analysed O 0 8.451721669189283e-07
in O 0 1.289483364530497e-08
190 O 0 1.1884523019034532e-06
unrelated O 0 1.6681779015925713e-05
FAP B-Disease 0 2.68604198936373e-05
and O 0 5.889359613320266e-07
15 O 0 7.024567821645178e-06
non O 0 0.000445895449956879
- O 1 0.9989262223243713
FAP O 1 0.9998239874839783
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999959468841553
patients O 0 4.6786477469140664e-05
using O 0 4.111221016955824e-07
denaturing O 0 0.00011134401574963704
gradient O 0 5.472103657666594e-05
gel O 0 0.0003316957736387849
electrophoresis O 0 7.732788071734831e-05
, O 0 5.1899320396842086e-08
the O 0 9.355255237153415e-09
protein O 0 3.2213961276283953e-08
truncation O 0 5.769773906649789e-06
test O 0 9.315299394074827e-07
, O 0 1.6399015478896217e-08
and O 0 1.562860241222097e-08
direct O 0 3.0910037196463236e-08
sequencing O 0 2.2287931642495096e-05
. O 0 2.8378283332131105e-06

RESULTS O 0 0.00013736735854763538
Chain O 0 7.564960833406076e-05
terminating O 0 1.4648878277512267e-05
signals O 0 2.0602112726919586e-06
were O 0 1.0289426199960872e-06
only O 0 5.408815084706475e-08
identified O 0 1.0830039173015393e-05
in O 0 2.288338237121934e-06
patients O 0 3.4017517464235425e-05
belonging O 0 6.720583314745454e-06
to O 0 4.291147348567392e-08
the O 0 5.665286266776093e-07
FAP B-Disease 0 0.00030887589673511684
group O 0 1.793292904039845e-05
( O 0 2.591690986264439e-07
105 O 0 3.7475030694622546e-05
patients O 0 2.9854259992134757e-05
) O 0 4.4058859316464805e-07
. O 0 1.2952165207025246e-06

Amino O 0 2.6888610591413453e-05
acid O 0 3.901484524249099e-05
changes O 0 2.497063178452663e-07
were O 0 3.909583483618917e-07
identified O 0 1.8267526229465147e-06
in O 0 1.227102615075637e-07
four O 0 1.938457899086643e-05
patients O 0 3.7951813283143565e-05
, O 0 1.823404147671681e-07
three O 0 9.47238021353769e-08
of O 0 5.539631615647522e-07
whom O 0 0.0002039723622146994
belonged O 0 2.4934181055868976e-05
to O 0 5.186488394315347e-08
the O 0 1.785507208751369e-07
non O 0 9.757075531524606e-06
- O 0 0.002725193975493312
FAP O 0 9.395038796355948e-05
group O 0 4.927510963170789e-05
of O 0 0.05952659621834755
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999958276748657
patients O 0 0.051610931754112244
. O 0 3.485522393020801e-05

Genotype O 0 0.012227158062160015
- O 0 0.11261196434497833
phenotype O 0 0.001360467285849154
correlations O 0 0.000688674976117909
identified O 0 0.0015159017639234662
significant O 0 1.3294947166286875e-05
differences O 0 7.774110599712003e-06
in O 0 1.9825338881673815e-07
the O 0 1.6855614148880704e-07
nature O 0 2.8550746833388985e-07
of O 0 5.9027087218055385e-08
certain O 0 9.950247914503052e-08
extracolonic O 0 0.0009708409779705107
manifestations O 0 3.242266984671005e-06
in O 0 1.6483581930515356e-06
FAP B-Disease 0 0.006838671397417784
patients O 0 1.5026094843051396e-05
belonging O 0 1.1925018270630972e-06
to O 0 1.7693489340331325e-08
three O 0 4.3552122974688245e-07
mutation O 0 8.373184755328111e-06
subgroups O 0 5.426964708021842e-05
. O 0 2.9089846975693945e-06

CONCLUSIONS O 0 3.7436919228639454e-05
Extended O 0 5.924018751102267e-06
genotype O 0 0.00020794413285329938
- O 0 0.004850148689001799
phenotype O 0 7.597015064675361e-05
correlations O 0 2.3851067453506403e-05
made O 0 2.115677034453256e-06
in O 0 2.4714762503208476e-07
this O 0 5.146912229747613e-08
study O 0 2.618879761939752e-06
may O 0 1.5675102986278944e-05
have O 0 8.995440481385231e-08
the O 0 4.360120087198993e-08
potential O 0 1.3026626675127773e-06
to O 0 1.4447370411119209e-08
determine O 0 5.634015565192385e-08
the O 0 2.732685899786702e-08
most O 0 1.9062600387087514e-08
appropriate O 0 6.593376955521535e-09
surveillance O 0 7.008248417150753e-07
and O 0 9.142203225565027e-07
prophylactic O 0 5.9806254284922034e-05
treatment O 0 6.413787104975199e-06
regimens O 0 4.6170427481229126e-07
for O 0 1.1702005764391288e-07
those O 0 7.405193400700227e-07
patients O 0 2.9222476314316737e-06
with O 0 7.405221822409658e-07
mutations O 0 2.103976294165477e-05
associated O 0 1.3563517313741613e-06
with O 0 2.018602799580549e-06
life O 0 8.013368642423302e-05
threatening O 0 0.04524478688836098
conditions O 0 2.051526098512113e-05
. O 0 5.5774717111489736e-06

This O 0 2.020970214289264e-06
study O 0 4.216736215312267e-06
also O 0 7.245941446853976e-07
provided O 0 9.080477525458264e-08
evidence O 0 3.841105353785679e-07
for O 0 1.7649108485784382e-07
the O 0 1.0363977480665199e-06
pathological O 0 0.00024587931693531573
nature O 0 2.0102851294723223e-07
of O 0 4.2860431648250596e-08
amino O 0 1.1799528465417097e-06
acid O 0 2.6312845875509083e-06
changes O 0 3.2544612338369916e-08
in O 0 1.223884993351021e-07
APC O 0 0.0007477478939108551
associated O 0 5.151125606062124e-07
with O 0 7.765670062553909e-08
both O 0 2.7459159923637344e-07
FAP B-Disease 0 8.016211359063163e-05
and O 0 8.791461368673481e-06
non O 0 0.004029183182865381
- O 1 0.9996044039726257
FAP O 1 0.9998124241828918
colorectal B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999977350234985
patients O 0 0.0037210951559245586
. O 0 2.0863394638581667e-06
. O 0 6.086548637540545e-06

Inherited B-Disease 1 0.9996479749679565
colorectal I-Disease 1 0.9999849796295166
polyposis I-Disease 1 0.9998626708984375
and O 1 0.9273948073387146
cancer B-Disease 1 0.9996345043182373
risk O 0 0.00031059779576025903
of O 0 2.198293884703162e-07
the O 0 5.298276391840773e-06
APC O 0 0.006268590223044157
I1307K O 0 0.0004803480696864426
polymorphism O 0 0.00023368507390841842
. O 0 6.868856871733442e-06

Germ O 0 0.09024767577648163
- O 0 0.006648908834904432
line O 0 1.5813642676221207e-05
and O 0 1.7793333029203495e-07
somatic O 0 3.910596660716692e-06
truncating O 0 2.9157308745197952e-05
mutations O 0 2.0822610622417415e-06
of O 0 2.189021586218587e-08
the O 0 2.9073657970002387e-07
APC B-Disease 0 8.261659240815789e-05
gene O 0 1.42052513751878e-07
are O 0 1.4081399157817032e-08
thought O 0 1.0174618836344962e-07
to O 0 1.6509400779796124e-07
initiate O 0 0.0004721972218248993
colorectal B-Disease 1 0.9999980926513672
tumor I-Disease 1 0.9608511328697205
formation O 0 0.0018968621734529734
in O 0 0.006614163983613253
familial B-Disease 1 0.9999871253967285
adenomatous I-Disease 1 0.9999923706054688
polyposis I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999825954437256
and O 0 0.00015622407954651862
sporadic O 0 0.07676994055509567
colorectal O 1 0.9999980926513672
carcinogenesis O 1 0.9989529848098755
, O 0 0.00016082006914075464
respectively O 0 0.0002540941350162029
. O 0 1.4424963410419878e-05

Recently O 0 0.0015657328767701983
, O 0 1.9190742932551075e-06
an O 0 7.94022525951732e-07
isoleucine O 0 0.01771370880305767
- O 0 0.016207754611968994
- O 0 0.002132873749360442
> O 0 5.203931323194411e-06
lysine O 0 4.1440063796471804e-05
polymorphism O 0 8.203969628084451e-06
at O 0 4.458586602140713e-07
codon O 0 1.2793236692232313e-06
1307 O 0 6.763919373042881e-05
( O 0 1.1937827082419972e-07
I1307K O 0 1.5386486893476103e-06
) O 0 2.6708335543190742e-09
of O 0 3.0299509568010308e-09
the O 0 8.67245617541812e-08
APC B-Disease 0 3.668814315460622e-05
gene O 0 6.449015472753672e-07
has O 0 4.996814482183254e-07
been O 0 6.00725797994528e-07
identified O 0 6.008845048199873e-07
in O 0 3.767961231915251e-08
6 O 0 2.9427635581669165e-06
% O 0 1.5058094504638575e-07
- O 0 5.111955033498816e-05
7 O 0 1.3153158988643554e-06
% O 0 7.656771217057212e-09
of O 0 5.4725797227206385e-09
the O 0 2.1559189633535425e-07
Ashkenazi O 0 4.887479008175433e-05
Jewish O 0 2.441481683490565e-06
population O 0 8.942884051066358e-07
. O 0 1.7624259953663568e-06

To O 0 3.846952495223377e-06
assess O 0 2.4667795514687896e-05
the O 0 1.0562615671005915e-06
risk O 0 3.4771767332131276e-06
of O 0 1.3546857857704708e-08
this O 0 2.1860131482753786e-08
common O 0 3.8542233937732817e-07
APC B-Disease 0 5.967857941868715e-05
allelic O 0 5.0025795644614846e-05
variant O 0 0.00021107537031639367
in O 0 0.00018462128355167806
colorectal O 1 0.9999986886978149
carcinogenesis O 1 0.9993394017219543
, O 0 3.631720392149873e-05
we O 0 1.5372552297776565e-07
have O 0 2.9351403085797756e-08
analyzed O 0 3.196150544226839e-07
a O 0 1.3160759237962338e-07
large O 0 4.0880635765461193e-07
cohort O 0 9.710958693176508e-06
of O 0 9.602829464938623e-08
unselected O 0 0.0014671540120616555
Ashkenazi O 0 0.00011411715968279168
Jewish O 0 9.1512310973485e-07
subjects O 0 1.048203557729721e-06
with O 0 2.4118942292261636e-06
adenomatous B-Disease 1 0.5720379948616028
polyps I-Disease 1 0.5049238801002502
and O 0 1.1672113032545894e-05
. O 0 1.33752946567256e-05
or O 1 0.598136305809021
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999949932098389
, I-Disease 0 3.020627445948776e-06
for O 0 1.789789507711248e-07
the O 0 1.0189878594246693e-06
APC O 0 0.0019717745017260313
I1307K O 0 0.0001591184118296951
polymorphism O 0 0.00011363188968971372
. O 0 5.336378762876848e-06

The O 0 3.6761691717401845e-06
APC O 0 0.0003342731506563723
I1307K O 0 0.00012354293721728027
allele O 0 1.927482480823528e-05
was O 0 4.326561247580685e-05
identified O 0 4.050755705975462e-06
in O 0 9.430287661871262e-08
48 O 0 4.422832262207521e-06
( O 0 2.6678716125161372e-08
10 O 0 6.037179645090873e-08
. O 0 6.415972642059842e-09
1 O 0 9.797049216331288e-08
% O 0 3.1361071961555353e-08
) O 0 1.0216268719887012e-08
of O 0 9.705541970106424e-08
476 O 0 0.024891920387744904
patients O 0 0.0002871203178074211
. O 0 3.9742790249874815e-06

Compared O 0 0.00016738215344958007
with O 0 5.096690074424259e-07
the O 0 5.392045210328433e-08
frequency O 0 1.147595369843657e-07
in O 0 7.813418356761304e-09
two O 0 8.876826385062486e-09
separate O 0 1.0011604700821408e-07
population O 0 1.9606292767093692e-07
control O 0 4.0004076140576217e-07
groups O 0 3.299059869732446e-08
, O 0 6.674205366152819e-08
the O 0 8.097661208239515e-08
APC O 0 5.077910464024171e-05
I1307K O 0 6.6476286519900896e-06
allele O 0 6.281985633904696e-07
is O 0 6.334904156801713e-08
associated O 0 8.636240522719163e-08
with O 0 7.520159073237664e-08
an O 0 6.617682402065839e-07
estimated O 0 0.00018710875883698463
relative O 0 3.037888018297963e-05
risk O 0 5.324153335095616e-06
of O 0 2.0093419550448743e-07
1 O 0 9.325618520961143e-06
. O 0 1.0010237019741908e-05

5 O 0 7.359541632467881e-05
- O 0 0.0017600766150280833
1 O 0 1.7957247109734453e-05
. O 0 4.540905592875788e-06

7 O 0 0.00027129013324156404
for O 0 0.0007104763062670827
colorectal B-Disease 1 0.9999945163726807
neoplasia I-Disease 1 0.9996800422668457
( O 0 2.62506291619502e-05
both O 0 1.3819265404890757e-05
P O 0 0.102379709482193
= O 0 0.00018929262296296656
. O 0 2.943126844456856e-07
01 O 0 0.0001872794091468677
) O 0 4.183248734079825e-07
. O 0 1.1428666084611905e-06

Furthermore O 0 9.68187814578414e-05
, O 0 1.978530690394109e-06
compared O 0 5.320874606695725e-06
with O 0 4.406663265399402e-07
noncarriers O 0 0.0016135290497913957
, O 0 1.0330210216125124e-06
APC O 0 3.544091305229813e-05
I1307K O 0 1.701126166153699e-05
carriers O 0 2.2112258193374146e-06
had O 0 6.944749202375533e-07
increased O 0 4.238355799657256e-08
numbers O 0 3.050875818644272e-08
of O 0 2.008629422789454e-07
adenomas B-Disease 0 0.3445654809474945
and O 0 0.011049403809010983
colorectal B-Disease 1 0.9999995231628418
cancers I-Disease 1 0.9968061447143555
per O 0 0.0012077601859346032
patient O 0 0.0018736467463895679
( O 0 3.2601760722172912e-06
P O 0 0.027882443740963936
= O 0 0.00023135310038924217
. O 0 2.0064659622676118e-07
03 O 0 3.894005931215361e-05
) O 0 7.658599798787691e-08
, O 0 4.430268774058277e-08
as O 0 4.0423856262350455e-08
well O 0 3.0279881713113355e-08
as O 0 5.198710084641789e-08
a O 0 4.1085360180659336e-07
younger O 0 2.6736626750789583e-05
age O 0 1.0723249033617321e-05
at O 0 3.43902429449372e-05
diagnosis O 0 0.00040747306775301695
. O 0 1.1010662092303392e-05

We O 0 1.9120884644507896e-06
conclude O 0 3.3240901302633574e-06
that O 0 3.0154236441148896e-08
the O 0 6.0691604630847e-08
APC O 0 6.449225475080311e-05
I1307K O 0 9.900806617224589e-06
variant O 0 1.7338500128971646e-06
leads O 0 2.1831647245562635e-06
to O 0 1.3121423307893565e-06
increased O 0 0.0006573331193067133
adenoma B-Disease 1 0.9999513626098633
formation O 0 3.968314194935374e-05
and O 0 1.5209607227006927e-06
directly O 0 1.1505277797141389e-07
contributes O 0 1.6354651677374932e-07
to O 0 1.5488534899077422e-08
3 O 0 2.0839367209646298e-07
% O 0 3.16116199883254e-08
- O 0 8.252857696788851e-06
4 O 0 2.093809428060922e-07
% O 0 6.3327876276275674e-09
of O 0 3.631643874513202e-09
all O 0 1.9160918895977375e-07
Ashkenazi O 0 0.020268047228455544
Jewish O 1 0.5247007012367249
colorectal B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9998546838760376
. O 0 3.336642112117261e-05

The O 0 4.625915153155802e-06
estimated O 0 7.548329449491575e-05
relative O 0 7.90198755566962e-05
risk O 0 3.891823143931106e-05
for O 0 1.1598792752920417e-06
carriers O 0 0.00016548510757274926
may O 0 1.5007357205831795e-06
justify O 0 1.862691760834423e-07
specific O 0 3.418844318758829e-09
clinical O 0 9.480893936597568e-08
screening O 0 8.161810427509408e-08
for O 0 4.6163027178636185e-08
the O 0 1.10523679097696e-07
360 O 0 3.477548261798802e-06
, O 0 3.960651042689278e-07
000 O 0 1.2053718592142104e-06
Americans O 0 4.1249546711696894e-07
expected O 0 3.155222998429963e-07
to O 0 3.750050936446314e-08
harbor O 0 3.581956843845546e-05
this O 0 7.448281991173644e-09
allele O 0 4.048354753649619e-07
, O 0 9.823338587011676e-08
and O 0 1.8832436410320952e-07
genetic O 0 1.2879000905741123e-06
testing O 0 4.2964629187736136e-07
in O 0 3.8402109936441775e-08
the O 0 3.212719335010661e-08
setting O 0 6.290283067755809e-07
of O 0 7.158437824728026e-07
long O 0 0.00029284664196893573
- O 0 0.014109374023973942
term O 0 3.230255242669955e-05
- O 0 6.432837835745886e-05
outcome O 0 7.241002890623349e-07
studies O 0 3.228008438327379e-07
may O 0 6.06276898906799e-07
impact O 0 1.6549706742807757e-06
significantly O 0 2.406381827313453e-05
on O 1 0.8409209847450256
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999951124191284
prevention O 0 0.00014510778419207782
in O 0 3.1900540875540173e-07
this O 0 2.1727473153987376e-07
population O 0 3.1976919672160875e-06
. O 0 8.803483979136217e-06

Localization O 0 0.00012817821698263288
of O 0 2.1039948023826582e-06
human O 0 1.0919059604930226e-05
BRCA1 O 0 0.0001748048234730959
and O 0 8.201272976293694e-07
its O 0 4.80141352454666e-07
loss O 0 0.0006905407644808292
in O 0 6.932996257091872e-07
high O 0 0.0010622228728607297
- O 0 0.06789923459291458
grade O 0 0.001766346162185073
, O 0 4.006274139101151e-06
non B-Disease 0 0.0005534671945497394
- I-Disease 1 0.9880051016807556
inherited I-Disease 1 0.9826161861419678
breast I-Disease 1 0.9970707893371582
carcinomas I-Disease 1 0.9998818635940552
. O 0 9.286603017244488e-05

Although O 0 5.544284249481279e-06
the O 0 2.056911796444183e-07
link O 0 2.0827237676712684e-06
between O 0 3.498153944292426e-07
the O 0 1.7715625290293247e-05
BRCA1 O 1 0.8145383596420288
tumour B-Disease 1 0.9999794960021973
- O 0 0.00814108271151781
suppressor O 0 0.00023172618239186704
gene O 0 1.5851531998123392e-06
and O 0 2.9199216442066245e-05
hereditary B-Disease 1 0.9969066977500916
breast I-Disease 1 0.999955415725708
and I-Disease 1 0.9999576807022095
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
is O 0 5.0870079576270655e-05
established O 0 4.544085186353186e-06
, O 0 7.185098525042122e-07
the O 0 3.012975184901734e-07
role O 0 3.414194679862703e-06
, O 0 2.7472518127069634e-07
if O 0 8.988010335997387e-09
any O 0 3.574154083807457e-09
, O 0 1.525236292820864e-08
of O 0 6.80603733371754e-08
BRCA1 O 0 4.9005237087840214e-05
in O 0 7.902597189968219e-07
non B-Disease 0 0.0008089326438494027
- I-Disease 1 0.9315957427024841
familial I-Disease 1 0.8683958053588867
cancers I-Disease 1 0.989780068397522
is O 0 3.4503543702157913e-06
unclear O 0 7.328164883801946e-06
. O 0 1.4130484487395734e-05

BRCA1 O 1 0.70084547996521
mutations O 0 0.0016445748042315245
are O 0 1.1791013321271748e-06
rare O 0 1.3790563571092207e-05
in O 0 1.2084980198778794e-06
sporadic B-Disease 0 0.005183665547519922
cancers I-Disease 1 0.9933053851127625
, O 0 9.027217856782954e-06
but O 0 3.2932621252257377e-06
loss O 0 0.0005959174013696611
of O 0 4.0295228131981276e-07
BRCA1 O 0 0.000463609816506505
resulting O 0 5.641107691189973e-06
from O 0 1.8600871953822207e-06
reduced O 0 1.9043949578190222e-05
expression O 0 2.1096919056162733e-07
or O 0 2.3153420514177014e-08
incorrect O 0 3.229350795663777e-07
subcellular O 0 4.804519448953215e-06
localization O 0 2.6403682568343356e-05
is O 0 4.135203539590293e-07
postulated O 0 1.4588363228540402e-06
to O 0 3.7553189002892395e-08
be O 0 2.3990986974808948e-08
important O 0 1.0935003125212006e-08
in O 0 1.5977839495917578e-07
non B-Disease 0 9.743599366629496e-05
- I-Disease 1 0.5532289743423462
familial I-Disease 1 0.5054789185523987
breast I-Disease 1 0.998902440071106
and I-Disease 1 0.9885159730911255
ovarian I-Disease 1 0.9999979734420776
cancers I-Disease 1 0.9999467134475708
. O 0 6.768616003682837e-05

Epigenetic O 0 0.12984530627727509
loss O 1 0.7316281199455261
, O 0 2.281746310472954e-05
however O 0 2.7694165964931017e-06
, O 0 6.291015210990736e-07
has O 0 3.61094919298921e-07
not O 0 6.529488949524875e-09
received O 0 1.176843937855665e-07
general O 0 5.281247581478965e-07
acceptance O 0 3.911394742317498e-06
due O 0 1.1864013913509552e-06
to O 0 2.800367226996059e-08
controversy O 0 1.8981570804044168e-07
regarding O 0 1.9711688281631723e-08
the O 0 2.1034635366845578e-08
subcellular O 0 9.968832728191046e-07
localization O 0 4.124351107748225e-06
of O 0 7.195726539066527e-07
BRCA1 O 0 0.0001642631395952776
proteins O 0 1.4528119152146246e-07
, O 0 3.3356570838805055e-08
reports O 0 7.246301692021007e-08
of O 0 3.3861056181194726e-08
which O 0 1.8266362644681067e-07
have O 0 9.199842310181339e-08
ranged O 0 1.4203505998011678e-06
from O 0 5.7434604627815133e-08
exclusively O 0 1.828171605211537e-07
nuclear O 0 1.8426453607389703e-05
, O 0 3.6611833564847984e-08
to O 0 1.828859907959668e-08
conditionally O 0 2.576973201939836e-05
nuclear O 0 3.37113015120849e-05
, O 0 2.134392929065143e-08
to O 0 5.083066856315099e-09
the O 0 6.534013152759144e-08
ER O 0 4.193024506093934e-05
/ O 0 2.5737354008015245e-06
golgi O 0 6.099494930822402e-05
, O 0 4.6571521750138345e-08
to O 0 5.511064049557035e-09
cytoplasmic O 0 4.587635373809462e-07
invaginations O 0 3.5842781471728813e-06
into O 0 6.971356381058058e-09
the O 0 5.0552138475268293e-08
nucleus O 0 4.179220013611484e-06
. O 0 1.0428242376292474e-06

In O 0 6.844636573077878e-06
an O 0 1.8690599290493992e-06
attempt O 0 1.3990683328302111e-05
to O 0 4.0850002847037103e-07
resolve O 0 1.959740802703891e-05
this O 0 2.8088512848967184e-08
issue O 0 1.1948878864131984e-06
, O 0 3.5722757729672594e-07
we O 0 5.3088140106183346e-08
have O 0 1.445004897959734e-07
comprehensively O 0 0.0002463758864905685
characterized O 0 6.503788426925894e-06
19 O 0 2.711082015594002e-05
anti O 0 0.0020976101513952017
- O 0 0.10271146148443222
BRCA1 O 0 0.0016030892729759216
antibodies O 0 1.1370361789886374e-05
. O 0 2.1719861251767725e-06

These O 0 9.307982509199064e-07
reagents O 0 2.2670148609904572e-05
detect O 0 1.899459857668262e-05
a O 0 3.6324601637716114e-07
220 O 0 2.2736742266715737e-06
- O 0 0.00018109042139258236
kD O 0 3.899635703419335e-05
protein O 0 4.324580515913112e-08
localized O 0 4.2829213953154976e-08
in O 0 3.5266367603981053e-09
discrete O 0 1.6345904896297725e-07
nuclear O 0 0.00014560381532646716
foci O 0 1.4281538824434392e-05
in O 0 9.581881244002943e-08
all O 0 4.5735603748653375e-08
epithelial O 0 0.00015616109885741025
cell O 0 9.107173536904156e-05
lines O 0 1.404048362019239e-05
, O 0 1.7285391606947087e-07
including O 0 1.0443893216915967e-07
those O 0 4.7733532682059376e-08
derived O 0 5.375962928155786e-07
from O 0 1.1596920558076818e-05
breast B-Disease 1 0.5429602861404419
malignancies I-Disease 0 0.15401729941368103
. O 0 1.6028758182073943e-05

Immunohistochemical O 0 0.0014180883299559355
staining O 0 0.0003260015801060945
of O 0 4.839191205974203e-06
human O 0 9.761956607690081e-05
breast O 1 0.5005773901939392
specimens O 0 0.001992360223084688
also O 0 1.885588062577881e-05
revealed O 0 0.00035369122633710504
BRCA1 O 0 0.000644671032205224
nuclear O 0 0.001512170652858913
foci O 0 0.00016437703743577003
in O 0 7.070404990372481e-06
benign O 0 0.21215063333511353
breast O 1 0.6875367164611816
, O 0 0.00029489415464922786
invasive B-Disease 1 0.9419156908988953
lobular I-Disease 1 0.9998977184295654
cancers I-Disease 1 0.990816593170166
and O 0 5.63914654776454e-05
low B-Disease 0 0.013108963146805763
- I-Disease 1 0.8229714632034302
grade I-Disease 1 0.6225985884666443
ductal I-Disease 1 0.9993108510971069
carcinomas I-Disease 1 0.9999094009399414
. O 0 0.0001298296410823241

Conversely O 0 0.0005034811329096556
, O 0 1.5041851838759612e-05
BRCA1 O 0 0.00035608350299298763
expression O 0 1.4813319921813672e-06
was O 0 5.27879674336873e-05
reduced O 0 4.727064606413478e-06
or O 0 6.068767675060371e-07
undetectable O 0 8.064392750384286e-05
in O 0 2.6393358609766437e-08
the O 0 5.1535725020812606e-08
majority O 0 2.533763279188861e-07
of O 0 2.784724699722574e-07
high O 0 0.007636346388608217
- O 0 0.11747828871011734
grade O 0 0.021513845771551132
, O 0 0.00021174397261347622
ductal B-Disease 1 0.9964973330497742
carcinomas I-Disease 1 0.9999868869781494
, O 0 4.133582842769101e-05
suggesting O 0 4.7957495553418994e-05
that O 0 3.683626346173696e-07
absence O 0 8.97162919955008e-07
of O 0 1.065159153768036e-06
BRCA1 O 0 0.03242385759949684
may O 0 4.247251581546152e-06
contribute O 0 1.3808860899189312e-07
to O 0 2.1899236202216343e-08
the O 0 6.657219842054474e-08
pathogenesis O 0 5.24804318047245e-06
of O 0 2.37199433428259e-08
a O 0 3.9256747186300345e-07
significant O 0 2.457417167534004e-07
percentage O 0 5.854841219843365e-06
of O 0 6.594196975129307e-07
sporadic B-Disease 0 0.009630836546421051
breast I-Disease 1 0.9986214637756348
cancers I-Disease 1 0.7986360788345337
. O 0 3.138122792734066e-06
. O 0 6.530663995363284e-06

